# EDGAR Filing Document

**Accession Number:** 0002020737
**File Stem:** 0001641172-25-025114
**Filing Date:** 2025-8
**Character Count:** 1781251
**Document Hash:** 7a2f7648409c527b4d3b5782608447d3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-025114.hdr.sgml**: 20250821

**ACCESSION NUMBER**: 0001641172-25-025114

**CONFORMED SUBMISSION TYPE**: S-1

**PUBLIC DOCUMENT COUNT**: 66

**FILED AS OF DATE**: 20250821

**DATE AS OF CHANGE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Caring Brands, Inc.
- **CENTRAL INDEX KEY:** 0002020737
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 994103908
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289767
- **FILM NUMBER:** 251241774

**BUSINESS ADDRESS:**
- **STREET 1:** 1061 E. INDIANTOWN ROAD
- **STREET 2:** SUITE 110
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477
- **BUSINESS PHONE:** 561-896-7616

**MAIL ADDRESS:**
- **STREET 1:** 1061 E. INDIANTOWN ROAD
- **STREET 2:** SUITE 110
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33477

**As filed with the Securities and Exchange Commission on August 21, 2025.**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**CARING BRANDS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Nevada** | **2844** | **99-4103908** |
| (State or Other Jurisdiction of <br> Incorporation or Organization) | (Primary Standard Industrial <br> Classification Code Number) | (I.R.S. Employer<br> Identification Number) |

---

**130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950**

**Tel: (561) 896-7616**

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**Glynn Wilson**

**Chief Executive Officer**

**130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950**

**Tel: (561) 896-7616**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***

---

| | |
|:---|:---|
| **Gregory Sichenzia, Esq.**<br> **Arthur S. Marcus, Esq.**<br> **Sichenzia Ross Ference Carmel LLP**<br> **1185 Avenue of the Americas, 31<sup>st</sup> Floor**<br> **New York, NY 10036**<br> **Telephone: (212) 930-9700**<br> **Facsimile: (212) 930-9725** | <br> **Joseph M. Lucosky, Esq.**<br> **Lucosky Brookman LLP**<br> **101 S Wood Ave,**<br> **Iselin, NJ 08830**<br> **Telephone: (215) 360-3626**<br> **Facsimile: (215) 360-3627**<br>|

---

------

Approximate date of commencement of proposed sale to the public: **As soon as practicable after this Registration Statement becomes effective.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.**

**<u>EXPLANATORY NOTE</u>**

This Registration Statement contains two forms of prospectuses: (i) one to be used in connection with the public offering of up to 1,000,000 shares of common stock, par value $0.001 (the "Common Stock") through the underwriters named on the cover page of this prospectus (the "Public Offering Prospectus"); and (ii) one to be used in connection with the potential resale by a selling stockholders of up to 2,710,000 shares of Common Stock (the "Resale Prospectus"). The Public Offering Prospectus and the Resale Prospectus will be identical in all respects except for the alternate pages for the Resale included herein which are labeled "Alternate Pages for Resale Prospectus."

The Resale Prospectus is substantively identical to the Public Offering Prospectus, except for the following principal points:

● they contain different outside and inside front covers;

● they contain different Offering sections in the Prospectus Summary section;

● they contain different Use of Proceeds sections;

● the Capitalization section is deleted from the Resale Prospectus;

● the Dilution section is deleted from the Resale Prospectus;

● A Selling Stockholder section is included in the Resale Prospectus;

● the Underwriting section from the Public Offering Prospectus is deleted from the Resale a Plan of Distribution is inserted in its place; and

● the Legal Matters section in the Resale Prospectus deletes the reference to counsel for the underwriters.

We have included in this Registration Statement, after the financial statements, a set of alternate pages to reflect the foregoing differences of the Resale Prospectus as compared to the Public Offering Prospectus.

**The information in this prospectus is not complete and may be changed. Neither we, nor the selling stockholders may sell the securities described herein until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.**

---

| | | |
|:---|:---|:---|
| **PRELIMINARY PROSPECTUS** | **SUBJECT TO COMPLETION** | **DATED AUGUST 21, 2025** |

---

![](formdrs_001.jpg)

**CARING BRANDS, INC.**

**Up to 1,000,000 shares of Common Stock**

This is a public offering of 1,000,000 shares of our Common Stock, $0.001 par value per share (the "Common Stock") of Caring Brands, Inc., a Nevada corporation (the "Company", "we", "us", "our", "Caring Brands").

Currently, our common stock is quoted on the OTCQB under the symbol "CBRA". On July 29, 2025, the last reported sale price of our common stock on the OTCQB was $2.21 per share. The final public offering price of the shares of common stock in this offering will be determined through negotiation between us and the underwriters in the offering and the recent market price of our common stock used throughout this prospectus may not be indicative of the final offering price.

Currently, there is a limited market for our common stock. We intend to apply to list our common stock on The Nasdaq Capital Market ("NASDAQ") under the symbol "CBRA". Accordingly, we expect our common stock to begin trading on NASDAQ on or around the date of this prospectus, at which point our common stock will cease to be traded on the OTCQB. There is no assurance that an active trading market for our common stock will develop or be sustained. If our common stock is not approved for listing on NASDAQ, we will not consummate this offering.

We are a "smaller reporting company," as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and have elected to take advantage of certain scaled disclosure available to smaller reporting companies. We are also an emerging growth company under the Jumpstart our Business Startups Act of 2012, or JOBS Act, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings. See the section titled "Prospectus Summary — Implications of Being an Emerging Growth Company and a Smaller Reporting Company."

The registration statement of which this prospectus forms a part also relates to the registration for resale of an aggregate of 2,710,000 shares of common stock including: (i) 2,110,000 shares of Common Stock (the "Warrant Shares") issuable upon the exercise of the warrants to purchase shares of Common Stock (the "Warrants") issued to selling shareholders pursuant to the private placements between April and June 2024 (the "Private Placements"), and (ii) 600,000 shares of Common Stock (the "Distributed Shares," together with the Private Shares and the Warrant Shares as the "Resale Shares") distributed to our parent Safety Shot, Inc. formerly known as Jupiter Wellness Inc. ("Safety Shot"). Between April and June 2024 Caring Brands, Inc., a Florida corporation ("Caring Brands Florida") entered into a series of securities purchase agreements with the selling shareholders, pursuant to which the selling shareholders were issued shares of Common Stock and warrants to purchase shares of Common Stock in Caring Brands Florida. Following the execution of the Separation and Exchange Agreement, the shares and warrants issued to the selling shareholders by Caring Brands Florida were exchanged for the Private Shares and the Warrants.

The registration statement of which this prospectus forms a part, in addition to the firm commitment underwritten offering of our common stock by us pursuant to this prospectus, also registers the distribution by Safety Shot of 600,000 shares of our Common Stock it owns to its stockholders and certain warrant holders. Safety Shot has no obligation to affect a distribution of any of its remaining ownership interest, and it may retain its ownership interest in us indefinitely or dispose of all or a portion of its ownership interest in us in a sale or other transaction. No shares will be sold under the Resale Prospectus if our common stock is not approved for listing on NASDAQ.

**An investment in our securities is highly speculative, involves a high degree of risk and should be considered only by persons who can afford the loss of their entire investment. See "Risk Factors" beginning on page 10 of this prospectus.**

**Neither the U.S. Securities and Exchange Commission nor any state or foreign securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.**

---

| | | |
|:---|:---|:---|
|  | **Per Share** | **Total** |
| Public offering price<sup>(1)</sup> | $4.00 | $4000000 |
| Underwriting discounts, expenses and commissions<sup>(2)</sup> | $0.32 | $320000 |
| Proceeds to us, before expenses | $3.68 | $3680000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The public offering price per share is assumed to be $4.00 per share. The table above assumes no exercise of the over-allotment option by the underwriters. For more information, see "Underwriting."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Represents underwriting discounts equal to eight percent (8%) of the gross proceeds of the offering per share (or $0.32 per share). We have agreed to pay a non-accountable expense allowance equal to 1% of the gross proceeds of this offering ($0.04 per share) payable to the representative of the underwriters and to reimburse certain expenses of the underwriters. In addition, we have agreed to issue to the representative of the underwriters warrants to purchase the number of shares of Common Stocks in the aggregate equal to 3% of the shares of Common Stock to be issued and sold in this offering (including any shares of Common Stock sold upon exercise of the over-allotment option). See "Underwriting".

We have granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of Common Stock solely to cover over-allotments, if any.

**Sole** **Underwriter**

**D. BORAL CAPITAL**

**The date of this prospectus is , 2025**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
| [INDUSTRY AND MARKET DATA](#a_001) | ii |
| [TRADEMARKS, SERVICE MARKS AND TRADE NAMES](#a_002) | ii |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS](#a_003) | ii |
| [PROSPECTUS SUMMARY](#a_004) | 1 |
| [THE OFFERING](#a_025) | 7 |
| [RISK FACTORS](#a_006) | 10 |
| [USE OF PROCEEDS](#a_007) | 30 |
| [DIVIDEND POLICY](#a_008) | 30 |
| [Consolidated Financial Statements](#a_009) | 32 |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_010) | 35 |
| [BUSINESS](#a_011) | 40 |
| [MANAGEMENT](#a_012) | 51 |
| [EXECUTIVE AND DIRECTOR COMPENSATION](#a_013) | 56 |
| [CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS](#a_014) | 57 |
| [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#a_015) | 62 |
| [DESCRIPTION OF SECURITIES](#a_018) | 63 |
| [SHARES ELIGIBLE FOR FUTURE SALE](#a_019) | 66 |
| [CERTAIN INCOME TAX CONSIDERATIONS](#a_020) | 68 |
| [UNDERWRITING](#Va_001) | 71 |
| [LEGAL MATTERS](#a_021) | 76 |
| [EXPERTS](#a_022) | 76 |
| [WHERE YOU CAN FIND MORE INFORMATION](#a_023) | 76 |
| [INDEX TO FINANCIAL STATEMENTS](#a_024) | F-1 |

---

Please read this prospectus carefully. It describes our business, our financial condition, and our results of operations. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision. You should rely only on the information contained in this prospectus or in any related free writing prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information different from that contained in this prospectus or in any related free writing prospectus.

Neither we, the selling stockholders nor any of the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. Neither we, the selling stockholders nor any of the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock.

**For investors outside the United States:** Neither we, the selling stockholders nor any of the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States.

i

**INDUSTRY AND MARKET DATA**

This prospectus includes market, industry and economic data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third party sources referred to in this prospectus or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying economic and other assumptions relied upon by such sources. The Company believes that its market, industry and economic data is accurate and that its estimates and assumptions are reasonable, but there can be no assurance as to the accuracy or completeness thereof. The accuracy and completeness of the market, industry and economic data used throughout this prospectus are not guaranteed and the Company does not make any representation as to the accuracy or completeness of such information.

**TRADEMARKS, SERVICE MARKS AND TRADE NAMES**

We have proprietary rights to trademarks used in this prospectus that are important to our business that are to be subject to prosecution before the respective national intellectual property organizations responsible for trademark registration. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus are without the®,™ and other similar symbols, but the absence of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names.

This prospectus contains additional trademarks, service marks and trade names of others. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies' trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other person.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

We have made statements in this prospectus, including under "Prospectus Summary," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Our Business" and elsewhere that constitute forward-looking statements. Forward-looking statements involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "should," "will," "could" and similar expressions denoting uncertainty or an action that may, will or is expected to occur in the future. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward-looking statements.

Examples of forward-looking statements include:

● the
 timing of the development of future services,

● projections
 of revenue, earnings, capital structure and other financial items,

● statements
 regarding the capabilities of our business operations,

● statements
 of expected future economic performance,

● statements
 regarding competition in our market, and

● assumptions
 underlying statements regarding us or our business.

The ultimate correctness of these forward-looking statements depends upon a number of known and unknown risks and events. We discuss our known material risks under the heading "Risk Factors" above. Many factors could cause our actual results to differ materially from those expressed or implied in our forward-looking statements. Consequently, you should not place undue reliance on these forward-looking statements. The forward- looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward- looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

ii

**PROSPECTUS SUMMARY**

*The following summary highlights information that we present more fully in the rest of this prospectus. This summary does not contain all of the information you should consider before buying shares of common stock in this offering. This summary contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "should," "will," "could," and similar expressions denoting uncertainty or an action that may, will or is expected to occur in the future. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward- looking statements.*

*You should read the entire prospectus carefully, including the "Risk Factors" section and the financial statements and the notes to those statements and our management's discussion and analysis of financial condition and results of operations. As used throughout this prospectus, the terms "Caring Brands," "Caring Brands Florida," the "Company," "we," "us," or "our" refer to Caring Brands, Inc.*

**Company Overview**

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability.

Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team. We are currently preparing for its relaunch in the United States, which is targeted for 2026, as we explore manufacturing and marketing options. The product formulation has not been changed since its removal from the US markets, and no changes to the formulation are planned for the proposed U.S. market relaunch. Photocil is a narrow band UV filter that focuses UV in the 311nm range which is therapeutic for vitiligo and psoriasis. Dimethicone, also called polymethylsiloxane, is a silicon-based polymer used as a lubricant and conditioning agent. It is the USP (United States Pharmacopeia, which is the official compendium of standards for medicines and healthcare products in the United States) monographed ingredient in Photocil. Dimethicone is used to create a smooth feel and a water-resistant barrier on the skin. In addition to dimethicone, Photocil contains two UV filters that restrict the band width of UV rays on the skin to a narrow-range ~ 308 nm. This narrow-band UV has therapeutic properties. These proprietary technologies are not found in other sunscreens and Photocil does not contain conventional UV blockers found in the majority of sunscreens. The product is categorized as an OTC product in the United States, using an USP monographed ingredient as a skin protectant, with FDA-registered labeling (USP monographed: A reference to ingredients listed in the United States Pharmacopeia (USP), which is the official compendium of standards for medicines and healthcare products in the United States). Photocil does not require FDA pre-market approval as it uses GRASE (Generally Recognized as Safe and Effective) ingredients and is currently marketed in India under local cosmetic regulations. Photocil is a cosmetic product designed to block certain UV radiation while allowing other UV radiation to pass through when applied to the skin. The product contains ingredients that are listed in the USP monograph for skin protectants. As a cosmetic product, Photocil has not been evaluated by the FDA for safety and effectiveness. The product contains ingredients that are listed in the USP monograph for skin protectants and is marketed as a cosmetic product in compliance with FDA regulations for cosmetics. The Joint American Academy of Dermatology and National Psoriasis Foundation guidelines for the management and treatment of psoriasis with phototherapy, published in JAMA Dermatology in 2019, strongly recommend narrow-band UVB phototherapy as a monotherapy for treating plaque psoriasis in adults, supported by a systematic review and meta-analysis of 41 randomized controlled trials involving 2,416 patients.

Phototherapy

Management believes that phototherapy treatments, used for conditions such as psoriasis and vitiligo, are set for substantial growth globally. However, there can be no guarantees that this growth will materialize as expected, as it is subject to various market conditions, regulatory developments, and other external factors beyond the Company's control. Specific market data focused solely on the Indian phototherapy treatment segment is limited, and the available market data focuses primarily on phototherapy devices. However, according to Future Market Insights (2023)<sup>1</sup>, the Indian market is expected to experience strong growth, driven by the rising prevalence of skin disorders, increased healthcare spending, and improved access to treatment in both urban and rural areas.

According to Future Market Insights (2023), the global phototherapy treatment market is projected to rise from ~ USD $1.9 billion in 2023 to ~ USD $3.23 billion by 2033, at a CAGR of around 5.2% during the forecast period from 2023 to 2033. In India, the market is expected to expand even faster, with an estimated CAGR of approximately 7.8% as of 2023, driven by a large patient base, increasing prevalence of skin disorders, greater awareness of noninvasive treatments, and improved healthcare infrastructure (Future Market Insights, 2023).

Psoriasis

According to a report by Nature Reviews Drug Discovery (2024)<sup>2</sup>, the global psoriasis treatment market was worth ~ $34 billion globally in the 12 months ending June 2023. The report shows the US remains the dominant market for psoriasis therapies, accounting for approximately 78% of total sales and growing at a compound annual growth rate of approximately 18%.

<sup>1.</sup> Future Market Insights (2023) – Phototherapy Treatment Market: https://www.futuremarketinsights.com/reports/north-america-and-europe-phototherapy-treatment-market

<sup>2.</sup> Nature Reviews Drug Discovery (2024) – The Pipeline and Market for Psoriasis Drugs, Vol. 23, Issue 7, Pages 492-493. Doi: https://doi.org/10.1038/d41573-024-00018-2

According to the same report (Nature Reviews Drug Discovery, 2024), with the current growth rate (CAGR of 8–10% from 2023 to 2030), the global market is expected to reach ~ USD $54-67 billion by 2030. Estimates from a report published on the National Center for Biotechnology Information<sup>3</sup>, indicate that the prevalence of psoriasis in India ranges from 0.44% to 2.8% of the population, highlighting Management's belief in the significant market opportunity in India. However, actual market growth may be influenced by factors such as regulatory changes, competition, and economic conditions, which could impact the overall demand for psoriasis treatments. Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India. However, actual market penetration will depend on various factors, including the development of a dedicated sales and marketing team at Caring Brands, market demand, competitive landscape, and regulatory considerations. There can be no assurance that these efforts will result in significant market adoption.

Vitiligo

According to a report by Expert Market Research (2024)<sup>4</sup>, the global vitiligo treatment market was valued at ~ USD 538.90 million in 2024. The global market is projected to grow at a compound annual growth rate (CAGR) of 4.60% from 2025 to 2034, reaching ~ USD 807.70 million by 2034 (Expert Market Research, 2024). According to Expert Market Research (2024), this growth is attributed to the increasing global prevalence of vitiligo and the rising demand for effective treatments, and Management believes that these factors may contribute to expanding market opportunities. However, actual market expansion may be influenced by factors such as regulatory changes, competition, and advancements in alternative therapies, which could impact the overall demand for vitiligo treatments.

According to the report by Expert Market Research (2024), the US market is expected to remain the dominant market for vitiligo treatments. The report also states that the Asia Pacific region is expected to witness the fastest growth during the forecast period due to increasing awareness, emerging treatment options, growing research and development activities, and favorable government initiatives in developing nations. As part of this Asia Pacific region, management believes India presents a potential opportunity for market expansion. However, there is no certainty that this growth will materialize as expected, as it depends on various external factors, which will impact the overall demand.

As per reports published on the National Centre for Biotechnology Information<sup>5 6</sup>, across studies from India, the prevalence of vitiligo has consistently been reported to be between 0.25%-4% (Cureus Report)<sup>5</sup> and can reach as high as 8.8% of the population in certain regions like Gujarat and Rajasthan (Indian Journal of Community Medicine)<sup>6</sup>, making India a highly affected region globally. However, even though Management believes that this presents a potential market opportunity, Vitiligo treatment with Photocil is expected to address only a very small fraction of the total global market. Future market penetration is uncertain and subject to factors such as regulatory approvals, competitive dynamics, and effective marketing strategies. There can be no assurances that Photocil will achieve meaningful adoption in the market.

Our licensee in India, Cosmofix and San Pellegrino Cosmetics, is currently exploring additional sub-licensing opportunities in Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia. We are also in preliminary discussions regarding potential licensing opportunities in Europe and South America, though no formal agreements are currently in place. The results of clinical trials on Photocil have been published in Expert Opin Pharmacother, including 2014 Dec;15(18):2623-7; Dermatol Ther. 2014 Jul-Aug;27(4):195-7; Dermatol Ther. 2014 Sep-Oct;27(5):260-3. In July 2021, Safety Shot (then Jupiter Wellness) obtained an exclusive license from Applied Biology Inc. to manufacture and sell Photocil. Subsequently, in June 2022, Safety Shot (then Jupiter Wellness) acquired all assets of Applied Biology Inc., including Photocil, through an asset purchase agreement. The product was commercially launched in India in September 2022 under a licensing agreement with Cosmofix and San Pellegrino Cosmetics and entered the U.S. market in Q4 2022 via Amazon. However, it was removed from the U.S. market in February 2023 due to insufficient sales resulting from the lack of a dedicated sales and marketing team. In India, Photocil is currently marketed as an OTC product compliant with local regulatory standards. In the United States, it was previously commercialized with FDA-registered labeling as a Jupiter Wellness product. We plan to apply for a National Drug Code (NDC) number for FDA registration prior to relaunching the product in the U.S. market. Photocil has been evaluated in clinical trials for the treatment of vitiligo and psoriasis, demonstrating significant efficacy.

Our Hair Enzyme Booster (JW-700), previously known as Minoxidil Booster, was initially developed by Applied Biology Inc. and was acquired by Safety Shot (then Jupiter Wellness) in June 2022 through an asset purchase agreement. The product received labelling approval as a cosmetic from the Central Drugs Standard Control Organization (CDSCO) and is currently being manufactured and sold in India through our agreement with Cosmofix and San Pellegrino Cosmetics. Hair Enzyme Booster (JW-700) was launched on Amazon on October 28, 2024, and became available on NOVODX's e-commerce platform on December 11, 2024. As of the date of this prospectus, the Hair Enzyme Booster (JW-700) is currently only for sale on Amazon.

The Hair Enzyme Booster has been clinically shown to increase the enzymes needed for minoxidil (an FDA-approved over-the-counter medication used to treat hair loss and promote hair regrowth) to work, sulfotransferase enzymes, by using the product topically in conjunction with topical minoxidil. The Hair Enzyme Booster (JW-700) is marketed and sold as a cosmetic product in the U.S., containing GRASE ingredients that do not require FDA pre-market approval and complying with FDA labeling requirements. In India, it is currently marketed under local cosmetic regulations. The Company launched the Hair Enzyme Booster (JW-700) in the U.S in the fourth quarter of 2024. The product is designed to improve Minoxidil efficacy and is available as a topical solution. It is designed to enhance the efficacy of minoxidil by increasing necessary enzyme levels and must be used in combination with FDA-approved minoxidil products. JW-700 does not independently treat hair loss or promote hair regrowth. Clinically shown to increase the sulfotransferase enzyme needed for minoxidil to work, has 2 granted and 5 pending patents.

Minoxidil market was valued at $1.5 billion in 2022 and is expected to grow to $2.5 billion by 2032. Licensed to Taisho, a $2.6 billion revenue company and Japan's leading seller of minoxidil products. They expect to launch the product commercially in 2025. The term of the Taisho License is for five (5) years with an automatic renewal of one (1) year unless terminated otherwise. As consideration, Caring Brands shall receive up to $200,000 in milestone payments and a 3% royalty subject to the terms and conditions of the Taisho License. On September 1, 2022, Safety Shot (then Jupiter Wellness), entered into a license agreement with Cosmofix and San Pellegrino cosmetics to market and manufacture the Hair Enzyme Booster (JW-700) and Photocil for the Indian market and 31 other companies in Africa and Far East. The license is for three years with an automatic renewal of one (1) year unless terminated otherwise. Photocil and the Hair Enzyme Booster (JW-700) are being sold in India. As consideration a 3% royalty subject to the terms and conditions of the Cosmofix/San Pellegrino license. The License was transferred to the Company, pursuant to the Separation and Exchange Agreement (as defined below). The Company launched the Hair Enzyme Booster (JW-700) in the US in 4Q, 2024. As the product contains components that are generally regarded as safe (GRASE) it does not require FDA approval. Clinical studies on the Hair Enzyme Booster (JW-700) have been published: Journal of Cosmetic Dermatology (2022), Vol.21, Issue 4, 1647-1650. The Hair Enzyme Booster (JW-700) has undergone multiple clinical trials, demonstrating its potential efficacy in treating androgenetic alopecia (AGA). The Hair Enzyme Booster (JW-700) is designed to enhance the efficacy of minoxidil by increasing necessary enzyme levels and must be used in combination with FDA-approved minoxidil products. The Hair Enzyme Booster (JW-700) does not independently treat hair loss or promote hair regrowth.

<sup>3.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC4252960/ Kumar S, Nayak C., Padhi T, et al. (November, 2014). *Epidemiological pattern of psoriasis, vitiligo, and atopic dermatitis in India: A hospital-based point prevalence.* Indian Dermatology Online Journal, 5(Suppl 1), S2–S8. Doi: 10.4103/2229-5178.144499

<sup>4.</sup> Expert Market Research (2024) – Vitiligo Treatment Market: https://www.expertmarketresearch.com/reports/vitiligo-treatment-market

<sup>5.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC11112533/ Saha D, Roy S, Ahmed R, et al. (April 23, 2024). *Clinico-Epidemiological Profile of Vitiligo Among Patients Attending a Tertiary Care Centre of North-East India.* Cureus 16(4): e58804. doi:10.7759/cureus.58804

<sup>6.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC4134529/ Vora R V., Patel B., Chaudhary A.H., et al. (July – Sept 2014). *A Clinical Study of Vitiligo in a Rural Set up of Gujarat*. Indian Journal of Community Medicine 39(3):p 143-146, Jul–Sep 2014. Doi: 10.4103/0970-0218.137150

CB-101 treatment for Atopic Dermatitis (Eczema) is a topical over-the-counter treatment for atopic dermatitis (eczema) with dual-action relief from aspartame (ASN or artificial sweetener being used in a new formulation for skin treatment) and colloidal oatmeal (an FDA-approved ingredient for skin protection and relief of minor skin irritations). In clinical studies of the prior formulation (containing CBD), JW-100 cleared or reduced eczema following 2 weeks of use and may prove potentially superior to existing prescription drugs. It currently has 4 pending patents, with the global eczema treatment market valued at $14 billion in 2022. 31.6 million Americans, or 10% of the population, have eczema; 86% are not satisfied with their treatment and want more and better treatment options. CB-101 eczema treatment development is on hold pending reformulation, which we expect to resume and complete in Q4 2025/Q1 2026, with anticipated online availability in the US in the second quarter of 2026 as an over-the-counter product under a USP monograph. We intend to utilize a portion of the offering proceeds to fund this reformulation and related development activities. CB-101 will be marketed as an OTC product under the applicable USP monograph. It contains colloidal oatmeal, which is covered under the USP monograph for skin protectant products. The product will comply with all requirements outlined in the applicable USP monograph and will require FDA registration and an NDC number prior to marketing. The clinical study on JW-100 was published in the Journal of Cosmetic Dermatology, Vol. 21, Issue 4, April 2022, pp: 1647-1650. The primary endpoint of this research was a reduction in the Investigator's Static Global Assessment (ISGA) score. The treatment group achieved an average ISGA score reduction of 1.28 compared to 0.70 in the placebo group (p=0.042). Additionally, 50% of subjects in the treatment group achieved an ISGA rating of "clear" or "almost clear" with a two-grade improvement, compared to 15% in the placebo group (p=0.028). No adverse events were reported during the study. The original formulation, JW-100, contained CBD as an active ingredient, while the new formulation, CB-101, removes CBD, while maintaining aspartame (ASN) and introducing colloidal oatmeal as key ingredients. This dual-action formulation is designed to provide relief from eczema symptoms and allows the product to be marketed as an OTC product under a USP monograph for skin protectants. The reformulated product retains the therapeutic approach of the original while utilizing ingredients compliant with applicable USP monographs. The development process is expected to move into its final stages upon resumption, with approximately $150,000 anticipated to be allocated to completing formulation development, $200,000 for the initial production run, and $50,000 for clinical testing, to be funded from offering proceeds. The target launch date for the product remains Q2 2026.

NoStingz is planned to be reformulated under Caring Brands as a sunscreen product designed to provide protection against both UV rays and jellyfish stings. NoStingz was previously commercialized in the United States market from July 2022 and was removed from the market in September 2023 due to insufficient sales resulting from the lack of a dedicated sales and marketing team. The previously commercialized version contained FDA-compliant sunscreen active ingredients. Reformulation and stability testing are expected to resume utilizing a portion of the offering proceeds. All actives are intended to meet the USP specifications mandated by the FDA in its sunscreen monograph. The new formulation, once resumed, will explore a combination of rubidium iodide and menthol, which has demonstrated promising results in a small trial conducted in the Florida Keys.

<u>Trial Details</u>

The trial was conducted from May 29 - June 17, 2023, in Key West, Florida to evaluate the efficacy of NoStingz formulations against Portuguese man-o'-war (Physalia physalis) stings. The study was conducted by independent researchers who collected specimens from Atlantic waters near Key West.

<u>Methodology and Design</u>

The researchers developed a controlled, blind testing protocol using preserved Portuguese man-o'-war specimens collected from the Atlantic waters near Key West. The methodology involved carefully preserving the stinging tentacles through a controlled dehydration process, followed by systematic rehydration of small portions for standardized testing applications. The study evaluated multiple formulation types, including mineral-based sprays and lotions with SPF levels of 30 and 50. To ensure scientific validity, the researchers incorporated placebo controls using untreated skin areas. The evaluators assessed sting responses and protective efficacy of the different formulations against the control areas.

<u>Results and Safety</u>

The combination of rubidium iodide and menthol demonstrated promising initial results in reducing sting severity. However, we note that this was a small preliminary trial and further testing is needed to establish statistical significance. No adverse events or safety concerns were reported during the trial period.

<u>Mechanism of Action</u>

Rubidium iodide and menthol were selected based on their potential protective properties:

● Rubidium
 iodide acts as a potential inhibitor of the nematocyst discharge mechanism

● Menthol
 provides a cooling sensation and may help reduce localized inflammatory response

We plan to conduct additional stability testing and formulation work before proceeding with larger scale trials to validate these preliminary findings. The reformulated product is intended to provide dual protection against both UV rays and jellyfish stings. Reformulation activities are expected to resume utilizing a portion of the offering proceeds. We have not yet established a timeline for commercial launch. As the product contains ingredients with well-established safety profiles, it does not require FDA approval. NoStingz will be regulated as a sunscreen product and will comply with the FDA's sunscreen guidelines. It will contain FDA-approved sunscreen active ingredients and will require FDA registration and an NDC number prior to marketing.

Our products are tested for quality and stability each time they are manufactured. One of our manufacturers is Stella Industries Ltd., Haryana, India, which manufactures the Hair Enzyme Booster (JW-700) and Photocil for the Indian market. Stability on commercial batches manufactured in India indicates a shelf life of at least 24 months. Stella Industries is compliant with the FDA's Current Good Manufacturing Practice, or CGMP, regulations in accordance with 21 CFR 210/211 required for over-the-counter drug products. It is ISO-9001 certified. Another manufacturer is DCR Labs, Daytona Beach, Florida, which is also fully compliant with the FDA's Current Good Manufacturing Practice, or CGMP, for cosmetic products.

We expect to continually update and expand upon our corporate website and further refine our online retail strategies on an ongoing basis. CaringBrands.com is our primary corporate website, which will serve as the primary source of information about us for investors and will contain press releases, clinical trial pipeline, lab reports, blog posts, and additional information about each of our brands. We have built an e-commerce platform designed to connect us directly to consumers. We use the platform to sell products, educate customers, and build brand loyalty.

For further information in relation to the clinical trials of our products, please see the section "Business - Clinical Trials of our Products" beginning on page 43, of this prospectus.

**Recent Developments**

In April 2024, the Company received gross proceeds of $2,110,000 from a private placement of units (the "Bridge Financing"), at a price per unit of $1.00, consisting of one share of common stock and a warrant to purchase one share of common stock at a price of $3.00 per share, which warrants expire on April 15, 2029. We used the net proceeds of the Bridge Financing to fund our continuing working capital and capital expenditure requirements leading up to this offering. D. Boral Capital LLC, the lead underwriter of this offering ("D. Boral"), served as the lead placement agent for the Bridge Financing. D. Boral received fees and reimbursement of expenses in an aggregate amount of $211,000.

On May 14, 2024 the Company issued 7,600,000 shares to certain of its insiders and founding stockholders, pursuant to a subscription agreement dated March 15, 2024, at a purchase price of $0.001 per share of Common Stock. The form of subscription agreement is included as Exhibit 10.1 of this registration statement and prospectus.

On June 20, 2024, the Company entered into a Research Collaboration and Non-Exclusive License Agreement, as amended and restated on July 22, 2024 (the License Agreement") with NOVODX Corporation, a Delaware corporation, and a related party, ("NOVODX"). NOVODX is a diagnostic company dedicated to the development and commercialization of innovative health products, with a primary focus on rapid diagnostic screenings and their companion therapeutics (see section "Certain Relationships And Related Party Transactions" below). NOVODX is engaged in the research and development of rapid diagnostic devices intended for both Over the Counter ("OTC") and Point of Care ("POC") applications. NOVODX aims to manufacture, market, and sell these devices, either directly or indirectly, for use in at-home diagnostic screenings. NOVODX possesses or has the rights to use (through licenses or other agreements) certain assets, patent applications, and associated know-how, technology, scientific, and technical information. Collectively, these resources are referred to as the GoldNTM Ebola Rapid Test Technical Information, which pertains to the development of an Ebola diagnostic test (the "Ebola Rapid Test").

Pursuant to the License Agreement, NOVODX granted the Company two non-exclusive licenses during the term of the License Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;1. Research
 License: This license allows the Company to use and market the Ebola Rapid Test in the research field, following the directives and
 standards set by the Joint Development Committee (JDC) and the research plan of reasonably collaborating with each other to develop
 a pre-clinical research or other plan for the Ebola Rapid Test. This license is valid only in jurisdictions where NOVODX has a valid
 claim. NOVODX is pursuing patent protection through U.S. and Patent Cooperation Treaty (PCT) applications, with a particular focus
 on markets in Africa and Asia. As of the date of this prospectus, NOVODX has not yet submitted any patent applications. NOVODX
 is in the process of preparing these applications and evaluating entry into specific jurisdictions. Decisions regarding entry
 into national phase applications in specific jurisdictions will be evaluated on a case-by-case basis as the patent prosecution process
 progresses. The ultimate scope of patent protection will be determined by the jurisdictions where NOVODX successfully obtains valid
 claims through these patent applications.

&nbsp;&nbsp;&nbsp;&nbsp;2. Commercial
 License: This license permits the Company to use, market, and sell the Ebola Rapid Test within the commercial field. the Company
 cannot engage in sales, directly or indirectly, until NOVODX obtains 510K or EUA approval or authorization. Sales and distribution
 are restricted to jurisdictions where such approval or authorization is valid and where NOVODX has a valid claim. NOVODX is pursuing
 patent protection through U.S. and Patent Cooperation Treaty (PCT) applications, with a particular focus on markets in Africa and
 Asia. As of the date of this prospectus, NOVODX has not yet submitted any patent applications. NOVODX is in the process of preparing
 these applications and evaluating entry into specific jurisdictions. Decisions regarding entry into national phase applications
 in specific jurisdictions will be evaluated on a case-by-case basis as the patent prosecution process progresses. The ultimate scope
 of patent protection will be determined by the jurisdictions where NOVODX successfully obtains valid claims through these patent
 applications.

**Corporate History**

Caring Brands was incorporated in the State of Nevada on April 23, 2024, On May 13, 2024, an Amendment to the Articles of Incorporation was submitted with the State of Nevada to revise the par value to $0.001 per share, followed by an amendment on July 9, 2024 to add 1,000,000 preferred shares with a par value of $0.001 to the authorized share capital. Caring Brands was incorporated for the purpose of the separation of our business operation from Safety Shot, and have not historically operated as a standalone company. Pursuant to the Separation and Exchange Agreement, we acquired 100% equity in Caring Brands Florida. Consequently, Caring Brands Florida now operates as an operating subsidiary of the Company.

Caring Brands, Inc., a Florida Corporation ("Caring Brands Florida") was originally incorporated in the State of Florida on February 12, 2020, under the name Jupiter Wellness Inc. In June 2020, Articles of Amendment were filed with the Florida Department of State Division of Corporations to amend the articles of incorporation to change the name of the company to Caring Brands, Inc.

Our principal business address is 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950. We are currently authorized to issue a total of 100,000,000 shares of common stock with a par value of $0.001. As of the date of this registration statement, we had 13,336,925 shares of common stock issued and outstanding.

**Safety Shot Inc Ownership and Our Separation from Safety Shot Inc**

Effective as of the date of the Separation Agreement the Company operates as a separate entity from Safety Shot. At all times prior to the date of the Separation Agreement, we were an operating subsidiary of Safety Shot Inc ("Safety Shot"). Safety Shot owns 3,000,000 shares of our Common Stock, representing approximately 22.5% of the outstanding shares of our Common Stock, at an assumed offering price of $4.00 per share. Following the completion of the separation, Safety Shot no longer consolidates its financial results with our financial results.

On September 24, 2024, we entered into a separation and exchange agreement (the "Separation and Exchange Agreement") with Safety Shot to govern the separation of our business from Safety Shot. We expect to consummate the separation on or prior to the effective date of the registration statement of which this prospectus forms a part and the distribution will be paid on or after the effective time of the registration statement of which this prospectus forms a part but prior to the closing of this offering. Safety Shot owns majority of the issued and outstanding ordinary shares of Caring Brands Florida, which currently sells innovative wellness consumer products industries (the "CB Business") and owns all of the assets and liabilities related thereto. Pursuant to the Separation and Exchange Agreement the CB Business was contributed to us and all expenses related thereto shall be our responsibility, in each case, on the terms and subject to the conditions set forth therein, and in exchange Safety Shot was transferred to us all of the issued and outstanding ordinary shares of Caring Brands Florida owned by Safety Shot (the "Business Transfer"). In conjunction to the Business Transfer and pursuant to the Separation and Exchange Agreement, Safety Shot transferred all the intellectual property to the Company. In the event this offering is not consummated, the Separation will be unwound.

In this prospectus, references to the term "separation" refers to the separation of our business from Safety Shot's other businesses pursuant to and subject to the conditions of the Separation and Exchange Agreement.

The registration statement of which this prospectus forms a part also registers the distribution by Safety Shot of 600,000 shares of our Common Stock it owns to its stockholders and certain warrant holders. Safety Shot has no obligation to effect a distribution of any of its remaining ownership interest, and it may retain its ownership interest in us indefinitely or dispose of all or a portion of its ownership interest in us in a sale or other transaction. Any such distribution or other disposition by Safety Shot of its remaining interest in us (each, an "other disposition") would be subject to market, tax and legal considerations, final approval by the Safety Shot board of directors (the "Safety Shot Board") and other customary requirements. Under current law, the distribution could be determined to be taxable to Safety Shot and its stockholders. Safety Shot has no obligation to pursue or consummate any further disposition of its ownership interest in us by any specified date or at all. Our separation from Safety Shot will be made in the context of a parent-subsidiary relationship and the Separation and Exchange Agreement were entered into in the overall context of our separation from Safety Shot. The terms of the Separation and Exchange Agreement may be more or less favorable to us than if they had been negotiated with unaffiliated third parties. See the section titled "*Risk Factors—Risks Related to Our Separation from Safety Shot*."

We believe, and Safety Shot has advised us that it believes, that the separation, this offering and the distribution will provide a number of benefits to our business and to Safety Shot' business. These intended benefits include improving the strategic and operational flexibility of both companies, increasing the focus of the management teams on their respective business operations and allowing each company to adopt the capital structure, investment policy and dividend policy best suited to its financial profile and business needs, and providing each company with its own equity currency to facilitate acquisitions and to better incentivize management. In addition, as we are a stand-alone company, potential investors will be able to invest directly in our business.

**Summary of Risks Affecting Our Company**

Our business is subject to numerous risks described in the section titled "Risk Factors" and elsewhere in this prospectus. The main risks set forth below and others you should consider are discussed more fully in the section entitled "Risk Factors" beginning on page 10, which you should read in its entirety.

Our business is subject to numerous risks as described in the section entitled "Risk Factors" and elsewhere in this prospectus. You should carefully consider these risks before making an investment. Some of these risks include:

● *Risks Relating to the Separation:* 

 

○ We may be unable to achieve some or all of the benefits that we expect to achieve from the Separation.

○ We may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as a publicly traded company, and we may experience increased costs after the Separation.

○ The distribution, together with certain related transactions, does not qualify as a transaction that is generally tax-free for U.S. federal income tax purposes, Safety Shot and its stockholders could be subject to significant tax liabilities.

○ Some of our directors and executive officers own Safety Shot common stock or options to acquire Safety Shot common stock and hold positions with Safety Shot, which could cause conflicts of interest, or the appearance of conflicts of interest, that result in our not acting on opportunities we otherwise may have.

● *Risk Related to Our Business:* 

○ Caring Brands has a limited operating history, which makes it difficult to accurately evaluate our business prospects.

○ We may not have adequate capital to fund our business.

○ We may not be able to successfully compete against companies with substantially greater resources.

○ The sale of our products involves product liability and related risks that could expose us to significant insurance and loss expenses.

● *Risks Related to our Financial Position and Capital Needs* 

○ Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or other assets

● *Risks Related to our Intellectual Property* 

○ We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.

○ If we are not able to adequately protect our intellectual property, then we may not be able to compete effectively, and we may not be profitable.

● *Risks Related to Ownership of Our Securities* 

○ We are an "emerging growth company" and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.

○ Our common stock may become subject to the SEC's penny stock rules and accordingly, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities may be adversely affected.

**Corporate Information**

Our principal executive offices are located at 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950 and our telephone number is (561) 896-7616. Our website address is www.caringbrands.com. Information contained in, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or the registration statement of which this prospectus forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference only.

**Going Concern**

We intend to overcome the circumstances that impact our ability to remain a going concern through a combination of expanding our revenues, with interim cash flow deficiencies being addressed through additional equity and debt financing; however, we may not have commitments from third parties for a sufficient amount of additional capital. We cannot be certain that any such financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations. Our ability to obtain additional funding will determine our ability to continue as a going concern. Failure to secure additional financing in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results of operations and stock price and may require us to curtail or cease operations, sell off our assets, seek protection from our creditors through bankruptcy proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of our common stock, and debt financing, if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require that we relinquish valuable rights. Please see note 1, in our financial statements, for further information.

We have a need for additional growth capital. There can be no assurance that sufficient funds required during the subsequent year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force us to substantially curtail or cease operations and would, therefore, have a material adverse effect on our business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on our existing stockholders.

**Implications of Being an Emerging Growth Company and a Smaller Reporting Company**

We are an "emerging growth company," as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (ii) the last day of the fiscal year in which we have total annual gross revenues exceeding $1.235 billion; (iii) the date on which we have issued more than $1 billion in nonconvertible debt in any three-year period; or (iv) the date on which we are deemed to be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable future but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company as described above. References herein to "emerging growth company" have the meaning associated with it in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies that are not emerging growth companies.

These exemptions include:

● being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced "Management's Discussion and Analysis of Financial Condition and Results of Operations" disclosure in this prospectus;

● not being required to comply with the requirement of auditor attestation of Section 404 of the Sarbanes-Oxley Act of 2002, as amended;

● reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and

● not being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

For as long as we continue to be an emerging growth company, we expect that we will take advantage of the reduced disclosure obligations available to us because of that classification. We have taken advantage of certain of those reduced reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.

An emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies.

We are also a "smaller reporting company" and to the extent that we continue to qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, the "**Exchange Act**"), after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures; and (3) the requirement to provide only two years of audited financial statements, instead of three years.

**The Offering**

---

| | |
|:---|:---|
| **Shares of common stock offered** | 1,000,000 shares of Common Stock. |
| **Public Offering Price** | $4.00 per share. |
| **Number of shares of common stock outstanding prior to offering** | 13,336,925 shares of Common Stock, as of June 30, 2025. |
| **Number of shares of common stock outstanding after this offering** | 14,336,925 shares of Common Stock (or 14,486,925 shares if the underwriters exercise their over-allotment option in full). |
| **Use of Proceeds** | We expect to receive approximately $3,200,000 in net proceeds from the sale of our shares of Common Stock offered by us in this offering (approximately $3,800,000 if the underwriters exercise their over-allotment option in full), after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds received from this offering for general and working capital purposes, including but not limited to investing in research and development, including in our technology, the repayment of debt and for working capital and general corporate purposes.<br>See "Use of Proceeds" on page 30 for a more complete description of the intended use of proceeds from this offering.<br>|
| **Listing** | Currently, our common stock is quoted on the OTCQB under the symbol "CBRA". We intend to apply to list our common stock on The Nasdaq Capital Market ("NASDAQ") under the symbol "CBRA". If our shares of common stock are not approved for listing on the NASDAQ, we will not consummate this offering. No assurance can be given that our application will be approved. |
| **Lock-up Agreements** | We have agreed with the underwriters not to sell additional equity securities for a period of 180 days after the effective date of this Offering. Our directors, officers and holders of 10% or more of our Common Stock have agreed with the underwriters not to offer for sale, sell, contract to sell, pledge or otherwise dispose of any of their shares of our common stock or securities convertible into our common stock, subject to certain exceptions, for a period of 180 days after the date of this prospectus, which restriction may be waived in the discretion of the Representative. See "Underwriting". |
| **Risk Factors** | **Investing in these securities involves a high degree of risk.** Investors should carefully consider the information set forth in the "Risk Factors" section of this prospectus on page 10 before deciding to invest in our shares of common stock. |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The number of shares of common
 stock to be outstanding immediately after this offering is based on 13,336,925 shares of common stock issued and outstanding
 as of June 30, 2025. Unless otherwise indicated, all information in this prospectus assumes, no exercise of outstanding warrants
 to purchase up to 2,110,000 shares of common stock at $3.00 per share which expire on May 1, 2027.

**THE DISTRIBUTION**

*The discussion in this prospectus of the distribution is subject to, and qualified by reference to, the Separation and Exchange Agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part and is incorporated by reference into this prospectus.*

**General**

On September 24, 2024, we entered into the Separation and Exchange Agreement with Safety Shot to govern the separation of our business from Safety Shot. The Separation and Exchange Agreement governs the separation of our business from Safety Shot. Pursuant to the securities purchase agreement, on March 15, 2024, we issued to the stockholders of Safety Shot 3,000,000 shares of our Common Stock (representing 22.5% of our outstanding Common Stock) of which 600,000 shares of common stock will be distributed to the shareholders of Safety Shot following the effectiveness of this registration statement (the "Distribution"). Pursuant to the Business Transfer, we acquired from Safety Shot by operation of law all assets and assume all liabilities comprising of CB Business, which were owned and held by Safety Shot. In conjunction to the Business Transfer and pursuant to the Separation and Exchange Agreement, Safety Shot transferred all the intellectual property to the Company. In the event this offering is not consummated, the Business Transfer and the Distribution will be unwound.

**Manner of Effecting the Distribution**

The general terms and conditions relating to the distribution are set forth in the Separation and Exchange Agreement. Under the Separation and Exchange Agreement, the Distribution will be paid on or after the effective date of the registration statement of which this prospectus forms a part but prior to the closing of this offering. For most Safety Shot stockholders who own Safety Shot Common Stock in registered form on the record date, our transfer and distribution agent will credit their shares of our Common Stock to book entry accounts established to hold these shares. Our transfer and distribution agent will send these stockholders a statement reflecting their ownership of our Common Stock. Book-entry refers to a method of recording stock ownership in our records in which no physical certificates are used. For stockholders who own Safety Shot Common Stock through a broker or other nominee, their shares of our Common Stock will be credited to these stockholders' accounts by the broker or other nominee. As further discussed below, fractional shares will not be distributed. Following the distribution, stockholders whose shares are held in book entry form may request that their shares of our Common Stock be transferred to a brokerage or other account at any time, as well as delivery of physical stock certificates for their shares, in each case without charge.

SAFETY SHOT STOCKHOLDERS WILL NOT BE REQUIRED TO PAY FOR SHARES OF OUR COMMON STOCK RECEIVED IN THE DISTRIBUTION, OR TO SURRENDER OR EXCHANGE SHARES OF SAFETY SHOT COMMON STOCK IN ORDER TO RECEIVE OUR COMMON STOCK, OR TO TAKE ANY OTHER ACTION IN CONNECTION WITH THE DISTRIBUTION. NO VOTE OF SAFETY SHOT STOCKHOLDERS IS REQUIRED OR SOUGHT IN CONNECTION WITH THE DISTRIBUTION, AND SAFETY SHOT STOCKHOLDERS HAVE NO APPRAISAL RIGHTS IN CONNECTION WITH THE DISTRIBUTION.

Fractional shares of our Common Stock will not be issued to Safety Shot stockholders as part of the distribution or credited to book entry accounts. In lieu of receiving fractional shares, the number of shares of Common Stock to be received in the distribution will be rounded down to the nearest whole share of Common Stock. An explanation of the tax consequences of the distribution can be found below in the subsection captioned "— *Material U.S. Federal Income Tax Consequences of the Distribution*." The distribution of Company Common Stock in respect of the Safety Shot shares is expected to be taxable to both Safety Shot and holders of the Safety Shot shares. See "*The Distribution — Material U.S. Federal Income Tax Consequences of the Distribution*."

In order to be entitled to receive shares of our Common Stock in the distribution, which will occur after the effectiveness of this registration statement and prior to the closing of this offering, holders of Safety Shot common stock must be holders of record of Safety Shot common stock as of the close of business, New York City time, on the record date, [ ], subject to the registration statement of which this prospectus forms a part being declared effective.

**Reasons for the Distribution**

The Safety Shot board of directors has determined that the separation of our business from the other business of Safety Shot is in the best interests of Safety Shot and its stockholders. The potential benefits considered by the Safety Shot board of directors in making the determination to consummate the distribution included the following:

● to provide each of Safety Shot and the Company with increased flexibility to fully pursue and fund its business plan, including capital expenditures, investments and acquisitions that would be more difficult to consider or effectuate in the absence of the distribution. This increased financial flexibility reflects the belief that investors in a company with the mix of assets that each of Safety Shot and the Company will own following the distribution will be more receptive to strategic initiatives that Safety Shot and the Company may respectively pursue;

● to create distinct and clear financial profiles and compelling investment cases. Investment in one or the other company may appeal to investors with different goals, interests and expectations. The distribution will allow investors to make independent investment decisions with respect to Safety Shot and the Company and may result in greater alignment between the interests of each company's stockholder base and the characteristics of its respective business, capital structure and financial results;

● to create independent equity securities and increased strategic opportunities. The distribution will afford Safety Shot and the Company the ability to offer their independent equity securities to the capital markets and enable each standalone company to use its own industry-focused stock to pursue portfolio enhancing acquisitions or other strategic opportunities that are more closely aligned with each company's strategic goals and expected growth opportunities;

● to facilitate incentive compensation arrangements for employees of each business more directly tied to the performance of the relevant company's business and enhance employee hiring and retention by, among other things, improving the alignment of management and employee incentives with performance and growth objectives of each of Safety Shot and the Company; and

● to increase the aggregate value of the stock of Safety Shot and the Company above the value that the stock of Safety Shot would have had if it had continued to represent an interest in both the businesses of Safety Shot and the Company, so as to: (i) allow each company to use its stock to pursue and achieve strategic objectives, including evaluating and effectuating acquisitions and increasing the long-term attractiveness of equity compensation programs in a significantly more efficient and effective manner with significantly less dilution to existing stockholders; and (ii) allow each company to offer a more focused investment profile to investors.

The Safety Shot board of directors also considered several factors that have a negative effect on Safety Shot as a result of the distribution. Safety Shot will have tax liabilities as a result of the distribution. The Safety Shot common stock may come under initial selling pressure as certain Safety Shot stockholders sell their shares because they are not interested in holding an investment in the remaining business of Safety Shot. In addition, the distribution would separate from Safety Shot the business and assets of the Company, which represent significant value. Safety Shot and its remaining business may need to absorb certain corporate and administrative costs previously provided to the Company. Finally, Safety Shot will not be eligible to consolidate the Company with its financial statements for reporting purposes.

The Safety Shot board of directors considered certain aspects of the distribution that may be adverse to the Company. The Company's Common Stock may come under initial selling pressure as certain Safety Shot stockholders sell their shares in the Company because they are not interested in holding an investment in the Company's business. As a result of the distribution, the Company will bear the incremental costs associated with being a publicly-held company and may need to absorb certain corporate and operational support costs previously provided by Safety Shot.

**Results of the Distribution**

Immediately after the distribution, we estimate that we will have in excess of 300 holders of record of our Common Stock and approximately 14,336,925 shares (14,486,925 shares if the underwriters exercise their over-allotment option in full), at an assumed public offering price of $4.00 per share.

In connection with the Distribution, we entered into the Separation and Exchange Agreement with Safety Shot, covering such areas as employee matters related to any shared employees, sharing of premises and other matters, including indemnification.

The Distribution will not affect the number of outstanding shares of Safety Shot Common Stock or any rights of Safety Shot stockholders.

**Tax Consequences of the Distribution**

The distribution will be a taxable event to holders of Safety Shot common stock. U.S. Holders will realize dividend income to the extent that the distribution is paid out of the current or accumulated earnings and profits of Safety Shot, then recover basis and possibly recognize capital gain to the extent that the distribution exceeds the current or accumulated earnings and profits of Safety Shot, Non-U.S. Holders will also realize dividend income, subject to 30% withholding, to the extent that the distribution is paid out of the current or accumulated earnings and profits of Safety Shot; however, Non-U.S. Holders with no presence in the United States should not realize capital gain to the extent that the distribution exceeds the current or accumulated earnings and profits of Safety Shot. Safety Shot may also recognize a capital gain on the Distribution. See "MATERIAL U.S. FEDERAL TAX CONSEQUENCES OF THE DISTRIBUTION OF, AND OF OWNING AND DISPOSING OF, OUR COMMON STOCK". The tax consequences of the distribution are complex and holders should consult their own tax advisors about these consequences.

**Listing and Trading of Our Common Stock**

Currently, our common stock is quoted on the OTCQB under the symbol "CBRA", and there is a limited market for our common stock. We intend to apply to list our common stock on The Nasdaq Capital Market ("NASDAQ") under the symbol "CBRA" No assurance can be given that our Common Stock will be approved for listing on NASDAQ and neither this offering nor the distribution will be completed if our Common Stock is not approved for listing.

**Reason for Furnishing this Prospectus**

This prospectus is being furnished by the Company and Safety Shot for the sale of shares in the offering and to provide information to holders of Safety Shot common stock in connection with the distribution. We and Safety Shot will not update the information in this prospectus except in the normal course of our and Safety Shot' respective public disclosure obligations and practices.

**RISK FACTORS**

*Investing in our securities is speculative and involves a high degree of risk. You should consider carefully the following risk factors, as well as the other information in this prospectus, including our consolidated financial statements and notes thereto, before you decide to purchase our securities. If any of the following risks actually occur, our business, financial condition, results of operations and prospects could be materially adversely affected, the value of our securities could decline, and you may lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below.*

**Risks Relating to the Separation**

***We may be unable to achieve some or all of the benefits that we expect to achieve from the Separation.***

 

We believe that, as a publicly traded company, we will be able to, among other things, better focus our financial and operational resources on our specific shipping business, implement and maintain a capital structure designed to meet our specific needs, design and implement corporate strategies and policies that are targeted to our business, more effectively respond to industry dynamics and create effective incentives for our management and employees that are more closely tied to our business performance. However, by separating from Safety Shot, we may be more susceptible to market fluctuations and have less leverage with customers, and we may experience other adverse events. In addition, we may be unable to achieve some or all of the benefits that we expect to achieve as a separate company in the time we expect, if at all. The completion of the Separation will also require significant amounts of our management's time and effort, which may divert management's attention from operating and growing our business.

***We may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as a publicly traded company, and we may experience increased costs after the Separation.***

 ****

Following the Separation, we will need to provide internally or obtain from unaffiliated third parties some of the services we currently receive from Safety Shot. We may be unable to replace these services in a timely manner or on terms and conditions as favorable as those we receive from Safety Shot. We may be unable to successfully establish the infrastructure or implement the changes necessary to operate independently or may incur additional costs. If we fail to obtain the services necessary to operate effectively or if we incur greater costs in obtaining these services, our business, financial condition and results of operations may be adversely affected.

***We have a limited operating history as a publicly traded company, and our historical financial information is not necessarily representative of the results we would have achieved as a publicly traded company and may not be a reliable indicator of our future results.***

 ****

We derived the historical financial information included in this prospectus in part from Safety Shot's consolidated financial statements, and this information does not necessarily reflect the results of operations and financial position we would have achieved as a separate publicly traded company during the periods presented or those that we will achieve in the future. This is primarily because of the following factors:

● Prior to the Separation, we operated as part of Safety Shot's broader corporate organization, and Safety Shot performed various administrative functions for us and our historical financial information does not reflect allocations any of these costs from Safety Shot as they are not material.

● Our historical financial information does not reflect changes that we expect to experience in the future as a result of our separation from Safety Shot, including changes in our cost structure, personnel needs, tax structure, financing and business operations. As part of Safety Shot, we enjoyed certain benefits from Safety Shot's operating diversity, size, borrowing leverage and available capital for investments, and we may lose these benefits after the Separation. As a separate entity, we may be unable to purchase services and technologies or access capital markets on terms as favorable to us as those we obtained as part of Safety Shot prior to the Separation.

Following the Separation, we will also be responsible for the additional costs associated with being a publicly traded company, including costs related to corporate governance, investor and public relations and public reporting.

In addition, certain costs incurred by Safety Shot, including accounting, legal, occupancy, information technology and other shared services, have historically been provided to us by Safety Shot. During the year ended December 31, 2024, the Company began to provide most of these services ourselves. Therefore, our historical financial statements may not be indicative of our future performance as a separate publicly traded company. We cannot assure you that our operating results will continue at a similar level when we are a separate publicly traded company. For additional information about our past financial performance and the basis of presentation of our financial statements, see "Operating and Financial Review and Prospects" and our historical financial statements and the notes thereto included elsewhere in this prospectus.

***We may not be able to access the credit and capital markets at the times and in the amounts needed on acceptable terms.***

 ****

From time to time we may need to access the capital markets to obtain long-term and short-term financing. We have not previously accessed the capital markets as a separate public company, and our access to, and the availability of, financing on acceptable terms and conditions in the future will be impacted by many factors, including our financial performance, our credit ratings or absence thereof, the liquidity of the overall capital markets and the state of the economy. We cannot assure you that we will have access to the capital markets at the times and in the amounts needed or on terms acceptable to us.

***The distribution, together with certain related transactions, does not qualify as a transaction that is generally tax-free for U.S. federal income tax purposes, Safety Shot and its stockholders could be subject to significant tax liabilities.***

The Internal Revenue Service (the "IRS") could determine that the distribution, together with certain related transactions, should be treated as a taxable transaction. Safety Shot has not requested, and does not intend to request, a ruling from the IRS with respect to the treatment of the distribution or certain related transactions for U.S. federal income tax purposes.

If the distribution, together with certain related transactions, were to fail to qualify as a transaction that is generally tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Code, in general, Safety Shot would recognize taxable gain as if it had sold our Common Stock in a taxable sale for its fair market value, and Safety Shot stockholders and warrant holders who receive shares of our Common Stock in the distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.

***Our ability to operate our business effectively may suffer if we are unable to cost-effectively establish our own administrative and other support functions in order to operate as a stand-alone company after the expiration of our shared services and other intercompany agreements with Safety Shot.***

As an operating subsidiary of Safety Shot, we relied on administrative and other resources of Safety Shot, including information technology, accounting, finance, human resources and legal services, to operate our business. In connection with this offering, we entered into the Amended and Restated Exchange Agreement to retain the ability for specified periods to use certain of these Safety Shot resources. See the section titled "*Certain Relationships and Related Party Transactions*." These services may not be provided at the same level as when we were a subsidiary of Safety Shot, and we may not be able to obtain the same benefits that we received prior to this offering. These services may not be sufficient to meet our needs, and after our agreements with Safety Shot expire (which will generally occur within 12 months following the completion of this offering), we may not be able to replace these services at all or obtain these services at prices and on terms as favorable as we currently have with Safety Shot. We will need to create our own administrative and other support systems or contract with third parties to replace Safety Shot's systems. In addition, we have received informal support from Safety Shot, which may not be addressed in the Amended and Restated Exchange Agreement we entered into with Safety Shot, and the level of this informal support may diminish as we become a more independent company. Any failure or significant downtime in our own administrative systems or in Safety Shot's administrative systems during the transitional period could result in unexpected costs, impact our results and/or prevent us from paying our suppliers or employees and performing other administrative services on a timely basis.

***The insurance that we maintain may not fully cover all potential exposures.***

We maintain liability insurance but such insurance may not cover all risks associated with the hazards of our business and is subject to limitations, including deductibles and maximum liabilities covered. We are potentially at risk if one or more of our insurance carriers fail. Additionally, severe disruptions in the domestic and global financial markets could adversely impact the ratings and survival of some insurers. In the future, we may not be able to obtain coverage at current levels, and our premiums may increase significantly on coverage that we maintain.

***Some of our directors and executive officers own Safety Shot common stock or options to acquire Safety Shot common stock and hold positions with Safety Shot, which could cause conflicts of interest, or the appearance of conflicts of interest, that result in our not acting on opportunities we otherwise may have.***

Some of our directors and executive officers own Safety Shot common stock, restricted shares of Safety Shot stock or options to purchase Safety Shot common stock.

Ownership of Safety Shot common stock, restricted shares of Safety Shot common stock and options to purchase Safety Shot Common Stock by our directors and executive officers after this offering and the presence of executive officers or directors of Safety Shot on our board of directors could create, or appear to create, conflicts of interest with respect to matters involving both us and Safety Shot that could have different implications for Safety Shot than they do for us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute between Safety Shot and us regarding terms of the Amended and Restated Exchange Agreement governing the separation and the relationship between Safety Shot and us thereafter. Potential conflicts of interest could also arise if we enter into commercial arrangements with Safety Shot in the future. As a result of these actual or apparent conflicts of interest, we may be precluded from pursuing certain growth initiatives.

**Risks Related to Our Business**

***Caring Brands has a limited operating history, which makes it difficult to accurately evaluate our business prospects.***

 ****

We have a limited operating history upon which an evaluation of its business plan or performance and prospects can be made. The business and prospects of the Company must be considered in the light of the potential problems, delays, uncertainties and complications encountered in connection with a newly established business and new industry. The risks include, but are not limited to, the possibility that we will not be able to develop functional and scalable products and services, or that although functional and scalable, our products and services will not be economical to market; that our competitors hold proprietary rights that preclude us from marketing such products; that our competitors market a superior or equivalent product; that we are not able to upgrade and enhance our technologies and products to accommodate new features and expanded service offerings; or the failure to receive necessary regulatory clearances for our products. To successfully introduce and market our products at a profit, we must establish brand name recognition and competitive advantages for our products. There are no assurances that we can successfully address these challenges. If it is unsuccessful, we and our business, financial condition and operating results could be materially and adversely affected.

The current and future expense levels are based largely on estimates of planned operations and future revenues rather than experience. It is difficult to accurately forecast future revenues because our business is new and our market has not been developed. If our forecasts prove incorrect, the business, operating results and financial condition of the Company may be materially and adversely affected. Moreover, we may be unable to adjust our spending in a timely manner to compensate for any unanticipated reduction in revenues. As a result, any significant reduction in revenues may immediately and adversely affect our business, financial condition and operating results.

 ****

***Our financial situation creates doubt whether we will continue as a going concern****.*

Since inception, the Company has had no operations for the period from inception to December 31, 2024, and has a working capital deficiency. This deficiency and lack of operations raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurances that we will be able to achieve a level of revenue adequate to generate sufficient cash flow from operations or obtain funding from this offering or additional financing through private placements, public offerings and/or bank financing necessary to support our working capital requirements. To the extent that funds generated from any private placements, public offerings and/or bank financing are insufficient, we will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern. If adequate working capital is not available, we may be forced to discontinue operations, which would cause investors to lose their entire investment.

***If we are unable to keep up with rapid technological changes, our products may become obsolete.***

The market for our products is characterized by significant and rapid change. Although we will continue to expand our product line capabilities in order to remain competitive, research and discoveries by others may make our processes, products or brands less attractive or even obsolete.

***We may not have adequate capital to fund our business.***

If our entire original capital is fully expended and additional costs cannot be funded from borrowings or capital from other sources, then our financial condition, results of operations, and business performance would be materially adversely affected. We may not be able to raise needed additional capital or financing due to market conditions or for regulatory or other reasons. We cannot assure that we will have adequate capital to conduct our business.

***Competition could adversely affect our business.***

Our industry in general is competitive. It is possible that future competitors could enter our market, thereby causing us to lose market share and revenues. In addition, some of our current or future competitors may have significantly greater financial, technical, marketing and other resources than we do or may have more experience or advantages in the markets in which we will compete that will allow them to offer lower prices or higher quality products. If we do not successfully compete with these competitors, we could fail to develop market share and our future business prospects could be adversely affected.

***We may not be able to successfully compete against companies with substantially greater resources.***

The skin care and hair growth product markets are intensely competitive, and we expect competition to intensify further in the future. We are subject to intense competition from cosmetic company competitors who have been on the market longer than us and which are manufactured and marketed by competitors with more resources and brand recognition than us. We cannot assure you that our products will compete effectively and experience continuing and growing sales. As a supplier, we compete with several larger and better-known companies that specialize in supplying and distributing a vast array of consumer goods to retailers. Barriers to entry are relatively low, and current and new competitors can launch new products that compete in the marketplace. We currently or potentially compete with a number of other companies, including a number of large health and medical therapy, cosmetics, and consumer product brand name manufacturers that have greater financial and managerial resources, more experience in developing products, and greater name recognition than we have.

***If we are unable to develop and maintain our brand and reputation for our product offerings, our business and prospects could be materially harmed.***

Our business and prospects depend, in part, on developing and then maintaining and strengthening our brand and reputation in the markets we serve. If problems with our products cause our customers to have a negative experience or failure or delay in the delivery of our products to our customers, our brand and reputation could be diminished. If we fail to develop, promote and maintain our brand and reputation successfully, our business and prospects could be materially harmed.

***We depend heavily on key personnel, and turnover of key senior management could harm our business.***

Our future business and results of operations depend in significant part upon the continued contributions of our senior management personnel. If we lose their services or if they fail to perform in their current positions, or if we are not able to attract and retain skilled personnel as needed, our business could suffer. Significant turnover in our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend on the skills and abilities of these key personnel in managing the product acquisition, marketing and sales aspects of our business, any part of which could be harmed by turnover in the future. We may not have written employment agreements with all of our senior management. We do not have any key person insurance.

 ****

***We are subject to government regulation, and unfavorable changes could substantially harm our business and results of operations***.

We are subject to general business regulations and laws as well as regulations and laws specifically governing our industries in the U.S. and other countries in which we operate. Uncertainty surrounding existing and future laws and regulations may impede our services and increase the cost of providing such services. These regulations and laws may cover taxation, tariffs, user pricing, distribution, consumer protection and the characteristics and quality of services.

***Our products may not meet health and safety standards or could become contaminated.***

We do not have control over all of the third parties involved in the manufacturing of our products and their compliance with government health and safety standards. Even if our products meet these standards, they could otherwise become contaminated. A failure to meet these standards or contamination could occur in our operations or those of our manufacturers, distributors or suppliers. This could result in expensive production interruptions, recalls and liability claims. Moreover, negative publicity could be generated from false, unfounded or nominal liability claims or limited recalls. Any of these failures or occurrences could negatively affect our business and financial performance.

***The sale of our products involves product liability and related risks that could expose us to significant insurance and loss expenses.***

We face an inherent risk of exposure to product liability claims if the use of our products results in, or is believed to have resulted in, illness or injury. Our products contain combinations of ingredients, and there is little long-term experience with the effect of these combinations. In addition, interactions of these products with other products, prescription medicines and over-the-counter treatments have not been fully explored or understood and may have unintended consequences.

Any product liability claim may increase our costs and adversely affect our revenue and operating income. Moreover, liability claims arising from a serious adverse event may increase our costs through higher insurance premiums and deductibles and may make it more difficult to secure adequate insurance coverage in the future. In addition, our product liability insurance may fail to cover future product liability claims, which, if adversely determined, could subject us to substantial monetary damages.

***The success of our business will depend upon our ability to create and expand our brand awareness.***

The skin care and hair growth markets we intend to compete in are highly competitive, with many well-known brands leading the industry. Our ability to compete effectively and generate revenue will be based upon our ability to create and expand awareness of our products distinct from those of our competitors. It is imperative that we are able to convey to consumers the benefits of our products. However, advertising and packaging and labeling of such products will be limited by various regulations. Our success will be dependent upon our ability to convey to consumers that our products are superior to those of our competitors.

***We must develop and introduce new products to succeed.***

Our industry is subject to rapid change. New products are constantly introduced to the market. Our ability to remain competitive depends in part on our ability to enhance existing products, to develop and manufacture new products in a timely and cost-effective manner, to accurately predict market transitions, and to effectively market our products. Our future financial results will depend to a great extent on the successful introduction of several new products. We cannot be certain that we will be successful in selecting, developing, manufacturing and marketing new products or in enhancing existing products.

The success of new product introductions depends on various factors, including, without limitation, the following:

● Successful sales and marketing efforts;

● Timely delivery of new products;

● Availability of raw materials;

● Pricing of raw materials;

● Regulatory allowance of the products; and

● Customer acceptance of new products

***We cannot assure you that we will develop additional products in the future.***

We have developed skin care and hair growth products lines. The lack of product diversity could adversely affect our financial condition and operating results and expose investors to a complete loss of their investment in us if our existing products fail to achieve sufficient sales to maintain us or enable us to earn a profit.

 ****

***Adverse publicity associated with our products or ingredients, or those of similar companies, could adversely affect our sales and revenue.***

Adverse publicity concerning any actual or purported failure by us to comply with applicable laws and regulations regarding any aspect of our business could have an adverse effect on the public perception of us. This, in turn, could negatively affect our ability to obtain financing, endorsers and attract distributors or retailers for our products, which would have a material adverse effect on our ability to generate sales and revenue.

Our distributors' and customers' perception of the safety and quality of our products or even similar products distributed by others can be significantly influenced by national media attention, publicized scientific research or findings, product liability claims and other publicity concerning our products or similar products distributed by others. Adverse publicity, whether or not accurate, that associates consumption of our products or any similar products with illness or other adverse effects, will likely diminish the public's perception of our products. Claims that any products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could have a material adverse effect on the market demand for our products, including reducing our sales and revenue.

***We do not have and may never have any products on the market that have been approved by the FDA for the treatment of disease. The labelling of Photocil was registered with the FDA and is an OTC product. The labelling of Photocil and Minoxidil Booster were approved by the Indian regulatory authorities. Our business is highly dependent upon complying with regulations for cosmetic and OTC product from various U.S. and international governmental agencies.***

If we decided to commercialize a product labelled for the treatment of any disease, we must obtain regulatory approvals of such treatment for that indication. Satisfying regulatory requirements is an expensive process that typically takes many years and involves compliance with requirements covering research and development, testing, manufacturing, quality control, labeling, and promotion of drugs for human use. To obtain necessary regulatory approvals, we must, among other requirements, complete clinical trials demonstrating that our products are safe and effective for a particular indication. There can be no assurance that our products will prove to be safe and effective, that our clinical trials will demonstrate the necessary safety and effectiveness of our product candidates, or that we will succeed in obtaining regulatory approval for any treatment we develop even if such safety and effectiveness are demonstrated. Our current products comply with the FDA requirements for cosmetic/OTC products and do not require additional clinical trials or FDA approval for their sale.

Any delays or difficulties we encounter in future clinical trials may delay or preclude regulatory approval from the FDA or from international regulatory organizations. Any delay or preclusion of regulatory approval would be expected to delay or preclude the commercialization of future products. Examples of delays or difficulties that we may encounter in our clinical trials include without limitation the following:

● Clinical trials may not yield sufficiently conclusive results for regulatory agencies to approve the use of our products;

● Our products may fail to be more effective than current therapies, or to be effective at all;

● We may discover that our products have adverse side effects, which could cause our products to be delayed or precluded from receiving regulatory approval or otherwise expose us to significant commercial and legal risks;

● It may take longer than expected to determine whether or not a treatment is effective;

● Patients involved in our clinical trials may suffer severe adverse side effects even up to death, whether as a result of treatment with our products, the withholding of such treatment, or other reasons (whether within or outside of our control);

● We may fail to be able to enroll a sufficient number of patients in our clinical trials;

● Patients enrolled in our clinical trials may not have the characteristics necessary to obtain regulatory approval for a particular indication or patient population;

● We may be unable to produce sufficient quantities of product to complete the clinical trials;

● Even if we are successful in our clinical trials, any required governmental approvals may still not be obtained or, if obtained, may not be maintained;

● If approval for commercialization is granted, it is possible the authorized use will be more limited than is necessary for commercial success, or that approval may be conditioned on completion of further clinical trials or other activities, which will cause a substantial increase in costs and which we might not succeed in performing or completing; and

● If granted, approval may be withdrawn or limited if problems with our products emerge or are suggested by the data arising from their use or if there is a change in law or regulation.

Any success we may achieve at a given stage of our clinical trials does not guarantee that we will achieve success at any subsequent stage, including without limitation final FDA approval.

We may encounter delays or rejections in the regulatory approval process because of additional government regulation resulting from future legislation or administrative action, or from changes in the policies of the FDA or other regulatory bodies during the period of product development, clinical trials, or regulatory review. Failure to comply with applicable regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products, total or partial suspension of production, or an injunction preventing certain activity, as well as other regulatory action against our product candidates or us. We have no experience in successfully obtaining regulatory approval for a product and thus may be poorly equipped to gauge, and may prove unable to manage, risks relating to obtaining such approval.

Our Hair Enzyme Booster (JW-700), previously known as Minoxidil Booster, was initially developed by Applied Biology Inc. and was acquired by Safety Shot (then Jupiter Wellness) in June 2022 through an asset purchase agreement. The product received labelling approval as a cosmetic from the Central Drugs Standard Control Organization (CDSCO), in compliance with India's cosmetic product guidelines, and is currently being manufactured and sold in India through our agreement with Cosmofix and San Pellegrino Cosmetics. Hair Enzyme Booster (JW-700) was launched on Amazon on October 28, 2024, and became available on NOVODX's e-commerce platform on December 11, 2024. We are currently in the early stages of commercialization and are refining our marketing strategies for both platforms. Sales have been minimal during this initial soft launch period as we optimize our marketing approach and distribution channels. As of the date of this prospectus, the Hair Enzyme Booster (JW-700) is currently only for sale on Amazon.

Outside the U.S., including India, our ability to market a product is contingent upon receiving clearances from appropriate non-U.S. regulatory authorities. Non-U.S. regulatory approval typically includes all of the risks associated with FDA clearance discussed above as well as geopolitical uncertainties and the additional uncertainties and potential prejudices faced by U.S. pharmaceutical companies conducting business abroad. In certain cases, pricing restrictions and practices can make achieving even limited profitability very difficult.

***We have limited experience in completing regulatory filings and any delays in regulatory filings could materially affect our financial condition.***

Although we have significant expertise in developing products and working with external manufacturers we have limited experience in obtaining marketing approvals, manufacturing or conduct sales and marketing activities necessary for the successful commercialization of a product. Consequently, we have no historical basis as a company by which one can evaluate or predict reliably our future success or viability.

Additionally, while our team has experience at prior companies with regulatory filings, we have limited experience with regulatory filings with agencies such as the FDA or the European Medicines Agency, or EMA, and will rely on third-party expertise to help us. Any delay in our regulatory filings for our product candidates, and any adverse development or perceived adverse development with respect to the applicable regulatory authority's review of such filings, including, without limitation, the FDA's issuance of a "refuse to file" letter or a request for additional information, could materially affect our financial condition.

***If serious adverse or undesirable side effects are identified during the development of our product candidates, we may abandon or limit our development or commercialization of such product candidates.***

If our product candidates are associated with undesirable side effects or have unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.

***If we experience delays or difficulties in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented, which could materially affect our financial condition.***

The timing of any future clinical trials depends on our ability to recruit patients to participate as well as to subsequently dose these patients and complete required follow-up periods.

In addition, we may experience enrollment delays related to increased or unforeseen regulatory, legal and logistical requirements at certain clinical trial sites. These delays could be caused by reviews by regulatory authorities and contractual discussions with individual clinical trial sites. Any delays in enrolling and/or dosing patients in our planned clinical trials could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or in termination of the clinical trials altogether.

Patient enrollment may be affected if our competitors have ongoing clinical trials with products for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in our competitors' clinical trials. Patient enrollment may also be affected by other factors, including:

● coordination with clinical research organizations to enroll and administer the clinical trials;

● coordination and recruitment of collaborators and investigators at individual sites;

● size of the patient population and process for identifying patients;

● design of the clinical trial protocol;

● eligibility and exclusion criteria;

● perceived risks and benefits of the product candidates under study;

● availability of competing commercially available therapies and other competing products' clinical trials;

● time of year in which the trials are initiated or conducted;

● severity of the diseases under investigation;

● ability to obtain and maintain subject consents;

● ability to enroll and treat patients in a timely manner;

● risk that enrolled subjects will drop out before completion of the trials;

● proximity and availability of clinical trial sites for prospective patients;

● ability to monitor subjects adequately during and after treatment; and

● patient referral practices of physicians.

Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which could materially affect our financial condition.

***If we or our licensees, development collaborators, or suppliers are unable to manufacture our products in sufficient quantities or at defined quality specifications, or are unable to obtain regulatory approvals for the manufacturing facility, we may be unable to develop or meet demand for our products and lose time to market and potential revenues.***

Completion of our clinical trials and commercialization of our product candidates require access to, or development of, facilities to manufacture a sufficient supply of our product candidates. We intend to utilize third parties to manufacture NoStingz, Photocil, CB-101 and the Hair Enzyme Booster (JW-700).

In the future we may become unable, for various reasons, to rely on our sources for the manufacture of our product candidates, either for clinical trials or, at some future date, for commercial distribution. We may not be successful in identifying additional or replacement third-party manufacturers, or in negotiating acceptable terms with any we do identify. We may face competition for access to these manufacturers' facilities and may be subject to manufacturing delays if the manufacturers give other clients higher priority than they give to us. Even if we are able to identify an additional or replacement third-party manufacturer, the delays and costs associated with establishing and maintaining a relationship with such manufacturer may have a material adverse effect on us.

Before we can begin to commercially manufacture CB-101 or any other product candidate, we must obtain regulatory approval of the manufacturing facility and process. Manufacturing of drugs for clinical and commercial purposes must comply with current Good Manufacturing Practices requirements, commonly known as "cGMP." The cGMP requirements govern quality control and documentation policies and procedures. Complying with cGMP and non-U.S. regulatory requirements will require that we expend time, money, and effort in production, recordkeeping, and quality control to ensure that the product meets applicable specifications and other requirements. We, or our contracted manufacturing facility, must also pass a pre-approval inspection prior to FDA approval. Failure to pass a pre-approval inspection may significantly delay or prevent FDA approval of our products. If we fail to comply with these requirements, we would be subject to possible regulatory action and may be limited in the jurisdictions in which we are permitted to sell our products and will lose time to market and potential revenues.

***It is uncertain whether product liability insurance will be adequate to address product liability claims, or that insurance against such claims will be affordable or available on acceptable terms in the future.***

Clinical research involves the testing of new drugs on human volunteers pursuant to a clinical trial protocol. Such testing involves a risk of liability for personal injury to or death of patients due to, among other causes, adverse side effects, improper administration of the new drug, or improper volunteer behavior. Claims may arise from patients, clinical trial volunteers, consumers, physicians, hospitals, companies, institutions, researchers, or others using, selling, or buying our products, as well as from governmental bodies. In addition, product liability and related risks are likely to increase over time, in particular upon the commercialization or marketing of any products by us or parties with which we enter into development, marketing, or distribution collaborations. Although we are contracting for general liability insurance in connection with our ongoing business, there can be no assurance that the amount and scope of such insurance coverage will be appropriate and sufficient in the event any claims arise, that we will be able to secure additional coverage should we attempt to do so, or that our insurers would not contest or refuse any attempt by us to collect on such insurance policies. Furthermore, there can be no assurance that suitable product liability insurance (at the clinical stage and/or commercial stage) will continue to be available on terms acceptable to us or at all, or that, if obtained, the insurance coverage will be appropriate and sufficient to cover any potential claims or liabilities.

***If the market opportunities for our current and potential future drug candidate***s ***are smaller than we believe they are, our ability to generate product revenues may be adversely affected and our business may suffer.***

Our understanding of the number of people who suffer from dermatitis or eczema, whom CB-101 may have the potential to treat, is based upon current market estimates.

***If we are unable to establish relationships with licensees or collaborators to carry out sales, marketing, and distribution functions or to create effective marketing, sales, and distribution capabilities, we will be unable to market our products successfully.***

Our business strategy may include out-licensing product candidates to or collaborating with larger firms with experience in marketing and selling pharmaceutical products. There can be no assurance that we will successfully be able to establish marketing, sales, or distribution relationships with any third-party, that such relationships, if established, will be successful, or that we will be successful in gaining market acceptance for any products we might develop. To the extent that we enter into any marketing, sales, or distribution arrangements with third parties, our product revenues per unit sold are expected to be lower than if we marketed, sold, and distributed our products directly, and any revenues we receive will depend upon the efforts of such third parties.

If we are unable to establish such third-party marketing and sales relationships, or choose not to do so, we would have to establish in-house marketing and sales capabilities. To market any products directly, we would have to establish a marketing, sales, and distribution force that has technical expertise and could support a distribution capability. Competition in the biopharmaceutical industry for technically proficient marketing, sales, and distribution personnel is intense and attracting and retaining such personnel may significantly increase our costs. There can be no assurance that we will be able to establish internal marketing, sales, or distribution capabilities or that these capabilities will be sufficient to meet our needs.

***Our ability to market our products in the United States depends on their regulatory classification and compliance with applicable regulations.***

While we believe our products either qualify as cosmetics or comply with applicable USP monographs, the FDA may disagree with our determinations. If the FDA determines that any of our products require pre-market approval or do not comply with applicable monographs, we may need to:

---

| |
|:---|
| Reformulate products |
| Undergo FDA approval process |
| Submit additional data |
| Cease marketing until compliance is achieved |
| Face enforcement action |

---

Such events could significantly impact our operations and ability to generate revenue.

***Commercial success of our OTC/Cosmetic product candidates will depend on the acceptance of these products by physicians, payers, and patients.***

Any of our OTC/Cosmetic product candidate that we may develop, may not gain market acceptance among physicians and patients. Market acceptance of and demand for any of our OTC/Cosmetic product candidates that we may develop will depend on many factors, including without limitation:

● Comparative superiority of the effectiveness and safety in the treatment of the disease indication compared to alternative treatments;

● Less prevalence and severity of adverse side effects;

● Potential advantages over alternative treatments;

● Cost effectiveness;

● Convenience and ease of administration;

● Sufficient third-party coverage and/or reimbursement;

● Strength of sales, marketing and distribution support; and

● Our ability to provide acceptable evidence of safety and efficacy.

If any non-OTC product candidate developed by us receives regulatory approval but does not achieve an adequate level of market acceptance by physicians, payers, and patients, we may generate insufficient, little, or no product revenue and may not become profitable.

In addition, pandemics, such as COVID-19, could decrease consumer spending and adversely affect demand for our products.

***If we obtain FDA approval for any of our product candidates, we will be subject to various federal and state fraud and abuse laws; these laws may impact, among other things, our proposed sales, marketing and education programs. Fraud and abuse laws are expected to increase in breadth and in detail, which will likely increase our operating costs and the complexity of our programs to insure compliance with such enhanced laws.***

If we obtain FDA approval for any of our product candidates and begin commercializing those products in the U.S., our operations may be directly, or indirectly through our customers, distributors, or other business partners, subject to various federal and state fraud and abuse laws, including, without limitation, anti-kickback statutes and false claims statutes which may increase our operating costs. These laws may impact, among other things, our proposed sales, marketing and education programs.

***If our operations are found to be in violation of any of the federal and state fraud and abuse laws or any other governmental regulations that apply to us, we may be subject to criminal actions and significant civil monetary penalties, which would adversely affect our ability to operate our business and our results of operations.***

If our operations are found to be in violation of any of the federal and state fraud and abuse laws, including, without limitation, anti-kickback statutes and false claims statutes or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our product candidates are ultimately sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.

***Natural disasters and other events beyond our control could materially adversely affect us.***

Natural disasters or other catastrophic events may cause damage or disruption to our operations, international commerce and the global economy, and thus could have a strong negative effect on us. Our business operations are subject to interruption by natural disasters, fire, power shortages, pandemics and other events beyond our control. Such events could make it difficult or impossible for us to deliver our services to our customers and could decrease demand for our services. The World Health Organization declared the COVID-19 outbreak a pandemic. The extent of the impact of any similar outbreak, the impact on our customers and employees, may be uncertain and we may not be able to predict the impact on our business and operations.

***We may not meet our product development and commercialization milestones.***

We have established milestones, based upon our expectations regarding our technologies at that time, which we use to assess our progress toward developing our products. These milestones relate to technology and design improvements as well as dates for achieving development goals. If our products exhibit technical defects or are unable to meet cost or performance goals, our commercialization schedule could be delayed and potential purchasers of our initial commercial products may decline to purchase such products or may opt to pursue alternative products.

We may also experience shortages equipment due to manufacturing difficulties. Multiple suppliers provide the components used in manufacturing our products. Our manufacturing operations could be disrupted by fire, earthquake or other natural disaster, a labor-related disruption, failure in supply or other logistical channels, electrical outages or other reasons. If there were a disruption to manufacturing facilities, we would be unable to manufacture until we have restored and re-qualified our manufacturing capability or developed alternative manufacturing facilities.

***Our operations in international markets involve inherent risks that we may not be able to control.***

Our business plan includes the marketing and sale of our proposed products in international markets. Accordingly, our results could be materially and adversely affected by a variety of uncontrollable and changing factors relating to international business operations, including:

● Macroeconomic conditions adversely affecting geographies where we intend to do business;

● Foreign currency exchange rates;

● Political or social unrest or economic instability in a specific country or region;

● Higher costs of doing business in foreign countries;

● Infringement claims on foreign patents, copyrights or trademark rights;

● Difficulties in staffing and managing operations across disparate geographic areas;

● Difficulties associated with enforcing agreements and intellectual property rights through foreign legal systems;

● Trade protection measures and other regulatory requirements, which affect our ability to import or export our products from or to various countries;

● Adverse tax consequences;

● Unexpected changes in legal and regulatory requirements;

● Military conflict, terrorist activities, natural disasters and medical epidemics; and

● Our ability to recruit and retain channel partners in foreign jurisdictions.

**Risks Related to our Financial Position and Capital Needs**

***Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or other assets.***

We may seek additional capital through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing ownership interests will be diluted and the terms of such financings may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financings may be coupled with an equity component, such as warrants to purchase shares, which could also result in dilution of our existing stockholders' ownership. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on such indebtedness, we could lose such assets and intellectual property.

***Our potential for rapid growth and our entry into new markets make it difficult for us to evaluate our current and future business prospects, and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment and could harm our business, financial condition, results of operations and cash flow.***

Our proliferation into new markets may place a significant strain on our resources and increase demands on our executive management, personnel and systems, and our operational, administrative and financial resources may be inadequate. We may also not be able to effectively manage any expanded operations, or achieve planned growth on a timely or profitable basis, particularly if the number of customers using our technology significantly increases or their demands and needs change as our business expands. If we are unable to manage expanded operations effectively, we may experience operating inefficiencies, the quality of our products and services could deteriorate, and our business and results of operations could be materially adversely affected.

***Changes in tax laws and unanticipated tax liabilities could adversely affect our effective income tax rate and ability to achieve profitability.***

Our effective income tax rate in the future could be adversely affected by a number of factors including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities and changes in tax laws. We regularly assess all of these matters to determine the adequacy of our tax provision which is subject to discretion. If our assessments are incorrect, it could have an adverse effect on our business and financial condition. There can be no assurance that income tax laws and administrative policies with respect to the income tax consequences generally applicable to us or to our subsidiaries will not be changed in a manner which adversely affects our shareholders.

**Risks Related to our Intellectual Property**

***We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.***

A third party may sue us or one of our strategic collaborators for infringing its intellectual property rights. Likewise, we may need to resort to litigation to enforce licensed rights or to determine the scope and validity of third-party intellectual property rights.

The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation would divert our efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. If we do not prevail in this type of litigation, we or our strategic collaborators may be required to pay monetary damages; stop commercial activities relating to the affected products or services; obtain a license in order to continue manufacturing or marketing the affected products or services; or attempt to compete in the market with a substantially similar product.

Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue some of our operations. In addition, a court may require that we pay expenses or damages, and litigation could disrupt our commercial activities.

***Any inability to protect our intellectual property rights could reduce the value of our products and brands, which could adversely affect our financial condition, results of operations and business.***

Our business is partly dependent upon our trademarks, trade secrets, copyrights and other intellectual property rights. Effective intellectual property rights protection, however, may not be available under the laws of every country in which we and our sub-licensees may operate. There is a risk of certain valuable trade secrets, beyond what is described publicly in patents, being exposed to potential infringers. Regardless of our technology being protected by patents or otherwise, there is a risk that other companies may employ the technology without authorization and without recompensing us.

The efforts we have taken to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectual property rights could harm our business or our ability to compete. In addition, protecting our intellectual property rights is costly and time consuming. There is a risk that we may have insufficient resources to counter adequately such infringements through negotiation or the use of legal remedies. It may not be practicable or cost effective for us to fully protect our intellectual property rights in some countries or jurisdictions. If we are unable to successfully identify and stop unauthorized use of our intellectual property, we could lose potential revenue and experience increased operational and enforcement costs, which could adversely affect our financial condition, results of operations and business.

***The intellectual property behind our products may include unpublished know-how as well as existing and pending intellectual property protection. All intellectual property protection eventually expires, and unpublished know-how is dependent on key individuals.***

The commercialization of our licensed products is partially dependent upon know-how and trade secrets held by certain individuals working with and for us. Because the expertise runs deep in these few individuals, if something were to happen to any or all of them, the ability to properly manufacture our products without compromising quality and performance could be diminished greatly.

Knowledge published in the form of any future intellectual property has finite protection, as all patents and trademarks have a limited life and an expiration date. While continuous efforts will be made to apply for patents and trademarks if appropriate, there is no guarantee that additional patents or trademarks will be granted. The expiration of patents and trademarks relating to our products may hinder our ability to sub-license or sell our products for a long period of time without the development of a more complex licensing strategy.

 ****

 ****

***If we are not able to adequately protect our intellectual property, then we may not be able to compete effectively, and we may not be profitable.***

Our existing proprietary rights may not afford remedies and protections necessary to prevent infringement, reformulation, theft, misappropriation and other improper use of our products by competitors. We own the formulations contained in our products and we consider these product formulations to be our critical proprietary property, which must be protected from competitors. Although trade secret, trademark, copyright and patent laws generally provide a certain level of protection, and we attempt to protect ourselves through contracts with manufacturers of our products, we may not be successful in enforcing our rights. In addition, enforcement of our proprietary rights may require lengthy and expensive litigation. We have attempted to protect some of the trade names and trademarks used for our products by registering them with the U.S. Patent and Trademark Office, but we must rely on common law trademark rights to protect our unregistered trademarks. Common law trademark rights do not provide the same remedies as are granted to federally registered trademarks, and the rights of a common law trademark are limited to the geographic area in which the trademark is actually used. Our inability to protect our intellectual property could have a material adverse impact on our ability to compete and could make it difficult for us to achieve a profit.

**Risks Related to Ownership of Our Securities**

***We are an "emerging growth company" and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.***

We are an "emerging growth company" as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

***The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we are no longer an "emerging growth company."***

We are required to comply with various regulatory and reporting requirements, including those required by the SEC. Complying with these reporting and other regulatory requirements is time-consuming and results in increased costs to us and could have a negative effect on our results of operations, financial condition or business.

As a public company, we are subject to the reporting requirements of the Exchange Act and the requirements of the Sarbanes-Oxley Act. These requirements may place a strain on our systems and resources. The Exchange Act requires that we file annual, quarterly and current reports with respect to our business and financial condition. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal controls over financial reporting. To maintain and improve the effectiveness of our disclosure controls and procedures, we will need to commit significant resources, hire additional staff and provide additional management oversight. We will be implementing additional procedures and processes for the purpose of addressing the standards and requirements applicable to public companies. Sustaining our growth also will require us to commit additional management, operational and financial resources to identify new professionals to join our firm and to maintain appropriate operational and financial systems to adequately support expansion. These activities may divert management's attention from other business concerns, which could have a material adverse effect on our results of operations, financial condition or business.

As an "emerging growth company" as defined in the JOBS Act, we intend to take advantage of certain temporary exemptions from various reporting requirements including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We may also delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, as permitted by the JOBS Act.

 ****

 ****

***Our management has limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our Company.***

The management team is responsible for the operations and reporting of the Company. The requirements of operating as a public company are many and sometimes difficult to navigate. This may require us to obtain outside assistance from legal, accounting, investor relations, or other professionals that could be more costly than planned. If we lack cash resources to cover these costs of being a public company in the future, our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our potential results of operations, cash flow and financial condition after we commence operations.

***Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.***

Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 and new regulations from the SEC, have created uncertainty for public companies such as ours. These laws, regulations, and standards are subject to varying interpretations in many cases, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations, and standards have resulted in, and are likely to continue to result in, increased expense and significant management time and attention.

***Certain of our stockholders hold a significant percentage of our outstanding voting securities, which could reduce the ability of minority stockholders to effect certain corporate actions.***

Our officers and directors are the beneficial owners of approximately 59.6% of our outstanding voting securities. As a result, they possess significant influence over our elections and votes. As a result, their ownership and control may have the effect of facilitating and expediting a future change in control, merger, consolidation, takeover or other business combination, or encouraging a potential acquirer to make a tender offer. Their ownership and control may also have the effect of delaying, impeding, or preventing a future change in control, merger, consolidation, takeover or other business combination, or discouraging a potential acquirer from making a tender offer.

***If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price could decline.***

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Once our common stock is quoted, if one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline.

***Our issuance of additional common stock or preferred stock may cause our common stock price to decline, which may negatively impact your investment.***

Issuances of a substantial number of additional shares of our common or preferred stock, or the perception that such issuances could occur, may cause prevailing market prices for our common stock to decline. In addition, our board of directors is authorized to issue additional series of shares of preferred stock without any action on the part of our stockholders. Our board of directors also has the power, without stockholder approval, to set the terms of any such series of shares of preferred stock that may be issued, including voting rights, conversion rights, dividend rights, preferences over our common stock with respect to dividends or if we liquidate, dissolve or wind up our business and other terms. If we issue cumulative preferred stock in the future that has preference over our common stock with respect to the payment of dividends or upon our liquidation, dissolution or winding up, or if we issue preferred stock with voting rights that dilute the voting power of our common stock, the market price of our common stock could decrease.

***Our common stock may become subject to the SEC's penny stock rules and accordingly, broker-dealers may experience difficulty in completing customer transactions and trading activity in our securities may be adversely affected.***

The SEC has adopted regulations, which generally define "penny stock" to be an equity security that has a market price of less than $5.00 per share, subject to specific exemptions. The market price of our common stock is less than $5.00 per share and therefore would be a "penny stock" according to SEC rules, unless we are listed on a national securities exchange. Under these rules, broker-dealers who recommend such securities to persons other than institutional accredited investors must:

● Make a special written suitability determination for the purchaser;

● Receive the purchaser's prior written agreement to the transaction;

● Provide the purchaser with risk disclosure documents which identify certain risks associated with investing in "penny stocks" and which describe the market for these "penny stocks" as well as a purchaser's legal remedies; and

● Obtain a signed and dated acknowledgment from the purchaser demonstrating that the purchaser has actually received the required risk disclosure document before a transaction in a "penny stock" can be completed.

Although our common stock is not currently subject to these rules, it were to become subject to such rules, broker-dealers may find it difficult to effectuate customer transactions and trading activity in our securities may be adversely affected. As a result, the market price of our securities may be depressed, and you may find it more difficult to sell your securities.

***If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and have an adverse effect on the value of our securities.***

As a public company, we would be required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Further, we will be required to report any changes in internal controls on a quarterly basis. In addition, we would be required to furnish a report by management on the effectiveness of internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. We will design, implement, and test the internal controls over financial reporting required to comply with these obligations. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of its internal control over financial reporting when required, investors may lose confidence in the accuracy and completeness of our financial reports and the value of our securities could be negatively affected. We also could become subject to investigations by the Commission or other regulatory authorities, which could require additional financial and management resources.

***As an emerging growth company, our auditor will not be required to attest to the effectiveness of our internal controls.***

 ****

Our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting while we are an emerging growth company. This means that the effectiveness of our financial operations may differ from our peer companies in that they may be required to obtain independent registered public accounting firm attestations as to the effectiveness of their internal controls over financial reporting and we are not. While our management will be required to attest to internal control over financial reporting and we will be required to detail changes to our internal controls on a quarterly basis, we cannot provide assurance that the independent registered public accounting firm's review process in assessing the effectiveness of our internal controls over financial reporting, if obtained, would not find one or more material weaknesses or significant deficiencies. Further, once we cease to be an emerging growth company and cease to be a smaller reporting company (as described below), we will be subject to independent registered public accounting firm attestation regarding the effectiveness of our internal controls over financial reporting. Even if management finds such controls to be effective, our independent registered public accounting firm may decline to attest to the effectiveness of such internal controls and issue a qualified report.

***Concurrent resale and potential dilution of stockholders' ownership.***

The resale of shares by the selling stockholders, pursuant to the Resale Prospectus, could adversely impact the market price, liquidity, and demand for our common stock. As these shares are introduced into the market, there may be a significant increase in the number of shares available for sale, which could result in downward pressure on our stock price and affect liquidity. Furthermore, as the resale shares are sold, the ownership percentage of existing stockholders will be diluted, potentially reducing the value of their holding. The extent of this dilution may vary depending on the timing and volume of resale transactions by the selling stockholders.

Further, the Selling Stockholders must sell their shares at a fixed price per share of $4.00, which is the per share price of the shares being offered under this prospectus, until such time as our shares are listed on a national securities exchange. Thereafter, the shares offered by the Resale Prospectus may be sold by the Selling Stockholders from time to time in the open market, through privately negotiated transactions or a combination of these methods, at market prices prevailing at the time of sale or at negotiated prices. Hence resale offering may occur at prices above or below the price at which our securities are initially offered under this prospectus.

**Risks Related to This Offering and Other Risks**

***Our management has limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our Company.***

The management team is responsible for the operations and reporting of the Company. The requirements of operating as a public company are many and sometimes difficult to navigate. This may require us to obtain outside assistance from legal, accounting, investor relations, or other professionals that could be more costly than planned. If we lack cash resources to cover these costs of being a public company in the future, our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our potential results of operations, cash flow and financial condition after we commence operations.

***Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.***

Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 and new regulations from the SEC, have created uncertainty for public companies such as ours. These laws, regulations, and standards are subject to varying interpretations in many cases, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations, and standards have resulted in, and are likely to continue to result in, increased expense and significant management time and attention.

***If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price could decline.***

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Once our common stock is quoted, if one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline.

***We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.***

 ****

Prior to this offering, our common stock was not traded on any market. We are in the process of applying to have our common stock listed on the NASDAQ; however, even if our common stock is approved for listing on the NASDAQ, an active trading market for our shares may never develop or be sustained following this offering. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. The public offering price for our common stock will be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of the common stock after the offering. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the public offering price. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.

***We may not be able to satisfy listing requirements of the NASDAQ or obtain or maintain a listing of our common stock on the NASDAQ.***

 ****

If our common stock is listed on the NASDAQ, we must meet certain financial and liquidity criteria to maintain such listing. If we violate the NASDAQ listing requirements, our common stock may be delisted. If we fail to meet any of the NASDAQ's listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from the NASDAQ may materially impair our stockholders' ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment.

***Investing in our Company is highly speculative and could result in the entire loss of your investment.***

 ****

Purchasing the offered shares is highly speculative and involves significant risk. The offered shares should not be purchased by any person who cannot afford to lose their entire investment. Our business objectives are also speculative, and it is possible that we would be unable to accomplish them. Our shareholders may be unable to realize a substantial or any return on their purchase of the offered shares and may lose their entire investment. For this reason, each prospective purchaser of the offered shares should read this prospectus and all of its exhibits carefully and consult with their attorney, business and/or investment advisor.

***We do not intend to pay dividends for the foreseeable future.***

We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends on our common stock in the foreseeable future.

***Our issuance of additional common stock or preferred stock may cause our common stock price to decline, which may negatively impact your investment.***

Issuances of a substantial number of additional shares of our common or preferred stock, or the perception that such issuances could occur, may cause prevailing market prices for our common stock to decline. In addition, our board of directors is authorized to issue additional series of shares of preferred stock without any action on the part of our stockholders. Our board of directors also has the power, without stockholder approval, to set the terms of any such series of shares of preferred stock that may be issued, including voting rights, conversion rights, dividend rights, preferences over our common stock with respect to dividends or if we liquidate, dissolve or wind up our business and other terms. If we issue cumulative preferred stock in the future that has preference over our common stock with respect to the payment of dividends or upon our liquidation, dissolution or winding up, or if we issue preferred stock with voting rights that dilute the voting power of our common stock, the market price of our common stock could decrease.

***Anti-takeover provisions in the Company's charter and bylaws may prevent or frustrate attempts by stockholders to change the board of directors or current management and could make a third-party acquisition of the Company difficult.***

The Company's bylaws contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. Furthermore, the Board of Directors has the ability to increase the size of the Board and fill newly created vacancies without stockholder approval. These provisions could limit the price that investors might be willing to pay in the future for shares of the Company's common stock.

***The public offering price for our shares of common stock may not be indicative of prices that will prevail in the trading market and such market prices may be volatile.***

The public offering price for our shares of common stock may vary from the market price of our shares of common stock following our public offering. The financial markets in the United States and other countries have experienced significant price and volume fluctuations in the last few years. If you purchase our shares of common stock in our public offering, you may not be able to resell those shares at or above the public offering price. We cannot assure you that the public offering price of our shares of common stock, or the market price following our public offering, will equal or exceed prices in privately negotiated transactions of our shares that have occurred from time to time prior to our public offering. The market price for our shares of common stock may be volatile and subject to wide fluctuations due to factors such as:

● the
 financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;

● actual
 or anticipated fluctuations in our quarterly operating results;

● changes
 in financial estimates by securities research analysts;

● negative
 publicity, studies or reports;

● our
 capability to catch up with the technology innovations in the industry;

● announcements
 by us or our competitors of acquisitions, strategic business relationships, joint ventures or capital commitments; and

● addition
 or departure of key personnel.

In addition, the securities market has from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our shares of common stock.

**USE OF PROCEEDS**

We estimate that the net proceeds we will receive from the sale of our Common Stock in this offering, after deducting the underwriting discount and estimated offering expenses payable by us, will be $3,200,000, at an assumed public offering price of $4.00 per share. If the Representative exercises its option to purchase additional shares in full, we estimate our net proceeds will be $3,800,000, after deducting the underwriting discount and estimated offering expenses payable by us, at an assumed public offering price of $4.00 per share. We currently intend to use the net proceeds of this offering as follows:

---

| | | |
|:---|:---|:---|
| ● | Product Development | 1900000 |
|  | &nbsp;&nbsp;&nbsp;a) Hair Enzyme Booster (JW-700) | 700000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing setup | 500000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketing campaign | 200000 |
|  | &nbsp;&nbsp;&nbsp;b) Photocil | 505000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing scale-up | 300000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketing and sales launch | 200000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical testing | 5000 |
|  | &nbsp;&nbsp;&nbsp;c) CB-101 | 385000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development costs | 150000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial production | 80000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketing materials | 1500000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical testing | 5000 |
|  | &nbsp;&nbsp;&nbsp;d) NoStingz | 310000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reformulation completion | 75000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stability testing | 50000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial production | 180000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FDA registration/NDC number | 5000 |
| ● | Legal & Compliance | 100000 |
| ● | General & Administrative expenses | 250000 |
| ● | General working capital | 950000 |
|  |  | $3200000 |

---

The proceeds are anticipated to fund operations for approximately 12 months based on our current business plan and assumptions. This allocation aligns with the anticipated net proceeds (~$3,200,000) from the offering, after deducting underwriting discounts, commissions, and estimated offering expenses payable by us.

A $1.00 increase (decrease) in the assumed public offering price would increase (decrease) the net proceeds to us from this offering by $800,000, assuming the number of shares to be sold by us in this offering remains the same and after deducting the underwriting discount and estimated offering expenses payable by us. Each increase (decrease) of 100,000 shares in the number of shares offered by us would increase (decrease) the net proceeds to us by approximately $320,000, assuming that the assumed public offering price of $4.00 per share, remains the same, and after deducting the underwriting discount and estimated offering expenses payable by us.

**DIVIDEND POLICY**

We have not, since the date of our incorporation, declared or paid any dividends or other distributions on our shares of common stock, and do not currently have a policy with respect to the payment of dividends or other distributions. We do not currently pay dividends and do not intend to pay dividends in the foreseeable future. The declaration and payment of any dividends in the future is at the discretion of the Board and will depend on numerous factors, including compliance with applicable laws, financial performance, working capital requirements of the Company and its subsidiaries, as applicable and such other factors as its directors consider appropriate.

**CAPITALIZATION**

The following table sets forth our cash and cash equivalents and capitalization as of June 30, 2025:

● on an actual basis;

● on a pro forma basis to give effect to the granting of shares in exchange for services, which were not issued and outstanding as of the date of this offering.

● on a pro forma as adjusted basis to give effect to (i) the granting of shares in exchange for services, which are not issued and outstanding as of the date of this offering; and (ii) the issuance of 1,000,000 shares of Common Stock in this offering at an assumed public offering price of $4.00 per share, and the receipt of net proceeds of $ in this offering, assuming no exercise of the Representative's over-allotment option or the Representative's Warrants.

---

| | | | |
|:---|:---|:---|:---|
|  | **Actual<sup>(1)</sup>**<br> **(unaudited)** | **Pro** <br> **Forma<sup>(2)</sup>** <br> **(unaudited)**  | **Pro Forma as Adjusted<sup>(3)</sup> (unaudited)** |
| Cash and cash equivalents | $73893 | $73893 | $3273893 |
| Indebtedness: |  |  |  |
| &nbsp;&nbsp;&nbsp; Related party loan payable | 50000 | 50000 | 50000 |
| &nbsp;&nbsp;&nbsp; Total Debt | 50000 | 50000 | 50000 |
| Equity: |  |  |  |
| &nbsp;&nbsp;&nbsp;Common Stock, $0.001 par value (100,000,000 authorized, issued and outstanding: 13,336,925 actual<sup>(1)</sup> and pro forma<sup>(2)</sup>, and 14,536,925 pro forma as adjusted<sup>(3)</sup> | 13337 | 13337 | 14337 |
| &nbsp;&nbsp;&nbsp;Common stock payable | 382000 | 732000 | 732000 |
| &nbsp;&nbsp;&nbsp;Subscription receivable | (1600) | (1600) | (1600) |
| &nbsp;&nbsp;&nbsp;Retained earnings (deficit) | (2062144) | (2412144) | (2412144) |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 4773430 | 4773430 | 7972430 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Equity (Deficit) | 3105023 | 3105023 | 6305023 |
| Total capitalization | $3155023 | $3155023 | $6355023 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Taken
 from the consolidated financial statements for the period ended June 30, 2025.

(2) Proforma
 reflects the issuance of 200,000 shares to a consultant in exchange for services. The fair value of the shares on the date of the
 agreement was $1.75 per share.

(3) Proforma
 adjusted reflects the sale of 1,000,000 shares of common stock at an offering price of $4.00 per share with net proceeds of $3,200,000.

A $1.00 increase (decrease) in the assumed public offering price of $4.00 per share shown on the cover page of this prospectus, would increase (decrease) the amount of cash and cash equivalents, additional paid-in capital, total stockholders' equity (deficit) and total capitalization on an as adjusted basis by approximately $800,000, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and assuming no exercise of the Representative's over-allotment option or the Representative's Warrants. Similarly, each increase (decrease) of 100,000 shares offered by us would increase (decrease) cash and cash equivalents, total stockholders' equity (deficit) and total capitalization on an as adjusted basis by approximately $320,000, assuming the assumed public offering price remains the same after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and assuming no exercise of the Representative's over-allotment option or the Representative's Warrants.

**DILUTION**

If you invest in our Common Stock, your ownership interest will be diluted to the extent that the initial public offering price per share of our Common Stock exceeds the tangible book value per share of our Common Stock immediately following this offering.

Pro forma net tangible book value per share represents our total tangible assets (total assets less intangible assets) less total liabilities, divided by the outstanding shares of Common Stock. As of June 30, 2025, our net tangible book value was $(94,977), or ($0.01) per share. After giving effect to the sale and issuance of 1,000,000 shares of our Common Stock in this offering at an assumed public offering price of $4.00 per share, and after deducting the underwriting discount and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2025 would have been $3,105,023, or $0.22 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of $0.23 per share to our existing stockholder, Safety Shot, and an immediate dilution of $3.77 per share to new investors participating in this offering.

The following table illustrates this dilution on a per share basis to new investors:

---

| | |
|:---|:---|
| Assumed initial price to public per share | $4.00 |
| Pro forma net tangible book value per share as of June 30, 2025 <sup>(1)</sup> | $0.00 |
| Increase per share attributable to existing shareholders<sup>(2)</sup> | $0.23 |
| Pro forma as adjusted net tangible book value per share after this offering<sup>(3)</sup> | $0.23 |
| Dilution per share to new investors | $3.77 |

---

(1) Represents
 the net tangible book value of the combined total assets (total assets less intangible assets) less total liabilities divided by
 13,336,925 shares of Common Stock which includes 7,600,000 shares of Common Stock issued to the Founders.

(2) Represents
 the difference between pro forma as adjusted net tangible book value per share after this offering and pro forma net tangible book
 value per share as of June 30, 2025.

(3) Determined
 by dividing (i) pro forma as adjusted net tangible book value, which is our pro forma net tangible book value plus the cash proceeds
 of this offering at an assumed public offering price of $4.00 per share, and after deducting the underwriting discount and
 estimated offering expenses payable by us, by (ii) the total number of our shares of Common Stock to be outstanding following this
 offering.

The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.

Each $1.00 increase (decrease) in the assumed public offering price of $4.00 per share, would increase (decrease) our pro forma as adjusted net tangible book value by approximately $800,000, or approximately $0.06 per share, and increase (decrease) the dilution per share to investors participating in this offering by approximately $0.95 per share per $1.00 increase and $0.95 per share per $1.00 decrease, assuming that the number of shares offered by us remains the same and after deducting the underwriting discount and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase (decrease) of 100,000 in the number of shares offered by us would increase (decrease) our pro forma as adjusted net tangible book value by approximately $320,000, to $0.02 per share, and increase (decrease) the dilution per share to investors participating in this offering by approximately $0.02 per share per 100,000 share increase and $0.02 per share per 100,000 share decrease, assuming that the assumed public offering price remains the same, and after deducting the underwriting discount and estimated offering expenses payable by us.

If the Underwriters exercise the option to purchase additional shares in full, the pro forma as adjusted net tangible book value per share after this offering would be $0.25 per share, the incremental increase in the pro forma net tangible book value per share to our existing stockholders would be $0.19 per share and the pro forma dilution to new investors participating in this offering would be $3.78 per share.

The following table summarizes, on the pro forma as adjusted basis described above as of June 30, 2025, the differences between the number of shares of Common Stock purchased from us, the total consideration and the price per share paid by our existing stockholders and by investors participating in this offering at an assumed public offering price of $4.00 per share, before deducting the underwriting discount and estimated offering expenses payable by us.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Shares Purchased** | **Shares Purchased** | **Total Consideration** | **Total Consideration** | **Weighted-<br> Average Price Per** |
|  | **Number** | **Percent** | **Amount** | **Percent** | **Share** |
| Safety Shot | 3000000<sup>(1)</sup> | 20.9% | $3000<sup>(2)</sup> | 0.0% | $0.001 |
| Founder shares | 4600000 | 32.1% | 4600 | 0.0% | 0.001 |
| Private Placement | 2110000 | 14.7% | 2110000 | 21.6% | 1.000 |
| Asset Purchase | 3000000 | 20.9% | 3000000 | 30.8% | 1.000 |
| Shares issued for services | 625000 | 4.4% | 625000 | 6.4% | 1.000 |
| Recent Private Placement | 1925 | 0.0% | 7700 | 0.1% | 4.000 |
| Investors participating in this offering | 1000000 | 7.0% | 4000000 | 41.1% | 4.000 |
| Total | 14336925 | 100.0% | $9750300 | 100.0% | $0.680 |

---

(1) Represents
 the total number of shares of Common Stock issued to Safety Shot in connection with the Founders round of financing, of which 600,000
 will be dividended to Safety Shot shareholders.

(2) Represents
 the total consideration paid by Safety Shot for its purchase of the shares of Common Stock of Caring Brands Florida.

The number of shares of Common Stock held by existing stockholders (and related consideration amounts) and to be outstanding immediately after this offering in the table above is based on 13,336,925 shares of Common Stock outstanding as of June 30, 2025, which include the issuance of 3,000,000 shares of Common Stock to Safety Shot on March 15, 2024, in connection with the separation, assumes no exercise of the Representative's option to purchase up to 150,000 additional shares of our Common Stock, and no exercise of the Representative's Warrants to purchase up to 30,000 shares of Common Stock, and excludes approximately 2,000,000 shares of our Common Stock reserved for issuance under our equity incentive plan for our employees and directors.

If the Representative exercises its option to purchase additional shares of Common Stock in full in this offering, the number of shares of Common Stock held by new investors will increase to 862,500, or 6.1% of the total number of shares of Common Stock issued and outstanding after this offering, and the percentage of shares of Common Stock held by existing stockholders will decrease to 93.9% of the total shares of Common Stock issued and outstanding.

**CONSOLIDATED FINANCIAL STATEMENTS** 

The consolidated financial statements reflect the impact of the separation as described in the section titled "*Certain Relationships and Related Party Transactions—Relationship with Safety Shot—Historical Relationship with Safety Shot*".

We have operated as an operating subsidiary of Safety Shot since inception. Prior to the Separation, Safety Shot provided certain administrative services to us, and costs associated with these functions were not material and no adjustments were made to the proforma financial statements.

Following the completion of this offering, we will be subject to the reporting requirements of the Exchange Act. We will be required to establish procedures and practices as a stand-alone public company in order to comply with our obligations under the Exchange Act and related rules and regulations. As a result, we will incur additional costs, including accounting, legal, investor relations, stock administration and regulatory compliance costs. These additional costs may differ from the costs that were historically provided to us from Safety Shot. To operate as a stand-alone company, we expect to incur costs to replace certain services previously provided by Safety Shot, which may be higher than those reflected in our historical combined financial statements. A component of these costs are legal, accounting and administrative costs. Actual costs that may have been incurred had we been a stand-alone company depend on a number of factors, including organizational structure and decisions made relating to various areas such as information technology and infrastructure.

The financial statements consist of the consolidated financial statements of Caring Brands, Inc. (Nevada) (the "Successor") for the period from Inception (April 24, 2024) to December 31, 2024, giving effect to the acquisition of Caring Brands (Florida) and the financial statements of Caring Brands, Inc. (Florida) (the "Predecessor") for the period from January 1, 2024 to September 24, 2024.

On September 24, 2024, we entered into the Separation and Exchange Agreement with Safety Shot to govern the separation of our business from Safety Shot, Inc. Under the terms of the Agreement, Safety Shot. Inc. exchanged all of the unissued, issued and outstanding shares of common stock of the Predecessor in consideration of the Successor assuming all the obligations and liabilities related to the Caring Brands Business.

The following financial statements and the related notes should be read in conjunction with the sections titled "*Management's Discussion and Analysis of Financial Condition and Results of Operations*" and the audited financial statements of the Company and the related notes included elsewhere in this prospectus.

**Caring Brands, Inc.**

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
|  | **Successor** | **Predecessor** |
|  | **December 31, 2024** | **December 31, 2023** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $468998 | $18161 |
| Accounts receivable |  | 354 |
| Inventory | 13689 |  |
| Prepaid expenses and deposits | 44794 | 4400 |
| &nbsp;&nbsp;&nbsp;Total current assets | 527481 | 22915 |
| Intellectual property (net) a related party | 2850000 |  |
| Investment in NovoDX a related party | 500000 | - |
| &nbsp;&nbsp;&nbsp;Total other assets | 3350000 | - |
| &nbsp;&nbsp;&nbsp;Total assets | $3877481 | $22915 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $169432 | $20665 |
| Accrued expenses and other payables | 16673 | 1069 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 186105 | 21734 |
| Loans from Safety Shot, Inc. (Parent) | - | 266955 |
| &nbsp;&nbsp;&nbsp;Total Liabilities |  | 288689 |
| Equity<sup>(1):</sup> |  |  |
| Successor Common Stock, $0.001 par value, 100,000,000 authorized shares 13,110,000 issued and outstanding | 13110 |  |
| Predecessor Common Stock, none issued |  |  |
| Additional paid-in capital | 4541057 |  |
| Retained Earnings (Deficit) | (862791) | (265774) |
| &nbsp;&nbsp;&nbsp;Total equity (deficit) | 3691376 | (265774) |
| &nbsp;&nbsp;&nbsp;Total liabilities and equity | $3877481 | $22915 |

---

*See notes to consolidated financial statements.*

**Caring Brands, Inc.**

 **Statement of Operations**

---

| | | | |
|:---|:---|:---|:---|
|  | **Successor** | **Predecessor** | **Predecessor** |
|  | **April 24 to<br> December 31, 2024** | **January 1 to<br> September 24, 2024** | **Year ended<br> December 31, 2023** |
| Revenue | $465 | $- | $20421 |
| Cost of revenue | 2072 | - | 118874 |
| Gross profit | (1607) |  | (98453) |
| Operating expenses | 871214 | 654573 | 52941 |
| Gain on sale of assets |  |  | (23308) |
| Interest expense (income) | (10030 | 67 | - |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(862791 | $(654640 | $(128086 |
| Pro forma net income (loss) per share: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.07) | n/a | $n/a |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.07) | n/a | $n/a |
| Pro forma weighted-average shares used to compute net income (loss) per share |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 11737251 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 11737251 |  |  |

---

**Notes to Consolidated Financial Statements**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) In
 May, 2024, we entered into Securities Purchase Agreements with our Founders totaling 7,600,000 shares (the Founder Shares").
 For purposes of calculating the weighted average net loss per share, the Founder Shares are assumed to have been issued on the
 inception date (April 24, 2024), the private placement shares issued in May and June, 2024 and the Ebola License shares
 in June 2024, and the services agreement in September 2024.

**(2)** The
 Predecessor had no shares of its common stock issued and outstanding as it was a wholly owned subsidiary of Safety Shot, Inc.

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following management's discussion and analysis of our financial condition and results of operations ("MD&A") should be read in conjunction with our unaudited interim consolidated financial statements as of and for the six months ended June 30, 2025 and 2024, and our audited financial statements and related notes thereto as of and for the years ended December 31, 2024 and 2023 which includes the consolidated financial statement of the Successor for the period from April 24, 2024 to December 31, 2024, the financial statement of the Predecessor for the period from January 1, 2024 to September 24, 2024 and the financial statement of the Predecessor for the year ended December 31, 2023 (the "Financial Statements"). Unless the context indicates otherwise, references to "Caring Brands," "the Company," "we," "us," and "our" in this MD&A refer to Caring Brands, Inc. and its associated subsidiaries. All dollar amounts are in U.S. dollars unless otherwise stated.*

**Presentation**

The discussion of the financial statements presented herein represent the results of operations of the Successor for the period from April 24, 2024 to December 31, 2024 and the six months ended June 30, 2025, the Predecessor for the period from January 1, 2024 to September 24, 2024 and the Predecessor for the year ended December 31, 2023.

**Our Relationship with Safety Shot**

The Separation and Exchange Agreement described in "*Certain Relationships and Related Party Transactions—Relationship with Safety Shot—Arrangements Between Safety Shot and Our Company*." sets forth the terms and conditions of the Company's Separation from Safety Shot. We have operated as an operating subsidiary of Safety Shot since inception. Prior to the Separation, Safety Shot provided certain administrative services to us and costs associated with these functions were not material.

Following the completion of this offering, we will be subject to the reporting requirements of the Exchange Act. We will be required to establish procedures and practices as a stand-alone public company in order to comply with our obligations under the Exchange Act and related rules and regulations. As a result, we may incur additional costs, including investor relations, stock administration and regulatory compliance costs. These additional costs may differ from the costs that were historically provided to us from Safety Shot. To operate as a stand-alone company, we may incur costs which may be higher than those reflected in our historical combined financial statements.

**Our Current Operations and Plan of Operations**

Set forth below is a description of our operations related to each of our products, and the plan of operations for each going forward.

**Hair Enzyme Booster (JW-700)**

Initial soft launch in the U.S markets was completed on October 28, 2024, through sales initiating on Amazon and December 11, 2024, on NOVODX. As of the date of this prospectus, the Hair Enzyme Booster (JW-700) is currently only for sale on Amazon. We plan to set up the manufacturing and develop initial marketing materials by the first quarter of 2026. Between the fourth quarter of 2025 and first quarter of 2026 the Company plans on a full marketing campaign rollout, expanding to additional e-commerce platforms, and the development of a retail distribution strategy. The total budget requirements are estimated to be approximately $500,000 for the manufacturing setup and $300,000 for the marketing campaign.

**Photocil**

Currently sold in India through the Cosmofix/San Pellegrino license. We plan to initiate preparation for scaling-up manufacturing between the third and fourth quarters of 2025. We also plan to initiate the FDA registration process by the fourth quarter of 2025. Between the fourth quarter of 2025 and first quarter of 2026 the Company plans on developing a marketing campaign, the U.S. market relaunch, and e-commerce platform integration for the product. The total budget requirements are estimated to be approximately $350,000 for scaling-up manufacturing, $245,000 for the marketing and sales launch; and $5,000 for the FDA registration/NDC number.

**CB-101 (Eczema Treatment)**

The Company's plan is to initiate the reformulation process in the fourth quarter of 2025, and progress to complete such reformulation and stability testing by the end of the first quarter 2026. The Company plans to initiate the production run and clinical testing for the product by the second quarter, and developing a marketing materials campaign, the U.S. market relaunch, and e-commerce platform integration for the product by the third quarter of 2026. The total budget requirements are estimated to be approximately $150,000 for the development and reformulations, $200,000 for the initial production; $100,000 for the marketing materials; and $50,000 for the clinical testing, which are expected to be funded from a portion of the offering proceeds.

**NoStingz**

Currently, NoStingz is planned to undergo reformulation, as described elsewhere in this registration statement. The Company intends to complete the reformulation and initiate the stability testing by the fourth quarter of 2025. The Company then plans to complete the stability testing and initiate the FDA registration process by the first quarter of 2026. Between the fourth quarter of 2025 and first quarter of 2026 the Company plans to initiate the production run and finalize the launch timeline of the product. The total budget requirements are estimated to be approximately $95,000 for the reformulation, $10,000 for the stability testing; $200,000 for the initial production; and $5,000 for the FDA registration/NDC number, which are expected to be funded from a portion of the offering proceeds.

**Ebola Rapid Test License**

We are currently evaluating market opportunities. The development timeline and costs will be determined following an initial market assessment.

The execution of this plan is contingent upon successful completion of this public offering and obtaining necessary regulatory approvals where applicable. Key dependencies include finalizing manufacturing agreements for U.S. production, completing FDA registration requirements, developing marketing infrastructure, enhancing our e-commerce platform, and establishing distribution channels.

**Components of Our Results of Operations**

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our product pipeline includes a diverse range of products, such as hair loss treatments, Eczema and Psoriasis Treatments, vitiligo solutions, Jellyfish sting protective suncare line and women's sexual wellness products, that cater to different health and wellness needs. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability.

 ****

***General and Administrative***

General and administrative expense consists primarily of personnel-related expense for certain executives, finance and accounting, human resources, information technology, professional fees, facility overhead, sales and marketing and other general corporate expense. We expect our general and administrative expense to increase in absolute dollars primarily as a result of the increased costs associated with being a stand-alone public company. However, we also expect our general and administrative expense to fluctuate as a percentage of our revenue in future periods based on fluctuations in our revenue and the timing of such expense.

***Other Income (Expense), Net***

Other income (expense), net primarily represents gains and losses on transactions denominated in foreign currencies and other miscellaneous income and expense.

***Income Taxes***

Our business has historically been included in Safey Shot's consolidated U.S. federal income tax return. We have adopted the separate return approach for the purpose of the Caring Brands financial statements. The income tax provisions and related deferred tax assets and liabilities that have been reflected in our historical combined financial statements have been estimated as if we were a separate taxpayer using guidance under ASC 740-10-30-27. The historic operations of the Caring Brands business reflect a separate return approach for each jurisdiction in which Caring Brands had presence and Jupiter Wellness filed a tax return. We record a provision for income taxes for the anticipated tax consequences of the reported results of operations using the asset and liability method. Under this method, we recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. We record a valuation allowance to reduce our deferred tax assets to the net amount that we believe is more likely than not to be realized. To effect the separation of the Caring Brands business from Safety Shot's other businesses, there will be changes to the organizational structure of the business, which will not impact our historical financial statements.

We recognize tax benefits from uncertain tax positions only if we believe that it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. As we expand internationally, we will face increased complexity in determining the appropriate tax jurisdictions for revenue and expense items which may differ from that of Jupiter Wellness. Our policy is to adjust these reserves when facts and circumstances change, such as the closing of a tax audit or refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and operating results. The provision for income taxes includes the effects of any accruals that we believe are appropriate, as well as the related net interest and penalties.

**Comparison of the Six Month Period Ended June 30, 2025 and 2024**

The following table presents our financial results for the periods as indicated below

---

| | | |
|:---|:---|:---|
|  | **Successor** | **Predecessor** |
|  | **Six Months Ended <br> June 30, 2025** | **Six Months Ended<br> June 30, 2024** |
| Revenue | $3056 | $- |
| Cost of revenue | 1400 | - |
| Gross profit | 1656 |  |
| Operating expenses | 1200582 | 498482 |
| Gain on sale of assets |  |  |
| Interest expense (income) | 427 | - |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(1199353) | $(498482) |

---

**Revenue**

During the six months ended June 30, 2025 for the Successor and 2024 for the Predecessor the Company had nominal revenue. The lack of revenues is attributed to the change in the focus of our parent company Safety Shot, Inc. and the related change of name from Jupiter Wellness, Inc. to Safety Shot, at which time the beverage Safety Shot became the primary focus of the consolidated entity's sales and marketing efforts.

**Cost of Revenue**

During the six months ended June 30, 2025 for the Successor and 2024 for the Predecessor the Company had nominal cost of sales, aligned with its revenue. Cost of sales consists primarily of product costs, shipping and merchant fees.

**Operating Expenses**

Operating expenses for the six months ended June 30, 2025 for the Successor and 2024 for the Predecessor were $1,200,582 and $498,482 respectively. The major components for the six month period ended June 30, 2025 include $607,000 of stock based compensation, $150,000 of amortization expense, $124,977 of professional fees and $249,534 of salary and wages. For the six months ended June 30, 2024 for the Predecessor the major components of operating expenses consisted of $224,194 of salary and wages, $201,571 of legal and professional fees and $72,717 of other expenses.

**Other income and expense**

During the six months ended June 30, 2025 the Successor had $427 of interest expense and during the six months ended June 30, 2024 the Predecessor had no interest expense. Interest expense is attributable to fees related to the company credit card.

**Net Operating Losses**

Net operating losses for the six months ended June 30, 2025 were $1,199,353 for the Successor and $498,482 for the six months ended June 30, 2024 for the Predecessor. Net operating losses were primarily attributable to the operating expenses of the Company.

**Liquidity and Capital Resources**

During the six months ended June 30, 2025, the Successor was funded through the private placement which was completed in 2024. Our cash and cash equivalents balance at June 30, 2025 was $73,893.

**Comparison of the Periods Ended December 31, 2024 and 2023**

The following table presents our financial results for the periods as indicated below

---

| | | | |
|:---|:---|:---|:---|
|  | **Successor** | **Predecessor** | **Predecessor** |
|  | **April 24 to<br> December 31, 2024** | **January 1 to<br> September 24, 2024** | **Year ended<br> December 31, 2023** |
| Revenue | $465 | $- | $20421 |
| Cost of revenue | 2072 | - | 118874 |
| Gross profit | (1607) |  | (98453) |
| Operating expenses | 871214 | 654573 | 52941 |
| Gain on sale of assets |  |  | (23308) |
| Interest expense (income) | (10030) | 67 | - |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(862791) | $(654640) | $(128086) |

---

**Revenue**

During the year ended December 31, 2024, the Company had nominal revenue. The lack of revenues is attributed to the change in the focus of our parent company Safety Shot, Inc. and the related change of name from Jupiter Wellness, Inc. to Safety Shot, at which time the beverage Safety Shot became the primary focus of the consolidated entity's sales and marketing efforts.

**Cost of Revenue**

During the year ended December 31, 2024, the Company had $2,072 in cost of sales respectively, which consisted of shipping and merchant fees.

Cost of revenue for the year ended December 31, 2023, was $118,874. During the year ended December 31, 2023, the Company had a write down of its inventory in the amounts of $107,408 which included manufacturing and regulatory issues and expired products. Excluding the write down, the cost of sales would have been $11,466.

**Operating Expenses**

Operating expenses for the year ended December 31, 2024 were $871,214, for the Successor. The major components for the year ended December 31, 2024 for the Successor includes salary and wages of $176,719, legal, consulting and professional fees of $516,652, and amortization expense of $150,000. For the Predecessor period of January 1, 2024 to September 24, 2024, total operating expenses were $654,573 which primarily consisted of $334,644 of salaries and wages and $243,057 of legal, consulting and professional fees.

During the year ended December 31, 2023, the Predecessor had $52,941 of operating expenses consisting of professional fees of $38,859 advertising of $4,430, depreciation of $4,400 and other of $5,252.

**Other income and expense**

During the year ended December 31, 2024, the Successor had $10,030 of interest income. For the period of January 1, 2024 to September 24, 2024, the Predecessor had $67 in interest expense. During the year ended December 31, 2023, the Predecessor had a gain of $23,308 from the sale of assets.

**Net Operating Losses**

Net operating losses for the year ended December 31, 2024 were $862,791 and $654,640 for the Successor and Predecessor respectively. For the year ended December 31, 2023 the Predecessor had a $128,086 net operating loss.

**Liquidity and Capital Resources**

During the year ended December 31, 2024 the Successor conducted a private placement which netted the Company $1,791,105 after operating expenses which funded the Company through the period. Our cash and cash equivalents balance at December 31, 2024 was $468,998.

***Commitments***

There are no fixed forward commitments for lease expense, license fees, or capital expenditures.

***Off-Balance Sheet Arrangements***

We did not have, during the periods presented, any off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

***Cash Flow***

The following table presents our cash flows for the periods presented:

---

| | | |
|:---|:---|:---|
|  | **Successor** | **Predecessor** |
|  | **Six Months Ended <br> June 30, 2025** | **Six Months Ended**<br> **June 30, 2024** |
| Net cash flows used in operating activities | $(451105) | $(362181) |
| Net cash provided by (used in) investing activities |  |  |
| Net cash flows provided by financing activities | 56000 | 667465 |
| Increase (decrease) in cash | $(395105) | $305284 |

---

Net cash used in operating activities for the six months ended June 30, 2025 was $451,105. Net cash used in operating activities was $362,181 for the six months ended June 30, 2024 for the Predecessor. The cash used in operations was primarily due to a net loss of $1,199,352 and $498,482, respectively for the Successor and Predecessor, offset by non-cash expenses of $757,000 of the Successor.

Net cash used in investing activities for the six months ended June 30, 2025 and 2024 for the Successor and Predecessor respectively were zero for both periods.

Net cash provided by financing activities during the six months ended June 30, 2025 were proceeds from the issuance of shares and the issuance of a note payable to a related party for $50,000. For the six months ended June 30, 2024 for the Predecessor net cash provided by financing activities consisted primarily of loan from affiliates of $664,995.

**Critical Accounting Policies and Estimates**

Our management's discussion and analysis of our financial condition and results of operations is based on our unaudited consolidated financial statements for the six months ended June 30, 2025 and for the years ended December 31, 2024 and 2023 taken from the audited consolidated financial statements for Caring Brands, Inc (Nevada) for the year ended December 31, 2024 and the audited financial statements for Caring Brands, Inc. (Florida) for the years ended December 31, 2023 and 2022, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and the rules and regulations of the Securities and Exchange Commission. The preparation of the financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenue generated, and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management's judgments and estimates.

The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and are expressed in United States Dollars. Critical accounting policies are summarized below:

***Revenue Recognition***

We generate our revenue from the sale of our products directly to the end user or distributor (collectively the "customer").

The Company recognizes revenues by applying the following steps in accordance with FASB Accounting Standards Codification 606 "Revenue from Contracts with Customers" ("ASC 606"). Under ASC 606, revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

● identify the contract with a customer;

● identify the performance obligations in the contract;

● determine the transaction price;

● allocate the transaction price to performance obligations in the contract; and

● recognize revenue as the performance obligation is satisfied.

The Company's performance obligations are satisfied when goods or products are shipped on an FOB shipping point basis as title passes when shipped. Our product is generally paid in advance of shipment or standard net 30 days and we offer no specific right of return, refund or warranty related to our products except for cases of defective products of which there have been none to date.

***Allowances for Doubtful Accounts***

***Equity Investments***

Equity investments, including our investment in NovoDX common stock, are recorded at cost and the carrying value is adjusted to fair market value for each reporting period.

***Intellectual Property***

Intellectual property, including license agreements, are recorded at cost and amortized over the life of the License using the straight-line method. We evaluate Intellectual Property for impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. Our intellectual property is still in early stages and there were no indicators of impairment that the company considered significant or to require testing at this time. The Company uses the guidelines in ASC 350 to determine if an asset has been impaired.

**Income Taxes**

We account for income taxes under ASC 740 Income Taxes ("ASC 740"). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on recognition, classification, interest and penalties, accounting in interim period, disclosure and transition.

**Recent Accounting Pronouncements**

For a complete description of recent accounting pronouncements, including the expected dates of adoption and estimated effects on financial condition and results of operations, refer to Note 1, *The Company, Basis of Presentation and Summary of Significant Accounting Policies*, in Notes to Financial Statements.

**BUSINESS**

**General Overview**

We are a wellness consumer products company. We offer several over-the-counter (OTC) and cosmetic consumer products. Our product pipeline includes a diverse range of products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. Our method of operation ensures that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability.

We are currently authorized to issue a total of 100,000,000 shares of common stock with a par value of $0.001. As of June 30, 2025, we had 13,336,925 shares of common stock outstanding.

We had nominal revenues and a loss of $1,199,353 for the six months ended June 30, 2025 and nominal revenues and a net loss of $1,517,431 for the year ended December 31. 2024 and revenues of $20,421 and a loss of $128,086, for the year ended December 31, 2023.

We are a wellness consumer products company. We offer several over-the-counter (OTC) and cosmetic consumer products. Our product pipeline includes a diverse range of products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. Our method of operation ensures that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability.

**Corporate History**

Caring Brands, Inc. was incorporated in State of Nevada on April 23, 2024, On May 13, 2024, an Amendment to the Articles of Incorporation was submitted with the State of Nevada to revise the par value to $0.001 per share, followed by an amendment on July 9, 2024 to add 1,000,000 preferred shares with a par value of $0.001 to the authorized share capital. Caring Brands was incorporated for the purpose of the separation of our business operation from Safety Shot and have not historically operated as a standalone company. Pursuant to the Separation and Exchange Agreement, we acquired 100% equity in Caring Brands Florida. Consequently, Caring Brands Florida now operates as an operating subsidiary of the Company.

Caring Brands, Inc., a Florida Corporation ("Caring Brands Florida") was originally incorporated in the State of Florida on February 12, 2020, under the name Jupiter Wellness Inc. In June 2020, Articles of Amendment were filed with the Florida Department of State Division of Corporations to amend the articles of incorporation to change the name of the company to Caring Brands, Inc.

Our principal business address is 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950. We are currently authorized to issue a total of 100,000,000 shares of common stock with a par value of $0.001. As of the date of this registration statement, we had 13,336,925 shares of common stock issued and outstanding.

**Our Products** 

Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team. We are currently preparing for its relaunch in the United States, which is targeted for 2026, as we explore manufacturing and marketing options. The product formulation has not been changed since its removal from the US markets, and no changes to the formulation are planned for the proposed U.S. market relaunch. Photocil is a narrow band UV filter that focuses UV in the 311nm range which is therapeutic for vitiligo and psoriasis. Dimethicone, also called polymethylsiloxane, is a silicon-based polymer used as a lubricant and conditioning agent. It is the USP (United States Pharmacopeia, which is the official compendium of standards for medicines and healthcare products in the United States) monographed ingredient in Photocil. Dimethicone is used to create a smooth feel and a water-resistant barrier on the skin. In addition to dimethicone, Photocil contains two UV filters that restrict the band width of UV rays on the skin to a narrow-range ~ 308 nm. This narrow-band UV has therapeutic properties. These proprietary technologies are not found in other sunscreens and Photocil does not contain conventional UV blockers found in the majority of sunscreens. The product is categorized as an OTC product in the United States, using an USP monographed ingredient as a skin protectant, with FDA-registered labeling (USP monographed: A reference to ingredients listed in the United States Pharmacopeia (USP), which is the official compendium of standards for medicines and healthcare products in the United States). Photocil does not require FDA pre-market approval as it uses GRASE (Generally Recognized as Safe and Effective) ingredients and is currently marketed in India under local cosmetic regulations. Photocil is a cosmetic product designed to block certain UV radiation while allowing other UV radiation to pass through when applied to the skin. The product contains ingredients that are listed in the USP monograph for skin protectants. As a cosmetic product, Photocil has not been evaluated by the FDA for safety and effectiveness. The product contains ingredients that are listed in the USP monograph for skin protectants and is marketed as a cosmetic product in compliance with FDA regulations for cosmetics. The Joint American Academy of Dermatology and National Psoriasis Foundation guidelines for the management and treatment of psoriasis with phototherapy, published in JAMA Dermatology in 2019, strongly recommend narrow-band UVB phototherapy as a monotherapy for treating plaque psoriasis in adults, supported by a systematic review and meta-analysis of 41 randomized controlled trials involving 2,416 patients.

Phototherapy

Management believes that phototherapy treatments, used for conditions such as psoriasis and vitiligo, are set for substantial growth globally. However, there can be no guarantees that this growth will materialize as expected, as it is subject to various market conditions, regulatory developments, and other external factors beyond the Company's control. Specific market data focused solely on the Indian phototherapy treatment segment is limited, and the available market data focuses primarily on phototherapy devices. However, according to Future Market Insights (2023)<sup>1</sup>, the Indian market is expected to experience strong growth, driven by the rising prevalence of skin disorders, increased healthcare spending, and improved access to treatment in both urban and rural areas.

According to Future Market Insights (2023), the global phototherapy treatment market is projected to rise from ~ USD $1.9 billion in 2023 to ~ USD $3.23 billion by 2033, at a CAGR of around 5.2% during the forecast period from 2023 to 2033. In India, the market is expected to expand even faster, with an estimated CAGR of approximately 7.8% as of 2023, driven by a large patient base, increasing prevalence of skin disorders, greater awareness of noninvasive treatments, and improved healthcare infrastructure (Future Market Insights, 2023).

Psoriasis

According to a report by Nature Reviews Drug Discovery (2024)<sup>2</sup>, the global psoriasis treatment market was worth ~ $34 billion globally in the 12 months ending June 2023. The report shows the US remains the dominant market for psoriasis therapies, accounting for approximately 78% of total sales and growing at a compound annual growth rate of approximately 18%.

<sup>1.</sup> Future Market Insights (2023) – Phototherapy Treatment Market: https://www.futuremarketinsights.com/reports/north-america-and-europe-phototherapy-treatment-market

<sup>2.</sup> Nature Reviews Drug Discovery (2024) – The Pipeline and Market for Psoriasis Drugs, Vol. 23, Issue 7, Pages 492-493. Doi: https://doi.org/10.1038/d41573-024-00018-2

According to the same report (Nature Reviews Drug Discovery, 2024), with the current growth rate (CAGR of 8–10% from 2023 to 2030), the global market is expected to reach ~ USD $54-67 billion by 2030. Estimates from a report published on the National Center for Biotechnology Information<sup>3</sup>, indicate that the prevalence of psoriasis in India ranges from 0.44% to 2.8% of the population, highlighting Management's belief in the significant market opportunity in India. However, actual market growth may be influenced by factors such as regulatory changes, competition, and economic conditions, which could impact the overall demand for psoriasis treatments. Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India. However, actual market penetration will depend on various factors, including the development of a dedicated sales and marketing team at Caring Brands, market demand, competitive landscape, and regulatory considerations. There can be no assurance that these efforts will result in significant market adoption.

Vitiligo

According to a report by Expert Market Research (2024)<sup>4</sup>, the global vitiligo treatment market was valued at ~ USD 538.90 million in 2024. The global market is projected to grow at a compound annual growth rate (CAGR) of 4.60% from 2025 to 2034, reaching ~ USD 807.70 million by 2034 (Expert Market Research, 2024). According to Expert Market Research (2024), this growth is attributed to the increasing global prevalence of vitiligo and the rising demand for effective treatments, and Management believes that these factors may contribute to expanding market opportunities. However, actual market expansion may be influenced by factors such as regulatory changes, competition, and advancements in alternative therapies, which could impact the overall demand for vitiligo treatments.

According to the report by Expert Market Research (2024), the US market is expected to remain the dominant market for vitiligo treatments. The report also states that the Asia Pacific region is expected to witness the fastest growth during the forecast period due to increasing awareness, emerging treatment options, growing research and development activities, and favorable government initiatives in developing nations. As part of this Asia Pacific region, management believes India presents a potential opportunity for market expansion. However, there is no certainty that this growth will materialize as expected, as it depends on various external factors, which will impact the overall demand.

As per reports published on the National Centre for Biotechnology Information<sup>5 6</sup>, across studies from India, the prevalence of vitiligo has consistently been reported to be between 0.25%-4% (Cureus Report)<sup>5</sup> and can reach as high as 8.8% of the population in certain regions like Gujarat and Rajasthan (Indian Journal of Community Medicine)<sup>6</sup>, making India a highly affected region globally. However, even though Management believes that this presents a potential market opportunity, Vitiligo treatment with Photocil is expected to address only a very small fraction of the total global market. Future market penetration is uncertain and subject to factors such as regulatory approvals, competitive dynamics, and effective marketing strategies. There can be no assurances that Photocil will achieve meaningful adoption in the market.

Our licensee in India, Cosmofix and San Pellegrino Cosmetics, is currently exploring additional sub-licensing opportunities in Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia. For further details in relation to the license agreement, please see "*Intellectual Property – License Agreements*" below. We are also in preliminary discussions regarding potential licensing opportunities in Europe and South America, though no formal agreements are currently in place. The results of clinical trials on Photocil have been published in Expert Opin Pharmacother, including 2014 Dec;15(18):2623-7; Dermatol Ther. 2014 Jul-Aug;27(4):195-7; Dermatol Ther. 2014 Sep-Oct;27(5):260-3. In July 2021, Safety Shot (then Jupiter Wellness) obtained an exclusive license from Applied Biology Inc. to manufacture and sell Photocil. Subsequently, in June 2022, Safety Shot (then Jupiter Wellness) acquired all assets of Applied Biology Inc., including Photocil, through an asset purchase agreement. The product was commercially launched in India in September 2022 under a licensing agreement with Cosmofix and San Pellegrino Cosmetics and entered the U.S. market in Q4 2022 via Amazon. However, it was removed from the U.S. market in February 2023 due to insufficient sales resulting from the lack of a dedicated sales and marketing team. In India, Photocil is currently marketed as an OTC product compliant with local regulatory standards. In the United States, it was previously commercialized with FDA-registered labeling as a Jupiter Wellness product. We plan to apply for a National Drug Code (NDC) number for FDA registration prior to relaunching the product in the U.S. market. In July 2021, Safety Shot, then Jupiter Wellness, obtained an exclusive license from Applied Biology Inc. to manufacture and sell Photocil. Subsequently, in June 2022, Safety Shot (then Jupiter Wellness). acquired all assets of Applied Biology Inc., including Photocil, through an asset purchase agreement. The product was commercially launched in India in September 2022 under a licensing agreement with Cosmofix and San Pellegrino Cosmetics and entered the U.S. market in Q4 2022 via Amazon. However, it was removed from the U.S. market in Q2 2023. In India, Photocil is currently marketed as an OTC product compliant with local regulatory standards. In the United States, it was previously commercialized with FDA-registered labeling as a Jupiter Wellness product. We plan to apply for a National Drug Code (NDC) number for FDA registration prior to relaunching the product in the U.S. market. Photocil has been evaluated in clinical trials for the treatment of vitiligo and psoriasis, demonstrating significant efficacy.

<sup>3.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC4252960/ Kumar S, Nayak C., Padhi T, et al. (November, 2014). *Epidemiological pattern of psoriasis, vitiligo, and atopic dermatitis in India: A hospital-based point prevalence.* Indian Dermatology Online Journal, 5(Suppl 1), S2–S8. Doi: 10.4103/2229-5178.144499

<sup>4.</sup> Expert Market Research (2024) – Vitiligo Treatment Market: https://www.expertmarketresearch.com/reports/vitiligo-treatment-market

<sup>5.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC11112533/ Saha D, Roy S, Ahmed R, et al. (April 23, 2024). *Clinico-Epidemiological Profile of Vitiligo Among Patients Attending a Tertiary Care Centre of North-East India.* Cureus 16(4): e58804. doi:10.7759/cureus.58804

<sup>6.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC4134529/ Vora R V., Patel B., Chaudhary A.H., et al. (July – Sept 2014). *A Clinical Study of Vitiligo in a Rural Set up of Gujarat*. Indian Journal of Community Medicine 39(3):p 143-146, Jul–Sep 2014. Doi: 10.4103/0970-0218.137150

Our Hair Enzyme Booster (JW-700), previously known as Minoxidil Booster, was initially developed by Applied Biology Inc. and was acquired by Safety Shot (then Jupiter Wellness) in June 2022 through an asset purchase agreement. The product received labelling approval as a cosmetic from the Central Drugs Standard Control Organization (CDSCO) and is currently being manufactured and sold in India through our agreement with Cosmofix and San Pellegrino Cosmetics. Hair Enzyme Booster (JW-700) was launched on Amazon on October 28, 2024, and became available on NOVODX's e-commerce platform on December 11, 2024. As of the date of this prospectus, the Hair Enzyme Booster (JW-700) is currently only for sale on Amazon.

The Hair Enzyme Booster has been clinically shown to increase the enzymes needed for minoxidil (an FDA-approved over-the-counter medication used to treat hair loss and promote hair regrowth) to work, sulfotransferase enzymes, by using the product topically in conjunction with topical minoxidil. The Hair Enzyme Booster (JW-700) is marketed and sold as a cosmetic product in the U.S., containing GRASE ingredients that do not require FDA pre-market approval and complying with FDA labeling requirements. In India, it is currently marketed under local cosmetic regulations. The Company launched the Hair Enzyme Booster (JW-700) in the U.S in the fourth Quarter of 2024. The product is designed to improve Minoxidil efficacy and is available as a topical solution. It is designed to enhance the efficacy of minoxidil by increasing necessary enzyme levels and must be used in combination with FDA-approved minoxidil products. JW-700 does not independently treat hair loss or promote hair regrowth. Clinically shown to increase the sulfotransferase enzyme needed for minoxidil to work, has 2 granted and 5 pending patents.

Minoxidil market was valued at $1.5 billion in 2022 and is expected to grow to $2.5 billion by 2032. Licensed to Taisho, a $2.6 billion revenue company and Japan's leading seller of minoxidil products. They expect to launch the product commercially in 2025. The term of the Taisho License is for five (5) years with an automatic renewal of one (1) year unless terminated otherwise. As consideration, Caring Brands shall receive up to $200,000 in milestone payments and a 3% royalty subject to the terms and conditions of the Taisho License. On September 1, 2022, Safety Shot (then Jupiter Wellness), entered into a license agreement with Cosmofix and San Pellegrino cosmetics to market and manufacture the Hair Enzyme Booster (JW-700) and Photocil for the Indian market and 31 other companies in Africa and Far East. The license is for three years with an automatic renewal of one (1) year unless terminated otherwise. Photocil and the Hair Enzyme Booster (JW-700) are being sold in India. As consideration a 3% royalty subject to the terms and conditions of the Cosmofix/San Pellegrino license. The License was transferred to the Company, pursuant to the Separation and Exchange Agreement (as defined below). The Company launched the Hair Enzyme Booster (JW-700) in the US in 4Q, 2024. As the product contains components that are generally regarded as safe (GRASE) it does not require FDA approval. Clinical studies on the Hair Enzyme Booster (JW-700) have been published: Journal of Cosmetic Dermatology (2022), Vol.21, Issue 4, 1647-1650. The Hair Enzyme Booster (JW-700) has undergone multiple clinical trials, demonstrating its potential efficacy in treating androgenetic alopecia (AGA). The Hair Enzyme Booster (JW-700) is designed to enhance the efficacy of minoxidil by increasing necessary enzyme levels and must be used in combination with FDA-approved minoxidil products. The Hair Enzyme Booster (JW-700) does not independently treat hair loss or promote hair regrowth.

CB-101 treatment for Atopic Dermatitis (Eczema) is a topical over-the-counter treatment for atopic dermatitis (eczema) with dual-action relief from aspartame (ASN) and colloidal oatmeal. In clinical studies of the prior formulation (containing CBD), JW-100 cleared or reduced eczema following 2 weeks of use and may prove potentially superior to existing prescription drugs. It currently has 4 pending patents, with the global eczema treatment market valued at $14 billion in 2022. 31.6 million Americans, or 10% of the population, have eczema; 86% are not satisfied with their treatment and want more and better treatment options. CB-101 eczema treatment is planned to undergo reformulation, which we expect to complete in Q4 2025/Q1 2026, and it is anticipated to be available online in the US in the second quarter of 2026 as an over-the-counter product under a USP monograph. Reformulation activities are expected to resume utilizing a portion of the offering proceeds. CB-101 will be marketed as an OTC product under the applicable monograph. It contains colloidal oatmeal, which is covered under the USP monograph for skin protectant products. The product will comply with all requirements outlined in the applicable USP monograph and will require FDA registration and an NDC number prior to marketing. The clinical study on JW-100 was published in the Journal of Cosmet. Dermatol., Vol. 21, Issue 4, April 2022, pp: 1647-1650. The original formulation, JW-100, contained CBD as an active ingredient, while the new formulation, CB-101, removes CBD, while maintaining aspartame (ASN) and introducing colloidal oatmeal as key ingredients. This dual-action formulation is designed to provide relief from eczema symptoms and allows the product to be marketed as an OTC product under a USP monograph for skin protectants. The reformulated product retains the therapeutic approach of the original while utilizing ingredients compliant with applicable monographs. The development process is expected to move into its final stages upon resumption, with $150,000 anticipated to be allocated to completing formulation development, $200,000 planned for the initial production run, and $50,000 for clinical testing. The target launch date for the product is Q2 2026, with these costs expected to be funded from a portion of the offering proceeds.

NoStingz is planned to undergo reformulation under Caring Brands as a sunscreen product designed to provide protection against both UV rays and jellyfish stings. The previously commercialized version contained FDA-compliant sunscreen active ingredients. Reformulation and stability testing are expected to resume utilizing a portion of the offering proceeds. All actives are intended to meet the USP specifications mandated by the FDA in its sunscreen monograph. We have not yet established a timeline for commercial launch. As the product contains ingredients with well-established safety profiles, it is not expected to require FDA approval. NoStingz will be regulated as a sunscreen product and will comply with the FDA's sunscreen guidelines. It will contain FDA-approved sunscreen active ingredients and will require FDA registration and an NDC number prior to marketing.

Our products are tested for quality and stability each time they are manufactured. One of our manufacturers is Stella Indusstries Ltd, Haryana, India, which manufactures The Hair Enzyme Booster (JW-700) and Photocil for the Indian market. Stability on commercial batches manufactured in India indicates a shelf life of at least 24 months. Stella Indusstries is compliant with the FDA's Current Good Manufacturing Practice, or CGMP, regulations in accordance with 21 CFR 210/211 required for over-the-counter drug products. It is ISO-9001 certified. Another manufacturer is DCR Labs, Daytona Beach, Florida, which is also fully compliant with the FDA's Current Good Manufacturing Practice, or CGMP, for cosmetic products.

We expect to continually update and expand upon our corporate website and further refine our online retail strategies on an ongoing basis. CaringBrands.com is our primary corporate website, which will serve as the primary source of information about us for investors and will contain press releases, clinical trial pipeline, lab reports, blog posts, and additional information about each of our brands. We have built an e-commerce platform designed to connect us directly to consumers. We use the platform to sell products, educate customers, and build brand loyalty.

**Clinical Trials of our Products**

*Hair Enzyme Booster (JW-700) Clinical Studies*

**Trial 1 - SULT1A1 Enhancement Study (2020)**

Design: Conducted over 14 days, the study involved 19 AGA patients who applied the booster twice daily, with follicular sulfotransferase activity measured before and after treatment.

Primary endpoint: Change in sulfotransferase enzyme activity

Scope: The study evaluated the effect of a topical booster on SULT1A1 activity in hair follicles of androgenetic alopecia (AGA) patients. SULT1A1 plays a role in enzymatic processes within the follicle, and the study aimed to measure any changes in its activity following booster application.

Results:

Pre-treatment average: 0.2206 (95% CI: 0.1661 to 0.2750)

Post-treatment average: 0.4946 (95% CI: 0.2036 to 0.7855)

Percentage change in SULT1A1 activity: 124%

p-value: p < 0.03 (The Company believes this is statistically significant.)

No adverse events reported

Trial was conducted by Applied Biology and conducted at the Department of Dermatology and Radiotherapy, São Paulo State University (UNESP) Botucatu – SP, Brazil. Principal Investigator: Dr. Paulo Müller Ramos, MD, PhD). Employees of Caring Brands were not authors on this paper.

\*SULT1A1 (sulfotransferase enzyme): A family of enzymes essential for activating minoxidil in the scalp by converting it into its active form (minoxidil sulfate).

\*AGA (Androgenetic Alopecia): Also known as male-pattern baldness or female-pattern hair loss. It is a common form of hair loss caused by a combination of genetic and hormonal factors, particularly the effects of dihydrotestosterone (DHT) on hair follicles.

\*CI (Confidence Interval): A statistical range used to estimate the true value of a population parameter based on sample data. It provides an interval within which the parameter is expected to fall with a certain level of confidence.

p-value: A statistical measure indicating the probability that the observed results occurred by chance. A lower p-value (typically <0.05) suggests stronger evidence against the null hypothesis.

**Trial 2 - Efficacy Study (2021): published in J.Cosmetic Dermatol. 2021, 1-4**

Design: 60-day randomized, double-blind, placebo-controlled study

Participants: 24 male AGA patients (Norwood scale 2-6)

Primary endpoint: Change in hair regrowth

Results:

Treatment group response rate: 75% (9 of 12 participants)<br> Placebo group response rate: 33% (4 of 12 participants)<br> p-value: 0.023 (The Company believes this is statistically significant.)

No adverse events reported

Clinical Evidence: In a randomized blinded clinical trial 24 males with androgenic alopecia (Norwood scale average 4.4, range 2–6) completed the trial: 12 in the active arm and 12 in placebo. 75% of the subjects in the treatment group exhibited hair regrowth, compared to 33% in the placebo group (p = 0.023).

Trial was conducted by Applied Biology at the Department of Dermatology, LTM Medical College & Hospital Sion, Mumbai, India, Principal Investigator Dr. Rachita Dhurat MD). Employees of Caring Brands were not authors on this paper.

\*Norwood Scale: A classification system used to measure the stages of male pattern baldness (androgenetic alopecia, AGA). It ranges from Stage 1 (minimal or no hair loss) to Stage 7 (severe baldness with only a horseshoe-shaped fringe of hair remaining on the sides and back of the scalp).

**Trial 3 - Latest Clinical Study (2024) Conducted by Caring Brands**

Design: Open-label, single-arm, single-period exploratory study evaluating JW-700, a topical treatment for androgenetic alopecia (AGA). The study enrolled 20 to 40 adult subjects who applied JW-700 to the scalp twice daily for 14 days. Sulfotransferase (SULT1A1) activity in the outer root sheath (ORS) of hair follicles was measured before and after treatment using the MX-IVD diagnostic test.

Primary endpoint: Change in SULT1A1 enzyme activity

Scope: Study aimed to assess the ability of JW-700 to upregulate SULT1A1 activity, a key enzyme involved in minoxidil activation. The primary objective was to determine whether JW-700 could enhance SULT1A1 expression, while the secondary objective focused on evaluating the treatment's safety and tolerability

Results:

32% increase in SULT1A1 enzyme activity across all subjects

47% increase in SULT1A1 in non-responder subgroup (OD<0.4)

75% of subjects showed increased enzyme activity

31% of non-responders converted to responders

Statistical significance: p=0.0700 (The Company believes this is not statistically significant. It should be noted that establishing statistical significance was not an objective of Trial 3, as this trial served primarily as a bridging study to assess the impact of a minor formulation change rather than to confirm efficacy.)

Duration: 14 days

No adverse events reported

Clinical Evidence: In an open-label study evaluating SULT1A1 enzyme activity, 75% of subjects exhibited an increase in enzyme levels, and 31% of non-responders demonstrated a shift to responder status. Changes in enzyme activity were observed across all subjects, with varying levels of increase among different subgroups.

Caring Brands Employees were involved in preparing the clinical protocol for, and in the execution of this trial. No paper has been published as of this date. The trial was conducted in India by Enem Nostrum Remedies Pvt. Ltd. Principal Investigators were Dr. Rajan Sharma, MD and Dr. Rohit Wadgaonkar, MD.

\*OD (Optical Density): A measure commonly used in biochemical assays to quantify enzyme activity, protein concentration, or cell density.

**Vitiligo Trial: Published in Dermatologic Therapy (2014) 27, 1-4**

Design: Double-blind, placebo-controlled study

Participants: 15 patients with acrofacial vitiligo

Duration: Average 11 weeks

Results:

28% achieved 70% re-pigmentation

28% achieved 50% re-pigmentation

44% achieved 30-40% re-pigmentation

Placebo group: Only 10% achieved 20% re-pigmentation

Statistical significance: p<0.0001 (The Company believes this is highly statistically significant.)

Clinical Evidence: A double-blind, placebo-controlled study evaluated re-pigmentation rates in 15 patients with acrofacial vitiligo over an average treatment period of 11.25 weeks. Among patients receiving the topical cream, 28% exhibited 70% re-pigmentation, 28% exhibited 50% re-pigmentation, and 44% exhibited 30-40% re-pigmentation. In the placebo group, 10% of patients exhibited 20% re-pigmentation. The study reported a p-value of <0.0001. No adverse events were observed.

Trial was conducted by Applied Biology at the Vimala Dermatological Center, Sanghvi Hospital, Mumbai, India, Principal Investigator Dr. Antonio Salafia. Employees of Caring Brands were not authors on this paper.

**Psoriasis Trial: Published in Dermatologic Therapy (2014) 27, 260-263**

Design: Double-blind, placebo-controlled study

Participants: 15 psoriasis patients

Duration: Average 38 sessions

Results:

43% achieved complete clearance

Remaining patients achieved at least 50% clearance

Mean lesion clearance: 75%

Placebo group: No patients exceeded 20% clearance

Statistical significance: p<0.00012 (The Company believes this is highly statistically significant.)

Clinical Evidence: A double-blind, placebo-controlled study evaluated lesion clearance in 15 psoriasis patients following an average of 38 sessions of treatment. In the treatment group, 43% of patients exhibited complete clearance, while the remaining patients exhibited at least 50% lesion clearance. The mean lesion clearance in the treatment group was 75%. In contrast**,** no patients in the placebo group exceeded 20% lesion clearance. The study reported a p-value of <0.00012, calculated using an unpaired two-tailed Student's t-test.

\*Student's t-test: A statistical test used to test whether the difference between the response of two groups is statistically significant or not.

\*Unpaired two-tailed student's t-test: Used to compare the means of two samples when each individual in one sample is independent of every individual in the other sample.

Trial was conducted by Applied Biology at the Vimala Dermatological Center, Sanghvi Hospital, Mumbai, India, Principal Investigator Dr. Antonio Salafia. Employees of Caring Brands were not authors on this paper.

All trials were independently conducted and funded, with Applied Biology or Caring Brands, Inc. providing study materials at no cost. The studies were conducted in compliance with Good Clinical Practices and received appropriate ethical approvals.

**Intellectual Property**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Caring Brands Reference** | **Scope & Technology** | **Type of Patent Protection** | **Country** | **Status** | **Application** <br> **Number** | **Patent No.** | **Expiry Date<br> (if applicable)** |
| JW-100/CB-101 | Topical product containing aspartame & colloidal oatmeal | Composition and methods for treatment of atopic dermatitis | Australia | Pending | 2020331290 |  |  |
| JW-100/CB-101 | Topical product containing aspartame & colloidal oatmeal | Composition and methods for treatment of atopic dermatitis | China | Published | 202080071037.7 |  |  |
| JW-100/CB-101 | Topical product containing aspartame & colloidal oatmeal | Composition and methods for treatment of atopic dermatitis | Mexico | Pending | MX/a/2022/001723 |  |  |
| JW-100/CB-101 | Topical product containing aspartame & colloidal oatmeal | Composition and methods for treatment of atopic dermatitis | United States of America | Published | 17/937,327 |  |  |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | United States of America | Granted | 16/593,577 | 11766392 | October 4, 2039 |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | United States of America | Published | <u>18/474,052</u> |  |  |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | United States of America | Granted | 16/747,685 | 11628132 | October 4, 2039 |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | United States of America | Published | <u>18/301,951</u> |  |  |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | United States of America | Published | 17/806,363 |  |  |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | Patent Cooperation Treaty | Published | PCT/US2023/062611 |  |  |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | India | Pending | 202317067100 |  |  |
| Hair Enzyme Booster<br> (JW-700) | Stimulates production and release of sulphotransferases in hair outer root sheet for conversion of minoxidil to active minoxidil sulphate. Correlated with improved hair growth. | Composition and methods for increasing level of sulphotransferases in hair outer root sheet. | Japan | Pending | 2023-540689 |  |  |
| TAAR Receptor Agonists for the Treatment of Alopecia |  |  | United States of America | Published | 17/155,865 |  |  |
| JW-710 | Topical product containing minoxidil and JW-700 | Composition and methods | United States of America | Pending | 63/594,884 |  |  |
| Photocil | Topical Narrow-band UV filter | Composition and methods for treatment of psoriasis and vitiligo | United States of America | Granted | 14/145,824 | 10111821 | November 5, 2032 |

---

**Research and Development and License Agreements**

On June 20, 2024, the Company entered into a Research Collaboration and Non-Exclusive License Agreement, as amended and restated on July 22, 2024 (the License Agreement") with NOVODX Corporation a Delaware corporation and a related party ("NOVODX"). NOVODX is a diagnostic company dedicated to the development and commercialization of innovative health products, with a primary focus on rapid diagnostic screenings and their companion therapeutics (see the Section "Certain Relationships And Related Party Transactions," below). NOVODX is engaged in the research and development of rapid diagnostic devices intended for both Over the Counter ("OTC") and Point of Care ("POC") applications. NOVODX aims to manufacture, market, and sell these devices, either directly or indirectly, for use in at-home diagnostic screenings. NOVODX possesses or has the rights to use (through licenses or other agreements) certain assets, patent applications, and associated know-how, technology, scientific, and technical information. Collectively, these resources are referred to as the GoldNTM Ebola Rapid Test Technical Information, which pertains to the development of an Ebola diagnostic test (the "Ebola Rapid Test"). The agreement provides for issuance of 3,000,000 shares of restricted common stock, which were issued upon the agreement's effectiveness. An initial payment of $100,000 is due within 30 days of the S-1 registration statement's effectiveness. Milestone payments include $1,000,000 payable upon NOVODX receiving 510K/EUA approval and $500,000 when annual net sales reach $5 million. Royalties are set at 5% of net sales under $500 million and 3% of net sales exceeding $500 million.

The agreement remains in effect until the earlier of the royalty term expiration or agreement termination. It does not permit sublicensing or assignment, and requires a 90-day notice for termination.

To date, no payments have been made under this agreement, other than the issuance of the restricted common stock, as the S-1 registration statement has not yet been declared effective. Additionally, no commercialization activities have commenced under this agreement.

Pursuant to the License Agreement, NOVODX granted the Company a license which contains the following provisions:

&nbsp;&nbsp;&nbsp;&nbsp;1. Research:
 The license allows the Company to use and market the Ebola Rapid Test in the research field, following the directives and standards
 set by the Joint Development Committee (JDC) and the research plan of reasonably collaborating with each other to develop a pre-clinical
 research or other plan for the Ebola Rapid Test. The license is valid only in jurisdictions where NOVODX has a valid claim. NOVODX
 is pursuing patent protection through U.S. and Patent Cooperation Treaty (PCT) applications, with a particular focus on markets in
 Africa and Asia. As of the date of this prospectus, NOVODX has not yet submitted any patent applications. NOVODX is in the process
 of preparing these applications and evaluating entry into specific jurisdictions. Decisions regarding entry into national phase
 applications in specific jurisdictions will be evaluated on a case-by-case basis as the patent prosecution process progresses. The
 ultimate scope of patent protection will be determined by the jurisdictions where NOVODX successfully obtains valid claims through
 these patent applications.

2. Commercial:
 The license permits the Company to use, market, and sell the Ebola Rapid Test within the commercial field. the Company cannot engage
 in sales, directly or indirectly, until NOVODX obtains 510K or EUA approval or authorization. Sales and distribution are restricted
 to jurisdictions where such approval or authorization is valid and where NOVODX has a valid claim. NOVODX is pursuing patent protection
 through U.S. and Patent Cooperation Treaty (PCT) applications, with a particular focus on markets in Africa and Asia. As of the
 date of this prospectus, NOVODX has not yet submitted any patent applications. NOVODX is in the process of preparing these applications
 and evaluating entry into specific jurisdictions. Decisions regarding entry into national phase applications in specific jurisdictions
 will be evaluated on a case-by-case basis as the patent prosecution process progresses. The ultimate scope of patent protection will
 be determined by the jurisdictions where NOVODX successfully obtains valid claims through these patent applications.

Ebola Rapid Test is a revolutionary point-of-care and home diagnostic test developed by NOVODX. Our advanced diagnostic solution addresses the critical need for highly sensitive and reliable rapid diagnostic tests (RDTs) for the detection of Ebola virus, surpassing the limitations of current market offerings.

<u>Key Features</u>**:**

1. *Unmatched Sensitivity* **:**

*2.* *Specificity:*

*3.* *Stability and Durability:*

<u>Compliance with WHO ASSURED Criteria</u>**:** Ebola Rapid Test meets the World Health Organization's ASSURED criteria for RDTs, which include being Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and Deliverable to end-users. Our test ensures that even without specialized personnel or nucleic acid extraction amplification steps, accurate and traceable results can be obtained.

<u>Public Health Impact</u>**:** Ebola Rapid Test by NOVODX represents a significant advancement in Ebola virus diagnostics, offering unparalleled sensitivity, specificity, and stability. Our commitment to innovation ensures that communities at risk can rely on Ebola Rapid Test for rapid, accurate, and reliable Ebola virus detection, reducing the risk of onward transmission and improving public health outcomes.

*Cosmofix/San Pellegrino license agreement*

On September 1, 2022, Safety Shot (then Jupiter Wellness) entered into a license agreement with Cosmofix and San Pellegrino Cosmetics (the "Cosmofix/San Pellegrino License") to manufacture and distribute Photocil and Hair Enzyme Booster (JW-700) in India and 31 other territories. The License was transferred to the Company pursuant to the Separation and Exchange Agreement. The Cosmofix/San Pellegrino License has an initial term of three years with automatic one-year renewals unless terminated. The licensee paid an upfront fee of $20,000 and is required to pay $25,000 after launch of all products in the first year, followed by minimum annual royalties of $50,000 from the second year onwards. After the second year, we may terminate with 30-day notice if annual royalties fall below $50,000. The license grants exclusive rights to manufacture and distribute the products in India and specified territories including Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia. The licensee is responsible for obtaining necessary regulatory approvals, and manufacturing must comply with quality specifications and applicable laws.

The Cosmofix/San Pellegrino License agreement is filed as Exhibit 10.7 in the registration statement, as it constitutes a material agreement for the development and commercialization of one of our key products.

*Applied Biology Inc. /Taisho Pharmaceutical Co. license agreement*

On May 1, 2022, Applied Biology Inc. entered into an exclusive license agreement with Taisho Pharmaceutical Co., Ltd., granting Taisho rights to certain intellectual property and products. This agreement was subsequently acquired by Safety Shot (then Jupiter Wellness) from Applied Biology via an asset acquisition and is now owned by the Company following the transfer from Safety Shot pursuant to the Separation Agreement. The license grants exclusive rights in Japan for the development, manufacture, and commercialization of Hair Enzyme Booster (JW-700) formulations, including solutions, shampoos, conditioners, and related test products.

The license covers a comprehensive range of intellectual property, including patents, know-how, trademarks, and trade secrets related to minoxidil booster products. The agreement applies to current and future formulations, including aerosol versions and successor products. The technology transfer under the agreement encompasses preclinical and clinical data, regulatory communications, chemistry, manufacturing, and control (CMC) data, as well as manufacturing processes.

The agreement is underpinned by robust intellectual property protection, including U.S. Patent 11,766,392 and U.S. Patent 11,628,132 for the Hair Enzyme Booster (JW-700) for treating alopecia, both expiring October 4, 2039.

The agreement is structured with an initial term of five years, automatically renewing for successive one-year periods unless terminated. Financial terms include a $200,000 upfront payment, which was paid to Applied Biology prior to the asset purchase, and a $100,000 milestone payment contingent upon the first regulatory authorization in Japan (not yet achieved). Additionally, a 3% royalty on net sales is payable under the agreement.

Under the agreement, Taisho holds exclusive rights to research, develop, market, manufacture, import, and sell the licensed product in Japan. The Company, as the successor to Applied Biology, retains rights for all other markets. Caring Brands is responsible for maintaining and defending the licensed intellectual property, while Taisho is obligated to use commercially reasonable efforts to market the products within the licensed territory.

The agreement allows either party to terminate with six months' notice prior to the expiration of the term or in the event of a material breach. Post-termination, a one-year non-compete provision restricts activities related to the licensed products.

The license gives Taisho the exclusive rights to market our Hair Enzyme Booster (the "Booster") in Japan for which the Company will receive a royalty on all sales of the Booster. The License was carried on the books of Safety Shot at zero value and the transfer of the License to the Company will be recorded at zero value.

The Taisho license agreement is included as Exhibit 10.9 in this registration statement as it constitutes a material agreement for the development and commercialization of one of our key products.

**Raw Material & Manufacturing**

Our products are manufactured by Sanpellegrino Cosmetics pvt. Ltd. through their manufacturing facility at Stella Indusstries Ltd., who sources raw materials from multiple qualified vendors. While we currently do not rely on any single or limited number of suppliers for raw materials, and have not experienced any shortages to date, we cannot provide absolute assurance that raw material availability will not be impacted in the future by supply chain disruptions, geopolitical events, or other factors beyond our control. Stella Indusstries Ltd., through our agreement with Sanpellegrino Cosmetics Pvt. Ltd., manufactures the Hair Enzyme Booster (JW-700) for our initial U.S. market launch. The agreement, effective May 1, 2024, governs the manufacturing of the Hair Enzyme Booster (JW-700) in accordance with brand owner specifications. Payment terms require 50% of the payment upon order placement and the remaining 50% upon product dispatch. Either party may terminate the agreement with a 30-day notice. We are also exploring the possibility of engaging DCR Labs, a former manufacturer for Jupiter Wellness, to potentially manufacture CB-101 in the future. However, no formal agreement is currently in place with DCR Labs. The manufacturing agreement with Sanpellegrino Cosmetics Pvt. Ltd. represents a material agreement for the production of our key products and will be filed as Exhibit 10.10 to the registration statement.

For our Hair Enzyme Booster (JW-700) and other planned products, our manufacturer maintains relationships with multiple vendors for each key ingredient to help ensure consistent supply and competitive pricing. While we anticipate adequate availability of raw materials for our current and planned production volumes, market conditions affecting raw material supply and costs could impact our operations and manufacturing timelines. We work closely with our manufacturer to monitor raw material inventory levels and maintain appropriate safety stock to mitigate potential supply disruptions.

The Cosmofix/San Pellegrino license agreement grants an exclusive, irrevocable, and perpetual license to manufacture, sell, and distribute Photocil and the Hair Enzyme Booster (JW-700) across India and 31 other territories, including key markets in Asia, the Middle East, and Africa. The license covers proprietary know-how, including technical information, processes, trade secrets, product formulas, manufacturing practices, and testing methods. Products must comply with quality specifications and applicable laws, and the licensee is responsible for obtaining regulatory approvals in the licensed territories.

The agreement is underpinned by robust intellectual property protection, including U.S. Patent 11,766,392 and U.S. Patent 11,628,132 for the Hair Enzyme Booster (JW-700) for treating alopecia, both expiring October 4, 2039, and U.S. Patent 10,111,821 for Photocil's methods of treating psoriasis, vitiligo, atopic dermatitis, and pruritus, expiring November 5, 2032.

Effective September 1, 2022, the agreement has an initial term of three years with automatic one-year renewals unless terminated. Financial terms include a $20,000 upfront payment, a $25,000 payment in the first year following the product launches, and a minimum annual royalty requirement of $50,000 starting in the second year. The licensor may terminate the agreement with 30 days' notice if royalties fall below the annual minimum after the second year. Additionally, Jupiter Wellness (now Caring Brands) retains the right to purchase products at cost plus 10%.

This agreement, filed as Exhibit 10.8 to the registration statement, represents a material arrangement for the development and commercialization of our key products in critical international markets

**Our Market Opportunity**

Hair Enzyme Booster (JW-700) was launched on Amazon on October 28, 2024, and became available on NOVODX's e-commerce platform on December 11, 2024. We are currently in the early stages of commercialization and are refining our marketing strategies for both platforms. Sales have been minimal during this initial soft launch period as we optimize our marketing approach and distribution channels. Once funding from this offering becomes available, we plan to expand our sales and marketing team, which we expect will accelerate product commercialization efforts and drive increased market penetration. As of the date of this prospectus, the Hair Enzyme Booster (JW-700) is currently only for sale on Amazon.

Discussions are ongoing to utilize an established third-party e-commerce platform to further expand our online presence. While retail channel opportunities are being explored, no formal agreements have been executed to date.

As our product line expands and market presence grows, we will continue to evaluate and pursue additional distribution channels. Our immediate focus remains on strengthening and growing our e-commerce presence before expanding into traditional retail channels.

**Our Growth Strategy**

We plan to seek acquisition opportunities in the branded consumer products space, including but not limited to additional OTC/cosmetic therapeutic brands and skin care brands that can be manufactured, marketed and distributed without additional FDA approval. We may market such products as they are currently formulated or may seek to modify the formulations for such products. We have no definitive agreements in place to acquire any other entities. We also intend to sell the product online directly through our own website, and other third-party marketplaces as these sites permit.

**Marketing**

We expect to continually update and expand upon our corporate website and further refine our online retail strategies on an ongoing basis. caringbrands.com is our primary corporate website, which will serve as the primary source of information about us for investors and contain press releases, clinical trial pipeline, lab reports, blog posts, and additional information about each of our brands. We anticipate that each brand will have its own front-facing website dedicated to retail sales and brand specific information. As we expand our brands we anticipate utilizing the same strategy and dedicating a new e-commerce website to each brand moving forward. We are also building a website dedicated to servicing our wholesale and larger distributor clients. This website will have more information about each product and provide a central location for larger retailers to find more in-depth information about all of our brands in one place.

**Competition**

The consumer product industry is highly fragmented with numerous companies, consisting of publicly- and privately-owned companies. There are also large, well-funded companies that have indicated their intention to compete in the hemp-based product category in the U.S. Our products feature unique mechanisms of action that have demonstrated clinical benefits, underscoring their effectiveness and value. We routinely assess internal and external opportunities to optimize stockholder value through the development of innovative new products, as well as strategic asset acquisitions or sales. With a strong foundation and expertise in the market, we believe we are well-positioned to capitalize on growth opportunities in the expanding over-the-counter skincare product category. We face competition from larger companies that are, or may be in the process of offering similar products to ours. Many of our current and potential competitors have longer operating histories, significantly greater financial, marketing and other resources than we have or may be expected to have. However, our products are differentiated through a unique mechanism of action that offers clinical benefits not provided by traditional products. This innovation positions us to compete effectively by demonstrating to consumers that our formulations deliver superior results. We plan to leverage targeted marketing strategies and education to build brand trust and establish ourselves as a competitive alternative to existing brands.

Competitors may include major pharmaceutical and biotechnology companies and public and private research institutions. Our management cannot be certain that we will be able to compete against current or future competitors or that competitive pressure will not seriously harm our business prospects. These competitors may be able to react to market changes, respond more rapidly to new regulations or allocate greater resources to the development and promotion of their products than we can.

Furthermore, some of these competitors may make acquisitions or establish collaborative relationships among themselves to increase their ability to rapidly gain market share. Large pharmaceutical companies may eventually enter the market.

*Competition faced for each product category*

 

For the treatment of psoriasis the market is dominated by biologics including IL-23 inhibitors (risankizumab (Skyrizi; AbbVie/Boehringer Ingelheim) and guselkumab (Tremfya; Janssen)) dominate the US psoriasis market with ~31% market share, followed by IL-17 inhibitors (ixekizumab (Taltz; Lilly) and secukinumab (Cosentyx; Novartis)) with ~23%, TNF inhibitors with 23% and ustekinumab (Stelara; Janssen) with 13%. Deucravacitinib (Sotyku; Bristol Myers Squibb) is a member of the Janus kinase inhibitor family. These biologicals can exhibit significant side-effects commonly including increasing susceptibility to infections. Janus kinase inhibitors in patients 50 years of age and older, with at least one cardiovascular risk factor, have shown higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers.

Most cases of localized, plaque-type psoriasis can be treated with topical glucocorticoids, although long-term use can be complicated by loss of effectiveness and atrophy of the skin. Calcipotriene, a vitamin D analogue, and tazarotene, a retinoic acid derivative, are also effective in the treatment of limited psoriasis. Narrow-band UV therapy, either alone or in combination with topical steroids has also been shown to be effective.

In contrast, Photocil allows narrow-band UV rays to target psoriasis with minimal side-effects. Phototherapy is considered to be one of the most effective therapies for psoriasis but conventional phototherapy lamp treatment requiring frequent physician visits has not gained patient acceptance. Topical Photocil treatment which can be used at home avoids this problem.

Treatments for vitiligo include the use of topical corticosteroids and tacrolimus. Ruxolitinib (Opzelura™) a JAK inhibitor is the only biologic medication approved by the U.S. Food and Drug Administration (FDA) to restore lost skin color in people who have vitiligo. It is marketed by Incyte. Phototherapy is used, alone or in combination with corticosteroids, and can lead to re-pigmentation. Topical Photocil treatment is more convenient and has fewer side effects than these other approaches.

Our Hair Enzyme Booster does not on its own increase hair growth but can work to improve the efficacy of minoxidil, an FDA-approved treatment for hair growth. There are many products on the market (most of them nutritional supplements) that address improved hair growth. The majority are not FDA approved. The Hair Enzyme Booster works with a clinically proven FDA-approved product to improve hair growth. The market for minoxidil in 2024 was over $1billion worldwide. Our license with Taisho, the largest supplier of minoxidil in Japan, shows the potential of the combination with Hair Enzyme Booster.

Given the rapid changes affecting the global, national, and regional economies in general and cannabis-related medical research and development in particular, we may not be able to create and maintain a competitive advantage in the marketplace. Time-to-market is an important factor in our industry and our success will depend on our ability to develop innovative products that will be accepted by patients as efficient and helpful to use.

Our success will also depend on our ability to respond quickly to, among other things, changes in the economy, market conditions, and competitive pressures. Any failure to anticipate or respond adequately to such changes could have a material effect on our financial condition, operating results, liquidity, cash flow and our operational performance.

**Government Regulations**

Our business and our products are subject to regulatory requirements for both over-the-counter (OTC) and cosmetic products in the U.S. and internationally, including by the US Food and Drug Administration (the "FDA"), the Consumer Product Safety Commission (the "CPSC"), the Federal Trade Commission (the "FTC"). These laws and regulations principally relate to the ingredients, proper labelling, advertising, packaging, marketing, manufacture, safety, shipment and disposal of our products. Further, as the vast majority of our products are imported from overseas manufacturers, we may also be subject to Customs Border Patrol clearance regulations prior to goods being released into the United States market.

We market certain non-prescription drug products, including certain products that are intended to be used as sunscreens, which are regulated as over-the-counter ("OTC") drug products by the FDA. In the U.S., OTC products must comply with the regulatory framework set forth by the FDA, which includes requirements related to acceptable active ingredients, required labeling, manufacturing specifications, quality control standards, registration requirements (including National Drug Code (NDC) numbers), and Good Manufacturing Practice (GMP) compliance.

Certain OTC drug products are subject to regulation pursuant to United States Pharmacopeia USP "monographs," which provide standards applicable to each therapeutic category of non-prescription drug, and establishes conditions, such as active ingredients, uses (indications), doses, labeling, and testing procedures, under which an OTC drug within that particular category may be generally recognized as a safe and effective ("GRASE"), and therefore can be marketed without obtaining pre-market approval of an new drug application ("NDA") or abbreviated new drug application ("ANDA"). To be legally marketed, among other things, OTC drug products marketed under an OTC monograph must be manufactured in compliance with the FDA's GMP requirements for drug products, and the failure to maintain compliance with these requirements could lead to FDA enforcement action. Moreover, a failure to comply with the OTC monograph requirements could lead the FDA to determine that the drug is not GRASE, and thus is a "new drug" requiring approval in accordance with the NDA or ANDA processes, or to make changes to its manufacturing processes or product formulations or labels.

We also market cosmetic products, which are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA), as amended by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Under these regulations, we are required to register our manufacturing facilities with the FDA, list our cosmetic products and their ingredients, maintain safety substantiation records, report serious adverse events, and comply with Good Manufacturing Practice (GMP) requirements. The FDA now has mandatory recall authority for cosmetic products that may cause serious adverse health consequences. Failure to comply with these new regulatory requirements could result in FDA enforcement actions, including mandatory recalls, facility inspections, and potential civil penalties.

Moreover, the FTC regulates and can bring enforcement action against cosmetic companies for deceptive advertising and lack of adequate scientific substantiation for claims. The FTC requires that companies have a reasonable basis to support marketing claims. What constitutes a reasonable basis can vary depending on the strength or type of claim made, or the market in which the claim is made, but objective evidence substantiating the claim is generally required. The FTC can seek civil monetary penalties, injunctive relief, and consumer redress for violations of the FTC Act.

In addition to U.S. regulations, our products are subject to varying regulatory frameworks internationally. For example, in India, our products must receive approval from the Central Drugs Standard Control Organization (CDSCO) before they can be marketed. All of our products currently marketed in India have received and maintain the necessary CDSCO approvals.

Our products in India are regulated under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 by the Central Drugs Standard Control Organization (CDSCO), the national authority responsible for drug and cosmetic safety and compliance in India.

Photocil was registered as a cosmetic product with CDSCO in October 2022 and complies with the Bureau of Indian Standards (BIS) requirements for sunscreen products. The Hair Enzyme Booster (JW-700) received CDSCO cosmetic labeling approval in June 2023 and is classified as a cosmetic product. Its manufacturing and quality control processes comply with Schedule M-II requirements for cosmetics.

Manufacturing partner, Stella Indusstries Ltd., holds all necessary state licenses and complies with Good Manufacturing Practice (GMP) standards, ensuring high-quality production. Ongoing regulatory compliance is maintained through regular quality control testing at CDSCO-approved laboratories, adherence to labeling requirements under the Drugs and Cosmetics Rules, proper documentation and record-keeping, and periodic facility inspections by state licensing authorities.

Our Indian licensee, Cosmofix and San Pellegrino Cosmetics, holds all required licenses and permits for importing, manufacturing, and distributing our products in India. All our product formulations comply with the safety standards set forth in the Drugs and Cosmetics Rules. Any new products introduced in India will undergo the necessary CDSCO review process prior to commercialization. We continue to work closely with our manufacturing and distribution partners to ensure ongoing compliance with all applicable Indian regulatory requirements.

Failure to comply with these regulatory requirements could result in product recalls, regulatory enforcement actions, manufacturing disruptions, reputational damage, and loss of market access. Additionally, changes in regulations or the interpretation of existing regulations may require significant resources to maintain compliance and could delay or prevent the launch of our products.

**Employees**

Currently, we have four full-time employees, which includes our Chief Executive Officer Dr. Glynn Wilson, our Chief Financial Officer, Markita Russell, our operations manager, Paul Jones and our Executive Chairman, Brian S John. We believe our relations with our employees to be good.

**Properties**

Currently, we do not own any real property. We currently lease office space at 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950.

**Legal Proceedings**

We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates are involved in a proceeding adverse to our business or have a material interest adverse to our business.

**MANAGEMENT**

**Executive Officers, Directors**

The following table sets forth our executive officers and directors, their ages and the positions held by them:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Age** | **Position** | **Date Appointed** |
| Dr. Glynn Wilson | 78 | Chief Executive Officer and Director | 03/26/2024 |
| Markita Russell | 51 | Chief Financial Officer | 03/15/2024 |
| Brian S John | 56 | Executive Chairman | 03/27/2024 |
| Dr. Hector Alila | 71 | Independent Director | 03/27/2024 |
| Christopher Galeta | 56 | Independent Director | 05/20/2025 |
| Christopher Melton | 52 | Independent Director | 09/17/2024 |

---

**Brian S. John, Executive Chairman,** is our founder since May 2024. For the past 20 years, Brian has been an investor and advisor to companies around the globe. He is the founder of Caro Partners, LLC, a financial consulting firm specializing in assisting emerging growth companies primarily in the sub- $100 million space and has worked with hundreds of companies in dozens of countries over the last 25 years. He also served on the board of directors of The Learning Center at the Els Center of Excellence–a school for children with autism in Jupiter, Florida from its opening until 2023. Mr. John founded and was CEO of Jupiter Wellness, now Safety Shot (NASDAQ: SHOT), He purchased SRM Entertainment in 2021 that now trades (NASDAQ: SRM) and was the CEO OF Jupiter Wellness Acquisition Corp NASDAQ: JWAC now CJET). Mr. John was appointed due to his proven track record in driving business growth, his entrepreneurial spirit, and his ability to navigate complex financial landscapes. His deep understanding of markets and his experience in successfully launching and managing publicly traded companies make him uniquely qualified to lead the company's strategic initiatives.

**Dr. Glynn Wilson, Chief Executive Officer and Director,** has served as one of our directors since 03/26/2024 Mr. Wilson was appointed our Chief Executive Officer in 04/01/2024. Dr. Wilson previously served as a Director of TapImmune, Inc. from February 2005 until October 2018 and as Chief Executive Officer from July 2009 through September 2017 until its merger with Marker Therapeutics. Dr. Wilson also served as President of Auriga Laboratories, Inc. from June 1, 2005 through March 13, 2006, and as Chief Scientific Officer from March 13, 2016 through August 25, 2006. He was the Chief Scientific Officer at Tacora Corporation from 1994 to 1997 and was the Vice-President, R&D, at Access Pharmaceuticals from 1997 to 1998. Dr. Wilson was Research Area Head, Cell and Molecular Biology in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals from 1984-1989 and Worldwide Head of Drug Delivery at SmithKline Beecham from 1989 to 1994. He was an Assistant Professor at Rockefeller University, New York, in the laboratory of the Nobel Laureates, Sanford Moore and William Stein, from 1974 to 1979. Dr. Wilson was appointed as CEO due to his demonstrated success in leading public companies and approach to transforming scientific innovation into market-ready solutions. His ability to lead both scientific teams and corporate strategies ensures that the company can capitalize on its innovations and navigate complex regulatory and market environments, making him ideally suited to drive the company's growth and operational success.

**Markita L. Russell, Chief Financial Officer**, has over 20 years of experience in accounting. From June 2017 to August 2019, Ms. Russell served as controller at Quantum Admin Services / Beachway Therapy Center, LLC. From September 2019 to March 2020, Ms. Russell served as acting controller and consultant of Nautical Ventures Group, Inc. From April 2020 to August 2021, Ms. Russell served as the Staff Accountant for Stem Holdings Inc. Since August 2021, Ms. Russell has served as the controller for SRM, performing accounting functions for SRM-from accounts receivable and accounts payable management to inventory and fixed asset management, cash management and financial reporting utilized for the Company's Form 10-Q and Form 10-K filings with the U.S. Securities and Exchange Commission. Ms. Russell was appointed as CFO due to her extensive experience in managing financial operations and her expertise in SEC compliance and reporting. Her deep knowledge of corporate finance, combined with her hands-on experience in financial controls and regulatory filings, positions her as a key figure in ensuring the company's fiscal integrity and operational efficiency as it continues to grow.

**Dr. Hector Alila, Director**, has served as one of our directors since 03/27/2024. Dr. Alila brings 30 years of demonstrated scientific experience in product development and successful management leadership in biopharmaceutical industry. He is the Founding President and Chief Executive Officer of Esperance Pharmaceutical Inc., a clinical stage biopharmaceutical company that has successfully developed novel targeted cancer therapeutics currently in clinical development. Dr. Alila founded Esperance Pharmaceutical, Inc. in 2006. Prior to Esperance, Dr. Alila served as Senior Vice President of Drug Development at Protalex, Inc., where he led the development of a drug currently in clinical trials for treatment of autoimmune diseases. He was previously Vice President of Product Development at Cell Pathways, Inc., where he was responsible for the development cancer drugs, and a director of Biology/pharmacology at GeneMedicine, Inc., where he led product development of gene medicines. He also held several research, product development and management positions at SmithKline Beecham Pharmaceuticals. He obtained his Ph.D. in physiology and immunology from Cornell University. Dr. Alila was appointed to the board because of his exceptional expertise in drug development and his work in the field of cancer therapeutics. His leadership in advancing breakthrough biopharmaceutical innovations from concept to clinical trials, along with his strategic insight into both research and commercial development, brings invaluable experience to guide the company's growth.

**Christopher Galeta, Director,** has been a member of Florida Bar for the past 27 years. He is admitted to practice in all Courts in the State of Florida and the United States District Court Southern District of Florida. His career began defending insureds for many of the largest insurance companies in Florida and nationally. He went on the work as Associate Counsel for Travelers Insurance Company and GEICO Insurance Company. He moved into private practice where he continued to litigate liability claims for major insurance carriers. His practice expanded to include property, business, commercial litigation; and representation of individuals injured because of another's negligence. In 2012, Mr. Galeta started Christopher M. Galeta P.A., where he continued to focus on the same areas of law. In 2018, Mr. Galeta opened Ocean View Title & Escrow in Palm Beach Gardens, Florida that serves residential and commercial markets. His law practice now includes representation of individual/corporate buyers and sellers of commercial and residential properties, aircraft and pleasure marine craft. Mr. Galeta currently serves as in-house counsel for Off The Hook YS Inc. Mr. Galeta has been awarded the prestigious AV Preeminent Rating from Martindale Hubbell and included in Florida's Legal Elite. He was selected to serve as a director because of his extensive legal experience with contracts and business agreements. His background in advising companies on contractual matters provides valuable perspective to the Board, and we believe his professional skills and judgment make him well-suited to serve as a director.

**Christopher Melton, Director,** was appointed to the board of Safety Shot in 2019. He has served as a specialist land acquisition advisor with SVN since 2019 and is a licensed real estate salesperson in the State of South Carolina and Georgia. Mr. Melton co-founded Callegro Investments in 2012 to invest in distressed master-planned communities. Mr. Melton also serves on several public and private boards, including Safe & Green Development and SRM Entertainment. From 2008 to 2012 Mr. Melton capitalized various media and retail ventures including Bestival and Any Old Iron. From 2000 to 2008, Mr. Melton was a Portfolio Manager for Kingdon Capital Management ("Kingdon") in New York City, where he ran an $800 million book in media, telecom and Japanese investment. Mr. Melton opened Kingdon's office in Japan, where he set up a Japanese research company. From 1997 to 2000, Mr. Melton served as a Vice President at JPMorgan Investment Management as an equity research analyst, where he helped manage $500 million in REIT funds under management. Mr. Melton was a Senior Real Estate Equity Analyst at RREEF Funds in Chicago from 1995 to 1997. RREEF Funds is the real estate investment management business of Deutsche Bank's Asset Management division. Mr. Melton earned a Bachelor of Arts in Political Economy of Industrial Societies from the University of California, Berkeley in 1995. Mr. Melton earned Certification from University of California, Los Angeles's Anderson Director Education Program in 2014. Mr. Melton earned a certificate in cybersecurity for managers from MIT in 2021 and certificate in AI strategy from Cornell in 2023. Mr. Melton was appointed to the board due to his extensive investment experience, combined with his strong background in finance and portfolio management. As the Audit Chair, he brings critical oversight and governance experience, ensuring the integrity of the company's financial reporting. His unique skill set in both public and private sectors, along with his strategic insights into emerging trends positions him as a key advisor to guide the company's strategic direction and investment opportunities.

**Family Relationships**

There are no family relationships among any of our officers or directors.

**Corporate Governance**

Corporate governance refers to the policies and structure of the board of directors of a corporation, whose members are elected by and are accountable to the shareholders of the company. Corporate governance encourages establishing a reasonable degree of independence of the board from executive management and the adoption of policies to ensure the board recognizes the principles of good management. Our Board is committed to sound corporate governance practices, as such practices are both in the interests of shareholders and help to contribute to effective and efficient decision-making.

**Board of Directors**

Our Board is responsible for the stewardship of the Company, overseeing management and the enhancement of shareholder value. The Board is responsible for:

(a) adopting
 a strategic plan for the Company and reviewing the plan in light of management's assessment of emerging trends, the competitive
 environment, the opportunities for the business of the Company, risk issues, and significant business practices and products;

(b) ensuring
 that the risk management of the Company is prudently addressed;

(c) reviewing
 the Company's approach to human resource management and overseeing succession planning for management;

(d) reviewing
 the Company's approach to corporate governance, including an evaluation of the adequacy of the mandate of the Board, director
 independence standards and compliance with the Company's Code of Business Conduct and Ethics to be adopted upon the consummation
 of this offering and;

(e) upholding
 a comprehensive policy for communications with shareholders and the public at large.

The frequency of meetings of the Board and the nature of agenda items may change from year to year depending upon the activities of Caring Brands. Our board of directors intend to meet at least quarterly and at each meeting there is a review of the business of Caring Brands.

Our Board facilitate its exercise of independent supervision over the Company's management through meetings of the board held for the purposes of obtaining an update on significant corporate activities and plans, both with and without members of the Company's management being in attendance.

**Board Composition; Independence**

The NASDAQ listing standards require that a majority of our board of directors must be composed of "independent directors," which is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion of the company's board of directors would interfere with the director's exercise of independent judgment in carrying out the responsibilities of a director. The Board has determined that Christopher Melton, Christopher Galeta and Dr. Hector Alila, are considered to be independent. Our Board currently consists of five directors, three of whom are independent.

**Board Committees**

Our Board directs the management of our business and affairs and conducts its business through meetings of the Board and its standing committees. As of the date hereof, the Board has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. In addition, from time to time, special committees may be established under the direction of the board of directors when necessary to address specific issues.

 ****

***Audit Committee***

Our audit committee consists of Messrs. Melton, Galeta and Alila with Mr. Melton serving as the chairman. Our Board has determined that Mr. Melton is an "audit committee financial expert" within the meaning of the SEC regulations. Our Board has also determined that each member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board has examined each audit committee member's scope of experience and the nature of their employment in the corporate finance sector. The functions of this committee include:

● selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;

● helping to ensure the independence and performance of the independent registered public accounting firm;

● discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;

● developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;

● reviewing our policies on risk assessment and risk management;

● reviewing related party transactions;

● obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality-control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and

● approving (or, as permitted, pre-approving) all audit and all permissible non-audit services, other than de minimis non-audit services, to be performed by the independent registered public accounting firm

***Compensation Committee***

Our compensation committee consists of Messrs. Galeta, Alila and Melton with Mr. Alila serving as the chairman. The functions of the compensation committee will include:

● reviewing and approving, or recommending that our Board approve, the compensation of our executive officers;

● reviewing and recommending that our Board approve the compensation of our directors;

● reviewing and approving, or recommending that our Board approve, the terms of compensatory arrangements with our executive officers;

● administering our stock and equity incentive plans;

● selecting independent compensation consultants and assessing conflict of interest compensation advisers;

● reviewing and approving, or recommending that our Board approve, incentive compensation and equity plans; and

● reviewing and establishing general policies relating to compensation and benefits of our employees and reviewing our overall compensation philosophy.

***Nominating and Corporate Governance Committee***

Our nominating and corporate governance committee consists of Messrs. Galeta, Alila and Melton with Mr. Galeta serving as the chairman.

The functions of the nominating and governance committee will include:

● identifying and recommending candidates for membership on our Board;

● including nominees recommended by stockholders;

● reviewing and recommending the composition of our committees;

● overseeing our code of business conduct and ethics, corporate governance guidelines and reporting; and

● making recommendations to our Board concerning governance matters.

The nominating and corporate governance committee also annually reviews the nominating and corporate governance committee charter and the committee's performance.

**Board Leadership Structure and Role in Risk Oversight**

Our Board is primarily responsible for overseeing our risk management processes. Our Board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our assessment of risks. Our Board focuses on the most significant risks we face our general risk management strategy, and also ensures that risks we undertake are consistent with our Board's appetite for risk. While our Board oversees our risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our Board leadership structure supports this approach.

Our bylaws provide our Board with flexibility in its discretion to combine or separate the positions of Chairman of the Board and Chief Executive Officer. The Board currently separates the roles of Chief Executive Officer and Chairman of the Board in recognition of the differences between the two roles. Our Chief Executive Officer, who is also a member of our Board, is responsible for setting the strategic direction of the Company and the day-to-day leadership and performance of the Company, while the Chairman of the Board provides guidance to the Chief Executive Officer, sets the agenda for the Board meetings, presides over meetings of the Board and tries to reach a consensus on Board decisions. Although these roles are currently separate, the Board believes it should be able to freely select the Chairman of the Board based on criteria that it deems to be in the best interest of the Company and its stockholders, and therefore one person may, in the future, serve as both the Chief Executive Officer and Chairman of the Board.

**Code of Business Conduct and Ethics**

We have adopted a code of business conduct and ethics, applicable to all of our directors, officers, employees and all persons performing similar functions. A copy of the code is attached as Exhibit 14.1 to the Registration Statement of which this prospectus forms a part thereof. We expect that any amendments to the code, or any waivers of its requirements, will be disclosed in our public filings with the Commission.

**Corporate Governance Guidelines**

We have adopted a corporate governance guidelines that serve as a flexible framework within which our Board and its committees operate. These guidelines cover a number of areas including the size and composition of the Board, Board membership criteria and director qualifications, director responsibilities, Board agenda, roles of the chairman of the Board and Chief Executive Officer and Chief Financial Officer, meetings of independent directors, committee responsibilities and assignments, Board member access to management and independent advisors, director communications with third parties, director compensation, director orientation and continuing education, evaluation of senior management and management succession planning. A copy of our corporate governance guidelines is attached hereto as Exhibit 14.2 to the Registration Statement of which this prospectus forms a part thereof.

**Family Relationships**

None of our directors or executive officers has a family relationship as defined in Item 401 of Regulation S-K.

**Involvement in Certain Legal Proceedings**

To our knowledge, our directors and executive officers have not been involved in any of the following events during the past ten years:

&nbsp;&nbsp;&nbsp;&nbsp;1. any
 bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer
 either at the time of the bankruptcy or within two years prior to that time;

&nbsp;&nbsp;&nbsp;&nbsp;2. any
 conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor
 offenses);

3. being
 subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
 permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking
 activities or to be associated with any person practicing in banking or securities activities;

4. being
 found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated
 a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

5. being
 subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed,
 suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law
 or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or
 fraud in connection with any business entity; or

6. being
 subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization,
 any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members
 or persons associated with a member.

**EXECUTIVE AND DIRECTOR COMPENSATION**

**Summary Compensation Table**

The following table sets out the compensation paid or payable to the Named Executive Officers ("NEO") of the Company during the last two fiscal years:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year** | **Salary<br> ($)** | **Bonus<br> ($)** | **Stock Awards<br> ($)** | **Option Awards<br> ($)** | **Non-Equity Incentive Plan Compensation<br> ($)** | **Nonqualified Deferred Compensation Earnings<br> ($)** | **All Other Compensation<br> ($)** | **Total<br> ($)** |
| Dr. Glynn Wilson | 2024 | $165000 |  |  |  |  |  |  | $165000 |
| Chief Executive Officer | 2023 | $- |  |  |  |  |  |  |  |
| Markita Russell | 2024 | $- |  |  |  |  |  |  |  |
| Chief Financial Officer | 2023 | $- |  |  |  |  |  |  |  |
| Brian S John | 2024 | $137500 |  |  |  |  |  |  | $137500 |
| Executive Chairman | 2023 | $- |  |  |  |  |  |  |  |

---

**Director Compensation**

To date, we have not compensated our directors for their service to the Company.

**2024 NEO and non-NEO Compensation**

During the year ended December 31, 2024, the Company paid $302,500 to NEOs and $135,480 was paid to non-NEOs. The Company has two employment agreements as follows:

***<u>Dr. Glynn Wilson – Chief Executive Officer</u>***

 ****

On April 1, 2024, we entered into a written employment agreement with Dr. Glynn Wilson, pursuant to which Dr. Wilson shall serve as our Chief Executive Officer (the "Wilson Employment Agreement"). The Wilson Employment Agreement has an initial term of two (2) years and shall automatically renew for two (2) year periods unless otherwise terminated by either party. Dr. Wilson shall be paid a base salary of $250,000 annually, of which $75,000 will accrue until the company completes its IPO listing. The base salary shall increase by 10% for each calendar year thereafter. Dr. Wilson shall also be entitled to bonus payments based on targets established by mutual agreement, with the bonus amount to be determined by the compensation committee. The agreement also provides that Dr. Wilson will be eligible for annual cost of living adjustments based on the Consumer Price Index, participation in the company's stock option or restricted stock programs, and standard company benefits including health insurance and 401(k).

In the event of termination by the Company without cause, Dr. Wilson is entitled to receive six months of base salary as severance pay, reimbursement of insurance premiums for six months, and a pro-rata portion of any annual incentive bonus for the fiscal year in which termination occurs. These same benefits apply in the event of a change of control resulting in loss of employment.

***<u>Brian John – Chief Investment Officer</u>***

 ****

On April 1, 2024, we entered into a written employment agreement with Brian John, pursuant to which Mr. John shall serve as our Chief Investment Officer (the "John Employment Agreement"). The John Employment Agreement has an initial term of two (2) years and shall automatically renew for two (2) year periods unless otherwise terminated by either party. Mr. John shall be paid a base salary of $250,000 annually, of which $75,000 will accrue until the company completes its IPO listing. The base salary shall increase by 10% for each calendar year thereafter. Mr. John shall also be entitled to bonus payments based on targets established by mutual agreement, with the bonus amount to be determined by the compensation committee. The agreement also provides that Mr. John will be eligible for annual cost of living adjustments based on the Consumer Price Index, participation in the company's stock option or restricted stock programs, and standard company benefits including health insurance and 401(k).

In the event of termination by the Company without cause, Mr. John is entitled to receive six months of base salary as severance pay, reimbursement of insurance premiums for six months, and a pro-rata portion of any annual incentive bonus for the fiscal year in which termination occurs. These same benefits apply in the event of a change of control resulting in loss of employment.

**External Management Companies**

The Company has not entered into any agreement with any external management company that employs or retains one or more of the NEOs or directors and, other than as disclosed below, the Company has not entered into any understanding, arrangement or agreement with any external management company to provide executive management services to the Company, directly or indirectly, in respect of which any compensation was paid by the Company.

**Stock Options and Other Compensation Securities**

As of the date of this prospectus, the Company has granted no options under the Stock Option Plan to directors and/or NEOs of the Company, and no other compensation securities were granted or issued to any director and/or NEO for services provided or to be provided, directly or indirectly, to the Company or any of its subsidiaries.

During the year ended December 31, 2023 there was no exercise of options granted under the Stock Option Plan or other rights to acquire securities of the Company by NEOs or directors of the Company.

**Equity Incentive** **Plan** 

 

On September 30, 2024, our Board and our stockholders approved our Equity Incentive Plan (the "Plan"), which reserved a total of 2,000,000 shares of common stock for grant of awards. The awards may generally be issued to officers, key employees, consultants and directors and include the grant of nonqualified stock options, incentive stock options, stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance shares and performance units. No awards have been granted through December 31, 2024.

**Employment, Consulting and Management Agreements**

As of the date hereof, other than as described below, the Company does not have any contract, agreement, plan or arrangement that provides for payments to the named executive officers (the "NEOs") at, following, or in connection with any termination (whether voluntary, involuntary or constructive), resignation, retirement, a change in control of the Company or a change in a director or NEO's responsibilities.

**Pension Plan Benefits**

The Company does not anticipate having any deferred compensation plan or pension plan that provides for payments or benefits at, following or in connection with retirement.

**CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS**

The following is a description of transactions or series of transactions since our incorporation, to which we were or are to be a participant and in which the amount involved exceeds the lesser of $120,000 or 1% of the average of the total assets at December 31, 2024 and 2023, and in which any of our directors, executive officers or persons who we know hold more than five percent of any class of our capital stock, including their immediate family members, had or will have a direct or indirect material interest, other than compensation arrangements with our directors and executive officers.

Prior to September 24, 2024 , Caring Brands Florida was consolidated into Safety Shot's financial statements as a majority-owned subsidiary of Safety Shot. Immediately following this offering, Safety Shot will continue to own approximately 21.26% of our outstanding Common Stock, and our financial results will not be consolidated with Safety Shot for financial statement reporting purposes. As a result, Safety Shot will not have the power acting alone to approve any action requiring the affirmative vote of a majority of the votes entitled to be cast and to elect all of our directors.

Caring Brands's principal stockholder, has advanced funds to Caring Brand Florida to cover operations and other cash requirements as a wholly-owned subsidiary. At December 31, 2023 the amount of unpaid advance totaled $290,263 As part of the terms of the Separation and Exchange Agreement, Safety Shot waived the outstanding balance of $275,876 at September 24, 2024 (the Closing Date), and treated it as additional paid in capital.

During the period from our inception to the date herein, Caring Brands, Inc (Florida) advanced us $745 for incorporation and formation fees of Caring Brands (Nevada).

During the year ended year December 31, 2024, cash flow from financing activities were sufficient to cover operations and at December 31, 2024 we had $341,406 of working capital.

On September 24, 2024, we entered into the Separation and Exchange Agreement with Safety Shot to govern the separation of our business from Safety Shot. The material terms of such agreement with Safety Shot relating to our historical relationship, this offering and our relationship with Safety Shot after this offering are described below.

Nancy Torres was a Director of the Company until May 21, 2025 and is the CEO of NOVODX Corporation, a Delaware corporation ("NOVODX"). In May 2024, NOVODX participated in the Company's private placement by acquiring 500,000 shares of the Company's common stock for $500,000 cash, representing an approximate 4% equity ownership in the Company. In June, 2024, the Company invested $500,000 in NOVODX's private placement to purchase 25,134 shares of NOVODX common stock representing less than 1% of NOVODX. On June 20, 2024, the Company entered into a Research Collaboration and Non-Exclusive License Agreement, as amended and restated on July 22, 2024 (the License Agreement") with NOVODX. NOVODX is a diagnostic company dedicated to the development and commercialization of innovative health products, with a primary focus on rapid diagnostic screenings and their companion therapeutics. The Company is engaged in the research and development of rapid diagnostic devices intended for both Over the Counter ("OTC") and Point of Care ("POC") applications. NOVODX aims to manufacture, market, and sell these devices, either directly or indirectly, for use in at-home diagnostic screenings. NOVODX possesses or has the rights to use (through licenses or other agreements) certain assets, patent applications, and associated know-how, technology, scientific, and technical information. Collectively, these resources are referred to as the GoldNTM Ebola Rapid Test Technical Information, which pertains to the development of an Ebola diagnostic test (the "Ebola Rapid Test"). The agreement provides for issuance of 3,000,000 shares of restricted common stock, which were issued upon the agreement's effectiveness. An initial payment of $100,000 is due within 30 days of the S-1 registration statement's effectiveness. Milestone payments include $1,000,000 payable upon NOVODX receiving 510K/EUA approval and $500,000 when annual net sales reach $5 million. Royalties are set at 5% of net sales under $500 million and 3% of net sales exceeding $500 million. The agreement remains in effect until the earlier of the royalty term expiration or agreement termination. It does not permit sublicensing or assignment, requires a 90-day notice for termination.

We do not currently expect to enter into any additional agreements or other transactions with Safety Shot outside the ordinary course or with any of our directors, officers or other affiliates, other than those specified below. Any transactions with directors, officers or other affiliates will be subject to requirements of Sarbanes-Oxley and SEC rules and regulations.

**Relationship with Safety Shot**

***Historical Relationship with Safety Shot***

Prior to January 1, 2024, Safety Shot provided certain services to Caring Brands Florida on a limited basis. Safety Shot made no allocations of these costs to us. The services include accounting, insurance and shared facilities. Beginning January 1, 2024, the Company ceased using any services previously provided by Safety Shot, except for office space for three employees at no cost to the Company.

Safety Shot owned majority of the issued and outstanding ordinary shares of Caring Brands Florida, which operated certain portions of Safety Shot's wellness consumer products business (the "CB Business") and owns all of the assets and liabilities related thereto.

Following the completion of this offering, we will be subject to the reporting requirements of the Exchange Act. We will be required to establish procedures and practices as a stand-alone public company in order to comply with our obligations under the Exchange Act and related rules and regulations. As a result, we may incur additional costs, including, investor relations, stock administration and regulatory compliance costs.

***Safety Shot as a Stockholder***

Subsequent to the closing of this offering and distribution of 600,000 shares its shares to its shareholders, Safety Shot will beneficially own [ ]% of the outstanding shares of Common Stock of the Company.

***Arrangements Between Safety Shot and Our Company***

We and Safety Shot entered into the Separation and Exchange Agreement that governs the separation of our business from Safety Shot, provides a framework for our relationship with Safety Shot after the separation and provides for the allocation between us and Safety Shot of Safety Shot's assets, liabilities and obligations attributable to periods prior to, at and after our separation from Safety Shot, as well as certain indemnification arrangements.

The material terms of the Separation and Exchange Agreement are summarized below. This summary is qualified in its entirety by reference to the full text of such agreement, which is filed as an exhibit to the registration statement of which this prospectus is a part.

When used in this section, "separation date" refers to the date on which we and Safety Shot effect the Business Transfer to contribute the Caring Brands business to us, which will occur prior to the date of this prospectus, and the term "distribution date" refers to the date, on which Safety Shot distributes a portion of its equity interest in us to the Safety Shot stockholders and certain warrant holders through the anticipated distribution.

 ****

***Safety Shot***  ***Related Party Transactions***

Prior to the separation, we will have a general policy that all material transactions with a related party, as well as all material transactions in which there is an actual, or in some cases, perceived, conflict of interest, will be subject to prior review and approval by our Audit Committee and its independent members, who will determine whether such transactions or proposals are fair and reasonable to Caring Brands and its stockholders. In general, potential related-party transactions will be identified by our management and discussed with our Audit Committee at its meetings. Detailed proposals, including, where applicable, financial and legal analyses, alternatives and management recommendations, will be provided to our Audit Committee with respect to each issue under consideration, and decisions will be made by our Audit Committee with respect to the foregoing related-party transactions after opportunity for discussion and review of materials. When applicable, our Audit Committee will request further information and, from time to time, will request guidance or confirmation from internal or external counsel or auditors.

After the distribution, certain of our directors and officers will continue to own stock and/or stock options or other equity awards of Safety Shot. These ownership interests could create actual, apparent or potential conflicts of interest when these individuals are faced with decisions that could have different implications for our Company and for Safety Shot and its subsidiaries.

In addition, the Company may engage in material business transactions with Safety Shot.

**Exchange Agreement**

On September 24, 2024, we entered into the Separation and Exchange Agreement with Safety Shot, which sets forth the agreement between us and Safety Shot to effect our separation from Safety Shot, this offering and the distribution of our shares to Safety Shot's stockholders.

 ****

***The Separation***

● On March 15, 2024, Safety Shot acquired 3,000,000 shares of our Common Stock (representing 22.83% of our outstanding common stock post-exchange);

● in exchange for all of the issued and outstanding ordinary shares of Caring Brand Florida owned by Safety Shot, the Company assumed all the expenses related to the CB Business;

● Currently both the Company and Safety Shot share the same office premises and related facilities. Safety Shot agrees that the Company may maintain its presence at the current office location until such time as it is mutually agreed that the Company requires its own office and facilities, or the Parties agree on a monthly sub-lease arrangement; and

● The separation agreement was effective on September 24, 2024.

***Claims***

At or prior to the effective time of the registration statement of which this prospectus forms a part, Safety Shot has agreed to, for itself and each of its subsidiaries and their respective successors and assigns, and, to the extent permitted by law, all individuals who at any time prior to the effective time of the registration statement of which this prospectus forms a part have been stockholders, directors, officers, agents or employees of Safety Shot (in each case, in their respective capacities as such), remise, release and forever discharge (i) the Company and their respective successors and assigns, including Caring Brand Florida, and (ii) all stockholders, directors, officers, agents or employees of the Company or Caring Brand Florida other than Safety Shot (the "Caring Brand Persons", in each case, in their respective capacities as such), and their respective heirs, executors, administrators, successors and assigns, from (A) all of the liabilities of Safety Shot, (B) all liabilities arising from or in connection with the transactions and all other activities to implement the separation of the Company from Safety Shot, Business Transfer, this offering and the Distribution and (C) all damages arising from or in connection with actions, inactions, events, omissions, conditions, facts or circumstances occurring or existing prior to or following the effectiveness of the registration statement of which this prospectus forms a part (whether or not such labilities cease being contingent, mature, become known, are asserted or foreseen, or accrue, in each case before, at or after the effectiveness of the registration statement of which this prospectus forms a part), in each case to the extent relating to, arising out of or resulting from the business of Safety Shot or any liability of Safety Shot (the "Safety Shot Liabilities"). To avoid ambiguity, Safety Shot agrees that in the event that an action is brought against Safety Shot related to the separation of the Company from Safety Shot, the Business Transfer, this offering or the distribution, Safety Shot agrees not to bring any claim against the Company or any Caring Brands Person.

***Public Offering***

For a description of Safety Shot's ownership interest in us after the completion of this offering, see the section titled "—*Safety Shot as a Stockholder*."

***The Distribution***

On [ ], 2025, the board of directors of Safety Shot declared the distribution by Safety Shot of 600,000 outstanding shares of our Common Stock to Safety Shot stockholders and certain warrant holders of record as of the close of business on [ ]. The distribution will be paid on or after the effective time of the registration statement of which this prospectus forms a part and prior to the closing of this offering.

Please see the section titled "*The Distribution*" for a description of the distribution of securities beginning on page 8.

In the Distribution, each holder of Safety Shot Common Stock will receive a distribution of one share of our Common Stock for every [ ] shares of Safety Shot Common Stock held as of the close of business on [ ], the record date.

**Manner of Effecting the Distribution**

The general terms and conditions relating to the distribution are set forth in the Separation and Exchange Agreement between us and Safety Shot. The distribution will be effective following the effectiveness of this registration statement date which the registration statement of which this prospectus forms a part is declared effective. For most Safety Shot stockholders who own Safety Shot common stock in registered form on the record date, our transfer and distribution agent will credit their shares of our Common Stock to book entry accounts established to hold these shares. Our transfer and distribution agent will send these stockholders a statement reflecting their ownership of our Common Stock. Book-entry refers to a method of recording stock ownership in our records in which no physical certificates are used. For stockholders who own Safety Shot common stock through a broker or other nominee, their shares of our Common Stock will be credited to these stockholders' accounts by the broker or other nominee. As further discussed below, fractional shares will not be distributed. Following the distribution, stockholders whose shares are held in book entry form may request that their shares of our Common Stock be transferred to a brokerage or other account at any time, as well as delivery of physical stock certificates for their shares, in each case without charge.

SAFETY SHOT STOCKHOLDERS WILL NOT BE REQUIRED TO PAY FOR SHARES OF OUR COMMON STOCK RECEIVED IN THE DISTRIBUTION, OR TO SURRENDER OR EXCHANGE SHARES OF SAFETY SHOT COMMON STOCK IN ORDER TO RECEIVE OUR COMMON STOCK, OR TO TAKE ANY OTHER ACTION IN CONNECTION WITH THE DISTRIBUTION. NO VOTE OF SAFETY SHOT STOCKHOLDERS IS REQUIRED OR SOUGHT IN CONNECTION WITH THE DISTRIBUTION, AND SAFETY SHOT STOCKHOLDERS HAVE NO APPRAISAL RIGHTS IN CONNECTION WITH THE DISTRIBUTION.

Fractional shares of our Common Stock will not be issued to Safety Shot stockholders as part of the distribution or credited to book entry accounts. In lieu of receiving fractional shares, the number of shares of Common Stock to be received in the distribution will be rounded down to the nearest whole share of Common Stock. An explanation of the tax consequences of the distribution can be found below in the subsection captioned "— *Material U.S. Federal Income Tax Consequences of the Distribution*." The distribution of Caring Brands Common Stock in respect of the Safety Shot shares and the July Warrants is expected to be taxable to both Safety Shot and holders of the Safety Shot shares or the July Warrants. See "*The Distribution — Material U.S. Federal Income Tax Consequences of the Distribution*."

If the Safety Shot board of directors terminates Safety Shot's obligation to complete the distribution or waives a material condition to the distribution after the date of this prospectus, we intend to issue a press release disclosing this waiver or Safety Shot will file a current report on Form 8-K with the SEC.

We will cooperate with Safety Shot to accomplish the distribution and will, at Safety Shot's direction, promptly take any and all actions necessary or desirable to effect the distribution.

Please see "*The Distribution*" for a more detailed description of the matters described below.

***Intellectual Property Matters***

All intellectual property is currently licensed in the name of Caring Brands, Inc.

***Termination***

The Separation and Exchange Agreement may be terminated and the separation and distribution may be amended, modified or abandoned at any time prior to the effective time of the registration statement of which this prospectus forms a part, but not after the entry into the underwriting agreement unless the closing of this offering does not occur following such entry in accordance with the terms of the underwriting agreement.

***Indemnification***

In addition, the Separation and Exchange Agreement provides for cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of our business with us and financial responsibility for the obligations and liabilities of Safety Shot's business with Safety Shot. Specifically, each party will indemnify, defend and hold harmless the other party, its affiliates and subsidiaries and their respective officers, directors, employees and agents (collectively, the "indemnified parties") for any losses arising out of or otherwise in connection with:

● the liabilities that each such party assumed or retained pursuant to the Separation and Exchange Agreement (which, in our case, would include the Caring Brands Liabilities and, in the case of Safety Shot, would include the Safety Shot Liabilities) and the other transaction agreements;

● the failure of Safety Shot or us to pay, perform or otherwise promptly discharge any of the Safety Shot Liabilities or the Caring Brands Liabilities, respectively, in accordance with their terms, whether prior to, at or after the separation;

● any breach by such party of the Separation and Exchange Agreement or the other transaction agreements (other than the intellectual property rights cross-license agreement, which specifies the parties' obligations therein); and

● except to the extent relating to any Caring Brands Liability, in the case of Safety Shot, or a Safety Shot Liability, in our case, any guarantee, indemnification or contribution obligation, surety bond or other credit support agreement or arrangement for the benefit of Safety Shot or us, respectively.

We will also indemnify, defend and hold harmless the Safety Shot indemnified parties for any losses arising out of or otherwise in connection with any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, with respect to all information (1) contained in our registration statement on Form S-1, of which this prospectus is a part, or any prospectus (other than information provided by Safety Shot to us specifically for inclusion in our registration statement on Form S-1, of which this prospectus is a part, or any prospectus), (2) contained in any of our public filings with the SEC following this offering or (3) provided by us to Safety Shot specifically for inclusion in Safety Shot's annual or quarterly or current reports following this offering to the extent (A) such information pertains to us or the Caring Brands business or (B) Safety Shot has provided prior written notice to us that such information will be included in one or more annual or quarterly or current reports, specifying how such information will be presented, and the information is included in such annual or quarterly or current reports (except, in the case of clause (B), for liabilities arising out of or resulting from, or in connection with, any action or inaction of any member of Safety Shot, including as a result of any misstatement or omission of any information by Safety Shot to us).

Safety Shot will also indemnify, defend and hold harmless the Caring Brands indemnified parties for any losses arising out of or otherwise in connection with any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, with respect to all information (1) contained in our registration statement on Form S-1, of which this prospectus is a part, or any prospectus provided by Safety Shot specifically for inclusion therein to the extent such information pertains to (A) Safety Shot or (B) Safety Shot's business (for the avoidance of doubt, other than the Caring Brands business) or (2) provided by Safety Shot to us specifically for inclusion in our annual or quarterly or current reports following this offering to the extent (A) such information pertains to (x) Safety Shot or (y) Safety Shot's business (for the avoidance of doubt, other than the Caring Brands business) or (B) we have provided written notice to Safety Shot that such information will be included in one or more annual or quarterly or current reports, specifying how such information will be presented, and the information is included in such annual or quarterly or current reports (except, in the case of clause (B), for liabilities arising out of or resulting from, or in connection with, any action or inaction of ours, including as a result of any misstatement or omission of any information by us to Safety Shot.

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following tables set forth certain information with respect to the beneficial ownership of our shares of common stock for:

● each
 shareholder known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock,

● each
 of our directors,

● each
 of our named executive officers, and

● all
 of our directors and executive officers as a group.

We have determined beneficial ownership in accordance with the rules of the SEC. Under such rules, beneficial ownership includes any shares of common stock over which the individual has sole or shared voting power or investment power as well as any shares of common stock that the individual has the right to subscribe for within 60 days of December 31, 2024, through the exercise of any warrants or other rights. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power or the power to receive the economic benefit with respect to all shares of common stock that they beneficially own, subject to applicable community property laws. None of the shareholders listed in the table are a broker-dealer or an affiliate of a broker dealer.

Applicable percentage ownership prior to the offering is based on 13,336,925 shares of common stock outstanding as of July 30, 2025 and 14,336,925 shares after the offering (assuming no exercise of the over-allotment option by the underwriters). Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Caring Brands, Inc., 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950.

---

| | | | |
|:---|:---|:---|:---|
| | | **Percentage of Shares**<br> **Beneficially Owned** | **Percentage of Shares**<br> **Beneficially Owned** |
| <br>**Name** | **Shares Beneficially**<br>**Owned before <br> Offering** | **Before <br> Offering** | **After <br> Offering<sup>(1)</sup>** |
| **Directors and Named Executive Officers** |  |  |  |
| Dr. Glynn Wilson | 2000000 | 15.0% | 13.9% |
| Markita Russell | 150000 | 1.1% | 1.0% |
| Brian S John | 2000000 | 15.0% | 13.9% |
| Dr. Hector Alila | 50000 | 0.4% | 0.3% |
| Chritopher Galeta |  |  |  |
| Christopher Melton |  |  |  |
| All Directors and Officers as a group (6 persons) | 4200000 | 31.5% | 29.3% |
| **5% Stockholders** |  |  |  |
| Safety Shot<sup>(1)</sup> | 3000000 | 22.5% | 20.9% |
| NovoDX | 3500000 | 26.2% | 24.4% |

---

(1) Includes 600,000 shares of common stock to be distributed
 to the Safety Shot shareholders

**DESCRIPTION OF SECURITIES**

*The following description of our capital stock and the provisions of our articles of incorporation and our bylaws are summaries and are qualified by reference to the articles of incorporation and the bylaws. We have filed copies of these documents with the SEC as exhibits to our registration statement of which this prospectus forms a part.*

**General**

Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.001 per share

**Common Stock**

*Common stock outstanding*

As of June 30, 2025, there were 13,336,925 shares of our common stock issued and outstanding.

*Voting rights*

Subject to the rights granted to holders of any preferred stock issued by us, each share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of stockholders. The holders are not permitted to vote their shares cumulatively.

*Dividend rights*

Subject to the rights granted to holders of any preferred stock issued by us, holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board out of funds legally available.

*Rights upon liquidation*

Subject to the rights granted to holders of any preferred stock issued by us, upon our liquidation, dissolution or winding up, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities.

*Other rights*

Holders of our common stock do not have any pre-emptive rights or other subscription rights, conversion rights, redemption or sinking fund provisions.

Preferred Stock

**Warrants and Options**

In April 2024, the Company conducted a private placement of units in which it entered into individual securities purchase agreements with certain accredited investors for the sale of units at a price per unit of $1.00, consisting of one share of common stock and a warrant to purchase one share of common stock at a price of $3.00 per share, which warrants expire on April 15, 2029.

During the second quarter of 2024, we sold 2,110,000 shares of common stock and issued 2,110,000 warrants exercisable at $3.00. The shares underlying the warrants are being registered for resale pursuant to the Resale Prospectus.

During 2024, four of our Directors, Dr. Alila, Mr. Glynn, Brian John, and Christopher Melton, each entered into an Independent Director's Agreement. In 2025, Christopher Galeta entered into an Independent Director's Agreement. In connection with the agreements, the Directors are "to be granted" granted stock options. To date no options have been granted.

**Anti-Takeover Effects**

Our amended articles of incorporation and bylaws will include a number of provisions that may have the effect of delaying, deferring or preventing a party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our Board rather than pursue non-negotiated takeover attempts. The provisions include the items described below.

 ****

***Potential Effects of Authorized but Unissued Stock***

We have additional shares of common stock available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock.

The existence of unissued and unreserved common stock and preferred stock may enable our Board to issue shares to persons friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, our Board has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the NRS and subject to any limitations set forth in our articles of incorporation. The purpose of authorizing the Board to issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock.

***Limitations of Director Liability and Indemnification of Directors, Officers and Employees***

Nevada law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors.

Our bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by law, and may indemnify employees and other agents. Our bylaws also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding.

We also maintain customary directors' and officers' liability insurance.

Our bylaws, subject to the provisions of Nevada Law, contain provisions which allow the corporation to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he or she reasonably believed was in the best interest of the corporation. Insofar as indemnification for liabilities arising under the Securities Act of 1933 as amended, or the Securities Act, may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

The limitation of liability and indemnification provisions in our bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

At present, there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.

***Requirements for Advance Notification of Stockholder Nominations and Proposals***

Our bylaws establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors.

 ****

***Limits on Special Meetings***

Special meetings may be called for any purpose and at any time by the Chairman of the Board, the President (if there be one) or by any member of the Board. Business transacted at each special meeting shall be confined to the purposes stated in the notice of such meeting.

***Election and Removal of Directors***

Our Board is elected annually by our stockholders. The number of directors that shall constitute the whole Board shall not be less than five nor more than seven directors. Directors are elected by a plurality of the votes of shares of our capital stock present in person or represented by proxy at a meeting and entitled to vote in the election of directors. Each director shall hold office until a successor is duly elected and qualified or until his or her earlier death, resignation or removal.

Newly created directorships resulting from any increase in the number of directors or any vacancies in the Board resulting from death, resignation, retirement, disqualification, removal from office or any other cause may be filled, so long as there is at least one remaining director, only by the Board, provided that a quorum is then in office and present, or by a majority of the directors then in office, if less than a quorum is then in office, or by the sole remaining director. Directors elected to fill a newly created directorship or other vacancies shall hold office until such director's successor has been duly elected and qualified or until his or her earlier death, resignation or removal as hereinafter provided.

Any director may be removed from office at any time for cause, at a meeting called for that purpose, but only by the affirmative vote of the holders of a majority of the shares entitled to vote at a meeting at which a quorum is present shall decide any question brought before such meeting, unless the question is one on which, by express provision of law, the articles of incorporation, or the bylaws, the vote of a greater number of shares is required,.

Our articles of incorporation and bylaws do not provide for cumulative voting in the election of directors.

***Amendments to Our Governing Documents***

The affirmative vote of the holders of a majority of the shares entitled to vote at a meeting at which a quorum is present shall decide any question brought before such meeting, unless the question is one on which, by express provision of law, the articles of incorporation, or the bylaws, the vote of a greater number of shares is required, in which case such express provision shall govern and control the decision of such question..

Our bylaws may be amended or repealed and new bylaws may be adopted by the stockholders and/or the Board. Any bylaws adopted, amended or repealed by the Board may be amended or repealed by the stockholders.

**Listing**

We intend to apply to list our common stock on the NASDAQ under the symbol "CBRA". No assurance can be given that our application will be approved.

**Transfer Agent, Warrant Agent and Registrar**

The transfer agent and registrar for our common stock and warrant agent for the Warrants offered in his offering is ClearTrust, LLC.

**SHARES ELIGIBLE FOR FUTURE SALE**

Prior to this offering, there has been no market for our shares of common stock, and a liquid trading market for our shares of common stock may not develop or be sustained after this offering. Future sales of substantial amounts of our shares of common stock in the public market or the perception that such sales might occur could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our shares of common stock in the public market after the restrictions lapse. This may adversely affect the prevailing market price of our shares of common stock and our ability to raise equity capital in the future.

After completion of this offering, we will have 14,336,925 shares of common stock outstanding, or 14,486,925 shares of Common Stock outstanding if the underwriters exercise their over-allotment option in full.

All the shares of common stock sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, unless the shares are purchased by our "affiliates" as that term is defined in Rule 144 and except certain shares that will be subject to the lock-up period described below after completion of this offering. Any shares owned by our affiliates may not be resold except in compliance with Rule 144 volume limitations, manner of sale and notice requirements, pursuant to another applicable exemption from registration or pursuant to an effective registration statement.

As of the date of this prospectus, all of our outstanding securities except the shares covered under the Resale Prospectus, are anticipated to be subject to 180 days lock-up restriction described under "Underwriting". Accordingly, there will be a corresponding increase in the number of shares that become eligible for sale after the lock-up period expires. As a result of these agreements, subject to the provisions of Rule 144 or Rule 701, shares will be available for sale in the public market as follows:

● beginning
 on the date of this prospectus, all the shares sold in this offering will be immediately available for sale in the public market
 (except as described above);

● beginning
 180 days following the date on which the trading of the securities on the NASDAQ commences, at the expiration of the lock-up period
 for the existing securityholders, all of our currently outstanding shares of common stock will become eligible for sale in the public
 market, of which [ ] shares will be held by affiliates and subject to the volume and other restrictions of Rule
 144 and Rule 701 as described below.

**Rule 144**

In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six (6) months, including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person would be entitled to sell those shares without complying with any of the requirements of Rule 144.

In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration of the lock-up agreements described above, within any three-month period, a number of shares that does not exceed the greater of:

● 1%
 of the number of shares of our shares of common stock then outstanding, which will equal approximately shares immediately after this
 offering; or

● the
 average weekly trading volume of our shares of common stock during the four calendar weeks preceding the filing of a notice on Form
 144 with respect to that sale.

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.

**Regulation S**

Regulation S under the Securities Act provides that securities owned by any person may be sold without registration in the United States, provided that the sale is affected in an "offshore transaction" and no "directed selling efforts" are made in the United States (as these terms are defined in Regulation S), subject to certain other conditions. In general, this means that our shares of common stock may be sold in some manner outside the United States without requiring registration in the United States.

**Rule 701**

Rule 701 generally allows a stockholder who purchased shares of our shares of common stock pursuant to a written compensatory plan or contract and who is not deemed to have been our affiliate during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also permits our affiliates to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares pursuant to Rule 701 and are subject to the lock-up agreements described above.

**CERTAIN INCOME TAX CONSIDERATIONS**

The following is a general discussion of certain material U.S. federal income tax considerations with respect to the ownership and disposition of shares of our common stock and Warrants applicable to non-U.S. holders who acquire our securities in this offering. This discussion is based on current provisions of the Internal Revenue Code, U.S. Treasury regulations promulgated thereunder and administrative rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time, possibly with retroactive effect.

For purposes of this discussion, the term "non-U.S. holder" means a beneficial owner of our securities that is not, for U.S. federal income tax purposes, a partnership or any of the following:

● a citizen or resident of the United States;

● a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia;

● an estate, the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or

● a trust if (1) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (2) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person for U.S. federal income tax purposes.

If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds shares of our securities, the tax treatment of a person treated as a partner generally will depend on the status of the partner and the activities of the partnership. Persons that for U.S. federal income tax purposes are treated as a partner in a partnership holding shares of our securities should consult their tax advisors.

This discussion assumes that a non-U.S. holder holds shares of our securities as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to a non-U.S. holder in light of that holder's particular circumstances or that may be applicable to holders subject to special treatment under U.S. federal income tax law (including, for example, financial institutions, brokers or dealers in securities, "controlled foreign corporations," "passive foreign investment companies," traders in securities that elect mark-to-market treatment, insurance companies, tax-exempt entities, holders who acquired our securities pursuant to the exercise of employee stock options or otherwise as compensation, entities or arrangements treated as partnerships for U.S. federal income tax purposes, holders liable for the alternative minimum tax, certain former citizens or former long-term residents of the United States and holders who hold our securities as part of a hedge, straddle, constructive sale or conversion transaction). In addition, this discussion does not address U.S. federal tax laws other than those pertaining to the U.S. federal income tax, nor does it address any aspects of the unearned income Medicare contribution tax pursuant to the Health Care and Education Reconciliation Act of 2010, any U.S. federal estate and gift taxes, or any U.S. state, local or non-U.S. taxes. Accordingly, prospective investors should consult with their own tax advisors regarding the U.S. federal, state, local, non-U.S. income and other tax considerations of acquiring, holding and disposing of shares of our securities.

**THIS SUMMARY IS FOR GENERAL INFORMATION ONLY AND IS NOT INTENDED TO CONSTITUTE A COMPLETE DESCRIPTION OF ALL TAX CONSEQUENCES RELATING TO THE OWNERSHIP AND DISPOSITION OF OUR SECURITIES. WE RECOMMEND THAT PROSPECTIVE HOLDERS OF OUR SECURITIES CONSULT WITH THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES TO THEM (INCLUDING THE APPLICATION AND EFFECT OF ANY FEDERAL, STATE, LOCAL, NON-U.S. INCOME AND OTHER TAX LAWS) OF THE OWNERSHIP AND DISPOSITION OF OUR SECURITIES.**

**Allocation of Investment in Securities**

An investor in this offering will be required to allocate cost of the acquisition of the securities between the shares of common stock and warrants acquired based on their relative fair market values.

**Dividends**

In general, any distributions we make to a non-U.S. holder with respect to its shares of our common stock that constitute dividends for U.S. federal income tax purposes will be subject to U.S. withholding tax at a rate of 30% of the gross amount (or a reduced rate prescribed by an applicable income tax treaty) unless the dividends are effectively connected with a trade or business carried on by the non-U.S. holder within the United States (and, if an income tax treaty applies, are attributable to a permanent establishment of the non-U.S. holder within the United States). A distribution will constitute a dividend for U.S. federal income tax purposes to the extent of our current or accumulated earnings and profits as determined for U.S. federal income tax purposes. Any distribution not constituting a dividend will be treated as first reducing the adjusted basis in the non-U.S. holder's shares of our common stock and, to the extent it exceeds the adjusted basis in the non-U.S. holder's shares of our common stock, as gain from the sale or exchange of such shares. Any such gain will be subject to the treatment described below under "—Gain on Sale or Other Disposition of our Common Stock."

Subject to the discussion below regarding "—Foreign Account Tax Compliance," dividends effectively connected with a U.S. trade or business (and, if an income tax treaty applies, attributable to a U.S. permanent establishment) of a non-U.S. holder generally will not be subject to U.S. withholding tax if the non-U.S. holder complies with applicable certification and disclosure requirements. Instead, such dividends generally will be subject to U.S. federal income tax on a net income basis, in the same manner as if the non-U.S. holder were a resident of the United States. A non-U.S. holder that is a corporation may be subject to an additional "branch profits tax" at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on its "effectively connected earnings and profits," subject to certain adjustments.

**Gain on Sale or Other Disposition of Our Securities**

In general, a non-U.S. holder will not be subject to U.S. federal income or, subject to the discussion below under the headings "Information Reporting and Backup Withholding" and "Foreign Account Tax Compliance," withholding tax on any gain realized upon the sale or other disposition of our securities unless:

● the gain is effectively connected with a trade or business carried on by the non-U.S. holder within the United States and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment of the non-U.S. holder;

● the non-U.S. holder is an individual and is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are satisfied; or

● we are or have been a U.S. real property holding corporation (a "USRPHC") for U.S. federal income tax purposes at any time within the shorter of the five-year period ending on the date of the disposition and the non-U.S. holder's holding period and certain other conditions are satisfied. We believe that we currently are not and we do not anticipate becoming, a USRPHC.

Gain that is effectively connected with the conduct of a trade or business in the United States generally will be subject to U.S. federal income tax, net of certain deductions, at regular U.S. federal income tax rates. If the non-U.S. holder is a foreign corporation, the branch profits tax described above also may apply to such effectively connected gain. An individual non-U.S. holder who is subject to U.S. federal income tax because the non-U.S. holder was present in the United States for 183 days or more during the year of sale or other disposition of our securities will generally be subject to a flat 30% tax on the gain derived from such sale or other disposition, which may be offset by U.S. source capital losses, provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses.

**Information Reporting and Backup Withholding**

We must report annually to the Internal Revenue Service and to each non-U.S. holder the amount of dividends paid to and the tax withheld with respect to, each non-U.S. holder. These reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable tax treaty. Copies of this information also may be made available under the provisions of a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established.

U.S. backup withholding tax (currently, at a rate of 28%) is imposed on certain payments to persons that fail to furnish the information required under the U.S. information reporting rules. Dividends paid to a non-U.S. holder generally will be exempt from backup withholding if the non-U.S. holder provides a properly executed IRS Form W-8BEN or W-8BEN-E, or otherwise establishes an exemption.

Under U.S. Treasury regulations, the payment of proceeds from the disposition of our securities by a non-U.S. holder effected at a U.S. office of a broker generally will be subject to information reporting and backup withholding, unless the beneficial owner, under penalties of perjury, certifies, among other things, its status as a non-U.S. holder or otherwise establishes an exemption. The payment of proceeds from the disposition of our securities by a non-U.S. holder effected at a non-U.S. office of a broker generally will not be subject to backup withholding and information reporting, except in the case of proceeds from a disposition of our securities by a non-U.S. holder effected at a non-U.S. office of a broker that is:

● a U.S. person;

● a "controlled foreign corporation" for U.S. federal income tax purposes;

● a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or

● a foreign partnership if at any time during its tax year (a) one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership, or (b) the foreign partnership is engaged in a U.S. trade or business.

Information reporting will apply unless the broker has documentary evidence in its files that the owner is a non-U.S. holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no knowledge or reason to know to the contrary). Backup withholding will apply if the sale is subject to information reporting and the broker has actual knowledge that the owner is a U.S. person.

Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder generally can be refunded or credited against the non-U.S. holder's U.S. federal income tax liability, if any, provided that the required information is furnished to the Internal Revenue Service in a timely manner. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.

**Foreign Account Tax Compliance**

Under Sections 1471 through 1474 of the Code and the Treasury regulations and administrative guidance promulgated thereunder (collectively, "FATCA"), a U.S. federal withholding tax of 30% generally is imposed on any dividends paid on our common stock and a U.S. federal withholding tax of 30% generally will be imposed on gross proceeds from the disposition of our securities (beginning January 1, 2019) paid to (i) a "foreign financial institution" (as specifically defined under FATCA) unless such institution enters into an agreement with the U.S. tax authorities to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) and (ii) certain other foreign entities unless such entity provides the withholding agent with a certification identifying its direct and indirect "substantial U.S. owners" (as defined under FATCA) or, alternatively, provides a certification that no such owners exist and, in either case, complies with certain other requirements. The withholding tax described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules and properly certifies its exempt status to a withholding agent or is deemed to be in compliance with FATCA. Application of FATCA tax does not depend on whether the payment otherwise would be exempt from U.S. federal withholding tax under the other exemptions described above. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. Foreign financial institutions and non-financial foreign entities located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Prospective non-U.S. holders should consult with their tax advisors regarding the possible implications of FATCA on their investment in our securities.

**UNDERWRITING**

We intend to enter into an underwriting agreement with D. Boral Capital LLC ("D. Boral") who is acting as the sole underwriter in connection with this offering (also, the "Representative"), with respect to the offering of shares of Common Stock. Under the terms and subject to the conditions in the underwriting agreement between us and the Representative, we have agreed to issue and sell to the underwriters, and the underwriters have agreed to purchase, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of shares of Common Stock listed next to its name in the following table, other than those shares of Common Stock covered by the over-allotment option described below:

---

| | |
|:---|:---|
|  | **Number of<br> Shares** |
| D. Boral Capital LLC | 1000000  |
| Total | 1000000 |

---

The underwriters are committed to purchase all of the securities offered by us other than those covered by the over-allotment option described below, if it purchases any securities. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters' obligations are subject to customary conditions, representations, and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers' certificates and legal opinions.

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities.

The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer's certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

**Over-Allotment Option**

We have granted to the Representative an over-allotment option. This option, which is exercisable for up to 45 days from the date of this prospectus, permits the Representative to purchase up to an additional 150,000 shares of Common Stock (fifteen (15%) of the shares of Common Stock sold in this offering) at the public offering price listed on the cover page of this prospectus, less the underwriting discounts and commissions. The Representative may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of Common Stock offered by this prospectus. If the Representative exercises the option in whole or in part, then the underwriters will be severally committed, subject to the conditions described in the underwriting agreement, to purchase the additional shares of Common Stock in proportion to their respective commitments set forth in the prior table.

**Commissions and Discounts**

The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession. After the initial offering, the public offering price, concession or any other term of this offering may be changed.

The following table shows the public offering price, underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the Representative of its option to purchase additional shares.

---

| | | | |
|:---|:---|:---|:---|
|  | **Per Share** | **Without <br> Over-allotment Option** | **With <br> Over-allotment Option** |
| Public offering price | $4.00 | $4000000 | $4600000 |
| Underwriting discount | $0.32 | $320000 | $368000 |
| Proceeds, before expenses, to us | $3.68 | $3680000 | $4232000 |

---

We have also agreed to reimburse the underwriters for certain of their expenses relating to the offering including but not limited to the following: (a) all filing fees and communication expenses associated with the review of this offering by FINRA; (b) all fees, expenses and disbursements relating to the registration, qualification or exemption of securities offered under the securities laws of foreign jurisdictions designated by the underwriters, including the reasonable fees and expenses of the underwriters' blue sky counsel; (c) up to $20,000 of the Representative's actual accountable road show expenses for the offering; (d) $29,500 for the underwriters' use of Ipreo's book-building, prospectus tracking and compliance software for this offering; (e) the costs associated with bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones not to exceed $5,000; and (f) the fees and expenses of the Representatives' legal counsel incurred in connection with this offering in an amount up to $175,000, or up to $50,000 if there is no closing of this offering

We have also agreed to pay the Representative a non-accountable expense allowance equal to one percent (1.0%) of the gross proceeds received from the sale of shares of Common Stock. The non-accountable expense allowance will be paid through a deduction from the net proceeds of the offering.

The expenses of this offering, not including the underwriting discount, are estimated at $ and are payable by us.

**Representative's Warrants**

We have agreed to issue to the Representative Representative's Warrants to purchase up to an aggregate of shares of 30,000 shares of Common Stock (equal to three percent (3.0%) of the shares of Common Stock sold in this offering, including any shares of Common Stock sold upon exercise of the Representative's over-allotment option) at per share price of $4.00 (equal to 100% of the public offering price per share in this offering). The Representative's Warrants may also be exercised on a cashless basis. The Representative's Warrants are exercisable at any time and from time to time, in whole or in part, beginning on a date that is six (6) months following the commencement of sales pursuant to this prospectus and will expire five years from the date of such commencement of sales.

The Representative's Warrants are deemed underwriter compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The Representative or its designees (or their permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days following the commencement of sales pursuant to this prospectus. In addition, the Representative's Warrants provide for registration rights, including a one-time demand registration right within five years and unlimited piggyback registration rights within seven years from the commencement of sales in this offering in compliance with FINRA Rule 5110(g)(8)(B)-(D). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the Representative's Warrants other than underwriting commissions incurred and expenses of any legal counsel payable by the holders. The exercise price and number of shares of Common Stock issuable upon exercise of the Representative's Warrants may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger, or consolidation.

**Lock-Up Agreements**

The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Representative, it will not, for a period of one-hundred and eighty (180) days after the Closing of the Offering (the "Lock-Up Period"), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or caused to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank, or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise. Additionally, the Company's directors and officers and any other holder(s) (except the ones covered under the Resale Prospectus) of 10% or more of the outstanding shares of Common Stock as of the effective date of the Registration Statement (and all such holders of securities exercisable for or convertible into shares of Common Stock) shall enter into customary "lock-up" agreements in favor of the Representative pursuant to which such persons and entities shall agree, for a period of one-hundred and eighty (180) days after the Closing of Offering, that they shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company, subject to customary exceptions. The foregoing restrictions shall also be contained and set forth in the Underwriting Agreement and customary "lock-up" agreements, as applicable.

**Tail Financing**

We have granted the Representative the right, subject to FINRA Rule 5110(g)(5)(B), for a period of twelve (12) months after the termination of the Representative's engagement with us, to receive a cash fee equal to eight percent (8.0%) of the gross proceeds received by us from the sale of any equity, debt and/or equity derivative instruments to any investor actually introduced by the Representative to the Company in connection with any public or private financing or capital raise, provided that such transaction is by a party actually introduced to us in an offering in which we have direct knowledge of such party's participation.

**Listing**

We have applied to list our Common Stock for trading on Nasdaq under the symbol "CBRA" We cannot guarantee that our Common Stock will be approved for listing on Nasdaq. However, the consummation of this offering and the distribution are contingent on such approval by Nasdaq. We will not consummate this offering or the distribution unless our Common Stock is so listed.

**Right of First Refusal**

We have granted the Representative the right of first refusal, for a period of twelve (12) months from the closing of the offering, to act as sole investment banker, sole book-runner, and/or sole placement agent, at the Representative's sole discretion, for each and every future public and private equity and debt offering, including all equity linked financings, subject to certain exceptions, during such twelve (12) month period, of the Company on terms and conditions customary to the representative for such subject transactions. The Representative shall have the sole right to determine whether any other broker dealer shall have the right to participate in a subject transaction and the economic terms of such participation. The Company shall not retain, engage or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent in a subject transaction without the express written consent of the Representative.

**Determination of the Public Offering Price**

Currently, our common stock is quoted on the OTCQB under the symbol "CBRA", and there is a limited market for our common stock. The public offering price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the public offering price are:

● the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,

● our financial information,

● the history of, and the prospects for, our company and the industry in which we compete,

● an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues,

● the present state of our development and

● the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.

An active trading market for the shares of Common Stock may not develop. It is also possible that after this offering the shares of Common Stock will not trade in the public market at or above the public offering price.

**Price Stabilization, Short Positions and Penalty Bids**

Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing our Common Stock. However, the representatives may engage in transactions that stabilize the price of the Common Stock, such as bids or purchases to peg, fix or maintain that price.

The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.

Similar to other purchase transactions, the underwriters' purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of shares of our Common Stock or preventing or retarding a decline in the market price of shares of our Common Stock. As a result, the price of shares of our Common Stock may be higher than the price that might otherwise exist in the open market. The underwriters may conduct these transactions on the NASDAQ, in the over-the-counter market or otherwise.

Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of shares of our Common Stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

**Electronic Distribution**

A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members. The Representative may agree to allocate a number of securities to underwriters and selling group members for sale to its online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us, and should not be relied upon by investors.

**Other Relationships**

The underwriters and their respective affiliates are full-service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates may, in the future, provide investment and commercial banking and financial advisory services to us and our affiliates in the ordinary course of business, for which they may receive customary fees and commissions. In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of ours. The underwriters and their respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

**Selling Restrictions Outside the United States**

No action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the Common Stock the possession, circulation or distribution of this prospectus or any other material relating to us or the Common Stock in any jurisdiction where action for that purpose is required. Accordingly, the Common Stock may not be offered or sold, directly or indirectly, and neither this prospectus nor any other material or advertisements in connection with the Common Stock may be distributed or published, in or from any country or jurisdiction except in compliance with any applicable laws, rules and regulations of any such country or jurisdiction.

***Japan.*** Shares of Common Stock have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) and, accordingly, will not be offered or sold directly or indirectly in Japan or to, or for the benefit of any Japanese person or to others, for re-offering or re-sale directly or indirectly in Japan or to any Japanese person, except in each case pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Securities and Exchange Law of Japan and any other applicable laws, rules and regulations of Japan. For purposes of this paragraph, "Japanese person" means any person resident in Japan, including any corporation or other entity organized under the laws of Japan.

***Malaysia.*** No prospectus or other offering material or document in connection with the offer and sale of the Common Stock has been or will be registered with the Securities Commission of Malaysia (the "Malaysia Commission") for the Malaysia Commission's approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Common Stock may not be circulated or distributed, nor may the Common Stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i) a closed end fund approved by the Malaysia Commission; (ii) a holder of a Capital Markets Services License; (iii) a person who acquires the Common Stock, as principal, if the offer is on terms that the Common Stock may only be acquired at a consideration of not less than RM 250,000 (or its equivalent in foreign currencies) for each transaction; (iv) an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM 3 million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v) an individual who has a gross annual income exceeding RM 300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi) an individual who, jointly with his or her spouse, has a gross annual income of RM 400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii) a corporation with total net assets exceeding RM 10 million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii) a partnership with total net assets exceeding RM 10 million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi) any other person as may be specified by the Malaysia Commission; provided that, in the each of the preceding categories (i) to (xi), the distribution of the Common Stock is made by a holder of a Capital Markets Services License who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Malaysia Commission under the Capital Markets and Services Act 2007.

***People's Republic of China.*** This prospectus may not be circulated or distributed in the PRC and the Common Stock may not be offered or sold, and will not offer or sell to any person for re-offering or resale directly or indirectly to any resident of the PRC except pursuant to applicable laws, rules and regulations of the PRC. For the purpose of this paragraph only, the PRC does not include Taiwan and the special administrative regions of Hong Kong and Macau.

***Taiwan.*** The Common Stock has not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the Common Stock in Taiwan.

***Philippines*.** This prospectus may not be circulated or distributed in the Philippines and the Common Stock may not be offered or sold, and will not offer or sell to any person for re-offering or resale directly or indirectly to any resident of the Philippines except pursuant to applicable laws, rules and regulations of the Philippines.

**LEGAL MATTERS**

Certain legal matters relating to the offering as to U.S. federal law and the law of the State of New York in connection with this offering will be passed upon for us by Sichenzia Ross Ference Carmel LLP, New York, New York. Certain legal matters will be passed on for the underwriters by Lucosky Brookman LLP, Woodbridge, New Jersey.

**EXPERTS**

The financial statements of the Company as of and for the fiscal years ended December 31, 2024 and 2023 included in this prospectus have been audited by M&K CPAS, PLLC, independent registered public accounting firm as set forth in their report thereon appearing elsewhere herein, and included in reliance on such report upon the authority of said firm as experts in accounting and auditing.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further information about us and the shares of common stock offered hereby, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance, we refer you to the copy of such contract or other document filed as an exhibit to the registration statement.

We are subject to the information and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the SEC. These periodic reports, and other information are available for inspection and copying at the website of the SEC referred to above. You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. A copy of the registration statement and the exhibits filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is *www.sec.gov.*

**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS**

**Caring Brands, Inc.**

**(a Nevada corporation)**

Financial Statements

Unaudited Interim Consolidated Financial Statements for the Six Months Ended June 30, 2025 (Successor), Year Ended December 31, 2024 (Successor) and for the Six Months Ended June 30, 2024 (Predecessor)

---

| | |
|:---|:---|
| [Balance Sheets](#vf_002) | F-2 |
| [Statements of Operations](#vf_003) | F-3 |
| [Statements of Shareholders' Equity](#vf_004) | F-4 |
| [Statements of Cash Flow](#vf_005) | F-5 |
| [Notes to Financial Statements](#vf_006) | F-6 |

---

Audited Consolidated Financial Statements for the Years Ended December 31, 2024 and 2023

---

| | |
|:---|:---|
| [Balance Sheets](#zH_001) | F-12 |
| [Statements of Operations](#zH_002) | F-13 |
| [Statements of Shareholders' Equity](#zH_003) | F-14 |
| [Statements of Cash Flow](#zH_004) | F-15 |
| [Notes to Financial Statements](#zH_005) | F-16 |

---

**Caring Brands, Inc.**

(a Nevada Corporation)

**Condensed Consolidated Balance Sheets** 

 ****

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025**<br> **(Unaudited)** | **December 31, 2024** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $73893 | $468998 |
| Inventory | 13047 | 13689 |
| Prepaid expenses and deposits | 49685 | 44794 |
| &nbsp;&nbsp;&nbsp;Total current assets | 136625 | 527481 |
| Intellectual property (net) a related party | 2700000 | 2850000 |
| Investment in NovoDX a related party | 500000 | 500000 |
| &nbsp;&nbsp;&nbsp;Total other assets | 3200000 | 3350000 |
| &nbsp;&nbsp;&nbsp;Total assets | $3336625 | $3877481 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $176367 | $169432 |
| Related party loan payable | 50000 |  |
| Accrued expenses and other payables | 5235 | 16673 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 231602 | 186105 |
| Shareholders' Equity: |  |  |
| Preferred Stock. $0.001 par value, 1,000,000 authorized, no shares issued and outstanding |  |  |
| Common Stock, $0.001 par value, 100,000,000 authorized shares 13,336,925 and 13,110,000 issued and outstanding as of June 30, 2025 and December 31, 2024 respectively | 13337 | 13110 |
| Additional paid-in capital | 4773430 | 4541057 |
| Common stock payable | 382000 |  |
| Subscription receivable | (1600) |  |
| Accumulated deficit | (2062144) | (862791) |
| &nbsp;&nbsp;&nbsp;Total equity | 3105023 | 3691376 |
| &nbsp;&nbsp;&nbsp;Total liabilities and equity | $3336625 | $3877481 |

---

The accompanying notes are an integral part of these financial statements.

**Caring Brands, Inc**

(a Nevada Corporation)

**Consolidated Statements of Operations**

---

| | | |
|:---|:---|:---|
|  | **Successor** | **Predecessor** |
|  | **Six Months Ended<br> June 30, 2025** | **Six Months Ended<br> June 30, 2024** |
| Revenue | $3056 | $- |
| Cost of revenue | 1400 | - |
| Gross profit | 1656 |  |
| Operating expenses | 1200582 | 498482 |
| Interest (income) expense | 427 | - |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(1199353) | $(498482) |
| Net income (loss) per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.09) | n/a |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.09) | n/a |
| Weighted-average shares used to compute net income (loss) per share |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 13276331 | n/a |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 13276331 | n/a |

---

The accompanying notes are an integral part of these financial statements

**Caring Brands, Inc.**

(a Nevada Corporation)

**Consolidated Statement of Changes in Shareholders' Equity**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common<br> Stock** | | | | |
|  | **Shares** | <br>**Amount** | **Additional**<br> **Paid-in**<br>**Capital** | <br>**Deficit** | <br>**Total** |
| January 1, 2024 (Predecessor) |  | $- | $- | $(265774) | $(265774) |
| Net loss for the six-months ended June 30, 2024 |  |  |  | (498482) | (498482) |
| **Balance, June 30, 2024 (Predecessor)** | - | $- | $- | $(764256) | $(764256) |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Additional**<br> **Paid-in**<br>**Capital** | **Common Stock**<br>**Payable** | **Subscription**<br>**Receivable** |<br>**Deficit** |<br>**Total** |
| January 1, 2025 (Successor) | 13110000 | $13110 | $4541057 | $- | $- | $(862791) | $3691376 |
| Issuance of shares | 1525 | 2 | 5998 |  |  |  | 6000 |
| Shares issued for services | 225000 | 225 | 224775 |  |  |  | 225000 |
| Shares sold on subscription | 400 | $- | 1600 |  | (1600) |  |  |
| Common stock to be issued |  |  |  | 382000 |  |  | 382000 |
| Net loss for the six months ended June 30, 2025 | - | - | - | - | - | (1199353) | (1199353) |
| **Balance, June 30, 2025 (Successor)** | 13336925 | $13337 | $4773430 | $382000 | $(1600) | $(2062144) | $3105023 |

---

The accompanying notes are an integral part of these financial statements

**Caring Brands, Inc.**

(a Nevada Corporation)

**Statement of Cash Flows**

---

| | | |
|:---|:---|:---|
|  | **Successor** | **Predecessor** |
|  | **Six Months Ended<br> June 30, 2025** | **Six Months Ended<br> June 30, 2024** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(1199353) | $(498482) |
| &nbsp;&nbsp;&nbsp;Amortization of license agreement | 150000 |  |
| &nbsp;&nbsp;&nbsp;Fair value of shares issued for services | 607000 |  |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable |  | 354 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 642 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | (4891) | (2525) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 6935 | 124467 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | (11438) | 14005 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) operating activities | (451105) | (362181) |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows from investing activities | - | - |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loans from Safety Shot (Parent) |  | 2470 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loans from Affiliate |  | 664995 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related party loan payable | 50000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from shares | 6000 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows from financing activities | 56000 | 667465 |
| Net increase (decrease) in cash and cash equivalents | (395105) | 305284 |
| Cash and cash equivalents at the beginning of the period | 468998 | 18161 |
| Cash and cash equivalents at the end of the period | $73893 | $323445 |
| SUPPLEMENTAL CASH FLOW INFORMATION: |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $- | $- |
| &nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- | $- |
| &nbsp;&nbsp;&nbsp;Non-cash items |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock sold on subscription | $1600 | $- |

---

The accompanying notes are an integral part of these financial statements

**Caring Brands, Inc.**

(a Nevada Corporation)

**Notes to Financial Statements**

**Note 1 - Organization and Business Operations**

Caring Brands, Inc. (the "Company") is a Nevada corporation and was incorporated on April 24, 2024. On September 24, 2024, the Company entered into a separation and exchange agreement (the "Separation and Exchange Agreement") with Safety Shot, Inc. ("Shot") pursuant to which, Shot exchanged its right, title and interest in and to Caring Brands, Inc., a Florida corporation ("CB FL"), free and clear of all liens and encumbrances, and in exchange thereof, the Company accepted and agreed to assume all obligations of CB FL (see note 2 – Basis of Presentation and note 8 – Acquisition of Caring Brands, Inc. a Florida corporation). The Company's principal business is the over-the-counter and prescription-grade health and wellness products.

**Going Concern Consideration**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company was recently formed and has no operations, however the Company is seeking to become listed on the NASDAQ or the small cap equity market of the NYSE in order to raise additional capital. There is no assurance that the Company will have sufficient resources to execute its business which has raised doubt about the Company's ability to continue as a going concern as noted by our auditors, M&K CPAS, PLLC in their opinion on the December 31, 2024 financial statements.

**Note 2 - Significant Accounting Policies**

**Basis of Presentation**

The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of US Securities and Exchange Commission ("SEC"). The financial statements include: (i) the consolidated balance sheets of Caring Brands, Inc. (Nevada) (the "Successor") as of June 30, 2025 and December 31, 2024, (ii) the statements of operations for the six months ended June 30, 2025 for the Successor and for the six months ended June 30, 2024 for Caring Brands (Florida) ("Predecessor"), (iii) the statement of shareholders' equity and the statement of cash flows for the six month period ended June 30, 2024 and 2025 for the Predecessor and Successor respectively.

**Emerging Growth Company Status**

The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended, (the "Securities Act"), as modified by the Jumpstart our Business Startups Act of 2012, (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

**Use of Estimates**

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

The Company considers all short-term investments with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of cash flows.

**Inventory**

Inventories will be stated at the lower of cost or market. The Company will periodically review the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Inventory is based upon the average cost method of accounting.

**Net Loss Per Share of Common Stock**

Net income (loss) per share of Common Stock is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding during the period. If applicable, diluted earnings per share assume the conversion, exercise or issuance of all common stock instruments such as options, warrants, convertible securities and preferred stock, unless the effect is to reduce a loss or increase earnings per share. As such, options, warrants, convertible securities, and preferred stock are not considered in the calculations, as the impact of the potential shares of Common Stock would be to decrease the loss per share.

**Fair Value of Financial Instruments**

The fair value of the Company's assets and liabilities, which qualify as financial instruments under ASC Topic 820, "Fair Value Measurements and Disclosures," approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.

**Revenue Recognition**

The Company will generate its revenue from the sale of its products directly to the end user (the "customer"). The Company recognizes revenues by applying the following steps in accordance with FASB Accounting Standards Codification 606 "Revenue from Contracts with Customers" ("ASC 606"). Under ASC 606, revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

● identify the contract with a customer;

● identify the performance obligations in the contract;

● determine the transaction price;

● allocate the transaction price to performance obligations in the contract; and

● recognize revenue as the performance obligation is satisfied.

The Company's performance obligations are satisfied when goods or products are shipped on a FOB shipping point basis as title passes when shipped. Our products are generally paid in advance of shipment or standard net 30 days and we offer no specific right of return, refund or warranty related to our products except for cases of defective products of which there have been none to date.

**Accounts Receivable and Credit Risk**

Accounts receivable are generated from sales of the Company's products. The Company provides an allowance, if applicable, for doubtful collections, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions.

**Equity Investments**

Equity investments, including our investment in NovoDX common stock, are recorded at cost and the carrying value is adjusted to fair market value for each reporting period.

**Intellectual Property**

Intellectual property, including license agreements, are recorded at cost and amortized over the life of the License using the straight-line method. We evaluate Intellectual Property for impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. The Company's intellectual property is still in the early stages and there were no indicators of impairment that the company considered significant or to require testing at this time.

**Research and Development**

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Any acquired Research and Development would also be expensed as incurred unless there is an alternative use. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. Research and Development costs were $0 and $39,558 for the six month period ended June 30, 2025 and 2024 respectively.

**Stock based compensation**

The Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 "Compensation - Stock Compensation" ("ASC 718"). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

The Company has adopted ASU No. 2018-07 "Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting." These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.

**Segment Reporting**

The Company operates under one business segment. Our Chief Operating Decision Maker (CODM) is our Chief Executive Officer. The CODM considers total net income in evaluating key business results and all of our revenue comes from one business segment.

**Income Taxes**

Prior to the separation of the Company from its then parent (see Note – 9), the Company was included as a wholly-owned subsidiary of Safety Shot, Inc., and as such, the Company followed the guidance under ASC 740-10-30-27 to account for income taxes using the separate return approach. The Company accounts for income taxes under ASC 740 Income Taxes ("ASC 740"). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company incurred losses of $862,791 and $1,199,353 through December 31, 2024 and the six months ended June 30, 2025 respectively. Using a 21% tax rate the Company's deferred tax asset at December 31, 2024 and June 30, 2025 would be is $181,186 and $433,088 respectively with a valuation allowance of $181,186 and $433,088.

**Related parties**

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20 the related parties include a. affiliates of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. See Note 4 – Intellectual Property – License Agreement with a Related Party, Note 5 – Investment in NovoDX, a Related Party, Note 8 – Acquisition of Caring Brands, Inc., a Florida Corporation – by a Related Party and Note 9 – Related Party Loan.

The related party mentioned in note 4 and note 5 is a former director at Safety Shot, a director of Caring Brands mentioned in this registration statement and the CEO and a director of NovoDX Corporation. Additionally, NovoDX is a related party due to the shares of the Company's common stock it holds as a result of the shares issued in connection with the License Agreement described in Note 4.

**Note 3 – Cash**

At June 30, 2025 and December 31, 2024, the Successor had a cash balance of $73,893 and $468,998 respectively.

**Note 4 – Intellectual Property – License Agreement with a Related Party**

On June 18, <u>2024</u>, the Successor entered into a License Agreement with NovoDX Corporation, a related party, to license the NovoDX's GoldN<sup>TM</sup> Ebola Rapid Diagnostic Test to market and sell the Licensed Product within the commercial field, which was Amended and Restated on July 22, 2024. In consideration for the License, the Successor issued 3,000,000 shares of its restricted common stock to Nov<u>o</u>DX. The shares were issued at $1.00 per share, the same price as the private placement offering as described below and are being amortized over a 10-year period. For the six months ended June 30, 2025 the Successor had recognized $150,000 of amortization expense.

**Note 5 – Investment in NovoDX, a Related Party** 

On May 14, 2024, the Successor purchased 25,134 shares of NovoDX Corporation's restricted common stock for $500,000. NovoDX is a diagnostic company, focusing on health products related to rapid diagnostic screenings and their companion therapeutics. NovoDX is researching and developing rapid diagnostic devices for Over the Counter and Point of Care with the focus on manufacturing, marketing and selling, directly and indirectly, those devices for at home diagnostic screening use. The investment in NovoDX Corporation's restricted common stock (25,134 shares purchased for $500,000), representing less than 1% of the outstanding shares of NovoDX, is recorded at cost and the carrying value is adjusted to fair market value for each reporting period. We have chosen the fair value option to account for investment in NovoDX Corporation in accordance with ASC 321. The Successor had an independent valuation completed as of October 4, 2024. The valuation focused on the market approach. The valuation concluded that the recent equity transactions at $19.89 per share were the best indicator of fair value (total value of $500,000).

**Note 6 - Capital Structure**

***Common Stock*** – The Successor has 100,000,000 shares of Common Stock, par value $0.001 authorized and has issued 13,336,925 shares of its common stock as of June 30, 2025, comprised of the following:

● 7,600,000 issued at par value pursuant to Founders Stock Subscription Agreements dated March 15, 2024, and valued at par value of $0.001

● 2,110,000 issued at $1.00, the per share purchase price pursuant to private placements dated April to June 2024,

● 625,000 issued at $1.00 per share (the per share price paid under the private placements representing the most recent sale price) pursuant to a service agreement dated March 2024 and amended September 30, 2024, to provide consulting, administrative and accounting support to the Successor for 400,000 shares and an advisory agreement and a services agreement dated January 31, 2025 and February 25, 2025 respectively in exchange for 100,000 shares and 125,000 shares respectively,

● 3,000,000 issued at $1.00 per share (the per share price paid under the private placements representing the most recent sale price) shares issues pursuant to an Amended and Restated License Agreement dated July 22, 2024,

● and 1,925 issued at $4.00 per share and sold to outside investors at the expected price of the public offering. The Company has a receivable of $1,600 as of June 30, 2025 for the purchase of 400 of these shares issued.

***Preferred Stock*** – The Successor has 1,000,000 shares of preferred stock, par value $0.001 authorized and has issued no preferred shares.

***Common Stock Payable*** – The Successor committed 200,000 shares as of June 30, 2025 with a fair value of $1.91 per share, or $382,000 in exchange for services provided to the Company.

 ***Warrants*** – In April 2024, the Company issued 2,110,000 warrants to purchase common stock at a price of $3.00 per share, expiring on April 15, 2029. The warrants are only settled in shares with no cash option and were issued as part of the private placement.

**Note 7 - Commitments and Contingencies**

***Legal Proceedings***

The Successor may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

**Note 8 – Acquisition of Caring Brands, Inc., a Florida Corporation – a Related Party**

On September 24, 2024, the Successor entered into a separation and exchange agreement (the "Separation and Exchange Agreement") with Safety Shot, Inc., a related part, ("Shot") pursuant to which, Shot exchanged its right, title and interest in and to Caring Brands, Inc., a Florida corporation (the "Predecessor"), free and clear of all liens and encumbrances, and in exchange thereof, the Successor paid no cash or other asset consideration; however, the Successor agreed to assume all future obligations of the Predecessor. The separation has been accounted for as a related party transaction in which the assets and liabilities are recorded at their respective historical value. The assets and liabilities assumed in the transaction are as follows:

---

| | |
|:---|:---|
| Cash | $132650 |
| Prepaid expenses | 48175 |
| &nbsp;&nbsp;&nbsp;Total Assets | 180825 |
| Accounts payable | $160167 |
| Accrued liabilities | 7887 |
| Intercompany debt | 657311 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 825363 |
| Net book value | $(644538) |

---

The following unaudited pro forma statement of operations for the year ended December 31, 2024, reflects the separation pursuant to the Separation Agreement, as if it occurred on January 1, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |<br>**Successor** |<br>**Predecessor** | **Pro Forma**<br>**Adjustments** |<br>**Pro Forma** |
| Revenue | $465 | $- | $- | $465 |
| Cost of revenue | 2072 | - | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | 2072 |
| Gross profit | (1607) |  |  | (1607) |
| Operating expenses | 871214 | 654573 |  | 1525787 |
| Interest expense (income) | (10030) | 67 |  | (9963) |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(862791) | $(654640) | $- | $(1517431) |

---

**Note 9 – Related Party Loan**

The Company entered into a short-term loan with one of its founders in June 2025 to provide short-term working capital funding to the business. The loan is due on October 30, 2025 and has an 8% interest rate.

**Note 10 - Subsequent Events**

In accordance with ASC Topic 855-10, the Successor has analyzed its operations through August 20, 2025, which is the date these financial statements were available to be issued.

In July 2025, the Company entered into a short-term loan with its chairman of the board to provide short-term working capital funding to the business. The loan is due on October 30, 2025 and has an 8% interest rate.

In July 2025, the Company entered into a consulting arrangement with a finance professional to provide services to the Company in connection with its registration statement. The agreement includes compensation of 100,000 stock options with a strike price of $1.45. Half of the options vest immediately and the remainder vest on a monthly basis in 10,000 option increments.

In August 2025, the Company entered into an agreement with a service provider to provide investor relation services to the business. The agreement becomes effective after the uplist of the Company to NASDAQ. The agreement includes compensation of 60,000 shares of restricted stock of the Company.

In August 2025, the Company entered into an agreement with Greentree Financial Group, Inc. to provide professional services to the company in exchange for a cash fee, and 200,000 shares of the Company's common stock. This agreement also includes an equivalent amount of warrants with an exercise price of $4.00 per share and expires on August 6, 2030. The Company also entered into a convertible promissory note for the amount of $200,000. The note has an annual interest rate of 10% and the note can be drawn in up to four tranches with the maturity date being five years from the date the tranche was drawn. The term of the agreement allows Greentree Financial Group, Inc. to convert all outstanding note balances, plus any outstanding interest charges and late fees, into common stock with a conversion price of $2.00 per share, or the latest sale price of common stock, whichever is less.

![](audit_001.jpg)

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Caring Brands, Inc. (a Nevada Corporation)

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheet of Caring Brands, Inc. (a Nevada Corporation) and (the Company) as of December 31, 2024 and the related consolidated statements of operations, statements of changes in shareholders' equity, and cash flows for the period from April 24, 2024 (inception) to December 31, 2024 ("the Successor"). We have also audited the accompanying balance sheet of Caring Brands, Inc. (a Florida Corporation), as of December 31, 2023 and the related statements of operations, changes in shareholders' equity, and cash flows for the period from January 1, 2024 to September 24, 2024 and the year ended December 31, 2023 ("collectively referred as "the Predecessor"), and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company and Predecessor as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the periods described above, in conformity with accounting principles generally accepted in the United States of America.

**The Company's Ability to Continue as a Going Concern**

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the accompanying financial statements, the Company has incurred recurring losses from operations, generated negative cash flows from operating activities and had an accumulated deficit that raises substantial doubt about the Company's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans in regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provides a reasonable basis for our opinion.

**Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

**Going Concern**

As discussed in Note 1, the Company has incurred recurring losses from operations, generated negative cash flows from operating activities and had an accumulated deficit that raises substantial doubt about the Company's ability to continue as a going concern.

We evaluated the appropriateness of the going concern, we examined and evaluated the financial information along with management's plans to mitigate the going concern and management's disclosure on going concern.

/s/ M&K CPAS, PLLC

We have served as the Company's auditor since 2024.

The Woodlands, Texas

April 7, 2025

**Caring Brands, Inc.**

(a Nevada Corporation)

**Balance Sheets**

 ****

---

| | | |
|:---|:---|:---|
|  | **Successor** | **Predecessor** |
|  | **December 31, 2024** | **December 31, 2023** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $468998 | $18161 |
| Accounts receivable |  | 354 |
| Inventory | 13689 |  |
| Prepaid expenses and deposits | 44794 | 4400 |
| &nbsp;&nbsp;&nbsp;Total current assets | 527481 | 22915 |
| Intellectual property (net) a related party | 2850000 |  |
| Investment in NovoDX a related party | 500000 | - |
| &nbsp;&nbsp;&nbsp;Total other assets | 3350000 | - |
| &nbsp;&nbsp;&nbsp;Total assets | $3877481 | $22915 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $169432 | $20665 |
| Accrued expenses and other payables | 16673 | 1069 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 186105 | 21734 |
| Loans from Safety Shot, Inc. (Parent) | - | 266955 |
| &nbsp;&nbsp;&nbsp;Total Liabilities |  | 288689 |
| Shareholders' Equity: |  |  |
| Preferred Stock. $0.001 par value, 1,000,000 authorized, no shares issued and outstanding |  |  |
| Successor Common Stock, $0.001 par value, 100,000,000 authorized shares 13,110,000 issued and outstanding | 13110 |  |
| Predecessor Common Stock, none issued |  |  |
| Additional paid-in capital | 4541057 |  |
| Retained Earnings (Deficit) | (862791) | (265774) |
| &nbsp;&nbsp;&nbsp;Total equity (deficit) | 3691376 | (265774) |
| &nbsp;&nbsp;&nbsp;Total liabilities and equity | $3877481 | $22915 |

---

The accompanying notes are an integral part of these financial statements.

**Caring Brands, Inc**

(a Nevada Corporation)

**Statement of Operations**

---

| | | | |
|:---|:---|:---|:---|
|  | **Successor** | **Predecessor** | **Predecessor** |
|  | **April 24 to December 31, 2024** | **January 1 to September 24, 2024** | **Year ended December 31, 2023** |
| Revenue | $465 | $- | $20421 |
| Cost of revenue | 2072 | - | 118874 |
| Gross profit | (1607) |  | (98453) |
| Operating expenses | 871214 | 654573 | 52941 |
| Gain on sale of assets |  |  | (23308) |
| Interest expense (income) | (10030) | 67 | - |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(862791) | $(654640) | $(128086) |
| Pro forma net income (loss) per share: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.07) | n/a | $n/a |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.07) | n/a | $n/a |
| Pro forma weighted-average shares used to compute net income (loss) per share |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 11737251 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 11737251 |  |  |

---

The accompanying notes are an integral part of these financial statements

**Caring Brands, Inc.**

(a Nevada Corporation)

**Statement of Changes in Shareholders' Equity**

**For the period from Inception (April 24, 2024) to December 31, 2024**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | **Subscriptions**<br>**Receivable** | **Additional**<br> **Paid-in**<br>**Capital** |<br>**Deficit** |<br>**Total** |
| Inception, April 24, 2024 |  | $- | $- | $- | $- | $- |
| Issuance of Founder shares | 7600000 | 7600 | (150) |  |  | 7450 |
| Issuance of private placement shares, net | 2110000 | 2110 |  | 1788995 |  | 1791105 |
| Shares issued and payable for intellectual property | 2500000 | 2500 |  | 2497500 |  | 2500000 |
| Shares issued for intellectual property | 500000 | 500 |  | 499500 |  | 500000 |
| Shares issued for services | 400000 | 400 |  | 399600 |  | 400000 |
| Cash received from subscriptions receivable |  |  | 150 |  |  | 150 |
| Net book value of assets and liabilities acquired |  |  |  | (644538) |  | (644538) |
| Net loss for the year months ended December 31, 2024 |  |  |  |  | (862791) | (862791) |
| **Balance, December 31, 2024** | 13110000 | $13110 | $- | $4541057 | $(862791) | $3691376 |

---

The accompanying notes are an integral part of these financial statements

**Caring Brands, Inc.**

(a Nevada Corporation)

**Statement of Cash Flows**

---

| | | | |
|:---|:---|:---|:---|
|  | **April 24 to December 31, 2024** | **January 1 to September 24, 2024** | **Year ended December 31, 2023** |
| Cash flows from operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(862791) | $(654640) | $(128086) |
| &nbsp;&nbsp;&nbsp;Depreciation |  |  | 2200 |
| &nbsp;&nbsp;&nbsp;Gain on sale of assets |  |  | (23308) |
| &nbsp;&nbsp;&nbsp;Amortization of license agreement | 150000 |  |  |
| &nbsp;&nbsp;&nbsp;Fair value of shares issued for services | 400000 |  |  |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable |  | 354 | 18 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (13689) |  | 81241 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | (44794) | (43775) | (4400) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 169432 | 139502 | 18711 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 16673 | 6816 | (5008) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) operating activities | (185169) | (551743) | (58632) |
| Cash flows from investing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of assets |  |  | 39100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase of NovoDX Stock | (500000) | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows from investing activities | (500000) | - | 39100 |
| Cash flows from financing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loans from Safety Shot (Parent) |  |  | 15390 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of Founder Shares | 7600 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from Private Placement (net) | 1791105 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loans to CBI FL prior to acquisition | (644538) | 666232 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows from financing activities | 1154167 | 666232 | 15390 |
| Net increase (decrease) in cash and cash equivalents | 468998 | 114489 | (4142) |
| Cash and cash equivalents at the beginning of the period | - | 18161 | 22303 |
| Cash and cash equivalents at the end of the period | $468998 | $132650 | $18161 |
| SUPPLEMENTAL CASH FLOW INFORMATION: |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $- | $- | $- |
| &nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- | $- | $- |
| &nbsp;&nbsp;&nbsp;Non-cash items |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares for intellectual property | $3000000 | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loan forgiveness by Safety Shot | $- | $275873 | $- |

---

The accompanying notes are an integral part of these financial statements

**Caring Brands, Inc.**

(a Nevada Corporation)

**Notes to Financial Statements**

**Note 1 - Organization and Business Operations**

Caring Brands, Inc. (the "Company") is a Nevada corporation and was incorporated on April 24, 2024. On September 24, 2024, the Company entered into a separation and exchange agreement (the "Separation and Exchange Agreement") with Safety Shot, Inc. ("Shot") pursuant to which, Shot exchanged its right, title and interest in and to Caring Brands, Inc., a Florida corporation ("CB FL"), free and clear of all liens and encumbrances, and in exchange thereof, the Company accepted and agreed to assume all obligations of CB FL (see note 2 – Basis of Presentation and note 8 – Acquisition of Caring Brands, Inc. a Florida corporation). The Company's principal business is the over-the-counter and prescription-grade health and wellness products.

**Going Concern Consideration**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company was recently formed and has no operations, however during the period of Inception to December 31, 2024, the Company has (i) completed a private placement for $2,110,000 (the "private placement") which netted the Company $1,791,105 after expenses, (ii) completed the acquisition of CB FL and (iii) is seeking to become listed on the NASDAQ or the small cap equity market of the NYSE. Although the Company completed the private Placement and acquisition, there is no assurance that the Company will have sufficient resources to execute its business which has raised doubt about the Company's ability to continue as a going concern as noted by our auditors, M&K CPAS, PLLC in their opinion on the December 31, 2024 financial statements.

**Note 2 - Significant Accounting Policies**

**Basis of Presentation**

The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of US Securities and Exchange Commission ("SEC"). The financial statements include: (i) the consolidated financial statements of Caring Brands, Inc. (Nevada)(the "Successor") for the period from Inception (April 24, 2024) to December 31, 2024, giving effect to the acquisition of Caring Brands (Florida) and the financial statements of Caring Brands, Inc. (Florida)(the "Predecessor") for the period from January 1, 2024 to September 24, 2024; and (ii) the financial statements of Predecessor for the year ended December 1, 2023.

**Emerging Growth Company Status**

The Company is an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended, (the "Securities Act"), as modified by the Jumpstart our Business Startups Act of 2012, (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

**Use of Estimates**

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

The Company considers all short-term investments with a maturity of three months or less when purchased to be cash and equivalents for purposes of the statement of cash flows.

**Inventory**

Inventories will be stated at the lower of cost or market. The Company will periodically review the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Inventory is based upon the average cost method of accounting.

**Net Loss Per Share of Common Stock**

Net income (loss) per share of Common Stock is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding during the period. If applicable, diluted earnings per share assume the conversion, exercise or issuance of all common stock instruments such as options, warrants, convertible securities and preferred stock, unless the effect is to reduce a loss or increase earnings per share. As such, options, warrants, convertible securities, and preferred stock are not considered in the calculations, as the impact of the potential shares of Common Stock would be to decrease the loss per share.

**Fair Value of Financial Instruments**

The fair value of the Company's assets and liabilities, which qualify as financial instruments under ASC Topic 820, "Fair Value Measurements and Disclosures," approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.

**Revenue Recognition**

The Company will generate its revenue from the sale of its products directly to the end user (the "customer").

The Company recognizes revenues by applying the following steps in accordance with FASB Accounting Standards Codification 606 "Revenue from Contracts with Customers" ("ASC 606"). Under ASC 606, revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

● identify the contract with a customer;

● identify the performance obligations in the contract;

● determine the transaction price;

● allocate the transaction price to performance obligations in the contract; and

● recognize revenue as the performance obligation is satisfied.

The Company's performance obligations are satisfied when goods or products are shipped on a FOB shipping point basis as title passes when shipped. Our products are generally paid in advance of shipment or standard net 30 days and we offer no specific right of return, refund or warranty related to our products except for cases of defective products of which there have been none to date.

**Accounts Receivable and Credit Risk**

Accounts receivable are generated from sales of the Company's products. The Company provides an allowance, if applicable, for doubtful collections, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions.

***Equity Investments***

Equity investments, including our investment in NovoDX common stock, are recorded at cost and the carrying value is adjusted to fair market value for each reporting period.

***Intellectual Property***

Intellectual property, including license agreements, are recorded at cost and amortized over the life of the License using the straight-line method. We evaluate Intellectual Property for impairment whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. The Company's intellectual property is still in the early stages and there were no indicators of impairment that the company considered significant or to require testing at this time.

**Research and Development**

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Any acquired Research and Development would also be expensed as incurred unless there is an alternative use. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. Research and development costs were $0 and $39,558 for the Successor and Predecessor respectively for the year ended December 31, 2024 and $0 for the year ended December 31, 2023 for the Predecessor.

**Stock based compensation**

The Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 "Compensation - Stock Compensation" ("ASC 718"). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

The Company has adopted ASU No. 2018-07 "Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting." These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.

**Segment Reporting**

The Company operates under one business segment. Our Chief Operating Decision Maker (CODM) is our Chief Executive Officer. The CODM considers total net income in evaluating key business results and all of our revenue comes from one business segment.

**Income Taxes**

Prior to the separation of the Company from its then parent (see Note – 9), the Company was included as a wholly-owned subsidiary of Safety Shot, Inc., and as such, the Company followed the guidance under ASC 740-10-30-27 to account for income taxes using the separate return approach. The Company accounts for income taxes under ASC 740 Income Taxes ("ASC 740"). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company was formed on April 24, 2024, and incurred losses of $862,791 through December 31, 2024. Using a 21% tax rate the Company's deferred tax asset at December 31, 2024 is $181,186 with a valuation allowance of $181,186.

**Related parties**

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20 the related parties include a. affiliates of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. See Note 4 – Intellectual Property – License Agreement with a Related Party, Note 5 – Investment in NovoDX, a Related Party and Note 8 – Acquisition of Caring Brands, Inc., a Florida Corporation – by a Related Party.

The related party mentioned in these notes is a former director at Safety Shot, a director of Caring Brands mentioned in this registration statement and the CEO and a director of NovoDX Corporation. Additionally, NovoDX is a related party due to the shares of the Company's common stock it holds as a result of the shares issued in connection with the License Agreement described in Note 4.

**Note 3 – Cash**

At December 31, 2024, the Successor had a cash balance of $468,998 and at December 31, 2023, the Predecessor had a balance of $18,161.

**Note 4 – Intellectual Property – License Agreement with a Related Party**

On June 18, <u>2024</u>, the Successor entered into a License Agreement with NovoDX Corporation, a related party, to license the NovoDX's GoldN<sup>TM</sup> Ebola Rapid Diagnostic Test to market and sell the Licensed Product within the commercial field, which was Amended and Restated on July 22, 2024. In consideration for the License, the Successor issued 3,000,000 shares of its restricted common stock to Nov<u>o</u>DX. The shares were issued at $1.00 per share, the same price as the private placement offering as described below and are being amortized over a 10-year period. As of December 31, 2024, the Successor had recognized $150,000 of amortization expense.

**Note 5 – Investment in NovoDX, a Related Party** 

On May 14, 2024, the Successor purchased 25,134 shares of NovoDX Corporation's restricted common stock for $500,000. NovoDX is a diagnostic company, focusing on health products related to rapid diagnostic screenings and their companion therapeutics. NovoDX is researching and developing rapid diagnostic devices for Over the Counter and Point of Care with the focus on manufacturing, marketing and selling, directly and indirectly, those devices for at home diagnostic screening use. The investment in NovoDX Corporation's restricted common stock (25,134 shares purchased for $500,000), representing less than 1% of the outstanding shares of NovoDX, is recorded at cost and the carrying value is adjusted to fair market value for each reporting period. We have chosen the fair value option to account for investment in NovoDX Corporation in accordance with ASC 321. The Successor had an independent valuation completed as of October 4, 2024. The valuation focused on the market approach. The valuation concluded that the recent equity transactions at $19.89 per share were the best indicator of fair value (total value of $500,000).

**Note 6 - Capital Structure**

***Common Stock*** – The Successor has 100,000,000 shares of Common Stock, par value $0.001 authorized and has issued 13,110,000 shares of its common stock as of December 31, 2024, comprised of the following:

● 7,600,000 issued at par value pursuant to Founders Stock Subscription Agreements dated March 15, 2024, and valued at par value of $0.001

● 2,110,000 issued at $1.00, the per share purchase price pursuant to private placements dated April to June 2024,

● 400,000 issued at $1.00 per share (the per share price paid under the private placements representing the most recent sale price) pursuant to a service agreement dated March 2024 and amended September 30, 2024, to provide consulting, administrative and accounting support to the Successor,

● and 3,000,000 issued at $1.00 per share (the per share price paid under the private placements representing the most recent sale price) shares issues pursuant to an Amended and Restated License Agreement dated July 22, 2024.

***Preferred Stock*** – The Successor has 1,000,000 shares of preferred stock, par value $0.001 authorized and has issued no preferred shares.

**Note 7 - Commitments and Contingencies**

***Legal Proceedings***

The Successor may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

**Note 8 – Acquisition of Caring Brands, Inc., a Florida Corporation – a Related Party**

On September 24, 2024, the Successor entered into a separation and exchange agreement (the "Separation and Exchange Agreement") with Safety Shot, Inc., a related part, ("Shot") pursuant to which, Shot exchanged its right, title and interest in and to Caring Brands, Inc., a Florida corporation (the "Predecessor"), free and clear of all liens and encumbrances, and in exchange thereof, the Successor paid no cash or other asset consideration; however, the Successor agreed to assume all future obligations of the Predecessor. The separation has been accounted for as a related party transaction in which the assets and liabilities are recorded at their respective historical value. The assets and liabilities assumed in the transaction are as follows:

---

| | |
|:---|:---|
| Cash | $132650 |
| Prepaid expenses | 48175 |
| &nbsp;&nbsp;&nbsp;Total Assets | 180825 |
| Accounts payable | $160167 |
| Accrued liabilities | 7887 |
| Intercompany debt | 657311 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 825363 |
| Net book value | $(644538) |

---

The following unaudited pro forma statement of operations for the year ended December 31, 2024, reflects the separation pursuant to the Separation Agreement, as if it occurred on January 1, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |<br>**Successor** |<br>**Predecessor** | **Pro Forma**<br>**Adjustments** |<br>**Pro Forma** |
| Revenue | $465 | $- | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | $465 |
| Cost of revenue | 2072 | - | - | 2072 |
| Gross profit | (1607) |  |  | (1607) |
| Operating expenses | 871214 | 654573 |  | 1525787 |
| Interest expense (income) | (10030) | 67 |  | (9963) |
| &nbsp;&nbsp;&nbsp;Net Income (loss) | $(862791) | $(654640) | $- | $(1517431) |

---

**Note 9 - Subsequent Events**

In accordance with ASC Topic 855-10, the Successor has analyzed its operations subsequent to December 31, 2024 to the date these financial statements were issued and has determined that it does not have any additional material subsequent events to disclose in these financial statements.

![](fin_001.jpg)

**CARING BRANDS, INC.**

**1,000,000** **shares of common stock**

**PRELIMINARY PROSPECTUS**

**Sole** **Underwriter**

**D. BORAL CAPITAL LLC**

**_________, 2025**

Until, (25 days after commencement of our public offering), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

**The information in this prospectus is not complete and may be changed. Neither we, nor the selling stockholders may sell the securities described herein until the registration statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.**

---

| | | |
|:---|:---|:---|
| **PRELIMINARY PROSPECTUS** | **SUBJECT TO COMPLETION** | **DATED July 30, 2025** |

---

![](fin_002.jpg)

**CARING BRANDS, INC.**

**Up to 2,710,000 Shares of Common Stock**

This Resale Prospectus relates to 2,710,000 shares of common stock, $0.001 par value per share (the "Common Stock"), that may be sold from time to time by our stockholders identified in this prospectus, or their permitted transferees (collectively as the "Selling Stockholders"), which includes: (i) 2,110,000 shares of Common Stock (the "Warrant Shares") issuable upon the exercise of the warrants to purchase shares of Common Stock (the "Warrants") issued to Selling Stockholders pursuant to the private placements between April and June 2024 (the "Private Placements"), and (ii) 600,000 shares of Common Stock (the Distributed Shares," together with the Private Shares and the Warrant Shares as the "Resale Shares") distributed to the shareholders of our parent Safety Shot, Inc. ("Safety Shot").

The registration statement of which this prospectus forms a part also registers the distribution by Safety Shot of 600,000 shares of our Common Stock it owns to its stockholders and certain warrant holders.

Between April to June 2024, Caring Brands, Inc., a Florida Corporation ("Caring Brands Florida") received gross proceeds of $2,110,000 from a private placement of units (the "Bridge Financing"), at a price per unit of $1.00, consisting of one share of common stock and a warrant to purchase one share of common stock. Caring Brands Florida issued an aggregate of 2,110,000 shares of common stock and warrants to purchase up to 2,110,000 shares of common stock at an exercise price of $3.00 per share. Following the execution of the Separation and Exchange Agreement, the shares and warrants issued to the Selling Stockholders by Caring Brands Florida were exchanged for the Private Shares and the Warrants.

The Selling Stockholders must sell their shares at a fixed price per share of $4.00, which is the per share price of the shares being offered in our public offering, until such time as our shares are listed on a national securities exchange. Thereafter, the shares offered by this prospectus may be sold by the Selling Stockholders from time to time in the open market, through privately negotiated transactions or a combination of these methods, at market prices prevailing at the time of sale or at negotiated prices. By separate prospectus (the "Public Offering Prospectus"), we have registered an aggregate of 1,000,000 shares which we are offering for sale to the public through our underwriters, excluding any shares issuable upon the underwriters' over-allotment option. Both prospectuses, this Resale Prospectus and the Public Offering Prospectus, shall go effective simultaneously. Completion of this resale offering is contingent on the effectiveness of the Public Offering Prospectus.

The 2,710,000 shares of Common Stock offered by the selling stockholders is defined herein as the "Resale Shares."

Currently, our common stock is quoted on the OTCQB under the symbol "CBRA", and there is a limited market for our common stock. Currently, there is a limited market for our common stock. We intend to apply to list our common stock on The Nasdaq Capital Market ("NASDAQ") under the symbol "CBRA". Accordingly, we expect our common stock to begin trading on NASDAQ on or around the date of this prospectus, at which point our common stock will cease to be traded on the OTCQB. There is no assurance that an active trading market for our common stock will develop or be sustained. If our common stock is not approved for listing on NASDAQ, we will not consummate this offering.

We are a "smaller reporting company," as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and have elected to take advantage of certain scaled disclosure available to smaller reporting companies. We are also an emerging growth company under the Jumpstart our Business Startups Act of 2012, or JOBS Act, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings. See the section titled "Prospectus Summary — Implications of Being an Emerging Growth Company and a Smaller Reporting Company" in the Public Offering Prospectus.

The distribution of securities offered hereby may be effected in one or more transactions that may take place on NASDAQ, including ordinary brokers' transactions, privately negotiated transactions or through sales to one or more dealers for resale of such securities as principals, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. Usual and customary or specifically negotiated brokerage fees or commissions may be paid by the Selling Stockholders. No sales of the shares covered by this prospectus shall occur until the shares of common stock sold in our public offering begin trading on NASDAQ. Currently, there is no public market for our common stock.

**Investing in our securities is highly speculative and involves a significant degree of risk. See "*Risk Factors*" beginning on page 10 of this prospectus for a discussion of information that should be considered before making a decision to purchase our securities.**

Sales of the shares of our common stock registered in this prospectus and the Public Offering Prospectus will result in two offerings taking place concurrently which might affect price, demand, and liquidity of our common stock.

You should rely only on the information contained in this prospectus and any prospectus supplement or amendment. We have not authorized anyone to provide you with different information. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus is only accurate on the date of this prospectus, regardless of the time of any sale of securities.

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus is , 2025.

**<br> **TABLE OF CONTENTS****

---

| | |
|:---|:---|
|  | **Page** |
| [RESALE PROSPECTUS SUMMARY](#Hz_001) | Alt-1 |
| [THE DISTRIBUTION](#Hz_002) | Alt-8 |
| [USE OF PROCEEDS](#Hz_003) | Alt-12 |
| [SELLING SHAREHOLDERS](#Hz_004) | Alt-13 |
| [PLAN OF DISTRIBUTION](#Hz_005) | Alt-14 |
| [LEGAL MATTERS](#Hz_006) | Alt-15 |

---

Alt-i

**RESALE PROSPECTUS SUMMARY**

*The following summary highlights information that we present more fully in the rest of this prospectus. This summary does not contain all of the information you should consider before buying shares of common stock in this offering. This summary contains forward-looking statements that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "should," "will," "could," and similar expressions denoting uncertainty or an action that may, will or is expected to occur in the future. These statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances or achievements expressed or implied by the forward- looking statements.*

*You should read the entire prospectus carefully, including the "Risk Factors" section and the financial statements and the notes to those statements and our management's discussion and analysis of financial condition and results of operations. As used throughout this prospectus, the terms "Caring Brands," "Caring Brands Florida," the "Company," "we," "us," or "our" refer to Caring Brands, Inc.*

**Company Overview**

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability.

Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team. We are currently preparing for its relaunch in the United States, which is targeted for 2026, as we explore manufacturing and marketing options. The product formulation has not been changed since its removal from the US markets, and no changes to the formulation are planned for the proposed U.S. market relaunch. Photocil is a narrow band UV filter that focuses UV in the 311nm range which is therapeutic for vitiligo and psoriasis. Dimethicone, also called polymethylsiloxane, is a silicon-based polymer used as a lubricant and conditioning agent. It is the USP (United States Pharmacopeia, which is the official compendium of standards for medicines and healthcare products in the United States) monographed ingredient in Photocil. Dimethicone is used to create a smooth feel and a water-resistant barrier on the skin. In addition to dimethicone, Photocil contains two UV filters that restrict the band width of UV rays on the skin to a narrow-range ~ 308 nm. This narrow-band UV has therapeutic properties. These proprietary technologies are not found in other sunscreens and Photocil does not contain conventional UV blockers found in the majority of sunscreens. The product is categorized as an OTC product in the United States, using an USP monographed ingredient as a skin protectant, with FDA-registered labeling (USP monographed: A reference to ingredients listed in the United States Pharmacopeia (USP), which is the official compendium of standards for medicines and healthcare products in the United States). Photocil does not require FDA pre-market approval as it uses GRASE (Generally Recognized as Safe and Effective) ingredients and is currently marketed in India under local cosmetic regulations. Photocil is a cosmetic product designed to block certain UV radiation while allowing other UV radiation to pass through when applied to the skin. The product contains ingredients that are listed in the USP monograph for skin protectants. As a cosmetic product, Photocil has not been evaluated by the FDA for safety and effectiveness. The product contains ingredients that are listed in the USP monograph for skin protectants and is marketed as a cosmetic product in compliance with FDA regulations for cosmetics. The Joint American Academy of Dermatology and National Psoriasis Foundation guidelines for the management and treatment of psoriasis with phototherapy, published in JAMA Dermatology in 2019, strongly recommend narrow-band UVB phototherapy as a monotherapy for treating plaque psoriasis in adults, supported by a systematic review and meta-analysis of 41 randomized controlled trials involving 2,416 patients.

Phototherapy

Management believes that phototherapy treatments, used for conditions such as psoriasis and vitiligo, are set for substantial growth globally. However, there can be no guarantees that this growth will materialize as expected, as it is subject to various market conditions, regulatory developments, and other external factors beyond the Company's control. Specific market data focused solely on the Indian phototherapy treatment segment is limited, and the available market data focuses primarily on phototherapy devices. However, according to Future Market Insights (2023)<sup>1</sup>, the Indian market is expected to experience strong growth, driven by the rising prevalence of skin disorders, increased healthcare spending, and improved access to treatment in both urban and rural areas.

According to Future Market Insights (2023), the global phototherapy treatment market is projected to rise from ~ USD $1.9 billion in 2023 to ~ USD $3.23 billion by 2033, at a CAGR of around 5.2% during the forecast period from 2023 to 2033. In India, the market is expected to expand even faster, with an estimated CAGR of approximately 7.8% as of 2023, driven by a large patient base, increasing prevalence of skin disorders, greater awareness of noninvasive treatments, and improved healthcare infrastructure (Future Market Insights, 2023).

Psoriasis

According to a report by Nature Reviews Drug Discovery (2024)<sup>2</sup>, the global psoriasis treatment market was worth ~ $34 billion globally in the 12 months ending June 2023. The report shows the US remains the dominant market for psoriasis therapies, accounting for approximately 78% of total sales and growing at a compound annual growth rate of approximately 18%.

According to the same report (Nature Reviews Drug Discovery, 2024), with the current growth rate (CAGR of 8–10% from 2023 to 2030), the global market is expected to reach ~ USD $54-67 billion by 2030. Estimates from a report published on the National Center for Biotechnology Information<sup>3</sup>, indicate that the prevalence of psoriasis in India ranges from 0.44% to 2.8% of the population, highlighting Management's belief in the significant market opportunity in India. However, actual market growth may be influenced by factors such as regulatory changes, competition, and economic conditions, which could impact the overall demand for psoriasis treatments. Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India. However, actual market penetration will depend on various factors, including the development of a dedicated sales and marketing team at Caring Brands, market demand, competitive landscape, and regulatory considerations. There can be no assurance that these efforts will result in significant market adoption.

Vitiligo

According to a report by Expert Market Research (2024)<sup>4</sup>, the global vitiligo treatment market was valued at ~ USD 538.90 million in 2024. The global market is projected to grow at a compound annual growth rate (CAGR) of 4.60% from 2025 to 2034, reaching ~ USD 807.70 million by 2034 (Expert Market Research, 2024). According to Expert Market Research (2024), this growth is attributed to the increasing global prevalence of vitiligo and the rising demand for effective treatments, and Management believes that these factors may contribute to expanding market opportunities. However, actual market expansion may be influenced by factors such as regulatory changes, competition, and advancements in alternative therapies, which could impact the overall demand for vitiligo treatments.

According to the report by Expert Market Research (2024), the US market is expected to remain the dominant market for vitiligo treatments. The report also states that the Asia Pacific region is expected to witness the fastest growth during the forecast period due to increasing awareness, emerging treatment options, growing research and development activities, and favorable government initiatives in developing nations. As part of this Asia Pacific region, management believes India presents a potential opportunity for market expansion. However, there is no certainty that this growth will materialize as expected, as it depends on various external factors, which will impact the overall demand.

As per reports published on the National Centre for Biotechnology Information<sup>5 6</sup>, across studies from India, the prevalence of vitiligo has consistently been reported to be between 0.25%-4% (Cureus Report)<sup>5</sup> and can reach as high as 8.8% of the population in certain regions like Gujarat and Rajasthan (Indian Journal of Community Medicine)<sup>6</sup>, making India a highly affected region globally. However, even though Management believes that this presents a potential market opportunity, Vitiligo treatment with Photocil is expected to address only a very small fraction of the total global market. Future market penetration is uncertain and subject to factors such as regulatory approvals, competitive dynamics, and effective marketing strategies. There can be no assurances that Photocil will achieve meaningful adoption in the market.

<sup>1.</sup> Future Market Insights (2023) – Phototherapy Treatment Market: https://www.futuremarketinsights.com/reports/north-america-and-europe-phototherapy-treatment-market

<sup>2.</sup> Nature Reviews Drug Discovery (2024) – The Pipeline and Market for Psoriasis Drugs, Vol. 23, Issue 7, Pages 492-493. Doi: https://doi.org/10.1038/d41573-024-00018-2

<sup>3.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC4252960/ Kumar S, Nayak C., Padhi T, et al. (November, 2014). *Epidemiological pattern of psoriasis, vitiligo, and atopic dermatitis in India: A hospital-based point prevalence.* Indian Dermatology Online Journal, 5(Suppl 1), S2–S8. Doi: 10.4103/2229-5178.144499

<sup>4.</sup> Expert Market Research (2024) – Vitiligo Treatment Market: https://www.expertmarketresearch.com/reports/vitiligo-treatment-market

<sup>5.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC11112533/ Saha D, Roy S, Ahmed R, et al. (April 23, 2024). *Clinico-Epidemiological Profile of Vitiligo Among Patients Attending a Tertiary Care Centre of North-East India.* Cureus 16(4): e58804. doi:10.7759/cureus.58804

<sup>6.</sup> National Center for Biotechnology Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC4134529/ Vora R V., Patel B., Chaudhary A.H., et al. (July – Sept 2014). *A Clinical Study of Vitiligo in a Rural Set up of Gujarat*. Indian Journal of Community Medicine 39(3):p 143-146, Jul–Sep 2014. Doi: 10.4103/0970-0218.137150

Our licensee in India, Cosmofix and San Pellegrino Cosmetics, is currently exploring additional sub-licensing opportunities in Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia. We are also in preliminary discussions regarding potential licensing opportunities in Europe and South America, though no formal agreements are currently in place. The results of clinical trials on Photocil have been published in Expert Opin Pharmacother, including 2014 Dec;15(18):2623-7; Dermatol Ther. 2014 Jul-Aug;27(4):195-7; Dermatol Ther. 2014 Sep-Oct;27(5):260-3. In July 2021, Safety Shot (then Jupiter Wellness) obtained an exclusive license from Applied Biology Inc. to manufacture and sell Photocil. Subsequently, in June 2022, Safety Shot (then Jupiter Wellness) acquired all assets of Applied Biology Inc., including Photocil, through an asset purchase agreement. The product was commercially launched in India in September 2022 under a licensing agreement with Cosmofix and San Pellegrino Cosmetics and entered the U.S. market in Q4 2022 via Amazon. However, it was removed from the U.S. market in February 2023 due to insufficient sales resulting from the lack of a dedicated sales and marketing team. In India, Photocil is currently marketed as an OTC product compliant with local regulatory standards. In the United States, it was previously commercialized with FDA-registered labeling as a Jupiter Wellness product. We plan to apply for a National Drug Code (NDC) number for FDA registration prior to relaunching the product in the U.S. market. Photocil has been evaluated in clinical trials for the treatment of vitiligo and psoriasis, demonstrating significant efficacy.

Our Hair Enzyme Booster (JW-700), previously known as Minoxidil Booster, was initially developed by Applied Biology Inc. and was acquired by Safety Shot (then Jupiter Wellness) in June 2022 through an asset purchase agreement. The product received labelling approval as a cosmetic from the Central Drugs Standard Control Organization (CDSCO) and is currently being manufactured and sold in India through our agreement with Cosmofix and San Pellegrino Cosmetics. Hair Enzyme Booster (JW-700) was launched on Amazon on October 28, 2024, and became available on NOVODX's e-commerce platform on December 11, 2024. As of the date of this prospectus, the Hair Enzyme Booster (JW-700) is currently only for sale on Amazon.

The Hair Enzyme Booster has been clinically shown to increase the enzymes needed for minoxidil (an FDA-approved over-the-counter medication used to treat hair loss and promote hair regrowth) to work, sulfotransferase enzymes, by using the product topically in conjunction with topical minoxidil. The Hair Enzyme Booster (JW-700) is marketed and sold as a cosmetic product in the U.S., containing GRASE ingredients that do not require FDA pre-market approval and complying with FDA labeling requirements. In India, it is currently marketed under local cosmetic regulations. The Company launched the Hair Enzyme Booster (JW-700) in the U.S in the fourth quarter of 2024. The product is designed to improve Minoxidil efficacy and is available as a topical solution. It is designed to enhance the efficacy of minoxidil by increasing necessary enzyme levels and must be used in combination with FDA-approved minoxidil products. JW-700 does not independently treat hair loss or promote hair regrowth. Clinically shown to increase the sulfotransferase enzyme needed for minoxidil to work, has 2 granted and 5 pending patents.

Minoxidil market was valued at $1.5 billion in 2022 and is expected to grow to $2.5 billion by 2032. Licensed to Taisho, a $2.6 billion revenue company and Japan's leading seller of minoxidil products. They expect to launch the product commercially in 2025. The term of the Taisho License is for five (5) years with an automatic renewal of one (1) year unless terminated otherwise. As consideration, Caring Brands shall receive up to $200,000 in milestone payments and a 3% royalty subject to the terms and conditions of the Taisho License. On September 1, 2022, Safety Shot (then Jupiter Wellness), entered into a license agreement with Cosmofix and San Pellegrino cosmetics to market and manufacture the Hair Enzyme Booster (JW-700) and Photocil for the Indian market and 31 other companies in Africa and Far East. The license is for three years with an automatic renewal of one (1) year unless terminated otherwise. Photocil and the Hair Enzyme Booster (JW-700) are being sold in India. As consideration a 3% royalty subject to the terms and conditions of the Cosmofix/San Pellegrino license. The License was transferred to the Company, pursuant to the Separation and Exchange Agreement (as defined below). The Company launched the Hair Enzyme Booster (JW-700) in the US in 4Q, 2024. As the product contains components that are generally regarded as safe (GRASE) it does not require FDA approval. Clinical studies on the Hair Enzyme Booster (JW-700) have been published: Journal of Cosmetic Dermatology (2022), Vol.21, Issue 4, 1647-1650. The Hair Enzyme Booster (JW-700) has undergone multiple clinical trials, demonstrating its potential efficacy in treating androgenetic alopecia (AGA). The Hair Enzyme Booster (JW-700) is designed to enhance the efficacy of minoxidil by increasing necessary enzyme levels and must be used in combination with FDA-approved minoxidil products. The Hair Enzyme Booster (JW-700) does not independently treat hair loss or promote hair regrowth.

CB-101 treatment for Atopic Dermatitis (Eczema) is a topical over-the-counter treatment for atopic dermatitis (eczema) with dual-action relief from aspartame (ASN) and colloidal oatmeal. In clinical studies of the prior formulation (containing CBD), JW-100 cleared or reduced eczema following 2 weeks of use and may prove potentially superior to existing prescription drugs. It currently has 4 pending patents, with the global eczema treatment market valued at $14 billion in 2022. 31.6 million Americans, or 10% of the population, have eczema; 86% are not satisfied with their treatment and want more and better treatment options. CB-101 eczema treatment is planned to undergo reformulation, which we expect to complete in Q4 2025/Q1 2026, and it is anticipated to be available online in the US in the second quarter of 2026 as an over-the-counter product under a USP monograph. Reformulation activities are expected to resume utilizing a portion of the offering proceeds. CB-101 will be marketed as an OTC product under the applicable monograph. It contains colloidal oatmeal, which is covered under the USP monograph for skin protectant products. The product will comply with all requirements outlined in the applicable USP monograph and will require FDA registration and an NDC number prior to marketing. The clinical study on JW-100 was published in the Journal of Cosmet. Dermatol., Vol. 21, Issue 4, April 2022, pp: 1647-1650. The original formulation, JW-100, contained CBD as an active ingredient, while the new formulation, CB-101, removes CBD, while maintaining aspartame (ASN) and introducing colloidal oatmeal as key ingredients. This dual-action formulation is designed to provide relief from eczema symptoms and allows the product to be marketed as an OTC product under a USP monograph for skin protectants. The reformulated product retains the therapeutic approach of the original while utilizing ingredients compliant with applicable monographs. The development process is expected to move into its final stages upon resumption, with $150,000 anticipated to be allocated to completing formulation development, $200,000 planned for the initial production run, and $50,000 for clinical testing. The target launch date for the product is Q2 2026, with these costs expected to be funded from a portion of the offering proceeds.

NoStingz is planned to undergo reformulation under Caring Brands as a sunscreen product designed to provide protection against both UV rays and jellyfish stings. The previously commercialised version contained FDA-compliant sunscreen active ingredients. Reformulation and stability testing are expected to resume utilising a portion of the offering proceeds. All actives are intended to meet the USP specifications mandated by the FDA in its sunscreen monograph. We have not yet established a timeline for commercial launch. As the product contains ingredients with well-established safety profiles, it is not expected to require FDA approval. NoStingz will be regulated as a sunscreen product and will comply with the FDA's sunscreen guidelines. It will contain FDA-approved sunscreen active ingredients and will require FDA registration and an NDC number prior to marketing.

<u>Trial Details</u>

The trial was conducted from May 29 - June 17, 2023, in Key West, Florida to evaluate the efficacy of NoStingz formulations against Portuguese man-o'-war (Physalia physalis) stings. The study was conducted by independent researchers who collected specimens from Atlantic waters near Key West.

<u>Methodology and Design</u>

The researchers developed a controlled, blind testing protocol using preserved Portuguese man-o'-war specimens collected from the Atlantic waters near Key West. The methodology involved carefully preserving the stinging tentacles through a controlled dehydration process, followed by systematic rehydration of small portions for standardized testing applications. The study evaluated multiple formulation types, including mineral-based sprays and lotions with SPF levels of 30 and 50. To ensure scientific validity, the researchers incorporated placebo controls using untreated skin areas. The evaluators assessed sting responses and protective efficacy of the different formulations against the control areas.

<u>Results and Safety</u>

The combination of rubidium iodide and menthol demonstrated promising initial results in reducing sting severity. However, we note that this was a small preliminary trial and further testing is needed to establish statistical significance. No adverse events or safety concerns were reported during the trial period.

<u>Mechanism of Action</u>

Rubidium iodide and menthol were selected based on their potential protective properties:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Rubidium
 iodide acts as a potential inhibitor of the nematocyst discharge mechanism

● Menthol
 provides a cooling sensation and may help reduce localized inflammatory response

We plan to conduct additional stability testing and formulation work before proceeding with larger scale trials to validate these preliminary findings. The reformulated product is intended to provide dual protection against both UV rays and jellyfish stings. Reformulation activities are expected to resume utilising a portion of the offering proceeds. We have not yet established a timeline for commercial launch. As the product contains ingredients with well-established safety profiles, it does not require FDA approval. NoStingz will be regulated as a sunscreen product and will comply with the FDA's sunscreen guidelines. It will contain FDA-approved sunscreen active ingredients and will require FDA registration and an NDC number prior to marketing.

Our products are tested for quality and stability each time they are manufactured. One of our manufacturers is Stella Industries Ltd., Haryana, India, which manufactures the Hair Enzyme Booster (JW-700) and Photocil for the Indian market. Stability on commercial batches manufactured in India indicates a shelf life of at least 24 months. Stella Industries is compliant with the FDA's Current Good Manufacturing Practice, or CGMP, regulations in accordance with 21 CFR 210/211 required for over-the-counter drug products. It is ISO-9001 certified. Another manufacturer is DCR Labs, Daytona Beach, Florida, which is also fully compliant with the FDA's Current Good Manufacturing Practice, or CGMP, for cosmetic products.

We expect to continually update and expand upon our corporate website and further refine our online retail strategies on an ongoing basis. CaringBrands.com is our primary corporate website, which will serve as the primary source of information about us for investors and will contain press releases, clinical trial pipeline, lab reports, blog posts, and additional information about each of our brands. We have built an e-commerce platform designed to connect us directly to consumers. We use the platform to sell products, educate customers, and build brand loyalty.

For further information in relation to the clinical trials of our products, please see the section "Business - Clinical Trials of our Products" beginning on page 43, of the Public Offering Prospectus.

**Recent Developments**

In April 2024, the Company received gross proceeds of $2,110,000 from a private placement of units, at a price per unit of $1.00 (the "Bridge Financing"), consisting of one share of common stock and a warrant to purchase one share of common stock at a price of $3.00 per share, which warrants expire on April 15, 2029. We used the net proceeds of the Bridge Financing to fund our continuing working capital and capital expenditure requirements leading up to this offering. D. Boral Capital LLC, the lead underwriter of this offering ("D. Boral"), served as the lead placement agent for the Bridge Financing. D. Boral received fees and reimbursement of expenses in an aggregate amount of $211,000.

On May 14, 2024 the Company issued 7,600,000 shares to certain of its insiders and founding stockholders, pursuant to a subscription agreement dated March 15, 2024, at a purchase price of $0.001 per share of Common Stock. The form of subscription agreement is included as Exhibit 10.1 of this registration statement and prospectus.

On June 20, 2024, the Company entered into a Research Collaboration and Non-Exclusive License Agreement, as amended and restated on July 22, 2024 (the License Agreement") with NOVODX Corporation, a Delaware corporation ("NOVODX"). NOVODX is a diagnostic company dedicated to the development and commercialization of innovative health products, with a primary focus on rapid diagnostic screenings and their companion therapeutics. The Company is engaged in the research and development of rapid diagnostic devices intended for both Over the Counter ("OTC") and Point of Care ("POC") applications. NOVODX aims to manufacture, market, and sell these devices, either directly or indirectly, for use in at-home diagnostic screenings. NOVODX possesses or has the rights to use (through licenses or other agreements) certain assets, patent applications, and associated know-how, technology, scientific, and technical information. Collectively, these resources are referred to as the GoldNTM Ebola Rapid Test Technical Information, which pertains to the development of an Ebola diagnostic test (the "Ebola Rapid Test").

Pursuant to the License Agreement, NOVODX granted the Company two non-exclusive licenses during the term of the License Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;1. Research
 License: This license allows the Company to use and market the Ebola Rapid Test in the research field, following the directives and
 standards set by the Joint Development Committee (JDC) and the research plan of reasonably collaborating with each other to develop
 a pre-clinical research or other plan for the Ebola Rapid Test. This license is valid only in jurisdictions where NOVODX has a valid
 claim. NOVODX is pursuing patent protection through U.S. and Patent Cooperation Treaty (PCT) applications, with a particular focus
 on markets in Africa and Asia. As of the date of this prospectus, NOVODX has not yet submitted any patent applications. NOVODX
 is in the process of preparing these applications and evaluating entry into specific jurisdictions. Decisions regarding entry
 into national phase applications in specific jurisdictions will be evaluated on a case-by-case basis as the patent prosecution process
 progresses. The ultimate scope of patent protection will be determined by the jurisdictions where NOVODX successfully obtains valid
 claims through these patent applications.

&nbsp;&nbsp;&nbsp;&nbsp;2. Commercial
 License: This license permits the Company to use, market, and sell the Ebola Rapid Test within the commercial field. the Company
 cannot engage in sales, directly or indirectly, until NOVODX obtains 510K or EUA approval or authorization. Sales and distribution
 are restricted to jurisdictions where such approval or authorization is valid and where NOVODX has a valid claim. NOVODX is pursuing
 patent protection through U.S. and Patent Cooperation Treaty (PCT) applications, with a particular focus on markets in Africa and
 Asia. As of the date of this prospectus, NOVODX has not yet submitted any patent applications. NOVODX is in the process of preparing
 these applications and evaluating entry into specific jurisdictions. Decisions regarding entry into national phase applications
 in specific jurisdictions will be evaluated on a case-by-case basis as the patent prosecution process progresses. The ultimate scope
 of patent protection will be determined by the jurisdictions where NOVODX successfully obtains valid claims through these patent
 applications.

**Corporate History**

Caring Brands was incorporated in State of Nevada on April 23, 2024, On May 13, 2024, an Amendment to the Articles of Incorporation was submitted with the State of Nevada to revise the par value to $0.001 per share, followed by an amendment on July 9, 2024 to add 1,000,000 preferred shares with a par value of $0.001 to the authorized share capital. Caring Brands was incorporated for the purpose of the separation of our business operation from Safety Shot, and have not historically operated as a standalone company. Pursuant to the Separation and Exchange Agreement, we acquired 100% equity in Caring Brands Florida. Consequently Caring Brands Florida now operates as an operating subsidiary of the Company.

Caring Brands, Inc., a Florida Corporation ("Caring Brands Florida") was originally incorporated in the State of Florida on February 12, 2020, under the name Jupiter Wellness Inc. In June 2020, Articles of Amendment were filed with the Florida Department of State Division of Corporations to amend the articles of incorporation to change the name of the company to Caring Brands, Inc.

Our principal business address is 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950. We are currently authorized to issue a total of 100,000,000 shares of common stock with a par value of $0.001. As of the date of this registration statement, we had 13,336,925 shares of common stock issued and outstanding.

**Safety Shot Inc Ownership and Our Separation from Safety Shot Inc**

Currently, and at all times prior to the date of this prospectus, we are an operating subsidiary of Safety Shot Inc ("Safety Shot"). Safety Shot owns 3,000,000 shares of our Common Stock, representing approximately 22.883% of the outstanding shares of our Common Stock, at an assumed offering price of $4.00 per share. Following the completion of the separation, Safety Shot no longer consolidates its financial results with our financial results.

On September 24, 2024, we entered into a separation and exchange agreement (the "Separation and Exchange Agreement") with Safety Shot to govern the separation of our business from Safety Shot. Safety Shot owns majority of the issued and outstanding ordinary shares of Caring Brands Florida, which currently sells innovative wellness consumer products industries (the "CB Business") and owns all of the assets and liabilities related thereto. Pursuant to the Separation and Exchange Agreement the CB Business was contributed to us and all expenses related thereto shall be our responsibility, in each case, on the terms and subject to the conditions set forth therein, and in exchange Safety Shot was transferred to us all of the issued and outstanding ordinary shares of Caring Brands Florida owned by Safety Shot (the "Business Transfer"). In conjunction to the Business Transfer and pursuant to the Separation and Exchange Agreement, Safety Shot transferred all the intellectual property to the Company. In the event this offering is not consummated, the Separation will be unwound.

In this prospectus, references to the term "separation" refers to the separation of our business from Safety Shot's other businesses pursuant to and subject to the conditions of the Separation and Exchange Agreement.

The registration statement of which this prospectus forms a part also registers the distribution by Safety Shot of 600,000 shares of our Common Stock it owns to its stockholders and certain warrant holders. Safety Shot has no obligation to effect a distribution of any of its remaining ownership interest, and it may retain its ownership interest in us indefinitely or dispose of all or a portion of its ownership interest in us in a sale or other transaction. Any such distribution or other disposition by Safety Shot of its remaining interest in us (each, an "other disposition") would be subject to market, tax and legal considerations, final approval by the Safety Shot board of directors (the "Safety Shot Board") and other customary requirements. Under current law, the distribution could be determined to be taxable to Safety Shot and its stockholders. Safety Shot has no obligation to pursue or consummate any further disposition of its ownership interest in us by any specified date or at all. Our separation from Safety Shot will be made in the context of a parent-subsidiary relationship and the Separation and Exchange Agreement were entered into in the overall context of our separation from Safety Shot. The terms of the Separation and Exchange Agreement may be more or less favorable to us than if they had been negotiated with unaffiliated third parties. See the section titled "*Risk Factors—Risks Related to Our Separation from Safety Shot*."

We believe, and Safety Shot has advised us that it believes, that the separation, this offering and the distribution will provide a number of benefits to our business and to Safety Shot' business. These intended benefits include improving the strategic and operational flexibility of both companies, increasing the focus of the management teams on their respective business operations and allowing each company to adopt the capital structure, investment policy and dividend policy best suited to its financial profile and business needs, and providing each company with its own equity currency to facilitate acquisitions and to better incentivize management. In addition, as we will be a stand-alone company, potential investors will be able to invest directly in our business.

**Corporate Information**

Our principal executive offices are located at 130 S Indian River Drive, Suite 202 pbm# 1232, Fort Pierce, FL 34950 and our telephone number is (561) 896-7616. Our website address is www.caringbrands.com. Information contained in, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or the registration statement of which this prospectus forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference only.

**Going Concern**

We intend to overcome the circumstances that impact our ability to remain a going concern through a combination of expanding our revenues, with interim cash flow deficiencies being addressed through additional equity and debt financing; however, we may not have commitments from third parties for a sufficient amount of additional capital. We cannot be certain that any such financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations. Our ability to obtain additional funding will determine our ability to continue as a going concern. Failure to secure additional financing in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results of operations and stock price and may require us to curtail or cease operations, sell off our assets, seek protection from our creditors through bankruptcy proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of our common stock, and debt financing, if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require that we relinquish valuable rights. Please see note 1, in our financial statements, for further information.

We have a need for additional growth capital. There can be no assurance that sufficient funds required during the subsequent year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force us to substantially curtail or cease operations and would, therefore, have a material adverse effect on our business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on our existing stockholders.

**Implications of Being an Emerging Growth Company and a Smaller Reporting Company**

We are an "emerging growth company," as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (ii) the last day of the fiscal year in which we have total annual gross revenues exceeding $1.235 billion; (iii) the date on which we have issued more than $1 billion in nonconvertible debt in any three-year period; or (iv) the date on which we are deemed to be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable future but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company as described above. References herein to "emerging growth company" have the meaning associated with it in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies that are not emerging growth companies.

These exemptions include:

● being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced "Management's Discussion and Analysis of Financial Condition and Results of Operations" disclosure in this prospectus;

● not being required to comply with the requirement of auditor attestation of Section 404 of the Sarbanes-Oxley Act of 2002, as amended;

● reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and

● not being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

For as long as we continue to be an emerging growth company, we expect that we will take advantage of the reduced disclosure obligations available to us because of that classification. We have taken advantage of certain of those reduced reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.

An emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies.

We are also a "smaller reporting company" and to the extent that we continue to qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures; and (3) the requirement to provide only two years of audited financial statements, instead of three years.

**THE DISTRIBUTION**

*The discussion in this prospectus of the distribution is subject to, and qualified by reference to, the Separation and Exchange Agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part and is incorporated by reference into this prospectus.*

**General**

On September 24, 2024, we entered into the Separation and Exchange Agreement with Safety Shot to govern the separation of our business from Safety Shot. The Separation and Exchange Agreement governs the separation of our business from Safety Shot. Pursuant to the securities purchase agreement, on September 24, 2024, we issued to the stockholders of Safety Shot 3,000,000 shares of our Common Stock (representing 22.883% of our outstanding Common Stock) of which 600,000 shares of common stock are to be distributed to the shareholders of Safety Shot following the effectiveness of this registration statement (the "Distribution"). Pursuant to the Business Transfer, we acquired from Safety Shot by operation of law all assets and assume all liabilities comprising of CB Business, which were owned and held by Safety Shot. In conjunction to the Business Transfer and pursuant to the Separation and Exchange Agreement, Safety Shot transferred all the intellectual property to the Company. In the event this offering is not consummated, the Business Transfer and the Distribution will be unwound.

**Manner of Effecting the Distribution**

The general terms and conditions relating to the distribution are set forth in the Separation and Exchange Agreement. Under the Separation and Exchange Agreement, the Distribution will be paid on or after the effective date of the registration statement of which this prospectus forms a part but prior to the closing of this offering. For most Safety Shot stockholders who own Safety Shot Common Stock in registered form on the record date, our transfer and distribution agent will credit their shares of our Common Stock to book entry accounts established to hold these shares. Our transfer and distribution agent will send these stockholders a statement reflecting their ownership of our Common Stock. Book-entry refers to a method of recording stock ownership in our records in which no physical certificates are used. For stockholders who own Safety Shot Common Stock through a broker or other nominee, their shares of our Common Stock will be credited to these stockholders' accounts by the broker or other nominee. As further discussed below, fractional shares will not be distributed. Following the distribution, stockholders whose shares are held in book entry form may request that their shares of our Common Stock be transferred to a brokerage or other account at any time, as well as delivery of physical stock certificates for their shares, in each case without charge.

SAFETY SHOT STOCKHOLDERS WILL NOT BE REQUIRED TO PAY FOR SHARES OF OUR COMMON STOCK RECEIVED IN THE DISTRIBUTION, OR TO SURRENDER OR EXCHANGE SHARES OF SAFETY SHOT COMMON STOCK IN ORDER TO RECEIVE OUR COMMON STOCK, OR TO TAKE ANY OTHER ACTION IN CONNECTION WITH THE DISTRIBUTION. NO VOTE OF SAFETY SHOT STOCKHOLDERS IS REQUIRED OR SOUGHT IN CONNECTION WITH THE DISTRIBUTION, AND SAFETY SHOT STOCKHOLDERS HAVE NO APPRAISAL RIGHTS IN CONNECTION WITH THE DISTRIBUTION.

Fractional shares of our Common Stock will not be issued to Safety Shot stockholders as part of the distribution or credited to book entry accounts. In lieu of receiving fractional shares, the number of shares of Common Stock to be received in the distribution will be rounded down to the nearest whole share of Common Stock. An explanation of the tax consequences of the distribution can be found below in the subsection captioned "— *Material U.S. Federal Income Tax Consequences of the Distribution*." The distribution of Company Common Stock in respect of the Safety Shot shares is expected to be taxable to both Safety Shot and holders of the Safety Shot shares. See "*The Distribution — Material U.S. Federal Income Tax Consequences of the Distribution*."

In order to be entitled to receive shares of our Common Stock in the distribution, which will occur after the effectiveness of this registration statement and prior to the closing of this offering, holders of Safety Shot common stock must be holders of record of Safety Shot common stock as of the close of business, New York City time, on the record date, April 7, 2025, subject to the registration statement of which this prospectus forms a part being declared effective.

**Reasons for the Distribution**

The Safety Shot board of directors has determined that the separation of our business from the other business of Safety Shot is in the best interests of Safety Shot and its stockholders. The potential benefits considered by the Safety Shot board of directors in making the determination to consummate the distribution included the following:

● to provide each of Safety Shot and the Company with increased flexibility to fully pursue and fund its business plan, including capital expenditures, investments and acquisitions that would be more difficult to consider or effectuate in the absence of the distribution. This increased financial flexibility reflects the belief that investors in a company with the mix of assets that each of Safety Shot and the Company will own following the distribution will be more receptive to strategic initiatives that Safety Shot and the Company may respectively pursue;

● to create distinct and clear financial profiles and compelling investment cases. Investment in one or the other company may appeal to investors with different goals, interests and expectations. The distribution will allow investors to make independent investment decisions with respect to Safety Shot and the Company and may result in greater alignment between the interests of each company's stockholder base and the characteristics of its respective business, capital structure and financial results;

● to create independent equity securities and increased strategic opportunities. The distribution will afford Safety Shot and the Company the ability to offer their independent equity securities to the capital markets and enable each standalone company to use its own industry-focused stock to pursue portfolio enhancing acquisitions or other strategic opportunities that are more closely aligned with each company's strategic goals and expected growth opportunities;

● to facilitate incentive compensation arrangements for employees of each business more directly tied to the performance of the relevant company's business and enhance employee hiring and retention by, among other things, improving the alignment of management and employee incentives with performance and growth objectives of each of Safety Shot and the Company; and

● to increase the aggregate value of the stock of Safety Shot and the Company above the value that the stock of Safety Shot would have had if it had continued to represent an interest in both the businesses of Safety Shot and the Company, so as to: (i) allow each company to use its stock to pursue and achieve strategic objectives, including evaluating and effectuating acquisitions and increasing the long-term attractiveness of equity compensation programs in a significantly more efficient and effective manner with significantly less dilution to existing stockholders; and (ii) allow each company to offer a more focused investment profile to investors.

The Safety Shot board of directors also considered several factors that have a negative effect on Safety Shot as a result of the distribution. Safety Shot will have tax liabilities as a result of the distribution. The Safety Shot common stock may come under initial selling pressure as certain Safety Shot stockholders sell their shares because they are not interested in holding an investment in the remaining business of Safety Shot. In addition, the distribution would separate from Safety Shot the business and assets of the Company, which represent significant value. Safety Shot and its remaining business may need to absorb certain corporate and administrative costs previously provided to the Company. Finally, Safety Shot will not be eligible to consolidate the Company with its financial statements for reporting purposes.

The Safety Shot board of directors considered certain aspects of the distribution that may be adverse to the Company. The Company's Common Stock may come under initial selling pressure as certain Safety Shot stockholders sell their shares in the Company because they are not interested in holding an investment in the Company's business. As a result of the distribution, the Company will bear significant incremental costs associated with being a publicly-held company and may need to absorb certain corporate and operational support costs previously provided by Safety Shot.

**Results of the Distribution**

Immediately after the distribution, we estimate that we will have in excess of 300 holders of record of our Common Stock and approximately 14,336,925 shares (14,486,925 shares if the underwriters exercise their over-allotment option in full), at an assumed public offering price of $4.00 per share.

In connection with the Distribution, we entered into the Separation and Exchange Agreement with Safety Shot, covering such areas as employee matters related to any shared employees, sharing of premises and other matters, including indemnification.

The distribution will not affect the number of outstanding shares of Safety Shot Common Stock or any rights of Safety Shot stockholders.

**Tax Consequences of the Distribution**

The distribution will be a taxable event to holders of Safety Shot common stock. U.S. Holders will realize dividend income to the extent that the distribution is paid out of the current or accumulated earnings and profits of Safety Shot, then recover basis and possibly recognize capital gain to the extent that the distribution exceeds the current or accumulated earnings and profits of Safety Shot, Non-U.S. Holders will also realize dividend income, subject to 30% withholding, to the extent that the distribution is paid out of the current or accumulated earnings and profits of Safety Shot; however, Non-U.S. Holders with no presence in the United States should not realize capital gain to the extent that the distribution exceeds the current or accumulated earnings and profits of Safety Shot. Safety Shot may also recognize a capital gain on the Distribution. See "MATERIAL U.S. FEDERAL TAX CONSEQUENCES OF THE DISTRIBUTION OF, AND OF OWNING AND DISPOSING OF, OUR COMMON STOCK". The tax consequences of the distribution are complex and holders should consult their own tax advisors about these consequences.

**Listing and Trading of Our Common Stock**

Currently, no public market exists for our Common Stock. We have submitted an application to list our Common Stock for trading on NASDAQ under the symbol "CBRA." No assurance can be given that our Common Stock will be approved for listing on NASDAQ and neither this offering nor the distribution will be completed if our Common Stock is not approved for listing.

**Reason for Furnishing this Prospectus**

This prospectus is being furnished by the Company and Safety Shot for the sale of shares in the offering and to provide information to holders of Safety Shot common stock in connection with the distribution. We and Safety Shot will not update the information in this prospectus except in the normal course of our and Safety Shot' respective public disclosure obligations and practices.

**THE OFFERING**

---

| | |
|:---|:---|
| **Shares of common stock offered** | 2,710,000 shares of Common Stock |
| **Number of shares of common stock outstanding prior to offering** | 13,336,925 shares of Common Stock, as of June 30, 2025 |
| **Number of shares of common stock outstanding after this offering** | 14,336,925 shares of Common Stock<sup>(1)(2)</sup> |
| **Use of Proceeds** | We will not receive any of the proceeds from the sale of the shares of our common stock being offered for sale by the selling stockholders. Upon the exercise of the warrants for an aggregate of 2,110,000 shares of common stock by payment of cash however, we will receive the exercise price of the warrants, or an aggregate of approximately $6,330,000. See "Use of Proceeds." |
| **Listing** | Currently, our common stock is quoted on the OTCQB under the symbol "CBRA". We intend to apply to list our common stock on The Nasdaq Capital Market ("NASDAQ") under the symbol "CBRA". If our shares of common stock are not approved for listing on the NASDAQ, we will not consummate this offering. No assurance can be given that our application will be approved. |
| **Risk Factors** | **Investing in these securities involves a high degree of risk.** Investors should carefully consider the information set forth in the "Risk Factors" section of this prospectus on page 10 before deciding to invest in our shares of common stock. |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The
 number of shares of common stock to be outstanding immediately after this offering is based
 on 13,336,925 shares of common stock issued and outstanding as of June 30,
 2025.

(2) Assumes
 the sale of all shares of common stock pursuant to the Public Offering Prospectus
 (but no exercise of the underwriters' over-allotment option in connection therewith).
 Also assumes the cash exercise of all warrants, shares of common stock issuable upon exercise
 of which are registered in this resale prospectus and the issuance of all shares of common
 stock registered in the registration statement, of which this prospectus forms a part. Does
 not assume issuance of the 2,110,000 shares pursuant to the exercise of the warrants being
 registered for sale pursuant to this Resale Prospectus.

**USE OF PROCEEDS**

We will not receive any of the proceeds from the sale of the shares of our common stock being offered for sale by the Selling Stockholders. Upon the exercise of the Warrants for an aggregate of 2,110,000 shares of Common Stock assuming all payments are made by cash, we will receive the exercise price for the warrants, or an aggregate of approximately $6,330,000. We will bear all fees and expenses incident to our obligation to register the shares of common stock. Underwriting fees, commissions and similar expenses, if any, attributable to the sale of shares offered hereby will be borne by the Selling Stockholders.

There is no assurance the warrants will be exercised for cash. We intend to use such proceeds, if any, for general corporate and working capital purposes.

**SELLING STOCKHOLDERS**

The following table sets forth the number of Resale Shares held by the Selling Stockholders and registered as common stock for resale by means of this prospectus.

This prospectus registers for Shares that are held by certain Selling Stockholders that include certain stockholders with "restricted" securities under the applicable securities laws and regulations who, because of their status as our affiliates pursuant to Rule 144 or because they acquired their capital stock from an affiliate or from us within the prior 12 months from the date of any proposed sale, would otherwise be unable to sell their securities pursuant to Rule 144 until we have been subject to the reporting requirements of Section 13 or Section 15(d) of the Exchange Act for a period of at least 90 days. See "Shares Eligible for Future Sale" for further information regarding sales of such "restricted" securities if not sold pursuant to this prospectus.

Information concerning the Selling Stockholders may change from time to time and any changed information will be set forth in supplements to this prospectus, if and when necessary. Because the Selling Stockholders may sell all, some, or none of the shares of our common stock covered by this prospectus, we cannot determine the number of such shares of our common stock that will be sold by the Selling Stockholders, or the amount or percentage of shares of our common stock that will be held by the Selling Stockholders upon consummation of any particular sale. In addition, the Selling Stockholders listed in the table below may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, our shares of common stock in transactions exempt from the registration requirements of the Securities Act, after the date on which they provided the information set forth in the table below. See "Management" and "Certain Relationships and Related Party Transactions" for further information regarding the Selling Stockholders.

We currently intend to use our reasonable efforts to keep the registration statement of which this prospectus forms a part effective for a period of 90 days after the effectiveness of the registration statement. We are not party to any arrangement with any Registered Stockholder or any broker-dealer with respect to sales of shares of our common stock by the Selling Stockholders (see "Plan of Distribution" section below).

We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable.

We have based percentage ownership of our common stock based on 13,336,925 shares of our common stock issued and outstanding as of June 30, 2025. These amounts are based upon information available to the Company as of the date of this filing.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Beneficial Ownership Prior to the Effectiveness <br> of the Registration Statement** | **Beneficial Ownership Prior to the Effectiveness <br> of the Registration Statement** | **Beneficial Ownership Prior to the Effectiveness <br> of the Registration Statement** | **Beneficial Ownership After the**<br> **Effectiveness <br> of the Registration Statement<sup>(1)</sup>** | **Beneficial Ownership After the**<br> **Effectiveness <br> of the Registration Statement<sup>(1)</sup>** |
|  | **Number of<br> Shares of<br> Common<br> Stock<br> Beneficially<br> Owned+** | **Total<br> Number of<br> Shares of Common<br> Stock Being Registered<br> Pursuant<br> to this<br> Prospectus** | **Percentage<br> Ownership of<br> Common<br> Stock+** | **Number of Shares of Common Stock Beneficially Owned+** | **Percentage Ownership of Common Stock+** |
| Layali Z Abujoudeh | 900000 | 400000 | 5.9% | 0 | 0% |
| William Batzer | 50000 | 25000 | 0.3% | 0 | 0% |
| Darren Brungardt | 100000 | 50000 | 0.7% | 0 | 0% |
| Ivan Caplan | 200000 | 100000 | 1.3% | 0 | 0% |
| Paul Dara And Virginia Dara Jtwros | 100000 | 50000 | 0.7% | 0 | 0% |
| Kyle A Demsar Ttee | 100000 | 50000 | 0.7% | 0 | 0% |
| William M Duncan | 100000 | 50000 | 0.7% | 0 | 0% |
| Evin J Dyches Ttee | 100000 | 50000 | 0.7% | 0 | 0% |
| Matthew J Eames | 160000 | 80000 | 1.0% | 0 | 0% |
| Kol Garland | 50000 | 25000 | 0.3% | 0 | 0% |
| Matthew George | 160000 | 80000 | 1.0% | 0 | 0% |
| Peter V Houmere And Sarah Winslow Houmere Ten Com | 100000 | 50000 | 0.7% | 0 | 0% |
| Jackson Doge Llc | 300000 | 150000 | 2.0% | 0 | 0% |
| Ajay V Jetley | 50000 | 25000 | 0.3% | 0 | 0% |
| Daniel L Koons And Margaret Koons | 100000 | 50000 | 0.7% | 0 | 0% |
| Maria Longodevivo | 100000 | 50000 | 0.7% | 0 | 0% |
| Keith Morris | 100000 | 50000 | 0.7% |  | 0% |
| Novodx Corporation | 1000000 | 500000 | 6.5% | 0 | 0% |
| Ralph G Potente | 100000 | 50000 | 0.7% | 0 | 0% |
| Robert G Riviere And <br>Mary W Riviere Jtwros | 100000 | 50000 | 0.7% | 0 | 0% |
| Rogue One Vfx | 100000 | 50000 | 0.7% | 0 | 0% |
| Mara Silvon | 100000 | 50000 | 0.7% | 0 | 0% |
| James Zollo | 150000 | 75000 | 1.0% | 0 | 0% |
| Safety Shot distribution shares | 3000000 | 600000<sup>(2)</sup> | [ ]% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0% |
| **Total** | 7320000 | 2710000 | [ ]% | 0**%** | **0%** |

---

\* Indicates beneficial ownership of less than 1% of the outstanding shares of our common stock.

---

| | |
|:---|:---|
| + | Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to shares of common stock. Shares of common stock subject to options, warrants and convertible debentures currently exercisable or convertible, or exercisable or convertible within 60 days, are counted as outstanding. |

---

(1) Assumes
 that the Selling Stockholders sell all of the Shares being registered for resale. These amounts are based upon information available
 to the Company as of the date of this filing.

(2) This includes shareholders of Safety Shot, Inc. as of [ ],
 2025 to whom the Company's shares of common stock will be issued under the Distribution.

**PLAN OF DISTRIBUTION**

We are registering the Resale Shares to permit the resale of the Resale Shares by the Selling Stockholders from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale of the Resale Shares. However, upon any exercise of the Warrants held by the Selling Stockholders, we will receive cash proceeds per share equal to the exercise price of such warrants. We will pay all expenses (other than discounts, commissions, and transfer taxes, if any) relating to the registration of the Resale Shares in the registration statement of which this prospectus forms a part.

The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers, or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for any underwriter discounts or commissions and any applicable transfer taxes. If any of the Selling Shareholders sell the Resale Shares through underwriters or broker-dealers, it would constitute a material change requiring a post-effective amendment. The Resale Shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,

● on
 any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

● in
 the over-the-counter market;

● in
 transactions otherwise than on these exchanges or systems or in the over-the-counter market;

● ordinary
 brokerage transactions and transactions in which the broker-dealer solicits purchasers;

● block
 trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block
 as principal to facilitate the transaction;

● purchases
 by a broker-dealer as principal and resale by the broker-dealer for its account;

● an
 exchange distribution in accordance with the rules of the applicable exchange;

● privately
 negotiated transactions;

● short
 sales;

● in
 transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated
 price per security;

● through
 the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

● a
 combination of any such methods of sale; or

● any
 other method permitted pursuant to applicable law

The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus. The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive Commissions or discounts from the Selling Stockholders (or, if any Broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a Customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

In connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

**LEGAL MATTERS**

The validity of the common stock covered by this prospectus will be passed upon by Sichenzia Ross Ference Carmel LLP.

![](fin_003.jpg)

**CARING BRANDS, INC.**

**2,710,000 shares of common stock**

**RESALE PROSPECTUS**

**Until [●], 2025, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriter with respect to their unsold subscriptions.**

**The date of this Resale Prospectus is , 2025**

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 13. Other Expenses of Issuance and Distribution**

The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by the Company in connection with the issuance and distribution of the securities being registered hereunder. All amounts are estimates except the SEC registration fee.

---

| | |
|:---|:---|
| SEC registration fee | $|
| FINRA filing fee | $|
| NASDAQ listing fee | $|
| Legal fees and expenses | $|
| Printing fees and expenses | $|
| Accounting fees and expenses | $|
| Miscellaneous fees and expenses | $|
| **Total** | **$** |

---

**Item 14. Indemnification of Directors, Officers, Employees and Agents**

Neither our Articles of Incorporation nor Bylaws prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statute ("NRS"). NRS Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses, including attorneys' fees, actually and reasonably incurred by him in connection with any defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.

NRS 78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys' fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed hereby in the Securities Act and we will be governed by the final adjudication of such issue.

**Item 15. Recent Sales of Unregistered Securities**

Between April to June 2024, Caring Brands Florida entered into separate securities purchase agreements (the "SPAs") with various accredited investors for the private placement of units (the "Purchasers") at a price per unit of $1.00, consisting of one share of common stock and a warrant to purchase one share of common stock. All of the Purchasers of the Bridge Financing are included in the Selling Shareholders table included on page Alt-13. Pursuant to the SPAs Caring Brands Florida received gross proceeds of $2,110,000 from the private placement of units. Subsequently Caring Brands Florida issued an aggregate of 2,110,000 shares of common stock and warrants to purchase up to 2,110,000 shares of common stock at an exercise price of $3.00 per share, which warrants expire on April 15, 2029. Following the execution of the Separation and Exchange Agreement, the shares and warrants issued to the Selling Stockholders by Caring Brands Florida were exchanged for the Private Shares and the Warrants. We used the net proceeds of the Bridge Financing to fund our continuing working capital and capital expenditure requirements leading up to this offering. D. Boral, the lead underwriter of this offering, served as the lead placement agent for the Bridge Financing. D. Boral received fees and reimbursement of expenses in an aggregate amount of $211,000.

On May 14, 2024, the Company issued 7,600,000 shares to certain of its insiders and founding stockholders, pursuant to a subscription agreement dated March 15, 2024, at a purchase price of $0.001 per share of Common Stock. The form of subscription agreement is included as Exhibit 10.1 of this registration statement and prospectus.

On January 31, 2025, the Company issued 100,000 shares to Layali Z Abujoudeh, pursuant to an advisory agreement dated January 28, 2025.

On March 4, 2025, the Company issued 125,000 shares to NexGenAI Solutions Group, Inc. pursuant to a master services agreement dated February 25, 2025.

On April 23, 2025, the Company issued 1,925 shares to various investors, pursuant to securities purchase agreements entered into with such investors, at a purchase price of $4 per share. The form of securities purchase agreement is included as Exhibit 10.13 of this registration statement and prospectus.

On September 24, 2024, we entered into the Separation and Exchange Agreement with Safety Shot to govern the separation of our business from Safety Shot. We expect to consummate the separation on or prior to the effective date of the registration statement of which this prospectus forms a part and the distribution will be paid on or after the effective time of the registration statement of which this prospectus forms a part but prior to the closing of this offering. Safety Shot owns majority of the issued and outstanding ordinary shares of Caring Brands Florida, which currently operates the CB Business and owns all of the assets and liabilities related thereto. Pursuant to the Separation and Exchange Agreement the CB Business was contributed to us and all expenses related thereto shall be our responsibility, in each case, on the terms and subject to the conditions set forth therein, and in exchange Safety Shot was transferred to us all of the issued and outstanding ordinary shares of Caring Brands Florida owned by Safety Shot. In conjunction to the Business Transfer and pursuant to the Separation and Exchange Agreement, Safety Shot transferred all the intellectual property to the Company. In the event this offering is not consummated, the Separation will be unwound.

**Item 16. Exhibits and Financial Statement Schedules**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description** |
| 1.1\* | [Form of Underwriting Agreement](ex1-1.htm) |
| 3.1\* | [Articles of Incorporation](ex3-1.htm) |
| 3.2\* | [Bylaws](ex3-2.htm) |
| 3.3\* | [Amendment to Articles of Incorporation](ex3-3.htm) |
| 3.4\* | [Second Amendment to Articles of Incorporation](ex3-4.htm) |
| 4.1\* | [Form of Common Stock Purchase Warrant (included as Exhibit A to the Bridge Financing - Form of Securities Purchase Agreement at Exhibit 10.10, and incorporated by reference herein)](ex10-10.htm) |
| 4.2\* | [Form of Representative's Warrant (included as Exhibit A to the Form of Underwriting Agreement at Exhibit 1.1, and incorporated by reference herein)](ex1-1.htm) |
| 5.1# | Opinion of Sichenzia Ross Ference Carmel LLP |
| 10.1\* | [Form of Subscription Agreement](ex10-1.htm) |
| 10.2\* | [Amended and Restated Research Collaboration and Non-Exclusive License Agreement dated July 22, 2024, by and between the Company and NovoDX Corporation](ex10-2.htm) |
| 10.3\* | [Employment Agreement with Dr. Glynn Wilson, dated April 1, 2024](ex10-3.htm) |
| 10.4\* | [Employment Agreement with Brian John, dated April 1, 2024](ex10-4.htm) |
| 10.5\* | [2024 Equity Incentive Plan](ex10-5.htm) |
| 10.6\* | [Form of Separation and Exchange Agreement dated September 24, 2024, by and between the Company and Safety Shot](ex10-6.htm) |
| 10.7\* | [Cosmofix and San Pellegrino Cosmetics License Agreement](ex10-7.htm) |
| 10.8\* | [Taisho License Agreement](ex10-8.htm) |
| 10.9\* | [Manufacturing agreement with Sanpellegrino Cosmetics Pvt. Ltd.](ex10-9.htm) |
| 10.10\* | [Bridge Financing – Form of Securities Purchase Agreement](ex10-10.htm) |
| 10.11\* | [Lease](ex10-11.htm) |
| 10.12\* | [Sales Agent Agreement](ex10-12.htm) |
| 10.13\* | [Form of Securities Purchase Agreement (April 2025 issuance).](ex10-13.htm) |
| 14.1\* | [Code of Business Conduct and Ethics](ex14-1.htm) |
| 14.2\* | [Corporate Governance Guidelines](ex14-2.htm) |
| 21\* | [List of Subsidiaries](ex21.htm) |
| 23.1\* | [Consent of M&K CPAS PLLC, an independent registered public accounting firm](ex23-1.htm) |
| 23.2# | Consent of Sichenzia Ross Ference Carmel LLP (included in exhibit 5.1) |
| 24.1\* | [Power of Attorney (included in signature page to this registration statement)](#poa_1) |
| 99.1\* | [Insider Trading Policy](ex99-1.htm) |
| 99.2\* | [Audit Committee Charter](ex99-2.htm) |
| 99.3\* | [Nomination and Corporate Governance Committee Charter](ex99-3.htm) |
| 99.4\* | [Compensation Committee Charter](ex99-4.htm) |
| 107\* | [Fee Table](ex107.htm) |

---

# To be filed by amendment

\* Filed herewith

**Item 17. Undertakings**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933, as amended (the "Securities Act");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of the securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) For the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities, other than the payment by the registrant of expenses incurred and paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding, is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The undersigned Registrant hereby undertakes that it will:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) for determining any liability under the Securities Act, treat the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1), or (4) or 497(h) under the Securities Act as part of this registration statement as of the time the Commission declared it effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) for determining any liability under the Securities Act, treat each post-effective amendment that contains a form of prospectus as a new registration statement for the securities offered in the registration statement, and that offering of the securities at that time as the initial bona fide offering of those securities.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in City Jupiter, State of Florida on August 21, 2025.

---

| | |
|:---|:---|
| **CARING BRANDS, INC.** | **CARING BRANDS, INC.** |
| By: | */s/ Dr. Glynn Wilson* |
|  | Dr. Glynn Wilson |
|  | Chief Executive Officer |
| By: | */s/ Markita Russell* |
|  | Markita Russell |
|  | Chief Financial Officer |

---

**POWER OF ATTORNEY**

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Brian S. John and Markita Russell, and each of them (with full power to each of them to act alone), his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and on his behalf and in his name, place and stead, in any and all capacities, to sign, execute and file this registration statement under the Securities Act of 1933, as amended, and any or all amendments (including, without limitation, post-effective amendments) to this registration statement, with all exhibits and any and all documents required to be filed with respect thereto, with the Securities and Exchange Commission or any other regulatory authority, granting unto such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing appropriate or necessary to be done in order to effectuate the same, as fully to all intents and purposes as he himself might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Dr. Glynn Wilson* | Chief Executive Officer | August 21, 2025 |
| Dr. Glynn Wilson | (Principal Executive Officer) |  |
| */s/ Markita Russell* | Chief Financial Officer | August 21, 2025 |
| Markita Russell | (Principal Accounting and Financial Officer) |  |
| */s/ Brian S John* | Chairman of the Board | August 21, 2025 |
| Brian S John |  |  |
| */s/ Dr. Hector Alila* | Director | August 21, 2025 |
| Dr. Hector Alila |  |  |
| */s/ Christopher Galeta* | Director | August 21, 2025 |
| Christopher Galeta |  |  |
| */s/ Christopher Melton* | Director | August 21, 2025 |
| Christopher Melton |  |  |

---

## Exhibit 1.1

**Exhibit 1.1**

**UNDERWRITING AGREEMENT**

**between**

**CARING BRANDS, INC., AND**

**D. BORAL CAPITAL LLC, CARING BRANDS, INC.**

**UNDERWRITING AGREEMENT**

New York, New York

[●], 2025

D. BORAL CAPITAL LLC as Representatives of the several Underwriters named on Schedule 1 attached hereto

c/o D. BORAL CAPITAL LLC

Syndicate Department

590 Madison Avenue, 39<sup>th</sup> Floor

New York, New York 10022

Ladies and Gentlemen:

The undersigned, Caring Brands, Inc., a corporation formed under the laws of the State of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries, the "**Company**"), hereby confirms its agreement (this "**Agreement**") with D. Boral Capital LLC ("**D. Boral**") (hereinafter referred to as "you" (including its correlatives) or the "**Representative**" or the "**Underwriter**") as follows:

**1. PURCHASE AND SALE OF SHARES.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1. Firm Securities.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1.1. <u>Nature and Purchase of Firm Securities</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell to the several Underwriters, an aggregate of [__] authorized but unissued shares (the "**Firm Shares**") of common stock of the Company, par value $0.001 per share (the "**Common Stock**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Firm Shares are to be offered initially to the public at the offering price set forth on the cover page of the Prospectus (as hereinafter defined).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1.2. <u>Payment and Delivery of Securities</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Delivery and payment for the Firm Securities shall be made at 10:00 a.m., Eastern time, on the first (1<sup>nd</sup>) Business Day following the effective date (the "**Effective Date**") of the Registration Statement (as defined in Section 2.1.1 below) (or the second (2<sup>rd</sup>) Business Day following the Effective Date if the Registration Statement is declared effective after 4:01 p.m., Eastern time) or at such earlier time as shall be agreed upon by the Representatives and the Company, at the offices of Lucosky Brookman LLP, 10 Wood Avenue South, 5<sup>th</sup> Floor, Woodbridge, NJ 08830, Attn. Joseph Lucosky ("**Representatives' Counsel**"), or at such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon by the Representatives and the Company. The hour and date of delivery and payment for the Firm Securities is called the "**Closing Date**."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Payment for the Firm Securities shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery of the certificates (in form and substance satisfactory to the Underwriters) representing the Firm Securities (or through the facilities of the Depository Trust Company ("**DTC**")) for the account of the Underwriters. The Firm Securities shall be registered in such name or names and in such authorized denominations as the Representatives may request in writing at least one (1) Business Day prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Securities except upon tender of payment by the Representatives for all of the Firm Securities. The term "**Business Day**" means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to "stay-at-home," "shelter-in-place," "non-essential employee" or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2. Over-allotment Option.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.1. <u>Option Securities</u>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Securities, the Company hereby grants to the Underwriters an option to purchase up to [__] additional shares of Common Stock (the "**Option Shares**"), representing fifteen percent (15%) of the Firm Shares sold in the offering, from the Company (the "**Over-allotment Option**"). The purchase price to be paid per Option shall be equal to the price per Firm Share set forth in Section 1.1.1 hereof. The Firm Securities and the Option Securities are hereinafter collectively referred to as the "**Primary Securities**" or the "**Public Securities**." The offering and sale of the Primary Securities is hereinafter referred to as the "**Offering**."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.2. <u>Exercise of Option</u>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representatives as to all (at any time) or any part (from time to time) of the Option Securities within 45 days after the Effective Date. The purchase price to be paid per Option Share shall be equal to the Firm Share purchase price set forth in Section 1.1.1(ii) hereof. The Underwriters shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option. The Over-allotment Option granted hereby may be exercised by the giving of oral notice to the Company from the Representatives, which must be confirmed in writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares to be purchased and the date and time for delivery of and payment for the Option Securities (the "**Option Closing Date**"), which shall not be later than one (1) Business Day after the date of the notice or such other time as shall be agreed upon by the Company and the Representatives, at the offices of Representatives' Counsel or at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representatives. If such delivery and payment for the Option Securities does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Option Securities, subject to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Option Shares specified in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the total number of Option Shares then being purchased as set forth in <u>Schedule 1</u> opposite the name of such Underwriter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2.3. <u>Payment and Delivery</u>. Payment for the Option Securities shall be made on the Option Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing the Option Shares (or through the facilities of DTC) for the account of the Underwriters. The Option Securities shall be registered in such name or names and in such authorized denominations as the Representatives may request in writing at least one (1) Business Day prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Securities except upon tender of payment by the Representatives for applicable Option Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3. Representatives' Warrants.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3.1. <u>Purchase Warrants</u>. The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date a warrant ("**Representatives' Warrants**") for the purchase of an aggregate of [__] shares of Common Stock, representing 3% of the number of Firm Shares. The agreement(s) representing the Representatives' Warrants, in the form attached hereto as <u>Exhibit A</u> (the "**Representatives' Warrant Agreement**"), shall be exercisable, in whole or in part, commencing on a date which is six (6) months after the Effective Date and expiring on the five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[__], which is equal to 100.0% of the initial public offering price of the Firm Shares. The Representatives' Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the "**Representatives' Securities**." The Representatives understand and agree that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representatives' Warrant Agreement and the underlying shares of Common Stock during the one hundred and eighty (180) days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representatives' Warrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred and eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representatives or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3.2. <u>Delivery</u>. Delivery of the Representatives' Warrant Agreement shall be made on the Closing Date, and shall be issued in the name or names and in such authorized denominations as the Representatives may request.

**2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.**

The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below), as of the Closing Date and as of the Option Closing Date, if any, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1. Filing of Registration Statement.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.1. <u>Pursuant to the Securities Act</u>. The Company has filed with the U.S. Securities and Exchange Commission (the "**Commission**") a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-___________), including any related prospectus or prospectuses, for the registration of the Public Securities and the Representatives' Securities under the Securities Act of 1933, as amended (the "**Securities Act**"). Except as the context may otherwise require, such registration statement, as amended, on file with the Commission at the time the registration statement became effective (including the Preliminary Prospectus included in the registration statement, financial statements, schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information deemed to be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A (the "**Rule 430A Information**") of the rules and regulations of the Commission promulgated thereunder (the "**Securities Act Regulations**"), is referred to herein as the "**Registration Statement**." If the Company files any registration statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term "**Registration Statement**" shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement has been declared effective by the Commission on the date hereof.

Each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a "**Preliminary Prospectus**." The Preliminary Prospectus, subject to completion, dated [●], 2024, that was included in the Registration Statement immediately prior to the Applicable Time is hereinafter called the "**Pricing Prospectus**." The final prospectus in the form first furnished to the Underwriters for use in the Offering, that includes the Rule 430A Information, is hereinafter called the "**Prospectus**." Any reference to the "most recent Preliminary Prospectus" shall be deemed to refer to the latest Preliminary Prospectus included in the Registration Statement.

"**Applicable Time**" means [●][a.m.][p.m.], Eastern time, on the date of this Agreement.

"**Issuer Free Writing Prospectus**" means any "issuer free writing prospectus," as defined in Rule 433 of the Securities Act Regulations ("**Rule 433**"), including without limitation any "free writing prospectus" (as defined in Rule 405 of the Securities Act Regulations) relating to the Firm Securities that is (i) required to be filed with the Commission by the Company, (ii) a "road show that is a written communication" within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Firm Securities or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g).

"**Issuer General Use Free Writing Prospectus**" means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a "*bona fide* electronic road show," as defined in Rule 433 (the "**Bona Fide Electronic Road Show**")), as evidenced by its being specified in <u>Schedule 2-B</u> hereto.

"**Issuer Limited Use Free Writing Prospectus**" means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.

"**Pricing Disclosure Package**" means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing Prospectus and the information included on <u>Schedule 2-A</u> hereto, all considered together.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2. Stock Exchange Listing.** The Common Stock has been approved for listing on the [_________________] (the "**Exchange**"), subject only to official notice of issuance, and the Company has taken no action designed to, or likely to have the effect of, delisting the Common Stock from the Exchange, nor has the Company received any notification that the Exchange is contemplating terminating such listing except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3. No Stop Orders, etc.** Neither the Commission nor, to the Company's knowledge, any state regulatory authority has issued any order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company's knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied with each request (if any) from the Commission for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4. Disclosures in Registration Statement.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.1. <u>Compliance with Securities Act and 10b-5 Representation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus, at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to the Commission's EDGAR filing system ("**EDGAR**"), except to the extent permitted by Regulation S-T promulgated under the Securities Act ("**Regulation S-T**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Pricing Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), did not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto does not conflict in any material respect with the information contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information furnished to the Company with respect to the Underwriters by the Representatives expressly for use in the Registration Statement, the Pricing Prospectus or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided by or on behalf of any Underwriter consists solely of the following disclosure contained in the "Underwriting" section of the Prospectus: the names of the Underwriters, the information in the second paragraph under the subheading titled "Discounts, Commissions and Expenses" and the information under the subheadings titled "Price Stabilization, Short Positions, and Penalty Bids" and "Electronic Distribution" (the "**Underwriters' Information**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Date or at any Option Closing Date, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to the Underwriters' Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.2. <u>Disclosure of Agreements</u>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound or affected and (i) that is referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or (ii) is material to the Company's business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company's knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors' rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. Except as disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, none of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company's knowledge, any other party is in material default thereunder and, to the Company's knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder except for such defaults that would not reasonably be expected to result in a Material Adverse Change (as defined in Section 2.5.1 below). To the Company's knowledge, performance by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental or regulatory agency, authority, body, entity or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each, a "**Governmental Entity**"), including, without limitation, those relating to environmental laws and regulations, that, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Change as defined in Section 2.5.1 below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.3. <u>Prior Securities Transactions</u>. No securities of the Company have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by, or under common control with the Company, except as disclosed in the Registration Statement, the Pricing Disclosure Package, the Preliminary Prospectus or filings made by the Company with the Commission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.4. <u>Regulations</u>. The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects of federal, state, local and all foreign laws, rules and regulations relating to the Offering and the Company's business as currently conducted or contemplated are correct and complete in all material respects and no other such laws, rules or regulations are required under the Securities Act and the Securities Act Regulations to be disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus which are not so disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4.5. <u>No Other Distribution of Offering Materials</u>. The Company has not, directly or indirectly, distributed and will not distribute any offering material in connection with the Offering other than any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus and other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.5. Changes After Dates in Registration Statement.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.1. <u>No Material Adverse Change</u>. Since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse change in the financial position or results of operations of the Company or its Subsidiaries taken as a whole, nor to the Company's knowledge, any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the Company or its Subsidiaries taken as a whole (a "**Material Adverse Change**"); (ii) there have been no material transactions entered into by the Company or its Subsidiaries, other than as contemplated pursuant to this Agreement; and (iii) no officer or director of the Company has resigned from any position with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5.2. <u>Recent Securities Transactions, etc</u>. Subsequent to the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its capital stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.6. Disclosures in Commission Filings.** None of the Company's filings with, or other documents furnished to, the Commission contained any untrue statement of a material fact or omitted to state any material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to the Underwriter's Information. The Company has made all filings with the Commission required under the Exchange Act and the rules and regulations of the Commission promulgated thereunder (the "**Exchange Act Regulations**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.7. Independent Accountants.** To the knowledge of the Company, M&K CPAS, PLLC (the "**Auditor**"), whose reports are filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.8. Financial Statements, etc.** The financial statements, including the notes thereto and supporting schedules included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present in all material respects the financial position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("**GAAP**"), consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules included in the Registration Statement present fairly in all material respects the information required to be stated therein. Except as included therein, no historical or pro forma financial statements are required to be included in the Registration Statement, the Pricing Disclosure Package or the Prospectus under the Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information and the related notes, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly compiled and prepared in accordance with the applicable requirements of the Securities Act and the Securities Act Regulations and present fairly in all material respects the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding "non-GAAP financial measures" (as such term is defined by the rules and regulations of the Commission), if any, comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement, the Pricing Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect on the Company's financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (a) since the date of the last balance sheet included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its direct and indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as being a subsidiary of the Company (each, a "**Subsidiary**" and, collectively, the "**Subsidiaries**"), has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries, or, other than in the ordinary course of business, any grants under any stock compensation plan, and (d) there has not been any material adverse change in the Company's long-term or short-term debt. The Company represents that it has no direct or indirect subsidiaries other than those listed in Exhibit 21.1 to the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.9. Authorized Capital; Options, etc.** The Company had, at the date or dates indicated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the Closing Date the adjusted capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Pricing Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option Closing Date, there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the Company or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts or commitments to issue or sell shares of Common Stock or any such options, warrants, rights or convertible securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.10. Valid Issuance of Securities, etc.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10.1. <u>Outstanding Securities</u>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission or the ability to force the Company or any of its Subsidiaries to repurchase such securities with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities were issued in violation of the preemptive rights, rights of first refusal or rights of participation of any holders of any security of the Company or similar contractual rights granted by the Company. The authorized shares of Common Stock, preferred shares, and any other securities outstanding or to be outstanding upon consummation of the Offering conform in all material respects to all statements relating thereto contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock, options, warrants and other outstanding securities convertible into or exercisable for shares of Common Stock, were at all relevant times either registered under the Securities Act and the applicable state securities or "blue sky" laws or, based in part on the representations and warranties of the purchasers of such shares of Common Stock, exempt from such registration requirements. The description of the Company's stock option, stock bonus and other related plans or arrangements, and options and/or other rights granted thereunder, as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, accurately and fairly present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10.2. <u>Securities Sold Pursuant to this Agreement</u>. The Public Securities and Representatives' Securities have been duly authorized for issuance and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability by reason of being such holders; the Public Securities and Representatives' Securities are and will be free from all preemptive rights of any holders of any security of the Company, or similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public Securities and Representatives' Securities has been duly and validly taken. The Representatives' Warrant Agreement, when issued and paid for pursuant to this Agreement, will constitute valid and binding obligations of the Company to issue and sell, upon exercise thereof and payment therefor, the underlying shares of Common Stock. The Public Securities and Representatives' Securities conform in all material respects to all statements with respect thereto contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Representatives' Warrant Agreement has been duly and validly taken; the shares of Common Stock issuable upon exercise of the Representatives' Warrant have been duly authorized and reserved for issuance by all necessary corporate action on the part of the Company and when paid for and issued in accordance with the Representatives' Warrant and the Representatives' Warrant Agreement, such shares of Common Stock will be validly issued, fully paid and nonassessable; the holders thereof are not and will not be subject to personal liability by reason of being such holders; and such shares of Common Stock are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.11. Registration Rights of Third Parties.** Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no holders of any securities of the Company or any options, warrants, rights or other securities exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include any such securities in the Registration Statement or any other registration statement to be filed by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.12. Validity and Binding Effect of Agreements.** The execution, delivery and performance of this Agreement and the Representatives' Warrant Agreement have been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors' rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.13. No Conflicts, etc.** The execution, delivery and performance by the Company of this Agreement the Representatives' Warrant Agreement, and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in a breach of, or conflict with any of the terms and provisions of, or constitute a default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement or any other agreement or instrument to which the Company is a party or as to which any property of the Company is a party except breaches, conflicts or defaults that would not reasonably be expected to result in a Material Adverse Change; (ii) result in any violation of the provisions of the Company's Articles of Incorporation (as the same have been amended or restated from time to time, the "**Charter**") or the bylaws of the Company; or (iii) violate in any material respect any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof having jurisdiction over the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.14. No Defaults; Violations.** Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no default exists in the due performance and observance of any term, covenant or condition of any license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation for borrowed money, or any other agreement or instrument to which the Company is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject except for any such default that would not be reasonably expected to result in a Material Adverse Change. The Company is not in violation of any term or provision of its Charter or bylaws, or in violation of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity, except for such violations that would not be reasonably expected to result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.15. Corporate Power; Licenses; Consents.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15.1. <u>Conduct of Business</u>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has all requisite corporate power and authority, and has all consents, authorizations, approvals, licenses, certificates, clearances, permits and orders and supplements and amendments thereto (collectively, "**Authorizations**") of and from all Governmental Entities that it needs as of the date hereof to conduct its business purpose as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except for such Authorizations, the absence of which would reasonably be expected to have a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15.2. <u>Transactions Contemplated Herein</u>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions and conditions hereof, and all Authorizations required in connection therewith have been obtained. No Authorization of, and no filing with, any Governmental Entity, the Exchange or another body is required for the valid issuance, sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this Agreement and the Representatives' Warrant Agreement and as contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, except with respect to applicable Securities Act Regulations, state securities laws and the rules and regulations of the Financial Industry Regulatory Authority, Inc. ("**FINRA**") and any required Exchange notification filing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.16. D&O Questionnaires.** To the Company's knowledge, all information contained in the questionnaires (the "**Questionnaires**") completed by each of the Company's directors and officers immediately prior to the Offering (the "**Insiders**") as supplemented by all information concerning the Insiders as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus provided to the Underwriters, is true and correct in all material respects and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.17. Litigation; Governmental Proceedings.** There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending or, to the Company's knowledge, threatened against, or involving the Company or, to the Company's knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or in connection with the Company's listing application for the listing of the Common Stock on the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.18. Good Standing.** The Company has been duly incorporated and is validly existing as a corporation and is in good standing under the laws of the State of Nevada as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.19. Insurance.** The Company carries or is entitled to the benefits of insurance (including, without limitation, as to directors and officers insurance coverage), with reputable insurers, in such amounts and covering such risks which the Company believes are adequate as are customary for companies engaged in similar business, and to the Company's knowledge all such insurance is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.20. Transactions Affecting Disclosure to FINRA.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20.1. <u>Finder's Fees</u>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder's, consulting or origination fee by the Company or any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements or understandings of the Company or, to the Company's knowledge, any of its stockholders that may affect the Underwriters' compensation, as determined by FINRA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20.2. <u>Payments Within Twelve (12) Months</u>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not made any direct or indirect payments in connection with the Offering (in cash, securities or otherwise) to: (i) any person, as a finder's fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the Effective Date, other than the payment to the Underwriters as provided hereunder in connection with the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20.3. <u>Use of Proceeds</u>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates, except as specifically authorized herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20.4. <u>FINRA Affiliation</u>. There is no (i) officer or director of the Company, (ii) beneficial owner of 10% or more of any class of the Company's securities or (iii) beneficial owner of the Company's unregistered equity securities which were acquired during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20.5. <u>Information</u>. All information provided by the Company in its FINRA questionnaire to Representatives' Counsel specifically for use by Representatives' Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.21. Foreign Corrupt Practices Act.** None of the Company and its Subsidiaries or, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of, and with authority from, the Company and its Subsidiaries, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any Governmental Entity (domestic or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i) might subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse Change or (iii) if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.22. Compliance with OFAC.** None of the Company and its Subsidiaries or, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of, and with authority from, the Company and its Subsidiaries, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury ("**OFAC**"), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.23. Money Laundering Laws.** The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the "**Money Laundering Laws**"); and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.24. Officers' Certificate.** Any certificate signed by any duly authorized officer of the Company and delivered to you or to Representatives' Counsel on the Closing Date or on the Option Closing Date shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.25. Lock-Up Agreements.** <u>Schedule 3</u> hereto contains a complete and accurate list of the Company's officers, directors and each owner of 10% or more of the Company's outstanding shares of Common Stock (or securities convertible or exercisable into shares of Common Stock) (collectively, the "**Lock-Up Parties**"). The Company has caused each of the Lock-Up Parties to deliver to the Representatives an executed Lock-Up Agreement, in a form substantially similar to that attached hereto as <u>Exhibit B</u> (the "**Lock-Up Agreement**"), prior to the execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.26. Subsidiaries.** All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify would not have a material adverse effect on the assets, business or operations of the Company taken as a whole. The Company's ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.27. Related Party Transactions.** There are no business relationships or related party transactions involving the Company or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that have not been described as required under the Securities Act and the Securities Act Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.28. Board of Directors.** The Board of Directors of the Company is comprised of the persons set forth under the heading of the Pricing Prospectus and the Prospectus captioned "Management." The qualifications of the persons serving as board members and the overall composition of the board comply with the Exchange Act, the rules and regulations of the Commission promulgated thereunder (the "**Exchange Act Regulations**"), the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the "**Sarbanes-Oxley Act**") applicable to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of the Board of Directors of the Company qualifies as an "audit committee financial expert," as such term is defined under Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of the persons serving on the Board of Directors qualify as "independent," as defined under the listing rules of the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.29. Sarbanes-Oxley Compliance.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.29.1. <u>Disclosure Controls</u>. The Company has developed and currently maintains disclosure controls and procedures that comply in all material respects with Rule 13a-15 or 15d-15 under the Exchange Act Regulations, and except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, such controls and procedures are effective to ensure that all material information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company's Exchange Act filings and other public disclosure documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.29.2. <u>Compliance</u>. The Company is and at the Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and has taken reasonable steps to ensure the Company's future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.30. Accounting Controls.** The Company and its Subsidiaries maintain systems of "internal control over financial reporting" (as defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply in all material respects with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management's general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management's general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal controls. The Company's auditor and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are known to the Company's management and that have adversely affected or are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company's management, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.31. No Investment Company Status.** The Company is not and, after giving effect to the Offering and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required to register as an "investment company," as defined in the Investment Company Act of 1940, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.32. No Labor Disputes.** No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is imminent. The Company is not aware that any officer, key employee or significant group of employees of the Company plans to terminate employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.33. Intellectual Property Rights.** The Company and each of its Subsidiaries owns or possesses or has valid rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights ("**Intellectual Property Rights**") and necessary for the conduct of the business of the Company and each of its Subsidiaries as currently carried on and as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company or any of its Subsidiaries necessary for the conduct of its business as currently carried on and as described in the Registration Statement and the Prospectus will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others. Neither the Company nor any of its Subsidiaries has received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change: (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together with any other claims in this Section 2.33, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the Company's knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 2.33, reasonably be expected to result in a Material Adverse Change; (D) there is no pending or, to the Company's knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with any other claims in this Section 2.33, reasonably be expected to result in a Material Adverse Change; and (E) to the Company's knowledge, no employee of the Company is in or has ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee's employment with the Company, or actions undertaken by the employee while employed with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company's knowledge, all material technical information developed by and belonging to the Company which has not been patented has been kept confidential. The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus and are not described therein. The Registration Statement, the Pricing Disclosure Package and the Prospectus contain in all material respects the same description of the matters set forth in the preceding sentence. None of the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company's knowledge, any of its officers, directors or employees, or otherwise in violation of the rights of any persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.34. <u>Taxes</u>.** Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the Company or such respective Subsidiary except those that are being contested in good faith or as would not have, individually or in the aggregate, result in a Material Adverse Change. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters, (i) no material issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the Company or its Subsidiaries. To the Company's knowledge, there are no tax liens against the assets, properties or business of the Company or its Subsidiaries. The term "**taxes**" means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto. The term "**returns**" means all returns, declarations, reports, statements and other documents required to be filed in respect to taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.35. ERISA Compliance.** The Company and any "employee benefit plan" (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, "**ERISA**")) established or maintained by the Company or its "ERISA Affiliates" (as defined below) are in compliance in all material respects with ERISA. "**ERISA Affiliate**" means, with respect to the Company, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the "**Code**") of which the Company is a member. No "reportable event" (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any "employee benefit plan" established or maintained by the Company or any of its ERISA Affiliates. No "employee benefit plan" established or maintained by the Company or any of its ERISA Affiliates, if such "employee benefit plan" were terminated, would have any "amount of unfunded benefit liabilities" (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any "employee benefit plan" or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each "employee benefit plan" established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.36. Compliance with Laws.** Each of the Company and each Subsidiary: (A) is and at all times has been in compliance with all statutes, rules, or regulations applicable to the business of the Company as currently conducted ("**Applicable Laws**"), except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice from any Governmental Entity alleging or asserting noncompliance with any Applicable Laws or any Authorizations; (C) possesses all Authorizations and such Authorizations are valid and in full force and effect and are not in violation of any term of any such Authorizations, except where the invalidity of such Authorizations or the failure of such Authorizations to be in full force and effect would not result in a Material Adverse Change; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any activity conducted by the Company is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Entity is considering such action; and (F) has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission), except where the failure to be so in compliance would not, individually or in the aggregate, result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.37. Reserved.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.38. Environmental Laws.** The Company is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment which are applicable to their businesses ("**Environmental Laws**"), except where the failure to comply would not, singularly or in the aggregate, result in a Material Adverse Change. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company (or, to the Company's knowledge, any other entity for whose acts or omissions the Company is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, except for any violation or liability which would not have, singularly or in the aggregate with all such violations and liabilities, a Material Adverse Change; and there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge, except for any such disposal, discharge, emission, or other release of any kind which would not have, singularly or in the aggregate with all such discharges and other releases, a Material Adverse Change. In the ordinary course of business, the Company conducts periodic reviews of the effect of Environmental Laws on its business and assets, in the course of which they identify and evaluate associated costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or governmental permits issued thereunder, any related constraints on operating activities and any potential liabilities to third parties). On the basis of such reviews, the Company has reasonably concluded that such associated costs and liabilities would not have, singularly or in the aggregate, a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.39. Title to Property.** Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company or any of its Subsidiaries holds properties described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, are, to the Company's knowledge, in full force and effect, and neither the Company nor any Subsidiary has received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or any Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.40. Contracts Affecting Capital.** There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company's or its Subsidiaries' liquidity or the availability of or requirements for their capital resources required to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus which have not been described or incorporated by reference as required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.41. Loans to Directors or Officers.** There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the officers or directors of the Company, its Subsidiaries, or any of their respective family members, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.42. Ineligible Issuer.** At the time of filing the Registration Statement and any post-effective amendment thereto, at the Effective Date and at the time of any amendment thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at the Effective Date, the Company was not and is not an "ineligible issuer," as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.43. Smaller Reporting Company.** As of the time of filing of the Registration Statement, the Company was a "smaller reporting company," as defined in Rule 12b-2 of the Exchange Act Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.44. Industry Data.** The statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company's good faith estimates that are made on the basis of data derived from such sources.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.45. Electronic Road Show.** The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) of the Securities Act Regulations such that no filing of any "road show" (as defined in Rule 433(h) of the Securities Act Regulations) is required in connection with the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.46. Margin Securities.** The Company owns no "margin securities" as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the "**Federal Reserve Board**"), and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the Public Securities to be considered a "purpose credit" within the meanings of Regulation T, U or X of the Federal Reserve Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.47. Dividends and Distributions.** Except as disclosed in the Pricing Disclosure Package, Registration Statement and the Prospectus, no Subsidiary of the Company is currently prohibited or restricted, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such Subsidiary's capital stock (to the extent that any such prohibition or restriction on dividends and/or distributions would have a material effect to the Company), from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary's property or assets to the Company or any other Subsidiary of the Company, except as may otherwise be provided in current loan or mortgage-related documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.48. Forward-Looking Statements.** No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.49. Integration.** Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.50. Confidentiality and Non-Competition.** To the Company's knowledge, no director, officer, key employee or consultant of the Company or any Subsidiary is subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any employer (other than the Company) or prior employer that could materially affect his or her ability to be and act in his or her respective capacity of the Company or such Subsidiary or be expected to result in a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.51. Corporate Records.** The minute books of the Company have been made available to the Representatives and Representatives' Counsel and such books (i) contain minutes of all material meetings and actions of the Board of Directors (including each board committee) and stockholders of the Company, and (ii) reflect all material transactions referred to in such minutes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.52. Diligence Materials.** The Company has provided to the Representatives and Representatives' Counsel all materials required or necessary to respond in all material respects to the diligence request submitted to the Company or Company Counsel by the Representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.53. Stabilization.** Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent of the Representatives) has taken, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Public Securities.

**3. COVENANTS OF THE COMPANY.**

The Company covenants and agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.1. Amendments to Registration Statement.** The Company shall deliver to the Representatives, at least one (1) Business Day (or such shorter time mutually agreed by the parties hereto) prior to filing, any amendment or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement to which the Representatives shall reasonably object in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2. Federal Securities Laws.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.1. <u>Compliance</u>. The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations, and will notify the Representatives promptly, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii) of its receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus or the Prospectus, or of the suspension of the qualification of the Public Securities and Representatives' Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement; or (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of the Public Securities and Representatives' Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company shall use its best efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.2. <u>Continued Compliance</u>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations ("**Rule 172**"), would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of Representatives' Counsel or Company Counsel, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser; or (iii) amend the Registration Statement or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or the Securities Act Regulations, the Company will promptly (A) give the Representatives notice of such event; (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or supplement; and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or Representatives' Counsel shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company shall give the Representatives notice of its intention to make any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration of the Over-allotment Option specified in Section 1.2 hereof and will furnish the Representatives with copies of the related document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or Representatives' Counsel shall reasonably object.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.3. <u>Exchange Act Registration</u>. For a period of three (3) years after the date of this Agreement, the Company shall use its reasonable best efforts to maintain the registration of the Common Stock under the Exchange Act. For a period of two (2) years after the date of this Agreement, the Company shall not deregister the Common Stock under the Exchange Act without the prior written consent of the Representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.4. <u>Free Writing Prospectuses</u>. The Company agrees that, unless it obtains the prior written consent of the Representatives, it shall not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a "free writing prospectus," or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives shall be deemed to have consented to each Issuer General Use Free Writing Prospectus set forth in <u>Schedule 2-B</u>. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an "issuer free writing prospectus," as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.5. <u>Testing-the-Waters Communications</u>. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representatives and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.3. Delivery to the Underwriters of Registration Statements.** The Company has delivered or made available or shall deliver or make available to the Representatives and Representatives' Counsel, without charge, conformed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also deliver to each Underwriter, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) upon receipt of a written request therefor from such Underwriter. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.4. Delivery to the Underwriters of Prospectuses.** The Company has delivered or made available or will deliver or make available to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.5. Effectiveness and Events Requiring Notice to the Representatives.** The Company shall use its best efforts to cause the Registration Statement to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representatives promptly and confirm the notice in writing: (i) of the effectiveness of the Registration Statement and any amendment thereto; (ii) of the issuance by the Commission of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (iii) of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v) of the receipt of any comments or request for any additional information from the Commission; and (vi) of the happening of any event during the period described in this Section 3.5 that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement, the Pricing Disclosure Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration Statement in order to make the statements therein not misleading, or (b) in the Pricing Disclosure Package or the Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall enter a stop order or suspend such qualification at any time, the Company shall use its commercially reasonable efforts to obtain promptly the lifting of such order.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.6. Review of Financial Statements.** For a period of three (3) years after the date of this Agreement, the Company, at its expense, shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company's financial statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.7. Listing.** The Company shall use its reasonable best efforts to maintain the listing of the Securities on the Exchange until at least three (3) years after the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.8. Reserved**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.9. Reports to the Representatives.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9.1. <u>Periodic Reports, etc</u>. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available to the Representatives copies of such financial statements and other periodic and special reports as the Company from time to time furnishes generally to holders of any class of its securities and also promptly furnish to the Representatives: (i) a copy of each periodic report the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy of each Form 8-K prepared and filed by the Company; (iv) a copy of each registration statement filed by the Company under the Securities Act; (v) a copy of each report or other communication furnished to stockholders and (vi) such additional documents and information with respect to the Company and the affairs of any future subsidiaries of the Company as the Representatives may from time to time reasonably request. Documents filed with the Commission pursuant to its EDGAR system or press releases shall be deemed to have been delivered to the Representatives pursuant to this Section 3.9.1. Any documents not filed with the Commission pursuant to its EDGAR system shall be delivered to dbccapitalmarkets@dboralcapital.com.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9.2. <u>Transfer Agent; Transfer Sheets</u>. For a period of three (3) years after the date of this Agreement, the Company shall retain a transfer agent and registrar acceptable to the Representatives (the "**Transfer Agent**") and shall furnish to the Representatives at the Company's sole cost and expense such transfer sheets of the Company's securities as the Representatives may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. VStock Transfer LLC is acceptable to the Representatives to act as Transfer Agent for the shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9.3. <u>Trading Reports</u>. For a period of three (3) years after the date of this Agreement, during such time as any of the Public Securities are listed on the Exchange, the Company shall provide to the Representatives, at the Company's expense, such reports published by the Exchange relating to price trading of the Public Securities, as the Representatives shall reasonably request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.10. Payment of Expenses**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10.1. <u>General Expenses Related to the Offering</u>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing Date, all expenses related to the Offering or otherwise incident to the performance of the obligations of the Company under this Agreement, including, but not limited to: (a) all filing fees and expenses relating to the registration of the Securities with the Commission; (b) all fees and expenses relating to the listing of the Common Stock on a national exchange, if applicable; (c) all fees, expenses and disbursements relating to the registration or qualification of the Securities under the "blue sky" securities laws of such states and other jurisdictions as the Underwriters may reasonably designate (including, without limitation, all filing and registration fees, and the reasonable fees and disbursements of the Company's "blue sky" counsel, which will be the Underwriters' counsel) unless such filings are not required in connection with the Company's proposed listing on a national exchange, if applicable; (d) all fees, expenses and disbursements relating to the registration, qualification or exemption of the Securities under the securities laws of such foreign jurisdictions as the Underwriters may reasonably designate; (e) the costs of all mailing and printing of the Offering documents; (f) transfer and/or stamp taxes, if any, payable upon the transfer of Securities from the Company to the Underwriters; (g) the fees and expenses of the Company's accountants; (h) all filing fees and communication expenses associated with the review of the Offering by FINRA; (i) up to $20,000 of the Underwriters' actual accountable road show expenses for the Offering; (j) the $29,500 cost associated with the Underwriters' use of Ipreo's book building, prospectus tracking and compliance software for the offering; (k) the costs associated with bound volumes of the Offering materials as well as commemorative mementos and lucite tombstones in an aggregate amount not to exceed $5,000; and (l) the fees for the Underwriters' legal counsel, in an amount not to exceed $175,000. The Company shall be responsible for the Underwriters' external legal costs detailed in this Section irrespective of whether the Offering is consummated or not, subject to $50,000 if there is not a Closing. At its own expense, the Company shall conduct background checks, by a background search firm acceptable to the Underwriters, on the Company's senior management and board of directors. Additionally, one percent (1.0%) of the gross proceeds of the Offering shall be provided to the Representatives for nonaccountable expenses. The Representatives may deduct from the net proceeds of the Offering payable to the Company on the Closing Date, or the Option Closing Date, if any, the expenses set forth herein to be paid by the Company to the Underwriters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.10.2. Tail Period**. The Underwriter shall be entitled to a cash fee equal to eight percent (8%) of the gross proceeds received by the Company from the sale of any equity, debt and/or equity derivative instruments to any investor actually introduced to the Company by the Underwriters during the Engagement Period, in connection with any public or private financing or capital raise (each a "**Tail Financing**"), and such Tail Financing is consummated at any time during the Engagement Period or within the twelve (12) month period following the expiration or termination of the Engagement Period (the "**Tail Period**"), provided that such Tail Financing is by a party actually introduced to the Company in an offering in which the Company has direct knowledge of such party's participation. Notwithstanding the foregoing, no fee shall be payable by the Company pursuant to this Section 3.10.2 if the Company terminates this Agreement for cause, which shall include the material failure of the Underwriter to provide underwriting services, as provided in FINRA Rule 5110(g)(5)(B).

"**Engagement Period**" means the period beginning on February 12, 2025 and ending upon the consummation of the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.12. Right of First Refusal**. Following the Closing of the Offering, only D. Boral shall have an irrevocable right of first refusal (the "**Right of First Refusal**"), for a period of twelve (12) months after the date the Offering is completed (the "**RoFR Period**"), to act as sole investment banker, sole book-runner, and/or sole placement agent, at D. Boral's sole discretion, for each and every future public and private equity and debt offering, including all equity linked financings (each, a "**Subject Transaction**"), during such twelve (12) month period, of the Company, or any successor to or any current or future subsidiary of the Company, on terms and conditions customary to D. Boral for such Subject Transactions. D. Boral shall have the sole right to determine whether any other broker dealer shall have the right to participate in a Subject Transaction and the economic terms of such participation. For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment banker, book-runner, financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written consent of D. Boral.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.13. Application of Net Proceeds.** The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application thereof described under the caption "Use of Proceeds" in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.14. Delivery of Earnings Statements to Security Holders.** The Company shall make generally available to its security holders as soon as practicable, but not later than the first day of the fifteenth (15<sup>th</sup>) full calendar month following the date of this Agreement, an earnings statement (which need not be certified by an independent registered public accounting firm unless required by the Securities Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.15. Stabilization.** Neither the Company nor, to its knowledge, any of its employees, directors or stockholders has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Public Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.16. Internal Controls.** For a period of one (1) year after the date of this Agreement, the Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management's general or specific authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management's general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.17. Accountants.** As of the date of this Agreement, the Company has retained an independent registered public accounting firm, as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board, reasonably acceptable to the Representatives, and the Company shall continue to retain a nationally recognized independent registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Representatives acknowledge that M&K CPAs PLLCis acceptable to the Representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.18. FINRA.** For a period of 90 days from the later of the Closing Date or the Option Closing Date, the Company shall advise the Representatives (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer or director of the Company, (ii) any beneficial owner of 10% or more of any class of the Company's securities or (iii) any beneficial owner of the Company's unregistered equity securities which were acquired during the 180 days immediately preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.19. No Fiduciary Duties.** The Company acknowledges and agrees that the Underwriters' responsibility to the Company is solely contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.20. Company Lock-Up Agreements.** The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Underwriters, it will not, during the Engagement Period (including any extensions thereof) and additionally for a period of 180 days after the Closing of the Offering (the "**Lock-Up Period**"), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file or caused to be filed any registration statement with the Commission relating to the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank, or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.

The restrictions contained in this Section 3.20 shall not apply to (i) the Primary Securities to be sold hereunder, as well as the Representatives' Warrants and any shares of Common Stock into which the Representatives' Warrants are exercisable; (ii) the issuance by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security, in each case outstanding on the date hereof, provided that such options, warrants, securities are disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus and have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities, (iii) the issuance of shares of Common Stock issued as part of the purchase price in connection with the acquisitions or strategic transactions, provided certain conditions are met, or (iv) the issuance by the Company of any shares of Common Stock or standard options to purchase Common Stock to directors, officers or employees of the Company in their capacity as such pursuant to an Approved Stock Plan (as defined below). "**Approved Stock Plan**" means any employee benefit plan which has been approved by the board of directors of the Company prior to or subsequent to the date hereof pursuant to which shares of Common Stock and standard options to purchase Common Stock may be issued to any employee, officer or director for services provided to the Company in their capacity as such.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.19. Release of D&O Lock-up Period.** If the Representatives, in their sole discretion, agree to release or waive the restrictions set forth in the Lock-Up Agreements described in Section 2.25 hereof for an officer or director of the Company and provides the Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of <u>Exhibit C</u> hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.20. Blue Sky Qualifications.** The Company shall use its best efforts, in cooperation with the Underwriters, if necessary, to qualify the Public Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Public Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.21. Reporting Requirements.** The Company, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Public Securities as may be required under Rule 463 under the Securities Act Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.22. Press Releases.** Prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with the past practices of the Company and of which the Representatives are notified), without the prior written consent of the Representatives, which consent shall not be unreasonably withheld, unless in the judgment of the Company and its counsel, and after notification to the Representatives, such press release or communication is required by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.23. Sarbanes-Oxley.** For a period of one (1) year after the date of this Agreement, the Company shall at all times comply in all material respects with all applicable provisions of the Sarbanes-Oxley Act in effect from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.24. IRS Forms.** If requested by the Representatives, the Company shall deliver to each Underwriter (or its agent), prior to or at the Closing Date, a properly completed and executed Internal Revenue Service ("**IRS**") Form W-9 or an IRS Form W-8, as appropriate, together with all required attachments to such form.

**4. CONDITIONS OF UNDERWRITERS' OBLIGATIONS.**

The obligations of the Underwriters to purchase and pay for the Public Securities, as provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date hereof and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1. Regulatory Matters.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.1. <u>Effectiveness of Registration Statement; Rule 430A Information</u>. The Registration Statement has become effective not later than 5:30 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by the Representative, and, at each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto shall have been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus shall have been issued and no proceedings for any of those purposes shall have been instituted or are pending or, to the Company's knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. A prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) under the Securities Act Regulations (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A under the Securities Act Regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.2. <u>FINRA Clearance</u>. On or before the date of this Agreement, the Representatives shall have received clearance from FINRA as to the amount of compensation allowable or payable to the Underwriters as described in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.3. <u>Exchange Clearance</u>. On the Closing Date, the Common Stock shall have been approved for listing on the Exchange, subject only to official notice of issuance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2. Company Counsel Matters.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.1. <u>Closing Date Opinion of Counsel</u>. On the Closing Date, the Representatives shall have received the favorable opinion and negative assurance letter of Sichenzia Ross Ference Carmel LLP ("**Company Counsel**"), counsel to the Company, dated the Closing Date and addressed to the Representatives, in form and substance satisfactory to the Representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.2. <u>Option Closing Date Opinions of Counsel</u>. On the Option Closing Date, if any, the Representatives shall have received the favorable opinion and negative assurance letter of Company Counsel listed in Section 4.2.1, dated the Option Closing Date, addressed to the Representatives and in form and substance reasonably satisfactory to the Representatives, confirming as of the Option Closing Date, the statements made by such counsel in its opinion delivered on the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.3. <u>Reliance</u>. The opinion of Sichenzia Ross Ference Carmel LLP and any opinion relied upon by Sichenzia Ross Ference Carmel LLP shall include a statement to the effect that it may be relied upon by Representatives' Counsel in its opinion delivered to the Underwriters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.3. Comfort Letters.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.1. <u>Comfort Letter</u>. At the time this Agreement is executed the Representatives shall have received a cold comfort letter from the Auditor containing statements and information of the type customarily included in accountants' comfort letters with respect to the financial statements and certain financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representatives and in form and substance satisfactory in all respects to the Representatives and to Representatives' Counsel from the Auditor, dated as of the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.2. <u>Bring-down Comfort Letter</u>. At each of the Closing Date and the Option Closing Date, if any, the Representatives shall have received from the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to Section 4.3.1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.4. Officers' Certificates.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4.1. <u>Officers' Certificate</u>. The Company shall have furnished to the Representatives a certificate, dated the Closing Date and any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive Officer or President, and its Chief Financial Officer stating that on behalf of the Company and not in an individual capacity that (i) such officers have examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto after the Effective Date, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement thereto after the Effective Date, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii) to their knowledge after reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date), the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other than the Closing Date), and (iii) there has not been, subsequent to the date of the most recent audited financial statements included in the Pricing Disclosure Package, a Material Adverse Change.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4.2. <u>Secretary's Certificate</u>. At each of the Closing Date and the Option Closing Date, if any, the Representatives shall have received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Closing Date, as the case may be, respectively, certifying on behalf of the Company and not in an individual capacity: (i) that each of the Charter and Bylaws is true and complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Company's Board of Directors relating to the Offering are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.5. No Material Changes.** Prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been no Material Adverse Change in the condition or prospects or the business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any Insider before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding may reasonably be expected to cause a Material Adverse Change, except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.6. No Material Misstatement or Omission.** The Underwriters shall not have discovered and disclosed to the Company on or prior to the Closing Date and any Option Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the opinion of Representatives' Counsel, is material or omits to state any fact which, in the opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading, or that the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which, in the opinion of Representatives' Counsel, is material or omits to state any fact which, in the opinion of Representatives' Counsel, is material and is necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.7. Corporate Proceedings.** All corporate proceedings and other legal matters incident to the authorization, form and validity of each of this Agreement, the Public Securities, the Registration Statement, the Pricing Disclosure Package, each Issuer Free Writing Prospectus, if any, and the Prospectus and all other legal matters relating to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to Representatives' Counsel, and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon such matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.8. Lock-Up Agreements.** On or before the date of this Agreement, the Company shall have delivered to the Representatives executed copies of the Lock-Up Agreements from each of the persons listed in <u>Schedule 3</u> hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.9. Additional Documents.** At the Closing Date and at each Option Closing Date (if any) Representatives' Counsel shall have been furnished with such documents and opinions as they may require for the purpose of enabling Representatives' Counsel to deliver an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities and Representatives' Securities as herein contemplated shall be satisfactory in form and substance to the Representatives and Representatives' Counsel.

**5. INDEMNIFICATION.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.1. Indemnification of the Underwriters.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.1. <u>General</u>. The Company shall indemnify and hold harmless each Underwriter, its affiliates and each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates, counsel and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the "**Underwriter Indemnified Parties**," and each an "**Underwriter Indemnified Party**"), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries, arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (i) the Registration Statement, the Pricing Disclosure Package, the Preliminary Prospectus, the Prospectus or any Issuer Free Writing Prospectus (as from time to time each may be amended and supplemented); (ii) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including any "road show" or investor presentations made to investors by the Company (whether in person or electronically); or (iii) any application or other document or written communication (in this Section 5, collectively called "**application**") executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities and the Representatives' Warrant Shares under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, the Underwriters' Information. With respect to any untrue statement or omission or alleged untrue statement or omission made in the Pricing Disclosure Package, the indemnity agreement contained in this Section 5.1.1 shall not inure to the benefit of any Underwriter Indemnified Party to the extent that any loss, liability, claim, damage or expense of such Underwriter Indemnified Party (a) is based on the Underwriters' Information, (b) results from the fact that a copy of the Prospectus was not given or sent to the person asserting any such loss, liability, claim or damage at or prior to the written confirmation of sale of the Public Securities to such person as required by the Securities Act and the Securities Act Regulations, and if the untrue statement or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance by the Company with its obligations under Section 3.3 hereof, or (c) is found in a final, non-appealable judgment of a court of competent jurisdiction to have resulted primarily from the willful misconduct or gross negligence of such Underwriter Indemnified Party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.2. <u>Procedure</u>. If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action and the Company shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval of such Underwriter Indemnified Party) and payment of actual expenses. Such Underwriter Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Underwriter Indemnified Party unless (i) the employment of such counsel at the expense of the Company shall have been authorized in writing by the Company in connection with the defense of such action, or (ii) the Company shall not have employed counsel to have charge of the defense of such action, or (iii) the action includes both the Company and the indemnified party as defendants and such indemnified party or parties shall have been advised by its counsel that there may be defenses available to it or them which are different from or additional to those available to the Company which makes it impossible or inadvisable for the Company and such indemnified party to be represented in the action by the same counsel (in which case the Company shall not have the right to direct the defense of such action on behalf of the indemnified party), in any of which events the reasonable fees and expenses of not more than one additional firm of attorneys selected by the Underwriter Indemnified Parties who are party to such action (in addition to local counsel) shall be borne by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter Indemnified Party shall assume the defense of such action as provided above, the Company shall have the right to approve the terms of any settlement of such action, which approval shall not be unreasonably withheld.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.2. Indemnification of the Company.** Each Underwriter, severally and not jointly, shall indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect to such losses, liabilities, claims, damages and expenses (or actions in respect thereof) which arise out of or are based upon untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity with, the Underwriters' Information. In case any action shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of Section 5.1.2. The Company agrees promptly to notify the Representatives of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Public Securities or in connection with the Registration Statement, the Pricing Disclosure Package, the Prospectus or any Issuer Free Writing Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.3. Contribution.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.1. <u>Contribution Rights</u>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and each of the Underwriters, on the other hand, from the Offering, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted in such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed to be in the same proportion as the total proceeds from the Offering purchased under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discount and commissions received by the Underwriters in connection with the Offering, in each case as set forth in the table on the cover page of the Prospectus. The relative fault of the Company, on the one hand, and the Underwriters, on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided that the parties hereto agree that the written information furnished to the Company through the Representatives by or on behalf of any Underwriter for use in any Preliminary Prospectus, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriters' Information. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section 5.3.1 no Underwriter shall be required to contribute any amount in excess of the total discount and commission received by such Underwriter in connection with the Offering less the amount of any damages which such Underwriter has otherwise paid or becomes liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.2. <u>Contribution Procedure</u>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party ("contributing party"), notify the contributing party of the commencement thereof, but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative of the commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available. The Underwriters' obligations to contribute as provided in this Section 5.3 are several and in proportion to their respective underwriting obligation, and not joint.

**6. DEFAULT BY AN UNDERWRITER.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.1. Default Not Exceeding 10% of Firm Securities or Option Securities.** If any Underwriter or Underwriters shall default in its or their obligations to purchase the Firm Securities or the Option Securities, if the Over-allotment Option is exercised hereunder, and if the number of the Firm Securities or Option Securities with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Securities or Option Securities to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.2. Default Exceeding 10% of Firm Securities or Option Securities.** In the event that the default addressed in Section 6.1 relates to more than 10% of the number of Firm Shares or Option Shares, the Representatives may in its discretion arrange for itself or for another party or parties to purchase such Firm Securities or Option Securities to which such default relates on the terms contained herein. If, within one (1) Business Day after such default relating to more than 10% of the number of Firm Shares or Option Shares, the Representatives does not arrange for the purchase of such Firm Securities or Option Securities, then the Company shall be entitled to a further period of one (1) Business Day within which to procure another party or parties satisfactory to the Representatives to purchase said Firm Securities or Option Securities on such terms. In the event that neither the Representatives nor the Company arrange for the purchase of the Firm Securities or Option Securities to which a default relates as provided in this Section 6, this Agreement will automatically be terminated by the Representatives or the Company without liability on the part of the Company (except as provided in Sections 3.10 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however, that if such default occurs with respect to the Option Securities, this Agreement will not terminate as to the Firm Securities; and provided, further, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.3. Postponement of Closing Date.** In the event that the Firm Securities or Option Securities to which the default relates are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of Representatives' Counsel may thereby be made necessary. The term "**Underwriter**" as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been a party to this Agreement with respect to such Firm Securities or Option Securities.

**7. ADDITIONAL COVENANTS.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.1. Prohibition on Press Releases and Public Announcements.** The Company shall not issue press releases or engage in any other publicity, without the Representatives' prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1<sup>st</sup>) Business Day following the fortieth (40<sup>th</sup>) day after the Closing Date, other than normal and customary releases issued in the ordinary course of the Company's business.

**8. EFFECTIVE DATE OF THIS AGREEMENT AND TERMINATION THEREOF.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.1. Effective Date.** This Agreement shall become effective when both the Company and the Representatives have executed the same and delivered counterparts of such signatures to the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.2. Termination.** The Representatives shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if any domestic or international event or act or occurrence has materially disrupted, or in the Representatives' opinion will in the immediate future materially disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction; or (iii) if the United States shall have become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared by a New York State or federal authority; or (v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States securities markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Securities or Option Securities; or (vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii) if the Representatives shall have become aware after the date hereof of a Material Adverse Change, or an adverse material change in general market conditions as in the Representatives' judgment would make it impracticable to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriters for the sale of the Public Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.3. [Reserved].** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.4. Indemnification.** Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.5. Representations, Warranties, Agreements to Survive.** All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Public Securities.

**9. MISCELLANEOUS.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.1. <u>Notices</u>.** All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall be deemed given when so delivered or emailed and confirmed (which may be by email) or if mailed, two (2) days after such mailing.

If to the Representatives:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Boral Capital LLC

590 Madison Avenue, 39th Floor

New York, NY 10022

Attn: Syndicate Department

E-mail: <u>syndicate@dboralcapital.com</u>

Phone: (212) 970-5150

with a copy (which shall not constitute notice) to:

Lucosky Brookman LLP

101 Wood Avenue South, 5th Floor

Woodbridge, NJ 08830

Attention: Joseph M. Lucosky, Esq.,

E-mail: <u>jlucosky@lucbro.com</u>

If to the Company:

Caring Brands, Inc. 1725 Skyway Dr., Suite 150

Longmont, CO 80504

Attn: Brian John , Chief Executive Officer

with a copy (which shall not constitute notice) to:

Sichenzia Ross Ference Carmel LLP

1185 Avenue of the Americas, 31<sup>st</sup> Floor

New York, NY 10036

Attn: Gregory Sichenzia, Esq.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.2. Headings.** The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.3. Amendment.** This Agreement may only be amended by a written instrument executed by each of the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.4. Entire Agreement.** This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.5. Binding Effect.** This Agreement shall inure solely to the benefit of and shall be binding upon the Representatives, the Underwriters, the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term "successors and assigns" shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.6. Governing Law; Consent to Jurisdiction; Trial by Jury.** This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys' fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.7. Execution in Counterparts.** This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.8. Waiver, etc.** The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

***[Signature Page Follows]***

If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.

---

| |
|:---|
| Very truly yours, |
| CARING BRANDS, INC. |
| By: |
| Name: |
| Title: |

---

---

| |
|:---|
| Confirmed as of the date first written above mentioned, on behalf of itself and as Representatives of the several Underwriters named on <u>Schedule 1</u> hereto: |
| D. BORAL CAPITAL LLC |
| By: |
| Name: |
| Title: |

---

**<u>SCHEDULE 1</u>**

---

| | | |
|:---|:---|:---|
| **Underwriter** | **Total Number of**<br> **Firm Shares<br> to be<br> Purchased** | **Number of Additional<br> Option Shares to be Purchased if<br> the Over-Allotment Option<br> is Fully Exercised** |
| D. Boral Capital LLC | [●] | [●] |
| **TOTAL** | [●] | [●] |

---

**<u>SCHEDULE 2-A</u>**

**Pricing Information**

Number of Firm Shares: [__]

Number of Option Shares: [__]

Public Offering Price per Firm Share: $[__]

Public Offering Price per Option Share: $[__]

Underwriting Discount per Firm Share: $[__]

Underwriting Discount per Option Share: $[__]

Proceeds to Company per Firm Share: $[__]

Proceeds to Company per Option Share: $[__]

**<u>SCHEDULE 2-B</u>**

**Issuer General Use Free Writing Prospectuses**

None.

**<u>SCHEDULE 3</u>**

**List of Lock-Up Parties**

[____________]

**<u>EXHIBIT A</u>**

**Form of Representative's Warrant Agreement**

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) D. BORAL CAPITAL LLC OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF D. BORAL CAPITAL LLC OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [________________] [**DATE THAT IS SIX MONTHS FROM THE EFFECTIVE DATE OF THE OFFERING**]. VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [**DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING**].

**COMMON STOCK PURCHASE WARRANT**

For the Purchase of [__] Shares of Common Stock

of

[_________]

1. <u>Purchase Warrant</u>. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of D. Boral Capital LLC ("**Holder**"), as registered owner of this Purchase Warrant, [_________], a [_________] corporation (the "**Company**"), Holder is entitled, at any time or from time to time from [________________] [**DATE THAT IS SIX MONTHS FROM THE EFFECTIVE DATE OF THE OFFERING**] (the "**Commencement Date**"), and at or before 5:00 p.m., Eastern time, [____________] [**DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING**] (the "**Expiration Date**"), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [__] shares of common stock of the Company, par value $0.001 per share (the "**Shares**"), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[__] per Share; <u>provided</u>, <u>however</u>, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term "**Exercise Price**" shall mean the initial exercise price or the adjusted exercise price, depending on the context. The term "**Effective Date**" shall mean [ ] , 2024, the date on which the Registration Statement on Form S-1 (File No. 333-_________) of the Company was declared effective by the Securities and Exchange Commission.

2. <u>Exercise</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Exercise Form</u>. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented hereby shall cease and expire.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Cashless Exercise</u>. If at any time after the Commencement Date there is no effective registration statement registering, or no current prospectus available for, the resale of the Shares by the Holder, then in lieu of exercising this Purchase Warrant by payment of cash or check payable to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Shares equal to the value of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to the Company, together with the exercise form attached hereto, in which event the Company shall issue to Holder, Shares in accordance with the following formula:

X = <u>Y(A-B)</u> <br> A

---

| | | | |
|:---|:---|:---|:---|
| Where, |  |  |  |
|  | X | = | The number of Shares to be issued to Holder; |
|  | Y | = | The number of Shares for which the Purchase Warrant is being exercised; |
|  | A | = | The fair market value of one Share; and |
|  | B | = | The Exercise Price. |

---

For purposes of this Section 2.2, the fair market value of a Share is defined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if
 the Company's common stock is traded on a securities exchange, the value shall be deemed to be the closing price on such exchange
 prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if
 the Company's common stock is actively traded over-the-counter, the value shall be deemed to be the closing bid price prior
 to the exercise form being submitted in connection with the exercise of the Purchase Warrant; if there is no active public market,
 the value shall be the fair market value thereof, as determined in good faith by the Company's Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Legend</u>. Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities have been registered under the Securities Act of 1933, as amended (the "**Securities Act**"):

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR APPLICABLE STATE LAW. NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE LAW WHICH, IN THE OPINION OF COUNSEL TO THE COMPANY, IS AVAILABLE."

3. <u>Transfer</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>General Restrictions</u>. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant or the securities issuable hereunder for a period of one-hundred and eighty (180) days following the Effective Date to anyone other than: (i) D. Boral Capital LLC ("**D. Boral Capital**") or an underwriter or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner of D. Boral Capital or of any such underwriter or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(e)(1), or (b) for a period of one-hundred and eighty (180) days following the Effective Date, cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(e)(2). On and after one-hundred and eighty (180) days after the Effective Date, transfers to others may be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto duly executed and completed, together with the Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) business days transfer this Purchase Warrant on the books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Restrictions Imposed by the Securities Act</u>. The securities evidenced by this Purchase Warrant shall not be transferred unless and until: (i) the Company has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption from registration under the Securities Act and applicable state securities laws, the availability of which is established to the reasonable satisfaction of the Company (the Company hereby agreeing that the opinion of [________] shall be deemed satisfactory evidence of the availability of an exemption), or (ii) a registration statement or a post-effective amendment to the Registration Statement relating to the offer and sale of such securities has been filed by the Company and declared effective by the U.S. Securities and Exchange Commission (the "**Commission**") and compliance with applicable state securities law has been established.

4 <u>Registration Rights</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Demand Registration</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.1 <u>Grant of Right</u>. The Company, upon written demand (a "**Demand Notice**") of the Holders of at least 51% of the Purchase Warrants and/or the underlying Shares, agrees to register, on one (1) occasion, all or any portion of the Shares underlying the Purchase Warrants (collectively, the "**Registrable Securities**"). On such occasion, the Company will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject to compliance with review by the Commission; <u>provided</u>, <u>however</u>, that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section 4.2 hereof and either: (i) the Holder has elected to participate in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holders to all other registered Holders of the Purchase Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such Demand Notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1.2 <u>Terms</u>. The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such states as are reasonably requested by the Holders; <u>provided</u>, <u>however</u>, that in no event shall the Company be required to register the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit to general service of process in such State, or (ii) the principal stockholders of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted under Section 4.1.1 to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities covered by such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell the shares covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding the provisions of this Section 4.1.2, the Holder shall be entitled to a demand registration under this Section 4.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary of the Effective Date in accordance with FINRA Rule 5110(g)(8)(C).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>"Piggy-Back" Registration</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.1 <u>Grant of Right</u>. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right, for a period of no more than seven (7) years from the Effective Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or Form S-4 or any equivalent form); <u>provided</u>, <u>however</u>, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of common stock which may be included in the Registration Statement because, in such underwriter(s)' judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included by such Holders; <u>provided</u>, <u>however</u>, that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2.2 <u>Terms</u>. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1 hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days' written notice prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the "piggy-back" rights provided for herein by giving written notice within ten (10) days of the receipt of the Company's notice of its intention to file a registration statement. Except as otherwise provided in this Purchase Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 4.2.2; <u>provided</u>, <u>however</u>, that such registration rights shall terminate on the fifth anniversary of the Commencement Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <u>General Terms</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.1 <u>Indemnification</u>. The Company shall indemnify the Holders of the Registrable Securities to be sold pursuant to any registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Securities Exchange Act of 1934, as amended ("**Exchange Act**"), against all loss, claim, damage, expense or liability (including all reasonable attorneys' fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section 5.1 of the Underwriting Agreement between the Underwriters and the Company, dated as of [___________], 2024. The Holders of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys' fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the provisions contained in Section 5.2 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.2 <u>Exercise of Purchase Warrants</u>. Nothing contained in this Purchase Warrant shall be construed as requiring the Holders to exercise their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.3 <u>Documents Delivered to Holders</u>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a "cold comfort" letter dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report on the Company's financial statements included in such registration statement, in each case covering substantially the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants' letter, with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer's counsel and in accountants' letters delivered to underwriters in underwritten public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditor and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and independent auditor, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.4 <u>Underwriting Agreement</u>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any Holders whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter shall be reasonably satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except as they may relate to such Holders, their Shares and their intended methods of distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.5 <u>Documents to be Delivered by Holders</u>. Each of the Holders participating in any of the foregoing offerings shall furnish to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3.6 <u>Damages</u>. Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company otherwise fails to comply with such provisions, the Holders shall, in addition to any other legal or other relief available to the Holders, be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <u>Termination of Registration Rights</u>. The registration rights afforded to the Holders under this Section 4 shall terminate on the earliest date when all Registrable Securities of such Holder either: (i) have been publicly sold by such Holder pursuant to a Registration Statement, (ii) have been covered by an effective Registration Statement on Form S-1 or Form S-3 (or successor form), which may be kept effective as an evergreen Registration Statement, or (iii) may be sold by the Holder within a 90 day period without registration pursuant to Rule 144 or consistent with applicable SEC interpretive guidance (including CD&I no. 201.04 (April 2, 2007) or similar interpretive guidance).

5. <u>New Purchase Warrants to be Issued</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Partial Exercise or Transfer</u>. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Lost Certificate</u>. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company.

6. <u>Adjustments</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Adjustments to Exercise Price and Number of Securities</u>. The Exercise Price and the number of Shares underlying the Purchase Warrant shall be subject to adjustment from time to time as hereinafter set forth:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.1 <u>Share Dividends; Split Ups</u>. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Shares is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the effective day thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Shares, and the Exercise Price shall be proportionately decreased.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.2 <u>Aggregation of Shares</u>. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Shares is decreased by a consolidation, combination or reclassification of Shares or other similar event, then, on the effective date thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease in outstanding Shares, and the Exercise Price shall be proportionately increased.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.3 <u>Replacement of Securities upon Reorganization, etc</u>. In case of any reclassification or reorganization of the outstanding Shares other than a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of such Shares, or in the case of any share reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding Shares), or in the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by a Holder of the number of Shares of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in a change in Shares covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant to Sections 6.1.1, 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications, reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1.4 <u>Changes in Form of Purchase Warrant</u>. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring after the Commencement Date or the computation thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Substitute Purchase Warrant</u>. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification or change of the outstanding Shares), the corporation formed by such consolidation or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise of such Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable upon such consolidation or share reconstruction or amalgamation, by a holder of the number of Shares for which such Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 6. The above provision of this Section shall similarly apply to successive consolidations or share reconstructions or amalgamations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <u>Elimination of Fractional Interests</u>. The Company shall not be required to issue certificates representing fractions of Shares upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the nearest whole number of Shares or other securities, properties or rights.

7. <u>Reservation and Listing</u>. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance upon exercise of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of the Exercise Price therefor, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any stockholder. The Company further covenants and agrees that upon exercise of the Purchase Warrants and payment of the exercise price therefor, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any stockholder. As long as the Purchase Warrants shall be outstanding, the Company shall use its commercially reasonable efforts to cause all Shares issuable upon exercise of the Purchase Warrants to be listed (subject to official notice of issuance) on all national securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market) on which the Shares issued to the public in the Offering may then be listed and/or quoted.

8. <u>Certain Notice Requirements</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <u>Holder's Right to Receive Notice</u>. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to receive notice as a stockholder for the election of directors or any other matter, or as having any rights whatsoever as a stockholder of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen (15) days prior to the date fixed as a record date or the date of closing the transfer books for the determination of the stockholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice given to the other stockholders of the Company at the same time and in the same manner that such notice is given to the stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <u>Events Requiring Notice</u>. The Company shall be required to give the notice described in this Section 8 upon one or more of the following events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company; (ii) the Company shall offer to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor; or (iii) a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and business shall be proposed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <u>Notice of Change in Exercise Price</u>. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section 6 hereof, send notice to the Holders of such event and change ("**Price Notice**"). The Price Notice shall describe the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company's Chief Financial Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <u>Transmittal of Notices</u>. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall be deemed to have been duly made when hand delivered or mailed by express mail or private courier service: (i) if to the registered Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to following address or to such other address as the Company may designate by notice to the Holders:

If to the Holder:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Boral Capital LLC

590 Madison Avenue, 39<sup>th</sup> Floor

New York, New York 10022

Attn: Syndicate Department

Email: <u>syndicate@dboralcapital.com</u>

Phone: (212) 970-5150

with a copy (which shall not constitute notice) to:

Lucosky Brookman LLP

101 Wood Avenue South, 5th Floor

Woodbridge, NJ 08830

Attention: Joseph M. Lucosky, Esq.,

E-mail: jlucosky@lucbro.com

If to the Company:

Caring Brands , Inc.

[_________]

[_________]

Attn: [_________]

with a copy (which shall not constitute notice) to:

Sichenzia Ross Ference Carmel LLP

[_________]

[_________]

Attn: [_________]

9. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <u>Amendments</u>. The Company and D. Boral may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company and D. Boral may deem necessary or desirable and that the Company and D. Boral deem shall not adversely affect the interest of the Holders. All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement of the modification or amendment is sought.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <u>Headings</u>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 <u>Entire Agreement</u>. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4 <u>Binding Effect</u>. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions herein contained.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5 <u>Governing Law; Submission to Jurisdiction; Trial by Jury</u>. This Purchase Warrant shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys' fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6 <u>Waiver, etc</u>. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7 <u>Execution in Counterparts</u>. This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic transmission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.8 <u>Exchange Agreement</u>. As a condition of the Holder's receipt and acceptance of this Purchase Warrant, Holder agrees that, at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and D. Boral enter into an agreement ("**Exchange Agreement**") pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

**[*Signature Page Follows*]**

IN WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the ____ day of _______, 2024.

---

| |
|:---|
| CARING BRANDS, INC. |
| By: |
| Name: |
| Title: |

---

[*Form to be used to exercise Purchase Warrant*]

Date: __________, 20___

The undersigned hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of common stock, par value $0.001 per share (the "**Shares**"), of Caring Brands, Inc., a Nevada corporation (the "**Company**"), and hereby makes payment of $____ (at the rate of $____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been exercised.

or

The undersigned hereby elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______ Shares, as determined in accordance with the following formula:

X = <u>Y(A-B)</u> <br> A

---

| | | | |
|:---|:---|:---|:---|
| Where, |  |  |  |
|  | X | = | The number of Shares to be issued to Holder; |
|  | Y | = | The number of Shares for which the Purchase Warrant is being exercised; |
|  | A | = | The fair market value of one Share which is equal to $_____; and |
|  | B | = | The Exercise Price which is equal to $______ per share |

---

The undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to the calculation shall be resolved by the Company in its sole discretion.

Please issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.

Signature ________________________________________

Signature Guaranteed ________________________________________

---

| | |
|:---|:---|
| INSTRUCTIONS FOR REGISTRATION OF SECURITIES | INSTRUCTIONS FOR REGISTRATION OF SECURITIES |
| Name: | |
|  | (Print in Block Letters) |

---

Address:

NOTICE: The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange.

[*Form to be used to assign Purchase Warrant*]

ASSIGNMENT

(To be executed by the registered Holder to effect a transfer of the within Purchase Warrant):

FOR VALUE RECEIVED, __________________ does hereby sell, assign and transfer unto the right to purchase shares of common stock, par value $0.001 per share, of Caring Brands, Inc., a Nevada corporation (the "**Company**"), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer such right on the books of the Company.

Dated: __________, 20__

Signature _______________________________________

Signature Guaranteed _______________________________________

NOTICE: The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange.

**<u>EXHIBIT B</u>**

**Form of Lock-Up Agreement**

**Lock-Up Agreement**

____________, 2025

D. BORAL CAPITAL LLC

as Representative of the Underwriters

590 Madison Avenue, 39<sup>th</sup> Floor

New York, New York 10022

Ladies and Gentlemen:

The undersigned understands that D. Boral Capital LLC (the "**Representative**") proposes to enter into an Underwriting Agreement (the "**Underwriting Agreement**") with Caring Brands, Inc., a Nevada corporation (the "**Company**"), providing for the public offering (the "**Public Offering**") of shares of common stock of the Company, par value $0.001 per share (the "**Common Stock**", or the "**Securities**").

To induce the Representative to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent of the Representative, the undersigned will not, during the period commencing on the date hereof and ending 180 days after the date of the final prospectus (the "**Prospectus**") relating to the Public Offering (the "**Lock-Up Period**"), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Securities or any securities convertible into or exercisable or exchangeable for the Securities, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the "**Lock-Up Securities**"); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Representative in connection with (a) transactions relating to Lock-Up Securities acquired in open market transactions after the completion of the Public Offering; <u>provided</u> that no filing under Section 13 or Section 16(a) of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or other public announcement shall be required or shall be voluntarily made during the Lock-Up Period in connection with subsequent sales of Lock-Up Securities acquired in such open market transactions; (b) transfers of Lock-Up Securities as a *bona fide* gift, by will or intestacy or to a family member or trust for the benefit of a family member (for purposes of this lock-up agreement, "family member" means any relationship by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution; or (d) if the undersigned, directly or indirectly, controls a corporation, partnership, limited liability company or other business entity, any transfers of Lock-Up Securities to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the case may be; <u>provided</u> that in the case of any transfer pursuant to the foregoing clauses (b), (c) or (d), (i) it shall be a condition to any such transfer that (i) the transferee/donee agrees to be bound by the terms of this lock-up agreement (including, without limitation, the restrictions set forth in the preceding sentence) to the same extent as if the transferee/donee were a party hereto; (ii) each party (donor, donee, transferor or transferee) shall not be required by law (including without limitation the disclosure requirements of the Securities Act of 1933, as amended (the "**Securities Act**"), and the Exchange Act) to make, and shall agree to not voluntarily make, any filing or public announcement of the transfer or disposition prior to the expiration of the Lock-Up Period; and (iii) the undersigned notifies the Representative at least two (2) business days prior to the proposed transfer or disposition.

In addition, the foregoing restrictions shall not apply to (i) the exercise or vesting of stock options or other equity awards granted pursuant to the Company's equity incentive plans; provided that it shall apply to any of the undersigned's Common Stock issued upon such exercise, (ii) the conversion or exercise of convertible debt or warrants; provided that it shall apply to any of the undersigned's Common Stock issued upon such exercise, or (iii) the establishment of any new plan (a "**Plan**") that satisfies all of the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act; provided that no sales of the undersigned's Securities shall be made pursuant to such new Plan prior to the expiration of the Lock-Up Period (as such may have been extended pursuant to the provisions hereof), and such a Plan may only be established if no public announcement of the establishment or existence thereof and no filing with the Securities and Exchange Commission or other regulatory authority in respect thereof or transactions thereunder or contemplated thereby, by the undersigned, the Company or any other person, shall be required, and no such announcement or filing is made voluntarily, by the undersigned, the Company or any other person, prior to the expiration of the Lock-Up Period (as such may have been extended pursuant to the provisions hereof).

The undersigned also agrees and consents to the entry of stop transfer instructions with the Company's transfer agent and registrar against the transfer of the undersigned's securities subject to this this lock-up agreement except in compliance with this this lock-up agreement.

If the undersigned is an officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any Securities that the undersigned may purchase in the Public Offering; (ii) the Representative agrees that, at least three (3) business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Lock-Up Securities, the Representative will notify the Company of the impending release or waiver; and (iii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two (2) business days before the effective date of the release or waiver. Any release or waiver granted by the Representative hereunder to any such officer or director shall only be effective two (2) business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms remain in effect at the time of such transfer.

The undersigned understands that the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned's heirs, legal representatives, successors and assigns.

The undersigned understands that, if the Underwriting Agreement does not become effective, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to be sold thereunder, the undersigned shall be released from all obligations under this lock-up agreement.

This lock-up agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

---

| |
|:---|
| Very truly yours, |
| (Name - Please Print) |
| (Signature) |
| (Name of Signatory, in the case of entities - Please Print) |
| (Title of Signatory, in the case of entities - Please Print) |
| Address: |

---

**<u>EXHIBIT C</u>**

**Form of Press Release**

**[_________]**

**[Date]**

[_________] (the "Company") announced today that D. Boral Capital LLC acting as representative for the underwriters in the Company's recent public offering of _______ shares of the Company's Common Stock, , is [waiving] [releasing] a lock-up restriction with respect to _______ shares of Common Stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on _______, 20___, and such shares of Common Stock may be sold on or after such date.

**This press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.**

## Exhibit 3.1

**Exhibit 3.1**

![](ex3-1_001.jpg)

![](ex3-1_002.jpg)

![](ex3-1_003.jpg)

![](ex3-1_004.jpg)

![](ex3-1_005.jpg)

![](ex3-1_006.jpg)

![](ex3-1_007.jpg)

![](ex3-1_008.jpg)

## Exhibit 3.2

**Exhibit 3.2**

BYLAWS

OF

**CARING BRANDS INC.**

A Nevada Corporation

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| ARTICLE ONE: OFFICES | 1 |
| &nbsp;&nbsp;&nbsp;1.01 Registered Office and Agent. | 1 |
| &nbsp;&nbsp;&nbsp;1.02 Other Offices. | 1 |
| ARTICLE TWO: SHAREHOLDERS | 1 |
| &nbsp;&nbsp;&nbsp;2.01 Place of Meetings. | 1 |
| &nbsp;&nbsp;&nbsp;2.02 Annual Meeting. | 1 |
| &nbsp;&nbsp;&nbsp;2.03 Special Meetings. | 1 |
| &nbsp;&nbsp;&nbsp;2.04 List of Shareholders. | 2 |
| &nbsp;&nbsp;&nbsp;2.05 Notice. | 2 |
| &nbsp;&nbsp;&nbsp;2.06 Quorum. | 2 |
| &nbsp;&nbsp;&nbsp;2.07 Majority Vote. | 3 |
| &nbsp;&nbsp;&nbsp;2.08 Voting of Shares. | 3 |
| &nbsp;&nbsp;&nbsp;2.09 Proxies. | 3 |
| &nbsp;&nbsp;&nbsp;2.10 Presiding Officials at Meetings. | 4 |
| &nbsp;&nbsp;&nbsp;2.11 Election Inspectors. | 4 |
| &nbsp;&nbsp;&nbsp;2.12 Closing of Transfer Books; Record Date. | 4 |
| ARTICLE THREE: DIRECTORS | 5 |
| &nbsp;&nbsp;&nbsp;3.01 Management. | 5 |
| &nbsp;&nbsp;&nbsp;3.02 Number; Election; Term; Qualification. | 5 |
| &nbsp;&nbsp;&nbsp;3.03 Removal. | 5 |
| &nbsp;&nbsp;&nbsp;3.04 Vacancies | 5 |
| &nbsp;&nbsp;&nbsp;3.05 First Meeting. | 5 |
| &nbsp;&nbsp;&nbsp;3.06 Regular Meetings. | 5 |
| &nbsp;&nbsp;&nbsp;3.07 Special Meetings. | 6 |
| &nbsp;&nbsp;&nbsp;3.08 Quorum; Majority Vote. | 6 |
| &nbsp;&nbsp;&nbsp;3.09 Procedure; Minutes. | 6 |
| &nbsp;&nbsp;&nbsp;3.10 Presumption of Assent. | 6 |
| &nbsp;&nbsp;&nbsp;3.11 Interested Directors. | 6 |
| &nbsp;&nbsp;&nbsp;3.12 Compensation. | 7 |
| &nbsp;&nbsp;&nbsp;3.13 Chairman of the Board. | 7 |
| &nbsp;&nbsp;&nbsp;3.14 Committees. | 7 |

---

---

| | |
|:---|:---|
| ARTICLE FOUR: GENERAL PROVISIONS RELATING TO MEETINGS | 8 |
| &nbsp;&nbsp;&nbsp;4.01 Notice. | 8 |
| &nbsp;&nbsp;&nbsp;4.02 Waiver of Notice. | 8 |
| &nbsp;&nbsp;&nbsp;4.03 Telephone and Similar Meetings. | 8 |
| &nbsp;&nbsp;&nbsp;4.04 Action by Written Consent. | 8 |
| ARTICLE FIVE: OFFICERS AND OTHER AGENTS | 9 |
| &nbsp;&nbsp;&nbsp;5.01 In General. | 9 |
| &nbsp;&nbsp;&nbsp;5.02 Election. | 9 |
| &nbsp;&nbsp;&nbsp;5.03 Removal. | 9 |
| &nbsp;&nbsp;&nbsp;5.04 Vacancies. | 9 |
| &nbsp;&nbsp;&nbsp;5.05 Authority. | 9 |
| &nbsp;&nbsp;&nbsp;5.06 Compensation. | 9 |
| &nbsp;&nbsp;&nbsp;5.07 Employment and Other Contracts. | 9 |
| &nbsp;&nbsp;&nbsp;5.08 President. | 10 |
| &nbsp;&nbsp;&nbsp;5.09 Vice Presidents. | 10 |
| &nbsp;&nbsp;&nbsp;5.10 Secretary. | 10 |
| &nbsp;&nbsp;&nbsp;5.11 Assistant Secretaries. | 10 |
| &nbsp;&nbsp;&nbsp;5.12 Treasurer. | 10 |
| &nbsp;&nbsp;&nbsp;5.13 Assistant Treasurers. | 10 |
| &nbsp;&nbsp;&nbsp;5.14 Bonding. | 11 |
| ARTICLE SIX: CERTIFICATES AND SHAREHOLDERS | 11 |
| &nbsp;&nbsp;&nbsp;6.01 Certificated and Uncertificated Shares. | 11 |
| &nbsp;&nbsp;&nbsp;6.02 Certificates for Certificated Shares. | 11 |
| &nbsp;&nbsp;&nbsp;6.03 Lost, Stolen, or Destroyed Certificates. | 11 |
| &nbsp;&nbsp;&nbsp;6.04 Transfer of Shares. | 12 |
| &nbsp;&nbsp;&nbsp;6.05 Registered Shareholders. | 12 |
| &nbsp;&nbsp;&nbsp;6.06 Legends. | 12 |
| ARTICLE SEVEN: MISCELLANEOUS PROVISIONS | 13 |
| &nbsp;&nbsp;&nbsp;7.01 Dividends. | 13 |
| &nbsp;&nbsp;&nbsp;7.02 Reserves. | 13 |
| &nbsp;&nbsp;&nbsp;7.03 Indemnification and Insurance. | 13 |
| &nbsp;&nbsp;&nbsp;7.04 Books and Records. | 13 |
| &nbsp;&nbsp;&nbsp;7.05 Fiscal Year. | 13 |
| &nbsp;&nbsp;&nbsp;7.06 Seal. | 13 |
| &nbsp;&nbsp;&nbsp;7.07 Checks. | 14 |
| &nbsp;&nbsp;&nbsp;7.08 Resignation. | 14 |
| &nbsp;&nbsp;&nbsp;7.09 Securities of Other Corporations. | 14 |
| &nbsp;&nbsp;&nbsp;7.10 Amendment. | 14 |
| &nbsp;&nbsp;&nbsp;7.11 Invalid Provisions. | 14 |
| &nbsp;&nbsp;&nbsp;7.12 Headings. | 14 |

---

BYLAWS

Of

**CARING BRANDS INC.**

A Nevada Corporation

ARTICLE ONE: OFFICES

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.01 Registered Office and Agent. The registered office and registered agent of Caring Brands Inc. (hereinafter referred to as the "Corporation") shall be as designated from time to time by the appropriate filing by the Corporation in the office of the Secretary of State of Nevada.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.02 Other Offices. The Corporation may also have offices at such other places, both within and without the State of Nevada, as the Board of Directors may from time to time determine or the business of the Corporation may require.

ARTICLE TWO: SHAREHOLDERS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.01 Place of Meetings. All annual meetings of shareholders shall be held at such place, within or without the State of Nevada, as may be designated by the Board of Directors and stated in the notice of the meeting or in a duly executed waiver of notice thereof. Special meetings of shareholders may be held at such place, within or without the State of Nevada, as shall be stated in the notice of the meeting or in a duly executed waiver of notice thereof. If no place for a meeting is designated, it shall be held at the registered office of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.02 Annual Meeting. The annual meetings of shareholders shall be held on a date and at a time to be determined by the Board of Directors. At the annual meeting, the shareholders shall elect directors and transact such other business as may properly be brought before the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.03 Special Meetings. Only such business shall be transacted at a special meeting as may be stated or indicated in the notice of such meeting. Special meetings of the shareholders may be called by (a) the President, the Board of Directors, the executive committee of the Board of Directors, or such other persons as may be authorized in the Certificate of Formation of the Corporation (the "Certificate"); or (b) the holders of at least ten percent (10%) of all shares entitled to vote at the special meeting, unless the Certificate provides for a percentage of shares greater or less than ten percent (10%), in which event a special meeting may be called by the holders of at least the percentage of shares specified in the Certificate. Upon request in writing to the CEO, President, Vice President or Secretary by any person or persons entitled to call a meeting of shareholders, the officer shall promptly cause a written notice to be given to the shareholders entitled to vote that a meeting will be held on a date and at a time, fixed by the officer, not less than ten (10) days after the date of receipt of the request. If the notice is not given within seven (7) days after the date of receipt of the request, the person or persons calling the meeting may fix the date and time of the meeting and give the notice in the manner provided in these Bylaws. If not otherwise stated in or fixed in accordance with these Bylaws, the record date for determining shareholders entitled to call a special meeting is the date on which the first shareholder receives the notice of such meeting. Nothing contained in this section shall be construed as limiting, fixing, or affecting the time or date on which a meeting of shareholders called by action of the Board of Directors may be held.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.04 List of Shareholders. At least ten (10) days before each meeting of shareholders, a complete list of the shareholders entitled to vote at such meeting, arranged in alphabetical order, with the address and the number of voting shares registered in the name of each, will be prepared by the officer or agent having charge of the stock transfer books. Such list will be kept on file at the registered office of the Corporation for a period of ten (10) days prior to such meeting and will be subject to inspection by any shareholder at any time during usual business hours. Such list will be produced and kept open at the time and place of the meeting during the whole time thereof, and will be subject to the inspection of any shareholder who may be present. The original stock transfer book shall be prima facie evidence as to who are the shareholders entitled to examine such list or to vote at any such meeting of shareholders. However, failure to prepare and to make available such list in the manner provided in this section shall not affect the validity of any action taken at the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.05 Notice. Written or printed notice stating the place, day, and hour of each meeting of shareholders and, in case of a special meeting, the purpose or purposes for which the meeting is called, shall be delivered not less than ten (10) days or more than sixty (60) days before the date of the meeting. Notice must be delivered either personally or by mail, by or at the direction of the President, the Secretary, or the officer or person calling the meeting, to each shareholder of record entitled to vote at such meeting. If mailed, such notice will be deemed to be delivered when deposited in the United States mail, addressed to the shareholder at his or her address as it appears on the stock transfer books of the Corporation, with postage thereon prepaid. When a meeting of shareholders is adjourned for thirty (30) days or more, notice of the adjourned meeting shall be given as in the case of an original meeting. When a meeting is adjourned for less than thirty (30) days, it shall not be necessary to give any notice of the time and place of the adjourned meeting or of the business to be transacted thereat, other than by announcement at the meeting at which the adjournment is taken.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.06 Quorum. The holders of a majority of the outstanding shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at any meeting of shareholders, except as otherwise provided by law, the Certificate, or these Bylaws. If a quorum shall not be present or represented at any meeting of shareholders, a majority of the shareholders entitled to vote at the meeting who are present in person or represented by proxy may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented. At any reconvening of an adjourned meeting at which a quorum shall be present or represented, any business may be transacted that could have been transacted at the original meeting as originally notified and called if a quorum had been present or represented. The shareholders present at a duly organized meeting may continue to transact business notwithstanding the withdrawal of some shareholders prior to adjournment, provided that the holders of at least one-third (1/3) of the shares entitled to vote continue to be represented at such meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.07 Majority Vote. The vote of the holders of a majority of the shares entitled to vote at a meeting at which a quorum is present shall decide any question brought before such meeting, unless the question is one on which, by express provision of law, the Certificate, or these Bylaws, the vote of a greater number of shares is required, in which case such express provision shall govern and control the decision of such question.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.08 Voting of Shares. Each outstanding share, regardless of class, shall be entitled to one vote on each matter submitted to a vote at a meeting of shareholders, except to the extent that the voting rights of the shares of any class are limited or denied by the Nevada Revised Statutes (the "NRS")At any election for directors, every shareholder entitled to vote in such election shall have the right to vote, in person or by proxy, the number of shares owned by such shareholder for as many persons as there are director positions to be filled with respect to which the shareholder has the right to vote, and shareholders are expressly prohibited from cumulating their votes in any election for directors of the Corporation. Treasury shares, shares owned by another corporation that is owned or controlled by the Corporation, and shares held by the Corporation in a fiduciary capacity shall not be shares entitled to vote or to be counted in determining the total number of outstanding shares of the Corporation. Shares held by an administrator, executor, guardian, or conservator may be voted by him or her, either in person or by proxy, without transfer of such shares into his or her name so long as such shares form a part of the estate and are in the possession of the estate being served by him or her. Shares standing in the name of a trustee may be voted by him or her, either in person or by proxy, only after the shares have been transferred into his or her name as trustee. Shares standing in the name of a receiver may be voted by such receiver, and shares held by or under the control of a receiver may be voted by such receiver without transfer of such shares into his or her name if authority to do so is contained in the court order by which such receiver was appointed. Shares standing in the name of another domestic or foreign corporation of any type or kind may be voted by such officer, agent, or proxy as the bylaws of such corporation may provide or, in the absence of such provision, as the board of directors of such corporation may by resolution determine. A shareholder whose shares are pledged shall be entitled to vote such shares until they have been transferred into the name of the pledgee, and thereafter the pledgee shall be entitled to vote such shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.09 Proxies. At any meeting of shareholders, every shareholder having the right to vote may vote either in person or by a proxy executed in writing by the shareholder or the shareholder's duly authorized attorney-in-fact. A telegram, telex, cablegram, or similar transmission by the shareholder, or a photographic, photo static, facsimile, or similar reproduction of a writing executed by the shareholder, shall be treated as an execution in writing for the purposes of this section. Each such proxy shall be filed with the Secretary of the Corporation before or at the time of the meeting. No proxy shall be valid after eleven (11) months from the date of its execution, unless otherwise provided in the proxy. If no date is stated on a proxy, such proxy shall be presumed to have been executed on the date of the meeting at which it is to be voted. Each proxy shall be revocable unless expressly provided therein to be irrevocable and if, and only so long as, it is coupled with an interest sufficient in law to support an irrevocable power. Voting on any question or in any election may be by voice or show of hands unless the presiding officer orders, or any shareholder demands that voting be by written ballot.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 Presiding Officials at Meetings. At every meeting of the shareholders, the chairman of the Board of Directors or, in his or her absence, the CEO or President or, in his or her absence, a person appointed at the meeting, shall preside, and the Secretary shall prepare minutes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 Election Inspectors. In advance of any meeting of shareholders, the Board of Directors may appoint any persons, other than nominees for office, as inspectors of election to act at such meeting or any adjournment thereof. If inspectors of election are not so appointed, the chairman of any such meeting may, and on the request of any shareholder or the shareholder's proxy shall, appoint inspectors of election at the meeting. The number of inspectors shall be either one or three. If appointed at a meeting on the request of one or more shareholders or proxies, the majority of shares present shall determine whether one or three inspectors are to be appointed. In case any person appointed as inspector fails to appear or fails or refuses to act, the vacancy may be filled by appointment by the Board of Directors in advance of the meeting, or at the meeting by the person acting as chairman. The inspectors of election shall (a) determine the number of shares outstanding and the voting power of each, the shares represented at the meeting, the existence of a quorum, and the authenticity, validity and effect of proxies; (b) receive votes, ballots or consents: (c) hear and determine all challenges and questions in any way arising in connection with the right to vote; (d) count and tabulate all votes or consents and determine the result; and (e) do such acts as may be proper to conduct the election or vote with fairness to all shareholders. The inspectors of election shall perform their duties impartially, in good faith, to the best of their ability and as expeditiously as is practical. If there are three inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all. On request of the chairman of the meeting or of any shareholder or his or her proxy, the inspectors shall make a report in writing of any challenge or question, or matter determined by them and execute a certificate of any fact found by them. Any report or certificate made by them is prima facie evidence of the facts stated therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 Closing of Transfer Books; Record Date. For the purpose of determining shareholders entitled to notice of, or to vote at, any meeting of shareholders or any reconvening thereof, or entitled to receive payment of any dividend, or in order to make a determination of shareholders for any other proper purpose, the Board of Directors may provide that the stock transfer books of the Corporation shall be closed for a stated period but not to exceed in any event sixty (60) days. If the stock transfer books are closed for the purpose of determining shareholders entitled to notice of, or to vote at, a meeting of shareholders, such books shall be closed for at least ten (10) days immediately preceding such meeting. In lieu of closing the stock transfer books, the Board of Directors may fix in advance a date as the record date for any such determination of shareholders, such date in any case to be not more than sixty (60) days and, in case of a meeting of shareholders, not less than ten (10) days prior to the date on which the particular action requiring such determination of shareholders is to be taken. If the stock transfer books are not closed and if no record date is fixed for the determination of shareholders entitled to notice of, or to vote at, a meeting of shareholders or entitled to receive payment of a dividend, the date on which the notice of the meeting is to be mailed or the date on which the resolution of the Board of Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of shareholders.

ARTICLE THREE: DIRECTORS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.01 Management. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, who may exercise all powers of the Corporation and do all lawful acts and things as are not by law, the Certificate, or these Bylaws directed or required to be exercised or done by the shareholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.02 Number; Election; Term; Qualification. The first Board of Directors shall consist of two directors. Thereafter, the number of directors that shall constitute the entire Board of Directors shall be determined by resolution of the Board of Directors at any meeting thereof or by the shareholders at any meeting thereof, but shall never be less than one. No decrease in the number of directors will have the effect of shortening the term of any incumbent director. At each annual meeting of shareholders, directors shall be elected, and each director shall hold office until his or her successors is elected and qualified or until his or her earlier death, resignation, or removal from office. No director need be a shareholder, a resident of the State of Nevada, or a citizen of the United States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.03 Removal. At any meeting of shareholders called expressly for that purpose, any director or the entire Board of Directors may be removed, with or without cause, by a vote of the holders of a majority of the shares then entitled to vote on the election of directors. If any or all directors are so removed, new directors may be elected at the same meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.04 Vacancies. Any vacancy occurring in the Board of Directors by death, resignation, removal, or otherwise may be filled by an affirmative vote of at least a majority of the remaining directors though less than a quorum of the Board of Directors. A director elected to fill a vacancy will be elected for the unexpired term of his or her predecessor in office. A directorship to be filled by reason of an increase in the number of directors may be filled by the Board of Directors for a term of office only until the next election of one or more directors by the shareholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.05 First Meeting. Each newly elected Board of Directors may hold its first meeting, if a quorum is present, for the purpose of organization and the transaction of business immediately after and at the same place as the annual meeting of shareholders, and no notice of such meeting shall be necessary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.06 Regular Meetings. Regular meetings of the Board of Directors may be held without notice at such times and places, within or without the State of Nevada, as may be designated from time to time by resolution of the Board of Directors and communicated to all directors. Regular meetings of the Board of Directors may be held when and if needed, and no more than one regular meeting of the Board of Directors shall be required in any calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.07 Special Meetings. A special meeting of the Board of Directors shall be held whenever called by any director at such time and place, within or without the State of Nevada, as such director shall designate in the notice of such special meeting. The director calling any special meeting shall cause oral or written notice of such special meeting to be given to each director at least twenty-four (24) hours before such special meeting. Neither the business to be transacted at, nor the purpose of, any special meeting of the Board of Directors need be specified in the notice or waiver of notice of any special meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.08 Quorum; Majority Vote. At all meetings of the Board of Directors, a majority of the directors fixed in the manner provided in these Bylaws shall constitute a quorum for the transaction of business. If a quorum is not present at a meeting, a majority of the directors present may adjourn the meeting from time to time, without notice other than an announcement at the meeting, until a quorum is present. The vote of a majority of the directors present at a meeting at which a quorum is in attendance shall be the act of the Board of Directors, unless the vote of a different number is required by law, the Certificate, or these Bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.09 Procedure; Minutes. At meetings of the Board of Directors, business shall be transacted in such order as the Board of Directors may determine from time to time. The Board of Directors shall appoint at each meeting a person to preside at the meeting and a person to act as secretary of the meeting. The secretary of the meeting shall prepare minutes of the meeting that shall be delivered to the Secretary of the Corporation for placement in the minute books of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 Presumption of Assent. A director of the Corporation who is present at any meeting of the Board of Directors at which action on any matter is taken shall be presumed to have assented to the action unless his or her dissent shall be entered in the minutes of the meeting or unless he or she shall file his or her written dissent to such action with the person acting as secretary of the meeting before the adjournment thereof, or shall forward any dissent by certified or registered mail to the Secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 Interested Directors. No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of the Corporation's directors or officers are directors or officers or have a financial interest, will be void or voidable solely for this reason, solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof that authorizes the contract or transaction, or solely because his, her, or their votes are counted for such purpose, if: (I) the material facts as to his or her relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (ii) the material facts as to his or her relationship or interest and as to the contract or transaction are disclosed or are known to the shareholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the shareholders; or (iii) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee thereof or the shareholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee that authorizes the contract or transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 Compensation. Directors, in their capacity as directors, may receive, by resolution of the Board of Directors, a stated salary or a fixed sum and expenses of attendance, if any, for attending meetings of the Board of Directors. No director shall be precluded from serving the Corporation in any other capacity or receiving compensation therefor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13 Chairman of the Board. The Board of Directors may, in its discretion, choose a Chairman of the Board from among the directors on the Board of Directors who will preside at all meetings of the shareholders and of the Board of Directors and will be an ex officio member of all committees of the Board of Directors. During the absence or disability of the CEO, the Chairman will exercise the powers and perform the duties of the CEO. The Chairman will have such other powers and will perform such other duties as shall be designated by the Board of Directors. The Chairman shall serve until a successor is chosen and qualified, but may be removed at any time by the affirmative vote of a majority of the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14 Committees. The Board of Directors, by resolution adopted by a majority of the full Board of Directors, may designate from among its members one or more committees, each of which, to the extent provided in such resolution, shall have and may exercise all of the authority of the Board of Directors, except that no such committee shall have the authority of the Board of Directors in reference to (a) amending the Certificate; (b) proposing a reduction of the stated capital of the Corporation in the manner permitted by the NRS; (c) approving a plan of merger or share exchange of the Corporation; (d) recommending to the shareholders the sale, lease or exchange of all or substantially all of the property and assets of the Corporation otherwise than in the usual and regular course of its business; (e) recommending to the shareholders a voluntary dissolution of the Corporation or a revocation thereof; (f) amending, altering or repealing these Bylaws or adopting new bylaws of the Corporation; (g) filling vacancies on the Board of Directors or any such committee; (h) electing or removing officers of the Corporation or members of any such committee; (I) fixing the compensation of any member of such committee; or (j) altering or repealing any resolution of the Board of Directors. Unless the resolution designating a particular committee so provides, no committee of the Board of Directors shall have the authority to authorize a distribution or to authorize the issuance of shares of the Corporation. Vacancies in the membership of any such committee shall be filled by the Board of Directors at a regular or special meeting of the Board of Directors. Any such committee shall keep regular minutes of its proceedings and report the same to the Board of Directors when required. The designation of a committee of the Board of Directors and the delegation thereto of authority shall not operate to relieve the Board of Directors, or any member thereof, of any responsibility imposed by law. Each director shall be deemed to have assented to any action of the executive committee or any other committee, unless the director shall, within seven (7) days after receiving actual or constructive notice of such action, deliver his or her written dissent thereto to the Secretary of the Corporation. Members of each committee shall serve at the pleasure of the Board of Directors.

ARTICLE FOUR: GENERAL PROVISIONS RELATING TO MEETINGS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.01 Notice. Whenever by law, the Certificate, or these Bylaws notice is required to be given to any shareholder, director, or committee member and no provision is made as to how such notice shall be given, it shall be construed to mean that notice may be given, in writing, either (I) in person, receipt acknowledged; (ii) by certified mail, return receipt requested; or (iii) by Federal Express, UPS, Airborne Express, or other national carrier, receipt acknowledged. Any notice required or permitted to be given hereunder (other than personal notice) shall be addressed to such shareholder, director, or committee member at his or her address as it appears on the books on the Corporation or, in the case of a shareholder, on the stock transfer records of the Corporation or at such other place as such shareholder, director, or committee member is known to be at the time notice is mailed or transmitted. Any notice required or permitted to be given by mail shall be deemed to be delivered and given at the time when such notice is deposited in the United States mail, postage prepaid. Any notice required or permitted to be given by telegram, telex, cable, telecopy or facsimile transmission, or similar means, shall be deemed to be delivered and given at the time transmitted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.02 Waiver of Notice. Whenever by law, the Certificate, or these Bylaws any notice is required to be given to any shareholder, director, or committee member of the Corporation, a waiver thereof in writing signed by the person or persons entitled to such notice, whether before or after the time notice should have been given, shall be equivalent to the giving of such notice. Attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.03 Telephone and Similar Meetings. Shareholders, directors, or committee members may participate in and hold a meeting by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other. Participation in such a meeting shall constitute presence in person at such meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.04 Action by Written Consent. Any action that may be taken, or is required by law, the Certificate, or these Bylaws to be taken, at a meeting of shareholders, directors, or committee members may be taken without a meeting, without prior notice, and without a vote, if a consent in writing setting forth the action so taken shall be (a) in the case of shareholders, signed and bear the date of signature by shareholders having not less than the minimum number of votes that would be necessary to take such action at a meeting at which the holders of all shares entitled to vote on the action were present and voted with respect to the subject matter thereof; or (b) in the case of directors or committee members, signed by all directors or committee members, as the case may be, entitled to vote with respect to the subject matter thereof. Any such consent shall have the same force and effect as a vote of such shareholders, directors, or committee members, as the case may be, and may be stated as such in any document filed with the Secretary of State of Nevada or in any certificate or other document delivered to any person. The consent may be in one or more counterparts, and the signed consent shall be placed in the minute book of the Corporation.

ARTICLE FIVE: OFFICERS AND OTHER AGENTS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.01 In General. The officers of the Corporation will be elected by the Board of Directors and will be a President and a Secretary. The Board of Directors may also elect Vice Presidents, Assistant Vice Presidents, a Treasurer, Assistant Secretaries and Assistant Treasurers, and such other officers and agents as the Board of Directors may deem desirable. Any two or more offices may be held by the same person. No officer or agent need be a shareholder, a director, a resident of the State of Nevada, or a citizen of the United States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.02 Election. The Board of Directors, at its first meeting after each annual meeting of shareholders, shall elect a President, a Secretary, and such other officers as they deem appropriate, none of whom must be a member of the Board of Directors. The Board of Directors then, or from time to time, may also elect or appoint one or more other officers or agents as it shall deem advisable. Each officer or agent shall hold office for the term for which he or she is elected or appointed and until his or her successor has been elected or appointed and qualified. Unless otherwise provided in the resolution of the Board of Directors electing or appointing an officer or agent, his or her term of office shall extend to and expire at the meeting of the Board of Directors following the next annual meeting of shareholders or, if earlier, at his or her death, resignation, or removal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.03 Removal. Any officer or agent elected or appointed by the Board of Directors may be removed by a majority of the Board of Directors only if, in the judgment of a majority of the Board of Directors, the best interests of the Corporation will be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Election or appointment of an officer or agent shall not of itself create contract rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.04 Vacancies. Any vacancy occurring in any office of the Corporation may be filled by the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.05 Authority. Officers shall have such authority and perform such duties in the management of the Corporation as are set forth in these Bylaws or, to the extent not inconsistent with these Bylaws, as specifically designated in the resolution of the Board of Directors creating such position and appointing or electing such person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.06 Compensation. The compensation, if any, of officers shall be fixed, increased, or decreased from time to time by the Board of Directors; provided, however, that the Board of Directors may, by resolution, delegate to any one or more officers of the Corporation the authority to fix such compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.07 Employment and Other Contracts. The Board of Directors may authorize any officer or officers or agent or agents of the Corporation to enter into any contract or execute and deliver any instrument in the name or on behalf of the Corporation, and such authority may be general or confined to specific instances. The Board of Directors may, when it believes the interest of the Corporation will best be served thereby, authorize executive employment contracts that will have terms no longer than ten years and contain such other terms and conditions as the Board of Directors deems appropriate. Nothing herein will limit the authority of the Board of Directors to authorize employment contracts for shorter terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.08 Chief Executive Officer. The Chief Executive Offcier ("CEO") will be the chief executive officer of the Corporation and subject to the control of the Board of Directors, will supervise and control all of the business and affairs of the Corporation. He or she will, in the absence of the Chairman of the Board, preside at all meetings of the shareholders and the Board of Directors. The CEO will have all powers and perform all duties incident to the office of CEO and will have such other powers and perform such other duties as the Board of Directors may from time to time prescribe.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.09 President and Vice President(s). Each President and Vice President will have the usual and customary powers and perform the usual and customary duties incident to the office of President and Vice President, and will have such other powers and perform such other duties as the Board of Directors or any committee thereof may from time to time prescribe or as the President may from time to time delegate to him or her. In the absence or disability of the President and the Chairman of the Board, a Vice President designated by the Board of Directors, or in the absence of such designation the Vice Presidents in the order of their seniority in office, will exercise the powers and perform the duties of the President.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10 Secretary. The Secretary will attend all meetings of the shareholders and record all votes and the minutes of all proceedings in a book to be kept for that purpose. The Secretary will perform like duties for the Board of Directors and committees thereof when required. The Secretary will give, or cause to be given, notice of all meetings of the shareholders and special meetings of the Board of Directors. The Secretary will keep in safe custody the seal of the Corporation. The Secretary will be under the supervision of the President. The Secretary will have such other powers and perform such other duties as the Board of Directors may from time to time prescribe or as the President may from time to time delegate to him or her.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11 Assistant Secretaries. The Assistant Secretaries in the order of their seniority in office, unless otherwise determined by the Board of Directors, will, in the absence or disability of the Secretary, exercise the powers and perform the duties of the Secretary. They will have such other powers and perform such other duties as the Board of Directors may from time to time prescribe or as the President may from time to time delegate to them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12 Treasurer. The Treasurer will have responsibility for the receipt and disbursement of all corporate funds and securities, will keep full and accurate accounts of such receipts and disbursements, and will deposit or cause to be deposited all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors. The Treasurer will render to the Directors whenever they may require it an account of the operating results and financial condition of the Corporation, and will have such other powers and perform such other duties as the Board of Directors may from time to time prescribe or as the President may from time to time delegate to him or her.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13 Assistant Treasurers. The Assistant Treasurers in the order of their seniority in office, unless otherwise determined by the Board of Directors, will, in the absence or disability of the Treasurer, exercise the powers and perform the duties of the Treasurer. They will have such other powers and perform such other duties as the Board of Directors may from time to time prescribe or as the President may from time to time delegate to them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.14 Bonding. The Corporation may secure a bond to protect the Corporation from loss in the event of defalcation by any of the officers, which bond may be in such form and amount and with such surety as the Board of Directors may deem appropriate.

ARTICLE SIX: CERTIFICATES AND SHAREHOLDERS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.01 Certificated and Uncertificated Shares. The shares of the Corporation may be either certificated shares or uncertificated shares. As used herein, the term "certificated shares" means shares represented by instruments in bearer or registered form, and the term "uncertificated shares" means shares not represented by such instruments and the transfers of which are registered upon books maintained for that purpose by or on behalf of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.02 Certificates for Certificated Shares. The certificates for certificated shares of capital stock of the Corporation shall be in such form as shall be approved by the Board of Directors in conformity with law. The certificates shall be consecutively numbered, shall be entered as they are issued in the books of the Corporation or in the records of the Corporation's designated transfer agent, if any, and shall state the shareholder's name, the number of shares, and such other matters as may be required by law. The certificates shall be signed by the President or any Vice President and also by the Secretary, an Assistant Secretary, or any other officer, and may be sealed with the seal of the Corporation or a facsimile thereof. If any certificate is countersigned by a transfer agent or registered by a registrar, either of which is other than the Corporation itself or an employee of the Corporation, the signatures of the foregoing officers may be a facsimile.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.03 Lost, Stolen, or Destroyed Certificates. The Corporation shall issue a new certificate in place of any certificate for certificated shares previously issued if the registered owner of the certificate satisfies the following requirements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Claim.
 The registered owner makes proof in affidavit form that a previously issued certificate for
 certificated shares has been lost, destroyed, or stolen;

b) Timely
 Request. The registered owner requests the issuance of a new certificate before the Corporation
 has notice that the certificate has been acquired by a purchaser for value in good faith
 and without notice of an adverse claim;

c) Bond.
 The registered owner gives a bond in such form, and with such surety or sureties, with fixed
 or open penalty, as the Board of Directors may direct, in its discretion, to indemnify the
 Corporation (and its transfer agent and registrar, if any) against any claim that may be
 made on account of the alleged loss, destruction, or theft of the certificate; and

d) Other
 Requirements. The registered owner satisfies any other reasonable requirements imposed by
 the Board of Directors.

When a certificate has been lost, destroyed, or stolen and the shareholder of record fails to notify the Corporation within a reasonable time after he or she has notice of it, if the Corporation registers a transfer of the shares represented by the certificate before receiving such notification, the shareholder of record is precluded from making any claim against the Corporation for the transfer or for a new certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.04 Transfer of Shares. With respect to certificated shares, upon surrender to the Corporation or the transfer agent of the Corporation of a certificate representing shares duly endorsed or accompanied by proper evidence of succession, assignment, or authority to transfer, the Corporation or its agent shall issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction upon its books. With respect to uncertificated shares, upon delivery to the Corporation of proper evidence of succession, assignment, or authority to transfer, the Corporation or its agent shall record the transaction upon its books. When a transfer of shares is requested and there is reasonable doubt as to the right of the person seeking the transfer, the Corporation or its transfer agent, before recording the transfer of the shares on its books or issuing any certificate therefor, may require from the person seeking the transfer reasonable proof of such person's right to the transfer. If there remains a reasonable doubt of the right to the transfer, the Corporation may refuse a transfer unless the person gives adequate security or a bond of indemnity executed by a corporate surety or by two individual sureties satisfactory to the Corporation as to form, amount and responsibility of sureties. The bond shall be conditioned to protect the Corporation, its officers, transfer agents and registrars, or any of them, against any loss, damage, expense or other liability to the owner of the shares by reason of the recordation of the transfer or the issuance of a new certificate for shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.05 Registered Shareholders. The Corporation shall be entitled to treat the shareholder of record as the shareholder in fact of any shares and, accordingly, shall not be bound to recognize any equitable or other claim to or interest in such shares on the part of any other person, whether or not it shall have actual or other notice thereof, except as otherwise provided by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.06 Legends. If the Corporation is authorized to issue shares of more than one class, each certificate representing shares issued by the Corporation (a) shall conspicuously set forth on the face or back of the certificate a full statement of (I) all of the designations, preferences, limitations, and relative rights of the shares of each class authorized to be issued; and (ii) if the Corporation is authorized to issue shares of any preferred or special class in series, the variations in the relative rights and preferences of the shares of each such series to the extent they have been fixed and determined and the authority of the Board of Directors to fix and determine the relative rights and preferences of subsequent series; or (b) shall conspicuously state on the face or back of the certificate that (I) such a statement is set forth in the Certificate on file in the office of the Secretary of State; and (ii) the Corporation will furnish a copy of such statements to the record holder of the certificate without charge upon written request to the Corporation at its principal place of business or registered office.

If the Corporation issues any shares that are not registered under the Securities Act of 1933, as amended, the transfer of any such shares shall be restricted in accordance with an appropriate legend.

In the event any restriction on the transfer, or registration of the transfer, of shares shall be imposed or agreed to by the Corporation, each certificate representing shares so restricted (a) shall conspicuously set forth a full or summary statement of the restriction on the face of the certificate; (b) shall set forth such statement on the back of the certificate and conspicuously refer to the same on the face of the certificate; or (c) shall conspicuously state on the face or back of the certificate that such a restriction exists pursuant to a specified document and (I) that the Corporation will furnish to the record holder of the certificate without charge upon written request to the Corporation at its principal place of business or registered office a copy of the specified document; or (ii) if such document is one required or permitted by law to be and has been filed, that such specified document is on file in the office of the Secretary of State and contains a full statement of such restriction.

ARTICLE SEVEN: MISCELLANEOUS PROVISIONS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.01 Dividends. Subject to any restrictions of law or in the Certificate, dividends may be declared by the Board of Directors at any meeting and may be paid in cash, in property, or in shares of capital stock of the Corporation. Such declaration and payment shall be at the discretion of the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.02 Reserves. The Board of Directors may create out of funds of the Corporation legally available therefor such reserve or reserves as the Board of Directors from time to time, in its discretion, considers proper to provide for contingencies, to equalize dividends, or to repair or maintain any property of the Corporation, or for such other purpose as the Board of Directors shall consider beneficial to the Corporation. The Board of Directors may modify or abolish any such reserve in the same manner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.03 Indemnification and Insurance. The Corporation will indemnify its directors, officers, and other persons referenced in the Certificate to the fullest extent permitted by the NRS and may, if and to the extent authorized by the Board of Directors, so indemnify any other person whom it has the power to indemnify against liability, reasonable expenses, or any other matters whatsoever. The Corporation may, at the discretion of the Board of Directors, purchase and maintain insurance on behalf of the Corporation and any person whom it has the power to indemnify under the NRS, the Certificate, these Bylaws, or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.04 Books and Records. The Corporation shall keep correct and complete books and records of account, shall keep minutes of the proceedings of its shareholders, Board of Directors, and any committee thereof, and shall keep at its registered office or principal place of business, or at the office of its transfer agent or registrar, a record of its shareholders, giving the names and addresses of all shareholders and the number and class of shares held by each shareholder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.05 Fiscal Year. The fiscal year of the Corporation shall be fixed by the Board of Directors, provided, however, that if such fiscal year is not fixed by the Board of Directors and the Board of Directors does not defer its determination of the fiscal year, it shall be the calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.06 Seal. The seal, if any, of the Corporation shall be in such form as may be approved from time to time by the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.07 Checks. All checks, drafts, or other orders for payment of money, notes, or other evidences of indebtedness issued in the name of or payable to the Corporation may be signed or endorsed by the President and/or such officer or officers or such other person or persons as the Board of Directors may from time to time designate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.08 Resignation. A director, committee member, officer, or agent may resign by so stating at any meeting of the Board of Directors or by giving written notice to the Board of Directors, the President, or the Secretary. Such resignation shall take effect at the time specified therein, or immediately if no time is specified. Unless it specifies otherwise, a resignation is effective without being accepted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.09 Securities of Other Corporations. The CEO, or, in his or her absence, the President or any Executive Vice President, shall have the power and authority to transfer, endorse for transfer, vote, consent, or take any other action with respect to any securities of another issuer that may be held or owned by the Corporation and to make, execute, and deliver any waiver, proxy, or consent with respect to any such securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10 Amendment. The power and authority to alter, amend, or repeal these Bylaws or to adopt new bylaws is vested in the Board of Directors, subject to the power of the shareholders to change or repeal any bylaws so made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11 Invalid Provisions. If any part of these Bylaws shall be held invalid or inoperative for any reason, the remaining parts, so far as possible and reasonable, shall remain valid and operative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.12 Headings. The headings used in these Bylaws are for convenience only and do not constitute matter to be construed in the interpretation of these Bylaws.

## Exhibit 3.3

**Exhibit 3.3**

![](ex3-3_001.jpg)

![](ex3-3_002.jpg)

## Exhibit 3.4

**Exhibit 3.4**

![](ex3-4_001.jpg)

![](ex3-4_002.jpg)

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

CARING BRANDS, INC.

(a Florida corporation)

SUBSCRIPTION AGREEMENT

THE SECURITIES SUBSCRIBED FOR PURSUANT TO THIS SUBSCRIPTION AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND TRANSFER OF THE SECURITIES IS RESTRICTED BY SUCH LAWS AND THE TERMS OF THIS SUBSCRIPTION AGREEMENT. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY OTHER FEDERAL OR STATE AGENCY OR AUTHORITY HAS PASSED ON, RECOMMENDED, OR ENDORSED THE MERITS OF THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

**FOR MORE INFORMATION, PLEASE CONTACT**:

**Caring brands, Inc.**

**Address: 1061 E. Indiantown Road, Suite 110**

**Jupiter, FL. 33477**

**(561)599-0080**

**E-mail: bj@carocg.com**

**SUBSCRIPTION AGREEMENT**

This Subscription Agreement (this "<u>Agreement</u>"), dated as of March 15, 2024, is by and between Caring Brands, Inc., a Florida corporation (the "<u>Company</u>"), and the undersigned (the "<u>Subscriber</u>").

**BACKGROUND**

WHEREAS, the Company is offering (the "<u>Offering</u>") to sell shares of its common stock, no par value per share (the "<u>Common Stock</u>") substantially on terms consistent with those set forth on the term sheet attached hereto at <u>Exhibit A</u> (the "<u>Term Sheet</u>");

WHEREAS, the Offering is being conducted in accordance with the exemption from the registration requirements of the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), in reliance upon the exemption from such registration provided by Rule 506(b) of Regulation D under the Securities Act;

WHEREAS, Subscriber has had the opportunity to review and reflect on the business focus, prospects and assets of the Company; and

WHEREAS, in connection with the Offering, and upon the terms and conditions set forth in this Agreement, the Company desires to sell to the Subscriber, and the Subscriber desires to purchase from the Company, shares of Common Stock for the consideration specified on the signature page hereto and on the terms specified herein.

NOW, THEREFORE, in consideration of the mutual promises, representations, warranties, covenants, agreements and conditions set forth in this Agreement, the parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Subscription</u>. The
 Subscriber hereby irrevocably subscribes for and agrees to purchase from the Company ____________________ shares of Common Stock at
 a purchase price of $0.001 per share of Common Stock for the aggregate subscription price in the amount of $____________________ (the
 " <u>Subscription Amount</u> "). Payment of the Subscription Amount shall be made simultaneously with the execution and delivery
 of this Agreement. If this subscription is not accepted by the Company for any reason, all documents, together with the Subscription
 Amount (without interest), will be returned to the Subscriber. Until such time as this subscription is accepted, all funds will be
 held in a segregated account. If this subscription is accepted by the Company, the Company will affect a book entry share issuance
 with the Company's stock transfer agent representing the shares of Common Stock purchased by the Subscriber and will deliver
 a confirmation of same to Subscriber promptly following such acceptance.

Subscriber shall wire the full Subscription Amount to the Company pursuant to the following wire instructions:

**Bank: TD Bank**

**Tequesta, FL 33469**

**Wire Routing Number: 067014822**

**Beneficiary Name: Caring brands, Inc.**

**Account Number: 4374418618**

**Swift Code: NRTHUS33XXX**

**Address: 1061 E. Indiantown Road, Suite 110. Jupiter, FL. 33477**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Representations and Warranties</u>. The Subscriber hereby represents, warrants and agrees, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) (i) The Subscriber is purchasing the shares of Common Stock for investment purposes only for the account of the Subscriber and not with any view toward the distribution or resale thereof; and (ii) the Subscriber has no contract, undertaking, agreement or arrangement with any person to sell, transfer or pledge to such person or anyone else the shares of Common Stock, and the Subscriber has no present plans to enter into any such contract, undertaking, agreement or arrangement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Subscriber has sufficient financial resources available to support the loss of all of the Subscriber's investment in the shares of Common Stock, can afford a complete loss of the investment in the shares of Common Stock and can afford to hold the investment in the shares of Common Stock for an indefinite period of time and is able to bear the economic risk of the investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Subscriber has such knowledge and experience in financial and business matters that the Subscriber is capable of evaluating the merits and risks of the Subscriber's investment in the shares of Common Stock and is able to bear such risks, and has obtained, in the Subscriber's judgment, sufficient information from the Company or its authorized representatives to evaluate the merits and risks of such investment. The Subscriber has evaluated the risks of investing in the shares of Common Stock and has determined that an investment in the shares of Common Stock is a suitable investment for the Subscriber.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Subscriber has not utilized any other person as a Purchaser Representative (as defined in Rule 501(h) of Regulation D under the Securities Act in connection with evaluating the merits and risks of the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Subscriber is an "accredited investor" (as defined in Rule 501(a) of Regulation D under the Securities Act) in that **(please check one of the following)**:

_____ (i) the Subscriber is an individual and either has an individual net worth, or with the Subscriber's spouse or spousal equivalent<sup>1</sup> has a combined net worth, as of the date hereof in excess of $1,000,000 (for purposes of this representation and warranty, "net worth" means the excess of total assets at fair market value (including personal and real property, but excluding the estimated fair market value of a person's primary home) over total liabilities);<sup>2</sup>

<sup>1</sup> The term spousal equivalent shall mean a cohabitant occupying a relationship generally equivalent to that of a spouse.

<sup>2</sup> Notwithstanding anything to the contrary herein, for purposes of determining "net worth," "total liabilities" excludes any mortgage on the primary home in an amount of up to the home's estimated fair market value as long as the mortgage was incurred more than 60 days before the shares of Common Stock are purchased, but includes (i) any mortgage amount in excess of the home's fair market value and (ii) any mortgage amount that was borrowed during the 60-day period before the closing date for the sale of shares of Common Stock for the purpose of investing in the shares of Common Stock.

_____ (ii) the Subscriber is an individual and had individual annual income (exclusive of any income attributable to the Subscriber's spouse or spousal equivalent) of more than $200,000 in each of the past two years or joint income with the Subscriber's spouse or spousal equivalent in excess of $300,000 in each of those years and reasonably expects to reach the same income level in the current year;<sup>3</sup>

_____ (iii) The Subscriber is an individual who is a "knowledgeable employee," as defined in rule 3c-5(a)(4) under the Investment Company Act (as defined below), of the Company;

_____ (iv) The Subscriber is a director or executive officer of the Company;

_____ (v) The Subscriber is a "family client," as defined in rule 202(a)(11)(G)-1 under the Advisers Act, of a "family office" meeting the requirements of rule 501(a)(12) under the Securities Act, and whose prospective investment in the Company is directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment;

_____ (vi) the Subscriber is a corporation, limited liability company, foundation, endowment or partnership, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered;

____ (vii) the Subscriber is a corporation, foundation, endowment or partnership that is an accredited investor because all of its equity owners are accredited investors;

<sup>3</sup> For purposes of this Agreement, individual income means adjusted gross income, as reported for federal income tax purposes, less any income attributable to a spouse or to property owned by a spouse, increased by the following amounts (but not including any amounts attributable to a spouse or to property owned by a spouse); (i) the amount of any tax-exempt interest income under Section 103 of the Internal Revenue Code of 1986, as amended (the "Code"), received, (ii) the amount of losses claimed as a limited partner in a limited partnership as reported on Schedule E of Form 1040, (iii) any deduction claimed for depletion under Section 611 et seq. of the Code, (iv) amounts contributed to an Individual Retirement Account (as defined in the Code) or Keogh retirement plan, (v) alimony paid, and (vi) any elective contributions to a cash or deferred arrangement under Section 401(k) of the Code.

_____ (viii) the Subscriber is a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D of the Securities Act;

_____ (ix) the Subscriber is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment adviser;

_____ (x) the Subscriber is an employee benefit plan whose total assets exceed $5,000,000 as of the date of this Agreement;

_____ (xi) the Subscriber is a self-directed employee benefit plan whose investment decisions are made solely by persons who are individuals who are accredited investors;

_____ (xii) the Subscriber is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity;

_____ (xiii) the Subscriber is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934;

_____ (xiv) the Subscriber is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in the Company;

_____ (xv) the Subscriber is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000; or

_____ (xvi) the Subscriber is an insurance company as defined in §2(13) of the Securities Act, or a registered investment company.

By signing this Agreement, the Subscriber hereby covenants to promptly advise the Company if at any time there shall occur a change in the Subscriber's accredited investor status.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Subscriber is not a nonresident alien (as such term is defined in the Internal Revenue Code of 1986, as amended, and Regulations) for purposes of income taxation. The Subscriber's principal residence is at the address shown on the signature page of this Agreement, at which address the Subscriber has subscribed for the shares of Common Stock, and the Subscriber's name, address and social security number or taxpayer identification number, as applicable, set forth on the signature page of this Agreement are true, correct and complete.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Subscriber has the full power and authority to execute, deliver and perform its obligations under this Agreement. Subscriber's execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby and thereby, will not (i) in the case of any Subscriber who is not a natural person, conflict with or result in a breach of any provision of the organizational documents of such Subscriber, (ii) with or without the passage of time, the giving of notice or both, constitute or result in a breach or default under or conflict with any order, ruling, judgment, writ, decree or regulation of any court or other tribunal or of any governmental commission or agency, or any agreement, instrument or other undertaking, to which the Subscriber is a party or by which the Subscriber is bound, or (iii) require Subscriber to obtain any consent, approval or action of, make any filing with, or give any notice to any person or entity as a result or under the terms of, or relieve any third party of any obligation of Subscriber under any such order, ruling, judgment, writ, decree, regulation, agreement, instrument or other undertaking. The signature on this Agreement is genuine, and the signatory has legal competence and capacity to execute the same and this Agreement constitutes legal, valid and binding obligations of the Subscriber, enforceable in accordance with their respective terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) The Subscription Amount contributed by Subscriber to the Company were not and will not be, directly or indirectly, derived from activities that may contravene any federal, state or international laws and regulations, including anti-money laundering laws and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Subscriber is not engaged in any activity, directly or indirectly, (i) in contravention of any United States, international or other applicable laws and regulations, including anti-money laundering laws and regulations, (ii) on behalf of terrorists, terrorist organizations, or other criminal organizations, (iii) on behalf of any country, territory, person or entity identified on the List of Specially Designated Nationals and Blocked Persons maintained by the United States Treasury Department's Office of Foreign Asset Control ("<u>OFAC</u>"), as such list may be amended from time to time,<sup>4</sup> (iv) for a senior foreign political figure, any member of a senior foreign political figure's immediate family or any close associate of a senior foreign political figure,<sup>5</sup> or (v) a foreign shell bank<sup>6</sup> (such persons or entities identified in (i) – (v) are collectively referred to as "<u>Prohibited Persons</u>").

<sup>4</sup> A current copy of this list is available on OFAC's web site at http://www.treas.gov/ofac.

<sup>5</sup> Senior foreign political figure means a senior official in the executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government-owned corporation. In addition, a senior foreign political figure includes any corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign political figure. The immediate family of a senior foreign political figure typically includes the political figure's parents, siblings, spouse, children and in-laws. A close associate of a senior foreign political figure is a person who is widely and publicly known internationally to maintain an unusually close relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial domestic and international financial transactions on behalf of the senior foreign political figure.

<sup>6</sup> Foreign shell bank means a foreign bank without a physical presence in any country but does not include a regulated affiliate. A post office box or electronic address would not be considered a physical presence. A regulated affiliate means a foreign shell bank that: (1) is an affiliate of a depository institution, credit union, or foreign bank that maintains a physical presence in the United States or a foreign country, as applicable; and (2) is subject to supervision by a banking authority in the country regulating such affiliated depository institution, credit union, or foreign bank.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) (i) Subscriber is not, nor is any person or entity controlling, controlled by or under common control with the Subscriber, a Prohibited Person, and (ii) to the extent the Subscriber has any beneficial owners<sup>7</sup>, (A) it has carried out thorough due diligence to establish the identities of such beneficial owners, (B) it reasonably believes that no such beneficial owners are Prohibited Persons, (C) it holds the evidence of such identities and status and will maintain all such evidence for at least five years from the date of the Subscriber's complete redemption from the Company, and (D) it will make available such information and any additional information that the Company may reasonably require upon request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) The Subscriber acknowledges and agrees that the Company may "freeze the account" of the Subscriber, including, but not limited to, declining any withdrawal requests and/or segregating the shares of Common Stock, in compliance with governmental regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) The Subscriber is not relying on the Company or the management of the Company with respect to any legal, investment or tax considerations involved in the purchase, ownership and disposition of the shares of Common Stock. The Subscriber has relied solely upon the advice of, or has consulted with, in regard to the legal, investment and tax considerations involved in the purchase, ownership and disposition of the shares of Common Stock, the Subscriber's legal counsel, business and/or investment adviser, accountant and tax adviser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) The Subscriber is not subject to any "bad boy" disqualifications as set forth in Rule 506(d) of Regulation D under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Acknowledgements and Covenants</u>. The Subscriber acknowledges and agrees that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) No federal or state agency has passed on, recommended or endorsed the merits of the shares of Common Stock or this Offering or made any findings or determination as to the fairness of this investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The shares of Common Stock have not been registered under the Securities Act or any applicable state securities laws by reason of exemptions from the registration requirements of the Securities Act and such laws, and the shares of Common Stock may not be sold, transferred, assigned, pledged or hypothecated or otherwise disposed of, in whole or in part, in the absence of an effective registration statement applicable thereto under the Securities Act and all applicable state securities laws, or unless an exemption from such registration is available.

<sup>7</sup> Beneficial owners include, but are limited to: (i) shareholders of a corporation; (ii) partners of a partnership; (iii) members of a limited liability company; (iv) investors in an investment fund, including indirect investors in a fund-of-funds; (v) the grantor of a revocable or grantor trust; (vi) the beneficiaries of an irrevocable trust; (vii) the individual who established an IRA; (viii) the participant in a self-directed pension plan; (ix) the sponsor of any other pension plan; and (x) any person being represented by the Subscriber in an agent, representative, intermediary, nominee or similar capacity. If the beneficial owner is itself an entity, the information and representations set forth herein must also be given with respect to its individual beneficial owners. Publicly traded companies need not conduct due diligence as to their beneficial owners.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Subscriber agrees and understands that the Subscriber will not sell, transfer, assign or otherwise dispose of the shares of Common Stock or any interest therein unless and until the Subscriber (i) complies with (x) all applicable requirements of federal and state securities laws and (ii) any requirements contained in any shareholder agreement or other agreement to which the Subscriber is a party; and (ii) in the absence of an effective registration statement, provides the Company with an opinion of counsel which is satisfactory to the Company (both as to the issuer of the opinion and the form and substance thereof) that the shares of Common Stock may be sold, transferred, assigned, pledged, hypothecated or otherwise disposed of without registration under the Securities Act, and without violation of any applicable state securities laws (including any investor suitability standards).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Subscriber has been furnished any and all materials that the Subscriber has requested relating to the Company or the Offering of the shares of Common Stock, and the Subscriber has been afforded the unrestricted opportunity to ask questions of the management of the Company concerning the terms and conditions of its commitment to purchase, and purchase, of the shares of Common Stock and to obtain any additional information necessary to verify the accuracy of the information provided to the Subscriber. The Subscriber understands that such material is current information about the Company and its Subsidiaries, is subject to completion and does not in any way guarantee future performance or the completion of future proposed events discussed in such material.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Subscriber has received confidential information in connection with Subscriber's potential investment in the Company and the proposed operations of the Company, which was prepared by the Company. Subscriber understands that such confidential information contains "forward-looking statements" (as such term is defined in Section 27A of the Securities Act). Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements, and include any statement containing a projection of revenues, income (including income loss), earnings (including earnings loss), capital expenditures, dividends, capital structure, or other financial items and statements of the plans and objectives of management for future operations. Forward-looking statements include statements preceded by, followed by or that include the words "may," "could," "would," "shall," "should," "believe," "expect," "anticipate," "plan," "estimate," "target," "project," "intend," or similar expressions. Subscriber understands that Forward-looking statements are only predictions and are not guarantees of performance. Subscriber understands that These statements are based on management OF THE COMPANY's beliefs and assumptions, which in turn are based on currently available information, and that Important assumptions relating to the forward-looking statements include, among others, assumptions regarding THE ability OF THE COMPANY to market and sell IT'S PROPRIETARY TECHNOLOGIES, the timing and cost of planned expenditures, competitive conditions and general economic conditions. Subscriber understands that These assumptions could prove inaccurate. Subscriber understands that Forward-looking statements also involve known and unknown risks and uncertainties, which invariably will cause actual results that differ materially from those contained in any forward-looking statement, and that Many of these factors are beyond the Company's ability to control or predict. Subscriber acknowledges and agrees that NO ASSURANCE has been GIVEN by the company or any of its personnel or representatives THAT THE COMPANY'S TARGET OF FUTURE PERFORMANCE WILL BE REALIZED, THAT THE COMPANY WILL OPERATE PROFITABLY OR THAT THE SUBSCRIBER WILL RECEIVE THE RETURN OF ALL OR ANY PART OF ITS INVESTMENT HEREIN.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Subscriber has carefully considered the numerous risks associated with an investment of this type. Subscriber further acknowledges that the occurrence of any of these risks could have a material and adverse impact on the Company's business and prospects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) The Subscriber understands that the shares of Common Stock are being offered and sold in reliance on specific exemptions from the registration requirements of Federal and state law and that the Company is relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings set forth herein in order to determine the applicability of such exemptions and the suitability of the Subscriber to acquire the shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) The Subscriber understands that the Subscriber is not entitled to cancel, terminate or revoke this subscription upon acceptance by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Representations and Warranties of the Company</u>. The Company represents and warrants to Subscriber that all of the following statements contained in this Section 4 are true in all material respects as of the date of this Agreement (or, if made as of a specified date, as of such date):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *<u>Organization</u>*. The Company is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization, with all requisite corporate or other legal entity power and authority to enter into this Agreement and to perform its obligations hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *<u>Authorization</u>*. The Company has the requisite power and authority to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby and thereby, have been duly authorized, and no other corporate or other legal entity action on the part of the Company is necessary to authorize the execution, delivery and performance by the Company of this Agreement or the consummation by the Company of the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) *<u>Execution; Validity of Agreement</u>*. This Agreement (i) has been duly and validly authorized, and when delivered by the Company will be executed and delivered by the Company and, assuming the due and valid authorization, execution and delivery of each other party hereto or thereto, (ii) constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *<u>Ownership and Possession of Interests</u>*. Upon the issuance of shares of Common Stock to Subscriber, such shares of Common Stock shall (i) be owned by Subscriber free and clear of all encumbrances (other than restrictions under the Securities Act of 1933, as amended, and any other agreement entered into by the Subscriber), and (ii) be duly authorized, validly issued, fully paid and nonassessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) *<u>Capitalization</u>*.

(i.) Except as may have been previously described to Subscriber or are disclosed in the Company's publicly available public company filings, there are no outstanding subscriptions, options, warrants, shares of restricted stock, calls, contracts, demands, commitments, convertible securities or other agreements or arrangements of any character or nature whatever (collectively "<u>Equity Rights</u>") under which the Company is obligated to issue any securities of any kind representing an ownership interest in the Company; and

(ii.) No holder of any securities of the Company is entitled to any preemptive or similar rights to purchase any securities of the Company from the Company, either as a result of this Agreement or any prior transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Piggy-Back Registration Rights; Name Change; Lockup Agreement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Piggy-Back Registration Rights</u>. Subscriber is hereby granted, subject to the terms and limitations set forth in this Agreement or in any agreement in place between the Company and any underwriter (or any placement agent used in connection with a PIPE offering), piggy-back registration rights when the Company next proposes to register any of its securities under the Securities Act of 1933, as amended, in connection with either (i) an underwritten public offering of its shares of Common Stock with gross proceeds to the Company of at least $10,000,000 or (ii) a resale registration for the benefit of securityholders. The Company shall give prompt written notice to you of its intention to effect any such registration and, subject to the terms herein, shall use its commercially reasonable efforts include for resale in such registration (and in all related registrations or qualifications under blue sky laws and in any related underwriting) all of the shares of Common Stock purchased by you under this Agreement with respect to which the Company has received written requests for inclusion therein within 10 days after delivery to you of the Company's notice. Note that the inclusion of your shares of Common Stock in any such registration statement shall be subject to underwriters' cutbacks (to the extent applicable) exercised in their sole discretion to and restrictions thereon under the Securities Act or any of the rules and regulations promulgated thereunder. If any of your shares of Common Stock are to be included in any registration statement in connection with an underwritten public offering or resale registration, the inclusion thereof shall be contingent upon your acceptance of the terms of the underwriting as agreed upon between the Company and its underwriters or placement agents, as applicable, and the inclusion of your shares of Common Stock in any such registration shall be further subject to the terms and conditions of such underwriting agreement or placement agency agreement. If the total number of securities, including your shares of Common Stock, requested by all holders of registration rights to be included in such registration statement exceeds the number of securities to be sold (other than by the Company) that the underwriters or placement agents in their reasonable discretion determine is compatible with the success of the offering or scheduled registration, then the Company shall be required to include in the offering only that number of such securities which the underwriters or placement agents and the Company in their sole discretion determine will not jeopardize the success of the offering or registration. If it is determined that less than all of the securities requested to be registered can be included in such offering or registration, then the securities (including your shares of Common Stock) that are approved to be included in such offering or registration shall be allocated by the Company fairly among those requesting inclusion in the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Name Change and Related Matters</u>. Subscriber understands that the Company intends to explore, and may effect, a change of the Company's name to a name that includes the word "Caring Brands." If a majority of the directors comprising the Company's board of directors (the "<u>Board</u>") approves a name change, Subscriber hereby consents to such name change and any related corresponding actions approved by the Board (including a trading symbol change and obtaining a new CUSIP number). Each Subscriber, on behalf of itself and each of its transferees, hereby constitutes and appoints each member of the Board with full power of substitution, as his, her or its true and lawful agent and attorney-in-fact, with full power and authority in his or its name, place and stead, to execute, swear to, acknowledge, deliver, file and record in the appropriate public offices all certificates, powers, conveyances, agreements and other instruments or documents that the Board deems appropriate or necessary to effect the name change and related matters. The foregoing power of attorney is irrevocable and coupled with an interest, and shall survive the death, disability, incapacity, dissolution, Bankruptcy, insolvency or termination of any Subscriber and the transfer of all or any portion of his, her or its shares and shall extend to such Subscriber's heirs, successors, assigns and personal representatives. Any Subscriber that does not comply with the terms and provisions of Section 5(b) shall pay all of the costs and fees, including attorneys' fees, incurred by the Company in connection with enforcing Section 5(b).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Resale Restrictions</u>. Subscriber hereby agrees that, subject to any registration contemplated under Section 5(a), for the period beginning on the date hereof and ending twelve (12) months after the date Subscriber's investment hereunder is accepted by the Company (the "<u>Restricted Period</u>"), Subscriber will not, without the prior approval of the Board, offer, pledge, sell, contract to sell, sell any option or contract to purchase, lend, transfer or otherwise dispose of any shares or any options, warrants or other rights to purchase shares or any other security of the Company which Subscriber owns as of the date hereof or comes to own after the date hereof (collectively, the "<u>Lockup Shares</u>"). Notwithstanding the foregoing restrictions on transfer, the Subscriber may, at any time and from time to time during the Restricted Period, transfer any such shares (i) as bona fide gifts or transfers by will or intestacy, (ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the Subscriber, provided that any such transfer shall not involve a disposition for value, (iii) to a partnership which is the general partner of a partnership of which the Subscriber is a general partner, provided, that, in the case of any gift or transfer described in clauses (i), (ii) or (iii), each transferee agrees in writing to be bound by the terms and conditions contained herein in the same manner as such terms and conditions apply to the undersigned, absent such agreement to be bound said transfer will be deemed null and void *ab initio*. For purposes hereof, "<u>immediate family</u>" means Subscriber's spouse, child or parent. During the Restricted Period, the Subscriber shall retain all rights of ownership in the Lockup Shares, including, without limitation, voting rights and the right to receive any dividends that may be declared in respect thereof. The Company is hereby authorized and required to disclose the existence of this Agreement to its transfer agent. The Company and its transfer agent are hereby authorized and required to decline to make any transfer of the shares if such transfer would constitute a violation or breach of this Agreement. The provisions of this Section 5 may be waived by the Company in whole or in part its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Indemnification</u>. The Subscriber understands the meaning of the representations, warranties, acknowledgments, covenants and agreements made by the Subscriber in this Agreement and hereby agrees to indemnify and hold harmless the Company, its members, managers, officers and employees, and all persons deemed to be in control of any of the foregoing from and against any and all losses, costs, expenses, damages, liabilities and interest (including, without limitation, court costs and attorneys' fees) arising out of or due to a breach by the Subscriber of any such representations, warranties, acknowledgments, covenants and agreements. All such representations, warranties, acknowledgments, covenants and agreements shall survive the delivery of this Subscription Agreement and the purchase by the Subscriber of the shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Confidentiality</u>. The Subscriber agrees that, except with the prior written consent of the Company, it shall at all times keep confidential and not divulge, furnish or make accessible to anyone any confidential information, knowledge or data concerning or relating to the business or financial affairs of the Company or its business to which such Subscriber has been or shall become privy by reason of this Agreement, discussions relating to this Agreement, the performance of any obligations hereunder or the ownership of shares of Common Stock purchased hereunder except for such disclosures required to be made by judicial or administrative process or by other requirements of law. The provisions of this Section 9 shall be in addition to, and not in substitution for, the provisions of any separate nondisclosure or other similar agreements executed or hereafter executed by any party hereto with respect to the Company or to the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Acceptance of Subscription</u>. The Subscriber understands and agrees that the Company, in its sole discretion, reserves the right to accept or reject this subscription, notwithstanding prior receipt by the Subscriber of notice of acceptance of this subscription. The Company shall have no obligation hereunder until the Company shall execute and deliver to the Subscriber an executed copy of this Agreement. If this subscription is rejected, all funds received from the Subscriber will be returned without interest, penalty, expense or deduction, and this Agreement shall thereafter be of no further force or effect (except for Section 7, which shall survive any termination).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Entire Agreement</u>. This Agreement constitutes the entire understanding among the parties with respect to the subject matter hereof, and supersedes any prior understanding and/or written or oral agreements among them with regard to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Governing Law; Jurisdiction</u>. This Agreement shall be governed by the laws of the State of FLORIDA, without regard to the principles of choice of law or conflicts of laws of any jurisdiction. The parties hereby expressly submit to the exclusive venue and personal jurisdiction of the courts of state of delaware or in the United States District Court within the state of delaware, and any appropriate appellate court thereof, for the resolution of disputes arising hereunder, and each party hereby waives any defense of improper venue or inconvenient forum as to any action brought in state courts in delaware, or in the United States District Court of delaware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Further Assurances</u>. At the request of the Company and without further conditions or consideration, the Subscriber shall from time to time promptly provide such information and execute and deliver such other documents or instruments as may be necessary in the discretion of the Company for the Company to comply with any and all laws, rules and regulations to which the Company is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Dispute Resolution</u>. The Subscriber and the Company will first attempt to settle each and every dispute, controversy or claim arising out of or relating to this Agreement ("<u>Disputes</u>") through good faith negotiations. Any Dispute not thus resolved within 30 days or such other period as the parties shall mutually agree in writing shall be resolved by binding arbitration conducted before a single "JAMS" arbitrator and that such binding arbitration shall be governed by the rules and procedures of JAMS for streamlined arbitrations. Such arbitration is to take place at JAMS' offices in the City of West Palm Beach, as an "expedited" arbitration. In addition, any claims or counterclaims that that may be raised shall be determined by the same binding arbitration procedure. All parties agree to be bound by the decision of the arbitrator, which we agree may be confirmed and enforced by a court of law. All parties agree to accept service of an arbitral complaint or statement of claim in the manner by which notices may be delivered pursuant to this Agreement. The arbitrator will be instructed to make a finding as to which party is the substantially prevailing party, and that party shall be entitled to reimbursement of its reasonable legal fees and costs, which fees shall be determined by the arbitrator. The arbitrator shall also award interest at no less than the statutory rate on any fee award running from the date on which the fees are determined to be owed. By signing this Agreement, each of the parties acknowledges that he, she or it has read the written rules and procedures for streamlined JAMS arbitrations which are available at www.jamsadr.com/rules-streamlined-arbitration. Notwithstanding the foregoing, any party may seek equitable or injunctive relief in any court of competent jurisdiction. The statute(s) of limitation applicable to any Dispute shall be tolled upon initiation of the Dispute resolution procedures under this Section 12 and shall remain tolled until the Dispute is resolved under this Section 12. However, tolling shall cease if the aggrieved party does not file a demand for arbitration of the Dispute with JAMS within 30 days after good faith negotiations have been terminated by either party. The parties, their representatives and participants and the arbitrator shall hold the content and result of the arbitration in confidence, except to the limited extent necessary to enforce a final settlement agreement or to obtain or enforce a judgment on an arbitration decision and award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Waivers</u>. The failure by any party hereto to insist upon or to enforce any of its rights will not constitute a waiver thereof, and nothing will constitute a waiver of such party's right to insist upon strict compliance with the provisions hereof. No delay in exercising any right, power or remedy created hereunder will operate as a waiver thereof, nor will any single or partial exercise of any right, power or remedy by any such party preclude any other or future exercise thereof or the exercise of any other right, power or remedy. No waiver by any party hereto to any breach of or default in any term or condition of this Agreement will constitute a waiver of or assent to any succeeding breach of or default in the same or any other term or condition hereof. Each party hereto may waive the benefit of any provision or condition for its benefit contained in this Agreement, but only if such waiver is evidenced by a writing signed by such party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Invalid Provisions</u>. Any term or provision of this Agreement that is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms or provisions of this Agreement or affecting the validity or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>Counterparts</u>. For the convenience of the parties, this Agreement may be executed in one or more counterparts, including in pdf or electronic format, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement.

[Signature Page Follows]

Pursuant to this Subscription Agreement, Subscriber's Capital Commitment of is $________, for a total of ___________ shares of Common Stock a price of $0.001 per share of Common Stock.

IN WITNESS WHEREOF, the parties executed this Subscription Agreement on the date first written above.

---

| | |
|:---|:---|
| **FOR INDIVIDUALS:** | **FOR ENTITIES:** |
| Print Name | Print Name of Entity |
| Signature | Signature of Authorized Signatory |
| Home Address:<br>| Print Name of Authorized Signatory |
|  | Print Title of Authorized Signatory<br>|
| Social Security Number | Business Address: |
|  | <br> Taxpayer Identification Number |

---

---

| | |
|:---|:---|
| **Accepted _____________:** | **Accepted _____________:** |
| CARING BRANDS, INC. | CARING BRANDS, INC. |
| By: |  |
| Name: | Dr. Glynn Wilson |
| Title: | CEO |

---

**<u>Exhibit A – Term Sheet</u>**

**SUMMARY OF THE TERMS OF THE OFFERING**

This Summary of Terms (this "<u>Term Sheet</u>") outlines the terms on which Caring Brands, Inc., a Florida corporation (the "<u>Company</u>"), currently proposes to offer shares of its Common Stock to a limited number of accredited investors (the "<u>Offering</u>"). This Term Sheet does not impose any binding obligations on the Company or any subscriber to proceed with a transaction or continue any negotiations.

---

| | |
|:---|:---|
| Issuer | Caring Brands, Inc., a Florida corporation.<br>|
| Security Offered | Common Stock, no par value per share (the "<u>Common Stock</u>").<br>|
| Amount of Offering | Up to an aggregate of $2,000,000, subject to increase to an amount of $3,000,000 at the discretion of the Company's board of directors (the "<u>Board</u>"). There is no minimum required raise for this Offering, and the Board may begin to accept subscriptions at any time in its sole discretion.<br>|
| Purchase Price/Minimum Investment<br>| $1.00 per share of Common Stock and one warrant per share exercisable at $3.00.<br>The minimum investment in the Common Stock by any subscriber is $50,000, although the Company may, in its sole discretion, accept lesser amounts.<br>|
| Closings | The Company has the ability to complete the Offering in multiple closings (each a "<u>Closing</u>"). The Closings may occur until the later of 60 days following the date of this Term Sheet or the date that the Company has accepted subscriptions for the full amount of the Offering (such date, the "<u>Expiration Date</u>"). The Company may, however, terminate the Offering in its sole discretion, at any time.<br>The Company may accept or reject subscriptions in its sole discretion, in whole or in part, for any reason or no reason. If a subscription is accepted by the Company, the Company will deliver to subscriber a counter-signed copy of the subscriber's subscription agreement. Once received, pending an actual Closing of the Offering, all funds will be held in a segregated, non-interest bearing account. Subscriptions are irrevocable on the part of a subscriber once delivered.<br>If the first Closing of the Offering is not consummated on substantially the same terms in the aggregate, as summarized in this Term Sheet, on or before the Expiration Date, all funds that have not been accepted and closed will be returned to the subscribers, without interest.<br>|
| Use of Proceeds | Proceeds of the Offering are anticipated to be used operations and expenses to become public company, reporting requirements, governance establishment and maintenance, and planned IPO to THE NYSE in 2024 and for general corporate and working capital purposes, and/or for other costs associated with pursuing, acquiring, operating and/or developing prospects.<br>|
| Voting Rights | Our Common Stock is a voting security, with one vote for each share of Common Stock on all matters submitted to our shareholders for a vote.<br>|
| Dividends | The Company will pay dividends to its shareholders only when and as declared by the Board of Directors. The Company does not anticipate declaring dividends for the foreseeable future.<br>|
| Limitations on Transfer | A subscriber's ability to transfer its shares of Common Stock will be severely restricted, and any such transfers will be subject to prior compliance with federal and state securities laws and the restrictions agreed to by the subscriber in the subscription agreement that accompanies this Term Sheet.<br>|
| Documentation; Risk Factors: | Each investment will be made pursuant to the Subscription Agreement provided by the Company, which will be entered into between the Company, on the one hand, and each respective subscriber, on the other hand. Each subscriber will also execute and deliver such additional documents relating to the subscription as the Company requests (the Subscription Agreement, together with this Term Sheet and all of the foregoing documents, the "<u>Subscription Materials</u>"). Investment in the Company involves significant risk, whether or not any prospective opportunity described in this Term Sheet is consummated. Prospective subscribers should review and consider these risks.<br>|
| Expenses | Each subscriber and the Company will be responsible for that party's own respective expenses incurred in connection with the negotiation and consummation of the transactions contemplated by this Term Sheet. |

---

 ****

 ****

## Exhibit 10.2

**Exhibit 10.2**

Confidential

**AMENDED AND RESTATED RESEARCH COLLABORATION AND NON-EXCLUSIVE LICENSE AGREEMENT**

**THIS AGREEMENT** is made and entered into as of July 22, 2024, by and between:

1. **NOVODX Corporation** a corporation organized and existing under the laws of the State of Delaware, with its principal office located at
 177 US Highway 1, Suite 309, Tequesta, Florida ()"**NOVODX** "); and

2. **Caring Brands Inc,** a corporation organized under the laws of the State Nevada, with its principal office located at 1061 E. Indiantown
 Road, Suite 110 Jupiter, Florida, 33477 ()"**CARING** ").

NOVODX and CARING are also sometimes hereinafter referred to as individually a "**Party**" and collectively the "**Parties**".

**<u>RECITALS</u>**

**WHEREAS**, NOVODX is a diagnostic company, focusing on health products related to rapid diagnostic screenings and their companion therapeutics. NOVODX is researching and developing rapid diagnostic devices for Over the Counter ("OTC") and Point of Care ("POC") with the ultimate focus of manufacturing, marketing and selling, directly and indirectly, those devices for at home diagnostic screening use; and

**WHEREAS**, NOVODX has the right to use (under license or otherwise) or owns certain assets and patents applications as well as related know-how, technology, scientific and other technical information (collectively, the GoldN™ Ebola Rapid Test Technical Information (as hereafter defined related to the development of an Ebola diagnostic test, the "Ebola Rapid Test"): and

**WHEREAS**, CARING is a company that engages in the development, marketing and sale of products intended to accelerate new treatments for women's and men's health for skin, hair metabolism and women's sexual health to access the market of such products for areas of unmet medical needs; and

**WHEREAS**, the Parties conducted initial exploratory due diligence and discussions under a Confidential Disclosure Agreement dated April 5th, 2024 (the "Confidentiality Agreement"); and

**WHEREAS**, the Parties wish to collaborate further in the development of an Ebola Rapid Diagnostic Test Kit which incorporates and is based upon the Ebola Rapid Test and will be marketed as the trademarked GoldN™ Ebola Rapid Diagnostic Test (the "Product") for POC products that is intended for use in the Research Field and Commercial Field (each as hereinafter defined) based upon the use of NOVODX's proprietary Know-How and technology, in accordance with and pursuant to, the terms, provisions and conditions of this Agreement; and

**WHEREAS,** the Parties are entering into this Agreement since the prior version of this Agreement had an error in the consideration to be received by NOVODX which is corrected in this Agreement.

1/22

**NOW THEREFORE**, in consideration of the covenants and agreements contained herein, and for other good and valuable consideration, each of NOVODX and CARING hereby agree as follows:

**1.**  **<u>Definitions and Interpretation</u>** 

1.1. In
 this Agreement the following words and expressions shall have the meanings set forth in this Section 1.1 as follows, unless any such
 term is defined elsewhere in the text of this Agreement:

---

| | |
|:---|:---|
| **Affiliate(s)** | means any company (corporation or limited liability company) or other entity which directly or indirectly controls, is controlled by or is under common control with, a Party, where "control" means the ownership of more than 50% (fifty percent) of the issued voting share capital or other equity interests or the legal power to direct or cause the direction of the general management and policies of a Party, or such company or other entity; |
| **Agreement** | means this Amended and Restated Research Collaboration and Non-Exclusive Licensing Agreement including all its exhibits hereto and any amendments to this Agreement that are made in accordance with this Agreement; |
| **Ebola Rapid Test** | means the asset being developed and licensed pursuant to this Agreement for collaboration and commercialization for research purposes in the Research Field and for commercial use in the Commercial Field once approved by the regulatory body governing the sales of the Product in the applicable geographical region where being sold; |
| **Research and Development Activities** | **means the research and development activities carried out by or under the control of NOVODX, or otherwise acquired by NOVODX, under license, sublicense or otherwise, to date, in order to develop the Ebola Rapid Test to its stage as of the date of this Agreement.** |
| **Change of Control** | means the occurrence of any of the following events: (i) any Third Party acquires control of (under the meaning of "control" set forth in the definition of Affiliate) CARING, directly or indirectly, by any means (including, without limitation, the acquisition, exchange or transfer of share or other equity interests); or (ii) CARING conveys, transfers, divests or leases (including general succession and all types of corporate split) in one or more transactions to any Third Party either: (x) all or substantially all of the assets of CARING or (y) all or substantially all of its assets that are material to the purpose of performance of its obligations under this Agreement; |
| **Licensing Target(s)** | means Ebola Rapid Test for OTC and POC targets for sales that are mutually agreed upon between the Parties; |
| **Commercial Field** | means any activities outside of the Research Field intended for OTC and or POC sales of the Licensed Product for use by consumers, whether directly or indirectly; |
| **Commercially Reasonable Efforts**<br>| means the effort, expertise and resources normally used by a similarly situated company in the same industry in the development or commercialization of a comparable product controlled by such company which is of similar market potential at a similar stage of development or commercialization in light of issues of safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the product, the regulatory structure involved, the profitability of the applicable products, product reimbursement and other relevant strategic and commercial factors normally considered by such a company in making product portfolio decisions;<br>|

---

2/22

---

| | |
|:---|:---|
| **Confidential Information** | **shall have the meaning given to that term in the Confidentiality Agreement, and shall also include any and all non-public information that are disclosed to or obtained by either Party directly or indirectly from the other Party at any time during the Term or prior to the Term under the terms and provisions of the Confidentiality Agreement, without regard to the form or manner in which such information is disclosed or obtained (including information disclosed orally, in documentary or electronic form or by way of model or obtained by observation) and including the terms of this Agreement, for which both Parties shall be discloser and recipient;** |
| **Good Manufacturing Practices or GMP**<br>| means the then-current Good Manufacturing Practices that apply to the manufacture of commercial rapid diagnostics devices (including clinical or commercial supply) applicable to the Licensed Product, including, the United States regulations set forth under the applicable provisions of the United States Code of Federal Regulations, as they may be amended from time-to-time, as well as all applicable guidance published from time-to-time by the FDA Good Manufacturing Practice and ISO13485 - Medical devices - Quality Management Systems or other applicable publications by the United States Food and Drug Administration (the "FDA");<br>|
| **510K/ EUA** | means a filing with the FDA or any other applicable Regulatory Authority that must be made prior to commencing commercialization and sale of a product such as the Ebola Rapid Test, to humans including (i) in the United States, and the regulations promulgated thereunder (21 CFR 312.1 et seq), including for Emergency Use Authorization, and (ii) in any other jurisdiction, a comparable filing and, in each case, any amendments and supplements thereto; |
| **Inventions** | means all inventions, whether or not patentable, that are discovered, made, conceived of, or reduced to practice by either Party in connection with any development, commercialization, or NOVODX Research Activities conducted under this Agreement with respect to the Ebola Rapid Test, the Product or any component thereof or in any manner from the collaboration by the Parties that is contemplated by this Agreement or by NOVODX in connection with manufacturing the Product; |
| **Know-How** | means, collectively, any and all inventions, discoveries, trade secrets and proprietary methods, whether or not patentable, owned or developed by or for NOVODX and implemented for the purpose of conducting the Research, Development and Commercialization of the Product to be trademarked as the GoldN™ Ebola Rapid Test, including: (a) methods of manufacture or use of, and structural and functional information pertaining to, chemical compounds and materials, (b) compositions of matter, data, formulations, processes, techniques, cell differentiation techniques and protocols, cell growth techniques and protocols, cell handling, cell assays and results, including preclinical, pharmaceutical, toxicological and clinical data, and (c) all aspects of the GoldN Rapid Ebola Test Technology; |
| **Licensed Product or Product** | means the GoldN™ Ebola Rapid Diagnostic Test; |
| **Net Sales** | means the gross amounts invoiced by CARING and its authorized distributors (any such distributor to be subject to the prior written approval of NOVODX in the sole discretion of NOVODX) for any Licensed Product sold or otherwise supplied on a commercial basis under the Commercial License (as hereafter defined) to Third Parties, less the following items to the extent that they are actually paid, allowed or granted (and not reimbursed to Caring Brands by a Third Party): |

---

(i) trade
 quantity and cash discounts customarily and actually allowed/ granted;

(ii) discounts,
 refunds, rebates, charge backs, and any other allowances actually granted which effectively reduce the net selling price or the net
 proceeds received;

3/22

(iii) product
 returns actually granted;

(iv) any
 tax imposed on the sale or delivery of the Licensed Product excluding federal, state or local taxes based on income) by an appropriate
 taxing authority of the applicable jurisdiction; and

(v) freight,
 postage, shipping, customs duties, excises and insurance charges actually allowed or paid for delivery of Licensed Products, to the
 extent included in the invoice.

---

| |
|:---|
| For the avoidance of doubt, none of the above items should be deducted from the gross invoice price in order to arrive at the calculation of Net Sales unless they are normally deducted from the gross invoice price in the reporting of revenues in accordance with United States Generally Accepted Accounting Principles (GAAP) in a manner consistent with CARING's normal practices used to prepare its audited financial statements for internal and external reporting purposes. |
| If any Licensed Product is sold or otherwise supplied by CARING on an arm's length commercial basis to Third Parties in the Territory under a capitated of bundling arrangement with other products or services, then such capitated arrangement or bundling arrangement, as applicable, shall be disaggregated for the purposes of revenue recognition and calculating Net Sales such that such Licensed Product included in such arrangement shall be deemed to be the same sales price and value it would have been allocated if it had been sold on a standalone basis in an arm's-length arrangement. |
| If any Licensed Product is sold or otherwise supplied by CARING other than at normal arms-length commercial terms exclusively for money (meaning other forms of consideration), the Net Sales of the Licensed Product sold or supplied shall be whichever is the higher of: |

---

(i) the
 Fair Market Value of such Licensed Products; or

(ii) the
 actual price at which the Licensed Product was sold,

---

| | |
|:---|:---|
|  | where "**Fair Market Value**" shall mean the value of the Licensed Product sold to companies in countries with similar pricing and reimbursement structures and for similar quantities as reasonably determined by NOVODX. |
| **Patent** | means an issued patent or pending patent application (which, for purposes of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country or region, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, re- examinations and extensions thereof which in any way relate to the Product; |
| **Regulatory Approval** | means, with respect to any country in the which the Product is to be sold, any approval, license, registration or authorization of any Regulatory Authority required for the manufacture, use, storage, importation, exportation, transport or distribution of the Product for use in such country; |
| **Regulatory Authority** | means any national, international, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity with authority having jurisdiction over the distribution, importation, exportation, manufacture, use, storage, transport, clinical testing, pricing, sale or reimbursement of the Licensed Product in the such jurisdiction; |

---

4/22

---

| | |
|:---|:---|
| **Regulatory Filings** | means, with respect to the Licensed Product, any submission to a Regulatory Authority of any appropriate regulatory application, including, without limitation, any 510K application, Emergency use Authorization ("EUA") and or other filing, any submission to a regulatory advisory board, any marketing authorization application, and any supplement or amendment thereto; |
| **Research Field** | means internal research purposes, including basic research and diagnostic discovery research and including 510k enabling studies or equivalents thereof and specifically excluding commercial sales and other activities that fall within the Commercial Field |
| **GoldN™ Ebola Rapid Test**<br> **Technical Information and**<br> **Know-How** | means the Know-How intellectual property existing at the Effective Date or hereafter development by or for NOVODX that is owned or controlled, under license or otherwise, by NOVODX related to rapid detection of Ebola virus via rapid diagnostic screening; |
| **Term** | means the period from Effective Date until the earlier of (x) the end of the Royalty Term and (y) the termination of this Agreement in accordance with its terms; |
| **Third Party** | means a person or entity other than NOVODX and CARING and the respective subsidiaries and Affiliates of any such person or entity; |
| **Valid Claim** | means any claim of (A) an unexpired Patent that a) has not been held unenforceable, unpatentable or invalid by a decision of a court or other government agency of competent jurisdiction, unappealable or has not been appealed within the time allowed for appeal and b) has not been admitted by NOVODX in any proceedings to be invalid or unenforceable, and (B) a pending patent application that confers provisional protection and has not been withdrawn, abandoned or finally rejected without the possibility of appeal or re-filing. |

---

1.2. In
 this Agreement, unless otherwise specified:

1.2.1. references
 to Sections are to the sections of this Agreement;

1.2.2. references
 to Exhibits are to the exhibits of this Agreement;

1.2.3. headings
 are used for convenience only and shall not affect the interpretation or construction of any term or provision of this Agreement;
 the words "include", "including" and "in particular" are to be construed as being by way of illustration
 or emphasis only and are not to be construed so as to limit the generality of any words preceding them;

1.2.4. the
 words "other" and "otherwise" shall not be construed as being limited by any words preceding them;

1.2.5. a
 reference to the singular includes a reference to the plural and vice versa and a reference to any gender includes a reference to
 all other genders; and

1.2.6. references
 to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to
 any subordinate legislation made under the statutory provision.

5/22

---

| | | |
|:---|:---|:---|
| **2.** | **<u>License</u>** |  |
| 2.1. | <u>Grant of License</u>. Subject to the terms and conditions set forth in this Agreement, NOVODX hereby grants to CARING during the Term only: | <u>Grant of License</u>. Subject to the terms and conditions set forth in this Agreement, NOVODX hereby grants to CARING during the Term only: |
|  | 2.1.1. | A non-exclusive license, without the right to sublicense or assign, under the Licensed Patents, when issued to NOVODX, and the GoldN™ Ebola Rapid Test Technical Information and Know-How to further use and market the Licensed Product in the Research Field only and during the Term in accordance with the directives and standards established by the JDC (as such term is hereinafter defined) and in accordance with the Research Plan (as such term is hereinafter defined) and only in those jurisdictions where NOVODX has a Valid Claim (the "**Research License**"); |
|  | 2.1.2. | A non-exclusive license, without the right to sublicense or assign, under the Licensed Patents, when issued to NOVODX, and GoldN™ Ebola Rapid Test Technical Information and Know-How to use, market and sell the Licensed Product within the Commercial Field only (the "**Commercial License**"). For avoidance of doubt, CARING shall not engage in any sales of the Licensed Product, directly or indirectly, through distributors or otherwise, under the Commercial License until such time as NOVODX has obtained 510K or EUA approval or authorization of the Licensed Product and then only in those jurisdictions where the Licensed Product can be sold and/or distributed under such approval or authorization and where NOVODX has a Valid Claim. |
|  | 2.1.3. | The current pending applications and/or Patents, as applicable for the Licensed Product and the status thereof is set forth on Exhibit A attached hereto. |
| 2.2. | <u>No other License; Retention of Rights</u>. Nothing in this Agreement shall be construed as conferring explicitly or by implication, estoppel or otherwise any license, right or immunity under any patents or patent applications or assets that NOVODX and/or its Affiliates, successors, assignees, licensors now owns or holds a license to, or acquires or obtains a license to in the future, other than the Licensed Research Patents and Licensed Patents and only as expressly permitted by this Agreement, regardless of whether such other patents or patent applications are dominant or subordinate to the Licensed Research Patents or Licensed Patents. This Agreement does not limit any of the rights under the Licensed Patents or the Ebola Rapid Test Technical Information and Know-How of NOVODX or any of its Affiliates, licensors, licensees, and/or their respective sublicensees and customers, in any way. In particular, NOVODX reserves the rights to itself, or through its Affiliates, to engage in any activity or business under the Licensed Patents, if applicable, and under the Ebola Rapid Test Technical Information and Know-How and to license to, assign to or otherwise exploit such rights directly and/or through Third Parties for any purpose whatsoever. CARING covenants and agrees that it shall not take any action, directly or indirectly, under the Research License or the Commercial License to enforce or extend the licensed rights thereunder without the prior written consent of NOVODX. | <u>No other License; Retention of Rights</u>. Nothing in this Agreement shall be construed as conferring explicitly or by implication, estoppel or otherwise any license, right or immunity under any patents or patent applications or assets that NOVODX and/or its Affiliates, successors, assignees, licensors now owns or holds a license to, or acquires or obtains a license to in the future, other than the Licensed Research Patents and Licensed Patents and only as expressly permitted by this Agreement, regardless of whether such other patents or patent applications are dominant or subordinate to the Licensed Research Patents or Licensed Patents. This Agreement does not limit any of the rights under the Licensed Patents or the Ebola Rapid Test Technical Information and Know-How of NOVODX or any of its Affiliates, licensors, licensees, and/or their respective sublicensees and customers, in any way. In particular, NOVODX reserves the rights to itself, or through its Affiliates, to engage in any activity or business under the Licensed Patents, if applicable, and under the Ebola Rapid Test Technical Information and Know-How and to license to, assign to or otherwise exploit such rights directly and/or through Third Parties for any purpose whatsoever. CARING covenants and agrees that it shall not take any action, directly or indirectly, under the Research License or the Commercial License to enforce or extend the licensed rights thereunder without the prior written consent of NOVODX. |
| 2.3. | <u>Commercialization</u>. During the Term, pursuant to the Commercial License CARING will use all Commercially Reasonable Efforts to maximize the sale of the Licensed Product by CARING and its authorized distributors, if any. | <u>Commercialization</u>. During the Term, pursuant to the Commercial License CARING will use all Commercially Reasonable Efforts to maximize the sale of the Licensed Product by CARING and its authorized distributors, if any. |
| **3.** | **<u>Financial Terms and Conditions.</u>** | **<u>Financial Terms and Conditions.</u>** |
| 3.1. | In consideration of the rights and licenses granted under this Agreement, CARING will pay the following compensation to NOVODX: | In consideration of the rights and licenses granted under this Agreement, CARING will pay the following compensation to NOVODX: |
|  | 3.1.1. | *<u>Initial Payment-Cash.</u>* Within 30 days of the date that a Registration Statement on Form S- 1 for a direct listing has been filed by CARING with the Securities and Exchange Commission (the "SEC") and is declared effective by the SEC, CARING shall pay to NOVODX the sum of $100,000 (One Hundred Thousand US Dollars) which amount shall be paid by wire transfer of funds to a bank account designated in writing by NOVODX and shall be non-refundable under any circumstances. (the Up-Front Payment"). |
|  | 3.1.2. | *<u>Initial Payment-Stock.</u>* As additional consideration for entering into this Agreement, promptly following the execution and delivery of this this Agreement, CARING shall issue to NOVODX 3,000,000 (three million shares of CARING's restricted common stock, which will contain a customary legend for restricted shares. |

---

6/22

---

| | | |
|:---|:---|:---|
|  | 3.1.3. | *<u>Milestone Payment-Authorization.</u>* Within thirty (30) days of NOVODX receiving 510 or EUA authorization/approval of the Licensed Product, CARING shall pay NOVODX the sum of $1,000,000 (US Dollars One Million) (the "Authorization Milestone Payment"). |
|  | 3.1.4. | *<u>Milestones Payment-Sales.</u>* CARING shall make a payment to NOVODX of $500,000 (US Dollars Five Hundred Thousand) within thirty (30) days of the calendar year during which when aggregate Net Sales of the Licensed Product reaches or exceed the following threshold indicated below: |
|  |  | $5,000,000 (US Dollars Five Million) (the "Sales Milestone Payment"; and the Authorization Milestone Payment and the sales Milestone Payment, collectively, the Milestone Payments"); The Milestone Payments resulting from section 3.1.2 and section 3.1.3 may be made in cash or in shares of the common stock of Caring Brands ("Shares") in the discretion of Caring Brands. If paid in Shares, the price of each Share shall be the average of the closing prices of the Shares for the immediately preceding seven (7) trading days in the principal securities exchange or market in which such Shares are traded, or if the Shares so not trade on a public securities exchange or market, at the price per Share in the then most recently closed round of institutional equity financing by Caring Brands. |
|  | 3.1.5. | *<u>Royalty.</u>* In addition to the Up-Front Payment and if applicable, the Milestone Payment, CARING shall pay royalties to NOVODX as follows." |
|  | (a) | *<u>CARING</u>* shall pay the following royalties to NOVODX: |
|  |  | |
|  | (i) | 5% (five percent) of Net Sales of Licensed Product for that portion of annual Net Sales that is less than $500 million; and |
|  | (ii) | 3% (three percent) of Net Sales of the Licensed Product for that portion of annual Net Sales that is equal to or greater than $500 million. |
|  | (b) | Royalties shall be payable on an aggregate basis for all sales of the Licensed Product in the Territory until the later of: (a) the expiration of the last Valid Claim that covers the Licensed Product in such country, or (b) the tenth anniversary of the date of the first commercial sale of the Licensed Product (the "**Royalty Term**"). Notwithstanding the forgoing, upon the termination of this Agreement in accordance with its terms by one of the Parties or the expiration of the Term of this Agreement, the Royalty Term shall automatically terminate; provided that CARING shall be obligated to pay the Royalty to NOVODX on all Net Sales made or committed to Third Parties by contract prior to the effective date of such expiration or termination. |
|  | (c) | Payments of the Royalty shall be made within thirty (30) days from the end of each calendar quarter during the Term and for any period after the Term for which Royalties are payable to NOVODX. It is understood and agreed by CARING that it shall not engage in any sales activities with respect to the Licensed Product under the Commercial License until such time as NOVODX obtains 510K or EUA approval/authorization and then only in those jurisdictions where there is a Valid Claim in effect with respect to the Licensed Product. For avoidance of doubt, the Royalty shall only be payable in cash. |
| 3.2. | Any and all amounts payable to NOVODX under this Agreement: | Any and all amounts payable to NOVODX under this Agreement: |
|  | 3.2.1. | Are exclusive of any taxes, which may be chargeable thereon, such as by way of example any Sales Tax, if any, which shall be paid by CARING directly to its competent tax authority; |

---

7/22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2.2. Shall
 be paid by wire transfer in US Dollars and in immediately available funds to a bank account of NOVODX designated in witing by NOVODX
 and identified to CARING from time to time by NOVODX.

3.2.3. Will
 be paid by CARING in US Dollars without deduction or withholding for taxes except to the extent that any such deduction or withholding
 is required by law in effect at the time of payment to be paid directly by NOVODX. CARING and NOVODX will cooperate with respect
 to all documentation required by any taxing authority or reasonably requested by CARING to secure a reduction in the rate of applicable
 withholding taxes or other taxes.

3.3. In
 case of dispute between the Parties for whatever reason, CARING has no right to withhold or suspend and CARING agrees that it shall
 not withhold or suspend any payments due to NOVODX under this Agreement. All amounts shall continue to be paid by CARING regardless
 of the dispute unless and until there is a final and non-appealable determination by a court of competent jurisdiction that that
 holds otherwise.

3.4. Payments
 are non-refundable and are not an advance or otherwise creditable against any other payments required to be paid under this Agreement.

3.5. Interest
 shall accrue on any payment due to be paid to NOVODX which is not made on the date such payment is due in accordance with this Agreement,
 at an annual interest rate equal to 5% (five percent) or the highest rate permissible by applicable law. Such interest shall accrue
 from the date the payment was originally due to NOVODX, until NOVODX receives payment in full (including all accrued interest). This
 Section shall in no way limit any other rights and remedies available to NOVODX, whether arising under this Agreement or at law or
 in equity.

3.6. Withholding
 taxes, if any, levied by a government of any country on payments made by CARING to NOVODX hereunder shall be borne by CARING and
 the amount of the payment shall be gross- up for the amount withheld. CARING shall lend its support to NOVODX to avoid any double
 taxing and provide it upon simple request with any document requested by NOVODX that necessary for this purpose. CARING shall use
 commercially reasonable efforts to help NOVODX claim exemption there from under any double taxation or similar agreement in force
 and shall produce to NOVODX proper evidence of payment of all withholding tax.

**4.**  **<u>Reports.</u>** 

4.1. Within
 30 (thirty) days after the end of each calendar quarter during the Term and thereafter (until no further Royalties are paid to NOVODX)
 and whenever the Milestone Payment or a Royalty is paid to NOVODX, CARING will provide a report to NOVODX (the "**Report** "),
 in reasonable detail satisfactory to NOVODX, reflecting the Net Sales and milestone events made for the period covered by the Report,
 including the quantity and identification of the Licensed Product sold in the Territory together with details of Net Sales calculation,
 royalty calculation and details of any deductions made, and any threshold achieved reached during the reporting period. Even if no
 Milestone Payment is due and/or no Royalty payable for a quarter, CARING shall provide NOVODX the Report certifying that no amount
 is payable to NOVODX for the applicable period.

4.2. CARING
 shall keep complete and accurate records of the Net Sales and any sales made for non- cash consideration, in accordance with GAAP
 and in sufficient detail to enable a determination of the amounts payable to NOVODX under Section 3 and to provide the Reports contemplated
 by Section 4.1 (the "**Records** "). NOVODX shall have the right to audit the Records no more than once in each calendar
 during the during the Term and within sixty (60) days after the last payment to NOVODX hereunder on provision of not less than 30
 (thirty) days written notice from NOVODX to CARING. Any audit shall be carried out within CARING business hours and CARING shall
 provide access to all documentation related to sales and supplies of the Licensed Product and calculation of the Milestone Payment
 the Royalty, Net Sales, and other sums due under the Agreement. CARING shall pay any underpayment of a Royalty payment identified
 by NOVODX following an audit under this Section 4.2 within thirty (30) days after receipt of an invoice from NOVODX which NOVODX
 will furnish to CAARING within thirty (30) days after completion of the audit. The invoice shall set forth in reasonable detail NOVODX's
 calculation of any such underpayment.

8/22

4.3. Where
 the audit report resulting from an audit under Section 4.2 identifies an underpayment of the Royalty of more than 5% (five percent)
 of total Royalty payable to NOVODX, CARING shall reimburse NOVODX for all costs and expenses incurred by NOVODX in carrying out the
 audit.

**5.**  **<u>Governance.</u>** 

5.1. <u>Alliance Managers</u>. Each Party will appoint one of its employees to be designated as the alliance manager (each and "Alliance Manger")
 to be the main point of contact for the other Party to exchange information, facilitate communication and coordinate the Parties'
 activities and obligations under this Agreement relating to Licensed Product (including all research, development and sales activities).

5.2. <u>Establishment of Joint Research Committee</u>. Within 30 (thirty) days of the Effective Date, NOVODX and CARING shall establish a joint development
 committee (the "**JDC** "). The JDC shall have and perform the responsibilities set forth in this Section 5; provided,
 that, the JDC shall have no authority to amend this Agreement or to grant any waivers of a Party's obligations hereunder.

5.3. <u>Membership</u>.
 Each Party's Alliance Manager or another representative designated by a Party in writing shall represent such Party in the
 JDC. The JDC may change its size from time to time by mutual written consent of the Parties (which consent may be withheld by either
 Party at its sole discretion) and each Party may replace its representatives at any time upon written notice to the other Party.

5.4. <u>Meetings</u>.
 The JDC shall meet on a regular basis, no less frequently than quarterly. In addition, each Party shall have the right to call a
 special meeting of the JDC upon not less than ten (10) days prior written notice given by the Party calling the special meeting.
 The meetings of the JDC may be held telephonically or by Zoom, Microsoft Teams or similar electronic means. An action of the JDC
 will only be authorized if it is approved by the representative of each Party then serving on the JDC.

**6.**  **<u>Research and Development Activities.</u>** 

6.1. <u>Research Plan</u>. In collaboration with each other to further develop and enhance the Ebola Rapid Test, during the Term, the Parties shall
 reasonably collaborate with each other to develop a pre- clinical research or other plan for the Licensed Product (each a "Research
 "Plan"), on a basis determined by the JDC. In furtherance thereof, the Parties shall promptly and in good faith discuss
 any questions or concerns that either Party may have with respect to a given portion of the proposals set forth in a draft Research
 Plan. Once mutual agreement is reached for a target/goal of all or part of a Research Plan (the "Collaboration Target")
 the Parties, through their representatives on the JDC, shall agree on the action steps to be taken to implement the applicable Collaboration
 Target (the "Collaborative Research and Development Activities"). Each Party may propose amendments to a given Research
 Plan and/or a Collaboration Target from time-to-time, but any such amendment shall be subject to the mutual written agreement of
 the Parties prior to being implemented.

6.2. <u>Conduct of Research Plan</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2.1. *<u>NOVODX Responsibilities</u>* 

(a) NOVODX
 shall perform those activities designated in the applicable Research Plan to be performed by NOVODX (the "Research and Development
 Activities") in accordance with the Research Plan with respect to the applicable Collaboration Target, at NOVODX' own
 cost and expense.

9/22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At
 such time as NOVODX has completed its Research and Development Activities with respect to a given Collaboration Target in accordance
 with the Research Plan, it shall provide the results thereof (including any physical materials, if applicable), to CARING together
 with a report on the Research and Development Activities to the extent that have not been previously reported to CARING.

6.2.2. *<u>CARING Responsibilities</u>* 

(a) If
 requested by NOVODX or authorized by the JDC, CARING shall provide NOVODX with such reasonable assistance as NOVODX may reasonably
 request with respect to the Research and Development Activities as requested by NOVODX.

6.2.3. <u>Costs</u>.
 Each Party will be responsible for all of its own costs and expenses associated with its activities under each Research Plan.

6.3. <u>Record Keeping</u>. During the Term, each Party shall maintain complete and accurate records (paper or electronic as applicable) of its
 Research and Development Activities under the Research Plan and with respect to each applicable Collaboration Target. in sufficient
 detail, including for purposes of making Patent filings, in good scientific manner, or otherwise in a manner that reflects all work
 done and results achieved.

**7.**  **<u>Regulatory Activities related to Research and Development Activities.</u>** 

7.1. <u>Responsibility for Research and Development</u>. As between the Parties, NOVODX shall oversee and control all regulatory activities related to the
 Research and Development Activities in accordance with the Research Plan.

7.2. <u>Development Assistance</u>. During the Term, at the request of NOVODX, CARING shall use Commercially Reasonable Efforts during the Term to assist
 NOVODX with its Research and Development Activities with respect to the Licensed Product.

7.3. <u>Progress Reports</u>. During the Term, each Party shall keep the other Party fully informed on a timely basis of the Research and Development
 Activities related activities conducted by such Party, including, without limitation, providing a high-level summary of material
 clinical trial-related progress, schedules, anticipated events, and milestones, which summaries shall include relevant activities
 conducted and being considered.

7.4. <u>Regulatory Matters</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4.1. *<u>Regulatory Filings</u>* . As between the Parties, NOVODX shall have the sole right and responsibility for (i) preparing, filing and maintaining
 all Regulatory Filings for Licensed Product and any related development products, and (ii) reporting to Regulatory Authorities all
 adverse, including serious, events occurring in any clinical trial conducted by or on behalf of NOVODX or CARING pursuant to this
 Agreement related to Licensed Products, to the extent required by all applicable laws

7.4.2. *<u>Licensed Product-Related Regulatory Interactions</u>* . NOVODX shall be solely responsible for any communications with any Regulatory Authorities
 regarding the Licensed Product. In the event that CARING receives any communication directly from a Regulatory Authority regarding
 Licensed Products being developed, commercialized, or otherwise exploited, by or on behalf of CARING, then CARING shall immediately
 furnish a copy of the communication to NOVODX, and CARING shall not respond to the communication or take any action without first
 consulting with NOVODX and obtaining the prior concurrence of NOVODX to the proposed response.

10/22

**8.**  **<u>Manufacture And Supply.</u>** 

8.1. GoldN™
 Ebola Rapid Diagnostic Test Supply-Research. NOVODX will supply CARING with GoldN Ebola Rapid Diagnostic Test of Licensed Product,
 in such quantities as are set forth in the Research Plan for CARING to meet its obligations with regard to a particular Collaboration
 Target in accordance with the Research Plan or as otherwise agreed upon by the JDC, in accordance with the terms and provisions (including
 those with respect to quantities and pricing) of a Supply Agreement to be negotiated in good faith by the Parties. Transfer price
 shall not be in excess of 10% of manufacturing cost.

8.2. GoldN™
 Ebola Rapid Diagnostic Test Supply. In anticipation of Patents being issued to NOVODX for the Licensed Product, the Parties shall
 reasonably promptly after the execution and delivery of this Agreement, negotiate in good faith a separate Supply Agreement (the
 "Supply Agreement") pursuant to which NOVODX will agree to have manufactured and supplied to CARING units of Licensed
 Product in order for Caring to maximize potential sales under the Commercial License, upon such terms and provisions, as the Parties
 shall mutually agree upon, including, without limitation, pre-payments by CARING prior to commencing manufacturing for any requested
 quantity of Licensed Products. At the option of NOVODX, either (i) NOVODX will enter into arrangements with Third Party manufacturers
 to manufacture the Licensed Products for the Supply Agreement or (ii) allow the Licensed Product to be manufactured directly for
 CARING under direct agreements between CARING and the manufacturers, the terms and provisions of which will be subject to the approval
 of NOVODX. If NOVODX chooses alternative set forth in clause (ii) of the immediately preceding sentence, NOVODX and CARING shall
 negotiate in good faith a possible expansion of the Commercial License in order to enable CARING or such Third-Party manufacturer
 to directly manufacture GMP grade GoldN™ Ebola Rapid Diagnostic Tests within the limit of the Commercial License. CARING shall not,
 and shall ensure that any authorized Third-Party Manufacturer shall not, use the GoldN Rapid Test Technology and Know-How for any
 other purpose other than the manufacture of GMP grade GoldN Ebola Rapid Diagnostic Tests as contemplated by this Section 8.2.

8.3. <u>Compliance</u>.
 CARING hereby covenants and agrees that (i) the use or sale or transfer by CARING or its Affiliates (as applicable) shall comply
 with all applicable laws and regulations, including, without limitation, all federal export laws and regulations and (ii) if CARING
 is responsible for or overseeing the manufacture it will use Commercially Reasonable Efforts such that the Licensed Product shall
 not be defective in manufacture.

**9.**  **<u>Intellectual Property Rights</u>** 

9.1. <u>Background Technology/Patents</u>. As between the Parties each Party shall own and retain all right, title and interest in and to any and all
 Patents and Know-How that are owned, licensed to, or otherwise controlled by such Party or any of its Affiliates, existing prior
 to the Effective Date or otherwise generated outside and independently of this Agreement, and the other Party shall not acquire any
 right, tile or interest therein by virtue of this Agreement.

9.2. <u>Ownership of Inventions and Know-How</u>.

---

| | |
|:---|:---|
| 9.2.1. | As between the Parties all rights, title and interest in any Inventions or Know-How conceived or created or first reduced to practice in connection with the exercise of rights or performance of obligations under this Agreement, on a Collaboration Target basis, during the Term with respect to such Collaboration Target, to the extent: |
| (a) | All Inventions, intellectual property and Know-How developed by or for NOVODX relating solely and specifically to (i) GoldN Ebola Rapid Diagnostic Test, (ii) design files and technologies, or (iii) stability related technologies, shall be owned solely by NOVODX ("**NOVODX Inventions**"), |

---

11/22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any
 Patents claiming or based upon a NOVODX Invention shall be referred to as "**NOVODX Patents** ". Any Inventions, intellectual
 property and Know-how developed by CARING alone or together with NOVODX in any way relating to or derived from the Licensed Product
 shall be considered a Joint Invention (a "Joint Invention"), invented by, and owned equally (on 50%-50% basis) by NOVODX
 and CARING. Any Patents claiming or based upon a Joint Invention shall be referred to as "**Joint Patents** ". Any
 exploitation of a Joint Patents shall be subject to the mutual agreement of NOVODX and CARING which the Parties will attempt to negotiate
 in good faith should the occasion arise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2.2. *<u>Notice, Assignments, Assistance</u>* 

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each
 Party shall (i) promptly notify the other Party of any Joint Invention (i.e., as described in Section 9.2.1) made by or on behalf
 of such Party or Parties, as applicable, and that would constitute a Joint Invention hereunder , and (ii) hereby assigns, transfers
 and conveys to the other Party, or its designee, fifty percent (50%) of such Party's worldwide right, title and interest in
 and to any and all such Joint Inventions or the related technology and Know-How that has been developed and/or invented by the assigning
 Party by such other Party in accordance with Section 9.2.1, including any and all moral rights and intellectual property rights inherent
 therein and appurtenant thereto, including the right in the case of NOVODX to make, and in the case of CARING, to be included as
 a 50% owner in, all applications for Patents, copyrights, trademarks, and all trade secrets and the rights to apply to any of the
 foregoing.

(b) Upon
 the request and at the reasonable expense of the other Party, each Party shall execute and deliver any and all instruments and documents
 and take such other acts as may be necessary or desirable in the reasonable opinion of the other Party to document and implement
 the assignment and transfer described in Section 9.2.2 or to enable such other Party to secure its rights in the applicable Joint
 Invention. Without limiting the foregoing, to the extent a Party is not available, or is unwilling to provide such assistance, within
 30 (thirty) days of a request therefor, the unavailable/unwilling Party hereby grants to the requesting Party a limited power of
 attorney to take such actions, and file such documents, on such unavailable/unwilling Party's behalf as may be necessary to
 secure such rights.

9.3. <u>Patent Prosecution</u>

9.3.1. *<u>NOVODX Patents</u>* . NOVODX shall be solely responsible for the filing, maintenance, prosecution and defense of the NOVODX Patents. CARING
 shall cooperate with and assist NOVODX, at the cost and expense of NOVODX, in all reasonable aspects in connection with NOVODX Patents
 prosecution (including review and comments regarding responses to office actions or official actions from worldwide patent offices)
 and NOVODX Patents defense, including by obtaining assignments to reflect chain of title consistent with the terms of this Agreement.
 All costs incurred by NOVODX in connection with the prosecution and defense of such NOVODX Patents shall be the sole responsibility
 of NOVODX.

9.3.2. *<u>Joint Patents</u>* . In the event the Parties conceive or generate any Joint Invention, the Parties will promptly meet to discuss and
 determine, based on mutual consent, whether to seek patent protection thereon. NOVODX will have the first right to file, maintain,
 prosecute and defend any Joint Patent. CARING shall cooperate with and assist NOVODX in all reasonable respects in connection with
 Joint Patent filing, prosecution and defense, which shall be controlled and overseen by NOVODX. All costs and expenses (a) incurred
 by NOVODX in connection with the filing, maintenance, prosecution and defense of such Joint Patents and (b) incurred by CARING in
 providing any such cooperation and assistance shall be equally (on a 50-50 basis) shared between the Parties. CARING shall not independently
 seek any Patent protection or other intellectual property protection with respect to any Joint Invention, any Joint Patent or any
 of its activities in any way related to, directly or indirectly, the Research and Development Activities contemplated by this Agreement
 or the results or proceeds from such activities.

12/22

9.4. <u>Enforcement; Third Party Infringement</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4.1. If
 either Party becomes aware of any suspected infringement of any NOVODX Patent or Joint Patent or other violation of related intellectual
 property rights by any Third Party (each, an "**Infringement** "), that Party shall promptly notify the other Party
 in writing of such Infringement of which it is aware (each, an "**Infringement Notice** ").

9.4.2. Except
 as provided under Section 9.4.3 below, NOVODX shall have the sole right, but not the obligation, to manage and prosecute any Infringement
 action or other response to an Infringement (an "**Infringement Response**") of any NOVODX Patent or a Joint Patent.
 NOVODX shall have the first right, but not the obligation, to manage, control and prosecute any Infringement Response with respect
 to any of the Joint Patents. NOVODX shall promptly notify CARING in writing if NOVDX does not assuming the Infringement Response.
 If NOVODX does not assume the management and prosecution of an Infringement Response to a Joint Patent, CARING shall have the right,
 but not the obligation, to assume control of the Infringement Response.

9.4.3. Each
 Party shall keep the other Party notified of an Infringement Response for that it is managing as provided in this Article 9. The
 other Party shall provide reasonable assistance to the Party that is managing the Infringement Response if requested by the managing
 Party. CARING shall provide all reasonable cooperation to NOVODX in connection with any such Infringement Response that is being
 managed by NOVODX. If NOVODX does not intend to prosecute or defend an Infringement of, or ceases to diligently pursue an Infringement
 Response with respect to, s an Infringement of one or more Joint Patents, it shall promptly inform CARING in such a manner that such
 Infringement Response will not be prejudiced and CARING may elect to exercise those rights, including, in NOVODX's name with
 respect to said Joint Patents. In such case NOVODX shall execute all instruments reasonably requested by CARING in order for CARING
 to assume and manage the prosecution of the Infringement Response to a Joint Patent. All costs, including attorneys' fees and
 expenses, relating to an Infringement Response that NOVODX has decided not to pursue or control shall be borne solely by CARING and
 CARING shall have sole discretion in settling any such Infringement Response: provided that CARING shall not, except with the prior
 written approval of NOVODX, take any actions or agree to any settlement terms that would limit the scope or protection, or jeopardize
 the Licensed Patent. For clarity, the settlement of an Infringement Response for a Joint Patent may involve entering a (sub)licensing
 agreement, which sublicensing agreement requires NOVODX' prior approval.

9.4.4. CARING
 shall have the right to participate and be represented by counsel that it selects, at CARING's sole cost and expense, in any
 Infringement Response instituted or controlled in relation to NOVODX Patents.

9.4.5. In
 any Infringement Response instituted under this Section 9.4, the Parties shall cooperate with and assist each other in all reasonable
 respects. Upon the reasonable request of the Party controlling the Infringement Response with respect to a Joint Patent, the other
 Party shall join such Infringement Response and shall be represented using counsel of its own choice.

9.4.6. In
 addition, any settlements, damages or monetary awards ()"**Recovery**") recovered pursuant to any Infringement Response
 shall, after reimbursing the Parties for their reasonable out-of-pocket expenses in making such recovery, be retained one hundred
 percent (100%) by NOVODX in the case of an Infringement Response with respect to a NOVDX Patent and fifty percent (50%) each with
 respect to an Infringement Response to a Joint Patent.

13/22

9.5. <u>Defense of Claims</u>. If any action, suit or proceeding is brought against either Party or any Affiliate of either Party alleging the misappropriation
 or infringement of the know-how or Patents of a Third Party by reason of the research, development, manufacture or commercialization
 of any Licensed Product in the Research Field or the Commercial Field or component thereof, such Party shall notify the other Party
 within 5 (five) days of the earlier of (a) receipt of service of process in such action, suit or proceeding, or (b) the date such
 Party becomes aware that such action, suit or proceeding has been instituted and the Parties shall meet as soon as possible to discuss
 the overall strategy for defense of such matter. Except as unanimously agreed by the Parties, (i) CARING shall have the right but
 not the obligation to defend such action, suit or proceeding at its sole expense; (ii) NOVODX shall have the right to have a separate
 counsel at its own expense in any such action, suit or proceeding; and (iii) the Parties shall cooperate with each other in all reasonable
 respects in any such action, suit or proceeding, including being joined as a named party. Each Party shall promptly furnish the other
 Party with a copy of each communication relating to the alleged infringement that is received by such Party including all documents
 filed in any litigation. Notwithstanding the foregoing, CARING shall not take any actions that would intentionally limit the scope
 or protection, or intentionally jeopardize NOVODX Patents or Know-How.

**10.**  **<u>Compliance</u>** 

10.1. <u>Applicable Laws</u>. Each Party shall perform its obligations hereunder in compliance with all applicable laws and regulations.

10.2. <u>Compliance with Anti-Corruption Laws</u>. In furtherance of Section 10.1, each Party agrees that connection with this Agreement, each such Party
 will comply with all applicable laws and regulations in connection with government procurement, conflicts of interest, corruption
 or bribery, including, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any laws enacted to implement
 the OECD Convention on Combating Bribery of Foreign Officials in International Business Transactions.

10.3. <u>Prohibited Conduct</u>. In connection with this Agreement, each Party represents and warrants to the other Party that it has not made, offered,
 given, promised to give, or authorized, and will not make, offer, give, promise to give, or authorize, any bribe, kickback, payment
 or transfer of anything of value, directly or indirectly, to any person, entity or to any government official for the purpose of:
 (a) improperly influencing any act or decision of such person, entity or government official; (b) inducing such person, entity or
 government official to do or omit to do an act in violation of a lawful or otherwise required duty; (c) securing any improper advantage;
 or (d) inducing such person, entity or government official to improperly influence the act or decision of any organization, including
 any government or government authority or instrumentality, to assist NOVODX or CARING in connection with its performance of its obligations
 hereunder or in connection with obtaining or retaining business.

10.4. <u>Export and Regulatory Compliance</u>. CARING acknowledges and understands that the Arms and Export Control Act (AECA), including its implementing
 International Traffic In Arms Regulations (ITAR) and the Export Administration Act (EAA), including its Export Administration Regulations
 (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. CARING further acknowledges
 and understands that the U.S. export laws and regulations include, but are not limited to the following: (i) the ITAR and EAR product/service/data-
 specific requirements; (ii) ITAR and EAR ultimate destination-specific requirements; (iii) ITAR and EAR end user-specific requirements;
 and (iv) antiboycott laws and regulations. During the Term, CARING shall comply with all then-current applicable export laws and
 regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed Product. CARING certifies
 and warrants that it shall not, directly or indirectly export, nor re-export the Licensed Products in violation of U.S. export laws
 and regulations or other applicable U.S. laws and regulations.

14/22

10.5. <u>Governmental Marking</u>. Once NOVODX obtains a Patent for the Licensed Product, NOVODX shall immediately inform CARING of that fact, and CARING,
 at its cost and expense. shall mark all Licensed Products in its possession or control or in the possession and control of one of
 its authorized distributors, if applicable, with a patent notice under, and in compliance with, 35 U.S.C. § 287. Nothing contained
 in this provision shall be deemed an admission that the requirements of 35 U.S.C. § 287 are applicable to such Licensed Products.
 CARING shall not be in violation of this Agreement if, in good faith, it removes such notice upon being notified by NOVODX or an
 appropriate Regulatory Authority that the marking provided for under this Section 10.5 is in violation of 35 U.S.C. § 292, or
 any other applicable law.

**11.**  **<u>Confidentiality</u>** 

11.1. During
 the Term and for a period of 10 (ten) years thereafter, each Party agrees to keep the Confidential Information of the other Party
 in strict confidence and not to disclose such Confidential Information to any Third Party.

11.2. The
 Parties may provide Confidential Information of the other Party to such of its officers, directors, employees, consultants, attorneys,
 and agents (each "Representative") who reasonably require access to it for the purpose of fulfilling the receiving Party's
 obligations under this Agreement; provided that before any of the disclosing Party's Confidential Information is disclosed
 to any of them, they are made aware of its confidential nature of the Confidential Information and that they are under a legally-binding
 obligation to the disclosing Party to treat that Confidential Information in the strictest confidence in accordance with the terms
 of this Agreement, which they shall confirm in a written instrument concurrently with their access to any Confidential Information.
 A Party shall be liable for any breach by one of its Representatives of such Representatives confidentiality obligations as contemplated
 hereby.

11.3. Each
 Party may disclose the terms of this Agreement to its Affiliates, licensors and investors provided that prior to disclosure such
 Affiliates, licensors and investors are under a legally-binding obligation to treat such information as confidential pursuant to
 a confidentiality agreement approved by the initial disclosing Party of the confidential Information.

11.4. The
 undertakings of Section 11.1 shall not apply to information that the recipient of such information can demonstrate by clear and convincing
 evidence that (thus such information shall not be considered Confidential Information):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) at
 the time of disclosure, said information was published publicly or otherwise generally available to the public; or

(b) after
 disclosure by the disclosing Party, said information was published or became generally available to the public otherwise than through
 any act or omission on the part of the recipient; or

(c) said
 information was in recipient's possession at the time of disclosure and was not acquired directly or indirectly from the discloser
 including from a Third Party which was to recipient's reasonable knowledge not under obligation of secrecy/confidentiality
 to the discloser; or

(d) said
 information was developed independently by the recipient with no reference to the Confidential Information of the Disclosing Party.

11.5. Neither
 Party will be in breach of its obligations under Section 11.1 to the extent that it is required to disclose any Confidential Information
 of the other Party under any law or by or to a court or other public, regulatory or financial authority or stock exchange that has
 jurisdiction over it: provided that (i) the Party compelled to make the disclosure gives the other Party written notice prior to
 disclosing the Confidential Information and that the disclosure is made only to the extent required and for the purpose of complying
 with the requirements and (ii) the Party compelled to make disclosure cooperates with the other Party, at such other Party's
 cost and expense with any reasonable efforts by such other Party to restrain or limit such disclosure.

15/22

11.6. Neither
 Party will use the other Party 's name or logo or with respect to name or logo, in any press release or product advertising,
 or for any other promotional purpose, without first obtaining the other Party's written consent, which may be granted or withheld
 in such other Party's sole discretion. Neither Party will, without the prior written consent of the other Party, issue any
 public announcement or press release relating to this Agreement or the terms of this Agreement or to the fact that the Parties have
 entered into this Agreement, unless a press release or other public announcement is required to be made by applicable law in which
 case the issuing Party will endeavour to accommodate the reasonable comments of the other Party before issuing the public announcement
 or press release.

11.7. To
 the extent there is a conflict between the terms of this Section 11 and those set forth in the Confidentiality Agreement, the terms
 and provisions of this Agreement shall control.

**12.**  **<u>General Representations and Warranties.</u>** 

12.1. NOVODX
 represents, and warrants to CARING that as of the Effective Date as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1.1. It
 is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware;

12.1.2. It
 has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder;

12.1.3. Its
 execution, delivery and performance of this Agreement has been duly authorized by applicable corporate power and authority, and this
 Agreement constitutes it legal, valid and binding obligation enforceable against it in accordance with its terms, except as enforceability
 may be limited by applicable bankruptcy and insolvency laws and general principles of equity applicable to creditors rights: and

12.1.4. Its
 execution, deliver and performance of this Agreement does not and will not violate its By-laws or cause a violation or breach any
 agreement, contract, court order or similar restriction to which it is a party or is otherwise bound or subject.

12.2. CARING
 represents and warrants to NOVODX that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2.1. It
 is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada;

12.2.2. It
 has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder enter into and agree the
 terms of this Agreement;

12.2.3. Its
 execution and delivery of this Agreement and the performance of its obligation hereunder have been duly authorized by all applicable
 corporate power and authority, and this Agreement constitutes its legal, valid and binding obligation, enforceable against in it
 accordance with its terms, except as enforceability may be limited by applicable bankruptcy and insolvency laws and general principles
 of equity applicable to creditors rights; and

12.2.4. Its
 execution, delivery and performance of this Agreement does not and will not violate of contravene it By-Laws or cause a violation
 or breach of any contract, court order or other similar restriction to which it is a party or is otherwise bound or subject;

12.2.5. It
 shall at all times use the Research License and the Commercial License granted to it under the Agreement in compliance with all applicable
 laws and regulations; and

12.2.6. Its
 marketing and sale of Licensed Products shall comply with all applicable laws and regulations.

16/22

12.3. Except
 as otherwise expressly set forth in Section 12.1, NOVODX makes no other representations and warranties regarding the GoldN™ Ebola
 Rapid Diagnostic Test, Licensed Patents or Licensed Product, whether express or implied, including without limitation any warranty
 regarding their use, safety, efficacy, performance, or fitness for a particular purpose, any warranty of merchantability or any warranty
 or representation that the GoldN™ Ebola Rapid Diagnostic Test, Equipment and anything made, used, sold, or otherwise disposed of
 under the Research License and the Commercial License granted under this Agreement is or will be free from infringement of patents,
 copyrights, and other rights of Third Parties or any other express or implied legal or contractual warranty. In no event shall NOVODX
 be liable for incidental or consequential damages of any kind, including economic damage or injury to property and lost profits,
 regardless of whether NOVODX shall be advised, shall have other reason to know, or in fact shall know of the possibility of the foregoing.
 NOVODX shall not incur any liability to CARING resulting from the supply or use of the GoldN™ Ebola Rapid Diagnostic Test and/or
 the Equipment.

12.4. CARING
 hereby release NOVODX and its regents, employees and agents forever from any and all suits, actions, claims, liabilities, demands,
 damages, losses, or expenses (including reasonable attorney's and investigative expenses) relating to the use or other disposition
 of a GoldN™ Ebola Rapid Diagnostic Test.

12.5. Throughout
 the Term, CARING shall maintain, in full force and effect comprehensive general liability ("CGL") insurance, with single
 and aggregate claim limits reasonably acceptable to NOVODX.

**13.**  **<u>Limitation of Liability</u>** 

13.1. Nothing
 in this Agreement limits or excludes any Party's liability for (a) death or personal injury caused by its negligence; (b) fraud;
 or (c) any sort of liability that, by law, cannot be limited or excluded.

13.2. CARING
 shall defend, indemnify and hold harmless NOVODX, its Affiliates, and their respective officers, directors, employees, representatives
 and licensors (together the "**Indemnitees**") from and against any and all liability, demands, claims, damages, expenses
 (including attorney's fees) and losses, direct or indirect, arising (i) its breach of this Agreement, the Research License
 or the Commercialization License; (ii) a breach of any representation or warranty made by CARING herein or in connections with transactions
 contemplated hereby, and (iii) the use of the Licensed Product in an manner outside the scope of, or in a manner inconsistent with,
 the Research License or the Commercial License by CARING, its successors, assignees, customers or clients.

**14.**  **<u>Term and Termination</u>** 

14.1. <u>Term</u>.
 This Agreement will become effective on the Effective Date and will remain in force and effect for the Term, unless earlier terminated
 as provided for herein.

14.2. <u>Termination</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2.1. CARING
 may terminate this Agreement, in its entirety or on a Collaboration Target basis, at any time upon not less than 90 (sixty) day's
 prior written notice to NOVODX for convenience and for no reason whatsoever, such termination to take effect on the date set forth
 in the notice. All sums due and owed by CARING prior to the effective date of termination of this Agreement shall remain due and
 payable and NOVODX shall have no obligation to reimburse any payment previously made by CARING.

14.2.2. NOVODX
 may terminate this Agreement by giving written notice to CARING, at any time upon not less than ten (10) business days' notice
 to CARING for convenience and for no reason whatsoever, such termination to take effect on the date set forth in the notice. NOVODX
 shall also have the right to terminate this Agreement immediately upon written notice the CARING upon a Change of Control with respect
 to CARING or as otherwise stated in the notice, in case of any Change of Control of CARING (other than a change in control resulting
 solely from internal restructuring measures within the corporate group of CARING).

17/22

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2.3. Either
 Party may terminate the Agreement if CARING is in breach of any material provision of this Agreement or in any material representation
 and warranty made herein and, the breach is not remedied within 30 (thirty) days after receipt of written notice specifying the breach,
 or within ten (10) days by NOVODX is CARING is in breach of any of its payment obligations to NOVODX pursuant to this Agreement.

14.2.4. Either
 Party may (without limiting any other remedy it may have) at any time terminate this Agreement with immediate effect by giving written
 notice to the other Party if the other Party becomes insolvent, becomes subject to bankruptcy proceedings (which if involuntary such
 proceedings are not dismissed within sixty (60) days after they are commenced) or if an order is made or a resolution is passed for
 its winding up (except voluntarily for the purpose of solvent amalgamation or reconstruction), or if an administrator, administrative
 receiver or receiver or other similar officer is appointed over the whole or a substantial part of the other Party's assets,
 or if the other Party makes any arrangement or assignment of with its creditors or ceases to carry on business or does or suffers
 any similar or analogous act existing under the laws of any country.

14.3. <u>Effect of termination</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.3.1. Termination
 of this Agreement will not release any Party from any obligation or liability which has which accrued or was performed or was due
 or in any way arose before the effective date of termination of this Agreement.

14.3.2. Upon
 termination or expiration of the Agreement, the Research License and the Commercial License granted herein shall automatically terminate
 and all rights granted revert to NOVODX whereupon CARING shall have no further right to use, market, distribute or sell the Licensed
 Product and CARING shall immediately cease any such use or such other activities.

14.3.3. Upon
 termination or expiration of the Agreement, CARING shall immediately cease to use and shall return to NOVODX or destroy, at NOVODX'
 option, all NOVODX' Confidential Information and all physical GoldN™ Ebola Rapid Diagnostic Tests in its possession, within
 10 (ten) days. CARING shall promptly send written confirmation of destruction to NOVODX, where appropriate.

**15.**  **<u>General</u>** 

15.1. <u>Notices</u>.
 Any notice to be given under this Agreement must be in writing and may be delivered to the other Party by hand or courier (in which
 case any such notice it shall be deemed received on the business day of delivery or on the first business day after delivery if delivered
 on a day which is not a business day) or by a means of overnight delivery from a recognized overnight delivery service (such as Federal
 Express by example) (in which case the notice shall be deemed received the next business day after being furnished to the delivery
 service for next day delivery, as evidenced by the receipt from such service). The Parties' respective representatives for
 the receipt of notices are, until changed by notice given in accordance with this Section 15.1, as follows:

---

| | |
|:---|:---|
| <u>For NOVODX</u>: | <u>For CARING</u>: |
| NOVODX Corporation | Caring Brands, Inc |
| 177 US Highway 1 unit 309 | 1061 E Indiantown Road |
| Tequesta, Fl 33469 USA | Suite 110 |
|  | Jupiter, Florida33477 |
| Email: Nancy@novo-dx.com | Email: drwilson@caringbrands.com |

---

18/22

15.2. <u>Assignment</u>.
 The rights and license granted by NOVODX to CARING in this Agreement is specific to CARING and the obligations of the Parties pursuant
 to this Agreement are specific to the respective Parties and may not be (i) assigned, delegated or otherwise transferred to any Third
 Party or to any of such Party's Affiliates, or (ii) in the case of CARING, subject to, or effected by, a Change of Control
 of CARING, without the prior written consent of the other Party. Any attempted assignment, transfer, sublicense or delegation without
 such consent will be null and void ab inito. It is agreed that an initial public offering by CARING shall not be considered a Change
 of Control of CARING for purposes of this Agreement.

15.3. <u>Illegal/unenforceable provisions</u>. If the whole or any part of any provision of this Agreement is determined to be illegal, void or unenforceable in
 any jurisdiction, the other provisions of this Agreement, and the rest of the void or unenforceable provision, will continue in force
 in that jurisdiction, and the validity and enforceability of that provision in any other jurisdiction will not be affected. The Parties
 request that any court t that determined such provision to be illegal, void or unenforceable modify ("blue pencil") such
 provision so that it will be legal valid and enforceable to the fullest extent permitted by applicable law.

15.4. <u>Waiver.</u> A wavier of any provision of this Agreement shall not be effective unless set forth in a written instrument executed by the Party
 granting the waiver. If a Party fails to enforce, or delays in enforcing, an obligation of the other Party, or fails to exercise,
 or delays in exercising, a right under this Agreement, that failure or delay will not affect its right to enforce that obligation
 or constitute a waiver of that right. Any waiver of any provision of this Agreement will not, unless expressly stated to the contrary,
 constitute a waiver of that provision on a future occasion.

15.5. <u>No Agency</u>. Nothing in this Agreement creates, implies or evidences any partnership or joint venture between the Parties, or the
 relationship between them of principal and agent. This Agreement is between two independent contracting entities. Neither Party has
 any authority to make any representation or commitment, or to incur any liability, on behalf of the other.

15.6. <u>Entire Agreement</u>. This Agreement, together with the Confidentiality Agreement, constitutes the entire understanding and agreement between
 the Parties relating to its subject matter and this Agreement supersedes all prior understandings and agreements between the Parties
 with respect to such subject matter (including, without limitation, the version of this Agreement which was signed but contained
 an error in a material term relating to the consideration to be received by NOVODX, which is corrected hereby), all of which, if
 any, are merged herein. Each Party acknowledges that it has not entered into this Agreement on the basis of any warranty, representation,
 statement, agreement or undertaking except those expressly set out in this Agreement. Each Party waives any claim for breach of this
 Agreement, or any right to rescind this Agreement in respect of, any representation which is not an express provision of this Agreement.
 However, this clause does not exclude any liability which either Party may have to the other (or any right which either Party may
 have to rescind this Agreement) in respect of any fraudulent misrepresentation or fraudulent concealment prior to the execution of
 this Agreement.

15.7. <u>Formalities</u>.
 Each Party will take any and all actions and execute any document reasonably required by the other Party to give effect and to implement
 this Agreement.

15.8. <u>Amendments</u>.
 No modification or amendment of this Agreement will be effective unless it is made in writing and signed by a duly authorized officer
 of each Party'.

15.9. <u>Third Parties</u>. No person or entity except a Party to this Agreement, and its successors and permitted assigns has any right to prevent
 the amendment of this Agreement or its termination, and no one except a Party to this Agreement may enforce any benefit conferred
 by this Agreement, unless this Agreement expressly provides otherwise. It is understood and agreed that an Indemnitee may directly
 enforce the indemnification right in Section 13.2.

19/22

15.10. <u>Governing Law; Jurisdiction</u>. This Agreement is governed by, and construed and enforced in in accordance with the laws of the State of Florida,
 without reference to any of its conflicts of law or choice of law principles. The prevailing Party in any such action, suit or other
 proceeding shall be reimbursed by the other Party for the prevailing Party's costs and expenses incurred in connection therewith,
 including, without limitation, reasonable attorneys' fees and expenses. Each of NOVODX and CARING hereby consents to the exclusive
 jurisdiction of the state and federal courts located in Palm Beach County, Florida (the Applicable Courts"), with regard to
 any action, suit or other proceeding relating to this Agreement and the transactions contemplated hereby. Each of the Parties hereby
 waives any right to assert that venue in the Applicable Courts is improper or that the Applicable Courts constitute an inconvenient
 forum. The prevailing Party in any such action, suit or proceeding shall be reimbursed by the other Party for the Prevailing Party's
 costs and expenses incurred in connection with such action, suit or proceeding, including, without limitation, reasonable attorneys'
 fees and expenses.

15.11. <u>Force Majeure.</u> Neither Party shall be liable for non-performance or delay in performance caused by an event of Force Majeure. The non-performing
 Party shall notify the other Party of such event of Force Majeure within five (5) days after such occurrence by giving written notice
 to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its
 effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing
 Party shall use, throughout the period of suspension of performance, commercially reasonable efforts to remedy its inability to perform;
 provided, however, that in the event the suspension of performance continues for thirty (30) days after the date such Force Majeure
 commences, the Parties shall meet to discuss in good faith how to proceed in order to carry out the intent of this Agreement. For
 purpose of this Agreement a Force Majeure shall not include (i) a Party's failure to commit sufficient resources, financial
 or otherwise, to its activities under this Agreement, or (ii) general market or economic conditions.

15.12. <u>Electronic signature/format</u>. For convenience, this Agreement may be signed electronically and/or electronically transmitted in Portable
 Document Format (PDF), in one or more copies, each of which shall be deemed to be an original and all of which shall constitute one
 and the same instrument. The Parties acknowledge that the exchange of the Agreement signed electronically or signed manually by one
 or both Parties but transmitted in PDF format shall have the same legal value and probative force as the exchange of original signatures,
 and that in the event of any dispute, controversy or claim arising from the Agreement, each of the Parties hereby waives the right
 to invoke any defence and/or claim for exemption based on the signature and/or transmission of an original of the Agreement in electronic
 form.

20/22

**IN WITNESS WHEREOF, each of NOVODX and CARING has caused this Agreement to be executed by one of its duly authorized officers as of the date first above written.**

---

| | | | |
|:---|:---|:---|:---|
| **SIGNED** for and on behalf of | **SIGNED** for and on behalf of | **SIGNED** for and on behalf of | **SIGNED** for and on behalf of |
| **CARING BRANDS, INC** | **CARING BRANDS, INC** | **NOVODX Corporation** | **NOVODX Corporation** |
| **By:** | | **By:** | |
| **Name:** | Dr. Glynn Wilson | **Name:** | **Nancy Torres** |
| **Position:** | Chief Executive Officer | **Position:** | Chief Executive Officer |

---

21/22

**Exhibit A**

**Licensed Patents**

List of NOVODX's patent applications related to GoldN™ Rapid Ebola Test

*Patent application number(s) to be added at a later date, no later than 07/31/2024*

22/22

## Exhibit 10.3

**Exhibit 10.3**

**CARING BRANDS, INC**

**EMPLOYMENT AGREEMENT – EXEMPT EMPLOYEE**

**THIS EMPLOYMENT AGREEMENT** (the "**Agreement**") is made and entered into as of April 1, 2024, (the "**Effective Date**"), between Caring Brands Inc., a Nevada corporation, whose principal place of business is 1061 E Indiantown Rd, Suite 110, Jupiter, FL 33477 (the "**Company**", or "**Employer**") and Dr Glynn Wilson, an individual whose mailing address is 277 Seabreeze Circle, Jupiter, FL 33477 (the "**Employee**").

**RECITALS**

**WHEREAS,** the Company desires to employ the Employee and the Employee desires to be employed by the Company and to enter into a formal employment agreement for the benefit and protection of all parties.

**NOW, THEREFORE,** in consideration of the mutual agreements herein made, the Company and the Employee do hereby agree as follows:

1.  **<u>Recitals.</u>** The above recitals are true, and correct, and are herein incorporated by reference.

2.  **<u>Employment.</u>** The Company hereby employs the Employee, and the Employee hereby accepts employment,
 upon the terms and conditions hereinafter set forth.

3.  **<u>Duties and Responsibilities.</u>** During the term of this Agreement, the Employee shall serve
 as Chief Executive Officer of the Company.

4.  **<u>Term.</u>** The term of employment hereunder will commence on April 1, 2024, and continue for
 a period of two (2) years, which shall auto-renew for successive two (2) year periods unless
 terminated in accordance herewith (collectively the "**Term** ").

5.  **<u>Compensation and Benefits.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Salary.</u>** During the Term of this Agreement, the Employee shall be paid an initial base salary
 (the "**Base Salary**") paid twice monthly, at an annualized rate of Two Hundred
 Fifty Thousand ($250,000). Employee will accrue $75,000 until the company completes its IPO
 listing. The base salary shall increase by 10% each calendar year thereafter for the duration
 of the Term of this agreement.

&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Bonus.</u>** The Company shall pay the Employee an annual bonus (the "**Bonus** ")
 based on targets (the "**Bonus Targets**") set forth below and established
 by mutual agreement. The Bonus amount shall be determined by the compensation committee.
 Upon each subsequent year's anniversary of employment, new Bonus Targets shall be established.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.  **<u>Bonus Targets.</u>** See Appendix B.

&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Pay Increase.</u>** The Employee's base salary may be increased at any time, at the Company's
 sole discretion, based on the Employee's performance, contributions to the Company,
 and other factors deemed relevant by the Employer. Any such increase shall be communicated
 to the Employee in writing and shall take effect on a date determined by the Employer.

&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>Cost of Living Adjustment.</u>** The Employee's base salary shall be subject to an annual
 Cost of Living Adjustment (the "**COLA**") based on the Consumer Price Index
 (CPI) for All Urban Consumers (CPI- U) for the previous year. The COLA shall be calculated
 as a percentage increase and shall take effect on the first day of each calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Stock Options.</u>** Under this Agreement, the Employee's compensation may include either
 stock options or restricted stock. Specific details about the issuance of these equity awards,
 such as the grant date, vesting schedule, and strike price, will be available in Appendix
 A. Please refer to this appendix and the 2024 Omnibus Equity Incentive Plan for more information.

&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>Benefits.</u>** Upon signing this Agreement, the Employee becomes eligible for mandatory employee
 benefits required by law and other benefits the Company may offer. Benefits may include health,
 life, and disability insurance coverage, a 401(k) plan, and an Employee Stock Ownership Plan.
 The Company can update or modify its offerings at any time, and the Employee will be notified
 of any changes. For more information, refer to the Caring Brands Employee Handbook.

&nbsp;&nbsp;&nbsp;&nbsp;g.  **<u>Vacation.</u>** The Company offers its employees two different time-off plans: Paid Time Off (PTO)
 and Responsible Time Off (RTO). The RTO plan is offered to benefit-eligible exempt employees
 in the United States, while the accrued PTO plan is offered to non-exempt (hourly) employees
 in the United States. Please refer to the Caring Brands Employee Handbook for specific details
 on each plan, including eligibility criteria and accrual rates. We are committed to providing
 our employees with comprehensive and competitive benefits packages, including generous time
 off policies, to support their well-being and work-life balance.

&nbsp;&nbsp;&nbsp;&nbsp;h.  **<u>Holidays.</u>** The Company shall provide the Employee with a certain number of paid holidays each
 calendar year, as determined by the U.S. federal holidays designated by Congress. While the
 specific observance dates may change from year to year, all Federal bank and market holidays
 shall be observed by the Company as paid vacation days.

&nbsp;&nbsp;&nbsp;&nbsp;i.  **<u>Business Expense Reimbursement.</u>** During the term of employment, the Employee shall be entitled
 to receive proper reimbursement for all reasonable, out-of-pocket expenses incurred by the
 Employee (in accordance with the policies and procedures established by the Company for its
 employees) in performing services hereunder, provided the Employee properly accounts therefor.

&nbsp;&nbsp;&nbsp;&nbsp;j.  **<u>Cell Phone Usage Reimbursement.</u>** The Employee will receive a $125 monthly stipend for business
 use of their personal cell phone. The stipend doesn't cover the device cost or the
 full monthly bill. To qualify, the Employee must agree to the Bring Your Own Device Policy.
 This policy covers data protection, security, and acceptable use. By accepting the stipend,
 the Employee agrees to comply with the policy and use their phone in line with company standards.

6.  **<u>Consequences of Termination of Employment.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Death.</u>** This Agreement and the Employee's employment hereunder shall be terminated
 by the death of the Employee and all vested but unexercised Options shall remain exercisable
 by the Employee's designated beneficiary, or, in the absence of such designation, to
 the estate or other legal representative of the Employee, through the term of such Option.

&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Disability.</u>** In the event of the Employee's disability, as hereinafter defined, the Employee
 shall be entitled to compensation in accordance with the Company's disability compensation
 practice for Employees.

&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Termination by the Company for Cause.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Nothing
 herein shall prevent the Company from terminating Employment for "Cause," as
 hereinafter defined. The Employee shall continue to receive the Base Salary through the date
 of such termination and any vested Stock Options shall remain exercisable pursuant to the
 terms of such grants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. "**Cause** "
 shall mean and include those actions or events specified below in subsections (A) through
 (D) to the extent the same occur, or the events constituting the same take place, subsequent
 to the date of execution of this Agreement: (A) committing or participating in an injurious
 act of, gross neglect or embezzlement against the Company; (B) committing or participating
 in any other injurious act or omission wantonly, willfully, recklessly or in a manner which
 was grossly negligent against the Company, monetarily or otherwise; (C) engaging in a criminal
 enterprise involving moral turpitude; or (D) the Employee being charged with or a conviction
 of an act or acts constituting a felony under the laws of the United States or any state
 thereof. Any other termination shall be deemed a termination "**Other than for Cause**."

&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>Termination by the Company Other than for Cause.</u>** The foregoing notwithstanding, the Company may
 terminate the Employee's employment for whatever reason it deems appropriate: On the
 date of termination, the Employee's unexercised vested Stock Options shall remain exercisable
 by the Employee through the term of such Options. On the date of termination, the Company
 shall pay to Employee the following benefits at the times specified below: (A) all Earned
 Compensation (to be paid on the date of termination), (B) an amount equal to six (6) months
 Base Salary (the "**Without Cause Severance Pay** "), (C) an amount equal to
 all accrued and unpaid annual incentive bonuses relating to any prior years, if any, at the
 time of Employee's termination of employment, (D) all Reimbursable Expenses, (E) reimbursement
 of insurance premiums payable to continue Employee's group health for a period of six
 (6) months from the date of termination, including coverage pursuant to the provisions of
 COBRA, if applicable, and, (F) a pro-rata portion of any annual incentive bonus becoming
 earned on performance for the fiscal year in which the date of termination occurs.

&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Voluntary Termination.</u>** In the event, the Employee terminates the Employee's employment
 of the Employee's own volition, on the date of termination the Employee's unexercised
 vested Stock Options shall remain exercisable by the Employee through the term of such Options.

&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>Change of Control:</u>** In the event of loss of employment due to Change of Control, employee
 will be entitled to all owed salary and benefits, as per the terms of Section 6(d), Termination
 by the Company Other than for Cause.

7.  **<u>Restrictive Covenant and Non-Disclosure of Information.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Restrictive Covenant.</u>** The Employee acknowledges and recognizes the highly competitive nature
 of the Company's business and the goodwill, continued patronage, and specifically the
 names and addresses of the Company's Clients (as hereinafter defined) constitute a
 substantial asset of the Company having been acquired through considerable time, money, and
 effort. Accordingly, in consideration of the execution of this Agreement, in the event the
 Employee's employment is terminated by reason of disability pursuant to Section 6(b)
 or for Cause pursuant to Section 6(c) or if the Employee voluntarily terminates this Agreement
 pursuant to Section 6(e), then the Employee agrees that during the Restricted Period and
 within the Restricted Area, the Employee will not, directly or indirectly, solicit, induce
 or influence any of the Company's Clients which have a business relationship with the
 Company at the time during the Restricted Period to discontinue or reduce the extent of such
 relationship with the Company and shall not solicit any current employee of the Company to
 offer them employment away from the Company.

&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Non-Disclosure of Information.</u>** In the event Employee's employment has been terminated, Employee
 agrees that, during the Restricted Period, Employee will not knowingly use or disclose any
 Proprietary Information of the Company for the Employee's own purposes or for the benefit
 of any entity engaged in Competitive Business Activities. As used herein, the term "**Proprietary Information**" shall mean trade secrets or confidential proprietary information of
 the Company which are material to the conduct of the business of the Company. No information
 can be considered Proprietary Information unless the same is a unique process or method material
 to the conduct of the Company's business, or is a customer list or similar list of
 persons engaged in business activities with the Company, or if the same is otherwise in the
 public domain or is required to be disclosed by order of any court or by reason of any statute,
 law, rule, regulation, ordinance or other governmental requirements. Employee further agrees
 that in the event his employment is terminated all Documents in his possession at the time
 of his termination shall be returned to the Company at the Company's principal place
 of business.

&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Documents.</u>** "**Documents**" shall mean all original written, recorded, or graphic
 matters whatsoever, and any and all copies thereof, including, but not limited to: papers;
 books; records; tangible things; correspondence; communications; telex messages; memoranda;
 work papers; reports; affidavits; statements; summaries; analyses; evaluations; client records
 and information; agreements; agendas; advertisements; instructions; charges; manuals; brochures;
 publications; directories; industry lists; schedules; price lists; client lists; statistical
 records; training manuals; computer printouts; books of account, records and invoices reflecting
 business operations; all things similar to any of the foregoing however denominated. In all
 cases where originals are not available, the term "Documents" shall also mean
 identical copies of original documents or non-identical copies thereof.

&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>Company's Clients.</u>** The "**Company's Clients**" shall be deemed to be any
 partnerships, corporations, professional associations or other business organizations with
 whom the Company has conducted business.

&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Competitive Business Activities.</u>** The term "**Competitive Business Activities** "
 as used herein shall be deemed to mean the business of the Company at the time of termination.

&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>Covenants as Essential Elements of this Agreement.</u>** It is understood by and between the parties
 hereto that the foregoing covenants contained in Sections 7(a) and (b) are essential elements
 of this Agreement, and that but for the agreement by the Employee to comply with such covenants,
 the Company would not have agreed to enter into this Agreement. Such covenants by the Employee
 shall be construed to be agreements independent of any other provisions of this Agreement.
 The existence of any other claim or cause of action, whether predicated on any other provision
 in this Agreement, or otherwise, because of the relationship between the parties shall not
 constitute a defense to the enforcement of such covenants against the Employee.

&nbsp;&nbsp;&nbsp;&nbsp;g.  **<u>Survival After Termination of Agreement.</u>** Notwithstanding anything to the contrary contained
 in this Agreement, the covenants in Sections 7(a) and (b) shall survive the termination of
 this Agreement and the Employee's employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;h.  **<u>Remedies.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. The
 Employee acknowledges and agrees that the Company's remedy at law for a breach or threatened
 breach of any of the provisions of Section 7(a) or (b) herein would be inadequate and a breach
 thereof will cause irreparable harm to the Company. In recognition of this fact, in the event
 of a breach by the Employee of any of the provisions of Section 7(a) or (b), the Employee
 agrees that, in addition to any remedy at law available to the Company, including, but not
 limited to monetary damages, all rights of the Employee to payment or otherwise under this
 Agreement and all amounts then or thereafter due to the Employee from the Company under this
 Agreement may be terminated and the Company, without posting any bond, shall be entitled
 to obtain, and the Employee agrees not to oppose the Company's request for equitable
 relief in the form of specific performance, temporary restraining order, temporary or permanent
 injunction or any other equitable remedy which may then be available to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. The
 Employee acknowledges that the granting of a temporary injunction, temporary restraining
 order, or permanent injunction merely prohibiting the use of Proprietary Information would
 not be an adequate remedy upon breach or threatened breach of Section 7(a) or (b) and consequently
 agrees, upon proof of any such breach, to the granting of injunctive relief prohibiting any
 form of competition with the Company. Nothing contained herein shall be construed as prohibiting
 the Company from pursuing any other remedies available to it for such breach or threatened
 breach.

8.  **<u>Indemnification.</u>** The Employee shall continue to be covered by the Certificate of Incorporation and/or
 the Bylaws of the Company with respect to matters occurring on or prior to the date of termination
 of the Employee's employment with the Company, subject to all the provisions of Nevada
 and Federal law and the Certificate of Incorporation and Bylaws of the Company then in effect.
 Such reasonable expenses, including attorneys' fees, that may be covered by the Certificate
 of Incorporation and/or Bylaws of the Company shall be paid by the Company on a current basis
 in accordance with such provision, the Company's Certificate of Incorporation, and
 Nevada law. To the extent that any such payments by the Company pursuant to the Company's
 Certificate of Incorporation and/or Bylaws may be subject to repayment by the Employee pursuant
 to the provisions of the Company's Certificate of Incorporation or Bylaws, or pursuant
 to Nevada or Federal law, such repayment shall be due and payable by the Employee to the
 Company within three (3) months after the termination of all proceedings, if any, which relate
 to such repayment and to the Company's affairs for the period prior to the date of
 termination of the Employee's employment with the Company and as to which Employee
 has been covered by such applicable provisions.

9.  **<u>Background.</u>** Caring Brands understands the importance of creating a safe and secure work environment
 for all employees. As such, the Company reserves the right to conduct background investigations
 and/or reference checks on all potential employees. Please note that any job offer extended
 by the Company is contingent upon the successful completion of such checks.

10.  **<u>Policies.</u>** Caring Brands employees are expected to follow the company's rules and standards
 to create a safe and respectful workplace for everyone. To ensure compliance with these standards,
 employees will receive a copy of the Caring Brands Employee Handbook, along with other relevant
 company policies, such as Regulation FD and Insider Trading Policies. The employee acknowledges
 that the terms of this contract are subject to and incorporate the policies and procedures
 set forth in the company's employee handbook and any other applicable policies, which
 the employee agrees to review and abide by. The contract will not become effective until
 the employee signs and acknowledges receipt of the employee handbook and any other applicable
 policies.

11.  **<u>Withholding.</u>** Anything to the contrary notwithstanding, all payments required to be made by the
 Company hereunder to the Employee or the Employee's estate or beneficiaries shall be
 subject to the withholding of such amounts, if any, relating to tax and other payroll deductions
 as the Company may reasonably determine it should withhold pursuant to any applicable law
 or regulation. In lieu of withholding such amounts, the Company may accept other arrangements
 pursuant to which it is satisfied that such tax and other payroll obligations will be satisfied
 in a manner complying with applicable law or regulation.

12.  **<u>Notices.</u>** Any notice required or permitted to be given under the terms of this Agreement shall
 be sufficient if in writing and if sent postage prepaid by registered or certified mail,
 return receipt requested; by overnight delivery; by courier; or by confirmed telecopy, in
 the case of the Employee to the Employee's last place of business or residence as shown
 on the records of the Company, or in the case of the Company to its principal office as set
 forth in the first paragraph of this Agreement, or at such other place as it may designate.

13.  **<u>Waiver.</u>** Unless agreed in writing, the failure of either party, at any time, to require performance
 by the other of any provisions hereunder shall not affect its right thereafter to enforce
 the same, nor shall a waiver by either party of any breach of any provision hereof be taken
 or held to be a waiver of any other preceding or succeeding breach of any term or provision
 of this Agreement. No extension of time for the performance of any obligation or act shall
 be deemed to be an extension of time for the performance of any other obligation or act hereunder.

14.  **<u>Completeness and Modification.</u>** This Agreement constitutes the entire understanding between the
 parties hereto superseding all prior and contemporaneous agreements or understandings among
 the parties hereto concerning the Employment Agreement. This Agreement may be amended, modified,
 superseded, or canceled, and any of the terms, covenants, representations, warranties, or
 conditions hereof may be waived, only by a written instrument executed by the parties or,
 in the case of a waiver, by the party to be charged.

15.  **<u>Counterparts.</u>** This Agreement may be executed in two or more counterparts, each of which shall be
 deemed an original but all of which shall constitute but one agreement.

16.  **<u>Binding Effect/Assignment.</u>** This Agreement shall be binding upon the parties hereto, their
 heirs, legal representatives, successors, and assigns. This Agreement shall not be assignable
 by the Employee but shall be assignable by the Company in connection with the sale, transfer,
 or other disposition of its business or to any of the Company's affiliates controlled
 by or under common control with the Company.

17.  **<u>Governing Law.</u>** This Agreement shall become valid when executed and accepted by Company. The
 parties agree that it shall be deemed made and entered into in the State of Florida and shall
 be governed and construed under and in accordance with the laws of the State of Florida.
 Anything in this Agreement to the contrary notwithstanding, the Employee shall conduct the
 Employee's business in a lawful manner and faithfully comply with applicable laws or
 regulations of the state, city, or other political subdivision in which the Employee is located.

18.  **<u>Further Assurances.</u>** All parties hereto shall execute and deliver such other instruments and
 do such other acts as may be necessary to carry out the intent and purposes of this Agreement.

19.  **<u>Headings.</u>** The headings of the sections are for convenience only and shall not control or affect
 the meaning or construction or limit the scope or intent of any of the provisions of this
 Agreement.

20.  **<u>Survival.</u>** Any termination of this Agreement shall not, however, affect the ongoing provisions
 of this Agreement which shall survive such termination in accordance with their terms.

21.  **<u>Severability.</u>** The invalidity or unenforceability, in whole or in part, of any covenant, promise
 or undertaking, or any section, subsection, paragraph, sentence, clause, phrase, or word
 or of any provision of this Agreement shall not affect the validity or enforceability of
 the remaining portions thereof.

22.  **<u>Enforcement.</u>** Should it become necessary for any party to institute legal action to enforce the
 terms and conditions of this Agreement, the successful party will be awarded reasonable attorney's
 fees at all trial and appellate levels, expenses, and costs.

23.  **<u>Venue.</u>** The Company and the Executive acknowledge and agree that the 15<sup>th</sup> Judicial
 Circuit of Florida shall be the venue and exclusive proper forum in which to adjudicate any
 case or controversy arising either, directly or indirectly, under or in connection with this
 Agreement and the parties further agree that, in the event of litigation arising out of or
 in connection with this Agreement in these courts, they will not contest or challenge the
 jurisdiction or venue of these courts.

24.  **<u>Construction.</u>** This Agreement shall be construed within the fair meaning of each of its terms and
 not against the party drafting the document.

25.  **<u>Superseding Agreement.</u>** This Agreement supersedes all prior or contemporaneous agreements, whether
 written or oral, and constitutes the entire understanding between the parties. Any changes
 to this Agreement must be in writing and signed by both parties. If there is any conflict
 between this Agreement and any other document or agreement related to the subject matter,
 this Agreement shall prevail.

26.  **<u>Approval of Named Officers.</u>** Notwithstanding any provision to the contrary, any compensation,
 incentive, or benefit arrangement for Named Officers of the company shall be deemed effective
 only upon the express approval of the Board of Directors, following a recommendation from
 the Compensation Committee.

**IN WITNESS WHEREOF**, the parties have executed this Agreement as of date set forth in the first paragraph of this Agreement.

---

| | |
|:---|:---|
| **THE COMPANY** | **THE COMPANY** |
| CARING BRANDS, INC. | CARING BRANDS, INC. |
| By: | /s/ |
|  | Brian John, Chairman |

---

---

| |
|:---|
| **THE EMPLOYEE** |
| /s/ |
| Dr. Glynn Wilson |

---

**APPENDIX A**

**EQUITY COMPENSATION DETAILS**

**This appendix contains additional information about the Employee's compensation through the issuance of either stock options or restricted stock. Please refer to this appendix for a detailed description of the grant date, vesting schedule, and strike price for these equity awards.**

Intentionally left blank

**APPENDIX B**

**ADDITIONAL COMPENSATION**

**This appendix contains additional information about the Employee's additional compensation and/or pay increases linked to predetermined milestones.**

Successful IPO listing, successful Money Raises, Successful M&A transactions and Revenue Bonus as outlined below.

---

| | |
|:---|:---|
| **Bonus:** | Based on company's annual revenue; Formula (as defined below) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) 5%
 of the first $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) 4%
 of the second $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) 3%
 of the third $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) 2%
 of the fourth $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) 1%
 of everything thereafter (above $4 million)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) Total
 bonus will be capped at $2 million annually

## Exhibit 10.4

**Exhibit 10.4**

**CARING BRANDS, INC**

**EMPLOYMENT AGREEMENT – EXEMPT EMPLOYEE**

**THIS EMPLOYMENT AGREEMENT** (the "**Agreement**") is made and entered into as of April 1, 2024, (the "**Effective Date**"), between Caring Brands Inc., a Nevada corporation, whose principal place of business is 1061 E Indiantown Rd, Suite 110, Jupiter, FL 33477 (the "**Company**", or "**Employer**") and Brian John, an individual whose mailing address is 16142 Cadence Pass, Jupiter, FL 33478 (the "**Employee**").

**RECITALS**

**WHEREAS,** the Company desires to employ the Employee and the Employee desires to be employed by the Company and to enter into a formal employment agreement for the benefit and protection of all parties.

**NOW, THEREFORE,** in consideration of the mutual agreements herein made, the Company and the Employee do hereby agree as follows:

1.  **<u>Recitals.</u>** The above recitals are true, and correct, and are herein incorporated by reference.

2.  **<u>Employment.</u>** The Company hereby employs the Employee, and the Employee hereby accepts employment,
 upon the terms and conditions hereinafter set forth.

3.  **<u>Duties and Responsibilities.</u>** During the term of this Agreement, the Employee shall serve
 as Chief Investment Officer of the Company.

4.  **<u>Term.</u>** The term of employment hereunder will commence on April 1, 2024, and continue for
 a period of two (2) years, which shall auto-renew for successive two (2) year periods unless
 terminated in accordance herewith (collectively the "**Term** ").

5.  **<u>Compensation and Benefits.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Salary.</u>** During the Term of this Agreement, the Employee shall be paid an initial base salary
 (the "**Base Salary**") paid twice monthly, at an annualized rate of Two Hundred
 Fifty Thousand ($250,000). Employee will accrue $75,000 until the company completes its IPO
 listing. The base salary shall increase by 10% each calendar year thereafter for the duration
 of the Term of this agreement.

&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Bonus.</u>** The Company shall pay the Employee an annual bonus (the "**Bonus** ")
 based on targets (the "**Bonus Targets**") set forth below and established
 by mutual agreement. The Bonus amount shall be determined by the compensation committee.
 Upon each subsequent year's anniversary of employment, new Bonus Targets shall be established.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.  **<u>Bonus Targets.</u>** See Appendix B.

&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Pay Increase.</u>** The Employee's base salary may be increased at any time, at the Company's
 sole discretion, based on the Employee's performance, contributions to the Company,
 and other factors deemed relevant by the Employer. Any such increase shall be communicated
 to the Employee in writing and shall take effect on a date determined by the Employer.

&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>Cost of Living Adjustment.</u>** The Employee's base salary shall be subject to an annual
 Cost of Living Adjustment (the "**COLA**") based on the Consumer Price Index
 (CPI) for All Urban Consumers (CPI- U) for the previous year. The COLA shall be calculated
 as a percentage increase and shall take effect on the first day of each calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Stock Options.</u>** Under this Agreement, the Employee's compensation may include either
 stock options or restricted stock. Specific details about the issuance of these equity awards,
 such as the grant date, vesting schedule, and strike price, will be available in Appendix
 A. Please refer to this appendix and the 2024 Omnibus Equity Incentive Plan for more information.

&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>Benefits.</u>** Upon signing this Agreement, the Employee becomes eligible for mandatory employee
 benefits required by law and other benefits the Company may offer. Benefits may include health,
 life, and disability insurance coverage, a 401(k) plan, and an Employee Stock Ownership Plan.
 The Company can update or modify its offerings at any time, and the Employee will be notified
 of any changes. For more information, refer to the Caring Brands Employee Handbook.

&nbsp;&nbsp;&nbsp;&nbsp;g.  **<u>Vacation.</u>** The Company offers its employees two different time-off plans: Paid Time Off (PTO)
 and Responsible Time Off (RTO). The RTO plan is offered to benefit-eligible exempt employees
 in the United States, while the accrued PTO plan is offered to non-exempt (hourly) employees
 in the United States. Please refer to the Caring Brands Employee Handbook for specific details
 on each plan, including eligibility criteria and accrual rates. We are committed to providing
 our employees with comprehensive and competitive benefits packages, including generous time
 off policies, to support their well-being and work-life balance.

&nbsp;&nbsp;&nbsp;&nbsp;h.  **<u>Holidays.</u>** The Company shall provide the Employee with a certain number of paid holidays each
 calendar year, as determined by the U.S. federal holidays designated by Congress. While the
 specific observance dates may change from year to year, all Federal bank and market holidays
 shall be observed by the Company as paid vacation days.

&nbsp;&nbsp;&nbsp;&nbsp;i.  **<u>Business Expense Reimbursement.</u>** During the term of employment, the Employee shall be entitled
 to receive proper reimbursement for all reasonable, out-of-pocket expenses incurred by the
 Employee (in accordance with the policies and procedures established by the Company for its
 employees) in performing services hereunder, provided the Employee properly accounts therefor.

&nbsp;&nbsp;&nbsp;&nbsp;j.  **<u>Cell Phone Usage Reimbursement.</u>** The Employee will receive a $125 monthly stipend for business
 use of their personal cell phone. The stipend doesn't cover the device cost or the
 full monthly bill. To qualify, the Employee must agree to the Bring Your Own Device Policy.
 This policy covers data protection, security, and acceptable use. By accepting the stipend,
 the Employee agrees to comply with the policy and use their phone in line with company standards.

6.  **<u>Consequences of Termination of Employment.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Death.</u>** This Agreement and the Employee's employment hereunder shall be terminated
 by the death of the Employee and all vested but unexercised Options shall remain exercisable
 by the Employee's designated beneficiary, or, in the absence of such designation, to
 the estate or other legal representative of the Employee, through the term of such Option.

&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Disability.</u>** In the event of the Employee's disability, as hereinafter defined, the Employee
 shall be entitled to compensation in accordance with the Company's disability compensation
 practice for Employees.

&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Termination by the Company for Cause.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. Nothing
 herein shall prevent the Company from terminating Employment for "Cause," as
 hereinafter defined. The Employee shall continue to receive the Base Salary through the date
 of such termination and any vested Stock Options shall remain exercisable pursuant to the
 terms of such grants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. "**Cause** "
 shall mean and include those actions or events specified below in subsections (A) through
 (D) to the extent the same occur, or the events constituting the same take place, subsequent
 to the date of execution of this Agreement: (A) committing or participating in an injurious
 act of, gross neglect or embezzlement against the Company; (B) committing or participating
 in any other injurious act or omission wantonly, willfully, recklessly or in a manner which
 was grossly negligent against the Company, monetarily or otherwise; (C) engaging in a criminal
 enterprise involving moral turpitude; or (D) the Employee being charged with or a conviction
 of an act or acts constituting a felony under the laws of the United States or any state
 thereof. Any other termination shall be deemed a termination "**Other than for Cause**."

&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>Termination by the Company Other than for Cause.</u>** The foregoing notwithstanding, the Company may
 terminate the Employee's employment for whatever reason it deems appropriate: On the
 date of termination, the Employee's unexercised vested Stock Options shall remain exercisable
 by the Employee through the term of such Options. On the date of termination, the Company
 shall pay to Employee the following benefits at the times specified below: (A) all Earned
 Compensation (to be paid on the date of termination), (B) an amount equal to six (6) months
 Base Salary (the "**Without Cause Severance Pay** "), (C) an amount equal to
 all accrued and unpaid annual incentive bonuses relating to any prior years, if any, at the
 time of Employee's termination of employment, (D) all Reimbursable Expenses, (E) reimbursement
 of insurance premiums payable to continue Employee's group health for a period of six
 (6) months from the date of termination, including coverage pursuant to the provisions of
 COBRA, if applicable, and, (F) a pro-rata portion of any annual incentive bonus becoming
 earned on performance for the fiscal year in which the date of termination occurs.

&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Voluntary Termination.</u>** In the event, the Employee terminates the Employee's employment
 of the Employee's own volition, on the date of termination the Employee's unexercised
 vested Stock Options shall remain exercisable by the Employee through the term of such Options.

&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>Change of Control:</u>** In the event of loss of employment due to Change of Control, employee
 will be entitled to all owed salary and benefits, as per the terms of Section 6(d), Termination
 by the Company Other than for Cause.

7.  **<u>Restrictive Covenant and Non-Disclosure of Information.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;a.  **<u>Restrictive Covenant.</u>** The Employee acknowledges and recognizes the highly competitive nature
 of the Company's business and the goodwill, continued patronage, and specifically the
 names and addresses of the Company's Clients (as hereinafter defined) constitute a
 substantial asset of the Company having been acquired through considerable time, money, and
 effort. Accordingly, in consideration of the execution of this Agreement, in the event the
 Employee's employment is terminated by reason of disability pursuant to Section 6(b)
 or for Cause pursuant to Section 6(c) or if the Employee voluntarily terminates this Agreement
 pursuant to Section 6(e), then the Employee agrees that during the Restricted Period and
 within the Restricted Area, the Employee will not, directly or indirectly, solicit, induce
 or influence any of the Company's Clients which have a business relationship with the
 Company at the time during the Restricted Period to discontinue or reduce the extent of such
 relationship with the Company and shall not solicit any current employee of the Company to
 offer them employment away from the Company.

&nbsp;&nbsp;&nbsp;&nbsp;b.  **<u>Non-Disclosure of Information.</u>** In the event Employee's employment has been terminated, Employee
 agrees that, during the Restricted Period, Employee will not knowingly use or disclose any
 Proprietary Information of the Company for the Employee's own purposes or for the benefit
 of any entity engaged in Competitive Business Activities. As used herein, the term "**Proprietary Information**" shall mean trade secrets or confidential proprietary information of
 the Company which are material to the conduct of the business of the Company. No information
 can be considered Proprietary Information unless the same is a unique process or method material
 to the conduct of the Company's business, or is a customer list or similar list of
 persons engaged in business activities with the Company, or if the same is otherwise in the
 public domain or is required to be disclosed by order of any court or by reason of any statute,
 law, rule, regulation, ordinance or other governmental requirements. Employee further agrees
 that in the event his employment is terminated all Documents in his possession at the time
 of his termination shall be returned to the Company at the Company's principal place
 of business.

&nbsp;&nbsp;&nbsp;&nbsp;c.  **<u>Documents.</u>** "**Documents**" shall mean all original written, recorded, or graphic
 matters whatsoever, and any and all copies thereof, including, but not limited to: papers;
 books; records; tangible things; correspondence; communications; telex messages; memoranda;
 work papers; reports; affidavits; statements; summaries; analyses; evaluations; client records
 and information; agreements; agendas; advertisements; instructions; charges; manuals; brochures;
 publications; directories; industry lists; schedules; price lists; client lists; statistical
 records; training manuals; computer printouts; books of account, records and invoices reflecting
 business operations; all things similar to any of the foregoing however denominated. In all
 cases where originals are not available, the term "Documents" shall also mean
 identical copies of original documents or non-identical copies thereof.

&nbsp;&nbsp;&nbsp;&nbsp;d.  **<u>Company's Clients.</u>** The "**Company's Clients**" shall be deemed to be any
 partnerships, corporations, professional associations or other business organizations with
 whom the Company has conducted business.

&nbsp;&nbsp;&nbsp;&nbsp;e.  **<u>Competitive Business Activities.</u>** The term "**Competitive Business Activities** "
 as used herein shall be deemed to mean the business of the Company at the time of termination.

&nbsp;&nbsp;&nbsp;&nbsp;f.  **<u>Covenants as Essential Elements of this Agreement.</u>** It is understood by and between the parties
 hereto that the foregoing covenants contained in Sections 7(a) and (b) are essential elements
 of this Agreement, and that but for the agreement by the Employee to comply with such covenants,
 the Company would not have agreed to enter into this Agreement. Such covenants by the Employee
 shall be construed to be agreements independent of any other provisions of this Agreement.
 The existence of any other claim or cause of action, whether predicated on any other provision
 in this Agreement, or otherwise, because of the relationship between the parties shall not
 constitute a defense to the enforcement of such covenants against the Employee.

&nbsp;&nbsp;&nbsp;&nbsp;g.  **<u>Survival After Termination of Agreement.</u>** Notwithstanding anything to the contrary contained
 in this Agreement, the covenants in Sections 7(a) and (b) shall survive the termination of
 this Agreement and the Employee's employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;h.  **<u>Remedies.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. The
 Employee acknowledges and agrees that the Company's remedy at law for a breach or threatened
 breach of any of the provisions of Section 7(a) or (b) herein would be inadequate and a breach
 thereof will cause irreparable harm to the Company. In recognition of this fact, in the event
 of a breach by the Employee of any of the provisions of Section 7(a) or (b), the Employee
 agrees that, in addition to any remedy at law available to the Company, including, but not
 limited to monetary damages, all rights of the Employee to payment or otherwise under this
 Agreement and all amounts then or thereafter due to the Employee from the Company under this
 Agreement may be terminated and the Company, without posting any bond, shall be entitled
 to obtain, and the Employee agrees not to oppose the Company's request for equitable
 relief in the form of specific performance, temporary restraining order, temporary or permanent
 injunction or any other equitable remedy which may then be available to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. The
 Employee acknowledges that the granting of a temporary injunction, temporary restraining
 order, or permanent injunction merely prohibiting the use of Proprietary Information would
 not be an adequate remedy upon breach or threatened breach of Section 7(a) or (b) and consequently
 agrees, upon proof of any such breach, to the granting of injunctive relief prohibiting any
 form of competition with the Company. Nothing contained herein shall be construed as prohibiting
 the Company from pursuing any other remedies available to it for such breach or threatened
 breach.

8.  **<u>Indemnification.</u>** The Employee shall continue to be covered by the Certificate of Incorporation and/or
 the Bylaws of the Company with respect to matters occurring on or prior to the date of termination
 of the Employee's employment with the Company, subject to all the provisions of Nevada
 and Federal law and the Certificate of Incorporation and Bylaws of the Company then in effect.
 Such reasonable expenses, including attorneys' fees, that may be covered by the Certificate
 of Incorporation and/or Bylaws of the Company shall be paid by the Company on a current basis
 in accordance with such provision, the Company's Certificate of Incorporation, and
 Nevada law. To the extent that any such payments by the Company pursuant to the Company's
 Certificate of Incorporation and/or Bylaws may be subject to repayment by the Employee pursuant
 to the provisions of the Company's Certificate of Incorporation or Bylaws, or pursuant
 to Nevada or Federal law, such repayment shall be due and payable by the Employee to the
 Company within three (3) months after the termination of all proceedings, if any, which relate
 to such repayment and to the Company's affairs for the period prior to the date of
 termination of the Employee's employment with the Company and as to which Employee
 has been covered by such applicable provisions.

9.  **<u>Background.</u>** Caring Brands understands the importance of creating a safe and secure work environment
 for all employees. As such, the Company reserves the right to conduct background investigations
 and/or reference checks on all potential employees. Please note that any job offer extended
 by the Company is contingent upon the successful completion of such checks.

10.  **<u>Policies.</u>** Caring Brands employees are expected to follow the company's rules and standards
 to create a safe and respectful workplace for everyone. To ensure compliance with these standards,
 employees will receive a copy of the Caring Brands Employee Handbook, along with other relevant
 company policies, such as Regulation FD and Insider Trading Policies. The employee acknowledges
 that the terms of this contract are subject to and incorporate the policies and procedures
 set forth in the company's employee handbook and any other applicable policies, which
 the employee agrees to review and abide by. The contract will not become effective until
 the employee signs and acknowledges receipt of the employee handbook and any other applicable
 policies.

11.  **<u>Withholding.</u>** Anything to the contrary notwithstanding, all payments required to be made by the
 Company hereunder to the Employee or the Employee's estate or beneficiaries shall be
 subject to the withholding of such amounts, if any, relating to tax and other payroll deductions
 as the Company may reasonably determine it should withhold pursuant to any applicable law
 or regulation. In lieu of withholding such amounts, the Company may accept other arrangements
 pursuant to which it is satisfied that such tax and other payroll obligations will be satisfied
 in a manner complying with applicable law or regulation.

12.  **<u>Notices.</u>** Any notice required or permitted to be given under the terms of this Agreement shall
 be sufficient if in writing and if sent postage prepaid by registered or certified mail,
 return receipt requested; by overnight delivery; by courier; or by confirmed telecopy, in
 the case of the Employee to the Employee's last place of business or residence as shown
 on the records of the Company, or in the case of the Company to its principal office as set
 forth in the first paragraph of this Agreement, or at such other place as it may designate.

13.  **<u>Waiver.</u>** Unless agreed in writing, the failure of either party, at any time, to require performance
 by the other of any provisions hereunder shall not affect its right thereafter to enforce
 the same, nor shall a waiver by either party of any breach of any provision hereof be taken
 or held to be a waiver of any other preceding or succeeding breach of any term or provision
 of this Agreement. No extension of time for the performance of any obligation or act shall
 be deemed to be an extension of time for the performance of any other obligation or act hereunder.

14.  **<u>Completeness and Modification.</u>** This Agreement constitutes the entire understanding between the
 parties hereto superseding all prior and contemporaneous agreements or understandings among
 the parties hereto concerning the Employment Agreement. This Agreement may be amended, modified,
 superseded, or canceled, and any of the terms, covenants, representations, warranties, or
 conditions hereof may be waived, only by a written instrument executed by the parties or,
 in the case of a waiver, by the party to be charged.

15.  **<u>Counterparts.</u>** This Agreement may be executed in two or more counterparts, each of which shall be
 deemed an original but all of which shall constitute but one agreement.

16.  **<u>Binding Effect/Assignment.</u>** This Agreement shall be binding upon the parties hereto, their
 heirs, legal representatives, successors, and assigns. This Agreement shall not be assignable
 by the Employee but shall be assignable by the Company in connection with the sale, transfer,
 or other disposition of its business or to any of the Company's affiliates controlled
 by or under common control with the Company.

17.  **<u>Governing Law.</u>** This Agreement shall become valid when executed and accepted by Company. The
 parties agree that it shall be deemed made and entered into in the State of Florida and shall
 be governed and construed under and in accordance with the laws of the State of Florida.
 Anything in this Agreement to the contrary notwithstanding, the Employee shall conduct the
 Employee's business in a lawful manner and faithfully comply with applicable laws or
 regulations of the state, city, or other political subdivision in which the Employee is located.

18.  **<u>Further Assurances.</u>** All parties hereto shall execute and deliver such other instruments and
 do such other acts as may be necessary to carry out the intent and purposes of this Agreement.

19.  **<u>Headings.</u>** The headings of the sections are for convenience only and shall not control or affect
 the meaning or construction or limit the scope or intent of any of the provisions of this
 Agreement.

20.  **<u>Survival.</u>** Any termination of this Agreement shall not, however, affect the ongoing provisions
 of this Agreement which shall survive such termination in accordance with their terms.

21.  **<u>Severability.</u>** The invalidity or unenforceability, in whole or in part, of any covenant, promise
 or undertaking, or any section, subsection, paragraph, sentence, clause, phrase, or word
 or of any provision of this Agreement shall not affect the validity or enforceability of
 the remaining portions thereof.

22.  **<u>Enforcement.</u>** Should it become necessary for any party to institute legal action to enforce the
 terms and conditions of this Agreement, the successful party will be awarded reasonable attorney's
 fees at all trial and appellate levels, expenses, and costs.

23.  **<u>Venue.</u>** The Company and the Executive acknowledge and agree that the 15<sup>th</sup> Judicial
 Circuit of Florida shall be the venue and exclusive proper forum in which to adjudicate any
 case or controversy arising either, directly or indirectly, under or in connection with this
 Agreement and the parties further agree that, in the event of litigation arising out of or
 in connection with this Agreement in these courts, they will not contest or challenge the
 jurisdiction or venue of these courts.

24.  **<u>Construction.</u>** This Agreement shall be construed within the fair meaning of each of its terms and
 not against the party drafting the document.

25.  **<u>Superseding Agreement.</u>** This Agreement supersedes all prior or contemporaneous agreements, whether
 written or oral, and constitutes the entire understanding between the parties. Any changes
 to this Agreement must be in writing and signed by both parties. If there is any conflict
 between this Agreement and any other document or agreement related to the subject matter,
 this Agreement shall prevail.

26.  **<u>Approval of Named Officers.</u>** Notwithstanding any provision to the contrary, any compensation,
 incentive, or benefit arrangement for Named Officers of the company shall be deemed effective
 only upon the express approval of the Board of Directors, following a recommendation from
 the Compensation Committee.

**IN WITNESS WHEREOF**, the parties have executed this Agreement as of date set forth in the first paragraph of this Agreement.

---

| | |
|:---|:---|
| **THE COMPANY** | **THE COMPANY** |
| CARING BRANDS, INC. | CARING BRANDS, INC. |
| By: | /s/ |
|  | Glynn Wilson, CEO\\ |

---

---

| |
|:---|
| **THE EMPLOYEE** |
| /s/ |
| Brain John |

---

**APPENDIX A**

**EQUITY COMPENSATION DETAILS**

**This appendix contains additional information about the Employee's compensation through the issuance of either stock options or restricted stock. Please refer to this appendix for a detailed description of the grant date, vesting schedule, and strike price for these equity awards.**

Intentionally left blank

**APPENDIX B**

**ADDITIONAL COMPENSATION**

**This appendix contains additional information about the Employee's additional compensation and/or pay increases linked to predetermined milestones.**

Successful IPO listing, successful Money Raises, Successful M&A transactions and Revenue Bonus as outlined below.

---

| | |
|:---|:---|
| **Bonus:** | Based on company's annual revenue; Formula (as defined below) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) 5%
 of the first $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) 4%
 of the second $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) 3%
 of the third $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) 2%
 of the fourth $1 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) 1%
 of everything thereafter (above $4 million)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) Total
 bonus will be capped at $2 million annually

## Exhibit 10.5

**Exhibit 10.5**

**CARING BRANDS, INC.**

**2024 EQUITY INCENTIVE PLAN**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Purpose of the Plan.

This 2024 Equity Incentive Plan (the "<u>Plan</u>") is intended as an incentive, to retain in the employ of and as directors, officers, consultants, advisors and employees to Caring Brands Inc, a Nevada corporation (the "<u>Company</u>"), and any Subsidiary of the Company, within the meaning of Section 424(f) of the United States Internal Revenue Code of 1986, as amended (the "<u>Code</u>"), persons of training, experience and ability, to attract new directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage the sense of proprietorship and to stimulate the active interest of such persons in the development and financial success of the Company and its Subsidiaries.

It is further intended that certain options granted pursuant to the Plan shall constitute incentive stock options within the meaning of Section 422 of the Code (the "<u>Incentive Options</u>") while certain other options granted pursuant to the Plan shall be nonqualified stock options (the "<u>Nonqualified Options</u>"). Incentive Options and Nonqualified Options are hereinafter referred to collectively as "<u>Options</u>."

The Company intends that the Plan meet the requirements of Rule 16b-3 ("<u>Rule 16b-3</u>") promulgated under the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), and that transactions of the type specified in subparagraphs (c) to (f) inclusive of Rule 16b-3 by officers and directors of the Company pursuant to the Plan will be exempt from the operation of Section 16(b) of the Exchange Act. In all cases, the terms, provisions, conditions and limitations of the Plan shall be construed and interpreted consistent with the Company's intent as stated in this Section 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Administration of the Plan.

The Board of Directors has the sole authority to grant options or restricted stock. The authority to manage the operation of and administer the Plan shall be vested in the Compensation Committee (the "<u>Committee</u>") consisting of two or more directors who are (i) "Independent Directors" (as such term is defined under the rules of the Nasdaq Stock Market) and (ii) "Non-Employee Directors" (as such term is defined in Rule 16b-3), which shall serve at the pleasure of the Board. The Committee, subject to Sections 3, 5 and 6 hereof, shall have full power and authority to designate recipients of Options and restricted stock ("<u>Restricted Stock</u>"), and to determine the terms and conditions of the respective Option and Restricted Stock agreements (which need not be identical) and to interpret the provisions and supervise the administration of the Plan. The Committee shall have the authority, without limitation, to designate which Options granted under the Plan shall be Incentive Options and which shall be Nonqualified Options. To the extent any Option does not qualify as an Incentive Option, it shall constitute a separate Nonqualified Option.

Subject to the provisions of the Plan, the Committee shall interpret the Plan and all Options and Restricted Stock (the "Securities") granted under the Plan, shall make such rules as it deems necessary for the proper administration of the Plan, shall make all other determinations necessary or advisable for the administration of the Plan and shall correct any defects or supply any omission or reconcile any inconsistency in the Plan or in any Securities granted under the Plan in the manner and to the extent that the Committee deems desirable to carry into effect the Plan or any Securities. The act or determination of a majority of the Committee shall be the act or determination of the Committee and any decision reduced to writing and signed by all of the members of the Committee shall be fully effective as if it had been made by a majority of the Committee at a meeting duly held for such purpose. Subject to the provisions of the Plan, any action taken or determination made by the Committee pursuant to this and the other Sections of the Plan shall be conclusive on all parties.

In the event that for any reason the Committee is unable to act or if the Committee at the time of any grant, award or other acquisition under the Plan does not consist of two or more Non-Employee Directors, or if there shall be no such Committee, or if the Board otherwise determines to administer the Plan, then the Plan shall be administered by the Board, and references herein to the Committee (except in the proviso to this sentence) shall be deemed to be references to the Board, and any such grant, award or other acquisition may be approved or ratified in any other manner contemplated by subparagraph (d) of Rule 16b-3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Designation of Optionees and Grantees.

The persons eligible for participation in the Plan as recipients of Options (the "<u>Optionees</u>") or Restricted Stock (the "<u>Grantees</u>" and together with Optionees, the "<u>Participants</u>") shall include directors, officers and employees of, and consultants and advisors to, the Company or any Subsidiary; provided that Incentive Options may only be granted to employees of the Company and any Subsidiary. In selecting Participants, and in determining the number of shares to be covered by each Option or award of Restricted Stock granted to Participants, the Committee may consider any factors it deems relevant, including, without limitation, the office or position held by the Participant or the Participant's relationship to the Company, the Participant's degree of responsibility for and contribution to the growth and success of the Company or any Subsidiary, the Participant's length of service, promotions and potential. A Participant who has been granted an Option or Restricted Stock hereunder may be granted an additional Option or Options, or Restricted Stock if the Committee shall so determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Stock Reserved for the Plan.

Subject to adjustment as provided in Section 8 hereof, a maximum of 2,000,000 shares of the Company's common stock, par value $0.001 per share (the "Common <u>Stock</u>"), shall be subject to the Plan. The shares of Common Stock subject to the Plan shall consist of unissued shares, treasury shares or previously issued shares held by any Subsidiary of the Company, and such number of shares of Common Stock shall be and is hereby reserved for such purpose. Any of such shares of Common Stock that may remain unissued and that are not subject to outstanding Options at the termination of the Plan shall cease to be reserved for the purposes of the Plan, but until termination of the Plan the Company shall at all times reserve a sufficient number of shares of Common Stock to meet the requirements of the Plan. Should any Securities expire or be canceled prior to its exercise, satisfaction of conditions or vesting in full, as applicable, or should the number of shares of Common Stock to be delivered upon the exercise or vesting in full of an Option or award of Restricted Stock be reduced for any reason, the shares of Common Stock theretofore subject to such Option or Restricted Stock, as applicable, may be subject to future Options or Restricted Stock under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Terms and Conditions of Options.

Options granted under the Plan shall be subject to the following conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall deem desirable:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Option Price</u>. The purchase price of each share of Common Stock purchasable under an Incentive Option shall be determined by the Committee at the time of grant, but shall not be less than 100% of the Fair Market Value (as defined below) of such share of Common Stock on the date the Option is granted; <u>provided</u>, <u>however</u>, that with respect to an Optionee who, at the time such Incentive Option is granted, owns (within the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or of any Subsidiary, the purchase price per share of Common Stock shall be at least 110% of the Fair Market Value per share of Common Stock on the date of grant. The purchase price of each share of Common Stock purchasable under a Nonqualified Option shall not be less than 100% of the Fair Market Value of such share of Common Stock on the date the Option is granted. The exercise price for each Option shall be subject to adjustment as provided in Section 8 below. "<u>Fair Market Value</u>" means the closing price on the final trading day immediately prior to the grant date of the Common Stock on the Nasdaq Stock Market or other principal securities exchange on which shares of Common Stock are listed (if the shares of Common Stock are so listed), or, if not so listed, the mean between the closing bid and asked prices of publicly traded shares of Common Stock in the over the counter market, or, if such bid and asked prices shall not be available, as reported by any nationally recognized quotation service selected by the Company, or as determined by the Committee in a manner consistent with the provisions of the Code. Anything in this Section 5(a) to the contrary notwithstanding, in no event shall the purchase price of a share of Common Stock be less than the minimum price permitted under the rules and policies of any national securities exchange on which the shares of Common Stock are listed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Option Term</u>. The term of each Option shall be fixed by the Committee, but no Option shall be exercisable more than ten years after the date such Option is granted and in the case of an Incentive Option granted to an Optionee who, at the time such Incentive Option is granted, owns (within the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or of any Subsidiary, no such Incentive Option shall be exercisable more than five years after the date such Incentive Option is granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Exercisability</u>. Subject to Section 5(j) hereof, Options shall be exercisable at such time or times and subject to such terms and conditions as shall be determined by the Committee at the time of grant; <u>provided</u>, <u>however</u>, that in the absence of any Option vesting periods designated by the Committee at the time of grant, Options shall vest and become exercisable as to one-third of the total number of shares subject to the Option on each of the first, second and third anniversaries of the date of grant; and provided further that no Options shall be exercisable until such time as any vesting limitation required by Section 16 of the Exchange Act, and related rules, shall be satisfied if such limitation shall be required for continued validity of the exemption provided under Rule 16b-3(d)(3).

Upon the occurrence of a "Change in Control" (as hereinafter defined), the Committee may accelerate the vesting and exercisability of outstanding Options, in whole or in part, as determined by the Committee in its sole discretion. In its sole discretion, the Committee may also determine that, upon the occurrence of a Change in Control, each outstanding Option shall terminate within a specified number of days after notice to the Optionee thereunder, and each such Optionee shall receive, with respect to each share of Common Stock subject to such Option, an amount equal to the excess of the Fair Market Value of such shares immediately prior to such Change in Control over the exercise price per share of such Option; such amount shall be payable in cash, in one or more kinds of property (including the property, if any, payable in the transaction) or a combination thereof, as the Committee shall determine in its sole discretion.

For purposes of the Plan, unless otherwise defined in an employment agreement between the Company and the relevant Optionee, a

Change in Control shall be deemed to have occurred if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a
 tender offer (or series of related offers) shall be made and consummated for the ownership
 of 50% or more of the outstanding voting securities of the Company, unless as a result of
 such tender offer more than 50% of the outstanding voting securities of the surviving or
 resulting corporation shall be owned in the aggregate by the stockholders of the Company
 (as of the time immediately prior to the commencement of such offer), any employee benefit
 plan of the Company or its Subsidiaries, and their affiliates;

(ii) the
 Company shall be merged or consolidated with another corporation, unless as a result of such
 merger or consolidation more than 50% of the outstanding voting securities of the surviving
 or resulting corporation shall be owned in the aggregate by the stockholders of the Company
 (as of the time immediately prior to such transaction), any employee benefit plan of the
 Company or its Subsidiaries, and their affiliates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the
 Company shall sell substantially all of its assets to another corporation that is not wholly
 owned by the Company, unless as a result of such sale more than 50% of such assets shall
 be owned in the aggregate by the stockholders of the Company (as of the time immediately
 prior to such transaction), any employee benefit plan of the Company or its Subsidiaries
 and their affiliates; or

(iv) a
 Person (as defined below) shall acquire 50% or more of the outstanding voting securities
 of the Company (whether directly, indirectly, beneficially or of record), unless as a result
 of such acquisition more than 50% of the outstanding voting securities of the surviving or
 resulting corporation shall be owned in the aggregate by the stockholders of the Company
 (as of the time immediately prior to the first acquisition of such securities by such Person),
 any employee benefit plan of the Company or its Subsidiaries, and their affiliates.

Notwithstanding the foregoing, if Change of Control is defined in an employment agreement between the Company and the relevant Optionee, then, with respect to such Optionee, Change of Control shall have the meaning ascribed to it in such employment agreement.

For purposes of this Section 5(c), ownership of voting securities shall take into account and shall include ownership as determined by applying the provisions of Rule 13d-3(d)(I)(i) (as in effect on the date hereof) under the Exchange Act. In addition, for such purposes, "Person" shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof; <u>provided</u>, <u>however</u>, that a Person shall not include (A) the Company or any of its Subsidiaries; (B) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries; (C) an underwriter temporarily holding securities pursuant to an offering of such securities; or (D) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportion as their ownership of stock of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>(d) Method of Exercise</u>. Options to the extent then exercisable may be exercised in whole or in part at any time during the option period, by giving written notice to the Company specifying the number of shares of Common Stock to be purchased, accompanied by payment in full of the purchase price, in cash, or by check or such other instrument as may be acceptable to the Committee. As determined by the Committee, in its sole discretion, at or after grant, payment in full or in part may be made at the election of the Optionee (i) in the form of Common Stock owned by the Optionee (based on the Fair Market Value of the Common Stock which is not the subject of any pledge or security interest, (ii) in the form of shares of Common Stock withheld by the Company from the shares of Common Stock otherwise to be received with such withheld shares of Common Stock having a Fair Market Value equal to the exercise price of the Option, or (iii) by a combination of the foregoing, such Fair Market Value determined by applying the principles set forth in Section 5(a), provided that the combined value of all cash and cash equivalents and the Fair Market Value of any shares surrendered to the Company is at least equal to such exercise price and except with respect to (ii) above, such method of payment will not cause a disqualifying disposition of all or a portion of the Common Stock received upon exercise of an Incentive Option. An Optionee shall have the right to dividends and other rights of a stockholder with respect to shares of Common Stock purchased upon exercise of an Option at such time as the Optionee (i) has given written notice of exercise and has paid in full for such shares, and (ii) has satisfied such conditions that may be imposed by the Company with respect to the withholding of taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Non-transferability of Options</u>. Options are not transferable and may be exercised solely by the Optionee during his lifetime or after his death by the person or persons entitled thereto under his will or the laws of descent and distribution. The Committee, in its sole discretion, may permit a transfer of a Nonqualified Option to (i) a trust for the benefit of the Optionee, (ii) a member of the Optionee's immediate family (or a trust for his or her benefit) or (iii) pursuant to a domestic relations order. Any other transfers must be approved by the Board of Directors. Any attempt to transfer, assign, pledge or otherwise dispose of, or to subject to execution, attachment or similar process, any Option contrary to the provisions hereof shall be void and ineffective and shall give no right to the purported transferee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Termination by Death</u>. Unless otherwise determined by the Committee, if any Optionee's employment with or service to the Company or any Subsidiary terminates by reason of death, the Option may thereafter be exercised, to the extent then exercisable (or on such accelerated basis as the Committee shall determine at or after grant), by the legal representative of the estate or by the legatee of the Optionee under the will of the Optionee, for a period of one (1) year after the date of such death (or, if later, such time as the Option may be exercised pursuant to Section 14(d) hereof) or until the expiration of the stated term of such Option as provided under the Plan, whichever period is shorter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Termination by Reason of Disability</u>. Unless otherwise determined by the Committee, if any Optionee's employment with or service to the Company or any Subsidiary terminates by reason of Disability (as defined below), then any Option held by such Optionee may thereafter be exercised, to the extent it was exercisable at the time of termination due to Disability (or on such accelerated basis as the Committee shall determine at or after grant), but may not be exercised after ninety (90) days after the date of such termination of employment or service (or, if later, such time as the Option may be exercised pursuant to Section 14(d) hereof) or the expiration of the stated term of such Option, whichever period is shorter; <u>provided</u>, <u>however</u>, that, if the Optionee dies within such ninety (90) day period, any unexercised Option held by such Optionee shall thereafter be exercisable to the extent to which it was exercisable at the time of death for a period of one (1) year after the date of such death (or, if later, such time as the Option may be exercised pursuant to Section 14(d) hereof) or for the stated term of such Option, whichever period is shorter. "Disability" shall mean an Optionee's total and permanent disability; *provided*, that if Disability is defined in an employment agreement between the Company and the relevant Optionee, then, with respect to such Optionee, Disability shall have the meaning ascribed to it in such employment agreement

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Termination by Reason of Retirement</u>. Unless otherwise determined by the Committee, if any Optionee's employment with or service to the Company or any Subsidiary terminates by reason of Normal or Early Retirement (as such terms are defined below), any Option held by such Optionee may thereafter be exercised to the extent it was exercisable at the time of such Retirement (or on such accelerated basis as the Committee shall determine at or after grant), but may not be exercised after ninety (90) days after the date of such termination of employment or service (or, if later, such time as the Option may be exercised pursuant to Section 14(d) hereof) or the expiration of the stated term of such Option, whichever date is earlier; <u>provided</u>, <u>however</u>, that, if the Optionee dies within such ninety (90) day period, any unexercised Option held by such Optionee shall thereafter be exercisable, to the extent to which it was exercisable at the time of death, for a period of one (1) year after the date of such death (or, if later, such time as the Option may be exercised pursuant to Section 14(d) hereof) or for the stated term of such Option, whichever period is shorter.

For purposes of this paragraph (h), "<u>Normal Retirement</u>" shall mean retirement from active employment with the Company or any Subsidiary on or after the normal retirement date specified in the applicable Company or Subsidiary pension plan or if no such pension plan, age 65, and "<u>Early Retirement</u>" shall mean retirement from active employment with the Company or any Subsidiary pursuant to the early retirement provisions of the applicable Company or Subsidiary pension plan or if no such pension plan, age 55.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Other Terminations</u>. Unless otherwise determined by the Committee upon grant, if any Optionee's employment with or service to the Company or any Subsidiary is terminated by such Optionee for any reason other than death, Disability, Normal or Early Retirement or Good Reason (as defined below), the Option shall thereupon terminate, except that the portion of any Option that was exercisable on the date of such termination of employment or service may be exercised for the lesser of ninety (90) days after the date of termination (or, if later, such time as the Option may be exercised pursuant to Section 14(d) hereof) or the balance of such Option's term, which ever period is shorter. The transfer of an Optionee from the employ of or service to the Company to the employ of or service to a Subsidiary, or vice versa, or from one Subsidiary to another, shall not be deemed to constitute a termination of employment or service for purposes of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In
 the event that the Optionee's employment or service with the Company or any Subsidiary
 is terminated by the Company or such Subsidiary for "cause" any unexercised portion
 of any Option shall immediately terminate in its entirety. For purposes hereof, unless otherwise
 defined in an employment agreement between the Company and the relevant Optionee, "Cause"
 shall exist upon a good-faith determination by the Board, following a hearing before the
 Board at which an Optionee was represented by counsel and given an opportunity to be heard,
 that such Optionee has been accused of fraud, dishonesty or act detrimental to the interests
 of the Company or any Subsidiary of Company or that such Optionee has been accused of or
 convicted of an act of willful and material embezzlement or fraud against the Company or
 of a felony under any state or federal statute; <u>provided</u>, <u>however</u>, that it
 is specifically understood that "Cause" shall not include any act of commission
 or omission in the good-faith exercise of such Optionee's business judgment as a director,
 officer or employee of the Company, as the case may be, or upon the advice of counsel to
 the Company. Notwithstanding the foregoing, if Cause is defined in an employment agreement
 between the Company and the relevant Optionee, then, with respect to such Optionee, Cause
 shall have the meaning ascribed to it in such employment agreement.

(ii) In
 the event that an Optionee is removed as a director, officer or employee by the Company at
 any time other than for "Cause" or resigns as a director, officer or employee
 for "Good Reason" the Option granted to such Optionee may be exercised by the
 Optionee, to the extent the Option was exercisable on the date such Optionee ceases to be
 a director, officer or employee. Such Option may be exercised at any time within one (1)
 year after the date the Optionee ceases to be a director, officer or employee (or, if later,
 such time as the Option may be exercised pursuant to Section 14(d) hereof), or the date on
 which the Option otherwise expires by its terms; whichever period is shorter, at which time
 the Option shall terminate; <u>provided</u>, <u>however</u>, if the Optionee dies before
 the Options terminate and are no longer exercisable, the terms and provisions of Section
 5(f) shall control. For purposes of this Section 5(i), and unless otherwise defined in an
 employment agreement between the Company and the relevant Optionee, Good Reason shall exist
 upon the occurrence of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) the assignment to Optionee of any duties inconsistent with the position in the Company that Optionee held immediately prior to the assignment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) a Change of Control resulting in a significant adverse alteration in the status or conditions of Optionee's participation with the Company or other nature of Optionee's responsibilities from those in effect prior to such Change of Control, including any significant alteration in Optionee's responsibilities immediately prior to such Change in Control; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) the failure by the Company to continue to provide Optionee with benefits substantially similar to those enjoyed by Optionee prior to such failure.

Notwithstanding the foregoing, if Good Reason is defined in an employment agreement between the Company and the relevant Optionee, then, with respect to such Optionee, Good Reason shall have the meaning ascribed to it in such employment agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Limit on Value of Incentive Option</u>. The aggregate Fair Market Value, determined as of the date the Incentive Option is granted, of Common Stock for which Incentive Options are exercisable for the first time by any Optionee during any calendar year under the Plan (and/or any other stock option plans of the Company or any Subsidiary) shall not exceed $100,000. Should it be determined that an Incentive Stock Option granted under the Plan exceeds such maximum for any reason other than a failure in good faith to value the Stock subject to such option, the excess portion of such option shall be considered a Nonqualified Option. To the extent the employee holds two (2) or more such Options which become exercisable for the first time in the same calendar year, the foregoing limitation on the exercisability of such Option as Incentive Stock Options under the Federal tax laws shall be applied on the basis of the order in which such Options are granted. If, for any reason, an entire Option does not qualify as an Incentive Stock Option by reason of exceeding such maximum, such Option shall be considered a Nonqualified Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Terms and Conditions of Restricted Stock.

Restricted Stock may be granted under this Plan aside from, or in association with, any other award and shall be subject to the following conditions and shall contain such additional terms and conditions (including provisions relating to the acceleration of vesting of Restricted Stock upon a Change of Control), not inconsistent with the terms of the Plan, as the Committee shall deem desirable:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Grantee rights</u>. A Grantee shall have no rights to an award of Restricted Stock unless and until Grantee accepts the award within the period prescribed by the Committee and, if the Committee shall deem desirable, makes payment to the Company in cash, or by check or such other instrument as may be acceptable to the Committee. After acceptance and issuance of a certificate or certificates, as provided for below, the Grantee shall have the rights of a stockholder with respect to Restricted Stock subject to the non-transferability and forfeiture restrictions described in Section 6(d) below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Issuance of Certificates</u>. The Company shall issue in the Grantee's name a certificate or certificates for the shares of Common Stock associated with the award promptly after the Grantee accepts such award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Delivery of Certificates</u>. Unless otherwise provided, any certificate or certificates issued evidencing shares of Restricted Stock shall not be delivered to the Grantee until such shares are free of any restrictions specified by the Committee at the time of grant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Forfeitability, Non-transferability of Restricted Stock</u>. Shares of Restricted Stock are forfeitable until the terms of the Restricted Stock grant have been satisfied. Shares of Restricted Stock are not transferable until the date on which the Committee has specified such restrictions have lapsed. Unless otherwise provided by the Committee at or after grant, distributions in the form of dividends or otherwise of additional shares or property in respect of shares of Restricted Stock shall be subject to the same restrictions as such shares of Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Change of Control</u>. Upon the occurrence of a Change in Control as defined in Section 5(c), the Committee may accelerate the vesting of outstanding Restricted Stock, in whole or in part, as determined by the Committee, in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Termination of Employment</u>. Unless otherwise determined by the Committee at or after grant, in the event the Grantee ceases to be an employee or otherwise associated with the Company for any other reason, all shares of Restricted Stock theretofore awarded to him which are still subject to restrictions shall be forfeited and the Company shall have the right to complete the blank stock power. The Committee may provide (on or after grant) that restrictions or forfeiture conditions relating to shares of Restricted Stock will be waived in whole or in part in the event of termination resulting from specified causes, and the Committee may in other cases waive in whole or in part restrictions or forfeiture conditions relating to Restricted Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Term of Plan.

No Securities shall be granted pursuant to the Plan on or after the date which is ten years from the effective date of the Plan, but Options and awards of Restricted Stock theretofore granted may extend beyond that date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Capital Change of the Company.

In the event of any merger, reorganization, consolidation, recapitalization, stock dividend, or other change in corporate structure affecting the Common Stock of the Company, the Committee shall make an appropriate and equitable adjustment in the number and kind of shares reserved for issuance under the Plan and (A) in the number and option price of shares subject to outstanding Options granted under the Plan, to the end that after such event each Optionee's proportionate interest shall be maintained (to the extent possible) as immediately before the occurrence of such event. The Committee shall, to the extent feasible, make such other adjustments as may be required under the tax laws so that any Incentive Options previously granted shall not be deemed modified within the meaning of Section 424(h) of the Code. Appropriate adjustments shall also be made in the case of outstanding Restricted Stock granted under the Plan.

The adjustments described above will be made only to the extent consistent with continued qualification of the Option under Section 422 of the Code (in the case of an Incentive Option) and Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Purchase for Investment/Conditions.

Unless the Options and shares covered by the Plan have been registered under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), or the Company has determined that such registration is unnecessary, each person exercising or receiving Securities under the Plan may be required by the Company to give a representation in writing that he is acquiring the securities for his own account for investment and not with a view to, or for sale in connection with, the distribution of any part thereof. The Committee may impose any additional or further restrictions on awards of Securities as shall be determined by the Committee at the time of award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. Taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company may make such provisions as it may deem appropriate, consistent with applicable law, in connection with any Securities granted under the Plan with respect to the withholding of any taxes (including income or employment taxes) or any other tax matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If any Grantee, in connection with the acquisition of Restricted Stock, makes the election permitted under Section 83(b) of the Code (that is, an election to include in gross income in the year of transfer the amounts specified in Section 83(b)), such Grantee shall notify the Company of the election with the Internal Revenue Service pursuant to regulations issued under the authority of Code Section 83(b).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If any Grantee shall make any disposition of shares of Common Stock issued pursuant to the exercise of an Incentive Option under the circumstances described in Section 421(b) of the Code (relating to certain disqualifying dispositions), such Grantee shall notify the Company of such disposition within ten (10) days hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. Effective Date of Plan.

The Plan was approved by the Board of Directors on September 30, 2024, and the effective date is January 1, 2024. The Plan shall be presented to the Shareholders at the next annual Shareholder's meeting for approval or other Shareholder meeting as may be called for the purpose of approving this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. Amendment and Termination.

The Board may amend, suspend, or terminate the Plan, except that no amendment shall be made that would impair the rights of any Participant under Securities theretofore granted without the Participant's consent, and except that no amendment shall be made which, without the approval of the stockholders of the Company would:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) materially
 increase the number of shares that may be issued under the Plan, except as is provided in
 Section 8;

(b) materially
 increase the benefits accruing to the Participants under the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) materially
 modify the requirements as to eligibility for participation in the Plan;

(d) decrease the exercise price of an Incentive Option to less
than 100% of the Fair Market Value per share of Common Stock on the date of grant thereof or the exercise price of a Nonqualified Option
to less than 100% of the Fair Market Value per share of Common Stock on the date of grant thereof;

(e) extend
 the term of any Option beyond that provided for in Section 5(b);

(f) except as otherwise provided in Sections 5(d) and 8 hereof,
reduce the exercise price of outstanding Options or effect repricing through cancellations and re-grants of new Options;

(g) increase the number of shares of Common Stock to be issued
or issuable under the Plan to an amount that is equal to or in excess of 19.99% of the number of shares of Common Stock outstanding before
the issuance of the stock or securities; or

(h) otherwise
 require stockholder approval pursuant to the rules and regulations of the Nasdaq Stock Market.

Subject to the forgoing, the Committee may amend the terms of any Option theretofore granted, prospectively or retrospectively, but no such amendment shall impair the rights of any Optionee without the Optionee's consent. It is the intention of the Board that the Plan comply strictly with the provisions of Section 409A of the Code and Treasury Regulations and other Internal Revenue Service guidance promulgated thereunder (the "<u>Section 409A Rules</u>") and the Committee shall exercise its discretion in granting awards hereunder (and the terms of such awards), accordingly. The Plan and any grant of an award hereunder may be amended from time to time (without, in the case of an award, the consent of the Participant) as may be necessary or appropriate to comply with the Section 409A Rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. Government Regulations.

The Plan, and the grant and exercise or conversion, as applicable, of Securities hereunder, and the obligation of the Company to issue and deliver shares under such Securities shall be subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies, national securities exchanges and interdealer quotation systems as may be required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. General Provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Certificates</u>. All certificates for shares of Common Stock delivered under the Plan shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations and other requirements of the Securities and Exchange Commission, or other securities commission having jurisdiction, any applicable Federal or state securities law, any stock exchange or interdealer quotation system upon which the Common Stock is then listed or traded and the Committee may cause a legend or legends to be placed on any such certificates to make appropriate reference to such restrictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Employment Matters</u>. Neither the adoption of the Plan nor any grant or award under the Plan shall confer upon any Participant who is an employee of the Company or any Subsidiary any right to continued employment or, in the case of a Participant who is a director, continued service as a director, with the Company or a Subsidiary, as the case may be, nor shall it interfere in any way with the right of the Company or any Subsidiary to terminate the employment of any of its employees, the service of any of its directors or the retention of any of its consultants or advisors at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Limitation of Liability</u>. No member of the Committee, or any officer or employee of the Company acting on behalf of the Committee, shall be personally liable for any action, determination or interpretation taken or made in good faith with respect to the Plan, and all members of the Committee and each and any officer or employee of the Company acting on their behalf shall, to the extent permitted by law, be fully indemnified and protected by the Company in respect of any such action, determination or interpretation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Registration of Stock</u>. Notwithstanding any other provision in the Plan, no Option may be exercised unless and until the Common Stock to be issued upon the exercise thereof has been registered under the Securities Act and applicable state securities laws, or are, in the opinion of counsel to the Company, exempt from such registration in the United States. The Company shall not be under any obligation to register under applicable federal or state securities laws any Common Stock to be issued upon the exercise of an Option granted hereunder in order to permit the exercise of an Option and the issuance and sale of the Common Stock subject to such Option, although the Company may in its sole discretion register such Common Stock at such time as the Company shall determine. If the Company chooses to comply with such an exemption from registration, the Common Stock issued under the Plan may, at the direction of the Committee, bear an appropriate restrictive legend restricting the transfer or pledge of the Common Stock represented thereby, and the Committee may also give appropriate stop transfer instructions with respect to such Common Stock to the Company's transfer agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. Non-Uniform Determinations.

The Committee's determinations under the Plan, including, without limitation, (i) the determination of the Participants to receive awards, (ii) the form, amount and timing of such awards, (iii) the terms and provisions of such awards and (iv) the agreements evidencing the same, need not be uniform and may be made by it selectively among Participants who receive, or who are eligible to receive, awards under the Plan, whether or not such Participants are similarly situated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. Governing Law.

The validity, construction, and effect of the Plan and any rules and regulations relating to the Plan shall be determined in accordance with the internal laws of the State of Nevada, without giving effect to principles of conflicts of laws, and applicable federal law.

## Exhibit 10.6

**Exhibit 10.6**

SEPARATION AND EXCHANGE AGREEMENT

between

SAFETY SHOT, INC., a Delaware corporation

CARING BRANDS, INC., a Florida corporation

CARING BRANDS, INC., a Nevada corporation

and

Brian S. John, the representative

Dated as of September 24, 2024

SEPARATION AND EXCHANGE AGREEMENT, dated as of September 24, 2024 between Safety Shot, Inc., a Delaware corporation (the "<u>Company</u>"), Caring Brands, Inc., a Nevada corporation ("<u>CB</u>"), Caring Brands, Inc, a Florida corporation ("CB Florida") and Brian S. John as the representative of the shareholders of CB Florida and CB (the "Representative") (the Company, CB, CB Florida and the Representative each a "<u>Party</u>" and together, the "<u>Parties</u>").

WHEREAS, the Company is a publicly held corporation organized under the laws of the State of Delaware and its shares of common stock are listed and traded on the Nasdaq Stock Market LLC under the symbol SHOT;

WHEREAS, Brian S. John is acting as the representative of the shareholders of CB Florida and CB, as specified in the Schedule I herein;

WHEREAS, the Company along with the other shareholders of CB (collectively the "Transferors"), own 100% of the issued and outstanding shares of common stock of CB Florida, which currently operates the Company's business segment that creates and sells innovative wellness consumer products industries (the "<u>CB Business</u>"), and owns all of the assets, intellectual property and liabilities related thereto;

WHEREAS, the Parties have determined to effect a separation of the CB Business from the Company (the "<u>Separation</u>") whereby the CB Business will be contributed to CB and all expenses related thereto shall be the responsibility of CB, in each case, on the terms and subject to the conditions set forth herein;

WHEREAS, to effect the Separation, the assumption of the expenses related to the CB Business shall be in exchange for all of the issued and outstanding shares of common stock of CB Florida, owned by the Transferors (the "<u>CB Florida Shares</u>"); and

WHEREAS, CB intends to file with the Securities and Exchange Commission ("<u>SEC</u>") a draft Registration Statement on Form S-1 (the "<u>IPO Registration Statement</u>") to register certain shares of common stock, par value $0.001 (the "CB Common Stock") to be sold in an initial public offering of CB (the "<u>CB IPO</u>") and to be distributed to stockholders of the Company as of a record date (the "<u>Record Date</u>") to be determined by the Company (the "<u>Distribution</u>"), drafts of which will first be confidentially submitted to the SEC.

NOW, THEREFORE, in consideration of the foregoing premises and the covenants and agreements contained in this Agreement, and intending to be legally bound hereby, the Parties hereby agree as follows:

**ARTICLE I**

**Share Exchange**

1.01. <u>Share Exchange</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Share Exchange</u>. On the terms and subject to the conditions set forth in this Agreement, within
 five (5) business days of the date hereof (the "Effective Time") the Transferors
 shall contribute, convey, transfer, assign and deliver to CB, as a contribution, all of their
 right, title and interest in and to the CB Florida Shares, free and clear of all liens and
 encumbrances, and in exchange therefor, CB hereby accepts and agrees to assume all obligations
 with respect to such CB Florida Shares, if any, from and after the Effective Time (the " <u>Share Exchange</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** **Separation. At the Effective Time, the Company will transfer to CB all CB Assets including but not limited to the intellectual property described on Schedule 1,01 hereto.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Costs and Expenses for Transfer of Assets and Liabilities</u>. Any costs and expenses incurred to effect any assignment, transfer, conveyance and delivery contemplated by this <u>Section 1.01</u> shall, except as set forth herein, be the responsibility of the Company. Other than costs and expenses incurred in accordance with the foregoing, nothing in this <u>Section 1.01(b)</u> shall require any Party to incur any material obligation or grant any material concession for the benefit of any member of the other Party in order to effect any transaction contemplated by this <u>Section 1.01</u>. Notwithstanding anything to the contrary in this Agreement, CB shall be liable for the rent of the office space located at 1061 E. Indiantown Rd., Ste. 110, Jupiter, FL 33477, upon CB raising a minimum of $4,000,000 in any public or private offering following the date hereof..

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In the event that at any time after the Effective Time, a Party becomes aware that a CB Asset (as defined below) has not been transferred pursuant to <u>Section 1.01(a)</u>, the Parties shall cause the prompt transfer of such CB Asset; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) On May 7, 2024 CB paid back a note payable in the amount of $300,000 owed to the Company by CB and any other advances to CB by the Company shall be waived as part of the Share Exchange.

1.02. <u>Licenses, Intellectual Property and other Contracts</u>.

All current contracts and agreements, licenses and intellectual property (the "Assets") pertaining to the CB Business are in the name of CB Florida. In the event that any Assets necessary to operate the business of CB are in the Company's name, the Company shall obtain the necessary consents to transfer such Assets to CB.

**ARTICLE II**

**THE CB IPO** 

2.01. <u>Sole and Absolute Discretion; Cooperation</u>.

The Company and CB shall mutually determine the terms of the CB IPO, including the form, structure and terms of any transaction(s) and/or offering(s) to effect the CB IPO and the timing and conditions to the consummation of the CB IPO. CB shall use its reasonable best efforts to accomplish the CB IPO and shall promptly take any and all actions necessary or desirable to effect the CB IPO, including, without limitation, the registration under the Securities Act of 1933, as amended (the Securities Act"), of shares of CB Common Stock on an appropriate registration form or forms.

2.02. <u>Actions Prior to the CB IPO</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to the conditions specified in this Section 2.02, CB shall use its reasonable best efforts to consummate the CB IPO. Such actions shall include, but not necessarily be limited to, those specified in this <u>Section 2.02</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *Registration Statements.* CB shall prepare and file the IPO Registration Statement, and shall file such amendments or supplements thereto, and shall use its reasonable best efforts to cause the same to become and remain effective as required by law, including, but not limited to, filing such amendments to the IPO Registration Statement as may be required the SEC or federal, state or foreign securities laws. The IPO Registration Statement and any preliminary, final or supplemental prospectus forming a part of the Registration Statement (each, a "<u>Prospectus</u>") shall contain such information as is required under the Securities Act. The Company and CB shall also cooperate in preparing, filing with the SEC and causing to become effective a registration statement registering the CB Common Stock under the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Company Shares. The Company shall retain 3,000,000 shares of common stock of CB.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *CB IPO Consultation.* The Company and CB shall consult with each other regarding the timing, pricing and other material matters with respect to the CB IPO.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) *Nasdaq Listing.* CB shall prepare, file and use its reasonable best efforts to have the CB Common Stock approved for listing on Nasdaq Capital Markets ("Nasdaq"), subject to official notice of issuance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) *Reserved*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) *CB IPO Costs.* CB shall pay all third-party costs, fees and expenses relating to the CB IPO, all of the costs of producing, printing, mailing and otherwise distributing the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) *CB Directors and Officers.* On or prior to the Effective Time, the Company and CB shall take all necessary actions so that, as of such time, the directors and executive officers of CB shall be those set forth in the IPO Registration Statement.

2.03. <u>Conditions Precedent to Consummation of the CB IPO</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to <u>Section 2.01</u>, as soon as practicable after the date of this Agreement, the Parties hereto shall use their reasonable best efforts to satisfy the conditions to the consummation of the CB IPO set forth in this <u>Section 2.03</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Share Exchange shall have occurred as contemplated by <u>Section 1.01</u> so that by operation of law CB owns all of the CB Assets or has licenses to any assets necessary to operate the CB Business as conducted by the Company and CB Florida immediately prior to the Effective Time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The IPO Registration Statement shall have been filed with the SEC, and there shall be no stop-order in effect with respect thereto, and no proceeding for that purpose shall have been instituted by the SEC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The shares of CB Common Stock shall have been approved for listing on Nasdaq, subject to official notice of issuance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Reserved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) No order, injunction or decree issued by any court or agency of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the Separation or the CB IPO or any of the other transactions contemplated by this Agreement shall be in effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) Such other actions as the parties hereto may, based upon the advice of counsel, reasonably requested to be taken prior to the Separation in order to assure the successful completion of the Separation and the other transactions contemplated by this Agreement shall have been taken.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) This Agreement shall not have been terminated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) No event or development shall have occurred or exist or be expected to occur that, in the judgment of the Company's Board of Directors, in its sole discretion, makes it inadvisable to effect the Share Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) The $300,000 note payable from CB to the Company has been paid back in full as per <u>Section 1.01(d)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The foregoing conditions are for the sole benefit of the Company and shall not give rise to or create any duty on the part of the Company to waive or not waive such conditions or in any way limit the Company's right to terminate this Agreement or alter the consequences of any such termination from those specified in such Article. This Agreement may only be terminated in accordance with <u>Section 9.01</u>.

**ARTICLE III** 

**THE DISTRIBUTION** 

3.01. <u>Sole and Absolute Discretion; Cooperation</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company shall effect the Distribution as promptly as possible following the Effective Time; <u>provided</u>, <u>however</u>, that prior to the Effective Time, the Company and CB may mutually determine whether to proceed with, the Distribution. The Company shall have the sole discretion to determine the declaration and payment dates of the Distribution at any time prior to the Effective Time, and the payment date as so determined by the Company is referred to herein as the "Distribution Date." The Distribution will not take place unless the IPO Registration Statement is declared effective by the SEC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) CB shall cooperate with the Company to accomplish the Distribution and shall, at the Company's direction, promptly take any and all actions necessary or desirable to effect the Distribution.

3.02. <u>Actions Prior to the Distribution</u>.

Prior to the Distribution Date and subject to the terms and conditions set forth herein, the Parties shall take, or cause to be taken, the following actions in connection with the Distribution:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Securities Law Matters*. The Company and CB shall prepare, prior to the Distribution, for the holders of shares of common stock of the Company, such information concerning CB, its business, operations and management, the Distribution and such other matters as the Company shall reasonably determine and as may be required by law. The Company and CB will prepare and file with the SEC any such documentation, which the Company and CB determine to be necessary or desirable to effectuate the Distribution, and the Company and CB shall each use its reasonable best efforts to obtain all necessary approvals from the SEC with respect thereto as soon as practicable. The IPO Registration Statement, being confidentially submitted, shall serve to have satisfied this requirement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *The Distribution Agent*. The Company shall enter into an agreement with ClearTrust, the Company's transfer agent (the "Agent"), or otherwise provide instructions to the Agent regarding the Distribution.

3.03 <u>Conditions to the Distribution</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The consummation of the Distribution will be subject to the satisfaction, or waiver by the Company in its sole and absolute discretion, of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The actions and filings necessary or appropriate under applicable U.S. federal, U.S. state or other securities laws, including, but not limited to the Securities Act and the Exchange Act and the rules and regulations promulgated thereunder, in connection with the Distribution shall have been taken or made, and, where applicable, have become effective or been accepted by the applicable governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) No order, injunction or decree issued by any governmental authority of competent jurisdiction or other legal restraint or prohibition preventing the consummation of the Distribution or any of the transactions related thereto shall be in effect, and no other event outside the control of the Company shall have occurred or failed to occur that prevents the consummation of the Distribution or any related transactions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The shares of CB Common Stock shall have been approved for listing on Nasdaq, subject to official notice of issuance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The foregoing conditions are for the sole benefit of the Company and shall not give rise to or create any duty on the part of the Company or the Company's board to waive or not waive any such condition or in any way limit the Company's right to terminate this Agreement or alter the consequences of any such termination from those specified herein. Any determination made by the Company's board prior to the Distribution concerning the satisfaction or waiver of any or all of the conditions set forth in <u>Section 2.03(a)</u> shall be conclusive and binding on the Parties. The Company's ability to terminate this Agreement shall cease upon the effectiveness of the IPO Registration Statement.

3.04. <u>The Distribution</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Subject to <u>Section 2.03</u>, on or prior to the Distribution Date, the Company will instruct the Agent to transfer 2,000,000 of the shares of CB Common Stock for the benefit of holders of shares of common stock of the Company on a record date to be determined by the Company (the "<u>Record Date</u>") to effect the Distribution, and shall cause the Agent to distribute, as of the Distribution Date, the appropriate number of whole shares of CB Common Stock to each such holder (the "<u>Record Holder</u>") or designated transferee or transferees of any Record Holder by way of direct registration in book-entry form. The Distribution shall be effective as of the Distribution Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each Record Holder will be entitled to receive in the Distribution a number of whole shares of CB Common Stock equal to the number of shares of common stock of the Company held by such Record Holder on the Record Date multiplied by the distribution ratio to be determined by the Company, rounded up to the nearest whole number.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Until the shares of CB Common Stock are duly transferred in accordance with this <u>Section 3.04</u> and applicable law, from and after the Distribution Date, CB will regard the individuals or entities entitled to receive such shares of CB Common Stock in accordance with this <u>Section 3.04</u> as record holders of shares of CB Common Stock in accordance with the terms of the Distribution without requiring any action on the part of such individuals or entities. CB agrees that, subject to any transfers of such shares, from and after the Distribution Date, (i) each such holder will be entitled to receive all dividends, if any, payable on, and exercise voting rights and all other rights and privileges with respect to, the shares of CB Common Stock then held by such holder, and (ii) each such holder will be entitled, without any action on the part of such holder, to receive evidence of ownership of the shares of CB Common Stock then held by such holder.

**ARTICLE IV** 

**COMPANY RELEASE; INDEMNIFICATION** 

4.01. <u>Release of Pre-Separation Claims</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Company Release of CB.* Effective as of the Effective Time, the Company does hereby, for itself and each of its subsidiaries and their respective successors and assigns, and, to the extent permitted by law, all individuals who at any time prior to the Effective Time have been stockholders, directors, officers, agents or employees of the Company (in each case, in their respective capacities as such), remise, release and forever discharge (i) CB and their respective successors and assigns, including CB Florida, and (ii) all stockholders, directors, officers, agents or employees of CB or CB Florida other than the Company (such persons released in this Section 4.01(a) shall be referred to as the "CB Persons", in each case, in their respective capacities as such), and their respective heirs, executors, administrators, successors and assigns, from (A) all of the liabilities of the Company, (B) all liabilities arising from or in connection with the transactions and all other activities to implement the Separation, the Share Exchange, the CB IPO and the Distribution and (C) all damages arising from or in connection with actions, inactions, events, omissions, conditions, facts or circumstances occurring or existing prior to or following the Effective Time (whether or not such labilities cease being contingent, mature, become known, are asserted or foreseen, or accrue, in each case before, at or after the Effective Time), in each case to the extent relating to, arising out of or resulting from the business of the Company or any liability of the Company (the "<u>Company Liabilities</u>"). To avoid ambiguity, the Company agrees that in the event that an action is brought against the Company related to the Separation, the Share Exchange, the CB IPO or the Distribution, the Company agrees not to bring any claim against CB or any CB Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *No Claims.* The Company shall not make any claim or demand, or commence any judicial proceeding asserting any claim or demand, including any claim of contribution or any indemnification, against CB, or any other CB Person released pursuant to <u>Section 4.01(b)</u>, with respect to any CB Liabilities (as defined below) released pursuant to <u>Section 4.01(b)</u>.

4.02. <u>Indemnification by CB</u>.

Except as otherwise specifically set forth in this Agreement, to the fullest extent permitted by Law, CB shall, indemnify, defend and hold harmless the Company and each stockholder, director, officer, agent or employees of the Company, and each of the heirs, executors, successors and assigns of any of the foregoing (collectively, the "<u>Company Indemnitees</u>"), from and against any and all liabilities of the Company Indemnitees relating to, arising out of or resulting from, directly or indirectly, any of the following items (without duplication):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any CB Business or CB Assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any CB Liability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any failure of CB to pay, perform or otherwise promptly discharge any CB Liability in accordance with their terms, whether prior to, on or after the Effective Time; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) any material breach by CB of this Agreement.

4.03. <u>Indemnification by the Company</u>.

Except as otherwise specifically set forth in this Agreement, to the fullest extent permitted by law, the Company shall, and shall cause the other members of the Company to, indemnify, defend and hold harmless CB and each CB Person or their respective past, present and future directors, officers, employees or agents, in each case in their respective capacities as such, and each of the heirs, executors, successors and assigns of any of the foregoing (collectively, the "<u>CB Indemnitees</u>"), from and against any and all liabilities of the CB Indemnitees relating to, arising out of or resulting from, directly or indirectly, any of the following items (without duplication):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any Company Liability or the Company's assets or business other than the CB Business or the CB Assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any failure of the Company to pay, perform or otherwise promptly discharge any of the Company Liabilities in accordance with their terms, whether prior to, on or after the Effective Time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any breach by the Company of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Company Taxes (as defined below);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) any untrue statement or alleged untrue statement of a material fact or omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, with respect to all information (i) contained in the IPO Registration Statement or any Prospectus (including in any amendments or supplements thereto), (ii) contained in any public filings made by the Company with the SEC following the date of the CB IPO, or (iii) provided by the Company to CB specifically for inclusion in CB's annual or quarterly or current reports following the date of the CB IPO; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) any action brought against CB relating to the CB IPO, the Separation, the Share Exchange or the Distribution.

4.04. <u>Indemnification Obligations Net of Insurance Proceeds and Other Amounts</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Parties intend that any liability subject to indemnification (an "<u>Indemnified Liability</u>"), contribution or reimbursement pursuant to this <u>Article IV</u> will be net of any insurance proceeds or other amounts actually recovered (net of any out-of-pocket costs or expenses incurred in the collection thereof) from any individual or entity by or on behalf of the Indemnitee (as defined below) in respect of any Indemnifiable Liability pursuant to an insurance policy (an "<u>Insurance Policy</u>"). Accordingly, the amount which either Party (an "<u>Indemnifying Party</u>") is required to pay to any person entitled to indemnification or contribution hereunder (an "<u>Indemnitee</u>") will be reduced by any insurance proceeds or other amounts actually recovered (net of any out-of-pocket costs or expenses incurred in the collection thereof) from any person by or on behalf of the Indemnitee in respect of the related Indemnified Liability. If an Indemnitee receives a payment (an "<u>Indemnity Payment</u>") required by this Agreement from an Indemnifying Party in respect of any Indemnified Liability and subsequently receives any insurance proceeds or any other amounts in respect of such Indemnified Liability, then within ten (10) calendar days of receipt of such insurance proceeds, the Indemnitee will pay to the Indemnifying Party an amount equal to the excess of the Indemnity Payment received over the amount of the Indemnity Payment that would have been due if the insurance proceeds or such other amounts (net of any out-of-pocket costs or expenses incurred in the collection thereof) had been received, realized or recovered before the Indemnity Payment was made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Parties agree that it is their intent that an insurer that would otherwise be obligated to pay any claim shall not be relieved of the responsibility with respect thereto or, solely by virtue of any provision contained in this Agreement , have any subrogation rights with respect thereto, it being understood that no insurer or any other Indemnified Party shall be entitled to a "windfall" (*i.e.*, a benefit they would not be entitled to receive in the absence of the indemnification provisions) by virtue of the indemnification and contribution provisions hereof. Each Party shall use commercially reasonable efforts (taking into account the probability of success on the merits and the cost of expending such efforts, including attorneys' fees and expenses) to collect or recover any Insurance Proceeds that may be collectible or recoverable respecting the Indemnified Liabilities for which indemnification or contribution may be available under this <u>Article IV</u>. Notwithstanding the foregoing, an Indemnifying Party may not delay making any indemnification payment required under the terms of this Agreement, or otherwise satisfying any indemnification obligation, pending the outcome of any action to collect or recover insurance proceeds, and an Indemnitee need not attempt to collect any insurance proceeds prior to making a claim for indemnification or contribution or receiving any Indemnity Payment otherwise owed to it under this Agreement.

4.05. <u>Procedures for Indemnification of Third-Party Claims</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Notice of Claims.* If, at or following the Effective Time, an Indemnitee shall receive notice or otherwise learn of the assertion by an individual or entity who is not themselves an Indemnified Party (including any federal, state or foreign government of government agency (a "Governmental Authority") who is not a subsidiary of the Company of any claim or of the commencement by any such person of any action (collectively, a "<u>Third-Party Claim</u>") with respect to which an Indemnifying Party may be obligated to provide indemnification to such Indemnitee pursuant to <u>Section 4.02</u> or <u>4.03</u>, or any other Section of this Agreement, such Indemnitee shall give such Indemnifying Party written notice thereof as soon as practicable, but in any event within fourteen (14) days (or sooner if the nature of the Third-Party Claim so requires) after becoming aware of such Third-Party Claim. Any such notice shall describe the Third-Party Claim in reasonable detail, including the facts and circumstances giving rise to such claim for indemnification, and include copies of all notices and documents (including court papers) received by the Indemnitee relating to the Third-Party Claim. Notwithstanding the foregoing, the failure of an Indemnitee to provide notice in accordance with this <u>Section 4.05(a)</u> shall not relieve an Indemnifying Party of its indemnification obligations under this Agreement, except to the extent to which the Indemnifying Party is actually prejudiced by the Indemnitee's failure to provide notice in accordance with this <u>Section 4.05(a)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *Control of Defense.* Subject to any insurer's rights pursuant to an Insurance Policy of either Party, an Indemnifying Party may elect to defend (and seek to settle or compromise), at its own expense and with its own counsel, any Third-Party Claim; <u>provided</u>, that, prior to the Indemnifying Party assuming and controlling defense of such Third-Party Claim, it shall first confirm to the Indemnitee in writing that, assuming the facts presented to the Indemnifying Party by the Indemnitee being true, the Indemnifying Party shall indemnify the Indemnitee for any such damages to the extent resulting from, or arising out of, such Third-Party Claim. Notwithstanding the foregoing, if the Indemnifying Party assumes such defense and, in the course of defending such Third-Party Claim, (i) the Indemnifying Party discovers that the facts presented at the time the Indemnifying Party acknowledged its indemnification obligation in respect of such Third-Party Claim were not true in all material respects and (ii) such untruth provides a reasonable basis for asserting that the Indemnifying Party does not have an indemnification obligation in respect of such Third-Party Claim, then (A) the Indemnifying Party shall not be bound by such acknowledgment, (B) the Indemnifying Party shall promptly thereafter provide the Indemnitee written notice of its assertion that it does not have an indemnification obligation in respect of such Third-Party Claim and (C) the Indemnitee shall have the right to assume the defense of such Third-Party Claim. Within thirty (30) days after the receipt of a notice from an Indemnitee in accordance with <u>Section 4.5(a)</u> (or sooner, if the nature of the Third-Party Claim so requires), the Indemnifying Party shall provide written notice to the Indemnitee indicating whether the Indemnifying Party shall assume responsibility for defending the Third-Party Claim and specifying any reservations or exceptions to its defense. If an Indemnifying Party elects not to assume responsibility for defending any Third-Party Claim as provided in this <u>Section 4.5(b)</u> or fails to notify an Indemnitee of its election within thirty (30) days after receipt of the notice from an Indemnitee as provided in <u>Section 4.5(a)</u>, then the Indemnitee that is the subject of such Third-Party Claim shall be entitled to continue to conduct and control the defense of such Third-Party Claim. Notwithstanding anything herein to the contrary, to the extent a Third-Party Claim involves or would reasonably be expected to involve both an CB Liability and the Company Liability (collectively, a "<u>Shared Third-Party Claim</u>"), the Company shall have the sole right to defend and control such portion of any Action relating to such Third-Party Claim to the extent it relates to a the Company Liability, and CB shall have the sole right to defend and control such portion of any Action relating to such Third-Party Claim to the extent it relates to an CB Liability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) *Allocation of Defense Costs*. If an Indemnifying Party has elected to assume the defense of a Third-Party Claim, whether with or without any reservations or exceptions with respect to such defense, then such Indemnifying Party shall be solely liable for all fees and expenses incurred by it in connection with the defense of such Third-Party Claim and shall not be entitled to seek any indemnification or reimbursement from the Indemnitee for any such fees or expenses incurred by the Indemnifying Party during the course of the defense of such Third-Party Claim by such Indemnifying Party, regardless of any subsequent decision by the Indemnifying Party to reject or otherwise abandon its assumption of such defense. If an Indemnifying Party elects not to assume responsibility for defending any Third-Party Claim or fails to notify an Indemnitee of its election within thirty (30) days after receipt of a notice from an Indemnitee as provided in <u>Section 4.05(a)</u>, and the Indemnitee conducts and controls the defense of such Third-Party Claim and the Indemnifying Party has an indemnification obligation with respect to such Third-Party Claim, then the Indemnifying Party shall be liable for all reasonable fees and expenses incurred by the Indemnitee in connection with the defense of such Third-Party Claim. In the event of a Shared Third-Party Claim, each Party shall be liable for the portion of the fees and expenses incurred by such Party in connection with the defense of such Shared Third-Party Claim that is equal to the relative portion of such Party's Liability in respect of such Shared Third-Party Claim, and shall be entitled to seek any indemnification or reimbursement from the other Party for any fees or expenses incurred by such Party during the course of the defense of such Shared Third-Party Claim in excess of such fees and expenses that are the responsibility of such Party pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *No Settlement.* Neither Party may settle or compromise any Third-Party Claim for which either Party is seeking to be indemnified hereunder without the prior written consent of the other Party, which consent may not be unreasonably withheld, unless such settlement or compromise is solely for monetary damages that are fully payable by the settling or compromising Party, does not involve any admission, finding or determination of wrongdoing or violation of Law or the Indemnitee and provides for a full, unconditional and irrevocable release of the other Party and the Indemnitee(s) from all Liability in connection with the Third-Party Claim. The Parties hereby agree that if a Party presents the other Party with a written notice containing a proposal to settle or compromise a Third-Party Claim for which either Party is seeking to be indemnified hereunder and the Party receiving such proposal does not respond in any manner to the Party presenting such proposal within thirty (30) days (or within any such shorter time period that may be required by applicable Law or court order) of receipt of such proposal, then the Party receiving such proposal shall be deemed to have consented to the terms of such proposal.

4.06. <u>Right of Contribution</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Contribution.* If any right of indemnification contained in <u>Section 4.02</u> or <u>Section 4.03</u> is held unenforceable or is unavailable for any reason, or is insufficient to hold harmless an Indemnitee in respect of any Indemnified Liability for which such Indemnitee is entitled to indemnification hereunder, then the Indemnifying Party shall contribute to the amounts paid or payable by the Indemnitees as a result of such Indemnified Liability (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party, on the one hand, and the Indemnitee.

4.07. <u>Limitation of an Indemnified Liability</u>.

The indemnification includes all liabilities and expenses incurred in connection with a matter resulting in the right to indemnification, including without limitation, any reasonable fees for independent legal counsel and accountants. No Indemnitee shall be entitled to indemnification for any special, punitive or exemplary damages, except to the extent such damages are finally awarded and actually paid by the Indemnitee to a third party in connection with a Third Party Claim.

4.08. <u>Survival of Indemnification</u>.

The indemnification provisions in this Article IV shall survive until the expiration of the applicable statute of limitations, plus sixty days. The right to indemnification with respect to claims of which notice was given prior to the expiration of the applicable survival period shall survive such expiration until such claim is finally resolved and any obligations with respect thereto are fully satisfied.

**ARTICLE V**

**ACCESS TO INFORMATION; PRIVILEGE**

Section 5.01. <u>Financial Statements and Accounting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Each of CB and the Company agrees to provide the other Party and its auditors reasonable assistance and reasonable access to the properties, books and records, other information and personnel of each Party or any of its subsidiaries set forth in this <u>Section 5.01</u>, from the Effective Time until the completion of each Party's respective audit for the fiscal year ending December 31, 2024, (i) in connection with the preparation and audit of each Party's respective quarterly and annual financial statements for the fiscal year ended December 31, 2024, and (ii) to the extent reasonably necessary to respond (and for the limited purpose of responding) to any written request or official comment from a Governmental Authority;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) CB shall authorize and request its auditors to make reasonably available to the Company's auditors the personnel performing its annual audits and work papers related thereto (subject to the execution of any reasonable and customary access letters that such party's auditors may require in connection with such review of such work papers), in all cases within a reasonable time prior to the Company's auditors' opinion date, so that the Company's auditors are able to perform the procedures they reasonably consider necessary to take responsibility for the work of CB's auditors as it relates to the Company's auditors' report on CB's financial statements, all within sufficient time to enable the Company to meet its timetable for the filing of its annual financial statements.

Section 5.02. <u>Ownership of Information</u>.

Any information owned by one Party or any of its subsidiaries that is provided to a requesting Party pursuant to this <u>Article V</u> shall be deemed to remain the property of the providing Party. Unless specifically set forth herein, nothing contained in this Agreement shall be construed as granting or conferring rights of license or otherwise in any such information.

Section 5.03. <u>Confidentiality</u>.

Notwithstanding any termination of this Agreement, the Parties shall hold, and shall each cause its and their other respective officers, directors, accountants, agents or attorneys ("<u>Representatives</u>") to hold, in strict confidence, and not to disclose or release or use, without the prior written consent of the other Party, any and all non-public information ("<u>Confidential Information</u>") concerning the other Party; <u>provided</u> that the Parties may disclose, or may permit disclosure of, Confidential Information (i) to their respective auditors, attorneys, financial advisors, bankers and other appropriate consultants and advisors who have a need to know such information and are informed of their obligation to hold such information confidential to the same extent as is applicable to the Parties and in respect of whose failure to comply with such obligations, the applicable Party will be responsible, (ii) if the Parties are required or compelled to disclose any such Confidential Information by judicial or administrative process or by other requirements of law or stock exchange rule, (iii) as required in connection with any legal or other proceeding by one Party against the other Party, or (iv) as necessary in order to permit a Party to prepare and disclose its financial statements, tax returns or other disclosures required by applicable law, including the rules and regulations of any securities exchange such Party's securities are traded on. Notwithstanding the foregoing, in the event that any demand or request for disclosure of Confidential Information is made pursuant to clause (ii) above, each Party, shall promptly notify the other of the existence of such request or demand and shall provide the other a reasonable opportunity to seek an appropriate protective order or other remedy, which such Parties will cooperate in obtaining. In the event that such appropriate protective order or other remedy is not obtained, the Party whose Confidential Information is required to be disclosed shall or shall cause the other Party to furnish, or cause to be furnished, only that portion of the Confidential Information that is legally required to be disclosed and shall take commercially reasonable steps to ensure that confidential treatment is accorded such information.

Section 5.04. <u>Limitation of Liability</u>.

IN NO EVENT SHALL ANY PARTY BE LIABLE TO THE OTHER PARTY OR ANY OF ITS SUBSIDIARIES FOR PUNITIVE, CONSEQUENTIAL, SPECIAL OR INDIRECT DAMAGES, INCLUDING LOSS OF FUTURE PROFITS, REVENUE OR INCOME, DIMINUTION IN VALUE OR LOSS OF BUSINESS REPUTATION OR OPPORTUNITY, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS AGREEMENT, REGARDLESS OF WHETHER SUCH DAMAGES WERE FORESEEABLE OR SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES EXCEPT TO THE EXTENT AWARDED BY A COURT OF COMPETENT JURISDICTION IN CONNECTION WITH A THIRD-PARTY CLAIM.

Section 5.05 <u>Liability for Information Provided</u>.

No Party shall have any Liability to the other Party in the event that any information exchanged or provided pursuant to this <u>Article V</u> is found to be inaccurate, in the absence of intentional misconduct by the Party providing such information.

**ARTICLE VI**

**CERTAIN OTHER MATTERS**

Section 6.01. <u>Insurance</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company and CB agree that from and after the Effective Date they shall maintain their own insurance policies, except that the Company's general liability policy shall cover CB to the extent that they share premises.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) CB shall notify the Company, as promptly as practicable, of any claim made by CB pursuant to this <u>Section 6.01</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as provided in <u>Section 6.01(a)</u>, from and after the Effective Date, CB shall not have any rights to or under any of the Policies of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) This Agreement shall not be considered as an attempted assignment of any policy shared by and between the Company and CB or CB Florida or as a contract of insurance and shall not be construed to waive any right or remedy of the Company in respect of any policy shared by and between the Company and CB or CB Florida.

Section 6.02. <u>Bulk Sales Laws</u>.

Each Party hereby waives compliance with the requirements and provisions of the "bulk-sale" or "bulk-transfer" Laws of any jurisdiction that may otherwise be applicable with respect to any of the transactions contemplated in this Agreement.

Section 6.03. <u>Shared Employees and Premises</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) *Reserved*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) *Office and Facilities*. Currently both the Company and CB share the same office premises and related facilities. The Company agrees that CB may maintain its presence at the current office location until such time as it is mutually agreed that CB requires its own office and facilities, or the Parties agree on a monthly sub-lease arrangement.

Section 6.04. <u>Further Actions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as otherwise provided in this Agreement, the Parties shall use their commercially reasonable efforts to take, or cause to be taken, all appropriate action, to do, or cause to be done, and to assist and cooperate with the other Party in doing, all things necessary, proper or advisable under applicable Law to execute and deliver the this Agreement, and such other documents and other papers as may be required to carry out the provisions of this Agreement and to consummate and make effective the transactions contemplated by this Agreement (the "Transaction Documents").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) From time to time after the Effective Time, without additional consideration, each Party shall execute and deliver such further instruments and take such other action as may be necessary or is reasonably requested by the other Party to make effective the transactions contemplated by this Agreement and the other Transaction Documents. Without limiting the foregoing, upon reasonable request of a Party, the other Party shall execute, acknowledge and deliver all such further assurances, deeds, assignments, consequences, powers of attorney and other instruments and papers as may be required for the transfer of direct or indirect ownership of the applicable Transferred Assets, as contemplated by this Agreement.

**ARTICLE VII** 

**REPRESENTATIONS AND WARRANTIES**

Section 7.01 <u>Mutual Representations</u>.

Each party hereto represents and warrants to the other that (i) it is duly authorized to enter into and perform this Agreement and has duly executed and delivered this Agreement, (ii) the execution, delivery and performance of its obligations under this Agreement will not conflict with or result in a breach of or default under or a violation of its or its subsidiaries' organizational documents, any material contract to which it is a party or by which any of its assets or subsidiaries are bound or any order, judgment, decree, permit, statute, law, rule or regulation to which it or any of its subsidiaries is subject, and (iii) this Agreement constitutes its valid and binding obligation, enforceable in accordance with its terms, subject to (A) bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement generally of creditors' rights and remedies, (B) general principles of equity (regardless of whether considered in a proceeding at law or in equity), including the discretion of any court of competent jurisdiction in granting specific performance or other equitable relief, and (C) an implied duty to take action and make determinations on a reasonable basis and in good faith.

Section 7.02 <u>Company Representations and Warranties</u>.

The Company represents and warrants to CB that (i) the assets and intellectual property of CB Florida include all tangible and intangible assets currently used in and necessary to conduct the CB Business as conducted by the Company and CB Florida immediately prior to the Effective Time (the "<u>CB Assets</u>"), including those assets accounted for in CB Florida's audited balance sheet for the year ended December 31, 2023 (the "<u>Balance Sheet</u>") as included in the IPO Registration Statement, and none of such CB Assets are owned by any other person, and (ii) the liabilities of CB Florida only consist of the liabilities exclusively related to the CB Business (the "<u>CB Liabilities</u>") and such liabilities are all accounted for in the Balance Sheet and will be repaid in the normal course of business of CB. From and after the date of the Balance Sheet, CB Florida has not incurred any liabilities not in the ordinary course of the CB Business or unrelated to the CB Business. The IPO Registration Statement shall include all material changes in the CB Assets or CB Liabilities since the date of the Balance Sheet through the date of the prospectus included therein.

**ARTICLE VIII** 

**TAX MATTERS**

Section 8.01. <u>Tax Indemnification</u>.

The Company shall be liable for, and shall indemnify and hold CB harmless from and against, any liability for taxes on the Company or imposed with respect to the income, receipts, property, profits, wages, capital, net worth, employees or operations of the Company attributable to any period prior to the Effective Time (the "<u>Pre-Separation Tax Period</u>") (including, for the avoidance of doubt, any withholding taxes imposed on payments made by CB to the Company) (the "<u>Company Taxes</u>"). CB shall be liable for, and shall indemnify and hold harmless the Company from and against, any liability for taxes imposed on CB or imposed with respect to the income, receipts, property, profits, wages, capital, net worth, employees or operations of CB attributable to any period after the Separation, inclusive of the date of the Effective Time (the "<u>Post-Separation Tax Period</u>") (including, for the avoidance of doubt, any withholding taxes) (the "<u>CB Taxes</u>").

Section 8.02. <u>Tax Contests</u>.

Each Party shall promptly notify the other Party in writing upon receipt by such Party or any of its officers or directors of a written communication from any governmental authority responsible for the collection of taxes (a "<u>Taxing Authority</u>") with respect to any pending or threatened audit, claim, dispute, suit, action, proposed assessment or other proceeding (a "<u>Tax Contest</u>") concerning any taxes for which the other Party may be liable pursuant to this Agreement. In the case of any Tax Contest relating to the Company Taxes that is undertaken against CB, CB shall (i) use reasonable best efforts to keep the Company informed regarding the progress and substantive aspects of such Tax Contest, (ii) offer the Company a reasonable opportunity to comment before submitting to any Taxing Authority any written materials prepared or furnished in connection with such Tax Contest, and allow the Company to participate in any related meeting or telephonic conference with the applicable Taxing Authority and (iii) not settle or otherwise dispose of any item subject to such Tax Contest that could reasonably be expected to adversely affect the Company without obtaining the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. In the case of any Tax Contest relating to CB Taxes that is undertaken against the Company, the Company shall (i) use reasonable best efforts to keep CB informed regarding the progress and substantive aspects of such Tax Contest, (ii) offer CB a reasonable opportunity to comment before submitting to any Taxing Authority any written materials prepared or furnished in connection with such Tax Contest, and allow CB to participate in any related meeting or telephonic conference with the applicable Taxing Authority and (iii) not settle or otherwise dispose of any item subject to such Tax Contest that could reasonably be expected to adversely affect CB without obtaining the prior written consent of CB, which consent shall not be unreasonably withheld, conditioned or delayed.

Section 8.03. <u>Cooperation</u>.

The Parties shall cooperate (and cause their respective Affiliates to cooperate) with each other and with each other's agents, including accounting firms and legal counsel, in connection with Tax matters relating to the Parties and their Affiliates, including (i) preparation and filing of Tax returns, (ii) determining the liability for and amount of any Taxes due (including estimated Taxes) or the right to and amount of any refund of Taxes, (iii) examinations of Tax returns, and (iv) any administrative or judicial proceeding in respect of Taxes assessed or proposed to be assessed. Such cooperation shall include making all information and documents in their possession relating to the other Party and its Affiliates reasonably available to such other Party. Each Party shall also make available to the other Party, as reasonably requested and available, personnel (including officers, directors, employees and agents of the Parties or their respective Affiliates) responsible for preparing, maintaining, and interpreting information and documents relevant to Taxes, and personnel reasonably required as witnesses or for purposes of providing information or documents in connection with any administrative or judicial proceedings relating to Taxes. Any information or documents provided under this <u>Section 8.03</u> shall be kept confidential by the Party receiving the information or documents, except as may otherwise be necessary in connection with the filing of Tax returns or in connection with any administrative or judicial proceedings relating to Taxes. In addition, in the event that a Party determines that the provision of any information or documents to the other Party could be commercially detrimental, violates any law or agreement or waive any Privilege, the Parties shall use commercially reasonable efforts to permit each other's compliance with its obligations under this <u>Section 8.03</u> in a manner that avoids any such harm or consequence.

**ARTICLE IX**

**GENERAL PROVISIONS**

Section 9.01. <u>Termination</u>.

This Agreement may be terminated and the Separation and the Distribution may be abandoned at any time prior to the Effective Time by and in the sole discretion of the Company; provided, however, that this Agreement and the Separation and the Distribution may not be terminated or abandoned following the effectiveness of the Registration Statement.

Section 9.02. <u>Survival of Covenants</u>.

Except as expressly set forth in this Agreement or any other Transaction Document, all covenants and agreements contained in this Agreement and each of the other Transaction Documents shall survive the Distribution and remain in full force and effect in accordance with their applicable terms.

Section 9.03. <u>Expenses</u>.

Except as otherwise specified in this Agreement, all costs and expenses, including fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated by this Agreement shall be borne by the Party incurring such costs and expenses.

Section 9.04. <u>Notices</u>.

All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and, in the case of delivery in person or by overnight mail, shall be deemed to have been duly given upon receipt) by delivery in person or overnight mail to the respective parties or delivery by electronic mail transmission (providing confirmation of transmission) to the respective Parties. Any notice sent by electronic mail transmission shall be deemed to have been given and received at the time of confirmation of transmission. However, if such electronic mail transmission is sent after 5:00 pm, Eastern Time, notice shall be deemed to have been given on the next business day. All notices, requests, claims, demands and other communications hereunder shall be addressed as follows, or to such other address or email address for a Party as shall be specified in a notice given in accordance with this <u>Section 9.04</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if to the Company:

Safety Shot, Inc.

1061 E. Indiantown Rd., Suite 110

Jupiter, FL 33477

Email: <u>jboon@drinksafetyshot.com</u>

Attention: Jarrett Boon

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if to CB or CB Florida:

Caring Brands, Inc.

1061 E. Indiantown Rd., Suite 110

Jupiter, FL 33477

Email: <u>drwilson@caringbrands.com</u>

Attention: Glynn Wilson

with a copy to (which shall not constitute notice):

Sichenzia Ross Ference Carmel LLP

1185 Avenue of the Americas, 31<sup>st</sup> Floor

New York, NY 10036 USA

Email: <u>amarcus@srfc.law</u>

Attention: Arthur Marcus

Section 9.05. <u>Public Announcements</u>.

From and after the Effective Time, the Parties shall consult with each other before issuing, and give each other the opportunity to review and comment upon, that portion of any press release or other public statements that relates to the transactions contemplated by this Agreement, and shall not issue any such press release or make any such public statement prior to such consultation, except: (a) as may be required by applicable law or applicable stock exchange regulation, in which case the Party that is so required shall, to the extent legally permissible, consult with the other Party before issuing such press release or making such public statement; (b) for disclosures made that are substantially consistent with disclosure contained in the IPO Registration Statement or related prospectus or any press release or public statement previously issued with the prior written consent of the other Party; or (c) as may pertain to disputes between CB, on one hand, and the Company on the other hand.

Section 9.06. <u>Severability</u>.

If any provision of this Agreement shall be held to be illegal, invalid or unenforceable under any applicable law, then such contravention or invalidity shall not invalidate the entire Agreement. Such provision shall be deemed to be modified to the extent necessary to render it legal, valid and enforceable, and if no such modification shall render it legal, valid and enforceable, then this Agreement shall be construed as if not containing the provision held to be invalid, and the rights and obligations of the Parties shall be construed and enforced accordingly.

Section 9.07. <u>Entire Agreement; Construction</u>.

This Agreement constitutes the entire agreement of the Parties and their Affiliates (as defined below) with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both written and oral, among the Parties with respect to the subject matter hereof and thereof, including, but not limited to, the Original Agreement.

Section 9.08. <u>Assignment</u>.

This Agreement may not be assigned by a Party without the consent of the other Party; <u>provided</u> that a Party may assign this Agreement or any of its rights and obligations hereunder to an entity that controls, is controlled by, or is under common control with such Party (an "<u>Affiliate</u>") without the consent of the other Party <u>provided</u> that (a) no such assignment shall relieve the assignor of any of its obligations hereunder and (b) such rights shall be assigned back to the assigning Party if such Affiliate ceases to be an Affiliate of the assigning Party; provided, however, that this Agreement may not be assigned following the pricing of the CB IPO. Any attempted assignment that is not in accordance with this <u>Section 9.08</u> shall be null and void.

Section 9.09. <u>Amendment</u>.

This Agreement may not be amended or modified except (a) by an instrument in writing signed by, or on behalf of, each Party that expressly references the Section of this Agreement to be amended or (b) by a waiver in accordance with <u>Section 9.10</u>.

Section 9.10. <u>Waiver</u>.

Any Party may (a) extend the time for the performance of any of the obligations or other acts of the other Party; (b) waive any inaccuracies in the representations and warranties of the other Party contained herein or in any document delivered by the other Party pursuant to this Agreement; or (c) waive compliance with any of the agreements of the other Party or conditions to such obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the Party to be bound thereby. Notwithstanding the foregoing, no failure or delay by any Party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or future exercise of any other right hereunder. Any waiver of any term or condition hereof shall not be construed as a waiver of any subsequent breach or as a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement.

Section 9.11. <u>Specific Performance</u>.

The Parties acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Each Party agrees that, in the event of any breach or threatened breach by the other Party of any obligation contained in this Agreement, the non-breaching Party shall be entitled to (a) an order of specific performance to enforce the observance and performance of such obligation and (b) an injunction restraining such breach or threatened breach. Each Party further agrees that the non-breaching Party shall not be required to obtain, furnish or post any bond or similar instrument in connection with or as a condition to obtaining any remedy referred to in this <u>Section 9.11</u>, and each Party irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument.

Section 9.12. <u>Governing Law</u>.

This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without giving effect to any applicable principles of conflict of laws that would cause the laws of another state to otherwise govern this Agreement.

Section 9.13. <u>Waiver of Jury Trial</u>.

EACH OF THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION AMONG THE PARTIES DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT. EACH OF THE PARTIES (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <u>SECTION 9.13</u>.

Section 9.14. <u>No Duplication; No Double Recovery</u>.

Nothing in this Agreement is intended to confer to or impose upon any Party a duplicative right, entitlement, obligation or recovery with respect to any matter arising out of or resulting from the same facts and circumstances (including with respect to the rights, entitlements, obligations and recoveries that may arise out of <u>Article IV</u>).

Section 9.15. <u>Mutual Drafting</u>.

The Parties have participated jointly in the negotiation and drafting of this Agreement with the assistance of counsel and other advisors and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement or interim drafts of this Agreement.

Section 9.16. <u>Counterparts</u>.

This Agreement may be executed in any number of counterparts and by different Parties in separate counterparts, and delivered by means of electronic mail transmission or otherwise, each of which when so executed and delivered shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement.

IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed as of the date first written above by its respective officers thereunto duly authorized.

---

| | |
|:---|:---|
| SAFETY SHOT, INC. (Delaware Corporation) | SAFETY SHOT, INC. (Delaware Corporation) |
| By: | */s/ Jarrett Boon* |
| Name: | Jarrett Boon |
| Title: | Chief Executive Officer |
| CARING BRANDS, INC (Nevada Corporation) | CARING BRANDS, INC (Nevada Corporation) |
| By: | */s/* Glynn Wilson |
| Name: | Glynn Wilson |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| CARING BRANDS, INC (Florida Corporation) | CARING BRANDS, INC (Florida Corporation) |
| By: | */s/* |
| Name: |  |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| Shareholder Representative | Shareholder Representative |
| By: | */s/* Brian S. John |
| Name: | Brian S. John |

---

[Signature Page to Stock Exchange Agreement]

**<u>SCHEDULE I</u>**

**CB Florida Shareholders**

---

| | |
|:---|:---|
| **Name** | **Number of Shares** |

---

## Exhibit 10.7

**Exhibit 10.7**

**TRIPARTITE AGREEMENT TO MANUFACTURE, SELL AND DISTRIBUTE**

THIS TRIPARTITE AGREEMENT TO MANUFACTURE, SELL AND DISTRIBUTE ("Agreement") is made and executed on this 1st day of September, 2022.

**By and Between**

**Jupter Wellness Inc** , a company existing under Laws of United States of America and having its Registered Office at 109 E. 17th **St., Suite 5925, Cheyenne, WY 82001 USA** (hereinafter referred to as **"JW"** which expression shall, unless otherwise repugnant to the context thereof, be deemed to include its successors and permitted assigns)

**AND**

**COSMOFIX TECHNOVATION PVT LTD** a company registered under the Companies Act, 1956 bearing CIN Number U24290MH2022PTC375154 having its Registered Office at Cosmofix Technovation Private Limited ,306, BUILDING NO 2C, BUSINESS CLASSIC CHS LTD CHINCHOLI SUNDER ROAD.MALAD WEST, MUMBAI - 400064 (hereinafter referred to as **"COSMOFIX",** which expression shall, unless otherwise repugnant to the context thereof, be deemed to include its permitted assigns)

**AND**

**SANPELLEGRINO COSMETICS PRIVATE LIMITED,** a company registered under the Companies Act, 1956 bearing CIN Number U51909DL2013PTC248536 having its Registered Office at IS, Chelmsford Country Club (hereinafter referred to as **"SCPL",** which expression shall unless repugnant to the context or meaning thereof be deemed to include its successors and permitted assigns).

**WHEREAS:**

&nbsp;&nbsp;&nbsp;&nbsp;A. **JW** is a Biotechnology company in United States of America and is, inter alia, engaged has
 been carrying on the business of focusing on hair science including breakthrough drugs and
 medical devices for the treatment of hair disorders.;

B. COSMOFIX
 & SCPL have signed a Term Sheet dated 3rd February 2022, wherein SCPL has granted to
 COSMOFIX an exclusive, perpetual and a right to sub-license and to use and exploit the proprietary
 Know-How required to manufacture distribute, market and sell products (Know-How) in the territories
 listed in Annexure A.

![](ex10-7_004.jpg)

Page 1 of **10**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Using
 technical information given by **JW** & **SCPL,** Cosmofix wish to manufacture
 products, sell, distribute to various customers in countries as mentioned in **Annexure A.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. **Cosmofix** has also assured, represented and warranted that it has obtained all licenses, authorizations
 and necessary permissions required by law for the manufacturing of drugs, pharmaceutical,
 dermaceutical, health, nutrition, cosmetics products etc and that all such licenses, authorizations
 and permissions are presently in full force and effect and shall be kept in full force and
 effect during the entire term of this Agreement in accordance with the laws and regulations
 applicable from time to time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. **JW and SCPL** have agreed to grant to COSMOFIX an exclusive, irrevocable, perpetual and a
 right to sub-license and to use and exploit the proprietary Know-How required to manufacture
 distribute, market and sell products (Know-How) in the territories listed in Annexure A and
 treat Cosmofix as it's exclusive manufacturing licensee and distributor for countries
 mentioned in Annexure A.

NOW THEREFORE THIS AGREEMENT WITNESSETH and it is hereby agreed by and between the parties hereto as follows:

**1.** **Definitions and Interpretations:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1.** **Definitions:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. **"Applicable Laws"** means all applicable international, central, state, provincial and local
 laws, statutes, codes, rules, regulations, directives, guidelines, ordinances, orders, decrees,
 standards or other pronouncements of any governmental, administrative or judicial authority,
 whether currently in existence or hereafter promulgated, enacted, adopted or amended, in
 India, including, those dealing with occupational safety and health, those dealing with public
 safety and health, Environmental Laws, labour laws, service laws, tax laws and economic laws,
 The Drugs and Cosmetics Act, 1940, Environmental Laws, Good Manufacturing Guidelines (under
 Schedule M of the rules under the Drugs and Cosmetics Act, 1940) and Good Clinical Practice
 Guidelines issued by the Central Drugs Standard Control Organization (COSCO), Ministry of
 Health and Family Welfare, Government of India, Standards of Weights & Measures Act,
 Standards of Weights & Measures (Packaged Commodities) Rules, safety laws and Pollution
 Control Acts, the Central Excise Act and the Rules.

b. **"Affiliate"** means with respect to a Party, any person or entity, whether directly or indirectly,
 controlling, controlled by, or under common control with, such person, or entity, as applicable.
 For the purposes of this definition, the term "control" means (i) direct or indirect
 ownership of more than fifty percent (50%) of the equity having the power to vote on or direct
 the affairs of such Party or person or entity, as applicable, or (ii) the power to direct
 decisions of such Party or person or entity, as applicable, including the power to direct
 management and policies of such Party or person or entity, as applicable, whether by reason
 of ownership, by agreement or otherwise.

![](ex10-7_004.jpg)

Page 2 of **10**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. **"Confidential Information"** shall mean all non-public and proprietary information, in whatever
 form (whether tangible, orally communicated, physically communicated or disclosed in writing
 or otherwise including without limitation information disclosed by samples) which has been,
 is or will be disclosed by and between **JW, SCPL** and **Cosmofix,** during the term
 of this agreement relating to inventions, processes, products, designs and quality standards
 and specifications/ compositions formula and formulations, know-how, test and other data
 and other information relating to the development analysis, approval, manufacture and packing
 of pharmaceutical products, as defined herein but not limited to, any kind of business, commercial
 or technical information and data disclosed by and between **JW, SCPL and Cosmofix** in
 connection with this agreement irrespective of the medium in which such information or data
 is embedded. Any confidential information provided by the disclosing party to the recipient
 at any point of time will be marked as "Confidential". Provided that Confidential
 Information shall not include that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. At
 the time of disclosure is known publicly or thereafter becomes known publicly through no
 fault of such Recipients or its agents;

ii. Becomes
 available to such Recipients other than on a confidential basis from a third party who is
 lawfully in possession of such information and not subject to contractual or fiduciary relationship
 to the Discloser with respect thereto;

iii. Was
 developed by such Recipient independently of such information obtained from the Discloser
 and such independent development can be properly demonstrated with written records by the
 Recipients; or

iv. Was
 already known to such Recipient before receipt from the Discloser as shown by its prior written
 records.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. **"Compliance Information"** shall mean and include but shall not be limited to i)
the specifications/ compositions prescribed by **JW** & **SCPL** ii) the applicable laws and iii) the quality and standards
prescribed by **JW** iv) the pharmacopoeia requirements v) good manufacturing practices as per the applicable laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. **"Effective Date"** shall mean the date of commencement of this Agreement shall be from the date
 of execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. **"Product"** shall mean and include the products listed in **Annexure B.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. "Intellectual
 Property Right **(IPR)"** means "Patents, Trademark and Copyright" in
 connection with the manufacture, supply and delivery of the Products. Trademark includes
 the registered/unregistered Trademarks / trade name/ trade dress / product name/ labels/
 designs of **JW** & SCPL used by **Cosmofix** during the term of this agreement
 for a limited purpose of mentioning such trademark
in the finished product. Copyright includes artwork, design in the label and packing materials, etc.

![](ex10-7_004.jpg)

Page 3 of **10**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h. "Licensed
 Use" means permitted and limited use of the IPR by Cosmofix solely for the purpose
 of manufacturing the said products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. **"Manufacture"** with its grammatical variations means any manufacturing, processing, testing, filling,
 packaging, storage, release, sourcing and other activities undertaken by **Cosmofix** for the manufacture of the Products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j. **"Packaging Materials"** shall mean materials used for packaging the Product, including, without
 limitation, vials, stoppers, caps, pouches, labels, leaflets, printing materials, secondary
 and tertiary packing material.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k. **"Raw Material"** shall mean the ingredients, all auxiliary material and excipients used
 in the Manufacture of the Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l. **"Specifications"** shall mean the standards and specifications provide by **JW** & SCPL relating
 to the Product as set out in **Appendix B.** 

2. **Nature of the Agreement:** Using technical information given by **JW 8: SCPL, Cosmofix** shall
 manufacture Products and sell it to various customers in the list of countries as listed
 in **Annexure A. Cosmofix** shall also obtain from the concerned authorities of those
 countries and maintain at all times during the continuance of this Agreement all authorizations,
 permits, approvals and licenses requisite, usual, expedient or proper in relation to or in
 connection with the manufacturing, packaging and selling of the Products under this Agreement.
 The parties may mutually agree and decide upon change in Product specifications/compositions.
 The parties may add/delete products from the list of products attached in **"Annexure B".** The Products shall bear the name and address of **JW** *I* SCPL with
 a legend **"Manufactured** & **Marketed by" "Cosmofix Technology Pvt Ltd."** on labels/cartons of each individual pack of the Product manufactured
 pursuant to this Agreement. JW shall have the right to purchase products from Cosmofix at
 cost+ 10%.

3. **Rights and duties:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.1.** **Of JW 8: SCPL:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. JW
 8: **SCPL** hereby grants to **Cosmofix** a irrevocable, assignable, perpetual and
 exclusive license to manufacture, sale and distribute products of **AB** for Sale and
 Distribution in Countries as mentioned in Annexure A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. **JW 8: SCPL** shall provide to **Cosmofix Know How. Know How** includes among other things,
 all technical information, procedures, processes, trade secrets, formulae for the product,
 methods, practices, techniques, information, specifications, lists of materials, labor &
 general costs, production manuals, manufacture,
production, inspection, and testing known by and available to , used and owned by **JW** & **SCPL** 

Page 4 of **10**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. **JW** & **SCPL** shall bear any and all costs related to required Technology Transfer
 not including the costs related to testing and validation of the batches as long

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. The
 obligation to furnish the **Know How** shall extend to **Know How** existing at the
 date of this agreement and to any relevant **Know How** which is acquired by **JW** or made improvement or enhancement to such **Know How** in future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. JW
 & SCPL shall provide Cosmofix with marketing guidelines for the Products as well as any
 reasonable help eventually required by Cosmofix in relation to the training of the sales
 force and the marketing of Products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. **JW/ SCPL** shall provide to **Cosmofix,** Technology Transfer License, QC of Batches, Training
 twice a year in India at the expense of Cosmofix, provide continuous support for marketing
 activities via lectures twice a year, Free access to Product improvements, Assistance in
 Documentation for registration, Access to future products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2. **Of Cosmofix:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. **Cosmofix** hereby agrees and undertakes to manufacture, test the Products mentioned in **"Annexure A".** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. **Cosmofix** undertakes to have the products manufactured using the Know How pursuant to **JW's** & **SCPL** specifications, and in compliance with all the applicable laws. For
 the purpose of this agreement, the term Applicable Laws shall include, but not be limited
 by any law, regulation, rule, guideline, best practice or other requirements of the competent
 Authorities in the territory, concerning the manufacture, storage, use, marketing distribution
 and sale of the Products, and/or order, judgment having effect from time to time in the territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The
 products packaging shall be in accordance with any specification provided by **JW** in
 compliance with Applicable laws of the relevant territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. All
 manufacturing activities shall be performed in compliance with **AB** & **SCPL** quality
 system specification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. At
 any time on specific request by JW & SCPL, Cosmofix shall provide JW/ SCPL with a sample
 of any product, in order to allow **AB** / SCPL to perform quality control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. **Cosmofix** undertakes, at its own responsibility and cost, to file, in the name of **Cosmofix,** any marketing authorization application required by the relevant applicable laws in order
 to place the Products in the Territories. For this purpose, **JW** / **SCPL** shall
 provide to **Cosmofix at Cosmofix sole expense,** any information required by the competent
 authority in order to obtain such marketing authorization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. **Cosmofix** shall be responsible for the payment for all regulatory fees and expensed relate to the
 marketing authorization and the relevant maintenance, including renewals thereof.

![](ex10-7_004.jpg)

Page 5 of **10**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Royalties** 

In consideration of the Know How, **Cosmofix** shall pay to JW Royalties as specified in Annexure C. In addition to an Upfront of USD20,000 to JW.

During the term of this Agreement, In the first year Cosmofix will pay JW $25,000 after launch of all products, From 2nd year onwards if in any given calender year Cosmofix failes to pay royalties less than $50,000 USD per year to JW, JW has the right to terminate this Agreement with a 30 days notice with no further obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Miscellaneous** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**a)** **Governing Law and Dispute Resolution** 

The Definitive Agreement shall be governed by the laws of India. Any dispute Arising out of this Term Sheet shall be settled in the courts of Mumbai, India.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**b)** **Cosmofix** shall undertake to complete with diligence its accounting records and to maintain complete
 and accurate records of all transactions involving its sale and distribution of the Products.

JW *I* SCPL shall have the right, at all times, upon adequate prior notice to **Cosmofix,** to have access to the abovementioned documentation and to any material, including packaging components and labelling, related to the Products, as well as to manufacturing plant, in order to verify their compliance with the Agreement.

In case the Audit reveals a breach of **Cosmofix's** obligations unde the Agreement, **Cosmofix** shall bear all costs of the Audit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Term:** 

This TRIPARTITE AGREEMENT TO MANUFACTURE, SELL AND DISTRIBUTE shall be effective from date of this agreement for a period of 3 years and after that, shall automatically renew for a period for 1 years unless either party give a 30 days advance notice. Nothwithstanding the foregoing, during the term of this Agreement, if in any given calender year Cosmofix failes to pay royalties less than $50,000 USD per year to JW 2<sup>nd</sup> year onwards , JW has the right to terminate this Agreement with a 30 days notice with no further obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **Amendment:** 

Any amendment to this agreement shall be valid when accepted and signed by all the three parties, JW, SCPL and Comsofix

Signature Page Follows

![](ex10-7_004.jpg)

Page 6 of **10**<br>

Page 7 of **10**<br>

Annexure A

List of Countries

India , Nepal, Bangladesh, Sri Lanka , Vietnam , Phillipines , Malaysia , Cambodia , laos , Indonesia , Uae , Egypt , Algeria , Tunisia , Congo Nigeria , Kenya , Thailand , Algeria ,Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia

![](ex10-7_004.jpg)

Page 8 of **10**<br>

Annexure B

List of Products

Photocil

Minoxidil Booster

After Minoxidil Spray

![](ex10-7_004.jpg)

Page 9 of **10**<br>

Annexure C

Royalty Payments to JW

![](ex10-7_003.jpg)

![](ex10-7_004.jpg)

Page 10 of **10**<br>

## Exhibit 10.8

**Exhibit 10.8**

**LICENSE AGREEMENT**

THIS LICENSE AGREEMENT (this "Agreement") is made and entered into as of May 1, 2022 (the "Effective Date"), by and between Applied Biology Inc. ("Applied Biology"), a Wyoming Corporation having its principal place of business at 109 E. 17th St., Cheyenne, WY 82001 USA and TAISHO PHARMACEUTICAL CO., LTD., a company organized and existing under the laws of Japan with its registered office at 3-24-1,Takada Toshima-ku, Tokyo 170-8633 Japan ("Taisho").

WHEREAS, Applied Biology has or shall develop certain proprietary technology related to minoxidil boosters;

WHEREAS, Applied Biology and Taisho desire to enter into a license agreement whereby Taisho has the right to become the exclusive licensee for such products in Japan;

NOW, THEREFORE, Applied Biology and Taisho hereby agree as follows:

**ARTICLE** I

**DEFINITIONS**

The defined terms set forth herein shall have the meanings as indicated below, except where the context otherwise requires, and shall be equally applicable in the singular or the plural form.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 **"Agreement Payments"** shall mean as defined in Section 4.4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 **"Applied Biology** IP" shall mean the inventions, proprietary technology, copyrights, Patents, Know-How, Trademark, trade-secrets and any other intellectual property of Applied Biology with respect to the Product. For the avoidance of doubt, Applied Biology New Technology shall be included into Applied Biology IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 **"Applied Biology New Technology"** shall mean as defined in Section 1.15.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 **"Audit"** shall mean as defined Section 4.5.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 **"Business Day"** shall mean days between and including Monday to Friday and shall not include public holidays in USA and Japan and weekends (Saturday and Sunday).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 **"Confidentiality Agreement"** shall mean the Confidentiality Agreement as of January 18, 2021 between Applied Biology and Taisho.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 **"Competing Products"** shall mean products with the same formulation and content with the Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.8 "Existing Patent"** shall mean all issued patents and patent applications relating to the Product as of the Effective Date set forth on Schedule I which is included in Applied Biology IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 **"Inventions"** shall mean discoveries, improvements, processes, formulas, data, inventions, know-how and trade secrets, patentable or otherwise, developed or invented in connection with the Product during the Term of this Agreement, including all intellectual property rights therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 **"Infringement"** shall mean as defined Section 7.5.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 **"Joint New Technology"** shall mean as defined in Section 1.15.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 **"Know-How"** shall mean any and all proprietary or confidential information and materials (including samples of products, and active pharmaceutical ingredients and drug substances), now existing or hereafter arising, which are necessary or useful in connection with, the research, development, marketing, manufacture and having manufactured, advertising, promotion, distribution, import, or sale of the Product in the Territory during the Term of this Agreement, whether patentable or not, including: (i) trade secrets and know-how; (ii) specifications, discoveries, inventions methods, procedures, formulas, processes, tests, assays, techniques; (iii) test data, including pharmacological, toxicological, clinical and non-clinical test data; (iv) safety and quality control data and information; and (v) technical and non-technical data and other information related to the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13 **"Liabilities"** shall mean as defined in Section 9.1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14 **"Net Sales"** shall mean in the ordinary course of business and with respect to Taisho on a basis consistent with Taisho's audited financial statements, the total gross revenues invoiced by Taisho for the Products to independent or unaffiliated third party purchasers of the Products (e.g., wholesalers, medical institutions, pharmacies, etc.) in the Territory less the total of the following: normal and customary cash and trade discounts, rebates, transportation charges, returns, allowances, VAT not ultimately recovered by Taisho, and agent commissions, if any, paid or allowed by Taisho directly to the such third party in connection with the sale of the Products or other marketing and advertisement expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.15 **"New Technology"** shall mean all Inventions made, created, discovered or conceived during the Term (i) jointly by employees and/or third party contractors of Applied Biology together with employees and/or third party contractors of Taisho **("Joint New Technology"),** (ii) solely by Applied Biology's employees and/or third party contractors **("Applied Biology New Technology"),** or (iii) solely by Taisho's employees and/or third party contractors **("Taisho New Technology").**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.16 **"Patents"** shall mean all patents and patent applications including any continuations, continuations-in-part, or divisional applications, reissues, renewals, reexaminations, extensions, corrections, or modifications related thereto in any jurisdiction in connection with the Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.17 **"Product"** shall mean Applied Biology's minoxidil booster with current and future formulations as solution, shampoo or conditioner and minoxidil response test with current and future formulations as device. In addition, the Product shall include its improved Products (including without limitation to aerosol agent of minoxidil booster) or its successors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.18 **"Taisho New Technology"** shall mean as defined in Section 1.15.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.19 **"Territory"** shall mean Japan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.20 **"Trademark"** shall mean any trademark, trade name, trade dress, logo, slogan, and/or design which will be used for the Products.

**ARTICLE** II

**TERM**

The term of this Agreement shall commence on the Effective Date and shall continue for five (5) years from the Effective Date (the **"Term").** Thereafter, this Agreement shall be extended for a successive one (1) year period, unless either Applied Biology or Taisho gives the other party written notice of non-extension pursuant to the Agreement at least six (6) months prior to the expiration of the current Term.

**ARTICLE III**

**LICENSE; OBLIGATIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 Subject to all the terms and conditions of this Agreement, Applied Biology hereby grants to Taisho an exclusive, non-transferable, irrevocable license to research, develop, market, manufacture and have manufactured, import, sell, advertise, promote and distribute the Product in/for the Territory under Applied Biology IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 Taisho acknowledges that Applied Biology retains rights to the Products for all purposes (manufacture, sale, etc.) in any markets other than the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 Applied Biology shall have the sole responsibility for, and pay all costs for, maintaining, defending and prosecuting any Applied Biology IP in its discretion, such as patent filings and all regulatory matters, for the Product.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 Taisho represents and warrants that it will use its commercially reasonable efforts in marketing and selling the Products in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 Within sixty (60) days of the execution of this Agreement, Applied Biology and/or its affiliates shall provide Taisho with then available Applied Biology IP (the **"Technology Transfer").** Subject to Section 3.5, Applied Biology IP shall be provided on an "as is" basis, and shall include the preclinical and clinical data, regulatory data and communications, CMC data, manufacturing processes and relationships (including ongoing formulation development efforts) that are set forth in Schedule I. Applied Biology shall bear the costs of such Technology Transfer. Applied Biology shall, from time to time thereafter, during the Term of this Agreement, disclose to Taisho all Applied Biology IP in a timely manner subsequently available to Applied Biology upon Taisho's reasonable request, to the extent necessary to enable Taisho to exercise its right for use in the Territory or to fulfill its obligations under this Agreement. Applied Biology shall remain at all times the sole owner of the Applied Biology IP, and except as expressly permitted under this Agreement, Taisho may not sell, transfer, disclose or otherwise alienate it to any third party nor use for any reason other than for the purposes of this Agreement, without Applied Biology's prior written consent.

**ARTICLE IV**

**SALES AND PROFIT SHARING; AUDIT**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 In consideration for the license grant herein, Taisho shall pay Applied Biology the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) two
 hundred thousand U.S. Dollars ($200,000 USD) within sixty (60) days after execution of this Agreement

(ii) one
 hundred thousand U.S. Dollars ($100,000 USD) upon the completion of the first authorization/notarization of manufacturing and sales
 of a Product by Taisho in the Territory as cosmetics

(iii) three
 percent (3%) royalty of Net Sales paid within sixty (60) days after the end of each half of the calendar year ending on June 30 and
 December 31.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 From and after the Effective Date, within thirty (30) days following the end of each half of the calendar year ending on June 30 and December 31, Taisho shall furnish to Applied Biology a written report for the Products sold by Taisho during the half year, showing the following on a Product-by-Product basis: (i) gross sales of each Product; and (ii) Net Sales of each Product, including a reconciliation of the gross sales to Net Sales calculation for each element of the Net Sales calculation. Applied Biology shall furnish invoice within five (5) days from the receipt of report.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 All payments to be made by Taisho to Applied Biology under this Agreement shall be paid by bank wire transfer in immediately available funds to such bank account as is designated by Applied Biology on an invoice. All payments shall be made in US dollar. If, due to restrictions or prohibitions imposed by national or international authority, payments cannot be made as aforesaid, the parties shall consult with a view to finding a prompt and acceptable solution, and Taisho shall make such payments in any manner as Applied Biology may reasonably and lawfully direct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 The amount of upfront payment and royalty payment in Section 4.l(i)(ii)(iii) shall include any taxes. Except as otherwise expressly provided in this Agreement, each party is responsible for its own taxes based on its own income, gross receipts, capital, right or ability to do business in a jurisdiction, property, payroll or otherwise; Applied Biology shall be responsible for paying any and all taxes levied by the regulatory authorities of the jurisdiction(s) where Applied Biology is incorporated or conducts business, on account of, or measured in whole or in part by reference to any amounts payable by Taisho to Applied Biology pursuant to this Agreement (the **"Agreement Payments").** If applicable laws require the withholding of taxes, Taisho shall make such withholding payments in a timely manner and shall make the Agreement Payments with deduction of such withholding payments. For the avoidance of doubt, the Agreement Payments shall be made after deduction or withholding of taxes that is required by the applicable laws from the amounts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 Taisho shall maintain all records necessary to calculate the royalty stipulated in Section 4.1 (iii) during the Term of this Agreement and for a period of one (1) year thereafter. Upon Applied Biology's request, Taisho shall permit an independent certified public accounting firm of internationally recognized standing designated by Applied Biology reasonably acceptable to Taisho to audit such records, for the purpose of determining compliance with the royalty payment in Section 4.1 (the **"Audit").** The Audit shall be conducted at Applied Biology's sole cost and expense and not more than once per annum. Applied Biology shall provide reasonable advance notice of an Audit at least prior to sixty (60) days of such Audit. Applied Biology shall and shall cause said public accounting firm to treat such records as the Proprietary Information of Taisho. Further, both parties acknowledge that the accounting firm shall disclose to Applied Biology in the written report only whether the Net Sales Reports are correct or incorrect and the amount of any underpayment. In the event the Audit discloses that Taisho underpaid Applied Biology, in excess of five percent (5%), Taisho shall immediately correct any underpaid amounts, and in the event the Audit discloses that Taisho underpaid Applied Biology in excess of ten percent (10%), Taisho shall additionally reimburse Applied Biology for its reasonable costs and expenses associated with such Audit.

**ARTICLE V**

**COMPLIANCE**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Authorization.</u> Each party hereby represents and warrants to the other that: (a) it has the requisite power and authority to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby; (b) this Agreement has been duly authorized, executed and delivered by such party, constitutes legal, valid and binding obligation of such party and is enforceable against such party in accordance with its terms; and (c) the execution of this Agreement by such party, and the performance by such party of its obligations and duties hereunder, do not and will not violate any agreement to which such party is a party or by which it is otherwise bound.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Compliance with Applicable Laws.</u> Taisho shall comply with all laws and regulations applicable to Taisho in marketing, selling and manufacturing the Products hereunder. Without limiting the generality of the foregoing, Taisho shall, at its own expense, make, obtain, and maintain in force at all times during the term of this Agreement, all filings, registrations, licenses, permits and authorizations in its geographical region in the Territory.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <u>Status as [ndependent Contractor.</u> The relationship established between Applied Biology and the Taisho by this Agreement is that of a licensor to its licensee and nothing herein contained shall be deemed to establish or otherwise create a relationship of principal and agent between Applied Biology and the Taisho. Taisho represents that it is an independent contractor who will not be deemed an agent of Applied Biology for any purpose whatsoever and neither the Taisho nor any of its agents or employees will have any right or authority to assume or create any obligation of any kind, whether express or implied, on behalf of Applied Biology.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <u>Taxes.</u> Taisho shall bear the cost of any taxes, levies, duties and fees of any kind, nature or description whatsoever applicable to selling or importing the Products.

**ARTICLE VI**

**ASSIGNMENT, SOLICITATION AND COMPETITION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Assignment.</u> Either party may not, without prior written consent of the other party, assign or sublicense this Agreement to any third party except to a buyer of substantially all of assigning party's business. In the event of any permitted sublicense or assignment of the Agreement in accordance with the terms hereof, Taisho or Applied Biology shall ensure that any assignee agrees to and complies with the terms and conditions of this Agreement. Notwithstanding the above, Applied Biology consents to Taisho's assignment of this Agreement to Taisho's affiliates, provided said subsidiary are subject to the terms of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Competition.</u> In the event Applied Biology terminates this Agreement due to a material breach by Taisho, Taisho shall not, during the one (1) year following termination, offer, sell or promote the Competing Products in the Territory; notwithstanding the foregoing, during the Term, Taisho shall not sell or promote Competing Products in the Territory.

**ARTICLE VII**

**INTELLECTUAL PROPERTY RIGHTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <u>Retention of Intellectual Property Rights.</u> Taisho acknowledges that Applied Biology is the owner of all Applied Biology IP. Applied Biology shall retain all right, title and interest in and to Applied Biology IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <u>Use of Applied Biology IP</u>. During the Term and in accordance with the terms of this Agreement, Taisho shall have the right to use the Applied Biology IP solely in connection with Taisho's researching, developing, marketing, manufacture, selling, advertising, promotion and distribution of the Products. Taisho hereby covenants and agrees that its use of Applied Biology IP will not dilute Applied Biology IP. Taisho shall have right to use any Taisho's intellectual property in the marketing of the Products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <u>New Technology.</u> The entire right, title and interest in Joint New Technology shall be owned jointly by Applied Biology and Taisho. Ownership ratio of such Joint New Technology shall be determined according to contribution by the respective party. The parties shall separately agree on a case-by-case basis on prosecution, defense and enforcement of intellectual property rights relating to Joint New Technology. Each party shall promptly (but no less often than quarterly) disclose to the other party the New Technology made, created, discovered or conceived by its employees and/or third party contractors during the Term. As between Applied Biology, on the one hand, and Taisho, on the other hand, Applied Biology New Technology shall be solely owned by Applied Biology and Taisho New Technology shall be solely owned by Taisho.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <u>Prosecution of Patents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Responsibility and Control. Applied Biology shall be responsible for the filing, prosecution and maintenance of the Applied Biology IP at Applied Biology's expense. Applied Biology shall have sole control over such filings, prosecution and maintenance, but it shall keep Taisho reasonably apprised of the status of any such filings or pending applications, including sending Taisho drafts for submission to patent offices prior to submission where practicable to do so, prosecution and maintenance and consider in good faith any feedback or requests from Taisho with respect to the Territory. Taisho shall have the sole right (but not the obligation) for the filing, prosecution and maintenance of Taisho New Technology at Taisho's expense. Taisho shall have sole control over such filings, prosecution and maintenance, but it shall keep Applied Biology reasonably apprised of the status of any such filings or pending applications, including sending Applied Biology drafts for submission to patent offices prior to submission where practicable to do so, prosecution and maintenance and consider in good faith any feedback or requests from Applied Biology with respect to outside the Territory. For the avoidance of doubt, Taisho may decide at its sole discretion the handling of filing, prosecution and maintenance of Taisho New Technology in the Territory. Either party shall have the right to review and comment on any patent filings, prosecution and maintenance of patents related to the Product to be made by the other party in the Territory provided that such party which will make such filings, prosecution and maintenance shall provide (X) a written notice to the other party at least (i) sixty (60) days prior to the filings, (ii) twenty (20) days prior to the prosecution, and (Y) a written annual report to the other party regarding the maintenance, in order for the other party to review and comment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Option to Prosecute. In the event that Applied Biology desires to abandon or cease prosecution or maintenance of any Applied Biology IP in the Territory under which Taisho then has a license under this Agreement, Applied Biology shall provide reasonable prior written notice to Taisho of such intention to abandon (which notice shall be given no later than ninety (90) days prior to the next deadline for any action that must be taken with respect to any such Applied Biology IP in the relevant patent office). In such case, Applied Biology shall permit Taisho at Taisho's sole discretion, to continue prosecution and maintenance of such Applied Biology IP in the Territory, in Taisho's name and at Taisho's own expense and Taisho shall provide to Applied Biology the latest information described in Section 7.4 (a) with respect to such Applied Biology IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Cooperation. The non-prosecuting party shall reasonably assist and cooperate with the prosecuting party, at the prosecuting party's expense, as the prosecuting party may reasonably request from time to time, in the prosecution of the Applied Biology IP in the Territory, as applicable, including that the non-prosecuting party shall provide access to relevant documents and other evidence and make inventors and employees available at reasonable business hours (provided, however, that neither party shall be required to provide legally privileged information with respect to such intellectual property unless and until procedures reasonably acceptable to such party are in place to protect such privilege).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <u>Enforcement of Applied Biology IP.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Notification. In the event that either Taisho or Applied Biology becomes aware of (i) any alleged or threatened infringement by a third party of any issued patent within the Applied Biology IP with respect to a Product that is sold or used by Taisho in the Territory or (ii) any declaratory judgment action or other similar challenge by a third party with respect to the same (in each case (i) and (ii), referred to for purposes of this Agreement as "Infringement"), it shall notify the other party in writing to that effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Taisho Rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Subject to Section 7.5(c), Taisho shall have the first right, but not the obligation, to seek to obtain a discontinuance of such Infringement or bring and prosecute an action against any third party infringer under the Applied Biology IP as applicable, in the Territory, using counsel Taisho chooses. For clarity, the foregoing includes the rights to defend the validity or enforceability of the Applied Biology IP from any challenge. Taisho shall bear the expenses of any action brought by it, except as otherwise expressly provided in this Section 7.5. Applied Biology shall have the right to participate in any such action, at its own expense using counsel of its choice. In the event that Applied Biology has elected to so participate, Taisho shall consult with Applied Biology regarding any settlement, consent judgment or other voluntary final disposition of the action. Notwithstanding the foregoing, unless otherwise set forth herein, and subject to Section7.5(c), Taisho shall have the right to settle any action brought or being defended in accordance with this Section 7.5(b)(i); provided, however, that Taisho may not settle any such suit or action under this Section 7.5(b)(i) in a manner that imposes any costs or liability on or involves any admission by Applied Biology or otherwise adversely affects Applied Biology's rights under this Agreement, the Applied Biology IP or other Applied Biology business, without Applied Biology's express written consent, such consent not to be unreasonably withheld, conditioned or delayed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any recovery obtained by either or both Taisho and Applied Biology in connection with or as a result of any action contemplated by this section, whether by settlement or otherwise, shall be shared in order as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) the
 party which initiated and prosecuted the action shall recoup all of its costs and expenses incurred in connection with the action;

(2) the
 other party shall then, to the extent possible, recover its costs and expenses incurred in connection with the action; and

(3) any
 remaining amount of such recovery actually collected shall be equally distributed to Taisho and Applied Biology.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Applied Biology Rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Taisho shall promptly inform Applied Biology if it elects not to exercise its first rights in the Territory of any Applied Biology IP as set forth in Section 7.5(b)(i). Applied Biology shall notify Taisho if it intends to seek to obtain a discontinuance of such Infringement or bring and prosecute an action against the third party with respect to the Applied Biology IP. Prior to Applied Biology seeking discontinuance or initiating an action against such third party, the parties shall, promptly after Taisho's informing to Applied Biology above, meet and confer regarding Taisho's decision not to exercise its first right and Applied Biology shall consider Taisho's decision and the underlying reasons. Within thirty (30) Business Days of such meeting, Taisho shall inform Applied Biology whether it instead elects to enforce itself any of its rights. If Taisho so elects, it shall do so in accordance with Section 7.5(b). Otherwise, Applied Biology shall thereafter have the right but not the obligation to, within one hundred and twenty (120) days of Taisho's failure to elect, seek to obtain a discontinuance of such Infringement or bring and prosecute an action against the third party with respect to the Applied Biology IP. Applied Biology shall bear the expenses of any action brought by it. Applied Biology shall not be obligated to consult with Taisho regarding any settlement, consent judgment or other voluntary final disposition of the suit or action. Notwithstanding the foregoing, unless otherwise set forth herein, Applied Biology shall have the right to settle any suit or action brought or being defended in accordance with this Section 7.5(c)(i); provided, however, that Applied Biology may not settle any such suit or action under this Section 7.5(c)(i) in a manner that imposes any costs or liability on or involves any admission by Taisho or otherwise adversely affects Taisho's rights under this Agreement or Taisho business, without Taisho's express written consent (which consent shall not be unreasonably conditioned, withheld or delayed).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any recovery obtained by either or both Taisho and Applied Biology in connection with or as a result of any action contemplated by this section, whether by settlement or otherwise, shall be shared in order as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) the
 party which initiated and prosecuted the action shall recoup all of its costs and expenses incurred in connection with the action;

(2) the
 other party shall then, to the extent possible, recover its costs and expenses incurred in connection with the action; and

(3) any
 remaining amount of such recovery actually collected shall be equally distributed to Taisho and Applied Biology.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <u>Cooperation.</u> Where a party controls any Infringement action or other activities pursuant to Section 7.5 or Section 7.7, the other party shall assist and cooperate with the controlling party, as such controlling party may reasonably request from time to time and at such controlling party's expense, in connection with its activities set forth in this Section 7.6, including where necessary, providing access to relevant documents and other evidence and making its employees available at reasonable business hours.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 <u>Enforcement and Defense of Taisho Technology</u>. Taisho shall have the sole right (but not the obligation) to bring and control any action or proceeding with respect to infringement of any Taisho New Technology (including any declaratory judgment action or other similar challenge by a third party with respect to the same), worldwide, at its own expense and by counsel of its own choice. In the event that Applied Biology becomes aware of (i) any alleged or threatened infringement by a third party of any issued patent within the Taisho Technology or (ii) any declaratory judgment action or other similar challenge by a third party with respect to the same, Applied Biology shall notify Taisho in writing to that effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <u>Patent Term Extension.</u> The parties shall cooperate fully with each other in their efforts of obtaining patent term extension or supplemental protection certificates or their equivalents in the Territory where applicable to the Applied Biology IP. The parties shall discuss in good faith election as to the patent term extension of which Applied Biology IP shall be pursued, and if the parties do not agree thereon, Applied Biology shall have the right to make the election of the Applied Biology IP to be extended. Provided that, in case Applied Biology does not desire to obtain such extension but Taisho desires the extension, Applied Biology shall obtain such extension at Taisho's out-of-pocket expenses and Taisho shall use commercially reasonable efforts to support Applied Biology to obtain such extensions to Applied Biology IP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9 <u>Third Party Intellectual Property Rights.</u> On a Product-by-Product basis, in the event that a court or a governmental agency of competent jurisdiction in the Territory determines that the Applied Biology IP infringes the patent rights or other intellectual property rights of a third party in the Territory, or if Taisho, following consultation with outside counsel from a reputable law firm, reasonably determines in good faith that it is necessary to obtain a license from a third party under such third party's Patents in order for Taisho to use, research develop market, manufacture, import, sell, advertise, promote and/or distribute such Product in the Territory, Taisho shall promptly notify Applied Biology. If Taisho obtains such a license from a third party to enable itself to use, develop, market, manufacture, import, sell, advertise, promote and/or distribute any Product in the Territory, Taisho may, in addition to any other remedy under or in connection with this Agreement, deduct an aggregate of the amounts actually paid to such third party pursuant to such license (including any license fees, milestones and royalty payments) from the payment to Applied Biology under this Agreement. Taisho will keep Applied Biology reasonably informed of the decision to in-license third party's patents and in connection with the negotiations with such third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10 <u>Patent License Registration.</u> Applied Biology shall register by itself or cooperate with Taisho to register the exclusive license of the Applied Biology IP granted pursuant to Section 3.1 to Taisho in the Territory as a *"Senyou Jisshiken"* in accordance with Article 77 of the Japanese Patent Law of 1959, or a *"Kari-Senyou Jisshiken"* in accordance with Article 34-2 thereof, in Japan, at Applied Biology's expense upon Taisho's request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11 <u>Trademarks.</u> Unless otherwise specified herein, Taisho shall, at its discretion, select Trademarks. In the event that Taisho files for the registration of the Trademark by itself, Taisho shall be responsible for filing, prosecuting and maintaining such Trademarks in force and effect throughout the Term of the Agreement in the Territory at its sole cost and expense. Applied Biology and Taisho both agree that each party shall not use any trade name or trademark similar to or resembling any Trademark in the Territory as to be likely to cause confusion, deception, or mistake with respect to the Trademarks. Each party shall not apply to register or register, any trademark which would be similar to, or resemble any Trademark as to be likely to cause confusion or any trademark which includes any Trademark in the Territory. Provided, however, that in the case that Taisho sells the finished Products manufactured by Applied Biology, unless required by law, Taisho shall not remove Applied Biology's copyright notice or the trademarks from the Products and any supporting technical marketing materials, forms and documents.

**ARTICLE VIII**

**REPRESENTATION, WARRANTY AND COVENANTS**

Applied Biology hereby represents and warrants to Taisho as of the Effective Date and covenants, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) it
 has sufficient legal and/or beneficial rights under the Applied Biology IP to grant the exclusive licenses and any other rights granted
 to Taisho hereunder, and it will not grant any licenses or rights to any other person or entity that would conflict with the exclusive
 licenses and any other rights granted to Taisho hereunder;

(ii) Applied
 Biology is the sole and exclusive owner of the entire right, title and interest in the Applied Biology IP existing as of the Effective
 Date, free and clear of any lien, or claim of ownership of any third party;

(iii) (A)
 all issued Existing Patent are in full force and effect and subsisting; (B) none of the Existing Patent is currently involved in
 any interference, reissue, reexamination, or opposition proceeding; and (C) Applied Biology has not received any written notice from
 any person, or has knowledge, of such actual or threatened proceeding;

(iv) Applied
 Biology has not previously entered into any agreement, whether written or oral, with respect to the assignment, transfer, license,
 conveyance or encumbrance of, or otherwise assigned, transferred, licensed, conveyed or encumbered its right, title, or interest
 in or to, any Applied Biology IP, including by granting any covenant not to sue with respect thereto;

(v) there
 are no legal proceedings pending, Applied Biology has not received written notice, and to the best of Applied Biology's knowledge,
 there are no claims;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) that is challenging the ownership, validity or enforceability of the Applied Biology IP,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) that the use or practice of the Applied Biology IP in the development, manufacture or commercialization of the Products for purposes in the Territory does or would infringe, violate or misappropriate the intellectual property rights of a third Party; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) that is otherwise involving any Applied Biology IP.

---

| | |
|:---|:---|
|  | To the best of Applied Biology's knowledge, there exists no patents of third parties that would be infringed by the parties to perform their obligations hereunder; |
| (vi) | to the best of Applied Biology's knowledge, no third party is infringing or misappropriating any existing Applied Biology IP; |
| (vii) | to the best of Applied Biology's knowledge, all information and data related to the Product provided in writing or any other tangible form by or on behalf of Applied Biology to Taisho on or before the Effective Date (including the information made available by or on behalf of Applied Biology to Taisho for the purpose of the due diligence performed by Taisho) is true and accurate and not misleading in any material respects, and Applied Biology has disclosed or made available to Taisho any such information or data which would reasonably interpreted as material in the pharmaceutical business to Taisho's decision to enter into this Agreement; and |
| (viii) | all information and data related to the Product provided by or on behalf of Applied Biology to Taisho before, on or after the Effective Date, to be incorporated into regulatory document is accurate. |

---

**ARTICLE IX**

**INDEMNIFICATION AND LIMITATION ON LIABILITY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <u>Applied Biology Indemnity</u>. Applied Biology shall indemnify, defend and hold harmless Taisho, its affiliates, officers, directors, agents and employees against, any and all loss, liability, third party liability, claims, allegations, losses, damages, suits, demands, actions, proceedings, judgements, costs or expenses (including attorneys' fees and expenses as reasonably incurred) (collectively, the **"Liability")** arising out of or relating to (i) any breach by Applied Biology of any of its representations warranties or obligations under this Agreement, (ii) the gross negligence or willful misconduct of Applied Biology or its employees, officers, directors or agents in performing any activities or obligations hereunder, or (iii) the infringement of the patent, copyright, trademark, trade secret or other intellectual property rights of any third party arising out of Taisho's activities conducted in compliance with this Agreement. Provided that in the case of any third-party claim, Taisho shall (a) promptly notify Applied Biology of the claim (in any event, within twenty (20) days after Taisho becomes aware of the claim), (b) authorize and allow Applied Biology to have sole control of the defense and settlement of the claim, and (c) provide all information and cooperation reasonably requested by Applied Biology at Applied Biology's expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <u>Taisho Indemnity.</u> Taisho shall indemnify and hold harmless Applied Biology, its affiliates, officers, directors, agents and employees against the Liability arising out of or relating to (i) any breach by Taisho of any of its representations warranties or obligations under this Agreement, (ii) the gross negligence or willful misconduct of Taisho or its employees, officers, directors or agents in performing any activities or obligations hereunder, or (iii) the infringement of the patent, copyright, trademark, trade secret or other intellectual property rights of any third party arising out of Taisho's activities not conducted in compliance with this Agreement. Provided that in the case of any third-party claim, Applied Biology shall (a) promptly notify Taisho of the claim (in any event, within twenty (20) days after Applied Biology becomes aware of the claim) (b) authorize and allow Taisho to have sole control of the defense and settlement of the claim, and (c) provide all information and cooperation reasonably requested by Taisho at Taisho's reasonable expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 <u>Disclaimers.</u> **EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES NO WARRANTIES, EXPRESS OR IMPLIED, TO THE OTHER PARTY UNDER THIS AGREEMENT AND HEREBY DISCLAIMS ALL IMPLIED AND EXPRESSED WARRANTIES, INCLUDING ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND ANY IMPLIED WARRANTIES ARISING OUT OF A COURSE OF PERFORMANCE OR DEALING.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4 <u>Limitation on Liability.</u> **APPLIED BIOLOGY AND TAISHO WILL NOT BE LIABLE FOR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, THE PRODUCTS, PRODUCT INFORMATION AND APPLIED BIOLOGY IP. APPLED BIOLOGY'S AND TAISHO'S AGGREGATE LIABILITY ARISING WITH RESPECT TO THIS AGREEMENT WILL NOT EXCEED THE TOTAL AMOUNT OF FEES PAID BY TAISHO HEREUNDER PRIOR TO THE DATE SUCH LIABILITY IN INCURRED. PROVIDED, HOWEVER THAT LIMITATION OF LIABILITY SPECIFIED** IN **THIS SECTION 9.4 SHALL NOT BE APPLIED IN THE CASE OF** (I) **WILLFUL MISCONDUCT,** (II) **GROSS NEGLIGENCE, (Ill) INDEMNIFICATION UNDER SECTIONS 9.1 AND 9.2 AGAINST THIRD PARTY LIABILITY, (IV) INTELLECTUAL PROPERTY INFRINGEMENT OR (V) BREACH OF CONFIDENTIAL OBLIGATION.**

**ARTICLEX**

**TERMINATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <u>Termination for Breach.</u> In the event of a material breach by a party to this Agreement, the non-breaching party has a right to terminate this Agreement with a thirty (30) days prior written notice; provided, the breaching party had failed to cure the breach within fifteen (15) days from the date ofreceiving the notice. If the breach is cured within this window, the termination notice shall automatically be deemed to have been withdrawn.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <u>Termination Without Cause.</u> In the event this Agreement is renewed once in accordance with Article 2, on and after April I, 2027, Taisho may terminate this Agreement at any time, with or without cause, with a six (6) month prior written notice to the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 <u>Force Majeure, Suspension and Termination.</u> In the event that either party is unable to perform any of its obligations under this Agreement or to enjoy any of its benefits because of (or if loss of Products is caused by) any cause beyond the reasonable control of the affected party including but not limited to natural disaster, actions or decrees of governmental bodies or communications line failure (the **"Force Majeure Event"),** the party who has been so affected shall not be liable or responsible for such non-performance or non-enjoyment to the other party. Provided however, that in such case, the party affected immediately shall give notice to the other party and shall make commercially reasonable effort to eliminate, cure or overcome any such causes and to resume performance of its obligations as soon as possible. If the period of nonperformance exceeds sixty (60) days from the receipt of notice of the Force Majeure Event, the party whose ability to perform has not been so affected may by giving written notice terminate this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 <u>Effect of Insolvency.</u> This Agreement shall automatically terminate (i) if either party files a petition in bankruptcy, or is adjudicated bankrupt, or a petition in bankruptcy filed against either party is not dismissed or stayed within One Hundred and Eighty (180) days; or (ii) if either party makes an assignment for the benefit of its creditors; or (iii) if a receiver, custodian, trustee or liquidator is appointed for the party or its business. In the event that a party who falls under any of above items shall immediately notify the other party in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5 <u>Paid Up.</u> (i) In the event that Taisho terminates this Agreement for the cause attributable to Applied Biology under Sections 10.1 and 10.4, following such termination of this Agreement, or (ii) in the case this Agreement terminates or expires after the expiration of the last Existing Patents, Taisho shall have the perpetual, irrevocable and fully paid-up license to research, develop, market, manufacture and have manufactured, import, sell, advertise, promote and distribute the Product solely to customers in the Territory under Applied Biology IP.

**ARTICLE XI**

**PROPRIETARY INFORMATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 Applied Biology and Taisho each acknowledges that it may, in the course of performing its obligations under this Agreement, have access to the confidential, proprietary and commercially valuable information disclosed by the other party including, but not limited to, non-public information concerning the other party's, business partners and employees, customers and future plans.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2 The parties shall keep confidential and treat the following items under the same terms and conditions as the Confidentiality Agreement as if the Confidentiality Agreement remains in force during the duration of this Section 11.2, mutatis mutandis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any
 and all information disclosed from the other party in connection with the negotiation hereunder which would fall within the definition
 of **"Proprietary Information"** under the Confidentiality Agreement

(ii) the
 existence and content of this Agreement; and

(iii) the
 fact that discussions or negotiations are taking place with respect to a potential transaction involving the parties and the content
 of such discussion and negotiation,

Provided that the parties shall use the above information only for the exercise of their rights and performance of their obligations under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3 Neither party shall issue a press release or make a public statement of any type, including but not limited to advertisement, that mentions the other party, unless the other party provides prior written approval of such press release or public statement.

**ARTICLE XII**

**MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 <u>Governing Law; Jurisdiction.</u> This Agreement shall be governed by and construed in accordance with the law of the State of Delaware without regard to conflict of law provisions. Any disputes arising out of or in relation to this Agreement shall be settled by arbitration under the Arbitration Rule of International Chamber of Commerce held in Delaware, U.S.A. The proceeding of arbitration shall be conducted in English and three (3) arbitrators shall be appointed for the proceeding in accordance with the said rule. The result of the arbitration shall be final and binding the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2 <u>Notices.</u> All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows or as subsequently modified by written notice given in accordance with this Section 12.2.

if to Applied Biology, to:

Address: 109 E. 17th St., Cheyenne, WY 8200 I

Attn: Scott Olson

if to Taisho, to:

Address: Taisho Pharmaceutical Co., Ltd.

3-24-1, Takada, Toshima-ku, Tokyo, 170-8633 Japan

Attn: Self Medication Business Planning

All notices given or made pursuant to this Agreement shall be deemed effectively given upon the earlier of actual receipt or (a) personal delivery to the party to be notified, (b) one (1) business day after deposit with a nationally - recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt or (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.3 <u>Severability.</u> If any term or provision of this Agreement shall to any extent be held to be invalid or unenforceable, the remainder of this Agreement shall not be affected thereby, and each remaining term and provision of this Agreement shall be valid and enforced to the fullest extent permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.4 <u>Reservation of Rights.</u> Neither party shall receive any rights under this Agreement except for those rights expressly and unambiguously set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.5 <u>Entire Agreement.</u> This Agreement represents the complete agreement and understanding between Applied Biology and Taisho with respect to the subject matter herein and supersedes any other prior written or oral agreement with respect to the subject matter herein. The terms and conditions of this Agreement may only be modified in a writing signed by both parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.6 <u>Recovery of Costs</u>. In any action to enforce rights under this Agreement, the prevailing party shall be entitled to recover costs and attorneys' fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.7 <u>No Implied Waiver.</u> Any failure by either party to enforce any of the terms and provisions of this Agreement shall not be considered a continuing waiver of that party's right thereafter to enforce such terms and provisions. No provision of this Agreement shall be deemed waived unless such waiver is in writing signed by both parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.8 <u>SurvivaJ.</u> Notwithstanding any termination or expiration of this Agreement, Articles VI (ASSIGNMENT, SOLICITATION AND COMPETITION), VII (INTELLECTUAL PROPERTY RIGHTS), IX (INDEMNIFICATION AND LIMITATION ON LIABILITY), X (TERMINATION) and XII (MISCELLANEOUS) shall survive such termination or expiration. Article XI (PROPRIETARY INFORMATION) shall survive for ten (10) years from the termination or expiration of this Agreement. Unless otherwise specified herein, any obligations of the parties under this Agreement which by their nature will continue beyond the termination of this Agreement shall survive.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in duplicate by their duly authorized representatives.

---

| | | | |
|:---|:---|:---|:---|
| Taisho Pharmaceutical Co., Ltd. | Taisho Pharmaceutical Co., Ltd. | Applied Biology, Inc. | Applied Biology, Inc. |
| By: | ![](ex10-8_001.jpg) | By: |  |
| Name: | rtsumi Takahashi | Name: | Andy Goren<br>|
| Title: | Member of the Board Execulive Ofliccr | Title: | Chief Medi.cal Officer |

---

SCHEDULE!

Minoxidil Adjuvant Therapies US 62/741,990

Minoxidil Adjuvant Therapies 62/756,293

Minoxidil Adjuvant Therapies 62/800,065

Minoxidil Adjuvant Therapies 62/895,627

Minoxidil Adjuvant Therapies 16/593,577 (and PCT derivatives)

TAAR Receptor Agonists for the Treatment of Alopecia PCT/US2019/0231 48

## Exhibit 10.9

**Exhibit 10.9**

![](ex10-9_001.jpg)

Jupiter, FL

05/01/2024

**Agreement for Manufacturing Hair Enzyme Booster**

This Agreement is made on May 1, 2024 between Caring Brands Inc, located at 1061 E Indiantown Rd, Suite 110, Jupiter, FL 33477 ("Brand Owner"), and Sanpellegrino Cosmetics pvt. Ltd., located at H-130, ground floor, Sushant shopping arcade, Sushant lok, ph-1, Gurgaon -122009, India ("Manufacturer").

1. Manufacturing Services

The Manufacturer agrees to produce the Hair Enzyme Booster according to the specifications provided by the Brand Owner.

2. Orders and Delivery

The Brand Owner will place orders for the Hair Enzyme Booster, and the Manufacturer will confirm and deliver the products by the agreed date.

3. Pricing and Payment

The Brand Owner will pay the Manufacturer 50% of the agreed price for the Hair Enzyme Booster upon placing the order and the remaining 50% upon dispatch of the products.

4. Term and Termination

This Agreement begins on May 1, 2024 and continues until terminated by either party with 30 days' notice.

5. Confidentiality

The Manufacturer will keep all information about the Hair Enzyme Booster confidential, as per existing confidentiality agreements.

6. Governing Laws

This Agreement will be governed by the laws of Florida, USA.

1061 E. Indiantown Road, Suite 110, Jupiter, FL 33477

<u>www.caringbrands.com</u> \| info@caringbrands.com \| (561) 896-7616

![](ex10-9_001.jpg)

---

| | |
|:---|:---|
| Signed: | Signed: |
| Caring Brands Inc. | Caring Brands Inc. |
| By: | */s/ Dr. Glynn Wilson* |
| Name: | Dr. Glynn Wilson |
| Title: | CEO |

---

---

| | |
|:---|:---|
| Sanpellegrino Cosmetics pvt. Ltd | Sanpellegrino Cosmetics pvt. Ltd |
| By: | */s/ Arjun Khurana* |
| Name: | Arjun Khurana |
| Title: | Arjun Khurana |

---

1061 E. Indiantown Road, Suite 110, Jupiter, FL 33477

<u>www.caringbrands.com</u> \| info@caringbrands.com \| (561) 896-7616

## Exhibit 10.10

**Exhibit 10.10**

**SECURITIES PURCHASE AGREEMENT**

This Securities Purchase Agreement (this "<u>Agreement</u>") is dated as of June , 2024, between Caring Brands, Inc., a Florida corporation (the "<u>Company</u>"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "<u>Purchaser</u>" and collectively, the "<u>Purchasers</u>").

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

**ARTICLE I.**

**DEFINITIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Definitions</u>. In addition to the terms defined elsewhere in this Agreement the following terms have the meanings set forth in this Section 1.1:

"<u>Acquiring Person</u>" shall have the meaning ascribed to such term in Section 4.6.

"<u>Action</u>" shall have the meaning ascribed to such term in Section 3.1(h).

"<u>Affiliate</u>" means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

"<u>Board of Directors</u>" means the board of directors of the Company.

"<u>Business Day</u>" means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to "stay at home", "shelter-in-place", "non-essential employee" or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally are open for use by customers on such day.

"<u>Closing</u>" means any closing of the purchase and sale of the Securities pursuant to Section 2.1.

"<u>Closing Date</u>" means the Business Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) a Purchaser's obligations to pay its Subscription Amount and (ii) the Company's obligations to deliver the Securities, in each case, have been satisfied or waived. Pursuant to the terms of this Agreement, there may be one or more Closing Dates hereunder.

"<u>Commission</u>" means the United States Securities and Exchange Commission. "<u>Common Stock</u>" means the common stock of the Company, having no par value per share, and any other class of securities into which such securities may hereafter be reclassified or changed.

"<u>Common Stock Equivalents</u>" means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

"<u>Company Counsel</u>" means Sichenzia Ross Ference Carmel LLP, with offices located at 1185 6<sup>th</sup> Avenue, 31<sup>st</sup> Floor, New York, NY 10036.

"<u>Escrow Agent</u>" means Sichenzia Ross Ference Carmel LLP.

"<u>Exchange Act</u>" means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

"<u>FCPA</u>" means the Foreign Corrupt Practices Act of 1977, as amended. "<u>GAAP</u>" means generally accepted accounting principles.

"<u>Indebtedness</u>" shall have the meaning ascribed to such term in Section 3.1(x).

"<u>Intellectual Property Rights</u>" shall have the meaning ascribed to such term in Section 3.1(n).

"<u>Legend Removal Date</u>" shall have the meaning ascribed to such term in Section 4.1(c).

"<u>Liens</u>" means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

"<u>Material Adverse Effect</u>" shall have the meaning assigned to such term in Section 3.1(b).

"<u>Material Permits</u>" shall have the meaning ascribed to such term in Section 3.1(1).

"<u>Maximum Amount</u>" means an aggregate of $2,000,000, which may be increased by an additional $1,000,000 in the sole discretion of the Board of Directors.

"<u>Offering</u>" means the offering of Common Stock pursuant to this Agreement and the other Transaction Documents.

"<u>Offering Period</u>" means the earlier of (i) the sale of the Maximum Amount, (ii) termination of the Offering as determined by the Company and the Placement Agent or (iii) April 30, 2024 ("Initial Offering Period"), which date may be extended by the Placement Agent and the Company in their joint discretion until June 30, 2024.

"<u>Person</u>" means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

"<u>Placement Agent(s)</u>" means EF Hutton LLC.

"<u>Proceeding</u>" means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.

"<u>Purchased Shares</u>" means the shares of Common Stock issued and issuable pursuant to the terms of this Agreement.

"<u>Purchaser Party</u>" shall have the meaning ascribed to such term in Section 4.9.

"<u>Qualified Offering</u>" shall mean a registered offering of Common Stock (or units consisting of Common Stock and warrants to purchase Common Stock) resulting in the listing for trading of the Common Stock on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).

"<u>Repurchase Date</u>" means the date that is eight months from the date of the initial Closing.

"<u>Required Approvals</u>" shall have the meaning ascribed to such term in Section 3.1(e).

"<u>Rule 144</u>" means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

"<u>Rule 424</u>" means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

"<u>Securities</u>" means the Purchased Shares, the Warrants and the Warrant Shares.

"<u>Securities Act</u>" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

"<u>Short Sales</u>" means all "short sales" as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).

"<u>Subscription Amount</u>" means, as to each Purchaser, the aggregate amount to be paid for the Units purchased hereunder as specified below such Purchaser's name on the signature page of this Agreement and next to the heading "Subscription Amount," in United States dollars and in immediately available funds.

"<u>Subsidiary</u>" means any subsidiary of the Company as set forth in Schedule 3.1(a) and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

"<u>Termination Date</u>" means the date on which the Offering expires or is terminated.

"<u>Trading Day</u>" means a day on which the principal Trading Market is open for trading.

"<u>Trading Market</u>" means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

"<u>Transaction Documents</u>" means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

"<u>Transfer Agent</u>" means the initial transfer agent of the Company to be appointed, and any successor transfer agent of the Company.

"<u>Unit</u>" has the meaning set forth in Section 2.1.

"<u>Warrant</u>" means a common stock purchase warrant, in the form of <u>Exhibit A</u> attached hereto, entitling the holder thereof to purchase shares of Common Stock at a purchase price of $3.00 per share.

"<u>Warrant Shares</u>" means the shares of Common Stock issuable upon exercise of the Common Stock.

**ARTICLE II.**

**PURCHASE AND SALE**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Closings</u>. On each Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser participating in the applicable Closing, severally and not jointly, agrees to purchaser units (each, a "<u>Unit</u>") for a price per unit of $1.00, consisting of one share Common Stock and a Warrant to purchase one share of Common Stock at a price per share of $3.00. The number of Units to be purchased by a Purchase at the applicable closing shall be set forth on such Purchaser's signature page hereto; provided that no purchase of Units by a Purchaser in a closing shall consist of fewer than 50,000 Units, unless waived by the Company in its sole discretion. Each Purchaser shall have delivered to the Escrow Agent pursuant to the instructions contained on <u>Schedule 2.1</u>, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Subscription Amount as set forth on the signature page hereto executed by such Purchaser. Upon the exchange of items set forth in Section 2.2, the Company and the Placement Agent may give notice to the Escrow Agent to arrange an initial Closing. At any Closing hereunder, the Company shall deliver to each Purchaser its respective Common Stock and Warrant, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. If the initial Closing is not in the Maximum Amount, subsequent closings may be held up to the sale of the Maximum Amount. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, each Closing shall occur at such location as the parties shall mutually agree. Closings hereunder shall only be held during the Offering Period and in no event shall a Closing occur after the Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Deliveries</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On or prior to each Closing Date, the Company shall deliver or cause to be delivered to each of the Placement Agent on behalf of each Purchaser participating in the applicable Closing the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) this Agreement duly executed by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) a stock certificate or book entry statement for each Purchaser from the Transfer Agent representing an amount of shares of Common Stock equal to such Purchaser's Subscription amount divided by 1;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a Warrant to purchase a number of shares of Common Stock equal to such Purchaser's Subscription amount divided by 1, duly executed by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) a copy of a good standing certificate of the Company , dated a date reasonably close to each Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) for initial Closing Date only, a certificate, dated as of the Closing Date, duly executed, and delivered by an officer of the Company, certifying the resolutions of the Company's Board of Directors then in full force and effect authorizing, to the extent relevant, all aspects of the transaction and the execution, delivery and performance of each Transaction Document to be executed and the transactions contemplated hereby and thereby;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) opinion of counsel to the Company in form satisfactory to the counsel to the Placement Agent; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) such other approvals, opinions, or documents as the Placement Agent may request in form and substance reasonably satisfactory to the Placement Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) On or prior to the Closing Date in which respect of a Purchaser is participating, such Purchaser shall deliver or cause to be delivered to the Company the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) this Agreement duly executed by such Purchaser;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) such Purchaser's Subscription Amount as to the Closing by wire transfer to the Escrow Agent to the account specified in <u>Schedule 2.1 hereto</u>; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Purchaser Questionnaire in the form of <u>Exhibit B</u> hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Closing Conditions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the accuracy in all material respects on (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The respective obligations of the Purchasers hereunder in connection with a Closing are subject to the following conditions being met (it being understood that the Company may waive any of the conditions for any Closing hereafter):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the applicable Closing Date shall have been performed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) there shall have been no Material Adverse Effect since the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <u>Repurchase</u>. In the event that the Company shall have not completed an initial public offering of the Common Stock at an offering price of not less than $4.00 per share on or before the Repurchase Date, then upon a Purchaser's request the Company shall repurchase from such Purchaser their Units for their Subscription Amount.

**ARTICLE III.**

**REPRESENTATIONS AND WARRANTIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Representations and Warranties of the Company</u>. The Company hereby makes the following representations and warranties to each Purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Subsidiaries</u>. All of the direct and indirect subsidiaries of the Company are set forth on <u>Schedule 3.1(a)</u>. Except as set forth on <u>Schedule 3.1(a)</u>, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company's ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a "<u>Material Adverse Effect</u>") and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company's stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>No Conflicts</u>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company's or any Subsidiary's certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.6 of this Agreement, and (ii) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively, the "<u>Required Approvals</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Issuance of the Securities</u>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. The Purchased Shares, the Warrants and the Warrant Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Capitalization</u>. The capitalization of the Company as of the date hereof is set forth on <u>Schedule 3.1(g)</u>. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and, except as disclosed in <u>Schedule 3.1(g)</u>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings, or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or "phantom stock" plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities, except for shareholder approval to increase the number of authorized shares of Common Stock. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company's capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company's stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Litigation</u>. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an "<u>Action</u>") which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Labor Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company or any Subsidiary, which could reasonably be expected to result in a Material Adverse Effect. None of the Company's or its Subsidiaries' employees is a member of a union that relates to such employee's relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Compliance</u>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Environmental Laws</u>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, "<u>Hazardous Materials</u>") into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder ("<u>Environmental Laws</u>"); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as currently conducted, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect ("<u>Material Permits</u>"), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Title to Assets</u>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>Intellectual Property</u>. Except as set forth on <u>Schedule 3.1(n)</u>, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as currently conducted and which the failure to so have could have a Material Adverse Effect (collectively, the "<u>Intellectual Property Rights</u>"). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest financial statements provided to the Placement Agent, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality, and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) <u>Insurance</u>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <u>Transactions with Affiliates and Employees</u>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from providing for the borrowing of money from or lending of money to, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, other than for (i) payment of salary, board fees or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) <u>Sarbanes-Oxley</u>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) <u>Certain Fees</u>. Except with respect to the fees and expenses payable to the Placement Agent as described in Section 5.2 hereto, no brokerage or finder's fees or commissions or other remuneration are or will be payable by the Company or any Subsidiaries directly or indirectly to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) <u>Private Placement</u>. Assuming the accuracy of the Purchasers' representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) <u>Investment Company</u>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an "investment company" within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an "investment company" subject to registration under the Investment Company Act of 1940, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) <u>Registration Rights</u>. Except as disclosed on <u>Schedule 3.1(u)</u>, no Person has any right to cause the Company or any Subsidiary to affect the registration under the Securities Act of any securities of the Company or any Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Disclosure</u>. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Transaction Documents and disclosure schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) <u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers' representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act which would require the registration of any such securities under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) <u>Solvency</u>. The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. There is no outstanding Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, "<u>Indebtedness</u>" means (x) any liabilities for borrowed money or amounts owed in excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company's consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Except as disclosed on <u>Schedule 3.1(x)</u>, neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) <u>Taxes</u>. (a) Except as disclosed on <u>Schedule 3.1(y)</u> each of the Company and its Subsidiaries has timely paid all taxes and other charges due by the Company to any local or foreign tax authorities, including, without limitation, income taxes, estimated taxes, excise taxes, sales taxes, value added taxes, use taxes, gross receipts taxes, franchise taxes, national insurance taxes, national healthcare contributions, employment and payroll related taxes, property taxes and import duties, whether or not measured in whole or in part by net income (hereinafter, "**Taxes**" or, individually, a "**Tax**") which have come due and are required to be paid by it through the date hereof or the date of the relevant Closing, and all deficiencies or other additions to Tax, interest and penalties owed by it in connection with any such Taxes; (b) except as set forth in Schedule 3.1(y), each of the Company and its Subsidiaries has duly and timely submitted or caused to be submitted all returns for Taxes that it is required to submit on and through the date hereof or the date of the relevant Closing, as applicable (including, in each case, all applicable extensions), and all such Tax returns are accurate and complete in all material respects; (c) with respect to all Tax returns of the Company and its Subsidiaries, (i) there is no unassessed Tax deficiency proposed or, to the knowledge of the Company, threatened against the Company or its Subsidiaries and (ii) no audit is in progress with respect to any return for Taxes, no extension of time is in force with respect to any date on which any return for Taxes was or is to be submitted and no waiver or agreement is in force for the extension of time for the assessment or payment of any Tax; (d) all provisions for Tax liabilities of the Company and its Subsidiaries have been made consistent with GAAP consistently applied, and all liabilities for Taxes of the Company and its Subsidiaries attributable to periods prior to or ending on the date hereof or the date of the relevant Closing, as applicable, have been adequately provided for; (e) there are no liens for Taxes on the assets of the Company or its Subsidiaries; (f) all monies required to be withheld by the Company (including from employees for income Taxes and social security and other payroll Taxes) have been collected or withheld, and either paid to the respective taxing authorities, set aside in accounts for such purpose, or accrued, reserved against and entered upon the books of the Company; (g) to the knowledge of the Company, there are no circumstances which will or may, whether by lapse of time or the issue of any notice of assessment or otherwise, give rise to any dispute with any relevant taxation authority in relation to the Company's or its Subsidiaries' liability or accountability for Tax under currently enacted statutes and regulations, any claim made by any of them, any relief, deduction, or allowance afforded to any such company, or in relation to the status or character of the Company or its Subsidiaries under or for the purpose of any provision of any legislation relating to Tax; (h) the Company has duly collected all amounts on account of any sales transfer Taxes or valued added taxes, including goods and services, harmonized sales and provincial or territorial sales Taxes, required by law to be collected by it, and has duly and timely remitted to the appropriate governmental authority any such amounts required by law to be remitted by it; and (i) the Company has not refunded or deducted any input valued added taxes that it was not so entitled to deduct or refund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) <u>No General Solicitation</u>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and certain other "accredited investors" within the meaning of Rule 501 under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) <u>Foreign Corrupt Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb) <u>No Disagreements with Accountants and Lawyers</u>. There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers presently or, to the knowledge of the Company, formerly employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company's ability to perform any of its obligations under any of the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc) <u>Acknowledgment Regarding Purchasers' Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers' purchase of the Securities. The Company further represents to each Purchaser that the Company's decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd) <u>Acknowledgment Regarding Purchaser's Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(g) and 4.11 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or "derivative" securities based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or "derivative" transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company's publicly-traded securities, (iii) any Purchaser, and counter-parties in "derivative" transactions to which any such Purchaser is a party, directly or indirectly, may presently have a "short" position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm's length counter-party in any "derivative" transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Purchased Shares or Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such hedging activities do not constitute a breach of any of the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee) <u>Stock Option Plans</u>. No stock options are outstanding as of the date hereof. (ff) <u>Office of Foreign Assets Control</u>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department ("<u>OFAC</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg) <u>U.S. Real Property Holding Corporation</u>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser's request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hh) <u>Bank Holding Company Act</u>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the "<u>BHCA</u>") and to regulation by the Board of Governors of the Federal Reserve System (the "<u>Federal Reserve</u>"). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record- keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the "<u>Money Laundering Laws</u>"), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(jj) <u>No Disqualification Events</u>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an "<u>Issuer Covered Person</u>" and, together, "<u>Issuer Covered Persons</u>") is subject to any of the "Bad Actor" disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a "<u>Disqualification Event</u>"), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(kk) <u>Other Covered Persons</u>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ll) <u>Notice of Disqualification Events</u>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Issuer Covered Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the applicable Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Organization; Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Own Account</u>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser's right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser understands that the Securities are "restricted securities" and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser's right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Purchaser Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, either an "accredited investor" as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Experience of Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication, and experience in business and financial matters to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser can bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>General Solicitation</u>. Such Purchaser is not, to such Purchaser's knowledge, purchasing the Securities because of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Access to Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment, respectively, the investor presentation attached as <u>Exhibit C</u> to this Agreement, and Risk Factors attached as <u>Exhibit D</u> to this Agreement and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Certain Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser's assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser's representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any actions with respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities of the Company for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions in the future.

The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser's right to rely on the Company's representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document, or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares to effect Short Sales or similar transactions in the future.

**ARTICLE IV.**

**OTHER AGREEMENTS OF THE PARTIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Transfer Restrictions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following form:

[NEITHER] THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an "accredited investor" as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser's expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities have been registered for resale pursuant to a registration statement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of selling stockholders thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Certificates evidencing the Purchased Shares, the Warrant Shares or the Warrants shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such Purchased Shares, Warrant Shares or Warrants pursuant to Rule 144 or (iii) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall, at its expense, cause its counsel, or at the option of a Purchaser, counsel determined by such Purchaser, to issue a legal opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively subject to compliance with the Securities Act and/or Rule 144 (for the avoidance of doubt, the Company shall pay all costs associated with such opinions). If the Purchased Shares or Warrant Shares may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Purchased Shares or Warrant Share shall be issued free of all legends. The Company agrees that at such time as such legend is no longer required under this Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Purchased Shares or Warrant Shares, as applicable, issued with a restrictive legend (such date, the "<u>Legend Removal Date</u>"), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates for Purchased Shares or Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser's prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein, "<u>Standard Settlement Period</u>" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Purchased Shares or Warrant Shares, as applicable, issued with a restrictive legend.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will only sell Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company's reliance upon this understanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>Acknowledgment of Dilution</u>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Purchased Shares or Warrant Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <u>Furnishing of Information; Public Information</u>. From the date of the Qualified Offering, until the time that no Purchaser owns Securities, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <u>Publicity</u>. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except to the extent such disclosure is required by law or Trading Market regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <u>Shareholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an "<u>Acquiring Person</u>" under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <u>Non-Public Information</u>. The Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser's consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. Following the date of the Qualified Offering, to the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 <u>Use of Proceeds</u>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and for expenses relating to its initial public offering and shall not use such proceeds: (a) for the satisfaction of any portion of the Company's debt (other than payment of trade payables in the ordinary course of the Company's business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation (d) in violation of FCPA or OFAC regulations or (e) to lend, give credit or make advances to any officers, directors, employees or affiliates of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 <u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.9, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a "<u>Purchaser Party</u>") harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys' fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party's representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company's prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party's breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.9 shall be made by periodic payments of the amount thereof during the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10 <u>Equal Treatment of Purchasers</u>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to such Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.11 <u>Certain Transactions and Confidentiality</u>. Notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser's assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.12 <u>Form D; Blue Sky Filings</u>. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or "Blue Sky" laws of the states of the United States and shall provide evidence of such actions promptly upon request of any Purchaser.

**ARTICLE V.**

**MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Termination</u>. This Agreement may be terminated by any Purchaser, as to such Purchaser's obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the initial Closing has not been consummated on or before the tenth calendar day following the date hereof, <u>provided</u>, <u>however</u>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants, and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery, and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. In addition, EF Hutton LLC is acting as placement agent for this private offering pursuant to a placement agency agreement with the Company and will receive 10% cash and 10% warrant compensation on amounts closed on pursuant to this Agreement, as well as an expense reimbursement from the Company of an amount to be mutually agreed among the Company and the Placement Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup>nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least a majority of the Units based initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition, or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially, and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 <u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7 <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the "Purchasers."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8 <u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.10. Notwithstanding the foregoing, each of the Placement Agent shall be deemed a third-party beneficiary of the representations and warranties of the Company as contained in Section 3.1 of this Agreement and shall have the right to enforce such provisions directly to the extent it may deem such enforcement necessary or advisable to protect its rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9 <u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees, or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.10, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10 <u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11 <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page was an original thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12 <u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants, and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13 <u>Rescission and Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.14 <u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen, or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.15 <u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.16 <u>Payment Set Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.17 <u>Independent Nature of Purchasers' Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non- performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.18 <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken, or such right may be exercised, on the next succeeding Business Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.19 <u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.20 **<u>WAIVER OF JURY TRIAL</u>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.**

*(Signature Pages Follow)*

 

IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **CARING BRANDS, INC.** | <u>Address for Notice:</u><br> 1061 E. Indiantown Road<br> Suite 110<br> Jupiter, FL 33477<br> Attention: Brian John |

---

By:   <u>Email:</u> <br> Name: Dr. Glynn Wilson <br> Title: Chief Executive Officer

With a copy to (which shall not constitute notice):

Sichenzia Ross Ference Carmel LLP

1185 6<sup>th</sup> Avenue

31<sup>st</sup> Floor

New York, NY 10036

Attn: Arthur Marcus

Email: amarcus@srfc.law

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

[PURCHASER SIGNATURE PAGES TO

SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: ____________________________________________________

*Signature of Authorized Signatory of Purchaser*: ____________________________________________________

Name of Authorized Signatory: ____________________________________________________

Title of Authorized Signatory: ____________________________________________________

Email Address of Authorized Signatory: ____________________________________________________

Facsimile Number of Authorized Signatory: ____________________________________________________

Address for Notice to Purchaser:

Address for Delivery of Securities to Purchaser (if not same as address for notice):

Subscription Amount: $______________

Number of Units purchase:_____________

EIN Number:________________________

[SIGNATURE PAGES CONTINUE]

EXHIBIT LIST

&nbsp;&nbsp;&nbsp;&nbsp;a. Form
 of Warrant

b. Purchaser
 Questionnaire

c. Investor
 Presentation

d. Risk
 Factors

**Exhibit A**

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

COMMON STOCK PURCHASE WARRANT

CARING BRANDS, INC.

Initial Exercise Date: <br>June __, 2024

THIS COMMON STOCK PURCHASE WARRANT (the "<u>Warrant</u>") certifies that, for value received______________, or its assigns (the "<u>Holder</u>") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the "<u>Initial Exercise Date</u>") and on or prior to 5:00 p.m. (New York City time) on the fifth (5<sup>th</sup>) anniversary of the Initial Exercise Date (the "<u>Termination Date</u>") but not thereafter, to subscribe for and purchase from Caring Brands, Inc., a corporation organized under the laws of Florida (the "<u>Company</u>"), up to_______________ shares of Common Stock (as subject to adjustment hereunder, the "<u>Warrant Shares</u>"). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

<u>Section 1</u>. <u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the "<u>Purchase Agreement</u>"), dated as of June , 2024, by and among the Company and the purchasers signatory thereto.

<u>Section 2</u>. <u>Exercise</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the "<u>Notice of Exercise</u>"). Within the earlier of (i) two (2) Business Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(c)(i)) following the date of exercise as aforesaid, the Holder shall deliver to the Company the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier's check drawn on a United States bank. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Business Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be equal to $3.00 (as subject to adjustment hereunder, the "<u>Exercise Price</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Mechanics of Exercise</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by its transfer agent to the Holder by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system ("<u>DWAC</u>") if, following the Initial Exercise Date, the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Business Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Business Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the "<u>Warrant Share Delivery Date</u>"). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate (but not Rule 144) purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price is received within the earlier of (i) two (2) Business Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. As used herein, "<u>Standard Settlement Period</u>" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrants shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. <u>Rescission Rights</u>. If the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to Section 2(c)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or roundup to the next whole share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares. The Company shall pay all attorney fees required for the issuance of attorney legal opinions for removal of restrictive legends on Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Holder's Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder's Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder's Affiliates (such Persons, "<u>Attribution Parties</u>")), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The "<u>Beneficial Ownership Limitation</u>" shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(d) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup>st</sup> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

<u>Section 3</u>. <u>Certain Adjustments</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "<u>Distribution</u>"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions(including any asset or <u>group</u> of assets, regardless whether then so classified by the Company, which would constitute a Significant Subsidiary, as such term is defined in Rule 1-02(w) of Regulation S-X), (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a "<u>Fundamental Transaction</u>"), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitations in Section 2(d) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the "<u>Alternate Consideration</u>") receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(d) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the "<u>Successor Entity</u>") to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory inform and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the "Company" shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date herein after specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

<u>Section 4</u>. <u>Transfer of Warrant</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.01 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Business Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "<u>Warrant Register</u>"), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 4.01of the Purchase Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

<u>Section 5</u>. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>No Rights as Stockholder Until Exercise</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(c)(i), except as expressly set forth in Section 3. In no event shall the Company be required to net cash settle an exercise of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a BusinessDay, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Authorized Shares</u>.

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consent hereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h) <u>Notices</u>. Any notice, request or other document required or permitted to begiven or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l) <u>Amendment; Waivers</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder. Further, any modifications, amendments or waivers of the provisions hereof shall be subject to Section 5.05 of the Purchase Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o) <u>Equal Treatment of Holders</u>. No consideration (including any modification of this Warrant) shall be offered or paid to any Person (as such term is defined in the Purchase Agreement) to amend or consent to a waiver or modification of any provision hereof unless the same consideration is also offered to all of the Holders. For clarification purposes, this provision constitutes a separate right granted to each Holder by the Company and negotiated separately by each Holder, and is intended for the Company to treat the Holders as a class and shall not in any way be construed as the Holders acting in concert or as a group with respect to the Warrants or the shares of Common Stock issuable upon exercise of the Warrants.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

---

| |
|:---|
| CARING BRANDS, INC. |
| By: |
| Name: |
| Title: |

---

NOTICE OF EXERCISE

TO: [_________________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The undersigned hereby elects to purchase_________________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. Payment shall take the form of lawful money of the United States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) The Warrant Shares shall be delivered to the following DWAC Account Number:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) <u>Accredited Investor</u>. The undersigned is an "accredited investor" as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity: ___________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: _____________________________________________________

Name of Authorized Signatory: _______________________________________________________________________

Title of Authorized Signatory: ________________________________________________________________________

Date: ___________________________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:

(Please Print)

Address:

(Please Print)

Phone Number:

Email Address:

Dated: _____________, _______

Holder's Signature: ___________________________

Holder's Address: ___________________________

**EXHIBIT B**

**U.S. Accredited Investor Confirmation Certificate**

**(For U.S. Purchasers that are Accredited Investors)**

---

| | |
|:---|:---|
| **To:** | **(the "Seller")** |

---

Reference is made to the Share Purchase Agreement by and among (the "Seller",) the undersigned (also referred to herein as the "Purchaser") (the "Agreement"). Terms not otherwise defined herein have the meanings ascribed to them in the Agreement.

The Purchaser understands and agrees that the Purchased Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any applicable U.S. state securities laws, and the Purchased Shares are being offered and sold by the Seller to the Purchaser in reliance upon available exemptions under the Securities Act.

The undersigned represents, warrants and covenants (which representations, warranties and covenants shall survive the Closing) to the Seller (and acknowledges that the Seller is relying thereon) that the Purchaser is an "accredited investor", as defined under the Securities Act (an "Accredited Investor"), and satisfies one or more of the categories indicated below (please initial on the appropriate line or lines), and is:

---

| | |
|:---|:---|
| _________Category 1. | A bank, as defined in Section 3(a)(2) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section 15 of the United States Securities Exchange Act of 1934, as amended; an insurance company as defined in Section 2(a)(13) of the U.S. Securities Act; an investment company registered under the United States Investment Seller Act of 1940, as amended; a business development company as defined in Section 2(a)(48) of the United States Investment Seller Act of 1940, as amended; a small business investment company licensed by the U.S. Small Business Administration under Section 301 (c) or (d) of the United States Small Business Investment Act of 1958, as amended; any Rural Business Investment Seller as defined in section 384A of the United States Consolidated Farm and Rural Development Act of 1972, as amended; a plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, with total assets in excess of U.S.$5,000,000; or an employee benefit plan within the meaning of the United States Employee Retirement Income Security Act of 1974, as amended, in which the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company or registered investment adviser, or if the employee benefit plan has total assets in excess of U.S.$5,000,000 or, if a self-directed plan, with investment decisions made solely by persons who are "accredited investors" (as such term is defined in Rule 501 under the U.S. Securities Act); or |

---

---

| | |
|:---|:---|
| ___________Category 2. | A private business development company as defined in Section 202(a)(22) of the United States Investment Advisers Act of 1940, as amended; or |
| ___________Category 3. | An organization described in Section 501(c)(3) of the United States Internal Revenue Code of 1986, as amended, a corporation, a Massachusetts or similar business trust or a partnership, or a limited liability company, not formed for the specific purpose of acquiring the securities being offered, with total assets in excess of U.S.$5,000,000; or |
| ___________Category 4. | A director or executive officer of the Seller (for purposes of this Schedule "A", "executive officer" means the president; any vice president in charge of a principal business unit, division or function, such as sales, administration or finance; or any other person or persons who perform(s) similar policymaking functions for the Seller); or |
| ___________Category 5. | A natural person whose individual net worth, or joint net worth with that person's spouse or spousal equivalent, at the time of purchase exceeds U.S.$1,000,000; provided, however, that (i) the person's primary residence shall not be included as an asset; (ii) indebtedness that is secured by the person's primary residence, up to the estimated fair market value of the primary residence at the time of the sale of securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of the sale of securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability); and (iii) indebtedness that is secured by the person's primary residence in excess of the estimated fair market value of the primary residence at the time of the sale of securities shall be included as a liability; or |
|  | **(Note:** For the purposes of calculating "joint net worth", joint net worth can be the aggregate net worth of the investor and spouse or spousal equivalent, and assets need not be held jointly to be included in the calculation. Reliance on the joint net worth standard does not require that the securities be purchased jointly. |
|  | **(Note:** The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.) |

---

---

| | |
|:---|:---|
| ___________Category 6. | A natural person who had an individual income in excess of U.S.$200,000 in each of the two most recent years or joint income with that person's spouse or spousal equivalent in excess of U.S.$300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; or |
|  | (**Note**: The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.) |
| ___________Category 7. | A trust, with total assets in excess of U.S.$5,000,000, not formed for the specific purpose of acquiring the securities being offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) under the U.S. Securities Act; or |
| ___________Category 8. | An entity in which all of the equity owners are "accredited investors" (as such term is defined in Rule 50l(a) of Regulation D under the U.S. Securities Act); or |
|  | (**Note**: It is permissible to look through various forms of equity ownership to natural persons in determining the accredited investor status of entities under this category. If those natural persons are themselves accredited investors, and if all other equity owners of the entity seeking accredited investor status are accredited investors, then this category may be available.) |
| ___________Category 9. | An entity of a type not listed in Category 1, 2, 3, 7 or 8 above or in Category 11 below, owning investments in excess of U.S.$5,000,000 that is not formed for the specific purpose of acquiring the Securities; or |
| ___________Category 10. | A natural person that holds one of the following licenses in good standing: General Securities Representative license (Series 7), the Private Securities Offerings Representative license (Series 82), or the Investment Adviser Representative license (Series 65); or |
| ___________Category 11. | An investment adviser registered pursuant to section 203 of the United States Investment Advisers Act of 1940, as amended, or registered pursuant to the laws of a state, or an investment adviser relying on the exemption from registering with the U.S. Securities and Exchange Commission **("SEC")** under section 203(1) or (m) of the United States Investment Advisers Act of 1940, as amended; or |
| ___________Category 12. | A "family office," as defined in Rule 202(a)(ll)(G)-1 under the United States Investment Advisers Act of 1940, as amended (17 CFR 275.202(a)(l l)(G)-1): (i) with assets under management in excess of U.S.$5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose prospective investment is directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment; or |
| ___________Category 13. | A "family client," as defined in Rule 202(a)(ll)(G)-1 under the United States Investment Advisers Act of 1940, as amended (17 CFR 275.202(a)(ll)(G)-l), of a family office meeting the requirements in Category 12 above and whose prospective investment in the issuer is directed by such family office pursuant to (iii) of Category 12 above. |

---

The undersigned agrees that by accepting the Purchased Shares it shall be representing and warranting that the representations and warranties above are true as at the closing with the same force and effect as if they had been made by it at the Closing and that they shall survive the purchase by it of the Purchased Shares and shall continue in full force and effect notwithstanding any subsequent disposition by it of the Purchased Shares.

The foregoing representations and warranties are true an accurate as of the date of this U.S. Accredited Investor Confirmation Certificate and will be true and accurate as of Closing. If any such representations and warranties shall not be true and accurate prior to Closing, the Purchaser shall give immediate written notice of such fact to the Seller.

Dated at________________________________________ , on_________________________________ , 2024

(Full Name of Purchaser - please print)

(Authorized Signature)

(Name and Official Capacity - please print)

Exhibit C

Caring Brands, Inc.

**RISK FACTORS**

An investment in our securities involves a high degree of risk and is subject to many uncertainties. These risks and uncertainties may adversely affect our business, operating results and financial condition. In order to attain an appreciation for these risks and uncertainties, investors should read this filing in its entirety and consider all of the information and advisements contained herein, including the following risk factors and uncertainties. All capitalized terms used herein and not otherwise defined shall have the meaning set forth in the accompanying securities purchase agreement.

***We have limited operational history in an emerging and evolving industry, making it difficult to accurately predict and forecast business operations.***

 ****

As we have limited operations in our business, it is extremely difficult to make accurate predictions and forecasts on our finances. Our products are designed for the wellness industry which is an emerging industry. There is no guarantee that our products or services will remain attractive to potential and current users as these industries undergo rapid change, or that potential customers will utilize our services.

***We have a limited operating history upon which you can evaluate us.***

 ****

We were part of a larger public company and have not operated as an independent entity. The likelihood of our creation of a viable business must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the growth of a business, operation in a competitive industry, and the continued development of our technology and products. We anticipate that our operating expenses will increase for the near future, and there is no assurance that we will be profitable in the near future. You should consider our business, operations and prospects in light of the risks, expenses and challenges faced as an emerging growth company.

***The Company's management has broad discretion over the use of proceeds from this offering, and the failure of management to apply these funds effectively could seriously harm our business.***

 ****

The Company and its management will have broad discretion as to how to spend the proceeds from this Offering, and shareholders may not agree with how the funds are used. You will not have the opportunity to evaluate the economic, financial or other information on which management will base its decisions on how to use the proceeds. Management may not be successful in using the proceeds from this Offering in ways that will yield favorable operating results. See "Use of Proceeds".

***We may be unable to manage growth, which may impact our potential profitability.***

Successful implementation of our business strategy requires us to manage our growth. Growth could place an increasing strain on our management and financial resources. To manage growth effectively, we will need to:

● Establish definitive business strategies, goals and objectives;

● Maintain a system of management controls; and

● Attract and retain qualified personnel, as well as develop, train, and manage management-level and other employees.

If we fail to manage our growth effectively, our business, financial condition, or operating results could be materially harmed, and our stock price may decline.

***Our business depends on maintaining and strengthening our brand and generating and maintaining ongoing demand for our products, and a significant reduction in such demand could harm our results of operations.***

 ****

We believe our success depends on our ability to maintain and grow the value and reputation of our company and products. Maintaining, promoting and positioning our brand and reputation will depend on, among other factors, the success of our product offerings, quality assurance, marketing and merchandising efforts, the reliability and reputation of our supply chain, and our ability to provide a consistent, high-quality consumer experience. We have made substantial investments in these areas in order to maintain and enhance our brand and these experiences, but such investments may not be successful. Any negative publicity, regardless of its accuracy, could materially adversely affect our business. For example, our business depends in part on our ability to maintain a strong community of engaged customers and social media and athlete influencers. We may not be able to maintain and enhance a loyal customer base if we receive customer complaints, negative publicity or otherwise fail to live up to consumers' expectations, which could materially adversely affect our business, operating results and growth prospects.

The growing use of social and digital media by us, our consumers and third parties increases the speed and extent that information or misinformation and opinions can be shared. Negative publicity about us, our brand or our products on social or digital media could seriously damage our brand and reputation. For example, consumer perception could be influenced by negative media attention regarding any consumer complaints about our products, our management team, ownership structure, sourcing practices and supply chain partners, employment practices, ability to execute against our mission and values, and our products or brand, such as any advertising campaigns or media allegations that challenge the sustainability of our products and our supply chain, or that challenge our marketing efforts regarding the quality of our products, which could have an adverse effect on our business, brand and reputation. Similar factors or events could impact the success of any brands or products we introduce in the future.

Our company image and brands are very important to our vision and growth strategies. We will need to continue to invest in actions that support our mission and values and adjust our offerings to appeal to a broader audience in the future in order to sustain our business and to achieve growth, and there can be no assurance that we will be able to do so. If we do not maintain the favorable perception of our company and our brand, our sales and results of operations could be negatively impacted. Our brand and company image is based on perceptions of subjective qualities, and any incident that erodes the loyalty of our consumers, customers, suppliers or manufacturers, including adverse publicity or a governmental investigation or litigation, could significantly reduce the value of our brand and significantly damage our business, which would have a material adverse effect on our business, financial condition, results of operations and cash flows.

***Our growth depends, in part, on expanding into additional consumer markets, and we may not be successful in doing so.***

 ****

We believe that our future growth depends not only on continuing to provide our current customers with new products, but also continuing to enlarge our customer base. The growth of our business will depend, in part, on our ability to continue to expand our customer base. We are investing significant resources in these areas, and although we hope that our products will gain popularity, we may face challenges that are different from those we currently encounter, including competitive, merchandising, distribution, hiring, and other difficulties. We may also encounter difficulties in attracting customers due to a lack of consumer familiarity with or acceptance of our brand, or a resistance to paying for premium products, particularly in international markets. In addition, although we are investing in sales and marketing activities to further penetrate newer regions, including expansion of our dedicated sales force, we may not be successful. If we are not successful, our business and results of operations may be harmed.

***Fluctuations in the cost and availability of raw materials, equipment, labor, and transportation could cause manufacturing delays or increase our costs.***

 ****

The price and availability of key components used to manufacture our products has been increasing and may continue to fluctuate significantly. In addition, the cost of labor within our company or at our third-party manufacturers could increase significantly due to regulation or inflationary pressures. Additionally, the cost of logistics and transportation fluctuates in large part due to the price of oil, and availability can be limited due to political and economic issues. Any fluctuations in the cost and availability of any of our raw materials, packaging, or other sourcing or transportation costs could harm our gross margins and our ability to meet customer demand. If we are unable to successfully mitigate a significant portion of these product cost increases or fluctuations, our results of operations could be harmed.

***We rely on third-parties for raw materials and to manufacture and compound our products. We have no control over these third parties and if these relationships are disrupted our results of operations in future periods will be adversely impacted.***

 ****

Our products are manufactured, compounded, and packaged by unaffiliated third parties and the use of these third-parties changes from time to time due to customer demand and the composition of our product mix and product portfolio. We do not have any long-term contracts with any of these third parties, and we expect to compete with other companies for raw materials, production and imported packaging material capacity. If we experience significant increased demand or need to replace an existing raw material supplier or third-party manufacturer, there can be no assurances that replacements for these third-party vendors will be available when required on terms that are acceptable to us, or at all, or that any manufacturer or compounder would allocate sufficient capacity to us in order to meet our requirements. In addition, even if we are able to expand existing or find new sources, we may encounter delays in production and added costs as a result of the time it takes to engage third parties. Any delays, interruption or increased costs in raw materials and/or the manufacturing or compounding of our products could have an adverse effect on our ability to meet retail customer and consumer demand for our products and result in lower revenues and net income both in the short and long-term.

***Our future success depends on the continuing efforts of our management and key employees, and on our ability to attract and retain highly skilled personnel and senior management.***

 ****

We depend on the talents and continued efforts of Brian John and Dr. Glynn Wilson. The loss of either would disrupt our business and harm our results of operations. Furthermore, our ability to manage further expansion will require us to continue to attract, motivate, and retain additional qualified personnel. Competition for this type of personnel is intense, and we may not be successful in attracting, integrating, and retaining the personnel required to grow and operate our business effectively. There can be no assurance that our current management team, or any new members of our management team, will be able to successfully execute our business and operating strategies.

***We may require additional capital to fund the expansion of our business, and our inability to obtain such capital could materially adversely affect our business, financial condition and operating results.***

 ****

To support our anticipated business expansion, we must have sufficient capital to continue to make significant investments. We cannot assure you that our existing cash and cash equivalents, together with cash generated from operations and this Offering will be sufficient to allow us to fund such expansion. If cash flows from operations are not sufficient, we may need additional equity or debt financing to provide the funds required to expand our business. If such financing is not available on satisfactory terms or at all, we may be unable to expand our business or to develop new business at the rate desired, and our operating results may suffer. Debt financing increases expenses, may contain covenants that restrict the operation of our business, and must be repaid regardless of operating results. Equity financing, or debt financing that is convertible into equity, could result in dilution to our existing stockholders.

Our inability to obtain adequate capital resources, whether in the form of equity or debt, to fund our business and growth strategies may require us to delay, scale back or eliminate some or all of our operations or the expansion of our business, which could materially adversely affect our business, financial condition and operating results.

***There is no market for the Company's Units and as such your investment is illiquid.***

 ****

There is no market for our Units and one will not develop and as such you may not be able to sell your Units (and such sales would be subject to compliance with the Company's organizational documents). Without a secondary market, one is not easily able to sell or trade our Units after purchasing them, and therefore may be stuck with their Units rendering them illiquid.

 **

***An investment in the Units is speculative and there can be no assurance of any return on any such investment.***

 **

An investment in the Units is speculative and there is no assurance that investors will obtain any return on their investment. Investors will be subject to substantial risks involved in an investment in the Company, including the risk of losing their entire investment.

***The offering price of the Units has been arbitrarily determined by the Company and such offering should not be used by an investor as an indicator of the fair market value of the Units.***

There is no public market for the Company's Units and there likely will be no market in the future. The offering price for the Units have been arbitrarily determined by the Company and does not necessarily bear any direct relationship to the assets, operations, book or other established criteria of value of the Company. Thus, an investor should be aware that the offering price does not reflect the fair market price of Units.

***Because the ownership of Units involves complex tax issues, each investor should consult with its own tax advisor prior to acquiring any Units.***

 ****

The tax consequences of purchasing and owning the Units are complex. Therefore, each prospective investor should consult its own tax adviser prior to acquiring any Units as to the tax consequences of an investment in the Units. It is strongly recommended that prospective investors obtain individual tax advice, particularly, because the income tax consequences of an investment in the Units and of securities transactions in general are complex and certain of these consequences may vary significantly with the particular financial and other economic situations of each prospective investor. Neither the Company nor the Manager has provided any tax advice.

**AS A RESULT OF THESE FACTORS, THE OFFERING IS ONLY SUITABLE FOR THOSE INVESTORS WHO ARE WILLING TO RELY ON OUR MANAGEMENT AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT IN THE UNITS. THE FOREGOING LIST OF RISK FACTORS DOES NOT PURPORT TO BE A COMPLETE ENUMERATION OF EXPLANATION OF THE RISK INVOLVED IN AN INVESTMENT IN THE UNITS.**

**SCHEDULE 2.1**

## Exhibit 10.11

**Exhibit 10.11**

**LEASE AGREEMENT**

**<u>REYNOLDS PLAZA</u>**

**SUMMARY OF TERMS**

As used in this Lease, the following terms shall have the following meanings:

---

| | |
|:---|:---|
| **LANDLORD:** | NRNS ACQUISITION REYNOLDS, LLC ("Landlord")<br> 6360 NW 5th Way, Suite 302<br> Fort Lauderdale, Florida 33309 |
| **TENANTS:** | JUPITER WELLNESS, INC. ("Tenant")<br> 725 N. Hwy AlA, Suite C106<br> Jupiter, FL 33477 |
| **GUARANTORS:** | *NIA* |
| **BUILDING:** | Reynolds Plaza<br> 1061 E. Indiantown Road<br> Jupiter, Florida 33477 |
| **PREMISES:** | A portion of the First Floor, Vacant Suite 110, consisting of approximately 6,908 +/- Rentable Square Feet as depicted on the space plan of premises attached hereto as <u>Exhibit "A"</u> |
| **1ENANT'S SHARE:** | 11.89 % (6,908 out of 58,070 square feet) |
| **EFFECTIVE AND COMMENCEMENT DATE:** | July 1, 2021 |
| **EXPIRATION DATE:** | Midnight on the last day of the calendar month, Sixty (60) full calendar months after the Commencement Date of July 1, 2021. |
| **TERM:** | The period commencing on the Commencement Date, July 1st, 2021 and ending at midnight on the last day of the 60th month from the Commencement Date, June 30<sup>th</sup>, 2026, (the "Term"). |
| **RENEWAL:** | So long that Tenant is not in default of the terms of the Lease at any time during the Lease Term, Tenant shall have one (1) lease renewal option for an additional three (3) year lease. In order for Tenant to exercise the Renewal Option under the Lease, Tenant shall provide a notice of exercising the renewal option at least nine (9) months prior to the termination of the current lease period. The Base Rent payable by Tenant to Landlord in the event of a renewal shall escalate at 3.0% per year, from the rate of the last year of the current Lease term. |

---

---

| | |
|:---|:---|
| **SECURITY DEPOSIT:** | In addition to the prepaid rent, Tenant shall provide Landlord two checks as Security Deposit as follows: (i) first security deposit check in the amount of $15,037.98representing the amount of rent paid by tenant for the initial month Rent; and (ii) a second security deposit check in the amount of $19,471.06 representing the amount of paid for Rent for the last month of the current Lease Term which shall be delivered to Landlord prior to the Commencement Date. At the end of the pt year, so long as Tenant is current on all payments and have not defaulted throughout the year on payments, Landlord shall return to tenant the first security deposit check of $15,037.98 back to Tenant. Landlord shall retain the second security deposit check throughout the Lease Term. |
| **PARKING:** | Tenant shall have the right to use up to 4 unreserved spaces per 1,000 square feet during the Term of the Lease. Ample unreserved surface parking is available to Tenant and its visitors at no additional cost. Landlord agrees to provide Tenant with five (5) reserved parking spaces located near Tenant's rear entry door located on the North side of the Building. |
| **BROKER:** | NAI/Merin Hunter Codman, Inc., serves as Broker on behalf of Landlord. Tenant warrants to Landlord that Tenant is not represented by a Broker. Tenant agrees to indemnify Landlord for any claim by any third-party broker for commissions to be paid as part of this transaction. |
| **LANDLORD'S WORK:** | Landlord to build out the Premises using building standard materials and finishes based on mutually agreed space plan, attached hereto as Exhibit "C", at Landlord's expense, with Landlord managing the construction. |
| **RADON GAS:** | Radon is a naturally occurring radioactive gas that, when it has accumulated in a building in sufficient quantities, may present health risks to persons who are exposed to it over time. Levels of radon that exceed Federal and State guidelines have been found in buildings in Florida. Additional information regarding radon and radon testing may be obtained from your county public health unit. |
| **ELECTRICITY:** | Electricity is included in Operating Expenses for lights and outlets. HVAC is included during the hours of 6:00 AM to 11:00 PM. |

---

---

| | |
|:---|:---|
| **ACCESS:** | Tenant shall be allowed to enter the Premises on June 1, 2021, to begin setting up its operations, so long such access does not hinder Landlord from preforming any of Landlord's Work required to prepare the space prior to the Commencement Date. Tenant shall have 24-hour access to the Premises. In addition, lobby doors shall remain unlocked until 8:00 pm Monday through Thursday, except on Holidays. **With Landlord's prior approval, Tenant, at Tenant's expense, may install a security entry pad for employees to enter the Premises.** |
| **AIR CONDITIONING:** | Air conditioning is provided to the Premises between 6:00 AM to 11:00 PM. |
| **SIGNAGE:** | Landlord will provide lobby signage on directory and at suite entry. With respect to the Premises glass doors, Landlord shall approve the design prior to the glass door being tinted to ensure the logo maintains characteristic of a professional office building. After obtaining Landlord's approval, Tenant at Tenant's expense may have the double glass entry doors tinted with Tenant's logo added to the door. With respect to the back door of the Premises Tenant, at Tenant's sole expense, may place a small sign stating, "Jupiter Wellness employees and loading only." Tenant, at Tenant's expense, may install approved signage which must match existing signs of tenants on the Monument facing Indiantown Road. Tenant shall be responsible for obtaining any required approvals from the local building department. |
| **GUARANTY:** | *NIA* |
| **EXHIBIT(S)** | Exhibit "A" Space Plan and Specifications<br> Exhibit "B" Legal Description of Land<br> Exhibit "C" Work Letter Agreement<br> Exhibit "D" Rules and Regulations<br> Exhibit "E"Building Standard Services<br> Exhibit "F" Building Standard Janitorial Services<br> Exhibit "G" Rent Schedule |

---

Capitalized terms not defined in this Summary of Terms shall have the meanings ascribed to such terms in the Lease.

**LEASE AGREEMENT**

THIS LEASE AGREEMENT (the **"Lease"),** made as of the 14th day of May, 2021, by and between NRNS ACQUISITION REYNOLDS LLC, a Florida limited liability company **("Landlord")** and IDPITER WELLNESS, INC., a Delaware publicly-traded corporation **("Tenant").**

<u>WITNESETH:</u>

**1.** **PREMISES AND TERM**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Landlord hereby rents and leases to Tenant, and Tenant hereby rents and leases from Landlord, the Premises, as more particularly shown and outlined on the space plans attached hereto as <u>Exhibit "A",</u> and made a part hereof, designated as vacant Suite 110 in the Building. For all purposes under this Lease, Landlord and Tenant have agreed that the Premises shall be deemed to include 6,908 +/- square feet of space.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Term shall commence on the Commencement Date, i.e. July 1, 2021, and end at midnight on the Expiration Date, i.e. June 30th, 2026, or on such earlier date as the Term may expire or be terminated pursuant to the provisions of this Lease or pursuant to law. This Lease shall be effective and enforceable between Landlord, Tenant, and Guarantors on the Effective Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Building and the land upon which said Building is located, described on <u>Exhibit "B"</u> attached hereto and by reference incorporated herein (the **"Land"),** is referred to as the **"Property".** All drives, parking areas, parking lots, walkways, terraces and landscaped areas that shall be used and maintained in connection with the Building that are contiguous to the Property whether in fact located within the boundaries of the Land for purposes of this Lease shall be included in the definition of **"Building"** and **"Property".**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Subject to the terms herein provided, the Premises shall include the appurtenant right to use on a non-exclusive basis in common with others the public lobbies, entrances, stairs, corridors, elevators, all drives, parking areas, parking lots and other public portions of the Building. All the windows and outside walls of the Premises, and any space in the Premises used for shafts, pipes, conduits, ducts, telephone ducts and equipment, electric or other utilities, sinks or other Building facilities, and the use thereof and access thereto through the Premises for the purposes of operation, maintenance, inspection, display and repairs are hereby reserved exclusively by Landlord. No easement for light, air or view, is granted or implied hereunder, and the reduction or elimination of Tenant's light, air or view will not affect Tenant's liability under this Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) **RENEWAL:** So long that Tenant is not in default of the terms of the Lease at any time during the Lease Term, Tenant shall have one (1) lease renewal option for an additional three (3) year lease. In order for Tenant to exercise the Renewal Option under the Lease, Tenant shall provide a notice of exercising the renewal option at least nine (9) months prior to the termination of the current lease period. The Base Rent payable by Tenant to Landlord in the event of a renewal shall escalate at 3.0% per year, from the rate of the last year of the current Lease term.

**2. RENT.** Upon signing the Lease, in addition to a security deposit, Tenant shall pay Landlord as prepaid Rent the following: (i) first month Rent in the amount of $15,037.98; and (ii) last month's Rent in the amount of $19,471.06, totaling: $34,509.04. Tenant shall pay to Landlord, at the address set forth in the Summary of Terms, or to such other person or at such other place, including a lockbox, as Landlord may designate in writing, and without any prior demand, deduction or set off whatsoever, the applicable Base Rent then in effect as set forth on <u>Exhibit "G"</u> attached to this Lease in equal monthly installments (the **"Monthly Base Rent")** in advance on the first (1st) day of each calendar month during the Term. Any payment not paid on the first (1<sup>st</sup>) day of each calendar month, and which Tenant fails to cure by making payment by the fifth (5<sup>th</sup>) day of the same month, shall be deemed late and shall subject to a late fee of ten (10%) percent. The Base Rent shall be $18.00 per RSF, and payable by Tenant to Landlord under this Lease shall escalate at 3.0% per year as more particularly set forth on <u>Exhibit "G"</u> to this Lease. The term **"Additional Rent"** as used herein shall mean Tenant's Share (as defined below) of Operating Costs (also known as "CAM") (as defined below) and any additional amounts or charges due from Tenant hereunder. The term **"Rent"** as used herein shall mean Monthly Base Rent and Additional Rent collectively.

Should this Lease commence at any time other than the first day of a calendar month or terminate at any time other than the last day of a calendar month, the amount of Rent due from Tenant shall be proportionately adjusted based on that portion of the month that this Lease is in effect.

At all times that Landlord shall direct Tenant to pay Monthly Base Rent and/or Additional Rent to a "lockbox" or other depository whereby checks issued in payment of Rent are initially cashed or deposited by a person or entity other than Landlord (albeit on Landlord's authority), then, for any and all purposes under this Lease: (i) Landlord shall not be deemed to have accepted such payment until ten (10) days after the date on which Landlord shall have actually received such funds, and (ii) Landlord shall be deemed to have accepted such payment if (and only if) within said ten (10) day period, Landlord shall not have refunded (or attempted to refund) such payment to Tenant. Nothing contained in the immediately preceding sentence shall be construed to place Tenant in default of Tenant's obligation to pay Rent if and for so long as Tenant shall timely pay the rent required pursuant to this Lease in the manner designated by Landlord.

**Rent Calculation and CAM Calculation:** Landlord and Tenant agree that: (a) at all times from the Commencement Date and during the Term of the Lease, Tenant shall be responsible to pay Operating Expenses and Real Estate Taxes for the which shall be based on the entire square footage of the Premises encompassing 6,908 RSF; and (b) only Tenant's Base Rent shall be calculated and paid according to the below phased RSF schedule:

● For year one of t<sup>'</sup>he Lease, Tenant's Base
 Rent will be calculated based on Five Thousand (5,000)
 RSF;

● For
 year two of the Lease, Tenant's Base Rent will be calculated based on Five Thousand
 Nine Hundred and Eight (5,908) RSF; and

● For
 years three, four, and five of the Lease, Tenant's Base Rent will be calculated based
 on entire Six Thousand Nine Hundred and Eight (6,908) RSF which Tenant is leasing.

**3.** **REIMBURSEMENT FOR OPERATING COSTS AND TAXES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Base Rent provided for herein does not include an Operating Costs component. Tenant shall pay to Landlord, as Operating Costs, prorated for that part of the Term within the applicable calendar year, Tenant's Share, as hereafter defined, of the total amount of (i) the annual Operating Costs, as hereafter defined, and (ii) the annual taxes **("Taxes"),** as hereafter defined. Operating Costs for 2021 ("Base Year") are estimated at $11.50 per square foot of space. For all years during the Tem1, Landlord shall, in advance, reasonably estimate for each such calendar year the total amount of the Operating Costs. Tenant shall pay one-twelfth (1/12) of the estimated Operating Costs monthly to Landlord, along with Tenant's monthly payment of the Monthly Base Rent. Landlord shall use its reasonable efforts to make such estimate on or before January 1 of each calendar year. On or before April 30 following a year for which Operating Costs are payable hereunder, Landlord shall use its reasonable efforts to provide Tenant with the amount of the actual Operating Costs for the previous year, and a reasonable breakdown of the items included therein, together with an invoice for any underpayments of Operating Costs (to be paid within thirty (30) days following receipt of such invoice) or a credit to Rent to reimburse Tenant for any overpayment of Operating Costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The term **"Operating Costs"** (also known as "CAM") shall mean any and all operating expenses of the Building, all of which shall be computed on a modified cash basis and which shall include all expenses, costs and disbursements of every kind and nature, which Landlord (i) shall pay; or (ii) become obligated to pay in connection with the ownership, operation, management, maintenance, repair, replacement and security of the Building, including, but not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Wages and salaries of all employees engaged in the operation and maintenance of the Building, including, but not limited to, taxes, insurance and benefits relating thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ii) All supplies, tools and materials used in the operation and maintenance of

the Building;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Cost of water, sewage, electricity (lights, outlets, and HVAC as provided in Section 8 of this Lease), and other utilities furnished in connection with the operation of the Building;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Cost of all service agreements and maintenance for the Building and/or the Property and/or the equipment therein, including, but not limited to, trash removal, security services, alarm services and systems, sprinkler system upgrades and/or replacement costs, window cleaning, janitorial service, HVAC maintenance, replacements and upgrades, elevator maintenance and upgrades, installation of new roof and all associated continuing repairs and/or maintenance related thereto, backup generators, traffic control, security, policing and supervising, and grounds maintenance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Cost of all insurance relating to the Building including, but not limited to, insurance against fire and other casualties, public liability and property damage, loss of rents and/or business interruption, and any other risks with respect to the Premises and Landlord's personal property used in connection therewith;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) All taxes (ad valorem and otherwise); assessments, and governmental charges whether Federal, state, county, or municipal, and whether by taxing districts or authorities presently taxing the Building or by others, subsequently created or otherwise, and any other taxes (other than Federal and state income taxes) and assessments attributable to any portion of the Building or its operation or any Rent or any personal property in connection with the operation of the Building (collectively, **"Taxes"),** and any consultants and legal fees incurred with respect to issues, concerns or appeals involving the taxes or the Building;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Cost of repairs, cleaning and general maintenance of the interior and exterior of the Building (including, but not limited to, glass breakage, lighting, electrical and security systems, and striping, resurfacing, seal coating, curbing, signage, pavement or other repairs and replacement or overlay of the parking area, drainage areas, sidewalks, walkways and driveways of the Premises), and refurbishment, painting and remodeling as required, from time to time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) Cost of management fees for general operation and management of the Building, which service may be provided by an affiliated company or subsidiary of Landlord at comparable market rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) A reasonable amortization cost due to any capital expenditures incurred (i) which are incurred to have the effect of reducing or limiting Operating Costs of the Building, or improving the operating efficiency of the Building and the Property, if such reduction or limitation would inure to Tenant's benefit, or (ii) which may be required by governmental authority or by Landlord's insurance carrier, or (iii) which are designed to protect or enhance the health, safety or welfare of the tenants in the Building or their invitees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) Amounts collected and held by Landlord with respect to reserve accounts for those items designated by Landlord, including painting, refurbishing, re-carpeting, redecorating, or landscaping any portion of the Building and the Prope1iy and/or common and public areas of the Building exclusive of any tenant space, which shall include (a) roof maintenance or replacement, (b) repainting the Building, and (c) maintenance of the parking lot;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) Cost of repairs, replacements, damages in respect to the Building incurred due to casualties or other causes to the extent uninsured including any deductible amounts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) Cost of auditing and maintaining accounting books and records in respect to the Building and the Property; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) Cost of conducting any indoor air quality testing in any portions of the Building deemed necessary or desirable by Landlord, including regularly scheduled testing, and any costs incurred in connection with work arising out of the results of such tests or reports or the recommendations in such tests or reports.

Landlord shall be permitted to contract with its affiliates for supplies, materials, and services used for the operation, maintenance, and management of the Property and the Building and its affiliates shall be permitted to subcontract for the acquisition of said supplies, materials, and services, so long as the contracts for the above-mentioned items are at the fair market rate or such other favorable rate.

Notwithstanding anything herein to the contrary, the following items shall not be included within Operating Costs:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) costs and expenditures for the replacement of capital investment items (excepting those expenditures referred to above);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ii) paid leasing commissions for the leasing of any space in the Building;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) reimbursements paid by other tenants of the Building or other third parties for direct costs incurred at such applicable parties' request;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iv) depreciation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (v) principal, interest, and other costs directly related to financing the

Property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) the cost of any repairs or general maintenance paid by the proceeds of insurance policies carried by Landlord on the Property; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) the wages and salaries of any supervisory or management employees of Landlord not involved in the day-to-day operation and maintenance of the Building.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The term **"Tenant's Share"** shall mean 11.89% which is the ratio of 6,908 (the square footage of the Premises) to 58,070 (the total square footage of the Building). Notwithstanding anything to the contrary contained herein, if the Building does not have an average occupancy of ninety-five percent (95%) during any calendar year, appropriate adjustments shall be made to determine Operating Costs as though the Building had been ninety-five percent (95%) occupied, but in no event shall Tenant ever be required to pay more than Tenant's Share of the determined Operating Costs. The average occupancy shall be determined by adding together the total leased space on the last day of each month during the calendar year in question and dividing by twelve (12). In no event shall Landlord adjust costs that remain constant regardless of occupancy levels. Furthermore, in no event will the total amount collected from all the tenants of the Building for a calendar year exceed 100% of the actual Operating Costs for the Building for the applicable calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The term **"Projected Operating Costs"** for any calendar year shall mean Landlord's estimate of projected Operating Costs for such calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Prior to January 1 of each calendar year during the Term of this Lease, Landlord shall provide Tenant with a statement of Tenant's Share of the Projected Operating Costs for such calendar year, if there is a projected change in the amount expected from the previous year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Landlord shall, within a period of one hundred twenty (120) days (or as soon thereafter as practical) after the close of each calendar year, provide Tenant with an unaudited statement of the actual Operating Costs for the prior calendar year. If the actual Operating Costs for a calendar year are greater than the Projected Operating Costs, Tenant shall pay Landlord, within thirty (30) days of such statement's receipt, Tenant's Share of the difference thereof (the amount of such difference is sometimes hereinafter refe1Ted to as the **"Excess Operating Costs").** If the Projected Operating Costs are greater than the actual Operating Costs for a calendar year, Landlord shall credit Tenant, within thirty (30) days of such statement issuance, Tenant's Share of the difference between the actual Operating Costs for the applicable calendar year and the Projected Operating Costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Should this Lease commence at any time other than the first day of a calendar year or terminate at any time other than the last day of a calendar year, the amount of Additional Rent due from Tenant shall be proportionately adjusted based on that portion of the year that this Lease was in effect.

**4. DELIVERY OF THE PREMISES.** Landlord will deliver possession of the Premises to Tenant upon the Commencement Date in the condition required under the terms of this Lease. Tenant shall be allowed to enter the Premises on June 15, 2021, to begin setting up its operations, so long such access does not hinder Landlord from preforming any of Landlord's Work required to prepare the space prior to the Commencement Date.

**5. ACCEPTANCE OF THE PREMISES; ACCESS.** The taking of possession of any portion of the Premises by Tenant shall be conclusive evidence that Tenant has inspected the Premises and accepts the same in its "As Is" "Where Is" condition as required under the terms of this Lease on the Commencement Date and that said portion of the Premises is in good and satisfactory condition for the Permitted Use (as defined below). Upon acceptance of the Premises, Tenant shall have 24/7 access to the Premises. In the event that Tenant, at its sole expense and with Landlord's prior approval, chooses to install a security entry pad to the Premises, Tenant agrees to provide Landlord and the Fire Department with copies of the access codes to the Premises in order to allow for access in the event of an emergency on the Premises.

**6. PERMITTED USE.** Tenant shall use and occupy the Premises for corporate office use only (the **"Permitted Use").** Tenant shall not use or occupy the Premises for any other purpose or business without the prior written consent of Landlord. The Premises shall not be used for any illegal purposes; nor in any manner to create any nuisance or trespass; nor in any manner to vitiate the insurance or increase the rate of insurance on the Premises. Tenant's use of the Premises shall not violate any ordinance, law or regulation of any governmental body. Tenant's use shall comply with the "Rules and Regulations" of the Building (the **"Rules")** as set forth in <u>Exhibit "D"</u> attached hereto and made a part hereof. Tenant shall not cause an unreasonable use of any of the services provided in the Building. Tenant agrees, at its sole cost and expense, to promptly comply with all municipal, county, state and federal statutes, regulations, or requirements applicable or in any way relating to the use and occupancy of the Premises. Tenant agrees to conduct its business in the manner and according to the generally accepted business principles of the business or profession in which Tenant is engaged. All the Rules shall apply to Tenant and its employees, agents, licensees, invitees, guests, contractors, and Landlord permitted subtenants and assignees, if any. Tenant shall be responsible for ensuring ADA Compliance, or similar municipality, county, or state regulation with solely respect to any and all prohibitions of discriminatory practices of covered individuals under such act or similar municipality, county, or state regulation, within the Premises.

**7.** **CARE OF THE PREMISES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Landlord's Repairs.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Except to the extent expressly set forth in this Lease, Tenant agrees that no representations respecting the Premises or the Building, or the condition thereof, and that no promises to decorate, alter, repair or improve the Premises, either before or after the execution hereof, have been made by Landlord or its agents to Tenant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Landlord shall only have the obligation to maintain and repair the common hallways and corridors of the Building, common rest rooms and main lobby area of the Building, the HVAC systems of the Building, the driveways and parking areas located on the Land, and the roof, foundation, floors, exterior walls and glass of the Building. Tenant shall immediately give Landlord written notice of any defect or need for repairs for which Landlord is responsible to perform under this Section 7(a)(ii), after the receipt of such written notice Landlord shall have a reasonable time within which to repair same or cure such defect. In the event that the HVAC unit cannot be repaired it shall be replaced by Landlord. Landlord's liability hereunder shall be limited only to the cost of correcting such defects or making such repairs. Notwithstanding Landlord's obligation to maintain and repair under this Section 7(a)(ii), Tenant shall reimburse Landlord for the repair of any damage caused by Tenant, or Tenant's employees, agents, contractors, invitees or licensees, or caused by an Event of Default (as defined below) by Tenant under this Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Notwithstanding any other prov1s1ons herein, other than repairing the structure of the Premises, Landlord shall not be liable to Tenant for any damage occasioned by plumbing, electrical, gas, water, steam or other utility pipes, systems or facilities or by the bursting, stopping, leaking or running of any tank, sprinkler, washstand, water closet or pipes in or about the Premises or the Building; nor for any damage occasioned by water being upon or coming through or around the roof or any flashing, window, skylight, vent, door, or the like unless directly resulting from Landlord's act or willful neglect after reasonable written notice is provided to Landlord by Tenant; nor for any damage arising out of any acts or neglect of co-tenants, other occupants of the Building, occupants of adjacent property or the public.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Tenant's Repairs.** Except as otherwise set forth herein, during the Term of this Lease, Tenant will, at its sole cost and reasonable expense, maintain the Premises and the fixtures and appurtenances therein in good order, condition and repair, and shall not commit any active or permissive waste to the Premises or allow the damages thereto. At all times during the Tem1 of this Lease, Tenant shall maintain the Premises in accordance with all applicable laws, the Rules, and the terms of this Lease. Tenant's responsibilities in conjunction therewith shall include, but not be limited to maintain the Premises in a first-class condition and state of repair. All such repair work, maintenance and any alterations permitted by Landlord in its sole and absolute discretion: (i) shall be done at Tenant's sole cost and expense; (ii) shall be done by Landlord's employees or agents or, with Landlord's express written consent in its sole and absolute discretion, by persons requested by Tenant in writing; and (iii) shall first be consented to in writing by Landlord. In accordance with the terms of this Section 7(b), Tenant shall, at Tenant's sole cost and reasonable expense, promptly repair any injury or damage to the Premises or the Building (including without limitation, any damage caused in connection with Tenant's move into or out of the Premises) caused by the misuse or neglect thereof by Tenant, or by Tenant's contractors, subcontractors, customers, employees, licensees, agents, or invitees permitted or invited (whether by express or implied invitation). In the event any such repairs are required to be made in or to the Premises or the Building by Tenant, Tenant shall promptly make such repairs at its sole cost and expense in accordance with the terms of this Section 7(b). If Tenant does not make repairs promptly and adequately, Landlord may, but need not, make repairs, and Tenant shall promptly reimburse Landlord for the cost of such repairs and such amount shall constitute Additional Rent under this Lease. Tenant shall pay Landlord as Additional Rent for any overtime reasonable expense incurred by Landlord and for any other reasonable expense incurred by Landlord in the event repairs, alterations, decorating or other work in the Premises are not made during ordinmy business hours.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Alterations.** Tenant shall not, without Landlord's prior written consent, and which consent Landlord's may grant or withhold in Landlord's sole and absolute discretion, make any alterations, additions, or improvements whatsoever (including, but not limited to, structural alterations, additions or improvements) in or about the Premises, and will not do anything to or on the Premises which will increase the rate of fire or other insurance on the Building or the Property. If Landlord shall fail to notify Tenant in writing of its approval of any Tenant requested alteration, addition, or improvement within thirty (30) days of the date of Landlord's receipt of such request, Landlord shall be deemed to have elected to deny its consent to the applicable Tenant requested alteration, addition or improvement. All alterations, additions or improvements of a permanent nature made or installed by Tenant to the Premises shall become the property of Landlord at the expiration or earlier termination of this Lease. Landlord reserves the right to require Tenant, at Tenant's sole cost and expense, to remove any alterations, improvements or additions made to the Premises by Tenant and to repair and restore the Premises to their condition prior to such alteration, addition or improvement, reasonable wear and tear, unrepaired insured casualty not caused by Tenant (or by Tenant's contractors, subcontractors, customers, employees, licensees, agents or invitees permitted or invited, whether by express or implied invitation) and condemnation excepted. Landlord shall have the right to require Tenant to pay Landlord up to a $1,500.00 administrative fee to cover Landlord's and Landlord's agents' review of materials for any proposed Tenant alteration, addition or improvement and, it required, such administrative fee shall constitute Additional Rent under this Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **Condition of Premises on Surrender of Premises.** Upon the expiration or termination of the Term or the Renewal Term (if applicable) of this Lease, Tenant shall quit and surrender to Landlord the Premises, broom clean, in good order and condition as provided in this Lease, ordinary wear and tear excepted, and with all of Tenant's personal property removed. Tenant shall also return to Landlord all keys, access cards or entrance passes to the Premises and/or the Building. All property of Tenant remaining in the Premises after expiration of the Tem1 of this Lease or earlier termination of this Lease shall be conclusively deemed to have been abandoned by Tenant, and at the election of Landlord in its sole and absolute discretion, such abandoned property shall become the property of Landlord. In such event, Landlord may remove and dispose of such property in any way Landlord sees fit in its sole and absolute discretion without liability to Tenant. Tenant shall reimburse Landlord for the cost of removing and storing any such abandoned property. The foregoing notwithstanding, Landlord shall continue to have the right (which shall survive termination or expiration of the Lease) to require Tenant to remove any alterations, improvements or additions made to the Premises by Tenant pursuant to the terms of Section 7(b) above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) **Contractors Doing Work.** In doing any work related to the installation of Tenant's furnishings, fixtures, or equipment in the Premises, Tenant shall only use contractors or workers consented to by Landlord in writing prior to the time such work is commenced. Landlord may condition its consent to Tenant's use of any contractor or worker to Landlord's receipt and approval, in its sole and absolute discretion, of: (i) an executed lien waiver from such contractor or worker; and (ii) certificates of insurance evidencing that such contractors and/or workers have contractor's liability insurance with at least $2,000,000.00 coverage; automobile liability insurance with at least $1,000,000.00 coverage; and worker's compensation insurance in the statutory amounts required by the State of Florida, and which required insurance coverage shall be obtained from insurance carriers satisfactory to Landlord. Landlord shall have the right to periodically review and modify the coverages required hereunder by delivery of written notice to Tenant. Landlord and Landlord's property manager shall be named additional insureds on the policies required hereunder. Tenant shall within ten (10) days of filing promptly remove any lien or claim of lien for material or labor claimed against the Premises, the Building, the Property or any or all of them, by such contractors or workers if such claim should arise, and Tenant shall and does hereby indemnify, defend and hold harmless Landlord from and against any and all claims, loss, cost, damage, expense or liabilities including, but not limited to, reasonable attorneys' fees, incurred by Landlord, as a result of or in any way related to such claims or liens.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) **Personal Property at Risk.** All personal property brought into the Premises by Tenant, its employees, licensees, and invitees shall be at the sole risk of Tenant. Landlord shall not be liable for theft thereof or for any damages thereto, such theft or damage being the sole responsibility of Tenant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) **Landlord's Right to do Work.** Provided Tenant's access into and out of the Premises, the Building and the Property is not otherwise unreasonably diminished, Landlord shall have the right, at any time, without the same constituting an actual or constructive eviction and without incurring any liability to Tenant therefor, to reasonably change the arrangement and/or location of entrances or passageways, doors and doorways, corridors, elevators, toilets or other public parts of the Building and/or the Property, and to reasonably close entrances, doors, corridors, elevators or other facilities temporarily in order to perform Landlord's obligations under this Lease.

**8. SERVICES.** Provided Tenant is in compliance with the terms and conditions of this Lease, Landlord shall furnish the Building Standard Services described on <u>Exhibit "E"</u> attached hereto and by reference made a part hereof (certain costs of which Buildings Standard Services shall be reimbursed to Landlord as Operating Costs in accordance with Section 3 of this Lease). Landlord reserve the right to limit HVAC service Monday through Friday between the hours of 11:00 p.m. - 6:00 a.m., and Saturday, Sunday, and Holidays, between the hours of 8:00 p.m. - 8:00 a.m. **("After Hours").** Landlord will also provide After Hours HVAC service, provided Tenant gives Landlord notice of the desire for such After Hours HVAC service, and which shall include the date and time of the requested After Hours HVAC service.

**9. DESTRUCTION OR DAMAGE TO PREMISES.** If the Premises or the Building are totally or partially destroyed by fire or other casualty during the Term of this Lease (a **"Casualty"),** then Landlord shall have the option of either rebuilding the Premises and/or the Building or terminating the Lease upon the giving of written notice to Tenant within sixty (60) days of the date of such Casualty. If this Lease is so terminated, (a) the Term shall expire upon the tenth (10<sup>th</sup>) day after such notice is given, (b) Tenant shall immediately vacate the Premises and surrender the same to Landlord, (c) Tenant's liability for Rent shall cease as of the date of Casualty, and (d) any prepaid Rent for any period after the date of the Casualty shall be refunded by Landlord to Tenant within five (5) business days of date on which Tenant surrenders the Premises to Landlord under the terms of this Section 9. If Landlord elects to repair the Premises and/or the Building, Landlord shall commence, in good faith, repair and restoration work within 120 days from the date of receipt by Landlord of all insurance proceeds paid with respect to such casualty and proceed with due diligence to complete said restoration of the Premises.

Nothing herein shall be construed to obligate Landlord to expend for such repair an amount in excess of the net insurance proceeds actually received as a result of the applicable Casualty and in no event shall Landlord be required to repair or replace any alteration or improvement made by or for Tenant, including but not limited to any of tenant's work with respect to the Premises, nor any trade fixtures, furniture, equipment or other property belonging to Tenant. If Landlord chooses to restore the Premises, Rent shall abate with, respect to the untenantable portion of the Premises from the date of the Casualty until the date of substantial restoration thereof, provided, however; Rent shall not abate if the damage or destruction of the Premises, whether total or partial, is the result of the gross negligence of Tenant, its contractors, subcontractors, agents, employees, guests or invitees. Also, Tenant shall remain obligated to perform and discharge all of its remaining covenants under this Lease during the period of any abatement of Rent under this Section 9.

The Landlord shall not be liable for any inconvenience or interruption of business of the Tenant occasioned by any Casualty. Landlord shall not be liable to carry fire, casualty or extended damage insurance on the property of Tenant, on Tenant's employees or on any person or property which may now or hereafter be placed in the Premises.

Notwithstanding anything to the contrmy in this Section 9, if any Casualty during the final twelve (12) months of the Term of this Lease renders the Premises wholly untenantable, either Landlord or Tenant may terminate this Lease by written notice delivered to the other party within thirty (30) days after the occurrence of such Casualty and this· Lease shall expire on the thirtieth (30<sup>th</sup>) day after the date of such notice unless Tenant has the then-exercisable right to extend the Term and exercises such right within thirty (30) days following the date of the Casualty. If this Lease is so terminated, (a) the Term of this Lease shall expire upon the thirtieth (30<sup>th</sup>) day after such notice is given, (b) Tenant shall immediately vacate the Premises and surrender the same to Landlord in its current condition, (c) Tenant's liability for Rent shall cease as of the date of the Casualty, and (d) any prepaid Rent for any period after the date of the Casualty shall be refunded by Landlord to Tenant within five (5) business days of the date on which Tenant surrenders the Premises to Tenant under this Section 9. For purposes of this Section 9, the Premises shall be deemed wholly untenantable if Tenant shall be precluded from using more than 50% of the Premises for the conduct of its business and Tenant's inability to so use the Premises is reasonably expected to continue for more than ninety (90) days.

**10. EVENT OF DEFAULT BY TENANT; LANDLORD'S REMEDIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The occurrence of any of the following shall constitute an **"Event of Default"** by Tenant under this Lease:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Tenant shall fail to pay any Rent or any other sum of money payable by Tenant hereunder as and when such Rent or other sums becomes due and payable, unless cured no later than the fifth (5<sup>th</sup>) day thereafter;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Tenant fails to bond off or otherwise remove (in a manner acceptable to Landlord in its sole and absolute discretion) any lien filed against the Premises, the Building or any other part of the Property by reason of Tenant's actions within fifteen (15) days after Tenant has notice of the filing of such lien;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Tenant fails to observe, perform and keep any of the other non-monetary covenants, agreements, provisions, stipulations, conditions and Rules herein contained to be observed, performed and kept by Tenant under this Lease and such failure continues for more than fifteen (15) days after Landlord has provided Tenant with written notice of such failure; provided, however, Landlord shall only be required to provide written notice under this Section lO(a)(iii) once in any Lease Year;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) The filing of a petition under any section or chapter of the Bankruptcy Reform Act of 1986 as amended, provided the same is not discharged within sixty (60) days, or adjudication of Tenant as bankrupt or insolvent in proceedings filed against Tenant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) The appointment of a receiver or trustee for all or substantially all of the assets of Tenant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (vi) An assignment for the benefit of creditors by Tenant; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Tenant shall abandon, desert, or vacate any substantial portion of the Premises prior to the end of the Term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon occurrence of any event of default in section (a) above, Landlord shall have the option to do any one or more of the following without any notice or demand, in addition to any other remedy available to Landlord in law or equity, or pursuant to this Lease:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Landlord may terminate this Lease, in which event, Tenant shall immediately surrender the Premises to Landlord, but if Tenant shall fail to do so, Landlord may without notice and without prejudice to any other remedy Landlord may have, enter upon and take possession of the Premises and expel or remove Tenant and its effects without being liable to prosecution or any claim for damages therefore; and Tenant agrees to indemnify Landlord for all loss and damage which Landlord may suffer by reason of such termination, whether through inability to relet the Premise or otherwise, including any loss of rental for the remainder of the Term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Landlord may accelerate and declare all Rent and Additional Rent due for the balance of the Term of this Lease and declare the same, along with all sums past due, to be immediately due and payable. Upon Landlord's acceleration of Rent and Additional Rent, Tenant agrees to pay all accelerated sums due amounts to Landlord at once. Such payment shall constitute payment in advance of the Rent for the remainder of the Term. In determining the amount of any future payments due Landlord as a result of increases in Operating Costs and/or Taxes, Landlord may make such determination based upon the amount of Operating Costs and/or Taxes paid by Tenant for the full year immediately prior to the applicable Event of Default. The acceptance by Landlord of the payment of such rent shall not constitute a waiver of any default then existing or thereafter occurring hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Landlord may accelerate all Rent and Additional Rent due for the balance of the Term of this Lease and declare the same, along with all sums past due and late fees, to be immediately due and payable, and demand payment from Lease Guarantors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Landlord may immediately proceed to collect or bring action for the whole Rent or such part thereof as aforesaid, as well as for liquidated damages provided for hereinafter, as being Rent in arrears, or may file a Proof of Claim in any bankruptcy or insolvency proceeding for such Rent, or Landlord may institute any other proceedings, whether similar to the foregoing or not, to enforce payment thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Enter upon and take possession of the Premises as the agent of the Tenant without being liable to prosecution or any claim for damages therefore, and Landlord may relet the Premises as the agent of Tenant and receive the rent therefore, in which event Tenant shall pay to Landlord on demand the cost of renovating, repairing and altering the Premises for a new tenant or tenants and any deficiency that may arise by reason of such reletting; provided, however, that Landlord shall have no duty to relet the Premises and the failure of landlord to relet the Premises shall not release or affect Tenant's liability for rent or for damages.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Landlord shall have the right of injunction, in the event of a breach or threatened breach by Tenant of any of the agreements, conditions, covenants or tenns hereof, to restrain the same and the right to invoke any remedy allowed by law or in equity, whether or not other remedies, indemnity or reimbursements are herein provided.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) The rights and remedies given to Landlord in this Lease are distinct, separate and cumulative remedies, and no one of them, whether or not exercised by Landlord, shall be deemed to be in exclusion of any of the others. Any waiver of or redress of any violation of any covenant or condition contained in this Lease or any of the Rules now or hereafter adopted by Landlord shall not prevent Landlord from future enforcement upon a future violation. The receipt by Landlord of Rent with knowledge of the breach of any covenant in this Lease shall not be deemed a waiver of such breach. Unless otherwise expressly provided herein, Tenant's obligation to pay all the Rent due through the Expiration Date shall survive any termination or expiration of this Lease.

**11. ASSIGNMENT AND SUBLETTING**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as expressly permitted pursuant to this Section 11, Tenant shall not, without the prior written consent of Landlord, assign this Lease or any interest herein or sublet the Premises or any part thereof by operation of law or otherwise. Any of the foregoing acts without such consent shall be void ab initio and Landlord shall, at the option of Landlord, have the right to terminate this Lease. Notwithstanding the foregoing, a corporate Tenant may, without consent of the Landlord, assign this Lease to its parent or subsidiary in com1ection with a consolidation or merger of Tenant, provided the same assignee assumes, in full, the obligation of Tenant under the Lease, and such assigmnent shall not relieve the assignor of any of its obligations under this Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If at any time during the Term of this Lease Tenant desires to assign this Lease or sublet all or any part of the Premises, Tenant shall give written notice to Landlord of such intent. Landlord shall have the option, exercisable by notice given to Tenant within twenty (20) days after receipt of Tenant's notice, of terminating this Lease (in the case of a proposed assignment) or of recapturing the portion of the Premises proposed to be sublet and terminating the Lease with respect thereto (in the case of a proposed subletting). If the Landlord does not exercise such recapture option, Tenant shall be free to sublet such space or assign this Lease to any third-party subject to the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Consent of Landlord shall be obtained, which consent shall not be unreasonably withheld;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If the space or Lease is not subleased or assigned within ninety (90) days from the expiration of Landlord's option to terminate this Lease as set forth above, or any subsequent option as provided in this Section 1l(b), Tenant shall, prior to entering into a sublease or an assignment, once again give Landlord written notice and Landlord shall have twenty (20) days after the receipt thereof of terminating this Lease or recapturing the applicable portion of the Premises and terminating this Lease with respect thereto;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) No sublease or assignment shall be valid, and no subtenant or assignee shall take possession of the premises subleased or assigned until a fully executed copy of the applicable assignment or sublease has been delivered to Landlord;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (iv) No subtenant or assignee shall have a right further to sublet or assign; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Tenant shall promptly pay all costs and expenses (including, without limitation, actual attorneys' fees and costs) incmTed by Landlord in connection with processing and reviewing such sublease or assignment, which will be reasonably capped at $750.00 for a standard transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Any sums or other economic consideration received by Tenant as a result of any subletting or assignment whether denominated rentals under the assignment, sublease or otherwise, which exceed, in the aggregate, the total sums which Tenant is obligated to pay Landlord under this Lease (prorated to reflect obligations allocable to that portion of the Premises subject to such sublease or assignment) shall be payable to Landlord as Additional Rent under this Lease without affecting or reducing any other obligation of Tenant hereunder. If such subleasing or assignment has been made without the consent of the Landlord as provided herein, Landlord shall be entitled to all economic consideration received by Tenant in accordance with the provisions of this Section 11(c), but the receipt of such monies shall not be deemed to be a waiver of the provisions of this Section 11(c) with respect to assignn1ent and subletting, or the acceptance of such assignee or subtenant as Tenant hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Regardless of Landlord's consent, no subletting or assignment shall release Tenant of Tenant's obligation or alter the primary liability of Tenant to pay all Rent under this Lease and to perfmm all other obligations to be performed by Tenant hereunder. The acceptance of any Rent by Landlord from any other person shall not be deemed to be a waiver by Landlord of any provision hereof. Consent to one subletting or assigµment shall not be deemed consent to any subsequent assignment or subletting. In the event of default by any assignee of Tenant or any successor of Tenant in the performance of any of the terms hereof, Landlord may proceed directly against Tenant without the necessity of exhausting remedies against such assignee or successor. Landlord may consent to subsequent subletting or assignment of this Lease or amendments or modifications to this Lease with assignees of Tenant, with written notice to Tenant, or any successor of Tenant, and without obtaining its or their consent thereto and such action shall not relieve Tenant of liability under this Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In the event that (1) the Premises or any part thereof are sublet and Tenant is in default under this Lease, or (2) this Lease is assigned by Tenant, then, such agreement of assignment or subletting shall provide that upon notice from Landlord such assignee or subtenant shall remit all rents directly to Landlord, and Landlord may collect rent from the assignee or subtenant and apply the net amount collected to the Rent due under this Lease; but no such collection shall be deemed a waiver of the provisions of this Section 11 with respect to assignment and subletting, or the acceptance of such assignee or subtenant as Tenant hereunder, or a release of Tenant from further performance of the covenants herein contained.

**12. CONDEMNATION.** If: (i) the whole Building or the whole Premises, or if a portion of the Building or a portion of the Premises shall be taken by condemnation or in any other manner for any public or quasi-public use or purpose (a **"Taking")** and (ii) such Taking will permanently, materially and adversely have an effect on: (a) Tenant's use and occupancy of the Premises or Tenant's access to the Building; or (b) any parking areas serving the Building, then this Lease shall terminate as of the date of vesting of title on such Taking and the Base Rent and Additional Rent shall be prorated and adjusted as of such date. If there is a partial taking where this Lease is not terminated, the Rent shall be adjusted in proportion to the square footage of the Premises taken, as determined by Landlord's architect or engineer. In any event, Landlord shall be exclusively entitled to claim, any award made in any condemnation proceeding, action or ruling relating to any Taking. Notwithstanding the foregoing, in the event of a termination of this Lease following a Taking, Tenant shall be entitled to make a separate claim in any condemnation proceeding, action or ruling relating to such Taking for Tenant's moving expenses, loss of goodwill and the unamortized value of leasehold improvements in the Premises actually paid for by Tenant without contribution by Landlord; provided, however, Tenant's claim shall not in any manner impact upon or reduce Landlord's claim or award in such eminent domain proceeding, action or ruling in connection with such Taking and Tenant shall likewise have no claim against Landlord for the value of any unexpired portion of this Lease.

**13. INSPECTIONS.** Landlord, its agents, employees, contractors and subcontractors, may enter the Premises at reasonable times upon 24 hours' notice (except in the event of an emergency in which case only such reasonable notice as is possible shall be necessary) to (a) exhibit the Premises to prospective purchasers of the Building or prospective tenants of the Premises or the Building; (b) inspect the Premises to see that Tenant is complying with its obligations hereunder; (c) make repairs or alterations (i) required of Landlord under the terms hereof; (ii) to any adjoining space in the Building; or (iii) to any systems serving the Building which run through the Premises; and (d) perform any and all of Landlord's obligations under this Lease, or any other lease, where entry to such Premises is reasonably required for such performance. In addition to the foregoing, Landlord, its agents, employees, contractors and/or sub-contractors may enter the Premises at any time without notice if an emergency requires such entry. All inspections or subsequent repairs or alterations shall be conducted in a reasonable manner to ensure that Tenant may continue to use the space without intenuption. Any such entry shall not constitute an eviction of Tenant or be deemed as disturbing Tenant's quiet enjoyment of the Premises and no abatement of Rent shall result because of such entry and/or performance, so long as Landlord does not unreasonably interrupt the use of Tenant's space. Landlord shall be allowed to take all material into and upon the Premises that may be required to perform Landlord's obligations under this Lease without the same constituting an eviction of Tenant in whole or in part; and the Rent shall in no way abate while said decorations, repairs, alterations, improvements or additions are being made. If Tenant shall not be personally present to open and permit an entry into the Premises, at any time, when for any reason an entry therein shall be necessary or permissible, Landlord or Landlord's agents may enter the same by a key, a pass key, or when for any reason an entry therein shall be necessary in Landlord's sole and absolute discretion and such entry by key or pass key is not possible, may forcibly enter the same, without rendering Landlord or such agents liable therefor, and without in any manner affecting the obligations and covenants of Tenant under this Lease. All entries shall, where possible, be performed at such times and in such fashion so as not to unreasonably interfere with the conduct and operation of Tenant's business. Nothing herein contained, however, shall be deemed or construed to impose upon Landlord any obligation, responsibility or liability whatsoever, for the care, supervision or repair of the Premises or Building other than as herein provided. Notwithstanding anything contained herein to the contrary, the Landlord shall be responsible (at Landlord's expenses) for repairing any damage to the Premises caused by Landlord actions under this Paragraph.

**14. SUBORDINATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Lease shall be subject and subordinate to any underlying land leases or mortgage which may now or hereafter affect this Lease, the Building or the Property and also to all renewals, modifications, extension consolidations, replacements of such underlying land leases and such mortgages. In confirmation of the subordination set forth in this Section 14, Tenant shall, at Landlord's request, execute and deliver a subordination, attornment and non-disturbance agreement in the form desired by the holder(s) of the mortgage(s) (a **"Mortgagee")** or by any lessor under any such underlying land leases and reasonably acceptable to Tenant. Notwithstanding the foregoing, Landlord or such Mortgagee shall have the right to subordinate or cause to be subordinated, in whole or in part, any such underlying land leases or mortgage(s) to this Lease (but not in respect to priority of entitlement of insurance or condemnation proceeds). If any such underlying land leases or mortgage(s) terminates for any reason or any such m01igage(s) is foreclosed or a conveyance in lieu of foreclosure is made for any reason, Tenant shall, notwithstanding any subordination, deliver to Mortgagee or Landlord within ten (10) days of written request an attornn1ent agreement, providing that such Tenant shall continue to abide by and comply with the terms and conditions of this Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If any proceedings are brought for the foreclosure of, or in the event of exercise of the power of sale or conveyance in lieu of foreclosure under any mmigage, Tenant shall at the option of the purchaser at such foreclosure or other sale, attorn to such purchaser and recognize such person as Landlord under this Lease. Tenant agrees that the institution of any one suit, action or other proceeding by a Mortgagee or a sale of the Property pursuant to the powers granted to a Mortgagee under its mortgage, shall not, by operation of law or otherwise, result in the cancellation or the termination of this Lease or of the obligations of Tenant hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If such purchaser requests and accepts such attornment, from and after the time of such attornment, Tenant shall have the same remedies against such purchaser from the breach of an agreement contained in this Lease that Tenant might have had against Landlord if the mmigage had not been terminated or foreclosed, except that such purchaser shall not be (i) liable for any act or omission of the prior Landlord; (ii) subject to any offsets or defenses which Tenant might have against the prior Landlord; (iii) bound by any Rent or security deposit which Tenant might have paid in advance to the prior Landlord; (iv) obligated to cure any default of any prior Landlord under the Lease that occurred prior to the time that such purchaser succeeded to the interest of Landlord in the Property; or (v) bound by any amendment or modification of the Lease made without the prior written consent of such purchaser. Tenant's tenancy hereunder shall not be disturbed in the event that any of the foregoing occurs.

**15. INDEMNIFICATION AND HOLD HARMLESS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Tenant hereby indemnifies and holds harmless Landlord from and against any injmy, expense, damage, liability or claim, imposed on Landlord by any person whomsoever, whether due to damage to the Premises, claims for injuries to the person or property of any other tenant of the Building or of any other person in or about the Building or the Property for any purpose whatsoever, or administrative or criminal action by a governmental authority, if such injury, expense, damage, liability or claim results either directly or indirectly from the act, omission, negligence, misconduct or breach of any provisions of this Lease by Tenant, the agents, contractors, servants, or employees of Tenant, or any other person entering in the Building or upon the Premises under express or implied invitation or consent of Tenant. Tenant fmiher agrees to reimburse Landlord for any costs or expenses, including, but not limited to, court costs and reasonable attorneys' fees, which Landlord may incur in investigating, handling or litigating any such claim or any action by a governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Tenant shall report in writing to Landlord any defective condition in or about the Premises known to Tenant, and fmiher agrees to attempt to contact Landlord immediately in such instance.

**16. INSURANCE.** Tenant shall carry (at its sole expense during the Term): (i) Renter's Insurance coverage insuring Tenant's improvements and betterments to the Premises and any and all furniture, fixtures, equipment, supplies, contents and other prope1iy owned, leased, held or possessed by Tenant and contained therein, such insurance coverage to be equal to the full replacement value of such property and improvements and betterments, as such may increase from time to time; (ii) Worker's Compensation Insurance and Employers' Liability Insurance coverage as required by the State of Florida and as provided in this Section 16 below; and (iii) Comprehensive General Liability Insurance on an occurrence basis with broad form extended coverage, including Contractual Liability Insurance, and any other insurance coverages and endorsements as are reasonably requested by Landlord, against claims occurring upon, in or about the Premises and for injury to or death of a person or persons and for damage to property occasioned by or arising out of the condition, use, or occupancy of the Premises, or other portions of the Building with a minimum coverage of a combined single limit of not less than Two Million and No/100 Dollars ($2,000,000) for any bodily injury or property damage occurring as a result of or in connection with the above. Tenant shall ensure that each individual employee, member, officer shall hold an Auto Liability Insurance, including coverage for Hired & Non-Owned Auto Liability, with a policy minimum of 100,000/300,000 for each vehicle brought onto, and parked at, the property. Tenant shall also carry a Commercial Umbrella Insurance policy to insure against claims not covered by the Commercial General Liability Insurance, the Auto Liability Insurance, and Employers' Liability Insurance in the amount of Two Million and *Noll* 00 Dollars ($2,000,000). Tenant may provide any such policies through blanket policies of insurance. Landlord and Landlord's property manager, mortgagee and managing agents, and their respective partners, officers, shareholders, policyholders, employees, attorneys and agents, and employees shall be named additional insureds on the Tenant's policies required hereunder and such policies shall provide that the coverage thereunder is primary to, and not contributing with, any policy carried by any such additional insured. Tenant's Commercial General Liability Insurance, Auto Liability Insurance, Workers Compensation Insurance and Commercial Umbrella Insurance policies shall contain a Waiver of Subrogation in favor of Landlord and each additional insured.

Tenant shall have included in all policies of insurance respectively obtained by it with respect to the Building or Premises a waiver by the insurer of all right of subrogation against Landlord (to the extent that such waiver is permitted under the policy without invalidating the policy) in connection with any loss or damage thereby insured against, and Landlord shall have included in all insurance policies required to be maintained by Landlord under this Lease a waiver by the insurer of all right of subrogation against Tenant in connection with any loss or damage thereby insured against. To the full extent permitted by law, Landlord as to its property insurance policies and Tenant as to its property insurance policies, each waives all right of recovery against the other for, and agrees to release the other from liability for, loss or damage, including any applicable deductible required to be paid, to the extent such loss or damage results from a cause covered by valid and collectible insurance in effect at the time of such loss or damage; provided however, that the foregoing release by each party is conditioned upon the other party's carrying insurance with the above described waiver of subrogation to the extent required to be carried under this Lease, or actually carried, notwithstanding the negligence of either party.

Landlord will at all times during the Term of this Lease maintain a policy or policies of (i) Comprehensive General Liability Insurance coverage on an occurrence basis with broad form extended coverage for injury to or death of a person or persons and for damage to property occasioned by or arising out of Landlord's operation of the Building and Property, including Contractual Liability Insurance, such policy to have a minimum combined single limit of not less than Two Million and No/100 Dollars ($2,000,000) for any bodily iajury or property damage occurring as a result of or in connection with the above. Landlord may provide any such policies through blanket policies of insurance. Landlord reserves the right to self-insure in lieu of maintaining such policies. All waivers of subrogation required hereunder shall also apply to self-insurance.

All said insurance policies shall be carried with companies licensed to do business in the State of Florida reasonably satisfactory to Landlord having a Best's Rating of A- XII or better and shall be noncancelable and non-amendable except after thirty (30) days' written notice to Landlord. At Landlord's request, duly executed certificates of such insurance shall be delivered to Landlord prior to the Commencement Date of this Lease and at least thirty (30) days prior to the expiration of each respective policy term.

**17. REMEDIES CUMULATIVE.** The rights given to Landlord and Tenant herein are in addition to any rights that may be given to Landlord or Tenant by any statute or at law or in equity. The utilization by a party of any remedy shall not be deemed an election of remedies, so as to preclude said party from simultaneously utilizing other remedies.

**18. SURRENDER OF PREMISES; HOLDING OVER.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) This Lease shall terminate, and Tenant shall deliver up and surrender possession of the Premises on the Expiration Date of this Lease, and Tenant waives the right to any notice of termination or notice to quit. Tenant covenants that upon the Expiration Date of this Lease or the sooner termination of this Lease it shall without notice deliver up and surrender possession of the Premises in the same condition in which Tenant has agreed to keep the same during the continuance of this Lease and in accordance with the terms hereof, normal wear and tear excepted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon the failure of Tenant to surrender possession of the Premises upon the expiration or sooner termination of this Lease, Tenant shall pay to Landlord, as liquidated damages, an amount equal to twice the Base Rent and Additional Rent required to be paid under this Lease as applied to any period in which Tenant shall remain in possession after the Expiration Date of this Lease or sooner termination of this Lease. Acceptance by Landlord of Rent after such expiration or earlier termination shall not constitute a consent to a holdover tenancy by Tenant under this Lease nor result in any renewal of this Lease. The foregoing provisions of this Section 18 are an addition to and do not limit or constitute a waiver of Landlord's right of reentry or any other rights of Landlord hereunder or as otherwise provided by law.

**19. NOTICES.** Any notice by either party to the other shall be valid only if in writing and shall be deemed to be duly given only if delivered personally or sent by certified mail return receipt requested or by FEDEX, UPS, DHL or other overnight courier service, addressed (i) if to Tenant, at the address set forth above in the Summary of Terms, and (ii) if to Landlord, at Landlord's address set forth above in the Summary of Terms, or to such other address that either party may designate by written notice to the other. Notice shall be deemed given, if delivered personally, upon delivery thereof, and if sent by certified mail return receipt requested, five (5) business days after deposit with the United States Postal Service. In the event transmittal is made by FEDEX, UPS, DHL or other overnight courier service, notice shall be deemed given upon receipt. Notice by electronic mail shall be deemed acceptable if is accompanied by one of the mail transmission methods herein and includes a read receipt acknowledgment.

**20.** **SUCCESSORS.** The respective rights and obligations provided in this Lease shall bind and shall inure to the benefit of the parties hereto, their legal representatives, heirs, successors and assigns, provided, however, that no rights shall inure to the benefit of any successors of Tenant unless Landlord's written consent for the transfer to such successor has first been obtained as provided in Section l l(a) above.

**21.** **ATTORNEYS' FEES.** In the event of any lawsuit or court proceeding between Landlord and Tenant arising out of or under this Lease or the terms and conditions stated herein, the prevailing party in such lawsuit or comi proceeding shall be entitled to and shall collect from the non-prevailing party the reasonable attorneys' fees and comi costs actually incurred by the prevailing paiiy with respect to said lawsuit or court proceeding.

**22.** **TIME OF THE ESSENCE.** It is understood and agreed between the parties hereto that time is of the essence of all the terms, provisions, covenants and conditions of this Lease.

**23.** **NO ESTATE IN LAND.** Tenant has only a leasehold estate with the right to use the Premises for the Permitted Use for the Term of this Lease in accordance with the terms of this Lease, and such leasehold estate is not subject to levy or sale. Other than such leasehold estate, Tenant has no other real property interest nor estate in the Premises, the Building or the Property.

**24. SECURITY DEPOSIT.** On the execution date of this Lease, Tenant shall deposit with Landlord two checks as Security Deposit as follows: (i) first security deposit check in the amount of $15,037.98 representing the amount ofrent paid by tenant for the initial one month Rent; and, (ii) a second security deposit check in the amount of $19,471.06 representing the amount of paid for Rent for the last month of the current Lease Tenn. So long as Tenant is current on all payments and have not defaulted throughout the year on payments, at the end of the 1st year Landlord shall return to Tenant the first security deposit check of $15,037.98 back to Tenant. Landlord shall retain the second security deposit check throughout the Lease Term to secure Tenant's performance of all of Tenant's obligations and liabilities under this Lease. Unless required to do so by law, Landlord shall have no obligation to segregate the Security Deposit from any other funds of Landlord, and interest earned on the Security Deposit, if any, shall belong to Landlord. The Security Deposits shall not be considered an advance payment of any Rent or a measure of Landlord's damages if an Event of Default occurs under this Lease. Within thirty (30) days after the Expiration Date of this Lease, and provided that Tenant has fully performed its obligations hereunder and the Premises have been repaired and restored as required hereunder, the Landlord shall return the Security Deposit, or the remaining balance thereof, to Tenant. In the event Landlord fails to return the Security Deposit to Tenant within such thirty (30) day period, interest shall accrue as of the thirty-first (31<sup>st</sup>) day after the Expiration Date of this Lease. Regardless of any permitted assignment of this Lease by Tenant, Landlord may return the Security Deposit to the original Tenant in the absence of evidence satisfactory to Landlord of an assignment of the right to receive the Security Deposit or the remaining balance thereof, which shall satisfy in full Landlord's obligation to return the Security Deposit to Tenant under this Lease. Landlord shall have the right to apply all or any portion of the Security Deposit to cure an Event of Default under this Lease and if Landlord does so, Tenant shall upon demand deposit with Landlord the amount of the Security Deposit so applied by Landlord so that upon deposit, Landlord shall have the full amount of the Security Deposit set forth above in the Summary of Terms on deposit at all times during the Term of this Lease. In the event of a sale or lease of the Building subject to this Lease, Landlord shall transfer the Security Deposit to the purchaser or lessee of the Building, and Tenant hereby agrees that upon such transfer by Landlord, Landlord shall be released from all liability for the return of such Security Deposit and Tenant shall look solely to the purchaser or lessee, as applicable, for the return of the Security Deposit. This provision shall apply to every transfer or assignment made of the Security Deposit to a successor owner or lessee of the Building. The right to receive a refund of the Security Deposit shall not be assigned or encumbered by Tenant without the prior written consent of Landlord and any such unapproved assignment or encumbrance shall be void ab initio.

**25.** **COMPLETION OF THE PREMISES.** Exhibit "C" sets forth, among other things, Landlord's and Tenant's agreement regarding improvements if any, to be made to the Premises. Any work required by Tenant as provided for in said Exhibit "C" shall be performed within the provisions and according to all standards of said Exhibit "C".

**26. PARKING AND ACCESS AREAS.** Subject to such limitations and conditions from time to time imposed by Landlord upon all of the tenants of the Building and subject to the reservation of a limited number of parking spaces for particular tenants of the Building, Landlord shall maintain unreserved parking facilities on the Land surrounding the Building for parking by Tenant and Tenant's invitees and employees, and for parking by other tenants of the Building and their applicable invitees and employees. Said parking shall be maintained on the Property or on areas located in the vicinity of the Property. The parking facilities to be provided by Landlord under this Section 26 shall be provided in quantities which are in accordance with the zoning regulations or variances then in effect for the Property upon which the Building is located.

Tenant agrees that the actual number of parking spaces on the Property used by Tenant and its employees and invitees shall never at any time exceed the ratio of four (4) parking spaces per 1,000 square feet of square feet of the Premises. Landlord shall provide Tenant with five (5) reserved parking spaces near the rear entry door to Tenant's Premises located on the North Side of the Building. Landlord shall have the right to undertake any measures or promulgate and enforce any rules and regulations (in addition to the Rules) that Landlord deems necessary or appropriate so enforce this provision, including, by way of illustration but not limitation, restricting access to specific parking spaces on the Property, assessing parking fines against violators of the parking rules for the Property or towing the automobiles of violating parties at such parties' sole cost and expense.

Tenant hereby covenants and agrees to indemnify and hold Landlord harmless from and against any and all liability, claim, demands, loss or damage for injury or death of any person or damage to property, and any fines, suits, claims, demands and actions, in any way arising from or in connection with the occupancy or use of the parking facility by Tenant, Tenant's guests, employees, licensees, and/or invitees, except in the event that Landlord's actions were deemed to constitute gross negligence.

Tenant, as a material part of the consideration to be rendered to Landlord under the Lease, hereby waives all claims against Landlord for damages to property or injuries to persons arising from or occasioned by use of the parking facilities. Landlord shall not be liable to Tenant for any damages by or from any act or negligence of any tenant or other occupant of the Building or by any other person upon on in such parking facilities.

**27. RULES AND REGULATIONS.** The Rules set forth on <u>Exhibit "D"</u> attached to this Lease are incorporated into and made a part of this Lease. Landlord may from time to time amend, modify, delete or add new and additional reasonable Rules for the use, operation, safety, cleanliness and care of the Premises, the Building and the Land. Such new or modified Rules shall be effective upon notice thereof to Tenant. Tenant will cause its employees and agents, or any other invitees of Tenant who occupy or enter the Premises to abide by the Rules at all times. In the event of any breach of any Rules and failure to cure as permitted hereunder, Landlord shall have all remedies provided for in this Lease upon the occurrence of an Event of Default and shall, in addition, have any remedies available at law or in equity, including but not limited to, the right to enjoin any breach of the Rules. Landlord shall not be responsible to Tenant for the nonobservance of the Rules by any other tenant of the Building or by any other person, except in the event that Landlord fails to enforce the rules against any other tenant after reasonably written request by Tenant or any other tenant of the Building.

**28. LATE PAYMENTS - ACCORD AND SATISFACTION.** Any payment due by Tenant under this Lease that is not received by Landlord on the date when due, or within any cure period, shall be assessed a ten percent (10%) charge for Landlord's administrative and other costs in processing and pursuing the payment of such late payment and for each month thereafter until paid in full. No payment by Tenant or receipt by Landlord of a lesser amount than any installment or payment of Rent then due shall be deemed to be other than on account of the earliest stipulated Rent or other sums then due and payable under this Lease; nor shall any endorsement or statements on any check or any letter or other writing accompanying any check or payment be deemed an accord and satisfaction. Landlord may accept such check or payment without prejudice to Landlord's right to recover the balance of such Rent or other sums then due under this Lease or pursue any other remedy provided in this Lease.

**29. ESTOPPEL CERTIFICATE.** At any time, Tenant shall, within seven (7) days of the request by Landlord, execute, acknowledge and deliver to Landlord, or any mmigagee or prospective mortgagee or purchaser of the Property, an Estoppel Certificate in recordable fo1m, or in such other form which Landlord requires, evidencing (a) whether or not this Lease is in full force and effect; (b) whether or not this Lease has been amended in any way; (c) whether or not Tenant has accepted and is occupying the Premises; (d) whether or not there are any existing defaults on the part of Landlord hereunder or defenses or offsets against the enforcement of this Lease to the knowledge of Tenant (specifying the nature of such defaults, defenses or offsets, if any); (e) the date to which Rent and other amounts due hereunder, if any, have been paid; and (f) any such other information reasonably requested by Landlord. Each ce1iificate delivered pursuant to this Section 29 may be relied on by Landlord, any prospective purchaser or transferee of Landlord's interest hereunder, or any mortgagee or prospective mortgagee. Tenant irrevocably appoints Landlord as its attorney-in-fact, coupled with an interest, to execute and deliver, for and in the name of Tenant, any document or instrument provided for in this Section 29, if Tenant fails to provide same in a timely manner.

**30.** **SEVERABILITY.** If any provisions of this Lease shall be held to be invalid, void or unenforceable, the remaining provisions hereof shall in no way be affected or impaired and such remaining provisions shall remain in full force and effect.

**31.** **MULTIPLE TENANTS.** If more than one individual or entity comprises and constitutes Tenant, then all individuals and entities comprising Tenant are and shall be jointly and severally liable for the due and proper performance of Tenant's duties and obligations arising under or in connection with this Lease.

**32.** **FORCE MAJEURE.** Notwithstanding any provision in this Lease to the contrary, Landlord shall be excused for the period of any delay and shall not be deemed in default with respect to the performance of any of the terms, covenants, and conditions of this Lease when prevented from such performance by causes beyond Landlord's control, which shall include, but not be limited to, all labor disputes, governmental regulations or controls, fire or other casualty, inability to obtain any material or services, or acts of god.

**33. QUIET ENJOYMENT.** So long as Tenant is in full compliance with the terms and conditions of this Lease, Landlord shall warrant and defend Tenant in the quiet enjoyment and possession of the Premises during the Term against any and all claims made by, through or under Landlord, subject to the terms of this Lease.

**34. BROKERAGE COMMISSION; INDEMNITY.** Tenant warrants that except for the Broker named on page 3 of this Lease above, there are no claims for broker's commissions or finder's fees in connection with its execution of this Lease. If any claims for brokerage commissions or fees are ever made by any broker, other than the Broker named on page 3 of this Lease, against Landlord or Tenant in connection with the negotiation of this Lease transaction, all such claims shall be handled and paid by the party whose actions or alleged commitments form the basis of such claim, and said party who is responsible shall indemnify, defend and hold the other party harmless against any claim for brokerage or finder's fees, or other like payment based in any way upon agreements, arrangements, or understandings made or claimed to have been made by Landlord or Tenant with any third person.

**35. EXCULPATION OF LANDLORD.** Notwithstanding any provision in this Lease to the contrary, Landlord's liability with respect to or arising from or in connection with this Lease shall be limited solely to Landlord's equity interest in the Building. Neither Landlord, nor any of the members of Landlord, nor any officer, director, principal, trustee, policyholder, shareholder, attorney or employee of Landlord or its managing agent shall have any personal liability whatsoever with respect to this Lease.

**36.** **COUNTERPARTS; EXECUTION.** This Agreement may be executed in any number of counterparts and by different pmiies to this Agreement on separate counterparts, each of which, when so executed, will be deemed an original, but all such counterparts will constitute one and the same agreement. Any signature delivered by a party by facsimile transmission or electronic mail will be deemed to be an original signature.

**37. APPLICABLE LAW; JURISDICTION AND VENUE.** This Lease has been made under and shall be construed, interpreted, and enforced under and in accordance with the laws of the State of Florida, without regards to any conflict of law provision or rule. Tenant hereby agrees to the exclusive jurisdiction of the applicable State Comi of Florida sitting in Broward County, Florida, or in the applicable United States District Court having jurisdiction sitting in Broward County, Florida.

**38.** **NO RECORDATION OF LEASE.** Without the prior written consent of Landlord, neither this Lease nor any memorandum hereof shall be recorded or placed on public record.

**39. HAZARDOUS WASTES.** Neither Tenant, its successors or assigns, nor any permitted assignee or sublessee, licensee or other person or entity acting by or through Tenant, shall (either with or without negligence) cause or permit the escape, disposal or release of any "Hazardous Substances or Materials" (as hereinafter defined). Tenant shall not allow the storage or use of such Hazardous Substances or Materials in any manner not sanctioned by law and by the highest standards prevailing in the industry for the storage and use of such Hazardous Substances or Materials, nor allow to be brought into the Building, the Prope1iy or the Premises any such Hazardous Substances or Materials except to use in the ordinary course of Tenant's business, and then only if such Hazardous Substances or Materials are not prohibited by (and are only in amounts permitted by) law. Without limitation, **Hazardous Substances or Materials** shall include any biologically or chemically active substance and any waste, substance or material described in Section 101(14) of the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended from time to time, 42 U.S.C. Section 9601 et seq., the Resource Conservation and Recovery Act, as amended from time to time, 42 U.S.C. Section 6901 et seq., any applicable state or local laws and the regulations adopted under these acts. If any lender or governmental agency shall ever require testing to asce1iain whether or not there has been any release of Hazardous Substances or Materials, then the reasonable costs thereof shall be reimbursed by Tenant to Landlord, if the release of the Hazardous Substance or Material is due the acts or inaction of Tenant, upon demand as additional charges if such requirement applies to the Premises. In addition, Tenant shall execute affidavits, representations and the like from time to time at Landlord's request concerning Tenant's best knowledge and belief regarding the presence of Hazardous Substances or Materials on the Premises, the Building or the Property. Tenant indemnifies and covenants and agrees at its sole cost and expense, to protect and save Landlord harmless against and from any and all damages, losses, liabilities, obligations, penalties, claims, litigation, demands, defenses, judgments, suits, proceedings, costs, or expenses of any kind or of any nature whatsoever (including without limitation, reasonable attorneys' fees and expert's fees) which may at any time be imposed upon, incurred by or asserted or awarded against Landlord arising from or out of any Hazardous Substances or Materials on, in, under or affecting the Premises, the Building or the Property or any part thereof as a result of any act or omission by Tenant, its successors or assigns, or any permitted assignee, pe1mitted sublessee or licensee or other person or entity acting at the direction with the consent of Tenant. The within covenants shall survive the expiration or earlier termination of the Term of this Lease.

**40. SIGNS.** No sign of any type or description shall be erected, placed or painted in or about the Premises, the Building or the Property, except those signs submitted to Landlord in writing, and approved by Landlord in writing, which signs shall be in conformance with Landlord's sign criteria established for the Building. Tenant shall receive initial standard signage for the Building in the lobby directory board at Landlord's expense. Tenant shall receive entrance suite signage at the entrance to the Premises at Landlord's sole expense. With respect to the Premises glass doors, Landlord shall approve the design prior to the glass door being tinted to ensure the logo maintains characteristic of a professional office building. After obtaining Landlord's approval, Tenant at Tenant's expense may have the double glass entry doors tinted with Tenant's logo added to the door. With respect to the back door of the Premises Tenant, at Tenant's sole expense, may place a small sign stating, "Jupiter Wellness employees and loading only". Moreover, Tenant, at Tenant's expense, may install approved signage which must match existing signs of tenants on the Monument facing Indiantown Road. Tenant shall be responsible for obtaining any required approvals from the local building department.

**41. CONTROL OF COMMON AREAS AND PARKING FACILITIES.** All automobile parking areas, driveways, entrances and exits thereto, and other facilities furnished by Landlord, including all parking areas, truck way or ways, loading areas, pedestrian walkways and ramps, landscaped areas, stairways, corridors, and other areas and improvements provided by Landlord for the general use, in common (the **"Common Areas"),** of tenants, their officers, agents, employees, servants, invitees, licensees, visitors, patrons and customers, shall be at all times subject to the exclusive control and management of Landlord, and Landlord shall have the right but not the obligation from time to time to establish, modify, and enforce reasonable rules and regulations with respect to the Common Areas; to police same, from time to time; (it being expressly understood that such right of Landlord shall in no event be construed to create any affirmative duty or obligation on the part of Landlord to police or provide security or protection or give rise to any liability of Landlord in the event of a third party's criminal act); to change the area, level and location and arrangement of parking areas and other facilities hereinabove referred to; to restrict parking by, and enforce parking charges (by operation of meters or otherwise) to tenants, their officers, agents, invitees, employees, servants, licensees, visitors, patrons, and customers; to close all or any portion of said areas or facilities to such extent as may, in the opinion of Landlord's counsel, be legally sufficient to prevent a dedication thereof or the accrual of any rights to any person of the public therein; to close temporarily all or any portion of the Common Areas; to discourage non-tenant parking; and to do and perform such other acts in and to said areas and improvements as, in the sole judgment of Landlord, shall be advisable with a view to the improvement of the convenience and use thereof by tenants, their officers, agents, employees, servants, invitees, visitors, patrons, licensees and customers. Landlord will operate and maintain the Common Areas in such a reasonable manner as Landlord shall determine from time to time. Without limiting the scope of such discretion, Landlord shall have the full right and authority but not the obligation to designate a manager of the parking facilities or Common Areas or other facilities, who shall have full authority to make and enforce rules and regulations regarding the use of the same and to employ all personnel and to make and enforce all Rules pertaining to, and necessary for, the proper operation and maintenance of the parking areas or the Common Areas. Tenant shall comply (and shall require all persons within its control to comply) with such Rules, upon notice of same.

**42. NO SMOKING.** Tenant and Tenant's employees and invitees shall comply with the requirements of the Florida Clean Indoor Air Act, Chapter 386, Part II, as may be amended from time to time, and any administrative regulations promulgated thereunder. Landlord shall have the right from time to time to enact future Rules concerning smoking, including the right in Landlord's discretion to prohibit smoking in the Building, as may be necessary in order to comply with the requirements of the Florida Clean Indoor Air Act. For purposes hereof, **"smoking"** means inhaling, exhaling, burning or can-ying any lighted cigar, cigarette, pipe or other smoking equipment or device in any manner or form, including electronic cigarettes or vaping devices and equipment.

**43. PRIOR OCCUPANCY.** If Tenant, with Landlord's consent shall occupy the Premises prior to the beginning of the Term specified in Section 2 hereof, all provisions of this Lease shall be in full force and effect commencing upon such occupancy; and Rent for such period shall be paid by Tenant at the same rate herein specified for the Commencement Date of the Lease.

**44. PUBLICITY/CONFIDENTIALITY.** Landlord and Tenant expressly agree to keep this Lease confidential and not make any public or press announcements with respect to this Lease or the terms thereof without the prior written consent of the other party. Notwithstanding the foregoing, no provision of this Lease shall be deemed to prohibit Landlord or Tenant from disclosing information contained herein to such party's employees, agents, representatives and independent contractors, so long as the party disclosing such information insures that any party receiving such information is aware of the confidential nature of this Lease and agrees to keep such information confidential.

**45.** **HEADINGS.** The headings in this Lease are included for convenience only and shall not be taken into consideration in any construction or interpretation of any part of this Lease.

**46. NO PARTNERSHIPS.** Landlord shall not by the execution of this Lease in any way or for any purpose become a partner of Tenant in the conduct of its business or otherwise, or joint venturer or a member of a joint enterprise with Tenant.

**47. ADA.** Tenant shall be responsible for compliance with Title III of the American with Disabilities Act of 1990 **("ADA")** within the Premises as to ensuring compliance with non-discriminatm-y practices, and Landlord shall be responsible for compliance with the ADA relative to the Common Areas and the Building.

**48. WAIVER OF JURY TRIAL.** TO THE EXTENT PERMITTED BY LAW, IT IS MUTUALLY AGREED BY AND BETWEEN LANDLORD AND TENANT THAT THE RESPECTIVE PARTIES HERETO SHALL, AND THEY DO HEREBY, WAIVE TRIAL BY mRY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BETWEEN THE PARTIES HERETO OR THEIR SUCCESSORS OR ASSIGNS ON ANY MATTERS ARISING OUT OF, OR IN ANY WAY CONNECTED WITH, THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, AND/OR TENANT'S USE OF, OR OCCUPANCY OF, THE PREMISES. THIS WAIVER IS MADE FREELY AND VOLUNTARILY, WITHOUT DURESS AND ONLY AFTER EACH OF THE PARTIES HERETO HAS HAD THE BENEFIT OF ADVICE FROM LEGAL COUNSEL ON THIS SUBJECT.

**49. NO THIRD-PARTY BENEFICIARY.** This Lease is only intended to benefit, and is only enforceable by and against, the parties hereto, their successors and assigns and no provisions herein are intended to benefit or be enforceable by any persons not a party to or successor or assign to any of the parties herein.

**50. REPRESENTATIONS OF TENANT.** Tenant by its execution hereof, represents and warrants to Landlord and its successors and assigns that as of the date hereof Tenant is a duly established and validly existing limited liability company and that the individual(s) signing this Lease on behalf of Tenant has/have been duly authorized to do so and thereby bind Tenant.

**51. TENANT SHALL DISCHARGE ALL LIENS.** Nothing contained in this Lease shall be construed as consent on the part of Landlord to subject the estate of Landlord to liability under the Construction Lien Law of the State of Florida, it being expressly understood that Landlord's estate shall not be subject to such liability. Tenant shall strictly comply with the Construction Lien Law of the State of Florida as set forth in Florida Statutes, Section 713, including, but not limited to giving written notice to all persons performing services or furnishing materials on its behalf of the terms and conditions of this **Section 51.** In the event that a Mechanic's Claim of Lien is filed against the property in connection with any work performed by or on behalf of Tenant (except work for which Landlord is responsible), Tenant shall satisfy such claim or shall transfer same to security within ten (10) days from the date of filing or such failure shall constitute an Event of Default hereunder. In the event that Tenant fails to satisfy or transfer such claim within said ten (10) day period, Landlord may do so and thereafter charge Tenant, as Additional Rent, all costs incurred by Landlord in connection with satisfaction or transfer of such claim, including attorneys' fees. Further, Tenant agrees to indemnify, defend and save Landlord harmless from and against any damage or loss incurred by Landlord as a result of any such Mechanic's Claim of Lien. If so requested by Landlord, Tenant shall execute a short form or memorandum of this Lease, which may, in Landlord's discretion be recorded in the Public Records for the purpose of protecting Landlord's estate from Mechanics' Claims of Lien, as provided in Florida Statutes Section 713.10. Landlord has the right to record the memorandum without execution by Tenant in the event Tenant fails to execute the memorandum within seven (7) days of request. The security deposit paid by Tenant may be used by Landlord for the satisfaction or transfer of any Mechanics' Claim of Lien a provided in this **Section 51.** This **Section 51** shall survive the expiration or earlier termination of this Lease.

**52. LANDLORD'S LIEN AND SECURITY INTEREST.** Landlord shall have and enjoy a landlord's statutory lien, and in addition thereto and cumulative thereof, Landlord shall have, and Tenant hereby grants unto Landlord, a security interest in all of the furniture, fixtures, office equipment, supplies and other physical personal property of Tenant now or hereafter placed in, upon, or about the Premises, and all proceeds thereof, as security for all of the obligation of Tenant under this Lease, provided the Tenant shall have the right to make sales of its goods, ware, and merchandise to its customers in the normal regular course of its business conducted in the Premises free and clear of the aforesaid and security interest. Tenant shall not remove any of its personal property from the Premises until all of Tenant's obligations under this Lease have been satisfied in full. Without intending to exclude any other manner of giving Tenant any required notice or invalidate any waiver of notice by Tenant, any requirement of reasonable notice to Tenant of Landlord's intention to dispose of any collateral pursuant to the enforcement of such security interest shall be met if such notice is given in the manner prescribed in Section 19 of this Lease at least five (5) days before the time of any such disposition. Any sale made pursuant to the enforcement of such security interest shall be deemed to have been a public sale conducted in a commercially reasonable manner if held in the Demised Premises after the time, place and method of sale and a general description of the types of property to be sold have been advertised in a daily newspaper published in Palm Beach County, Florida, for five (5) consecutive days before the date of sale. Landlord shall have all of the rights and remedies of a secured party under the Florida Uniform Commercial Code, and upon request by Landlord, Tenant agrees to execute and deliver to Landlord a financing statement in form sufficient to perfect the security interest of Landlord in the aforementioned prope1ty and proceeds thereof.

**53. PERSONAL GUARANTY (IF APPLICABLE).**

(a) As
 a material inducement to Landlord executing and delivering this Lease and as a condition
 thereof, the Guarantors named on the first page hereof have agreed to execute and deliver
 the attached Guaranty Agreement attached hereto as Exhibit "H", agreeing to guarantee
 and act as surety for all the obligations of Tenant under this Lease. As a material inducement
 to Landlord executing and delivering this Lease and as a condition thereof, Tenant represents
 and warrants that the attached financial statements, delivered by Tenant, accurately and
 truthfully reflect the financial condition of Tenant. Any misrepresentation by Tenant regarding
 Tenant's financial stability and ability to pay shall be a material breach of this
 Lease.

(b) Guarantors
 shall sign a personal guarantee the entire Term of the Lease on behalf of Tenant. The Guaranty
 Agreement in Exhibit "H" shall be construed in accordance with this section 53(b)
 of the Lease.

**54. NO PETS *I* ANIMAL POLICY.** Tenant acknowledges and agrees that no animals, including emotional support animals, are allowed on the premises, except that as provided by the American with Disabilities Act ("ADA") to allow service dogs required to assist with a disability and so long as such service dog is not out of control or not house broken.

55. ENTIRE AGREEMENT - NO WAIVER

(a) This Lease contains the entire agreement of the parties hereto and no representations, inducements, promises or agreements, oral or otherwise, between the parties not embodied herein shall be of any force and effect. The failure of either party to insist in any instance on strict performance of any covenant or condition hereof, or to exercise any option herein contained, shall not be construed as a waiver of such covenant, condition or option in any other instance. This Lease (except for changes to any of the Rules pursuant to Section 27 above) cannot be changed or terminated orally, and can be modified only in writing, executed by each party hereto. Tenant acknowledges and agrees that Tenant has not relied upon any statement, representation, prior written promises, or prior oral promises, agreements or warranties, except such as are expressed herein.

(b) Failure of Landlord to declare any Event of Default immediately upon occurrence thereof, or delay in taking any action in connection therewith, shall not waive such Event of Default, but Landlord shall have the right to declare any such Event of Default at any time and take such action as might be lawful or authorized hereunder, or at law or in equity. No waiver by Landlord of an Event of Default shall be implied, and no express waiver by Landlord shall affect any Event of Default other than the Event of Default specified in such waiver, and that only for the time and extension therein stated.

[REMAINING OF PAGE LEFT BLANK INTENTIONALLY]

[Signature Page follows]

**IN WITNESS WHEREOF,** Landlord and Tenant have caused this Lease to be executed under seal, on the day and year first above written.

![](sig_001.jpg)

**IN ADDITION TO THE SIGNATURES ABOVE PLEASE INITIAL EACH PAGE OF THIS LEASE.**

**EXHIBIT "A"**

**<u>SPACE PLAN OF PREMISES</u>**

Suite 110

![](ex10-11_001.jpg)

**EXHIBIT "B"**

**<u>LEGAL DESCRIPTION OF LAND</u>**

A parcel of land in Government Lot 2, Section 5, Township 41 South, Range 43 East, Palm Beach C01mty, Florida, being more particularly described as follows:

Beginning at the Southwest co111er of the No1ihwest one quarter of said Section 5, also being the Sm1thwest comer of the said Government Lot 2; thence bear Nmth 1°44'40" East along the West line of Government Lot 2, a distance of 300.00 feet; thence South 89°41110" East, parallel to the South line of said Govenunent Lot 2, also being the Northerly right-of-way line of Indiantown Road, (S.R. 706), a distance of 539.69 feet; thence South 1°44'4011 West parallel to the West line of said Govennnent Lot 2, a distance of 300.00 feet to an intersection with the South line of said Government Lot 2, also being the Northerly right-of-way line of said Indiantown Road (S.R. 706); thence North 89°41'10" West along said line, a distance of 539.69 feet to the Point of Beginning. LESS however the West 34 feet thereof.

**EXHIBIT "C"**

**WORK LETTER AGREEMENT**

Landlord, at Landlord's sole cost (except where otherwise specified that Tenant shall bear the costs), shall build out Tenant space plan per Exhibit A using building standard materials and finishes, colors chosen by Tenant from Landlord's selection, which work shall include:

● Landlord shall build a room in open area aligned to the west of the conference room with a sidelight window of 4ft width. Entrance to room and window as shown on the attached floor plan in Exhibit A.

● Landlord shall install vinyl wood/laminate flooring in the reception entrance, conference room, Back hallway, and breakroom. Tenant selected gray silver oak color (9140 Silver Oak).

● Landlord shall install new standard carpet tile in open bullpen and all offices. Tenant selected blue- gray carpet tile (3642 Road Trip).

● Paint the entire premises with tenant selection of a standard color paint. Tenant at Tenant's expense for all materials, shall be permitted to have two or three walls painted with an accent color.

● Install Landlords Standard 5/8" X 5 1/2" standard white wood base molding throughout main open area, offices, reception lobby and conference room. Vinyl 4" white base to be used in back hallway and breakroom areas unless landlord elects to install wood base to be determined at time of installation.

● Landlord will refinish the back Metal door and paint.

● After obtaining Landlord's approval, Tenant at Tenant's expense may have the double glass entry doors tinted with Tenant's logo added to the door. Landlord shall approve the design prior to the glass door being tinted to ensure the logo maintains characteristic of a professional office building.

*Note: Tenant is responsible, at Tenant's sole expense, for all furniture, fixtures, cubical, file cabinets, chairs, tables, cabling, data, internet, phones, IT equipment and other related items, security alarms, conduits, break room appliances & furnishings, low voltage wiring, power poles & electrical supply to open area work stations.*

 

 

**EXHIBIT "D"**

**RULES AND REGULATIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I. The sidewalks, entries, passages, court corridors, stairways and elevators shall not be obstructed by any tenants or its invitees, employees or agents, or used by them for purposes other than ingress and egress to and from their respective premises in the Building. There shall be no loitering in front of the Building by the employees or agents of any tenant. Tenant may use the back sidewalk to load and unload products, provided, however, that Tenant does not block the sidewalk in order to comply with the fire code for ingress and regress. Landlord prohibits blocking, gathering, or congregating within 75 feet in front of the entrances of the Building.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Landlord shall have the right to prescribe the weight, position and manner of installation of heavy articles such as safes, filing cabinets, machines and other equipment which any tenant may use in its premises in the Building. No safes, furniture, boxes, large parcels or other kind of freight shall be taken to or from the premises or allowed in any elevator, hall or corridor at any time except by permission of and at time allowed by Landlord. A tenant shall make prior arrangements with Landlord for use of freight elevator for the purpose of transporting such articles and such articles may be taken in or out of said Building only between or during such hours as may be arranged with and designated by Landlord. The persons employed to move the same must be approved by Landlord. In no event shall any weight be placed upon any floor by any tenant so as to exceed 50 pounds per square foot of floor space without prior written approval from Landlord.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Each tenant will refer all contractors, contractors' representatives and installation technicians rendering any service on or such tenant's premises in the Building to Landlord for Landlord's written approval and supervision before performance of any contractual service. This provision shall apply to all work performed in the Building, including installation of telephones, telegraph equipment, electrical devices and attachments and installations of any nature affecting floors, walls, woodwork, trim, windows, ceiling, equipment or any other physical portion of the Building.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. No sign, advertisement or notice shall be inscribed, appointed or affixed on any part of the inside or outside of the said Building unless of such color, size, and style and in such place upon or in said Building as shall first be designated by Landlord in writing; there shall be no obligation or duty on Landlord to allow any sign, advertisement or notice to be inscribed, painted or affixed on any paii of the inside or outside of said Building, except as specifically set forth in the lease of a specific tenant with Landlord in connection with such tenant's lease of its premises in the Building from Landlord. Signs on doors shall be in accordance with Building standard as designated by Landlord. The cost of a tenant's graphics will be paid by the applicable tenant. A directory in a conspicuous place, with the names of all of the cun-ent tenants of the Building, will be provided by Landlord; any necessary revision in this will be made by Landlord within a reasonable time after notice from a tenant of the Building of the error or change making the revision necessary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5. Each tenant of the Building shall have the nonexclusive use in common with Landlord, other tenants of the Building, and their applicable guests, employees and invitees, of the uncovered vehicle parking areas, driveways and footways, subject to reasonable rules and regulations for the user thereof as prescribed from time to time by Landlord. No Building tenant's employees shall park in the visitor parking area(s) designated on the Property from time to time by Landlord.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. No Building tenant shall do or permit anything to be done in the such tenant's premises in the Building, or bring or keep anything therein, which will in any way increase the rate of the fire insurance on said Building, or on property kept therein, or unreasonably obstruct or interfere with the rights of other Building tenants, or conflict with the laws relating to fire, or with any regulations of the fire department, or with any insurance policy upon said Building or any part thereof, or conflict with any rules or ordinances o any governing bodies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. The janitor of the Building may at all times keep a pass key to the entry doors to all Building tenants' premises, and the janitor and other employees of Landlord shall at all times be allowed admittance to all Building premises.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Two (2) keys for the Premises will be furnished to Tenant without charge. No additional locks shall be placed upon any public entry doors without the written consent of Landlord. All necessary keys shall be furnished by Landlord, and the same shall be surrendered upon the termination of this Lease in accordance with the terms of this Lease, and Tenant shall then provide Landlord with the combination(s) to all locks upon the doors of any vaults installed in the Premises with Landlord's written consent during the Term of this Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. No windows or other openings that reflect or admit light into the corridors or passageways, or to any other place in said Building, shall be covered or obstructed by any Building tenants. No awnings, curtains, blinds, shades or screens shall be attached to or hung in or used in connection with any window or door of the Premises without the prior consent of Landlord, including approval by Landlord of the quality, type, design, color and mam1er of attachment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. The water closets and other water fixtures shall not be used for any purpose other than those for which they were constructed, and any damage resulting to them from misuse, or the defacing or injury of any part of the Building, shall be borne by the person who shall occasion it.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. No person shall disturb the occupants of the Building by the use of any musical instruments, the making of unseemly noises, of any unreasonable use. No dogs or other animals or pets of any kind, including emotional supp01i animals, will be allowed in the Building, except such being used pursuant to the ADA to assist handicapped persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. No bicycles, scooters, or other vehicles (electric or otherwise) are allowed in the Building.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. Nothing shall be thrown out of the windows of the Building or down the stairways or other passages.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. No Building tenant shall use or to keep in the Building any kerosene, camphene, burning fluid or other inflammable or toxic materials.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. If any Building tenant desires telegraphic, telephonic or other electric connections, Landlord or its agents will direct the electricians as to where and how the wires may be introduced, and without such directions no boring or cutting for wires will be permitted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. No portion of the Building shall be used for the purpose of lodging rooms or for any immoral or unlawful purpose.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. All glass, locks and trimmings in or about the doors and windows and all electric fixtures belonging to the Building shall be kept whole, and whenever broken by anyone shall be immediately replaced or repaired and put in order by the applicable Building tenant or tenants under the direction and to the satisfaction of Landlord, and on removal shall be left whole and in good repair.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. No cooking shall be permitted within any premises in the Building except by use of microwave and tabletop appliances (e.g. toaster ovens, coffee makers, etc.), provided that no cooking odors permeate from the premises.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. Tenants will not make any alterations or physical additions in or to the Premises without first obtaining the written consent of Landlord.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. All routine deliveries to a Building tenant's premises shall enter the Building through the loading dock only and be made through freight elevators. Passenger elevators are to be used only for the movement of persons unless otherwise approved by Landlord in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21. Con-idor doors when not in use, shall be kept closed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22. All Building tenants shall lock all office doors leading to c01Tidors and turn out all lights at the close of their working day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23. Building tenants shall not tamper with or attempt to adjust temperature control thermostats in their respective Premises. Landlord shall adjust thermostats to maintain required temperatures for heating, ventilating and air conditioning.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24. Each Building tenant and its applicable employees, invitees and business visitors shall have access to the applicable Building tenant's premises twenty-four (24) hours a day, seven (7) days a week, three hundred sixty-five (365) days per year (366 days in a leap year). During Non-Business Hours (the hours prior to 8 a.m. and after 6: p.m., Monday through Friday; the hours prior to 8:00 a.m. and after 12:00 p.m. on Saturdays; all Sundays and holidays), Landlord may implement a card access, badge or identification security system to control access. Each Building tenant and its applicable employees, invitees and business visitors will comply with any measures instituted for the security of the Building which may include the signing in or out in a register in the Building lobby during Non-Business Hours. Landlord shall not be liable for excluding any person from the Building unable to produce appropriate identification during Non-Business Hours, or for admission of any person to the Building at any time, or for damages or loss for theft resulting therefrom to any person, including any Building tenant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25. No Building tenants shall make or permit any improper noises to be made in the Building or otherwise interfere in any way with any other Building tenant or its applicable employees, invitees and business visitors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26. No vending machines of any type shall be allowed m any Building tenant premises without the prior written consent of Landlord.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27. Landlord shall not be responsible for lost or stolen personal property, money or jewelry from any Building tenant's premises or any Common Areas regardless of whether such loss occurs when area is locked against entry or not.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28. Canvassing, peddling, soliciting and distribution of handbills or other written materials in the Building are prohibited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29. Landlord shall have the right to change the name of the Building and to change the street address of the Building, provided that in the case of a change in street address, Landlord shall give all Building tenants not less than 180 days' prior written notice of the change in street address, unless such change is required by any governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30. Landlord may waive any one or more of these Rules and Regulations for the benefit of any particular tenant of the Building in accordance with such tenant's lease with Landlord, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant of the Building, nor prevent Landlord from thereafter enforcing any such Rules and Regulations against any or all of the other tenants of the Building.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31. These Rules and Regulations are supplemental to and shall not be construed to in any way modify or amend, in whole or in part, the terms, covenants, agreements and conditions of the Lease Agreement(s) to which the same are attached.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32. Tenant, its employees, agents, or invitees shall not engage in, or permit smoking within the Building or within 100 feet of any entrance to the Building. As set fmih in the Lease, <u>"smoking"</u> means inhaling, exhaling, burning or carrying any lighted cigar, cigarette, pipe or other smoking equipment or device in any manner or form, including electric cigarettes and vaping devices.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33. Prior to the Commencement Date of the Lease, Tenant shall schedule with Management a date and time to move-in into the Premises, and shall provide Management with Tenant's moving vendor's proof of insurance. Prior to the Termination of the Lease Term, unless extended, Tenant shall schedule with Management a date and time to move out from the premises, and shall provide Management with Tenant's moving vendor's proof of insurance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34. Landlord reserves the right to rescind any of these Rules and Regulations and to make such other and further Rules and Regulations as in its sole judgment shall from time to time, be required for the safety, protection, care and cleanliness of the Building, the operation thereof, the preservation of good order therein and the protection and comfort of the Buildings' tenants and their employees, invitees and business guests so long as such fu1iher Rules and Regulations do not conflict with the terms and conditions hereof. Such Rules and Regulations, when made and written notice thereof is given to a Building tenant, shall be binding upon it in like manner as if originally herein prescribed.

**EXHIBIT "E"**

**<u>BUILDING STANDARD SERVICES</u>**

Landlord shall furnish the following services to Tenant during the Term (the "Building Standard Services"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Municipal water and common-use restrooms and toilets at locations provided for general use and as reasonably deemed by Landlord to be in keeping with comparable office buildings to the Building.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Subject to curtailment as required by governmental laws, rules or mandatory regulations and subject to the design conditions hereinafter provided, central heat and air conditioning in season, at such temperatures and in such amounts as are reasonably deemed by Landlord to be in keeping with comparable office buildings to the Building. In order to enable the central heating and air conditioning system to operate efficiently, Tenant agrees that it will not place within the Premises more than one (1) person per 175 square feet of area. Such heating and air conditioning shall be furnished between 6:00 a.m. and 11:00 p.m. on weekdays (from Monday through Friday, inclusive) and between 9:00 a.m. and 3:00 p.m. on Saturdays, all exclusive of Holidays, as defined below (the <u>"Building Operating Hours"),</u> unless otherwise provided in the Lease.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Electric lighting service for all public areas and special service areas of the Building in the manner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Janitorial service for common area shall be provided five (5) days per week, exclusive of Holidays (as hereinbelow defined), in a manner that Landlord reasonably deems to be consistent with the first-class standards of the Building and as more particularly described on <u>Exhibit "F"</u> attached to this Lease. Janitorial services may be provided for tenant suites at an additional expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Sufficient electrical capacity to operate (i) incandescent lights, typewriters, calculating machines, photocopying machines and other machines of the same low voltage electrical consumption (120 volts), provided that the total rated electrical design load for said lighting and machines of low electrical voltage shall not exceed 1.25 watts per square foot of area; and (ii) lighting (277 volts or sufficient power for similar wattage), provided that the total rated electrical design load for said lighting shall not exceed basic power use for general office, approximately 1.40 watts per square foot of area (each such rated electrical design load to be hereinafter refen-ed to as the "Building Standard rated electrical design load").

Should Tenant's total rated electrical design load exceed the Building Standard rated electrical design load for either low or high voltage electrical consumption, or if Tenant's electrical design requires low voltage or high voltage circuits in excess of Tenants' share of the Building Standard circuits, Landlord will (at Tenants' expense) install such additional circuits and associated high voltage panels and/or additional low voltage panels with associated transformers shall be hereinafter referred to as the <u>"additional electrical equipment").</u> If the additional electrical equipment is installed because Tenant's low or high voltage rated electrical design load exceeds the applicable Building Standard rated electrical design load, then a meter shall also be added (at Tenant's expense) to measure the electricity used through the additional electrical equipment.

The design and installation of any additional electrical equipment (or any related meter) required by Tenant shall be subject to the prior approval of Landlord (which approval shall not be reasonably withheld). All expenses incurred by Landlord in connection with the review and approval of any additional electrical equipment shall also be reimbursed to Landlord by Tenant. Tenant shall also pay on demand the actual metered cost of electricity consumed through the additional electrical equipment (if applicable), plus any expenses incurred by Landlord in connection with the metering thereof.

Should Tenant's total rated electrical design load exceed the Building Standard rated electrical design load for either low or high voltage electrical consumption, or if Tenant's electrical design requires low voltage or high voltage circuits in excess of Tenant's share of the Building Standard circuits, Landlord will (at Tenant's expense) install such additional circuits and associated high voltage panels and/or additional low voltage panels with associated transfmmers shall be hereinafter referred to as the <u>("additional electrical equipment").</u> If the additional electrical equipment is installed because Tenant's low or high voltage rated electrical design load exceeds the applicable Building Standard rated electrical design load, then a meter shall also be added (at Tenant's expense) to measure the electricity used through the additional electrical equipment.

The design and installation of any additional electrical equipment (or any related meter) required by Tenant shall be subject to the prior approval of Landlord (which approval shall not be unreasonably withheld). All expenses incurred by Landlord in connection with the review and approval of any additional electrical equipment shall also be reimbursed to Landlord by Tenant. Tenant shall also pay on demand the actual metered cost of electricity consumed through the additional electrical equipment (if applicable), plus any expenses incurred by Landlord in connection with the metering thereof.

If any of Tenant's electrical equipment requires conditioned air in excess of Building Standard air conditioning, the same shall be installed by Landlord (on Tenant's behalf), and Tenant shall pay all design, installation, metering and operating costs relating thereto.

If Tenant requires that certain areas within Tenant's Premises must operate in excess of the normal Building Operating Hours (as hereinabove defined), the electrical service to such areas shall be separately circuited and metered (at Tenant's expense) such that Tenant shall be billed the costs associated with electricity consumed during hours other than Building Operating Hours.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) All Building Standard fluorescent bulb replacement in all areas and all incandescent bulb replacement in public areas, toilet and restroom areas, and stairwells.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Non-exclusive multiple elevator cab passenger service to the Premises during Building Operating Hours (as hereinabove defined) and at least one (1) elevator cab passenger service to the floor(s) on which the Premises are located twenty-four (24) hours per day during Building Operating Hours (all subject to temporary cessation for ordinary repair and maintenance and during times when life safety systems oven-ide normal building operating systems) with such freight elevator service available at other times upon reasonable prior notice and the payment by Tenant to Landlord of any additional expense actually incun-ed by Landlord in connection therewith.

To the extent the services described above require electricity and water supplied by public utilities, Landlord's covenants thereunder shall only impose on Landlord the obligation to use its best efforts to cause the applicable public utilities to furnish same. Except for deliberate and willful act of Landlord, failure by Landlord to furnish the services described herein, or any cessation thereof, shall not render Landlord liable for damages to either person or property, not be construed as an eviction of Tenant, or work an abatement of rent, nor relieve Tenant from fulfillment of any covenant or agreement hereof. In addition to the foregoing, should any of the equipment or machinery, for any cause, fail to operate, or function properly, Tenant shall have no claim for rebate of rent or damages on account of an inten-uption in services occasioned thereby or resulting therefrom; provided, however, Landlord agrees to use reasonable efforts to promptly repair said equipment or machinery and to restore said services during normal business hours.

The following dates shall constitute <u>"Holidays"</u> as the term is used in this Lease Agreement: New Year's Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day, Friday following Thanksgiving Day, Christmas, and any other holiday generally recognized as such by Landlord, and as determined by Landlord in good faith. If in the case of any specific holiday mentioned in the preceding sentence, a different day shall be observed than the respective day mentioned, then that day which constitutes the day observed by national banks in West Palm Beach County, Florida on account of said holiday shall constitute the Holiday under this Lease Agreement.

**EXHIBIT "F"**

**<u>BUILDING STANDARD JANITORIAL SERVICES</u>**

The following services are the Building Standard Janitorial Services. Landlord, at its sole discretion, reserves the right to make adjustments to this schedule of services.

A. Daily
 Services - Common Areas

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Empty
 all trash receptacles and replace liners, as necessary.

(2) Dust
 all horizontal surfaces, desks, chairs, files, telephones, pictures frames, etc.

(3) Damp
 wash and wipe dry all plastic or Formica desktops.

(4) Clean
 and sanitize drinking fountains, follow with stainless steel cleaner.

(5) Spot
 clean all windows and partition glass, including lobby doors.

(6) Dust
 mop and spot clean all tiled areas.

(7) Vacuum
 all carpeted areas.

B. Daily
 Services - Restrooms

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Remove
 trash and clean receptacles.

(2) Clean
 and sanitize lavatories, commodes and urinals.

(3) Clean
 out corners and edges.

(4) Clean
 mirrors and restroom fixtures.

(5) Spot
 clean wall tile and partitions.

(6) Replenish
 supplies.

(7) Sweep
 floor.

(8) Mop
 and disinfect floor.

C. Weekly
 Services - Elevators

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Bring
 down one elevator at a time using control panels located on ground level.

(2) Clean
 light lenses.

(3) Spot
 clean plastic walls.

(4) Use
 paste wax or appropriate treatment on finish metal.

(5) Clean
 edges, corners and tracks.

(6) Dust
 mop all hard surfaces.

D. Daily
 Services Marble/Ceramic Floors

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Dust
 mop all hard surfaces.

E. Daily
 Services as required - Corridors

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Vacuum
 all carpeted areas.

(2) Spot
 clean all walls, light switches and doors.

(3) Spot
 clean carpeted areas, as needed.

F. Monthly
 Services - Stairways

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Sweep
 from top to bottom.

(2) Dust
 handrails and ledges.

(3) Dust
 lights between floors.

G. Monthly
 Services -Tile Floors

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Clean
 all traffic lanes and other "high-wear" areas.

(2) Wax
 as required, from time to time.

H. Annual
 Services - General

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Clean
 inside of all exterior walls.

(2) Clean
 all Fluorescent light fixture lenses.

(3) Wash
 down all restroom walls and partitions.

I. Services
 as Required - Common Areas

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Spot
 clean carpeted areas.

(2) Shampoo
 public areas outside tenant space.

(3) Damp
 mop all tile floors.

(4) Machine
 buff all tile floors.

(5) Strip
 and re-coat all tile floors.

J. Services
 - Building Exterior

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Police
 building perimeter for trash.

(2) Remove
 trash from tree wells and planters.

(3) Hose
 down sidewalks and pressure wash from time to time.

K. Services
 - Day Crew

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Replenish
 supplies in all restrooms.

(2) Clean
 and vacuum all passenger elevators, as needed.

(3) Clean
 all ash urns, as needed.

(4) Clean
 all glass entrance doors in main lobby.

(5) Clean
 all windows on building parameter at street level, as needed.

L. Tenant
 is responsible for janitorial services within their suite at Tenant's expense.

**EXHIBIT "G"**

**<u>RENT SCHEDULE\*</u>**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Start**<br>**Date** | **End**<br>**Date** |<br>**Rent** |<br>**CAM** |<br>**Subtotal** | **6.50%**<br> **Sales**<br>**Taxes** | **Total**<br> **Monthly**<br>**Rent** |
| 7/1/2021 | f§/3Q/2022 | $*7500.00* | $6620.17 | $*14120.17* | $917.81 | $*15037.98* |
| 7/1/2022 | 6/30/2023 | $*9127.86* | $6620.17 | $*15748.03* | $1023.62 | $*16771.65* |
| 7/1/2023 | 6/30/2024 | $*10993.05* | $6620.17 | $*17613.21* | $1144.86 | $*18758.07* |
| 7/1/2024 | 6/30/2025 | $*11322.84* | $6620.17 | $*17943.00* | $1166.30 | $*19109.30* |
| 7/1/2025 | 6/30/2026 | $*11662.52* | $6620.17 | $*18282.69* | $1188.37 | $*19471.06* |

---

\*Estimated CAM, subject to change

## Exhibit 10.12

**Exhibit 10.12**

**<u>SALES AGENT AGREEMENT</u>**

SALES AGENT AGEEMENT dated as of December 11, 2024 (this "Agreement"), is by and between CARING BRANDS, INC., a Delaware corporation (the "Company"), and NOVODX CORPORATION, a Delaware corporation (the "SA"). Each of the Company and the SA are sometimes also referred to herein as a "Party" and collectively as the "Parties".

WHEREAS, the Company desires to designate and appoint the SA as sales agent for the Product (as hereinafter defined") through Shopify in the Market (as hereafter defined), upon the terms, provisions and conditions of this Agreement; and

WHEREAS, the SA desires to accept such engagement as the sales agent for the Product in the Market, upon the terms, provisions and conditions of this Agreement.

NOW THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and the mutual covenants contained herein, Company and SA agree as follows:

**1. Sales Agent Appointment.** The Company hereby designates and appoints the SA as the Company's sales agent to promote, market and solicit for sale the Company's Hair Enzyme Booster product as more fully identified on Exhibit A attached hereto (the "Product") through Shopify in the United States (the "Market"). The SA hereby accepts the appointment as Company's sales agent for the Product on Shopify in the Market and agrees to use its reasonable best efforts to promote, market and solicit orders for the Product through its Shopify account. The SA agrees that during the Term (as hereafter defined) it shall not offer or sell any products or goods which are competitive with, the same as, or similar to any of the Product. During the Term, the Company will not directly engage in sales of the Product on Shopify in the Market or appoint any person or entity to engage in sales of the Product on Shopify in the Market, directly or indirectly, other than the SA. For avoidance of doubt, the Company may sell and appoint other entities to market and sell the Product outside of the Market.

**2. SA's Responsibilities.** The SA shall use its reasonable best efforts to market and promote the Product and to sell the Product on Shopify using the SA's Shopify account. All proceeds from sales of the Product will be collected by the SA from Shopify and the net sales, after payment of the Commission (as hereafter defined) and the Marketing Fee (as hereafter defined), will be paid over by the SA to the Company on a weekly basis (the "Company Revenue"). The payment of the Company Revenue will be accompanied by a sales report in reasonable detail setting forth the sales for the applicable week. The SA will deduct the Commission and the Marketing Fee from gross proceeds concurrently with paying the Company Revenue to the Company. The description of the Product on the SA's Shopify site will be subject to review and approval by the Company. The SA will also be responsible for the fulfillment of sales of the Product with the designated warehouse where the Company maintains inventory of the Product.

**3. Company Responsibilities.** The Company shall be responsible for manufacturing of the Product and maintaining an inventory of the Product sufficient to satisfy the sales made through the SA in a timely manner and in accordance with the representations set forth on Shopify for delivery of the Product to the end-user consumer. In that regard, the Company shall always maintain at a mutually agreed upon fulfilment center a sufficient inventory of the Product to satisfy anticipated sales in the Market. All costs and expenses associated with the fulfillment activities and shipping and transportation of the Product to the end-user (including, without limitation, costs of insurance) will be the sole responsibility of the Company. The Company shall also be responsible for insuring the Product while in the fulfillment center and during the shipping process. The Company shall be responsible for ensuring that the Product at all times complies with all applicable laws and regulations and that all statements in advertising and marketing materials for the Product and on the Product's packaging are accurate, not misleading and in accordance with applicable law and regulations. The Company shall be responsible for managing any recall of the Product and all costs and expenses associated therewith.

**4. Pricing.** The sales price of the Product on Shopify will be $24.99. The sales price cannot be increased unless mutually agreed to in writing by the Parties. Any sales promotions or specials deals that the SA would like to run will be subject to the prior approval of the Company. Without prior written approval of Company, SA may not offer the Product for sale at a discount.

**5. Commission.** The SA will earn a Commission of ten percent (10%) on all sales of the Product in the Market (the "Commission"). The Commission shall be deducted by the SA from the gross proceeds received from the sales of the Product and will deducted directly by the SA and paid to the SA concurrently with the payment of the Company Revenue to the Company. The Commission will be paid after the termination of tis Agreement on all sales of the Product made prior to the effective time of the termination.

**6. Marketing Fee.** In consideration of the services to be performed by the SA pursuant to this Agreement, the Company will pay the SA a monthly marketing fee of $3,000.00 (the "Marketing Fee"). The Marketing Fee shall be paid the 15<sup>th</sup> of every month.

**7. Returns.** In addition to the other responsibilities of the Company, the Company shall be responsible for managing and addressing all customer complaints and Product returns. SA will make the company aware of the complaints and will provide reports of returns. SA and Company will agree on how to handle returns on a case-by-case basis. The Company will be responsible for recalls and all costs and expense related thereto. If requested by the Company, the SA will provide reasonable assistance with any recall at the cost and expense of the Company.

**8. Indemnification and Insurance.** The Company shall indemnify and hold harmless the SA and the SA's directors, officers, employees and agents (each an "SA Indemnitee"), and their respective successors and assigns, from and against any and all claims, actions, suits, demands, liabilities, costs and expenses (including, without limitation, attorneys' fees and expenses) incurred by any SA Indemnitee relating to (a) any product liability claim or the performance or use of the Product; (b) and claim or assertion that the Product does not comply with applicable law or regulations; and (c) a claim relating to false advertising or similar claims regarding the Product. In any matter for which the SA is entitled to be indemnified, the SA may defend itself with legal counsel of its own choosing at the cost and expense of the Company. The Company's indemnification obligation shall survive the expiration of the Term and the termination of this Agreement pursuant to its terms. During the Term the Company shall maintain Product Liability Insurance relating to Product in such amounts and with such deductibles as are mutually agreed to by the Parties in good faith. Any such policy shall be on an "as incurred" basis and will name the SA and the SA's directors, officers and employees as additional insureds. The insurance policy shall be written by an insurance company with a rating of not less than A- by AM Best.

**9. Confidential Information.** Each Party will not use or disclose any Confidential Information (as hereinafter defined) acquired as a result of this Agreement from the other Party for any purpose, except the purposes of performing under this Agreement, without the other Party's prior written consent, and will not disclose any such Confidential Information to third parties, or to such Party's agents, contractors, officers, directors or employees, other than those agents, contractors, officers, directors and employees who have a need to know the Confidential Information in order for such Party to perform its obligations hereunder. Each Party agrees to cause all of its agents, contractors, officers, directors and employees having access to the other Party's Confidential Information to agree, in writing, to maintain the confidentiality of all Confidential Information and not to use any such Confidential Information for any purpose other than the purposes of this Agreement. A Party will be responsible for a breach of this confidentiality obligation by its agents, contractors, officers, directors or employees. Upon termination of this Agreement, each Party will forthwith return to the other Party all Confidential Information of the other Party within its possession, custody or control, together with all copies thereof and extracts therefrom within fifteen (15) days of termination. For purposes of this Agreement, the term "Confidential Information" means all customer lists, prospect lists, methods of doing business, pricing information, processes, formulas, know how, and any documents or other information designated in by a Party in writing as "Confidential" of which a Party receiving such documents or information should reasonably consider it to be confidential or proprietary to the disclosing Party. Confidential Information shall not include information, materials or documents that (i) are publicly available through no breach of this Agreement (ii) were know by a Party prior to the execution and delivery of this Agreement or (iii) information developed by a Party without use or reference to the other Party's Confidential Information. The provisions of this Section 9 shall survive the expiration of the Term of this Agreement or the termination of this Agreement for a period of two (2) years. Each Party recognizes that the violation by such Party or any of its contractors, agents, employees, officers or directors the covenants of this Section 9 would cause irreparable injury to the other Party for which money damages could not fully compensate. Accordingly, each Party agrees that in the event of the violation or threatened violation of the restrictions of this Section 9 by the other Party or the other Party's contractors, agents, officers, directors or employees agents or employees, the other Party shall be entitled to seek injunctive or comparable relief (in addition to and not in lieu of any monetary relief sought) in any court of competent jurisdiction. Upon the expiration of the Term of this Agreement or the termination of this Agreement, at the request of a disclosing Party the receiving Party will return to the disclosing Party all documents and materials of the disclosing Party which contain or reflect any of the disclosing Party's Confidential Information without retaining any copies thereof. For avoidance of doubt, nothing in this Section 9 shall, or is intended, to modify or amend any existing non-disclosure agreement or confidentiality agreement between the Parties (the "Existing NDA"), which Existing NDA shall remain in full force and effect in accordance with its terms.

**10. SA's Obligations upon Termination.** As soon as reasonably after the expiration of the Term of this Agreement or the termination of this Agreement, the SA shall cease selling the Product in the Market and will delete all references to the Product on its Shopify account. In addition, the SA will make a final payment of Company Revenue to the Company for all sales of the Product made prior to the effective date of expiration or termination, as applicable, for which the Company has not yet received payment.

**11. Mutual Representations and Warranties.** Each of the Company and the SA represents and warrants to the other Party as follows: (a) it is duly organized and incorporated and its validly existing in the state of its incorporation; (b) it has the corporate power and authority to execute, deliver and perform this Agreement; (c) its execution, delivery and performance of this Agreement has been duly authorized; and (d) this Agreement constitutes its legal, valid and binding obligation, enforceable against such Party in accordance with its terms: and (e) its execution, delivery and performance of this Agreement will not violate conflict with or contravene its certificate of incorporation, any agreement to which it is a party or otherwise bound or any law or regulation applicable to such Party and/or its business.

**12. Competing Products.** During the Term of this Agreement, the SA will not, directly or indirectly represent, market or sell, for itself or on behalf of any other company, entity or individual, any product which is directly competitive with the Product.

.

**13. Term; Termination.** This Agreement shall be effective as of the date first set forth above and shall continue for a period of one (1) year thereafter (the "Initial Term"). Thereafter, this Agreement shall automatically renew for subsequent twelve (12) month periods (each, a "Renewal Term", and the Initial Term and each Renewal Term, if applicable, the "Term"), unless either Party informs the other Party that such Party does not agree to the automatic extension of this this Agreement by written notice at least thirty (30) days prior to the end of the Initial Term or any Renewal Term, as applicable. Party. In addition, either Party (the "Non-Breaching Party") may terminate this Agreement upon written notice to the other Party (the "Breaching Party"), if the Breaching Party breaches or otherwise violates or contravenes any covenant or obligation on its part to be observed or performed and such breach or violation is not cured within ten (10) days after written notice of such breach by the Non-Breaching Party. In the event that this Agreement is terminated the SA shall be paid all Comissions on all sales made prior to the effective date of the termination. payable

**14. Assignment and Delegation.** Neither Party may assign this Agreement or any of its rights or responsibilities under this Agreement to any person or entity without the prior written consent of the other Party. Any such assignment without such written consent shall be null and void and of no force or effect. Subject to the foregoing, this Agreement shall be binding upon, and inure to the benefit of, the Parties and their respective successors, and permitted assigns.

**15. Independent Contractor Status.** Nothing in this Agreement or the relationship established hereby is intended, nor shall it be construed, to establish a joint venture or partnership between the Parties. The relationship between the Parties pursuant to this Agreement shall be deemed for all purposes to be that of independently contracting entities. Notwithstanding the foregoing, it is agreed that the Company shall be bound by sales that are made by the SA in accordance with this Agreement.

**16. Entire Agreement.** This Agreement (together with the Exhibit attached hereto which forms an integral part of this Agreement and the Existing NDA) constitutes the entire understanding and agreement between the Parties with respect to the subject matter hereof and supersedes all previous agreements, arrangements and understandings, whether written or oral, with respect to the subject matter all of which are merged herein. Nothing herein shall amend or modify any other existing agreement between the Parties which shall remain in full force and effect in accordance with their terms.

**17. Amendment.** This Agreement cannot be modified, amended or waived except by a written instrument duly executed by both of the Parties .

**18. Notices.** All notices and other communications required or permitted to be given under this Agreement shall be in writing and shall be delivered in person, sent by certified mail (postage prepaid and with return receipt requested), overnight by a recognized international courier service, or sent by email to the following respective addresses or to such other address as either Party may designate for itself by notice duly given in accordance with this Agreement:

IF to the Company:

Caring Brands, Inc.

1061 E. Indiantown Rd, Suite 110

Jupiter, FL 33477<br>

IF to the SA:

NovoDX Corporation

1061 E. Indiantown Rd., Suite 110

Jupiter, FL 33477<br>

Any such notice or communication shall be considered delivered as follows: (i) if delivered in person , on the business day delivered if a receipt accepting delivery is signed; (ii) if sent by certified mail, four (4) business days after the date of mailing; (iii) if sent by recognized overnight courier service on the first business day after sent (with all costs prepaid); and (iv) if sent by email on the business day of transmission if received before 5:00 pm in the time zone of the intended recipient, or if received after that time, on the immediately following business day. notice so mailed shall be deemed received on the date indicated in the return receipt. Business Days shall be deemed to be days other than a Saturday or Sunday or a day when banks are closed in the particular location.

**19. Waiver.** The failure of either Party to enforce the provisions of this Agreement at any time shall not be construed to be a waiver of such provision or the right thereafter to enforce each and every provision hereof. No waiver by either Party, express or implied, of any breach of any term, condition or obligation of this Agreement shall be construed as a waiver of any subsequent breach of the same term, condition or obligation, or as a waiver of any breach of any other term, condition or obligation hereof. Any waiver to be effective must be executed in writing by the Party granting the waiver.

**20. Governing Law; Jurisdiction.** This Agreement and any disputes relating hereto will be interpreted, construed and enforced in all respects in accordance with the laws of the State of Florida, United States of America, without regard to any of its conflicts of law principles which could result in the application of the laws of another jurisdiction. Each of the Parties hereby irrevocably consents to the exclusive jurisdiction of the courts of the State of Florida sitting in Palm Beach County, and the Federal District Court of the United States of America for the Central District of Florida (the "Acceptable Forums") for resolution of all claims, actions, suits and disputes which the Parties may have arisen out of or relate to this Agreement and the matters contemplated hereby. Any judgment or other decision by any of the Acceptable Forums shall be enforceable, without further proceedings, against the named Party anywhere else in the world where such Party is located, does business or has assets. The prevailing Party shall be entitled to be reimbursed for its reasoanble costs and expenses incurred in any such proceeding(including any appeal), including, without limitation, attorneys' fees and expenses and court costs. Each of the Parties agrees to venue in the Acceptable Forums and consents to and agrees not to contest the jurisdiction of the Acceptable Forums . Each of the Parties knowingly and willingly waives any right to request a jury trial in any action, suit or proceeding brought relating to this Agreement and the/or the transactions contemplated hereby.

**21. Limitation of Liability.** Neither Party shall be liable hereunder to the other Party for indirect, consequential, exemplary or incidental damages arising out of or relating to this Agreement even if the Party at fault has been advised of the possibility of such damages.

**22. Severability.** If any provision of this Agreement is for any reason determined to be invalid, illegal or unenforceable, such provision shall be modified so that it will be valid, legal and enforceable to the maximum extent permitted by applicable law consistent with the intent of the Parties as herein expressed, and any such invalidity, illegality or unenforceability shall not affect any of the other provisions of this Agreement, which shall remain in full force and effect.

**23. Counterparts.** This Agreement may be executed in multiple counterparts, each of which shall be an original, and all of which when taken together shall constitute one and the same document. The exchange of copies of this Agreement and of signature pages by facsimile transmission or in "portable document format" (pdf) or by other electronic means intended to preserve the original graphic and pictorial appearance of a document shall be deemed the same as an original executed version of the document and shall be acceptable for all legal purposes.

**IN WITNESS WHEREOF**, each of the Parties has executed this Agreement effective as of the day and year first above written.

Caring Brands, Inc.

---

| | |
|:---|:---|
| By: |  |
| Name: | Dr. Glynn Wilson |
| Title: | CEO |
| NovoDX Corporation | NovoDX Corporation |
| By: |  |
| Name: | Nancy Torres |
| Title: | CEO |

---

EXHIBIT A

<u>Product Description</u>

## Exhibit 10.13

**Exhibit 10.13**

**SECURITIES PURCHASE AGREEMENT**

This Securities Purchase Agreement (this "<u>Agreement</u>") is dated as of April 15, 2025, between Caring Brands, Inc., a Nevada corporation (the "<u>Company</u>"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "<u>Purchaser</u>" and collectively, the "<u>Purchasers</u>").

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

**ARTICLE I.**

**DEFINITIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Definitions</u>. In addition to the terms defined elsewhere in this Agreement the following terms have the meanings set forth in this Section 1.1:

"<u>Acquiring Person</u>" shall have the meaning ascribed to such term in Section 4.6.

"<u>Action</u>" shall have the meaning ascribed to such term in Section 3.1(h).

"<u>Affiliate</u>" means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

"<u>Board of Directors</u>" means the board of directors of the Company.

"<u>Business Day</u>" means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to "stay at home", "shelter-in-place", "non-essential employee" or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally are open for use by customers on such day.

"<u>Closing</u>" means any closing of the purchase and sale of the Securities pursuant to Section 2.1.

"<u>Closing Date</u>" means the Business Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) a Purchaser's obligations to pay its Subscription Amount and (ii) the Company's obligations to deliver the Securities, in each case, have been satisfied or waived. Pursuant to the terms of this Agreement, there may be one or more Closing Dates hereunder.

"<u>Commission</u>" means the United States Securities and Exchange Commission.

"<u>Common Stock</u>" means the common stock of the Company, having no par value per share, and any other class of securities into which such securities may hereafter be reclassified or changed.

"<u>Common Stock Equivalents</u>" means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

"<u>Company Counsel</u>" means Sichenzia Ross Ference Carmel LLP, with offices located at 1185 6<sup>th</sup> Avenue, 31<sup>st</sup> Floor, New York, NY 10036.

"<u>Escrow Agent</u>" means Sichenzia Ross Ference Carmel LLP.

"<u>Exchange Act</u>" means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

"<u>FCPA</u>" means the Foreign Corrupt Practices Act of 1977, as amended.

"<u>GAAP</u>" means generally accepted accounting principles.

"<u>Indebtedness</u>" shall have the meaning ascribed to such term in Section 3.1(x).

"<u>Intellectual Property Rights</u>" shall have the meaning ascribed to such term in Section 3.1(n).

"<u>Legend Removal Date</u>" shall have the meaning ascribed to such term in Section 4.1(c).

"<u>Liens</u>" means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

"<u>Material Adverse Effect</u>" shall have the meaning assigned to such term in Section 3.1(b).

"<u>Material Permits</u>" shall have the meaning ascribed to such term in Section 3.1(1).

"<u>Maximum Amount</u>" means an aggregate of $1,000,000, which may be increased by an additional $1,000,000 in the sole discretion of the Board of Directors.

"<u>Offering</u>" means the offering of Common Stock pursuant to this Agreement and the other Transaction Documents.

"<u>Offering Period</u>" means the earlier of (i) the sale of the Maximum Amount, (ii) termination of the Offering as determined by the Company and the Placement Agent or (iii) June 31, 2025 ("Initial Offering Period"), which date may be extended by the Placement Agent and the Company in their joint discretion until June 31, 2025.

"<u>Person</u>" means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

"<u>Proceeding</u>" means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.

"<u>Purchased Shares</u>" means the shares of Common Stock issued and issuable pursuant to the terms of this Agreement.

"<u>Purchaser Party</u>" shall have the meaning ascribed to such term in Section 4.9.

"<u>Qualified Offering</u>" shall mean a registered offering of Common Stock (or units consisting of Common Stock and warrants to purchase Common Stock) resulting in the listing for trading of the Common Stock on the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).

"<u>Required Approvals</u>" shall have the meaning ascribed to such term in Section 3.1(e).

"<u>Rule 144</u>" means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

"<u>Rule 424</u>" means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

"<u>Securities</u>" means the Purchased Shares, the Warrants and the Warrant Shares.

"<u>Securities Act</u>" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

"<u>Short Sales</u>" means all "short sales" as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).

"<u>Subscription Amount</u>" means, as to each Purchaser, the aggregate amount to be paid for the Units purchased hereunder as specified below such Purchaser's name on the signature page of this Agreement and next to the heading "Subscription Amount," in United States dollars and in immediately available funds.

"<u>Subsidiary</u>" means any subsidiary of the Company as set forth in Schedule 3.1(a) and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

"<u>Termination Date</u>" means the date on which the Offering expires or is terminated.

"<u>Trading Day</u>" means a day on which the principal Trading Market is open for trading.

"<u>Trading Market</u>" means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

"<u>Transaction Documents</u>" means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

"<u>Transfer Agent</u>" means the initial transfer agent of the Company to be appointed, and any successor transfer agent of the Company.

"<u>Unit</u>" has the meaning set forth in Section 2.1.

"<u>Warrant Shares</u>" means the shares of Common Stock issuable upon exercise of the Common Stock.

**ARTICLE II.**

**PURCHASE AND SALE**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Closings</u>. On each Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser participating in the applicable Closing, severally and not jointly, agrees to purchaser units (each, a "<u>Common share</u>") for a price per unit of $4.00, consisting of one share Common Stock. The number of Units to be purchased by a Purchase at the applicable closing shall be set forth on such Purchaser's signature page hereto; Each Purchaser shall have delivered to the Company pursuant to the instructions contained on <u>Schedule 2.1</u>, via wire transfer or a certified check, immediately available funds equal to such Purchaser's Subscription Amount as set forth on the signature page hereto executed by such Purchaser. Upon the exchange of items set forth in Section 2.2. At any Closing hereunder, the Company shall deliver to each Purchaser its respective Common Stock, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. If the initial Closing is not in the Maximum Amount, subsequent closings may be held up to the sale of the Maximum Amount. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, each Closing shall occur at such location as the parties shall mutually agree. Closings hereunder shall only be held during the Offering Period and in no event shall a Closing occur after the Termination Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Deliveries</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On or prior to each Closing Date, the Company shall deliver or cause to be delivered to each of the Placement Agent on behalf of each Purchaser participating in the applicable Closing the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) this Agreement duly executed by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) a stock certificate or book entry statement for each Purchaser from the Transfer Agent representing an amount of shares of Common Stock equal to such Purchaser's Subscription amount divided by 1;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a copy of a good standing certificate of the Company , dated a date reasonably close to each Closing Date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) for initial Closing Date only, a certificate, dated as of the Closing Date, duly executed, and delivered by an officer of the Company, certifying the resolutions of the Company's Board of Directors then in full force and effect authorizing, to the extent relevant, all aspects of the transaction and the execution, delivery and performance of each Transaction Document to be executed and the transactions contemplated hereby and thereby;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) opinion of counsel to the Company in form satisfactory to the counsel to the Placement Agent; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) such other approvals, opinions, or documents as the Placement Agent may request in form and substance reasonably satisfactory to the Placement Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) On or prior to the Closing Date in which respect of a Purchaser is participating, such Purchaser shall deliver or cause to be delivered to the Company the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) this Agreement duly executed by such Purchaser;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) such Purchaser's Subscription Amount as to the Closing by wire transfer to the Escrow Agent to the account specified in <u>Schedule 2.1 hereto</u>; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Purchaser Questionnaire in the form of <u>Exhibit B</u> hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Closing Conditions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the accuracy in all material respects on (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The respective obligations of the Purchasers hereunder in connection with a Closing are subject to the following conditions being met (it being understood that the Company may waive any of the conditions for any Closing hereafter):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the applicable Closing Date shall have been performed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) there shall have been no Material Adverse Effect since the date hereof.

**ARTICLE III.**

**REPRESENTATIONS AND WARRANTIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Representations and Warranties of the Company</u>. The Company hereby makes the following representations and warranties to each Purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Subsidiaries</u>. All of the direct and indirect subsidiaries of the Company are set forth on <u>Schedule 3.1(a)</u>. Except as set forth on <u>Schedule 3.1(a)</u>, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Organization and Qualification</u>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company's ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a "<u>Material Adverse Effect</u>") and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company's stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>No Conflicts</u>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company's or any Subsidiary's certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.6 of this Agreement, and (ii) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively, the "<u>Required Approvals</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Issuance of the Securities</u>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents. The Purchased Shares, the Warrants and the Warrant Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Capitalization</u>. The capitalization of the Company as of the date hereof is set forth on <u>Schedule 3.1(g)</u>. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and, except as disclosed in <u>Schedule 3.1(g)</u>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings, or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or "phantom stock" plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities, except for shareholder approval to increase the number of authorized shares of Common Stock. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company's capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company's stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Litigation</u>. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an "<u>Action</u>") which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Labor Relations</u>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company or any Subsidiary, which could reasonably be expected to result in a Material Adverse Effect. None of the Company's or its Subsidiaries' employees is a member of a union that relates to such employee's relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Compliance</u>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Environmental Laws</u>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, "<u>Hazardous Materials</u>") into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder ("<u>Environmental Laws</u>"); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Regulatory Permits</u>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as currently conducted, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect ("<u>Material Permits</u>"), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Title to Assets</u>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>Intellectual Property</u>. Except as set forth on <u>Schedule 3.1(n)</u>, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as currently conducted and which the failure to so have could have a Material Adverse Effect (collectively, the "<u>Intellectual Property Rights</u>"). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest financial statements provided to the Placement Agent, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality, and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) <u>Insurance</u>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <u>Transactions with Affiliates and Employees</u>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from providing for the borrowing of money from or lending of money to, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, other than for (i) payment of salary, board fees or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) <u>Sarbanes-Oxley</u>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) <u>Certain Fees</u>. Except with respect to the fees and expenses payable to the Placement Agent as described in Section 5.2 hereto, no brokerage or finder's fees or commissions or other remuneration are or will be payable by the Company or any Subsidiaries directly or indirectly to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) <u>Private Placement</u>. Assuming the accuracy of the Purchasers' representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) <u>Investment Company</u>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an "investment company" within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an "investment company" subject to registration under the Investment Company Act of 1940, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) <u>Registration Rights</u>. Except as disclosed on <u>Schedule 3.1(u)</u>, no Person has any right to cause the Company or any Subsidiary to affect the registration under the Securities Act of any securities of the Company or any Subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Disclosure</u>. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Transaction Documents and disclosure schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) <u>No Integrated Offering</u>. Assuming the accuracy of the Purchasers' representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of the Securities Act which would require the registration of any such securities under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) <u>Solvency</u>. The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. There is no outstanding Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, "<u>Indebtedness</u>" means (x) any liabilities for borrowed money or amounts owed in excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company's consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Except as disclosed on <u>Schedule 3.1(x)</u>, neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) <u>Taxes</u>. (a) Except as disclosed on <u>Schedule 3.1(y)</u> each of the Company and its Subsidiaries has timely paid all taxes and other charges due by the Company to any local or foreign tax authorities, including, without limitation, income taxes, estimated taxes, excise taxes, sales taxes, value added taxes, use taxes, gross receipts taxes, franchise taxes, national insurance taxes, national healthcare contributions, employment and payroll related taxes, property taxes and import duties, whether or not measured in whole or in part by net income (hereinafter, "**Taxes**" or, individually, a "**Tax**") which have come due and are required to be paid by it through the date hereof or the date of the relevant Closing, and all deficiencies or other additions to Tax, interest and penalties owed by it in connection with any such Taxes; (b) except as set forth in Schedule 3.1(y), each of the Company and its Subsidiaries has duly and timely submitted or caused to be submitted all returns for Taxes that it is required to submit on and through the date hereof or the date of the relevant Closing, as applicable (including, in each case, all applicable extensions), and all such Tax returns are accurate and complete in all material respects; (c) with respect to all Tax returns of the Company and its Subsidiaries, (i) there is no unassessed Tax deficiency proposed or, to the knowledge of the Company, threatened against the Company or its Subsidiaries and (ii) no audit is in progress with respect to any return for Taxes, no extension of time is in force with respect to any date on which any return for Taxes was or is to be submitted and no waiver or agreement is in force for the extension of time for the assessment or payment of any Tax; (d) all provisions for Tax liabilities of the Company and its Subsidiaries have been made consistent with GAAP consistently applied, and all liabilities for Taxes of the Company and its Subsidiaries attributable to periods prior to or ending on the date hereof or the date of the relevant Closing, as applicable, have been adequately provided for; (e) there are no liens for Taxes on the assets of the Company or its Subsidiaries; (f) all monies required to be withheld by the Company (including from employees for income Taxes and social security and other payroll Taxes) have been collected or withheld, and either paid to the respective taxing authorities, set aside in accounts for such purpose, or accrued, reserved against and entered upon the books of the Company; (g) to the knowledge of the Company, there are no circumstances which will or may, whether by lapse of time or the issue of any notice of assessment or otherwise, give rise to any dispute with any relevant taxation authority in relation to the Company's or its Subsidiaries' liability or accountability for Tax under currently enacted statutes and regulations, any claim made by any of them, any relief, deduction, or allowance afforded to any such company, or in relation to the status or character of the Company or its Subsidiaries under or for the purpose of any provision of any legislation relating to Tax; (h) the Company has duly collected all amounts on account of any sales transfer Taxes or valued added taxes, including goods and services, harmonized sales and provincial or territorial sales Taxes, required by law to be collected by it, and has duly and timely remitted to the appropriate governmental authority any such amounts required by law to be remitted by it; and (i) the Company has not refunded or deducted any input valued added taxes that it was not so entitled to deduct or refund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) <u>No General Solicitation</u>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and certain other "accredited investors" within the meaning of Rule 501 under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) <u>Foreign Corrupt Practices</u>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb) <u>No Disagreements with Accountants and Lawyers</u>. There are no disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers presently or, to the knowledge of the Company, formerly employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company's ability to perform any of its obligations under any of the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc) <u>Acknowledgment Regarding Purchasers' Purchase of Securities</u>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers' purchase of the Securities. The Company further represents to each Purchaser that the Company's decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd) <u>Acknowledgment Regarding Purchaser's Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(g) and 4.11 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or "derivative" securities based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or "derivative" transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company's publicly-traded securities, (iii) any Purchaser, and counter-parties in "derivative" transactions to which any such Purchaser is a party, directly or indirectly, may presently have a "short" position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm's length counter-party in any "derivative" transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Purchased Shares or Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such hedging activities do not constitute a breach of any of the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee) <u>Stock Option Plans</u>. No stock options are outstanding as of the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ff) <u>Office of Foreign Assets Control</u>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department ("<u>OFAC</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg) <u>U.S. Real Property Holding Corporation</u>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser's request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hh) <u>Bank Holding Company Act</u>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the "<u>BHCA</u>") and to regulation by the Board of Governors of the Federal Reserve System (the "<u>Federal Reserve</u>"). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Money Laundering</u>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the "<u>Money Laundering Laws</u>"), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(jj) <u>No Disqualification Events</u>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an "<u>Issuer Covered Person</u>" and, together, "<u>Issuer Covered Persons</u>") is subject to any of the "Bad Actor" disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a "<u>Disqualification Event</u>"), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(kk) <u>Other Covered Persons</u>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ll) <u>Notice of Disqualification Events</u>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Issuer Covered Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the applicable Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Organization; Authority</u>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Own Account</u>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser's right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser understands that the Securities are "restricted securities" and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser's right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Purchaser Status</u>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, either an "accredited investor" as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Experience of Such Purchaser</u>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication, and experience in business and financial matters to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser can bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>General Solicitation</u>. Such Purchaser is not, to such Purchaser's knowledge, purchasing the Securities because of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Access to Information</u>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment, respectively, the investor presentation attached as <u>Exhibit C</u> to this Agreement, and Risk Factors attached as <u>Exhibit D</u> to this Agreement and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Certain Transactions and Confidentiality</u>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser's assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser's representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any actions with respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities of the Company for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions in the future.

The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser's right to rely on the Company's representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document, or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares to effect Short Sales or similar transactions in the future.

**ARTICLE IV.**

**OTHER AGREEMENTS OF THE PARTIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Transfer Restrictions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following form:

[NEITHER] THIS SECURITY [NOR THE SECURITIES INTO WHICH THIS SECURITY IS [EXERCISABLE] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] OF THIS SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN "ACCREDITED INVESTOR" AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an "accredited investor" as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser's expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities have been registered for resale pursuant to a registration statement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of selling stockholders thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Certificates evidencing the Purchased Shares, the Warrant Shares or the Warrants shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such Purchased Shares, Warrant Shares or Warrants pursuant to Rule 144 or (iii) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall, at its expense, cause its counsel, or at the option of a Purchaser, counsel determined by such Purchaser, to issue a legal opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively subject to compliance with the Securities Act and/or Rule 144 (for the avoidance of doubt, the Company shall pay all costs associated with such opinions). If the Purchased Shares or Warrant Shares may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Purchased Shares or Warrant Share shall be issued free of all legends. The Company agrees that at such time as such legend is no longer required under this Section 4.1(c), it will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Purchased Shares or Warrant Shares, as applicable, issued with a restrictive legend (such date, the "<u>Legend Removal Date</u>"), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates for Purchased Shares or Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser's prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein, "<u>Standard Settlement Period</u>" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Purchased Shares or Warrant Shares, as applicable, issued with a restrictive legend.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will only sell Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company's reliance upon this understanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>Acknowledgment of Dilution</u>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Purchased Shares or Warrant Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <u>Furnishing of Information; Public Information</u>. From the date of the Qualified Offering, until the time that no Purchaser owns Securities, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <u>Publicity</u>. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except to the extent such disclosure is required by law or Trading Market regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <u>Shareholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an "<u>Acquiring Person</u>" under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <u>Non-Public Information</u>. The Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any material, non-public information to a Purchaser without such Purchaser's consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. Following the date of the Qualified Offering, to the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 <u>Use of Proceeds</u>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and for expenses relating to its initial public offering and shall not use such proceeds: (a) for the satisfaction of any portion of the Company's debt (other than payment of trade payables in the ordinary course of the Company's business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation (d) in violation of FCPA or OFAC regulations or (e) to lend, give credit or make advances to any officers, directors, employees or affiliates of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 <u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.9, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a "<u>Purchaser Party</u>") harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys' fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party's representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company's prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party's breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.9 shall be made by periodic payments of the amount thereof during the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10 <u>Equal Treatment of Purchasers</u>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to such Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.11 <u>Certain Transactions and Confidentiality</u>. Notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser's assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser's assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.12 <u>Form D; Blue Sky Filings</u>. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or "Blue Sky" laws of the states of the United States and shall provide evidence of such actions promptly upon request of any Purchaser.

**ARTICLE V.**

**MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Termination</u>. This Agreement may be terminated by any Purchaser, as to such Purchaser's obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the initial Closing has not been consummated on or before the tenth calendar day following the date hereof, <u>provided</u>, <u>however</u>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants, and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery, and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup>nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least a majority of the Units based initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition, or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially, and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 <u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7 <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the "Purchasers."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8 <u>No Third-Party Beneficiaries</u>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.10. Notwithstanding the foregoing, each of the Placement Agent shall be deemed a third-party beneficiary of the representations and warranties of the Company as contained in Section 3.1 of this Agreement and shall have the right to enforce such provisions directly to the extent it may deem such enforcement necessary or advisable to protect its rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9 <u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees, or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.10, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10 <u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11 <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or ".pdf" signature page was an original thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12 <u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants, and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13 <u>Rescission and Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.14 <u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen, or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.15 <u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.16 <u>Payment Set Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.17 <u>Independent Nature of Purchasers' Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.18 <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken, or such right may be exercised, on the next succeeding Business Day.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.19 <u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.20 **<u>WAIVER OF JURY TRIAL</u>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.** 

*(Signature Pages Follow)*

 

IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

---

| | |
|:---|:---|
| **CARING BRANDS, Inc.** | <u>Address for Notice:</u> <br>|
|  | 1061 E. Indiantown Road |
|  | Suite 110 |
|  | Jupiter, FL 33477 |
|  | Attention: Brian John |

---

By: <u>Email</u>: bjohn@caringbrands.com <br> Name: Dr. Glynn Wilson <br> Title: Chief Executive Officer

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

[PURCHASER SIGNATURE PAGES TO

sECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: ________________________________________________________

*Signature of Authorized Signatory of Purchaser*: __________________________________

Name of Authorized Signatory: ____________________________________________________

Title of Authorized Signatory: _____________________________________________________

Email Address of Authorized Signatory: _____________________________________________

Facsimile Number of Authorized Signatory: __________________________________________

Address for Notice to Purchaser:

Address for Delivery of Securities to Purchaser (if not same as address for notice):

Subscription Amount: $_____________

Number of Units purchase: _____________

EIN Number: _______________________

[SIGNATURE PAGES CONTINUE]

EXHIBIT LIST

&nbsp;&nbsp;&nbsp;&nbsp;a. Purchaser Questionnaire

b. Investor Presentation

c. Risk Factors

**EXHIBIT B**

**U.S. Accredited Investor Confirmation Certificate**

**(For U.S. Purchasers that are Accredited Investors)**

**To: (the "Seller")** 

Reference is made to the Share Purchase Agreement by and among (the "Seller",) the undersigned (also referred to herein as the "Purchaser") (the "Agreement"). Terms not otherwise defined herein have the meanings ascribed to them in the Agreement.

The Purchaser understands and agrees that the Purchased Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or any applicable U.S. state securities laws, and the Purchased Shares are being offered and sold by the Seller to the Purchaser in reliance upon available exemptions under the Securities Act.

The undersigned represents, warrants and covenants (which representations, warranties and covenants shall survive the Closing) to the Seller (and acknowledges that the Seller is relying thereon) that the Purchaser is an "accredited investor", as defined under the Securities Act (an "Accredited Investor"), and satisfies one or more of the categories indicated below (please initial on the appropriate line or lines), and is:

---

| | |
|:---|:---|
| ______Category 1. | A bank, as defined in Section 3(a)(2) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section 15 of the United States Securities Exchange Act of 1934, as amended; an insurance company as defined in Section 2(a)(13) of the U.S. Securities Act; an investment company registered under the United States Investment Seller Act of 1940, as amended; a business development company as defined in Section 2(a)(48) of the United States Investment Seller Act of 1940, as amended; a small business investment company licensed by the U.S. Small Business Administration under Section 301 (c) or (d) of the United States Small Business Investment Act of 1958, as amended; any Rural Business Investment Seller as defined in section 384A of the United States Consolidated Farm and Rural Development Act of 1972, as amended; a plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, with total assets in excess of U.S.$5,000,000; or an employee benefit plan within the meaning of the United States Employee Retirement Income Security Act of 1974, as amended, in which the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company or registered investment adviser, or if the employee benefit plan has total assets in excess of U.S.$5,000,000 or, if a self-directed plan, with investment decisions made solely by persons who are "accredited investors" (as such term is defined in Rule 501 under the U.S. Securities Act); or |

---

---

| | |
|:---|:---|
| ______Category 2. | A private business development company as defined in Section 202(a)(22) of the United States Investment Advisers Act of 1940, as amended; or |
| ______Category 3. | An organization described in Section 501(c)(3) of the United States Internal Revenue Code of 1986, as amended, a corporation, a Massachusetts or similar business trust or a partnership, or a limited liability company, not formed for the specific purpose of acquiring the securities being offered, with total assets in excess of U.S.$5,000,000; or |
| ______Category 4. | A director or executive officer of the Seller (for purposes of this Schedule "A", "executive officer" means the president; any vice president in charge of a principal business unit, division or function, such as sales, administration or finance; or any other person or persons who perform(s) similar policymaking functions for the Seller); or |
| _____Category 5. | A natural person whose individual net worth, or joint net worth with that person's spouse or spousal equivalent, at the time of purchase exceeds U.S.$1,000,000; provided, however, that (i) the person's primary residence shall not be included as an asset; (ii) indebtedness that is secured by the person's primary residence, up to the estimated fair market value of the primary residence at the time of the sale of securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of the sale of securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability); and (iii) indebtedness that is secured by the person's primary residence in excess of the estimated fair market value of the primary residence at the time of the sale of securities shall be included as a liability; or |

---

**(Note:** For the purposes of calculating "joint net worth", joint net worth can be the aggregate net worth of the investor and spouse or spousal equivalent, and assets need not be held jointly to be included in the calculation. Reliance on the joint net worth standard does not require that the securities be purchased jointly.

**(Note:** The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.)

---

| | |
|:---|:---|
| ______Category 6. | A natural person who had an individual income in excess of U.S.$200,000 in each of the two most recent years or joint income with that person's spouse or spousal equivalent in excess of U.S.$300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; or |

---

(**Note**: The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.)

---

| | |
|:---|:---|
| _____Category 7. | A trust, with total assets in excess of U.S.$5,000,000, not formed for the specific purpose of acquiring the securities being offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) under the U.S. Securities Act; or |
| _____Category 8. | An entity in which all of the equity owners are "accredited investors" (as such term is defined in Rule 50l(a) of Regulation D under the U.S. Securities Act); or |

---

(**Note**: It is permissible to look through various forms of equity ownership to natural persons in determining the accredited investor status of entities under this category. If those natural persons are themselves accredited investors, and if all other equity owners of the entity seeking accredited investor status are accredited investors, then this category may be available.)

---

| | |
|:---|:---|
| _____Category 9. | An entity of a type not listed in Category 1, 2, 3, 7 or 8 above or in Category 11 below, owning investments in excess of U.S.$5,000,000 that is not formed for the specific purpose of acquiring the Securities; or |
| _____Category 10. | A natural person that holds one of the following licenses in good standing: General Securities Representative license (Series 7), the Private Securities Offerings Representative license (Series 82), or the Investment Adviser Representative license (Series 65); or |
| _____Category 11. | An investment adviser registered pursuant to section 203 of the United States Investment Advisers Act of 1940, as amended, or registered pursuant to the laws of a state, or an investment adviser relying on the exemption from registering with the U.S. Securities and Exchange Commission **("SEC")** under section 203(1) or (m) of the United States Investment Advisers Act of 1940, as amended; or |
| _____Category 12. | A "family office," as defined in Rule 202(a)(ll)(G)-1 under the United States Investment Advisers Act of 1940, as amended (17 CFR 275.202(a)(l l)(G)-1): (i) with assets under management in excess of U.S.$5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose prospective investment is directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment; or |

---

---

| | |
|:---|:---|
| _____Category 13. | A "family client," as defined in Rule 202(a)(ll)(G)-1 under the United States Investment Advisers Act of 1940, as amended (17 CFR 275.202(a)(ll)(G)-l), of a family office meeting the requirements in Category 12 above and whose prospective investment in the issuer is directed by such family office pursuant to (iii) of Category 12 above. |

---

The undersigned agrees that by accepting the Purchased Shares it shall be representing and warranting that the representations and warranties above are true as at the closing with the same force and effect as if they had been made by it at the Closing and that they shall survive the purchase by it of the Purchased Shares and shall continue in full force and effect notwithstanding any subsequent disposition by it of the Purchased Shares.

The foregoing representations and warranties are true an accurate as of the date of this U.S. Accredited Investor Confirmation Certificate and will be true and accurate as of Closing. If any such representations and warranties shall not be true and accurate prior to Closing, the Purchaser shall give immediate written notice of such fact to the Seller.

Dated at ____________________________, on __________________________, 2024

_______________________________

(Full Name of Purchaser - please print)

_______________________________

(Authorized Signature)

_______________________________

(Name and Official Capacity - please print)

**SCHEDULE 2.1**

**WIRE INSTRUCTIONS**

**DISCLOSURE SCHEDULES**

Schedule 3.1 (a) Subsidiaries—None

Schedule 3.1 (g) Capitalization-

The Company has 13,335,000 shares of Common Stock outstanding.

The Company has 2,110,000 outstanding options or warrants.

Schedule 3.1 (q) Intellectual Property. See attached list.

Schedule 3.1 (u)— Registration Rights—None

Schedule 3.1 (y) Outstanding Taxes—None

PATENTS

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Hoxie Reference** | **Jupiter Reference** | **Country** | **Status** | **Filed Date** | **Application Number** | **Publication Date** | **Publication Number** | **Grant Date** | **Patent No.** |
| JPW-01-AU | JW-100 | Australia | Pending | 2020-08-07 | 2020331290 |  |  |  |  |
| JPW-01-BR | JW-100 | Brazil | Abandoned | 2020-08-07 | BR1120220024916 |  |  |  |  |
| JPW-01-CA | JW-100 | Canada | Pending | 2020-08-07 | 3147353 |  |  |  |  |
| JPW-01-CN | JW-100 | China | Published | 2020-08-07 | 202080071037.7 | 2022-10-04 | CN115151241A |  |  |
| JPW-01-EP | JW-100 | European Patent | Published | 2020-08-07 | 20760708.6 | 2022-06-15 | 4009946 |  |  |
| JPW-01-IN | JW-100 | India | Abandoned | 2020-08-07 | 202217011675 | 2022-06-10 | 202217011675A |  |  |
| JPW-01-JP | JW-100 | Japan | Abandoned | 2020-08-07 | 2022-508456 | 2022-10-13 | 2022-543703 |  |  |
| JPW-01-KR | JW-100 | Korea, Republic of (KR) | Abandoned | 2020-08-07 | 10-2022-7007478 |  |  |  |  |
| JPW-01-MX | JW-100 | Mexico | Pending | 2020-08-07 | MX/a/2022/001723 |  |  |  |  |
| JPW-01-PCT | JW-100 | Patent Cooperation Treaty | Expired | 2020-08-07 | PCT/US2020/045408 | 2021-02-18 | WO 2021/030190 A1 |  |  |
| JPW-01-PROV | JW-100 | United States of America | Expired | 2019-08-09 | 62/884,955 |  |  |  |  |
| JPW-01-PROVB | JW-100 | United States of America | Expired | 2020-03-04 | 62/985,235 |  |  |  |  |
| JPW-01-US | JW-100 | United States of America | Abandoned | 2020-08-07 | 16/987,941 | 2021-02-11 | US 2021-0038513 A1 |  |  |
| JPW-01-USC | JW-100 | United States of America | Published | 2022-09-30 | 17/937,327 | 2023-01-26 | US-2023-0026847-A1 |  |  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;JPW-02-CA | &nbsp;&nbsp;Oronasal CBD Formulations and Uses Thereof | &nbsp;&nbsp;Canada | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2021-06-21 | &nbsp;&nbsp;3183864 |  |  |
| &nbsp;&nbsp;JPW-02-EP | &nbsp;&nbsp;Oronasal CBD Formulations and Uses Thereof | &nbsp;&nbsp;European Patent | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2021-06-21 | &nbsp;&nbsp;21742254.2 |  |  |
| &nbsp;&nbsp;JPW-02-PCT | &nbsp;&nbsp;Oronasal CBD Formulations and Uses Thereof | &nbsp;&nbsp;Patent Cooperation Treaty | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2021-06-21 | &nbsp;&nbsp;PCT/US2021/038269 | &nbsp;&nbsp;2021-12-30 | &nbsp;&nbsp;WO 2021/262607 A1 |
| &nbsp;&nbsp;JPW-02-PCTC | &nbsp;&nbsp;Oronasal CBD Formulations and Uses Thereof | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Pending | &nbsp;&nbsp;2021-06-21 | &nbsp;&nbsp;18/145,789 |  |  |
| &nbsp;&nbsp;JPW-02-PROV | &nbsp;&nbsp;Oronasal CBD Formulations and Uses Thereof | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2020-06-22 | &nbsp;&nbsp;63/042,458 |  |  |
| &nbsp;&nbsp;JPW-02-USP | &nbsp;&nbsp;Oronasal CBD Formulations and Uses Thereof | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2021-06-21 | &nbsp;&nbsp;17/353,573 | &nbsp;&nbsp;2021-12-23 | &nbsp;&nbsp;US-2021-0393576 A1 |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;JPW-03-PCT | &nbsp;&nbsp;CBD Sunscreen | &nbsp;&nbsp;Patent Cooperation Treaty | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2021-04-06 | &nbsp;&nbsp;PCT/US2021/025947 | &nbsp;&nbsp;2021-10-14 | &nbsp;&nbsp;WO 2021/207182 A1 |  |  |
| &nbsp;&nbsp;JPW-03-PCTC | &nbsp;&nbsp;CBD Sunscreen | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Published | &nbsp;&nbsp;2022-10-06 | &nbsp;&nbsp;17/938,613 | &nbsp;&nbsp;2023-02-02 | &nbsp;&nbsp;US-2023-0033849-A1 |  |  |
| &nbsp;&nbsp;JPW-03-PROV | &nbsp;&nbsp;CBD Sunscreen | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2020-04-06 | &nbsp;&nbsp;63/005,854 |  |  |  |  |
| &nbsp;&nbsp;JPW-03-PROVB | &nbsp;&nbsp;CBD Sunscreen | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2020-06-03 | &nbsp;&nbsp;63/034,305 |  |  |  |  |
| &nbsp;&nbsp;JPW-04-PROV | &nbsp;&nbsp;Systems and Methods for Treating Androgenetic Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-09-26 | &nbsp;&nbsp;62/736,675 |  |  |  |  |
| &nbsp;&nbsp;JPW-04-USP | &nbsp;&nbsp;Systems and Methods for Treating Androgenetic Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2019-09-25 | &nbsp;&nbsp;16/582,380 | &nbsp;&nbsp;2020-03-26 | &nbsp;&nbsp;US-2022-0094071 A1 |  |  |
| &nbsp;&nbsp;JPW-05-PROV | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-10-05 | &nbsp;&nbsp;62/741,990 |  |  |  |  |
| &nbsp;&nbsp;JPW-05-PROVB | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-11-06 | &nbsp;&nbsp;62/756,293 |  |  |  |  |
| &nbsp;&nbsp;JPW-05-PROVC | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2019-02-01 | &nbsp;&nbsp;62/800,065 |  |  |  |  |
| &nbsp;&nbsp;JPW-05-PROVD | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2019-05-17 | &nbsp;&nbsp;62/849,598 |  |  |  |  |
| &nbsp;&nbsp;JPW-05-PROVE | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2019-09-04 | &nbsp;&nbsp;62/895,627 |  |  |  |  |
| &nbsp;&nbsp;JPW-05-USP | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Granted | &nbsp;&nbsp;2019-10-04 | &nbsp;&nbsp;16/593,577 | &nbsp;&nbsp;2021-03-04 | &nbsp;&nbsp;US-2021-0059920 A1 | &nbsp;&nbsp;2023-09-26 | &nbsp;&nbsp;11766392 |
| &nbsp;&nbsp;JPW-05-USPD | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Pending | &nbsp;&nbsp;2023-09-25 | &nbsp;&nbsp;<u>18/474,052</u> |  |  |  |  |
| &nbsp;&nbsp;JPW-05-USPN | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Allowed | &nbsp;&nbsp;2020-01-21 | &nbsp;&nbsp;16/747,685 | &nbsp;&nbsp;2020-07-09 | &nbsp;&nbsp;US-2020-0214958 A1 | &nbsp;&nbsp;2023-04-18 | &nbsp;&nbsp;11628132 |
| &nbsp;&nbsp;JPW-05-USPNC | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Published | &nbsp;&nbsp;2023-04-17 | &nbsp;&nbsp;<u>18/301,951</u> | &nbsp;&nbsp;2023-12-21 | &nbsp;&nbsp;US-2023-0404886 A1 |  |  |
| &nbsp;&nbsp;JPW-05-USPNN | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Published | &nbsp;&nbsp;2022-06-10 | &nbsp;&nbsp;17/806,363 | &nbsp;&nbsp;2022-09-22 | &nbsp;&nbsp;US-2022-0296486-A1 |  |  |
| &nbsp;&nbsp;JPW-05-USPNN-PCT | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;Patent Cooperation Treaty | &nbsp;&nbsp;Published | &nbsp;&nbsp;2023-02-14 | &nbsp;&nbsp;PCT/US2023/062611 | &nbsp;&nbsp;2023-12-14 | &nbsp;&nbsp;WO 2023/239972 |  |  |
| &nbsp;&nbsp;JPW-05-IN | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;India | &nbsp;&nbsp;Pending | &nbsp;&nbsp;2023-02-14 | &nbsp;&nbsp;202317067100 |  |  |  |  |
| &nbsp;&nbsp;JPW-05-JP | &nbsp;&nbsp;JW-700 | &nbsp;&nbsp;Japan | &nbsp;&nbsp;Pending | &nbsp;&nbsp;2023-02-14 | &nbsp;&nbsp;2023-540689 |  |  |  |  |
| &nbsp;&nbsp;JPW-06-US | &nbsp;&nbsp;Methods and Compositions for Improving the Appearance of Hair Following Topical Minoxidil Application | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2020-06-08 | &nbsp;&nbsp;16/946,158 | &nbsp;&nbsp;2021-12-09 | &nbsp;&nbsp;US-2021-0378937 A1 |  |  |
| &nbsp;&nbsp;JPW-07-PROV | &nbsp;&nbsp;Methods for Protecting Hair Follicles | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2019-07-31 | &nbsp;&nbsp;62/880,940 |  |  |  |  |
| &nbsp;&nbsp;JPW-07-USP | &nbsp;&nbsp;Methods for Protecting Hair Follicles | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2020-07-31 | &nbsp;&nbsp;16/947,423 | &nbsp;&nbsp;2021-02-04 | &nbsp;&nbsp;US-2021-0030787 A1 |  |  |
| &nbsp;&nbsp;JPW-08-PCT | &nbsp;&nbsp;TAAR Receptor Agonists for the Treatment of Alopecia | &nbsp;&nbsp;Patent Cooperation Treaty | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2019-03-20 | &nbsp;&nbsp;PCT/US2019/023148 | &nbsp;&nbsp;2020-01-30 | &nbsp;&nbsp;WO 2020/023084 A1 |  |  |
| &nbsp;&nbsp;JPW-08-PCTC | &nbsp;&nbsp;TAAR Receptor Agonists for the Treatment of Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Published | &nbsp;&nbsp;2021-01-22 | &nbsp;&nbsp;17/155,865 | &nbsp;&nbsp;2021-05-13 | &nbsp;&nbsp;US-2021-0137854 A1 |  |  |
| &nbsp;&nbsp;JPW-08-PROV | &nbsp;&nbsp;TAAR Receptor Agonists for the Treatment of Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-07-26 | &nbsp;&nbsp;62/703,547 |  |  |  |  |
| &nbsp;&nbsp;JPW-08-PROVB | &nbsp;&nbsp;TAAR Receptor Agonists for the Treatment of Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-07-27 | &nbsp;&nbsp;62/711,236 |  |  |  |  |
| &nbsp;&nbsp;JPW-08-PROVC | &nbsp;&nbsp;TAAR Receptor Agonists for the Treatment of Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-07-27 | &nbsp;&nbsp;62/711,162 |  |  |  |  |
| &nbsp;&nbsp;JPW-08-PROVD | &nbsp;&nbsp;TAAR Receptor Agonists for the Treatment of Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-09-20 | &nbsp;&nbsp;62/733,962 |  |  |  |  |
| &nbsp;&nbsp;JPW-08-PROVE | &nbsp;&nbsp;TAAR Receptor Agonists for the Treatment of Alopecia | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2018-10-30 | &nbsp;&nbsp;62/752,608 |  |  |  |  |
| &nbsp;&nbsp;JPW-09-PROV | &nbsp;&nbsp;Post Acute Covid 19 Tinnitus | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2022-10-18 | &nbsp;&nbsp;63/380,019 |  |  |  |  |
| &nbsp;&nbsp;JPW-11-PROV | &nbsp;&nbsp;JW-710 | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Filed | &nbsp;&nbsp;2023-10-31 |  |  |  |  |  |
| &nbsp;&nbsp;JPW-12-PROV | &nbsp;&nbsp;Photocil | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2011-11-03 | &nbsp;&nbsp;61/555,130 |  |  |  |  |
| &nbsp;&nbsp;JPW-12-US-PCT | &nbsp;&nbsp;Photocil | &nbsp;&nbsp;Patent Cooperation Treaty | &nbsp;&nbsp;Expired | &nbsp;&nbsp;2013-07-23 | &nbsp;&nbsp;PCT/US2013/051721 | &nbsp;&nbsp;2014-05-08 | &nbsp;&nbsp;WO 2014/070266 A1 |  |  |
| &nbsp;&nbsp;JPW-12-US | &nbsp;&nbsp;Photocil | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2012-11-05 | &nbsp;&nbsp;13/669,435 | &nbsp;&nbsp;2013-05-09 | &nbsp;&nbsp;US-2013-0115180-A1 |  |  |
| &nbsp;&nbsp;JPW-12-USN | &nbsp;&nbsp;Photocil | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Abandoned | &nbsp;&nbsp;2013-07-22 | &nbsp;&nbsp;13/948,090 | &nbsp;&nbsp;2013-11-21 | &nbsp;&nbsp;US 2013-0310730-A1 |  |  |
| &nbsp;&nbsp;JPW-12-USN2 | &nbsp;&nbsp;Photocil | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Granted | &nbsp;&nbsp;2013-12-31 | &nbsp;&nbsp;14/145,824 | &nbsp;&nbsp;2014-05-01 | &nbsp;&nbsp;US-2014-0121732-A1 | &nbsp;&nbsp;2018-10-30 | &nbsp;&nbsp;10111821 |
| &nbsp;&nbsp;JPW-14-US |  | &nbsp;&nbsp;United States of America | &nbsp;&nbsp;Pending | &nbsp;&nbsp;2023-12-23 | &nbsp;&nbsp;18/395,565 |  |  |  |  |

---

**LICENSES**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Name | Country | Products | Signature Date | Term | Status |
| Cosmofix Technovation / Sanpellegrino Cosmetics | India \* | JW-700<br> Photocil | 9/1/2022 | 3 years | On sale in India |
| Taisho Pharmaceutical | Japan | JW-700 | 5/1/2022 | 5 years | In development |

---

&nbsp;&nbsp;\* India , Nepal, Bangladesh, Sri Lanka , Vietnam , Phillipines , Malaysia , Cambodia ,<br> laos , Indonesia , Uae , Egypt , Algeria , Tunisia , Congo Nigeria , Kenya , Thailand ,<br> Algeria ,Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar,<br> Saudi Arabia, Syria, Tunisia

## Exhibit 14.1

**Exhibit 14.1**

**CARING BRANDS, INC.**

**CODE OF BUSINESS CONDUCT AND ETHICS**

1. <u>Introduction</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 The Board of Directors of Caring Brands, Inc. (together with its subsidiaries, the "**Company**") has adopted this Code of Business Conduct and Ethics (the "**Code**") in order to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) promote full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission (the "**SEC**") and in other public communications made by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) promote compliance with applicable governmental laws, rules and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) promote the protection of Company assets, including corporate opportunities and confidential information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) promote fair dealing practices;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) deter wrongdoing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) ensure accountability for adherence to the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 All directors, officers and employees are required to be familiar with the Code, comply with its provisions and report any suspected violations as described below in Section 10, Reporting and Enforcement.

2. <u>Honest and Ethical Conduct</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 The Company's policy is to promote high standards of integrity by conducting its affairs honestly and ethically.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 Each director, officer and employee must act with integrity and observe the highest ethical standards of business conduct in his or her dealings with the Company's customers, suppliers, partners, service providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job.

3. <u>Conflicts of Interest</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 A conflict of interest occurs when an individual's private interest (or the interest of a member of his or her family) interferes, or even appears to interfere, with the interests of the Company as a whole. A conflict of interest can arise when an employee, officer or director (or a member of his or her family) takes actions or has interests that may make it difficult to perform his or her work for the Company objectively and effectively. Conflicts of interest also arise when an employee, officer or director (or a member of his or her family) receives improper personal benefits as a result of his or her position in the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 Loans by the Company to, or guarantees by the Company of obligations of, employees or their family members are of special concern and could constitute improper personal benefits to the recipients of such loans or guarantees, depending on the facts and circumstances. Loans by the Company to, or guarantees by the Company of obligations of, any director or officer or their family members are expressly prohibited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 Whether or not a conflict of interest exists or will exist can be unclear. Conflicts of interest should be avoided unless specifically authorized as described in Section 3.4.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 Persons other than directors and executive officers who have questions about a potential conflict of interest or who become aware of an actual or potential conflict should discuss the matter with, and seek a determination and prior authorization or approval from, their supervisor, the Chief Executive Officer or Chief Operating Officer. A supervisor may not authorize or approve conflict of interest matters or make determinations as to whether a problematic conflict of interest exists without first providing the Chief Executive Officer or Chief Operating Officer with a written description of the activity and seeking the Chief Executive Officer or Chief Operating Officer's written approval. If the supervisor is himself involved in the potential or actual conflict, the matter should instead be discussed directly with the Chief Executive Officer or Chief Operating Officer.

Directors and executive officers must seek determinations and prior authorizations or approvals of potential conflicts of interest exclusively from the Audit Committee.

4. <u>Compliance</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 Employees, officers and directors should comply, both in letter and spirit, with all applicable laws, rules and regulations in the cities, states and countries in which the Company operates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 Although not all employees, officers and directors are expected to know the details of all applicable laws, rules and regulations, it is important to know enough to determine when to seek advice from appropriate personnel. Questions about compliance should be addressed to the Legal Department.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 No director, officer or employee may purchase or sell any Company securities while in possession of material nonpublic information regarding the Company, nor may any director, officer or employee purchase or sell another company's securities while in possession of material nonpublic information regarding that company. It is against Company policies and illegal for any director, officer or employee to use material nonpublic information regarding the Company or any other company to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) obtain profit for himself or herself; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) directly or indirectly "tip" others who might make an investment decision on the basis of that information.

5. <u>Disclosure</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 The Company's periodic reports and other documents filed with the SEC, including all financial statements and other financial information, must comply with applicable federal securities laws and SEC rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 Each director, officer and employee who contributes in any way to the preparation or verification of the Company's financial statements and other financial information must ensure that the Company's books, records and accounts are accurately maintained. Each director, officer and employee must cooperate fully with the Company's accounting and internal audit departments, as well as the Company's independent public accountants and counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 Each director, officer and employee who is involved in the Company's disclosure process must:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) be familiar with and comply with the Company's disclosure controls and procedures and its internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business condition of the Company provide full, fair, accurate, timely and understandable disclosure.

6. <u>Protection and Proper Use of Company Assets</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 All directors, officers and employees should protect the Company's assets and ensure their efficient use. Theft, carelessness and waste have a direct impact on the Company's profitability and are prohibited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 All Company assets should be used only for legitimate business purposes. Any suspected incident of fraud or theft should be reported for investigation immediately.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 The obligation to protect Company assets includes the Company's proprietary information. Proprietary information includes intellectual property such as trade secrets, patents, trademarks, and copyrights, as well as business and marketing plans, engineering and manufacturing ideas, designs, databases, records and any nonpublic financial data or reports. Unauthorized use or distribution of this information is prohibited and could also be illegal and result in civil or criminal penalties.

7. <u>Corporate Opportunities</u>. All directors, officers and employees owe a duty to the Company to advance its interests when the opportunity arises. Directors, officers and employees are prohibited from taking for themselves personally (or for the benefit of friends or family members) opportunities that are discovered through the use of Company assets, property, information or position. Directors, officers and employees may not use Company assets, property, information or position for personal gain (including gain of friends or family members). In addition, no director, officer or employee may compete with the Company.

8. <u>Confidentiality</u>. Directors, officers and employees should maintain the confidentiality of information entrusted to them by the Company or by its customers, suppliers or partners, except when disclosure is expressly authorized or is required or permitted by law. Confidential information includes all nonpublic information (regardless of its source) that might be of use to the Company's competitors or harmful to the Company or its customers, suppliers or partners if disclosed.

9. <u>Fair Dealing</u>. Each director, officer and employee must deal fairly with the Company's customers, suppliers, partners, service providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job. No director, officer or employee may take unfair advantage of anyone through manipulation, concealment, abuse or privileged information, misrepresentation of facts or any other unfair dealing practice.

10. <u>Reporting and Enforcement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 Reporting and Investigation of Violations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Actions prohibited by this Code involving directors or executive officers must be reported to the Audit Committee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Actions prohibited by this Code involving anyone other than a director or executive officer must be reported to the reporting person's supervisor, the Chief Executive Officer or Chief Operating Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) After receiving a report of an alleged prohibited action, the Audit Committee, the relevant supervisor, the Chief Executive Officer or Chief Operating Officer must promptly take all appropriate actions necessary to investigate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) All directors, officers and employees are expected to cooperate in any internal investigation of misconduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 Enforcement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company must ensure prompt and consistent action against violations of this Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If, after investigating a report of an alleged prohibited action by a director or executive officer, the Nominating and Corporate Governance Committee determines that a violation of this Code has occurred, the Nominating and Corporate Governance Committee will report such determination to the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If, after investigating a report of an alleged prohibited action by any other person, the relevant supervisor, the Chief Executive Officer or Chief Operating Officer determines that a violation of this Code has occurred, the relevant supervisor, the Chief Executive Officer or Chief Operating Officer will report such determination to the General Counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Upon receipt of a determination that there has been a violation of this Code, the Board of Directors or the General Counsel will take such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal and, in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 Waivers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Audit Committee (in the case of a violation by a director or executive officer) and the General Counsel, and if the Company has not appointed a General Counsel then the Chief Compliance Officer, or such other officer as may be designated from time to time (in the case of a violation by any other person) may, in its discretion, waive any violation of this Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any waiver for a director or an executive officer shall be disclosed as required by SEC and NASDAQ rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 Prohibition on Retaliation.

The Company does not tolerate acts of retaliation against any director, officer or employee who makes a good faith report of known or suspected acts of misconduct or other violations of this Code.

**ACKNOWLEDGMENT OF RECEIPT AND REVIEW**

To be signed and returned to the Chief Executive Officer or Chief Operating Officer.

I, _______________, acknowledge that I have received and read a copy of the Caring Brands, Inc. Code of Business Conduct and Ethics. I understand the contents of the Code and I agree to comply with the policies and procedures set out in the Code.

I understand that I should approach my supervisor, the Chief Executive Officer or Chief Operating Officer if I have any questions about the Code generally or any questions about reporting a suspected conflict of interest or other violation of the Code.

---

| |
|:---|
| [NAME] |
| [PRINTED NAME] |
| [DATE] |

---

## Exhibit 14.2

**Exhibit 14.2**

**CARING BRANDS, INC. CORPORATE GOVERNANCE GUIDELINES**

**Responsibility of the Board**

The primary mission of the Board of Directors of Caring Brands, Inc. (and together with its subsidiaries, the "Company") is to advance the interests of the Company's stockholders by creating a valuable long-term business. The Board believes that this mission is best served by establishing a corporate culture of accountability, responsibility and ethical behavior through the careful selection and evaluation of senior management and members of the Board and by carrying out the Board's responsibilities with honesty and integrity.

The basic responsibility of the directors is to exercise their business judgment to act in what they reasonably believe to be the best interests of the Company and its stockholders. In discharging their obligations, directors should be entitled to rely on the honesty and integrity of the Company's senior executives and its outside advisors and auditors. The directors shall also be entitled to have the Company purchase reasonable directors' and officers' liability insurance on their behalf, to the benefits of indemnification to the fullest extent permitted by law and the Company's Certificate of Incorporation and Bylaws and to exculpation as provided by state law and the Company's Certificate of Incorporation. Board members are expected to attend meetings of the Board and the committees of the Board on which they serve and to spend the time needed to appropriately discharge their responsibilities.

**Director Selection**

***Board Membership Criteria*.** The Nominating and Corporate Governance Committee is responsible for reviewing with the Board, at least annually, the appropriate skills and experience of Board members, as well as the composition of the Board as a whole. This assessment should include factors such as independence, judgment, skill, diversity, integrity and experience in the context of the needs of the Board.

***Selection of Director Nominees*.** The Nominating and Corporate Governance Committee will recommend candidates for election to the Board in accordance with the policies and principles in its charter and the criteria described in these Guidelines. The invitation to join the Board should be extended by the Board jointly through the Chief Executive Officer of the Company (the "CEO") and the Chair of the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee will review the nomination of an incumbent director for re-election to the Board upon expiration of such director's term.

**Board Composition**

***Independent Directors.*** A majority of the members of the Board shall be "independent" under the rules of NASDAQ and under applicable law.

***Size of the Board.*** The Board presently has six members, and it is the sense of the Board that a size of between three and seven members is appropriate. The Board determines the number of directors as permitted in the Company's Certificate of Incorporation or Bylaws and will periodically review the size of the Board based on recommendations of the Nominating and Corporate Governance Committee.

***Positions of Chairman and CEO.*** The Board currently has no policy with respect to the separation of the offices of Chairman of the Board and the CEO. The Board believes that this issue is part of the succession planning process and that it is in the best interests of the Company for the Board, with the assistance of the Nominating and Corporate Governance Committee, to make a determination whenever it elects a new chief executive officer or elects to adopt a succession plan for the incumbent CEO.

***Service on Other Boards.*** No director should serve on more than three other boards of directors of publicly- held companies without the prior approval of the Nominating and Corporate Governance Committee. Directors should advise the CEO and the Chair of the Nominating and Corporate Governance Committee in advance of accepting an invitation to serve on the board of directors of another company. Additionally, the CEO and other executive officers must seek the approval of the Board before accepting membership on other boards (or similar bodies), including corporate and charitable boards.

***Changes in Professional Responsibility***. The Board should consider whether a change in an individual's professional responsibility directly or indirectly impacts that person's ability to fulfill his or her obligations as a director of the Company. Any director of the Company should submit his or her resignation upon retirement from, or other significant change in, his or her principal employment. The Board may accept or reject such resignation in its discretion after consultation with the Nominating and Corporate Governance Committee.

***Term Limits***. The Board does not believe it should establish term limits. While term limits could help ensure that there are fresh ideas and viewpoints available to the Board, they have the disadvantage of losing the contribution of directors who have been able to develop, over a period of time, increasing insight into the Company and its operations and, therefore, provide an increasing contribution to the Board as a whole.

**Director Compensation and Performance**

***Compensation Policy and Annual Compensation Review.*** It is the policy of the Board to provide independent directors with a mix of compensation, including an annual fee, as well as equity and/or derivative security awards, which may be contingent upon certain criteria as determined by the Board at the time of grant. Proposed changes in Board compensation shall initially be reviewed by the Compensation Committee, but any changes in the compensation of directors shall require the approval of the Board. The Compensation Committee shall periodically review the status of Board compensation in relation to other comparable companies and consider other factors the Committee deems appropriate, including whether directors' independence may be jeopardized if (i) director compensation and perquisites exceed customary levels, (ii) the Company makes substantial charitable contributions to organizations with which a director is affiliated, or (iii) the Company enters into consulting contracts with (or provides other indirect forms of compensation to) a director or an organization with which the director is affiliated. The Committee shall discuss its review with the Board. An assessment of any related party transactions, that may jeopardize the independence of the directors will also be made by the Audit Committee of the Board.

***Annual Performance Evaluation.*** Commencing in 2026, the Board of Directors will conduct an annual self- evaluation to determine whether it and its committees are functioning effectively. The Board of Directors will select an independent Director to oversee this process and, in connection with such evaluation, will receive comments from all directors and report annually to the Board with an assessment of the Board's performance and procedures. This will be discussed with the full Board following the end of each fiscal year.

***Transactions with Directors or their Affiliates.*** Except for employment arrangements with executive officers, the Company does not engage in transactions with directors or their affiliates if a transaction would cast into doubt the independence of a director, present the appearance of a conflict of interest, or is otherwise prohibited by law, rule or regulation. This includes, directly or indirectly, any extension, maintenance or renewal of an extension of credit to any director or member of management of the Company. This prohibition also includes significant business dealings with directors or their affiliates, substantial charitable contributions to organizations in which a director is affiliated, and consulting contracts with, or other indirect forms of compensation to, a director. Any waiver of this policy may be made only by the Board or a Board committee and must be promptly disclosed to the Company's stockholders.

**Board Meetings and Communications to Independent Directors**

***Schedule.*** Board meetings are scheduled in advance and held not less than quarterly. The Board holds special meetings as required.

***Agendas.*** The CEO and other members of senior management will establish the agenda for each Board meeting. Each Board member may submit items to be included on the agenda. Board members also may raise subjects that are not on the agenda at any meeting.

***Distribution of Board Material.*** Information that is important to the Board's understanding of the Company's business should be distributed to the Board members a reasonable period of time before the Board meeting.

***Strategic Planning.*** The Board will review the Company's long-term strategic plans and principal issues that the Company will face in the future during at least one Board meeting each year. The timing and agenda of this meeting shall be determined by the CEO.

***Meetings of Independent Directors.*** Independent directors shall meet at least annually without any non- independent directors present. Meetings of the independent directors should generally coincide with regularly scheduled Board meetings; however, a majority of the independent directors may call a meeting of the independent directors at any time. The director, or method for selecting a director, who presides at any meeting of independent directors will be decided by the directors entitled to attend such meeting, and his or her name or such method will be disclosed in the Company's annual proxy statement. The director presiding at any such meeting shall supervise the conduct of such meeting, shall communicate the results of the meeting to the CEO, as appropriate, and shall have other responsibilities which the non-management directors or independent directors may designate from time to time.

***Communications with Independent Directors.*** Interested parties wishing to communicate directly with the independent directors may do so by writing, addressed as follows: Independent Directors, 130 S Indian River Drive, Suite 202 pbm#1232, Fort Pierce, FL 34950, Attn: Chief Compliance Officer.

***Board Presentations and Access to Employees and Advisors.*** Directors shall have full access to officers and employees of the Company and, as necessary and appropriate, the Company's independent advisors, including legal counsel and independent accountants. Any meetings or contacts that a director wishes to initiate may be arranged through the CEO or directly by the director. The directors will use their judgment to ensure that any such contact is not disruptive to the business operations of the Company and will, to the extent appropriate, provide the CEO with a copy of any written communications between a director and an officer or employee of, or adviser to, the Company.

The Board encourages senior management to invite to Board meetings officers and other key employees who can provide additional insight into the items being discussed, or that senior management believes should be given exposure to the Board.

***Board Interaction with Investors, Media and Others.*** The Board believes that senior management speaks for the Company. Individual Board members may, from time to time, meet or otherwise communicate with various constituencies that are involved with the Company, but the Board members will do so only with the knowledge and prior consent of senior management and, in most instances, only at the request of senior management.

**Board Committees**

***Required Committees.*** Consistent with NASDAQ's listing requirements, the Board will have at all times an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. All of the members of those committees will be "independent" under the criteria established by NASDAQ and under applicable law.

Committees shall receive authority exclusively through delegation from the Board through the by-laws, Board resolutions, committee charters or as provided by these guidelines. All committee actions must be ratified by the Board before becoming effective, unless taken pursuant to an express delegation of authority. In addition to the authority granted hereunder or under each committee's charter, the Board and each committee have the power to hire independent legal, financial or other advisors as they may deem necessary without consulting or obtaining the approval of senior management.

***Appointment and Term of Service of Committee Members.*** Committee members will be appointed by the Board upon recommendation of the Nominating and Corporate Governance Committee with consideration of the desires of individual directors. Consideration will be given to rotating committee members periodically, but the Board does not believe that rotation should be mandated as a policy. Committee chairs shall be selected by the respective committee members, except with respect to the Audit Committee chair who will be selected by the Board.

***Committee Charters.*** Consistent with NASDAQ's listing requirements, the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, will have a written charter approved by the Board. The charters will set forth the purposes and responsibilities of the committees as well as qualifications for committee membership, procedures for appointment and removal, structure and operations, and reporting to the Board. The charters will also provide that each committee will annually evaluate its performance. Consistent with NASDAQ's listing requirements, the charters will be included on the Company's website and copies of the charters will be made available upon request. to the Company's Chief Compliance Officer.

***Committee Meetings and Committee Agenda.*** Each committee chair, in consultation with the committee members and appropriate officers of the Company, will determine the frequency of committee meetings consistent with any requirements in the committee's charter, provided that a majority of committee members may call a meeting of the committee on which they are members at any time. Each committee chair, in consultation with the other members of the committee and senior management, will develop the committee's agenda.

***Other Committees.*** The Board may, from time to time, establish or maintain additional committees as necessary or appropriate.

**Management Succession**

***CEO Selection.*** The Board shall select a CEO in a manner that is in the best interests of the Company.

***Evaluation of Executive Officers.*** The Compensation Committee will conduct an annual review of the performance of the CEO, and the other executive officers of the Company in light of the goals and objectives of the Company. The Compensation Committee will set executive officer compensation based on such factors as it deems appropriate.

***Succession Planning and Management Development.*** The Nominating and Corporate Governance Committee should, at least annually, make a report to the Board on succession planning. The Company's succession plan will include appropriate contingencies in case the CEO retires or is incapacitated. The Board, with the assistance of the Nominating and Corporate Governance Committee, will evaluate potential successors to the CEO. The CEO should at all times make available his recommendations and evaluations of potential successors, along with a review of any development plans recommended for such individuals.

These guidelines will be made available upon request. to the Company's Chief Compliance Officer or Chief Executive Officer.

## Ex-21

**Exhibit 21**

**CARING BRANDS, INC**

**LIST OF SUBSIDIARIES**

Caring Brands, Inc (Florida)

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_001.jpg)

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the inclusion in the foregoing Amendment No.4 on Form S-1/A Regulation Statement of our report dated April 7, 2025, relating to our audit the financial statements of Caring Brands, Inc. (a Florida Corporation "Predecessor") as of December 31, 2023 and the period from January 1, 2024 to September 24, 2024 and the consolidated financial statements Caring Brand, Inc. (a Nevada Corporation "Successor") as of and for the period from April 24, 2024 (Inception) to December 31, 2024, and for the periods then ended, and the reference to our firm under the caption "Experts" in the Offering Statement.

---

| |
|:---|
| /s/ M&K CPAS, PLLC |
| The Woodlands, Texas |
| August 21, 2025 |

---

## Exhibit 99.1

**Exhibit 99.1**

**CARING BRANDS INC. - Insider Trading Policy**

This Insider Trading Policy (the "Policy") provides guidelines to all employees, officers, and affiliates of Caring Brands Inc., and its subsidiaries (the "Company"), as well as members of the Company's Board of Directors (the "Directors"), with respect to transactions in the Company's securities and codifies the Company's standards on trading and enabling, or causing the trading of securities of the Company or other publicly-traded companies while in possession of material, non-public information.

**Scope of Policy**

The Policy applies to Directors, officers, employees, independent contractors and special consultants of the Company, and their respective immediate family members ("Insiders"), and is divided into two parts:

● Part I applies to all Insiders, and prohibits trading in the Company's and other companies' securities in certain circumstances; and

● Part II applies to Directors, certain officers and employees of the Company who typically have access to financial and other highly sensitive information regarding the Company's business, and imposes additional restrictions on those individuals with respect to trading in the Company's securities. Part II may also apply to certain other employees that the Company may from time to time designate as "covered persons" or "Insiders" under this policy, because of their position, responsibilities, or their actual or potential access to material information.

**Purpose of the Policy**

One of the principal purposes of the federal securities laws is to prohibit insider trading. Insider trading occurs when a person uses material nonpublic information obtained through involvement with the Company to make decisions to purchase, sell, give away or otherwise trade the Company's securities or the securities of certain other companies or to provide that information to others outside the Company. The prohibitions against insider trading apply to trades, tips and recommendations by virtually any person, including all persons associated with the Company, if the information involved is "material" and "non-public information" (defined below in this Policy.) The prohibitions would apply to any Insider who buys or sells securities on the basis of material nonpublic information that he or she obtained about the Company, its customers, suppliers, partners, competitors or other companies with which the Company has contractual relationships or may be negotiating transactions.

**Exceptions for Certain Transactions**

This Policy does not apply to all transactions involving the Company's securities. The following exceptions are intended to facilitate several common types of transactions.

● <u>Stock Option Exercises.</u> This Policy does not apply to the mere exercise of a stock option for cash under the Company's stock option plans. This Policy <u>does</u> apply, however, to:

○ Any sale of stock as part of a broker-assisted "cashless" exercise of an option (i.e., any market sale for the purpose of generating the cash needed to pay the exercise price of an option); and

○ Any sale of shares of Company stock received upon exercise of an option.

● <u>Net Settlement upon Vesting of Restricted Stock.</u> This Policy does not apply to a surrender of shares to the Company or the retention and withholding from delivery to the applicable officer, director, or employee of shares by the Company (i.e., a so-called "net settlement") upon vesting of restricted stock in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement or the Company plan pursuant to which the restricted stock was granted.

● <u>Employee Stock Purchase Plan.</u> This Policy does not apply to (i) an employee's election to participate in, or increase his or her participation in, the Company's employee stock purchase plan, (ii) purchases of Company stock in the plan resulting from periodic contributions of money to the plan pursuant to the elections made at the time of enrollment in the plan, or (iii) purchases of Company stock resulting from lump-sum contributions to the plan, provided that the participant elected to participate by lump-sum payment at the beginning of the applicable enrollment period. However, this Policy does apply to a participant's sale of Company stock purchased under the plan.

![](ex99-1_001.jpg)

**PART I**

**Insider Trading Prohibition (Applies to All Insiders)**

Insider trading occurs when a person in possession of material and non-public information obtained through involvement with the Company (1) uses that information to make decisions to purchase, sell, or otherwise trade in securities of the Company or another company, or (2) provides that information to others outside the Company to enable such trading.

U.S federal law, and the laws of all countries in which the Company operates, prohibit insider trading, and a violation of these laws may cause reputational and financial damage to the Company.

**1. Scope**

Part I of this Policy applies to all Insiders, and all transactions in the Company's securities, including common or preferred stock, options, and warrants to purchase common stock, notes, bonds, convertible securities, and any other debt or equity securities that the Company may issue, as well as to derivative securities relating to any of the Company's securities, whether or not issued by the Company.

**2. General Policy: No Trading or Causing Trading While in Possession of Material Non-public Information**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) No
 Insider may purchase or sell any Company security while in possession of material non-public
 information about the Company, its customers, suppliers, consultants, or other companies
 with which the Company has contractual relationships or may be negotiating transactions (the
 terms "material" and "non-public information" are defined in Part
 I, Section 4(a) and (b) below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) No
 Insider who knows of any material non-public information about the Company may communicate
 that information to any other person, including family and friends.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In
 addition, no Insider may purchase or sell any security of any other company, whether or not
 issued by the Company, while in possession of material non-public information about that
 company that was obtained in the course of their involvement with the Company. No Insider
 who knows of any such material non-public information may communicate that information to
 any other person, including family and friends.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) For
 compliance purposes, no Insider should ever trade, tip, or recommend securities (or otherwise
 cause the purchase or sale of securities) while in possession of information that the Insider
 has reason to believe is material and non-public unless the Insider first consults with,
 and obtains the advance approval of, the Compliance Officer (which is defined in Part I,
 Section 4(c) below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) From
 time to time, the Company may engage in transactions in its own securities. It is the Company's
 policy that any transactions in securities by the Company will comply with applicable laws
 with respect to insider trading.

![](ex99-1_001.jpg)

**3. Other Prohibited Transactions**

The Company considers it improper and inappropriate for Insiders to engage in short-term or speculative transactions in the Company's securities or in other transactions that may lead to inadvertent violations of the insider trading laws. Accordingly, trading in the Company's securities by Insiders is subject to the following additional restrictions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Short sales.</u> No Insider may sell the Company's securities short (sale of stock that the
 seller does not own or a sale that is completed by delivery of borrowed stock). Note that
 in addition to this Policy, Section 16(c) of the Exchange Act prohibits Section 16 Officers
 and Directors of the Company from engaging in short sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Options trading.</u> No Insider may buy or sell puts or calls or other derivative securities on the
 Company's securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Trading on margin; Pledging.</u> No Insider may hold Company securities in a margin account or pledge
 Company securities as collateral for a loan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Hedging.</u> No Insider may enter into hedging, monetization transactions, or similar arrangements
 with respect to Company securities.

**4. Definitions**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)  ***Material.*** Insider trading restrictions come into play only if the information that a director,
 officer, or employee of the Company possess is "material." Materiality, however,
 involves a relatively low threshold. Information is generally regarded as "material"
 if it has market significance, that is, if its public dissemination is likely to affect the
 market price of securities, or if it otherwise were information that a reasonable investor
 would want to know before making an investment decision. Information dealing with the following
 subjects is reasonably likely to be found material in particular situations, including, but
 not limited to:

○ Significant changes in the Company's prospects;

○ financial results, projections of future earnings or losses;

○ significant write-downs in assets;

○ the timelines or the results of preclinical studies or clinical trials;

○ scientific, medical, or financial data relating to the Company's products or products under development;

○ developments regarding significant litigation or government agency investigations;

○ impending bankruptcy or liquidity problems;

○ changes in earnings estimates or unusual gains or losses in major operations;

○ major changes in management;

○ a determination to declare a dividend;

○ extraordinary borrowings;

○ changes in debt ratings;

![](ex99-1_001.jpg)

○ entry into or modification or termination of a significant contract;

○ proposals, plans, or agreements, even if preliminary in nature, involving mergers, acquisitions or tender offers, divestitures, recapitalizations, strategic alliances, licensing arrangements, or purchases or sales of substantial assets;

○ public offerings; and

○ actions of regulatory and health agencies, particularly the U.S. Food and Drug Administration.

Material information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as a merger or acquisition, or the development of a new product, the point at which negotiations or new product development plans are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company's operations or stock price should it occur. Thus, information concerning an event that may have a large effect on stock prices, such as a merger, may be material even if the possibility that the event will occur is relatively small. *<u>When in doubt about whether non-public information is material, presume it is material.</u>*

 

Keep in mind that materiality is judged in hindsight, and while a development may not seem material at the time, if following its announcement to the public, the Company's stock price increases or decreases, a plaintiff's lawyer or the United States Securities and Exchange Commission ("SEC") will use this fact to demonstrate materiality. If you are unsure whether the information is material, you should consult with the Compliance Officer before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)  ***Non-public Information.*** Insider trading prohibitions come into play only when you possess information
 that is material and "non-public." The fact that information has been disclosed
 to a few members of the public does not make it public for insider trading purposes. To be
 "public" the information must have been disseminated in a manner designed to
 reach investors generally, and the investors must be given the opportunity to absorb the
 information. Even after the public disclosure of information about the Company, *<u>you must wait until the close of business on the second trading day after the information was publicly disclosed before you can treat the information as public</u>* .

*<u>As with questions of materiality, if you are not sure whether the information is considered public, you should either consult with the Compliance Officer or assume that the information is "non-public" and treat it as confidential.</u>*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)  ***Compliance Officer.*** The Company has appointed its Chief Financial Officer as the Compliance
 Officer for this Policy. The duties of the Compliance Officer include, but are not limited
 to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) assisting
 with the implementation of this Policy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) circulating
 this Policy to all Directors, officers, and employees of the Company and ensuring that this
 Policy is amended as necessary to remain up-to-date with insider trading laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) notifying
 Covered Persons (as defined in Part II below) and, if appropriate, other employees of the
 Company of the Company's imposition of a trading "blackout" period as described
 in Part II, Section 3 below;

![](ex99-1_001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) reviewing
 and approving Approved 10b5-1 Plans (as defined below) or revisions or amendments to such
 Plans, and referring such plans or revisions to such Plans to the Board or a duly appointed
 committee thereof for approval if required or otherwise appropriate, as described in Part
 II, Section 3(d) below;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) pre-clearing
 all trading in securities of the Company by all Covered Persons in accordance with the procedures
 set forth in Part II, Section 4 below: and

In the event that the Compliance Officer is not available or desires to effect a transaction in Company securities for which pre-clearance or approval is required under this Policy, the Chief Executive Officer of the Company shall serve as the Compliance Officer. In the event that the Compliance Officer is unavailable and such information is cleared by the Chief Executive Officer, the Compliance Officer must be informed of such clearance as soon as possible.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) providing
 a reporting system with an effective whistleblower protection mechanism.

**5. Violations of Insider Trading Laws**

Penalties for trading on or communicating material non-public information can be severe, both for individuals involved in such unlawful conduct and their employers and supervisors. Penalties may include jail terms, criminal fines, civil penalties, and civil enforcement injunctions. Given the severity of the potential penalties, compliance with this Policy is absolutely mandatory.

A person who tips others may also be liable for transactions by the tippees to whom he or she has disclosed material non-public information. Tippers can be subject to the same penalties and sanctions as the tippees. The SEC has imposed large penalties even when the tipper did not profit from the transaction.

Individuals who violate this Policy may be subject to disciplinary action by the Company, up to and including dismissal for cause. Any exceptions to the Policy, if permitted, may only be granted by the Compliance Officer in writing and must be provided before any activity contrary to the above requirements takes place.

**PART II**

**Additional Trading Restrictions for Covered Persons**

**1. Covered Persons**

Covered Persons are the individuals described below (collectively, "Covered Persons"):

● Current Directors of the Company and its affiliates;

● "Executive officers" of the Company as described in Rule 3b-7 under the Securities Exchange Act of 1934, as amended ("Exchange Act"), and all individuals designated as "officers" of the Company for purposes of Section 16 under the Exchange Act ("Section 16 Officers");

● All employees in the accounting, finance, investor relations, and law departments of the Company and its affiliates;

● Immediate family members (parents, siblings, spouses, children) and household members of each of the foregoing groups.

The Company's Compliance Officer may designate additional "Covered Persons" from time to time as described in Part II, Section 3.

**2. Scope**

Because Covered Persons are exposed to a wider range of material non-public information than their colleagues (e.g., information regarding quarterly results, strategic transactions, or the like), this Policy includes additional restrictions on transactions by such persons.

**3. Blackout Periods**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Persons Covered.</u> All Covered Persons are prohibited from trading the Company's securities
 during blackout periods, except in certain events, or with permission from the Compliance
 Officer. In addition, the Compliance Officer may notify other employees of the Company that
 they are prohibited from trading in the Company's securities during blackout periods,
 in which event such notified persons shall also be considered "Covered Persons."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Quarterly Blackout Periods.</u> Announcement of quarterly financial results almost always has the potential
 to have a material effect on the market for its securities. Therefore, to avoid even the
 appearance of trading on the basis of material, non-public information, and to assist in
 compliance with insider trading laws, the Company has created the following blackout periods
 during which Covered Persons must receive prior approval of all trades with the Compliance
 Officer:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) From
 December 16 until the end of the second trading day following the public announcement of
 fourth-quarter and year-end financial results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) From
 March 16 until the end of the second trading day following the public announcement of first-quarter
 financial results;

![](ex99-1_001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) From
 June 16 until the end of the second trading day following the public announcement of second-quarter
 financial results; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) From
 September 16 until the end of the second trading day following the public announcement of
 third-quarter financial results.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Other Blackout Periods.</u> From time to time, other types of material non-public information regarding
 the Company (such as negotiation of mergers, acquisitions or dispositions, new product developments,
 clinical trials, or other material events) may be pending and not be publicly disclosed.
 While such material non-public information is pending, the Company may impose special blackout
 periods during which Covered Persons are prohibited from trading in the Company's securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Approved Rule 10b5-1 Plan.</u> These trading restrictions do not apply to transactions by Covered
 Persons under a pre-existing written plan, contract, instruction, or arrangement under Exchange
 Act Rule 10b5-1 ("Approved 10b5-1 Plan") that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) has
 been reviewed and approved at least thirty days in advance of any trades thereunder by the
 Compliance Officer (or, if an Approved 10b5-1 plan is to be revised or amended, such revision
 or amendment has been reviewed and approved by the Compliance Officer at least thirty days
 in advance of any subsequent trades);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) was
 entered into in good faith by the Covered Person outside a Blackout Period and at a time
 when he or she was not in possession of material non-public information about the Company;
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) gives
 a third party the authority to execute such purchases and sales, outside the control of the
 applicable officer, Director, or employee, providing such third party does not possess any
 material non-public information about the Company, or explicitly specifies the security or
 securities to be purchased or sold, the number of shares, the prices and/or dates of transactions,
 or other formula(s) describing such transactions.

Notwithstanding that sales are made pursuant to an Approved 10b5-1 Plan, the SEC has recently eliminated the safe harbor for sales made pursuant to 10b5-1 plans. Accordingly, if you are in possession of material non-public information, you should advise the administrator of the 10b5-1 Plan, that you want to cancel your upcoming sale. For example, if you are scheduled to sell shares on June 1 and on May 29, you become aware that the FDA will not approve a product and that information has not yet been made public and you sell shares on June 1 pursuant to the 10b5-1 Plan, you can be charged with insider trading.

**4. Pre-clearance of Securities Transactions**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Because
 Covered Persons are likely to obtain material non-public information on a regular basis,
 the Company requires all Covered Persons to obtain a pre-clearance, even outside a Blackout
 Period, from the Compliance Officer for all transactions in the Company's securities.
 In addition, transactions made by a Section 16 Officer or Director require a supplemental
 pre-clearance by the Company's Chief Financial Officer (or, for trades by the CFO,
 by the Company's Chief Executive Officer).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) These
 procedures also apply to transactions by such person's spouse, other persons living
 in such person's household, and minor children, and to transactions by entities over
 which such person exercises control.

![](ex99-1_001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Unless
 revoked, a grant of permission will normally remain valid until the close of trading five
 days following the day on which it was granted. If the transaction does not occur during
 the five-day period, pre-clearance of the transaction must be re-requested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Pre-clearance
 is not required for purchases and sales of securities under an Approved 10b5-1 Plan. With
 respect to any purchase or sale under an Approved 10b5-1 Plan, the third-party effecting
 transactions on behalf of the applicable Covered Person should be instructed to send duplicate
 confirmations of all such transactions to the Compliance Officer. In addition, pre-clearance
 is not required for stock option exercises and net issuances of restricted stock under the
 limited circumstances described in the introduction to this Policy.

**5. Short-Term Trading by Covered Persons**

Section 16 Officers and Directors who purchase Company securities may not sell any Company securities of the same class for at least six months after the purchase. This prohibition does not apply to stock option exercises (whether regular or cashless) and Employee Stock Purchase Plan purchases.

Note that in addition to this Policy, under Section 16(b) of the Exchange Act, any "short-swing profits" realized by a Section 16 Officer or Director of the Company from a "matching" purchase and sale or "matching" sale and purchase of Company stock occurring within a six-month period would be subject to disgorgement to the Company. Note that under Section 16(b), the highest sale price is matched with the lowest purchase price in determining profit, and purchases and sales that result in a loss are ignored— meaning that under these rules, you could be deemed to have a profit to be disgorged even though you actually lose money on your trades in the aggregate. There is an active group of lawyers that track purchases and sales by Section 16 Officers and Directors for violation of these rules. There is no defense against a violation of these rules.

**I, the undersigned employee, acknowledge that I have read, understood, and agree to abide by the terms and conditions outlined in this policy document.**

---

| | |
|:---|:---|
| By: | /s/ |

---

## Exhibit 99.2

**Exhibit 99.2**

**CHARTER OF THE AUDIT COMMITTEE OF CARING BRANDS, INC.**

**<u>Membership</u>**

The Audit Committee (the "**Committee**") of the board of directors (the "**Board**") of Caring Brands, Inc. (the "**Company**") shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the requirements of Rule 10A-3 of the Securities Exchange Act of 1934 and the rules of the NASDAQ Stock Market LLC ("**NASDAQ**"). No member of the Committee can have participated in the preparation of the Company's or any of its subsidiaries' financial statements at any time during the past three years.

Each member of the Committee must be able to read and understand fundamental financial statements, including the Company's balance sheet, income statement and cash flow statement. At least one member of the Committee must have past employment experience in finance or accounting, requisite professional certification in accounting or other comparable experience or background that leads to financial sophistication. At least one member of the Committee must be an "audit committee financial expert" as defined in Item 407(d)(5)(ii) of Regulation S-K. A person who satisfies this definition of audit committee financial expert will also be presumed to have financial sophistication.

No member of the Committee may serve simultaneously on the audit committee of more than two other public companies without prior approval of the Board.

The members of the Committee shall be appointed by the Board based on recommendations from the nominating and corporate governance committee of the Board. The members of the Committee shall be appointed for one-year terms and shall serve for such term or terms as the Board may determine from time to time, or until earlier resignation or death. The Board may remove any member from the Committee at any time with or without cause.

**<u>Purpose</u>**

The purpose of the Committee is to assist the Board with oversight of: the integrity of the Company's financial statements; compliance with legal and regulatory requirements; the Company's independent registered auditors' qualifications and independence; and the performance of the Company's independent registered auditors. In addition, the purpose of the Committee is to assist the Board with enterprise risk management, including major financial, and cybersecurity risk exposure..

The primary role of the Committee is to oversee the financial reporting and disclosure process. To fulfill this obligation, the Committee relies on: management for the preparation and accuracy of the Company's financial statements; both management and the Company's internal audit department/management for establishing effective internal controls and procedures to ensure the Company's compliance with accounting standards, financial reporting procedures and applicable laws and regulations; and the Company's independent auditors for an unbiased, diligent audit or review, as applicable, of the Company's financial statements and the effectiveness of the Company's internal controls. The members of the Committee are not employees of the Company and are not responsible for conducting the audit or performing other accounting procedures.

**<u>Duties and Responsibilities</u>**

The Committee shall have the following authority and responsibilities:

To (1) select and retain an independent registered public accounting firm to act as the Company's independent auditors for the purpose of auditing the Company's annual financial statements, books, records, accounts and internal controls over financial reporting, which selection of the independent auditors, shall be submitted for ratification by the Company's stockholders, (2) set the compensation of the Company's independent auditors, (3) oversee the work done by the Company's independent auditors and (4) terminate the Company's independent auditors, if necessary.

To select, retain, compensate, oversee and terminate, if necessary, any other registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company.

To approve all audit engagement fees and terms; and to pre-approve all audit and permitted non- audit and tax services that may be provided by the Company's independent auditors or other registered public accounting firms, and establish policies and procedures for the Committee's pre- approval of permitted services by the Company's independent auditors or other registered public accounting firms on an on-going basis.

At least annually, to obtain and review a report by the Company's independent auditors that describes (1) the accounting firm's internal quality control procedures, (2) any issues raised by the most recent internal quality control review, peer review or Public Company Accounting Oversight Board review or inspection of the firm or by any other inquiry or investigation by governmental or professional authorities in the past five years regarding one or more audits carried out by the firm and any steps taken to deal with any such issues, and (3) all relationships between the firm and the Company or any of its subsidiaries; and to discuss with the independent auditors this report and any relationships or services that may impact the objectivity and independence of the auditors.

At least annually, to evaluate the qualifications, performance and independence of the Company's independent auditors, including an evaluation of the lead audit partner.

To review and discuss with the Company's independent auditors (1) the auditors' responsibilities under generally accepted auditing standards and the responsibilities of management in the audit process, (2) the overall audit strategy, (3) the scope and timing of the annual audit, (4) any significant risks identified during the auditors' risk assessment procedures and (5) when completed, the results, including significant findings, of the annual audit.

To review and discuss with the Company's independent auditors (1) all critical accounting policies and practices to be used in the audit; (2) all alternative treatments of financial information within generally accepted accounting principles ("**GAAP**") that have been discussed with management, the ramifications of the use of such alternative treatments and the treatment preferred by the auditors; and (3) other material written communications between the auditors and management.

To review with management and the Company's independent auditors: any major issues regarding accounting principles and financial statement presentation, including any significant changes in the Company's selection or application of accounting principles; any significant financial reporting issues and judgments made in connection with the preparation of the Company's financial statements, including the effects of alternative GAAP methods; and the effect of regulatory and accounting initiatives and off-balance sheet structures on the Company's financial statements.

To keep the Company's independent auditors informed of the Committee's understanding of the Company's relationships and transactions with related parties that are significant to the company; and to review and discuss with the Company's independent auditors the auditors' evaluation of the Company's identification of, accounting for, and disclosure of its relationships and transactions with related parties, including any significant matters arising from the audit regarding the Company's relationships and transactions with related parties.

To review with management, and the Company's independent auditors the adequacy and effectiveness of the Company's financial reporting processes, internal control over financial reporting and disclosure controls and procedures, including any significant deficiencies or material weaknesses in the design or operation of, and any material changes in, the Company's processes, controls and procedures and any special audit steps adopted in light of any material control deficiencies, and any fraud involving management or other employees with a significant role in such processes, controls and procedures, and review and discuss with management and the Company's independent auditors disclosure relating to the Company's financial reporting processes, internal control over financial reporting and disclosure controls and procedures, the independent auditors' report on the effectiveness of the Company's internal control over financial reporting and the required management certifications to be included in or attached as exhibits to the Company's annual report on Form 10-K or quarterly report on Form 10-Q, as applicable.

To review and discuss with the Company's independent auditors any other matters required to be discussed by PCAOB Auditing Standards No. 1301, *Communications with Audit Committees*, including, without limitation, the auditors' evaluation of the quality of the company's financial reporting, information relating to significant unusual transactions and the business rationale for such transactions and the auditors' evaluation of the company's ability to continue as a going concern, and other applicable requirements of the PCAOB and the SEC.

To review and discuss with the Company's independent auditors and management the Company's annual audited financial statements (including the related notes), the form of audit opinion to be issued by the auditors on the financial statements and the disclosure under "Management's Discussion and Analysis of Financial Condition and Results of Operations" to be included in the Company's annual report on Form 10-K before the Form 10-K is filed.

To recommend to the Board that the audited financial statements and the MD&A section be included in the Company's Form 10-K and whether the Form 10-K should be filed with the SEC; and to produce the audit committee report required to be included in the Company's proxy statement.

To review and discuss with the Company's independent auditors and management the Company's quarterly financial statements and the disclosure under "Management's Discussion and Analysis of Financial Condition and Results of Operations" to be included in the Company's quarterly report on Form 10-Q before the Form 10-Q is filed; and to review and discuss the Form 10-Q for filing with the SEC.

To set Company hiring policies for employees or former employees of the Company's independent auditors that participated in any capacity in any Company audit.

To establish and oversee procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential, anonymous submission by Company employees of concerns regarding questionable accounting or auditing matters.

To review and discuss with management the risks faced by the Company and the policies, guidelines and process by which management assesses and manages the Company's risks, including the Company's including any major financial risk exposures, cybersecurity risk exposures, or legal and regulatory compliance risk exposures, and the steps management has taken to monitor and control such exposures.

To review, with the General Counsel and outside legal counsel, legal and regulatory matters, including legal cases against or regulatory investigations of the Company and its subsidiaries, that could have a significant impact on the Company's financial statements.

To review, approve and oversee any transaction between the Company and any related person (as defined in Item 404 of Regulation S-K) and any other potential conflict of interest situations on an ongoing basis, in accordance with Company policies and procedures, and to develop policies and procedures for the Committee's approval of related party transactions.

**<u>Outside Advisors</u>**

The Committee shall have the authority, in its sole discretion, to retain and obtain the advice and assistance of independent outside counsel and such other advisors as it deems necessary to fulfill its duties and responsibilities under this Charter. The Committee shall set the compensation, and oversee the work, of any outside counsel and other advisors.

The Committee shall receive appropriate funding from the Company, as determined by the Committee in its capacity as a committee of the Board, for the payment of compensation to the Company's independent auditors, any other accounting firm engaged to perform services for the Company, any outside counsel and any other advisors to the Committee.

**<u>Structure and Operations</u>**

The Board shall designate a member of the Committee as the chairperson. The Committee shall meet at least four times a year at such time and place as it deems necessary to fulfill its responsibilities. The Committee shall report to the Board on its discussions and actions, including any significant issues or concerns that arise at its meetings, and shall make recommendations to the Board as appropriate. The Committee is governed by the same rules regarding meetings (including meetings in person or by telephone or other similar communications equipment), action without meetings, notice, waiver of notice, and quorum and voting requirements as are applicable to the Board.

The Committee shall meet separately, and periodically, with management, and representatives of the Company's independent auditors, and shall invite such individuals to its meetings as it deems appropriate, to assist in carrying out its duties and responsibilities. However, the Committee shall meet regularly without such individuals present.

The Committee shall review this Charter at least annually and recommend any proposed changes to the Board for approval.

**<u>Delegation of Authority</u>**

The Committee shall have the authority to delegate any of its responsibilities, along with the authority to take action in relation to such responsibilities, to one or more subcommittees as the Committee may deem appropriate in its sole discretion.

## Exhibit 99.3

**Exhibit 99.3**

**CHARTER OF**

**THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF**

**CARING BRANDS, INC.**

**<u>Membership</u>**

The Nominating and Corporate Governance Committee (the "**Committee**") of the board of directors (the "**Board**") of Caring Brands, Inc. (the "**Company**") shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the rules of the NASDAQ Stock Market LLC ("**NASDAQ**").

The members of the Committee shall be appointed by the Board based on recommendations from the Committee. The members of the Committee shall be appointed for one-year terms and shall serve for such term or terms as the Board may determine from time to time, or until earlier resignation or death. The Board may remove any member from the Committee at any time with or without cause.

**<u>Purpose</u>**

The purpose of the Committee is to carry out the responsibilities delegated by the Board relating to the Company's director nominations process and procedures, developing and maintaining the Company's corporate governance policies, practices and procedures, and any related matters required by the federal securities laws.

**<u>Duties and Responsibilities</u>**

The Committee shall have the following authority and responsibilities:

To determine the qualifications, qualities, skills, and other expertise required to be a director and to develop, and recommend to the Board for its approval, criteria to be considered in selecting nominees for director (the "Director Criteria")

To identify and screen individuals qualified to become members of the Board, consistent with the Director Criteria. The Committee shall consider any director candidates recommended by the Company's stockholders pursuant to the procedures set forth in the Company's corporate governance guidelines, and described in the Company's proxy statement.

To make recommendations to the Board regarding the selection and approval of the nominees for director to be submitted to a stockholder vote at the annual meeting of stockholders.

To develop and recommend to the Board a set of corporate governance guidelines applicable to the Company, to review these principles at least once a year and to recommend any changes to the Board.

To oversee the Company's corporate governance policies, practices and procedures, including identifying best practices and reviewing and recommending to the Board for approval any changes to the documents, policies and procedures in the Company's corporate governance framework, including its certificate of incorporation and by-laws.

To develop, subject to approval by the Board, a process for an annual evaluation of the Board and its committees and to oversee the conduct of this annual evaluation.

To review the Board's committee structure and composition and to make recommendations to the Board regarding the appointment of directors to serve as members of each committee and committee chairmen annually.

If a vacancy on the Board and/or any Board committee occurs, to identify and make recommendations to the Board regarding the selection and approval of candidates to fill such vacancy either by election by stockholders or appointment by the Board.

To develop and recommend to the Board for approval a Company policy for the review and approval of related party transactions and to review, approve and oversee any transaction between the Company and any related person (as defined in Item 404 of Regulation S-K) on an ongoing basis in accordance with the Company's related party transaction approval policy.

To develop and recommend to the Board for approval director independence standards in addition to those required by NASDAQ for determining whether a director has a material relationship with the Company that would impair its independence.

To review and discuss with management disclosure of the Company's corporate governance practices, including information regarding the operations of the Committee and other Board committees, director independence and the director nominations process, and to recommend that this disclosure be, included in the Company's proxy statement or annual report on Form 10-K, as applicable.

To develop and recommend to the Board for approval a Code of Business Conduct and Ethics (the "Code"), to monitor compliance with the Company's Code, to investigate any alleged breach or violation of the Code, to enforce the provisions of the Code and to review the Code periodically and recommend any changes to the Board.

To review any director resignation letter tendered in accordance with the Company's director resignation policy set out in the Company's corporate governance guidelines, and evaluate and recommend to the Board whether such resignation should be accepted.

**<u>Outside Advisors</u>**

The Committee shall have the authority, in its sole discretion, to select, retain and obtain the advice of a director search firm as necessary to assist with the execution of its duties and responsibilities as set forth in this Charter. The Committee shall set the compensation and oversee the work of the director search firm. The Committee shall have the authority, in its sole discretion, to retain and obtain the advice and assistance of outside counsel, an executive search firm, and such other advisors as it deems necessary to fulfill its duties and responsibilities under this Charter. The Committee shall set the compensation and oversee the work of its outside counsel, the executive search firm, the compensation consultant and any other advisors. The Committee shall receive appropriate funding from the Company, as determined by the Committee in its capacity as a committee of the Board, for the payment of compensation to its search consultants, outside counsel, compensation consultant and any other advisors.

**<u>Structure and Operations</u>**

The Board shall designate a member of the Committee as the chairperson. The Committee shall meet at least once a year at such time and place as it deems necessary to fulfill its responsibilities. The Committee shall report regularly to the Board regarding its actions and make recommendations to the Board as appropriate. The Committee is governed by the same rules regarding meetings (including meetings in person or by telephone or other similar communications equipment), action without meetings, notice, waiver of notice, and quorum and voting requirements as are applicable to the Board.

The Committee shall review this Charter at least annually and recommend any proposed changes to the Board for approval.

**<u>Delegation of Authority</u>**

The Committee shall have the authority to delegate any of its responsibilities, along with the authority to take action in relation to such responsibilities, to one or more subcommittees as the Committee may deem appropriate in its sole discretion.

**<u>Performance Evaluation</u>**

The Committee shall conduct an annual evaluation of the performance of its duties under this charter and shall present the results of the evaluation to the Board. The Committee shall conduct this evaluation in such manner as it deems appropriate.

## Exhibit 99.4

**Exhibit 99.4**

**<u>CHARTER OF THE COMPENSATION COMMITTEE OF</u>**

**<u>CARING BRANDS, INC.</u>**

**<u>Membership</u>**

**The Compensation Committee (the "Committee") of the board of directors (the "Board") of Caring Brands, Inc. (the "Company") shall consist of two or more directors. Each member of the Committee shall be independent in accordance with the rules of the NASDAQ Stock Market LLC ("NASDAQ").**

At least two members of the Committee must qualify as "non-employee directors" for the purposes of Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the "**Exchange Act**").

The members of the Committee shall be appointed by the Board, based on recommendations from the nominating and corporate governance committee of the Board. The members of the Committee shall be appointed for one-year terms and shall serve for such term or terms as the Board may determine from time to time, or until earlier resignation or death. The Board may remove any member from the Committee at any time with or without cause.

**<u>Purpose</u>**

The purpose of the Committee is to carry out the responsibilities delegated by the Board relating to the review and determination of executive compensation.

**<u>Duties and Responsibilities</u>**

The Committee shall have the following authority and responsibilities:

To review and approve annually the corporate goals and objectives applicable to the compensation of the chief executive officer ("**CEO**"), evaluate at least annually the CEO's performance in light of those goals and objectives, and determine and approve the CEO's compensation level based on this evaluation. In determining the long-term incentive component of CEO compensation, the Committee may consider the Company's performance and relative stockholder return, the value of similar incentive awards given to CEOs at comparable companies and the awards given to the Company's CEO in past years. The Committee's decisions regarding performance goals and objectives and the compensation of the CEO are reviewed and ratified by all independent directors on the Board. *The CEO cannot be present during any voting or deliberations by the Committee on his or her compensation*.

To review, determine and approve the compensation of all other executive officers.

To review, and make recommendations to the Board regarding incentive compensation plans and equity-based plans, which includes the ability to adopt, amend and terminate such plans. The Committee shall also have the authority to administer the Company's incentive compensation plans and equity-based plans, including designation of the employees to whom the awards are to be granted, the amount of the award or equity to be granted and the terms and conditions applicable to each award or grant, subject to the provisions of each plan.

To review, and approve and, when appropriate, recommend to the Board for approval, any employment agreements and any severance arrangements or plans, including any benefits to be provided in connection with a change in control, for the CEO and other executive officers, which includes the ability to adopt, amend and terminate such agreements, arrangements or plans.

To the extent deemed necessary, to determine stock ownership guidelines for the CEO and other executive officers and monitor compliance with such guidelines.

To the extent deemed necessary, to review, approve and, when appropriate make recommendations to the Board for approval, regarding all employee benefit plans for the Company, which includes the ability to adopt, amend and terminate such plans, and the ability to delegate oversight of such plans.

To review the Company's incentive compensation arrangements to determine whether they encourage excessive risk-taking, to review and discuss at least annually the relationship between risk management policies and practices and compensation, and to evaluate compensation policies and practices that could mitigate any such risk.

To review all director compensation and benefits for service on the Board and Board committees at least once a year and to recommend any changes to the Board as necessary.

To oversee, in conjunction with the Board, engagement with stockholders and proxy advisory firms on executive compensation matters.

To develop and recommend to the Board for approval one or more policies for the recovery or clawback of erroneously paid compensation, including any revisions to such policies, and monitor compliance with such policies, including determining the extent, if any, to which incentive-based compensation of any current or former employees should be recouped or forfeited.

**<u>Outside Advisors</u>**

The Committee shall have the authority, in its sole discretion, to select, retain and obtain the advice of a compensation consultant as necessary to assist with the execution of its duties and responsibilities as set forth in this Charter. The Committee shall set the compensation, and oversee the work, of the compensation consultant. The Committee shall have the authority, in its sole discretion, to retain and obtain the advice and assistance of outside legal counsel and such other advisors as it deems necessary to fulfill its duties and responsibilities under this Charter. The Committee shall set the compensation, and oversee the work, of its outside legal counsel and other advisors. The Committee shall receive appropriate funding from the Company, as determined by the Committee in its capacity as a committee of the Board, for the payment of compensation to its compensation consultants, outside legal counsel and any other advisors. However, the Committee shall not be required to implement or act consistently with the advice or recommendations of its compensation consultant, legal counsel or other advisor to the compensation committee, and the authority granted in this Charter shall not affect the ability or obligation of the Committee to exercise its own judgment in fulfillment of its duties under this Charter.

The Committee has the sole authority to retain consultants and advisors as it may deem appropriate in its discretion. The Committee has the sole authority to approve related fees and other retention terms. The Committee must assess such advisor's independence before retention of such advisors (other than advisors whose role is limited to activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K), taking into consideration the following factors: (i) whether the compensation consulting firm employing the compensation advisor is providing any other services to the Company; (ii) how much the compensation consulting firm who employs the compensation advisor has received in fees from the Company, as a percentage of that person's total revenue; (iii) what policies and procedures have been adopted by the compensation consulting firm employing the compensation advisor to prevent conflicts of interest; (iv) whether the compensation advisor has any business or personal relationship with a member of the Committee; (v) whether the compensation advisor owns any stock of the Company; and (vi) whether the compensation advisor or the person employing the advisor has any business or personal relationship with an executive officer of the Company.

**<u>Structure and Operations</u>**

The Board shall designate a member of the Committee as the chairperson. The Committee shall meet at least twice a year at such time and place as it deems necessary to fulfill its responsibilities. The Committee shall report regularly to the Board regarding its actions and make recommendations to the Board as appropriate. The Committee is governed by the same rules regarding meetings (including meetings in person or by telephone or other similar communications equipment), action without meetings, notice, waiver of notice, and quorum and voting requirements as are applicable to the Board.

The Committee may invite such members of management to its meetings as it deems appropriate. However, the Committee shall meet regularly without such members present, and in all cases the CEO and any other such officers shall not be present at meetings at which their compensation or performance is discussed or determined.

The Committee shall review this Charter at least annually and recommend any proposed changes to the Board for approval.

**<u>Delegation of Authority</u>**

The Committee shall have the authority to delegate any of its responsibilities, along with the authority to take action in relation to such responsibilities, to one or more subcommittees as the Committee may deem appropriate in its sole discretion.

The Committee may delegate to one or more executive officers the authority to make grants of equity compensation to employees who are not officers. Any person or body to whom the Committee grants such authority shall regularly report to the Committee grants so made and the Committee may revoke any such delegation of authority at any time.

**<u>Performance Evaluation</u>**

The Committee shall conduct an annual evaluation of the performance of its duties under this charter and shall present the results of the evaluation to the Board. The Committee shall conduct this evaluation in such manner as it deems appropriate.

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-1**

(Form Type)

**Caring Brands, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security<br> Type** | **Fee<br> Calculation<br> or Carry<br> Forward<br> Rule** | **Amount<br> Registered** | **Proposed<br> Maximum<br> Offering<br> Price** | **Maximum<br> Aggregate<br> Offering<br> Price** | **Fee Rate** | **Amount of<br> Registration<br> Fee** |
| Fees to be paid | Equity Common Stock, par value $0.001 per share<sup>(1)(2)</sup> | Rule 457(o) |  | $4.00 | $4000000 | 0.00015310 | $612.40 |
| Fees to be Paid | Equity Common Stock, issuable to Selling Stockholders upon exercise of the Warrants <sup>(3)</sup> | Rule 457(o) |  | $4.00 | $10840000 | 0.00015310 | $1659.60 |
|  |  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | $14840000 |  | $2272.00 |
|  |  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  | $— |
|  |  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  | $4337.34 |
|  |  | Net Fee Due | Net Fee Due | Net Fee Due |  |  | $0.00 |

---

(1) Estimated
 solely for the purpose of calculating the amount of the registration fee in pursuant to Rule 457(o) under the Securities Act of 1933,
 as amended.

(2) Includes
 the aggregate offering price of up to 112,500 additional shares of Common Stock that the underwriters have the option to purchase
 to cover over-allotments, if any.

(3) This
 Registration Statement also covers the resale by Selling Stockholders of up to 2,710,000 shares of Common Stock issuable on exercise
 of warrants by the Selling Stockholders as named in the Registration Statement.

**Table 2: Fee Offset Claims and Sources**

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Registrant or<br> Filer Name** | **Form or<br> Filing Type** | **File<br> Number** | **Initial<br> Filing Date** | **Filing<br> Date** | **Fee Offset<br> Claimed** | **Security Type Associated with Fee Offset Claimed** | **Security Title<br> Associated<br> with Fee<br> Offset Claimed** | **Unsold Securities Associated with Fee Offset Claimed** | **Unsold Aggregate Offering Amount Associated with Fee Offset Claimed** | **Fee<br> Paid with<br> Fee Offset<br> Source** |
| **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims<sup>(1)</sup> | Caring Brands, Inc. | S-1 | 333-285964 | March 20, 2025 |  | $4337.34 | Equity | Common Stock, $0.0001 par value per share |  | $28330000 |  |
| Fee Offset Sources<sup>(1)</sup> | Caring Brands, Inc. | S-1 | 333-285964 |  | March 20, 2025 |  |  |  |  |  | $4337.34 |

---

(1) The
 Registrant paid a registration fee of $4,337.34 in connection with the registration of $28,330,000 of shares of common stock, par
 value $0.001 per share, pursuant to the Registration Statement on Form S-1 (File No. 333-285964) (the "Prior Registration Statement").
 The Prior Registration Statement was not declared effective by the Securities and Exchange Commission, and no securities were issued
 or sold thereunder. The Prior Registration Statement was withdrawn by filing a Form RW on May 6, 2025. In accordance with Rule 457(p)
 under the Securities Act, the total amount of the registration fee due upon the initial filing of this Registration Statement is
 offset by $4,337.34, representing the fee paid in connection with the Prior Registration Statement.